<SEC-DOCUMENT>0001401914-22-000051.txt : 20220512
<SEC-HEADER>0001401914-22-000051.hdr.sgml : 20220512
<ACCEPTANCE-DATETIME>20220512160401
ACCESSION NUMBER:		0001401914-22-000051
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		59
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220512
DATE AS OF CHANGE:		20220512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Dare Bioscience, Inc.
		CENTRAL INDEX KEY:			0001401914
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				204139823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36395
		FILM NUMBER:		22917699

	BUSINESS ADDRESS:	
		STREET 1:		3655 NOBEL DRIVE
		STREET 2:		SUITE 260
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		858-926-7655

	MAIL ADDRESS:	
		STREET 1:		3655 NOBEL DRIVE
		STREET 2:		SUITE 260
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cerulean Pharma Inc.
		DATE OF NAME CHANGE:	20090714

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tempo Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070604
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>dare-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:fd319a35-eb86-476b-85ca-f1b0e0a14df0,g:c97ede0a-3f8a-49b3-9abb-a622ab8bee13,d:8cc494c450e145729b0695b37b951a0a--><html xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dare="http://darebioscience.com/20220331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>dare-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80L2ZyYWc6MWMxMTA1ZWNmNzA2NGI1MmIzNTgzMjljMzU5YTliYzcvdGFibGU6NTg2YjdlNGI3ZmY3NGZlZWI4OGEwNDYwMjQ2OTVlNjMvdGFibGVyYW5nZTo1ODZiN2U0YjdmZjc0ZmVlYjg4YTA0NjAyNDY5NWU2M18yLTEtMS0xLTM3NDkx_54127fec-8e70-4c0f-a2b0-59c195e6ac1e">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80L2ZyYWc6MWMxMTA1ZWNmNzA2NGI1MmIzNTgzMjljMzU5YTliYzcvdGFibGU6NTg2YjdlNGI3ZmY3NGZlZWI4OGEwNDYwMjQ2OTVlNjMvdGFibGVyYW5nZTo1ODZiN2U0YjdmZjc0ZmVlYjg4YTA0NjAyNDY5NWU2M180LTEtMS0xLTM3NDkx_b599f137-5fef-42b2-973a-0186335dd0b9">2022</ix:nonNumeric><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80L2ZyYWc6MWMxMTA1ZWNmNzA2NGI1MmIzNTgzMjljMzU5YTliYzcvdGFibGU6NTg2YjdlNGI3ZmY3NGZlZWI4OGEwNDYwMjQ2OTVlNjMvdGFibGVyYW5nZTo1ODZiN2U0YjdmZjc0ZmVlYjg4YTA0NjAyNDY5NWU2M181LTEtMS0xLTM3NDkx_644a86fe-77f9-4c67-b6d4-64ce03193910">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80L2ZyYWc6MWMxMTA1ZWNmNzA2NGI1MmIzNTgzMjljMzU5YTliYzcvdGFibGU6NTg2YjdlNGI3ZmY3NGZlZWI4OGEwNDYwMjQ2OTVlNjMvdGFibGVyYW5nZTo1ODZiN2U0YjdmZjc0ZmVlYjg4YTA0NjAyNDY5NWU2M183LTEtMS0xLTM3NDkx_2ff89c94-1a66-4a51-8207-d5b311019e00">0001401914</ix:nonNumeric><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80L2ZyYWc6MWMxMTA1ZWNmNzA2NGI1MmIzNTgzMjljMzU5YTliYzcvdGFibGU6NTg2YjdlNGI3ZmY3NGZlZWI4OGEwNDYwMjQ2OTVlNjMvdGFibGVyYW5nZTo1ODZiN2U0YjdmZjc0ZmVlYjg4YTA0NjAyNDY5NWU2M184LTEtMS0xLTM3NDkx_35689c6f-13fd-4d0f-89e6-e521fcab00ad">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMzIwMw_e12ce3aa-c3f3-4f18-b044-bf8fda01a7e9">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="dare-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94263204e2654add81cafbf53b703aaf_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ic0c2931b38c749a8aac31ab58ed72510_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie30a938a64fd46cd98becdc1551973ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida978f25ba59408b9386363eb6d6eed4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b251f7c118549ba9202433ab6104a64_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60a512d483cf43099a491a6ccc8400a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3bd3370ad994990ad0bd8c17e41e612_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81a6b1d8921a4c34b493ef15f6ac3565_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cdccf0de4054bd5be8b8f6ca8068dcd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifba16de9b31d4bb4b84e89fdde96c11f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a6c19246dbd43918fe1d5bdaf45781d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00586b33add54084bb2dbf880a0f3571_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i923566bd281646fdb2dc3656b54543af_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ccd4e062a2e4af6bc25a6f55d4bbc88_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6063f716c8274a639d5c2235427b50d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66dc24f087884625adfebe658a8e451b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d33e15987224e8e864a9bb0d4e41246_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie18313b3160d472981c6193072f6baa5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0526bb23c864be7babc6b325d2ae2b3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09b399c6925442f9bf8bab14218dd545_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11c9582a92634557be12814380daffe8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7777562075814792bdb540658b8e6a06_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7234840ac886468bb69f5d05bd2db206_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91f25005c087421eab865393d5efc0bc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70732a14fa594410af98fbfbbfc49572_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie20c398f1df046b288658ed72f3fea03_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68e625c64183408d9d544a2b64fc1d4a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ab03b72e1c442f393d5f68da2cd04dc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>dare:segment</xbrli:measure></xbrli:unit><xbrli:context id="ib8e755817cb04a57a08c4f99adb8ffd6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:OrganonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c840e118dda4da0839c1173ced12675_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:OrganonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d128dda6aad45f6928caa2a8b0ac74d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if261222bb7c7445a96aa0768ee93bdf6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa56362091f34c8cb0ef0c7d93a4dea5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i753c4d96be1e4ba3967076ff69f73d0d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id64ecf9188364d48a0817d2f74ce0032_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36a1700da3be4028993f5fe8ba965b06_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieae613e2bfc34e51b675c0145659b974_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a58ac7dc95d43f7af582f30cbdc5d98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie39ad353b32c4dc891e544e148bc9b66_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:BayerHealthcareLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b96da1d703849ca87cb722301f4332a_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia36cb4e021c8477c9cdd5cd2270d26f0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7e84f1a2279490fb994ed669d2a5794_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1a197ace83745b5af0af06d9e6a03ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica0953b3410b4366b3dd008e5682c91c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie54bf079d17049f89f976bde3354e8eb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1377eee01ae54f288857d7190cc24095_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:LicensedProductOrProcessForVaginalOrUrologicalUseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96570265e6d94bafb524501622be0afa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52d0dedfaf874adfb961664b9bce5b92_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id84a19a7b61f49aab03e5421a920942c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45bf9ce3d7014dd4a8cc904a8d6fdfe3_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24bd5f0c2d834a5386e1ac19b19670c4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:HammockPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3040a789d9a4c049500fc9df1a161d5_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:HammockPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie890f0c1b2d94ab1b54648bda60c9b9e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4e5b11922fb45baae7deef39cf719d8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id40ce46b765846a5aa2e57368b8b8e2e_D20170301-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cba105a870f4df89d49f7bf4d41b3b3_D20170301-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2502d37404a542acb2be44f30462a6db_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c82657d880d4e1fa411c307e0109b6c_D20170301-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:UponReachingCertainWorldwideNetSalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33b5825a9b744e5d8bdf4464e25fdeca_D20170301-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i2c11228dbbd544df9e87f818ade25d08_D20170301-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4370da4fa5342028ed801f0a9fa0408_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic670d6c2f83e480aaccaa11002b3fd82_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaac673f0f7dd48318f3456c2bd5051e6_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e73b75602364a808872b80c92bb1c3d_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88690cf0663d46c2a1f6398cdafd4e30_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6e9a4923f614a9492dd0238e4cca80f_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic39a296e2a1e45a29ed3a2a13c728ab9_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18e026cd749c470d865e295625b2d49f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:CatalentAndMilanaPharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i130fa20b36a240b182234edcc27974bf_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:CatalentAndMilanaPharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05dcf861082b438c816582ce5fd7e46e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:CatalentAndMilanaPharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb8485972ede4668ac56f750cad9b2ea_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:SalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0d7024baebb42f3921f362b71af0807_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9429fbf089249aeb34b9943fccfb3aa_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4550db8657fb446599597be07760a4e9_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id246537752c543dc90f3ce1157fa81db_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4871de07797e4ead9c91bde6f6f1da64_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0088c2d5b3d841d79733a7ba7eb77c3f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id046ca48ded64152a085f277ffdbdbd8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b39b4e982ff415dacb98beb58f1a039_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e1024a3a3274602a0b50c48b9aa2f4a_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8375b393afa24fd4b4172cd82f83fced_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i027223a9458b44d887cea8de9f1d3556_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:April2021AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba344274a14c460b96e230f0cbc5d2bb_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06ac362092d24b6bb3af02efaf7065e2_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:LincolnParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i860c63444c524b589d982ed7ae48fd65_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10618bb6d8c14b5885277741ae4a3091_I20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d4b21210fae4311928f3d408e82529a_I20180215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201711Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if840484cdcd14e6c9fa54cfcf591c465_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32d71d006cd64f2da751eaec03afcb7e_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b97f0e3d65145168bade1be8778dd8a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3314d2bef75a49b1a150ea0c2b067414_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea4b068280ea4864aa871809e542b4c1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc86055f4ef84234810f28d2d776d7ae_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf23d7941e8f4965a9fcb43805fcc930_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia882bdf1215042478edd6c0cd729a9d8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide7f913a931341588fd2f90818d1cee0_I20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0d3fa77cb2945be89df99f83cc05ff3_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i409dea6286e3437c8531176fdea88602_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20fdc0f111514e9491d559f7b5252a54_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if170fdedc89840ffbe1185f85069788b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bcbbadf58fc412c9319a78f2b9da62f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf2231aefe254fee96b7aeae2d91ae6e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied5f9449859d4a96a3953aabaec51ac8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29bec700eba84708bf53a7ae61f8afcc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibafd6f2e17734e039ee794c367b91ef1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia79e904977c04b448a641740a5804fd5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if248f08c609e432db641de162429b03e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6a8c036f5354223a3849ead24935854_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia70cb47052db467ab271c5cebe1a8cb5_I20180701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i10a03a7421004d2d9b8fe72bbc336117_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8152258bc79f4460a437ec7e86255593_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:MBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie288d155ad8e4f839c40e7b4157edee1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i715e356f19e949be97608ee8258262cb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa2f7c9e3aba42cea0f0485646d7bae0_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:NICHDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39725376a360492eb4ee1a813cb8c93c_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:NICHDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0417ba5df1e4483f9533526585cde1af_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:NICHDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4de0e117c45544bba3f02be2df728a46_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:CRADAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i328c1592bccd48bd90299695bcc0f38e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1668c60b90eb40c1b26a55cdec6001a8_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bda66626a774b0baba97582a51cae04_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia85f04efe0484874ad1aa6775fdee9cf_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dab52c413224c10ab210ce9f3988ef2_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREFRT1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5c7aa9a64ff4a88b42de5c106336b62_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREFRT1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18d65ffa0cea435eacda2d0f47db2080_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREPTB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a168cd74d64472ca8597b5ad0dc79dd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREPTB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33bd9119af634fbe93377ca5a92bc751_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i316cb86d094b4f0ca01c73b2980e9033_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45c466b7177d4d4c87ff8c12edc1f3ce_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaeedb8a01d9247389d7cf8d46e7e6514_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREFRT1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i010eed1efee345f4bd75243e4aa2a9c3_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie858a3b9009b46719e1b0cd4afebc54a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4385c5c549b145f4b28516d3328b7fae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3581e3652c314104b3dfff05b889fd6e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13cb5e160bd84532b3e28a94c5995894_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b95783721914c71aa6fe27dd4fcf58c_D20220401-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:ATMEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i8cc494c450e145729b0695b37b951a0a_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGV4dHJlZ2lvbjowNzRlODY5NDZjN2E0NWI2OTMwMWQ0MDk0MjNmMDFmMl8xNzMz_703bd075-3a64-4e6b-a183-e4665639897b">10-Q</ix:nonNumeric></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZGFkZTkyZmNiMTNmNGVjMzg0NzhlNDFiMzMwZTM1ZmQvdGFibGVyYW5nZTpkYWRlOTJmY2IxM2Y0ZWMzODQ3OGU0MWIzMzBlMzVmZF8wLTAtMS0xLTM3NDkx_1f42e577-c7e5-4e5a-9c3d-c1dc7d4d361b">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGV4dHJlZ2lvbjowNzRlODY5NDZjN2E0NWI2OTMwMWQ0MDk0MjNmMDFmMl8xMzE_f6ab0bc9-5bea-4617-9eab-68f29dee4a69">March 31, 2022</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center;text-indent:47.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6NTY3M2E2ZjBkYTRiNDg4YmE2NWUyY2QzOWQzZDQwOTcvdGFibGVyYW5nZTo1NjczYTZmMGRhNGI0ODhiYTY1ZTJjZDM5ZDNkNDA5N18wLTAtMS0xLTM3NDkx_1262f5d3-e265-4439-917e-da357fd597f2">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGV4dHJlZ2lvbjowNzRlODY5NDZjN2E0NWI2OTMwMWQ0MDk0MjNmMDFmMl8xMDk5NTExNjI5NTM3_4d59ef31-8c99-4c4a-8184-3806304fa183">001-36395</ix:nonNumeric></span></div><div style="text-align:center"><img src="dare-20220331_g1.jpg" alt="dare-20220331_g1.jpg" style="height:98px;margin-bottom:5pt;vertical-align:text-bottom;width:236px"/></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.994%"><tr><td style="width:1.0%"></td><td style="width:27.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl8wLTEtMS0xLTM3NDkxL3RleHRyZWdpb246ZDQzMjY3NGViYzFmNDI5MGJiMDI2NmQxYmNkYWQyZjBfNQ_a9832d2f-f750-40a6-a3bf-d89a2f9d9889">DAR&#201; BIOSCIENCE, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Exact Name of Registrant as Specified in its Charter)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl8xLTAtMS0xLTM3NDkxL3RleHRyZWdpb246YjExMTkyNjYxOGIyNDA4YTljMjM3YjZiNzIzNjg3YWZfNQ_71afc81d-9f85-402f-abec-3571bcf4f086">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or Other Jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">of Incorporation)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl8xLTItMS0xLTM3NDkxL3RleHRyZWdpb246YTRhYWNjOGViNGZlNDA4Mzg3NTUxNWNhZTRjODFkOWNfNQ_8f9abf5a-fcea-4bca-be7b-fac3cdb42c26">20-4139823</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl8zLTAtMS0xLTM3NDkxL3RleHRyZWdpb246MjYxZWRjMTM4NTdkNDBhOWIzZWE2OGZkNGMwNzRmNWVfNQ_325f1e88-d394-4052-8b69-98389f74ddca">3655 Nobel Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl8zLTAtMS0xLTM3NDkxL3RleHRyZWdpb246MjYxZWRjMTM4NTdkNDBhOWIzZWE2OGZkNGMwNzRmNWVfOQ_89c5ae3b-8b54-46e5-a4f6-1e1b2ec60e45">Suite 260</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl8zLTAtMS0xLTM3NDkxL3RleHRyZWdpb246MjYxZWRjMTM4NTdkNDBhOWIzZWE2OGZkNGMwNzRmNWVfMTI_7d5b159e-63a1-416e-934a-1e231daacc95">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl8zLTAtMS0xLTM3NDkxL3RleHRyZWdpb246MjYxZWRjMTM4NTdkNDBhOWIzZWE2OGZkNGMwNzRmNWVfMTY_dbee1c87-fd41-46ed-9261-45952f39924b">CA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl8zLTEtMS0xLTM3NDkxL3RleHRyZWdpb246NDliNjFkMzM4Mzk3NDY0NmIzNzQzMGU3YzFhNjRlOTNfNg_f7ca049d-2b8b-4643-abc1-213fff65f17a">858</ix:nonNumeric>) <ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl8zLTEtMS0xLTM3NDkxL3RleHRyZWdpb246NDliNjFkMzM4Mzk3NDY0NmIzNzQzMGU3YzFhNjRlOTNfMTA_d9238a26-75e2-4b0d-ab0b-fdf0525fcdbf">926-7655</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl8zLTItMS0xLTM3NDkxL3RleHRyZWdpb246ODgwZjIwOGE5OTJhNDI1OWE0NThlNjIwNjJhYTk2ZGFfNQ_e819e588-1d0d-4742-a579-e136074b7de2">92122</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Zip Code)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Former name, former address and former fiscal year, if changed since last report)</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl84LTAtMS0xLTM3NDkx_b1959cc3-2407-4e65-86eb-1d417833e4aa">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl84LTEtMS0xLTM3NDkx_93038d53-ef34-407e-bde7-f2b8c5f77192">DARE</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nasdaq Capital Market</span></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGV4dHJlZ2lvbjowNzRlODY5NDZjN2E0NWI2OTMwMWQ0MDk0MjNmMDFmMl8xNzM0_e2845123-8c34-4f6d-94aa-5982718af0ae">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGV4dHJlZ2lvbjowNzRlODY5NDZjN2E0NWI2OTMwMWQ0MDk0MjNmMDFmMl8xNzM1_2a62144e-5722-48ea-abe5-3613cfa2b78e">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6NzI5MzRlZGUxYTEzNDJkY2EwZWRlMjU3NTkyMmNiZjgvdGFibGVyYW5nZTo3MjkzNGVkZTFhMTM0MmRjYTBlZGUyNTc1OTIyY2JmOF8xLTAtMS0xLTM3NDkx_48c446fd-5c6d-448b-b6ce-99ab028cefce">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6NzI5MzRlZGUxYTEzNDJkY2EwZWRlMjU3NTkyMmNiZjgvdGFibGVyYW5nZTo3MjkzNGVkZTFhMTM0MmRjYTBlZGUyNTc1OTIyY2JmOF8xLTUtMS0xLTM3NDkx_1ad42086-90c3-4d1e-979a-2be5e3976475">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6NzI5MzRlZGUxYTEzNDJkY2EwZWRlMjU3NTkyMmNiZjgvdGFibGVyYW5nZTo3MjkzNGVkZTFhMTM0MmRjYTBlZGUyNTc1OTIyY2JmOF8yLTItMS0xLTM3NDkx_248cc766-7071-4459-908f-43bebf898914">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o </span></div><div style="margin-top:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGV4dHJlZ2lvbjowNzRlODY5NDZjN2E0NWI2OTMwMWQ0MDk0MjNmMDFmMl8xNzMy_2bdc0a09-45c6-4a1c-b13c-1d23209fa0bc">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x </span></div><div style="margin-top:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of May&#160;10, 2022, <ix:nonFraction unitRef="shares" contextRef="i94263204e2654add81cafbf53b703aaf_I20220510" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGV4dHJlZ2lvbjowNzRlODY5NDZjN2E0NWI2OTMwMWQ0MDk0MjNmMDFmMl8xNjQw_2ade7488-d291-4d16-b7e1-b2647ff87056">84,711,346</ix:nonFraction> shares of the Registrant&#8217;s Common Stock, par value $0.0001, were issued and outstanding.</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i8cc494c450e145729b0695b37b951a0a_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q, in particular &#8220;Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations,&#8221; of Part I. Financial Information, and the information incorporated by reference herein contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this report, including statements regarding our strategy, future operations, future financial position, projected revenue, funding and expenses, prospects, plans and objectives of management, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;design,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;could,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; "pursue," &#8220;should,&#8221; &#8220;would,&#8221; &#8220;contemplate,&#8221; "project,&#8221; &#8220;target,&#8221; &#8220;tend to,&#8221; or the negative version of these words and similar expressions.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including those factors described in Part II, Item 1A, "Risk Factors", in this report, and elsewhere in this report. Given these uncertainties, you should not place undue reliance on any forward-looking statement. The following factors are among those that may cause such differences:</span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to raise additional capital, under favorable terms or at all, and continue as a going concern;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to complete development of our product candidates, submit and obtain United States Food and Drug Administration, or FDA, or foreign regulatory authority approval and commercialize our products candidates on projected timelines or budgets, or at all; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to demonstrate sufficient safety and efficacy of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">The ability of third parties on which we rely to timely supply and manufacture our commercial product and our clinical trial supplies, including their components as well as the finished product, in the quantities needed in accordance with current good manufacturing practices, our specifications and other applicable requirements;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">The performance of third parties on which we rely to conduct nonclinical studies and clinical trials of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">The terms and conditions of our strategic collaborations, including our out-license agreements for commercialization of XACIATO&#8482; and Ovaprene&#174;;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">A decision by a commercial collaborator to discontinue its interest in our product or product candidate or to terminate our license agreement, or the failure of such license agreement to become fully effective;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">The performance of third parties on which we rely to commercialize, or assist us in commercializing, XACIATO and any future product;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Difficulties with establishing and maintaining collaborations relating to the development and/or commercialization of our product candidates on a timely basis or on acceptable terms, or at all;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Our loss of, or inability to attract, key personnel;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">The degree of market acceptance that XACIATO and any future product achieves;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Coverage and reimbursement levels for XACIATO and any future product by government health care programs, private health insurance companies and other third-party payors;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">A change in the FDA's prior determination that the Center for Devices and Radiological Health would lead the review of a premarket application for potential marketing approval of Ovaprene;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">A change in regulatory requirements for our product candidates, including the development pathway pursuant to Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or the FDA's 505(b)(2) pathway;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Unsuccessful clinical trial outcomes stemming from clinical trial designs, failure to enroll a sufficient number of patients, higher than anticipated patient dropout rates, failure to meet established clinical endpoints, undesirable side effects and other safety concerns;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Adverse differences between preliminary, interim or topline clinical study data reported by us and final study results;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Communication from the FDA or another regulatory authority, including a complete response letter, that it does not accept or agree with our assumptions, estimates, calculations, conclusions or analyses of clinical or nonclinical study data regarding a product candidate, or that it interprets or weighs the importance of study data differently than we have in a manner that negatively impacts the candidate's prospects for regulatory approval in a timely manner, or at all;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to monetize our portfolio candidates through licenses, partnerships or other types of commercialization agreements, or on our own;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to select product candidates that capitalize on the most scientifically, clinically or commercially promising or profitable indications or therapeutic areas within women's health including due to our limited financial resources;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Loss or impairment of our in-licensed rights to develop and commercialize XACIATO and our product candidates ;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Our payment and other obligations under our in-license and acquisition agreements for XACIATO and our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Developments by our competitors that make XACIATO or any potential product less competitive or obsolete;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of the macroeconomic conditions, geopolitical events, the COVID-19 pandemic and any future pandemic, epidemic, or similar public health threat or natural disasters on our business, operations and financial condition, or on those of third parties on which we rely;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cyber-attacks, security breaches or similar events compromising our technology systems or the technology systems of third parties on which we rely;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Difficulty in introducing branded products in a market made up of generic products;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to adequately protect or enforce our, or our licensor&#8217;s, intellectual property rights;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Lack of patent protection for the active ingredients in XACIATO and certain of our product candidates that expose those product candidates to competition from other formulations using the same active ingredients; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Higher risk of failure associated with product candidates in pre-clinical stages of development that may lead investors to assign them little to no value and make these assets difficult to fund;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dependence on grant funding for pre-clinical development of DARE-LARC1;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Disputes or other developments concerning our intellectual property rights;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Actual and anticipated fluctuations in our quarterly or annual operating results or that differ from investors' expectations for such results;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Price and volume fluctuations in the stock market, and in our stock in particular, which could cause investors to experience losses and subject us to securities class-action litigation;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to maintain the listing of our common stock on the Nasdaq Capital Market or another nationally recognized exchange;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Development of unexpected safety concerns related to our product or product candidates, or third-party products or product candidates that share similar characteristics or drug substances;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Product liability claims or governmental investigations;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Strict government regulations on our business, including various fraud and abuse laws, including, without limitation, the U.S. federal Anti-Kickback Statute, the U.S. federal False Claims Act and the U.S. Foreign Corrupt Practices Act;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Regulations governing the production or marketing of XACIATO and any future products; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Increased costs as a result of operating as a public company, and substantial time devoted by our management to compliance initiatives and corporate governance practices.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">All forward-looking statements in this report are current only as of the date of this report. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any statement is made or to reflect the occurrence of unanticipated events, except as required by law.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i8cc494c450e145729b0695b37b951a0a_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_13">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_16">Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_13">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_67">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_67">22</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_91">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_91">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_94">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_94">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_97">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_100">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_100">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_103">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_103">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_106">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_106">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_109">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_109">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_112">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_112">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_115">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_115">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_118">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_118">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_121">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8cc494c450e145729b0695b37b951a0a_121">37</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i8cc494c450e145729b0695b37b951a0a_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I.&#160;&#160;&#160;&#160;FINANCIAL INFORMATION</span></div><div id="i8cc494c450e145729b0695b37b951a0a_16"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-top:10pt"><span><br/></span></div><div id="i8cc494c450e145729b0695b37b951a0a_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dar&#233; Bioscience, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfNC0xLTEtMS0zNzQ5MQ_c8c01a90-95bf-4a5e-a4fc-18aeaac2b4c1">39,316,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfNC0zLTEtMS0zNzQ5MQ_3b526d9a-66a7-4e52-aa82-0b08a92d9bb6">51,674,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfNS0xLTEtMS0zNzQ5MQ_cdd0ef99-750f-4d57-82cc-675bdbffae71">1,729,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfNS0zLTEtMS0zNzQ5MQ_b31a78a9-d8ff-43fb-b92b-eb493aa087a0">1,145,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfNi0xLTEtMS0zNzQ5MQ_384b8a3d-5e47-42b2-a23b-aabd6167b3a0">6,770,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfNi0zLTEtMS0zNzQ5MQ_666d65ac-82b3-4be4-89a7-e1d91c0d3553">2,476,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfOC0xLTEtMS0zNzQ5MQ_0dd4ee5d-16a6-4e69-b51b-e00ae57d6a2b">47,817,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfOC0zLTEtMS0zNzQ5MQ_5835f1ce-47b8-4cd4-96e1-ca2ba7a53e2d">55,296,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfOS0xLTEtMS0zNzQ5MQ_2dc1f59d-ea8b-40f4-87fd-602f6d28bd6d">25,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfOS0zLTEtMS0zNzQ5MQ_913d4633-b1e3-4123-9473-716370a010a9">26,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMTEtMS0xLTEtMzc0OTE_424cac2b-aced-47f4-b74c-f4c41ea412bf">1,344,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMTEtMy0xLTEtMzc0OTE_2b82380e-af02-4109-af34-02d433edf63f">485,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMTItMS0xLTEtMzc0OTE_0109c0c5-bec1-4f6a-bd71-b96bdff2ffdc">49,186,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMTItMy0xLTEtMzc0OTE_c6a0ba0b-8e1c-4106-b0ea-9c3ec20aa907">55,807,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMTUtMS0xLTEtMzc0OTE_eb4a44d2-e72e-437b-a090-4d5386f0a0b9">2,830,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMTUtMy0xLTEtMzc0OTE_9891d66a-0c2c-4ced-bfcc-81d91e19aac6">2,103,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMTYtMS0xLTEtMzc0OTE_2d3699a6-fddb-47a7-8e92-b6d2ee35ca6e">3,537,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMTYtMy0xLTEtMzc0OTE_9f0311f1-85de-4ba0-843d-68728bb84935">3,136,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred grant funding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="dare:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMTctMS0xLTEtMzc0OTE_0a286aff-187d-455c-9d9d-d56fd451a930">9,731,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="dare:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMTctMy0xLTEtMzc0OTE_f8f4bf63-a804-485a-abb5-94164429ed78">10,542,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjAtMS0xLTEtMzc0OTE_924307de-c9a2-4350-8062-2f862c4316e9">294,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjAtMy0xLTEtMzc0OTE_a97f6a44-b62f-490b-8785-dbc0fd88d251">270,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjEtMS0xLTEtMzc0OTE_9d045794-bc91-46c1-a5ab-2930f49a59a4">16,394,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjEtMy0xLTEtMzc0OTE_942b8f42-414a-4cf1-ab4a-4153fd0e5d8d">16,052,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred license revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjItMS0xLTEtMzc0OTE_1c138e18-8752-4180-92e4-7cfc17b8bee3">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjItMy0xLTEtMzc0OTE_7602a92c-f56e-402c-a2c6-008eb29f6a21">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjQtMS0xLTEtMzc0OTE_aa56631a-aaa8-42a3-a139-5ea2cdca1723">913,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjQtMy0xLTEtMzc0OTE_e6342501-e7ee-43af-8ded-45ada8e2e2ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjUtMS0xLTEtMzc0OTE_7064301a-6110-4779-a7b1-805f564d9de9">18,307,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjUtMy0xLTEtMzc0OTE_fed555a4-46f8-45d2-943e-324b4aedd794">17,052,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjYtMS0xLTEtMzc0OTE_31ca97e9-b3f0-4804-9a7f-e53ad7af906d"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjYtMy0xLTEtMzc0OTE_96b20822-dd6e-47f9-b008-e200bfd12fb1"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjgtMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1YTFjYzQyOGNmNzU0MGNjOGU0MjhiMjE2MTM1MDIzNl8yMQ_2f014e27-e8f3-4f34-8d7a-769c1db5fb9f"><ix:nonFraction unitRef="usdPerShare" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjgtMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1YTFjYzQyOGNmNzU0MGNjOGU0MjhiMjE2MTM1MDIzNl8yMQ_9277fed5-75df-4333-a8d4-ee717272be7b">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjgtMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1YTFjYzQyOGNmNzU0MGNjOGU0MjhiMjE2MTM1MDIzNl8zNQ_65280670-4943-4685-82e2-8de0f65f0065"><ix:nonFraction unitRef="shares" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjgtMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1YTFjYzQyOGNmNzU0MGNjOGU0MjhiMjE2MTM1MDIzNl8zNQ_6b6662c1-42b3-49b9-8643-2acbf4c513b0">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjgtMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1YTFjYzQyOGNmNzU0MGNjOGU0MjhiMjE2MTM1MDIzNl81Nw_0f2d01d0-22c0-49f3-97eb-7f9e810d747a"><ix:nonFraction unitRef="shares" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjgtMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1YTFjYzQyOGNmNzU0MGNjOGU0MjhiMjE2MTM1MDIzNl81Nw_37c90d13-ce05-4da4-91a0-af13018a2da2"><ix:nonFraction unitRef="shares" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjgtMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1YTFjYzQyOGNmNzU0MGNjOGU0MjhiMjE2MTM1MDIzNl81Nw_5f2e1bc9-b544-4474-a9b6-bb559e1b0325"><ix:nonFraction unitRef="shares" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjgtMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1YTFjYzQyOGNmNzU0MGNjOGU0MjhiMjE2MTM1MDIzNl81Nw_92d6868f-8266-4866-b167-abf33a1f6623">None</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjgtMS0xLTEtMzc0OTE_64da2957-5c42-4760-9670-b65dd7e95929">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjgtMy0xLTEtMzc0OTE_7381e110-6c8e-4cba-9b7f-4ac5fd44e6f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjktMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1NDgwMzRkOTllMjI0OGFlYjg5Y2EzZGJlMDgyNTExM18xOA_69ad7aea-81c3-4b79-b9d0-e7859ef54e75"><ix:nonFraction unitRef="usdPerShare" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjktMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1NDgwMzRkOTllMjI0OGFlYjg5Y2EzZGJlMDgyNTExM18xOA_b6dec743-ed02-4527-8a3c-575ebc569f06">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjktMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1NDgwMzRkOTllMjI0OGFlYjg5Y2EzZGJlMDgyNTExM18zMg_9a1fff98-fbca-4ff2-aff5-b4b6c0e7c012"><ix:nonFraction unitRef="shares" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjktMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1NDgwMzRkOTllMjI0OGFlYjg5Y2EzZGJlMDgyNTExM18zMg_9c74f87d-ec6d-4555-9a83-c752d9737a4b">120,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjktMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1NDgwMzRkOTllMjI0OGFlYjg5Y2EzZGJlMDgyNTExM181NA_4baa8c6a-ee6b-4511-8fc4-61906d21674a"><ix:nonFraction unitRef="shares" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjktMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1NDgwMzRkOTllMjI0OGFlYjg5Y2EzZGJlMDgyNTExM181NA_ba3b518c-57a4-4afb-b6fb-12bcf73fc70b"><ix:nonFraction unitRef="shares" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjktMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1NDgwMzRkOTllMjI0OGFlYjg5Y2EzZGJlMDgyNTExM181NA_f66c1c94-a033-4568-b41e-9766dc6a1efc"><ix:nonFraction unitRef="shares" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjktMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1NDgwMzRkOTllMjI0OGFlYjg5Y2EzZGJlMDgyNTExM181NA_f918e475-42ad-42f2-b655-843ef2cf18c1">83,944,119</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2022 and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjktMS0xLTEtMzc0OTE_d9b1ab0c-7c49-406d-80ba-05d86f283652">8,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjktMy0xLTEtMzc0OTE_e430e126-bd32-4c52-8a79-6c57bde73565">8,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMzAtMS0xLTEtMzc0OTE_a80bf04b-1c30-452b-b926-299f00de779e">164,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMzAtMy0xLTEtMzc0OTE_2cbb52c8-0f94-4893-aaed-b2c66a183244">154,973</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMzEtMS0xLTEtMzc0OTE_5401a489-37b7-4be1-8ce5-629051cf99c3">149,560,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMzEtMy0xLTEtMzc0OTE_87fc7de8-05ef-45aa-aa34-fa1459c6f726">149,027,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMzItMS0xLTEtMzc0OTE_b804c9fa-efa7-4609-9640-20395dd0c19f">118,525,572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMzItMy0xLTEtMzc0OTE_a447a3fe-cd25-4f70-84b1-303235aca578">110,126,902</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMzMtMS0xLTEtMzc0OTE_9354dda9-789c-44fc-ba2c-b50010b49f2b">30,878,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMzMtMy0xLTEtMzc0OTE_6bb8f9bf-3e35-485c-b365-730daff83f50">38,754,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMzQtMS0xLTEtMzc0OTE_f1f76730-b37b-40f4-add2-e70a3f33c004">49,186,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMzQtMy0xLTEtMzc0OTE_dcb4af6a-9e22-4190-bfff-0cb714c1e77b">55,807,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:13pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i8cc494c450e145729b0695b37b951a0a_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dar&#233; Bioscience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.125%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMy0xLTEtMS0zNzQ5MQ_66e7e68b-da0e-4e8a-ada6-62f318ee783b">2,569,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMy0zLTEtMS0zNzQ5MQ_b09457a3-75e5-4abc-8d70-7c346cf8d669">1,940,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfNC0xLTEtMS0zNzQ5MQ_1f4a7244-5f16-4e42-a7c3-b649128c6d9f">5,805,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfNC0zLTEtMS0zNzQ5MQ_0a385fdd-316f-4fd9-bc07-64c893ac3b2b">5,728,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="dare:LicenseFee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfNS0xLTEtMS0zNzQ5MQ_8cefbc49-0e27-43d5-820c-3083464c83d3">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="dare:LicenseFee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfNS0zLTEtMS0zNzQ5MQ_356a4d13-648f-4802-ae77-7ce289a11d06">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfNi0xLTEtMS0zNzQ5MQ_1095b15e-8fd5-44a5-8848-22703a571d46">8,400,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfNi0zLTEtMS0zNzQ5MQ_ab525eaf-f8de-4f19-ac2d-7184c1a90acb">7,693,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfNy0xLTEtMS0zNzQ5MQ_4069f23f-8b00-426a-aae8-1c23b5763cf6">8,400,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfNy0zLTEtMS0zNzQ5MQ_280944aa-e18e-454e-b5da-1188a34d72c0">7,693,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfOC0xLTEtMS0zNzQ5MQ_fc7eea8d-c956-4341-8eda-2e03a3d1ccd7">1,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfOC0zLTEtMS0zNzQ5MQ_f8d07b13-97e5-49a8-bb2b-972ca2bf501a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on extinguishment of note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfOS0xLTEtMS0zNzQ5MQ_9de197d0-075f-4fd3-b3bb-ab98bbfd415d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfOS0zLTEtMS0zNzQ5MQ_54a7550d-8956-4ff8-b81c-487f44ab7f6c">369,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTAtMS0xLTEtMzc0OTE_e6860b9b-deab-472b-aeee-87994e7c62da">8,398,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTAtMy0xLTEtMzc0OTE_473c0c2d-888d-4183-abc5-eca12d29704f">7,323,644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTMtMS0xLTEtMzc0OTE_82760853-40dd-47c2-a8b7-998f6dc3a596">9,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTMtMy0xLTEtMzc0OTE_d6e8c6ba-756a-496f-84d6-661da9ebc145">6,841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTQtMS0xLTEtMzc0OTE_a88a3b0e-a2ab-4425-98b1-d9224be437f5">8,407,820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTQtMy0xLTEtMzc0OTE_f8f94d49-09c2-4a15-9e07-ce16a073030f">7,330,485</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per common share - basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTUtMS0xLTEtMzc0OTE_0b236db2-895e-4a29-809a-32e78eaa6d89"><ix:nonFraction unitRef="usdPerShare" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTUtMS0xLTEtMzc0OTE_4a56e04e-af3b-4f56-be8e-51b5db1efdc6">0.10</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTUtMy0xLTEtMzc0OTE_805ebb27-d52c-4f4a-8890-b33e388f26c4"><ix:nonFraction unitRef="usdPerShare" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTUtMy0xLTEtMzc0OTE_a7e58472-a609-4f59-abd4-c0d0f39527b4">0.16</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTctMS0xLTEtMzc0OTE_15a2d933-3fbd-4e92-bcbe-c9f7d5465f1e"><ix:nonFraction unitRef="shares" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTctMS0xLTEtMzc0OTE_434c5638-1214-4500-a7bd-b5bc35eb0389">83,944,119</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTctMy0xLTEtMzc0OTE_0a63dd9b-fe0d-4c96-98c6-f18d11551ac7"><ix:nonFraction unitRef="shares" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTctMy0xLTEtMzc0OTE_8469daf9-57fd-4c5a-8ed0-a089b0532ba6">44,502,582</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i8cc494c450e145729b0695b37b951a0a_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dar&#233; Bioscience, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.491%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.224%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">comprehensive</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">stockholders'</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">equity</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida978f25ba59408b9386363eb6d6eed4_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfNC0xLTEtMS0zNzQ5MQ_67418d7f-dbb3-4b31-a01d-4b6c87be8951">83,944,119</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida978f25ba59408b9386363eb6d6eed4_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfNC0zLTEtMS0zNzQ5MQ_1ed3d349-f700-462b-81af-6a9f8aeaeb88">8,394</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b251f7c118549ba9202433ab6104a64_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfNC01LTEtMS0zNzQ5MQ_10f0e4b2-e887-4c5a-9442-672c26008da9">149,027,802</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a512d483cf43099a491a6ccc8400a1_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfNC03LTEtMS0zNzQ5MQ_d34e9f54-1a36-46fc-b7d9-086143973797">154,973</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3bd3370ad994990ad0bd8c17e41e612_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfNC05LTEtMS0zNzQ5MQ_5f0f516b-c768-4f4e-b743-cbc01bb7787b">110,126,902</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfNC0xMS0xLTEtMzc0OTE_f68c52b4-2836-4aa2-b6c0-c44a09609574">38,754,321</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a6b1d8921a4c34b493ef15f6ac3565_D20220101-20220331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfNS01LTEtMS0zNzQ5MQ_e24bb004-36b4-4eed-9580-0fa76afcbeb1">532,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfNS0xMS0xLTEtMzc0OTE_903064b4-c9c3-4696-b8c5-fda42a529c13">532,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdccf0de4054bd5be8b8f6ca8068dcd_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfOS05LTEtMS0zNzQ5MQ_21a1b6d2-3e52-45f1-a651-4c05002bdb44">8,398,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfOS0xMS0xLTEtMzc0OTE_a6a1353a-0693-440b-a3f3-dae6920c2efe">8,398,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifba16de9b31d4bb4b84e89fdde96c11f_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfMTAtNy0xLTEtMzc0OTE_fd655f3c-4b28-41f3-98d5-162c8d5815ef">9,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfMTAtMTEtMS0xLTM3NDkx_c017ba73-2f7f-4cee-bb50-4180bb49da47">9,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3a6c19246dbd43918fe1d5bdaf45781d_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfMTEtMS0xLTEtMzc0OTE_06bea791-8ac5-410d-910e-85f877081634">83,944,119</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a6c19246dbd43918fe1d5bdaf45781d_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfMTEtMy0xLTEtMzc0OTE_9a696a6c-37ba-454f-9f4d-8fb152202e5e">8,394</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00586b33add54084bb2dbf880a0f3571_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfMTEtNS0xLTEtMzc0OTE_f1da40d3-af70-45d5-80d4-02aa5e527fa5">149,560,211</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i923566bd281646fdb2dc3656b54543af_I20220331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfMTEtNy0xLTEtMzc0OTE_8828a802-f419-4de0-88ca-ff31caf167e5">164,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ccd4e062a2e4af6bc25a6f55d4bbc88_I20220331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfMTEtOS0xLTEtMzc0OTE_a3792f30-9698-4f2d-b5b0-51445e8ff0b9">118,525,572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfMTEtMTEtMS0xLTM3NDkx_e3610e3e-edc5-48ff-a310-6dfb288f8a25">30,878,910</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.579%"><tr><td style="width:1.0%"></td><td style="width:26.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.916%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.276%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">comprehensive</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">stockholders'</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">equity</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6063f716c8274a639d5c2235427b50d2_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNC0xLTEtMS0zODYzNA_725fc3eb-1313-48bd-a705-9f88d789d9ff">41,596,253</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6063f716c8274a639d5c2235427b50d2_I20201231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNC0zLTEtMS0zODYzNA_b0c8f544-1164-4a22-be8e-ac967372b20e">4,159</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66dc24f087884625adfebe658a8e451b_I20201231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNC01LTEtMS0zODYzNA_6b352569-a208-4ee4-85cd-73104cec47c2">70,366,293</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d33e15987224e8e864a9bb0d4e41246_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNC03LTEtMS0zODYzNA_bc131462-70a3-4bfe-b9ca-d340920e2031">91,388</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie18313b3160d472981c6193072f6baa5_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNC05LTEtMS0zODYzNA_ffb9f334-2652-4f70-8451-2574ef82039c">71,430,797</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0526bb23c864be7babc6b325d2ae2b3_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNC0xMS0xLTEtMzg2MzQ_a388f2d4-9409-4862-b8e5-34694e74732e">1,151,733</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b399c6925442f9bf8bab14218dd545_D20210101-20210331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNC01LTEtMS0zNzQ5MQ_3905931a-d811-44ea-97b6-edcc8fb7f271">365,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNC0xMS0xLTEtMzc0OTE_f1239863-5158-40eb-9dc0-204b1c45288b">365,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11c9582a92634557be12814380daffe8_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNS0xLTEtMS0zNzQ5MQ_13ef03ad-2814-4e4e-bfd3-82de826955cf">5,664,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c9582a92634557be12814380daffe8_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNS0zLTEtMS0zNzQ5MQ_7cdff880-4548-46d4-b745-56ce0f519518">567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b399c6925442f9bf8bab14218dd545_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNS01LTEtMS0zNzQ5MQ_f679ef95-c046-4db7-a38a-bbb49fdc0277">11,323,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNS0xMS0xLTEtMzc0OTE_41ec0559-b58b-4c6a-98fc-d90db651b21a">11,324,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock from the exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11c9582a92634557be12814380daffe8_D20210101-20210331" decimals="INF" name="dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNi0xLTEtMS0zNzQ5MQ_9818e075-b479-43ca-b370-7432e66ec678">52,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c9582a92634557be12814380daffe8_D20210101-20210331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNi0zLTEtMS0zNzQ5MQ_03a4f1cd-f50b-4398-8e34-94b61269cf48">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b399c6925442f9bf8bab14218dd545_D20210101-20210331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNi01LTEtMS0zNzQ5MQ_44377aea-cc57-433d-bed1-29798127e71a">50,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNi0xMS0xLTEtMzc0OTE_d2203bf2-bf54-4c44-a465-eae021a47961">50,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7777562075814792bdb540658b8e6a06_D20210101-20210331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNy05LTEtMS0zNzQ5MQ_6b911e74-fdb0-4caa-b261-019c8c7e00f0">7,323,644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNy0xMS0xLTEtMzc0OTE_1e34c5d7-ab9e-4521-9235-8d00658921ce">7,323,644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7234840ac886468bb69f5d05bd2db206_D20210101-20210331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfOS03LTEtMS0zNzQ5MQ_e6713c87-2362-4d9b-b3a3-fefa43a14729">6,841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfOS0xMS0xLTEtMzc0OTE_68b26f12-01eb-4824-b1c8-e60b74e37de4">6,841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91f25005c087421eab865393d5efc0bc_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfMTAtMS0xLTEtMzc0OTE_399b349d-ae27-48fd-a9c1-6080722665cc">47,312,822</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91f25005c087421eab865393d5efc0bc_I20210331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfMTAtMy0xLTEtMzc0OTE_ae6a20ec-6048-4a51-bf9b-a137c333bc4e">4,731</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70732a14fa594410af98fbfbbfc49572_I20210331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfMTAtNS0xLTEtMzc0OTE_6d6bd0b4-3b62-43f0-826e-59b49912665a">82,106,172</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20c398f1df046b288658ed72f3fea03_I20210331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfMTAtNy0xLTEtMzc0OTE_9e0e0583-84cc-4b19-9b93-4fdb2710f692">98,229</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68e625c64183408d9d544a2b64fc1d4a_I20210331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfMTAtOS0xLTEtMzc0OTE_cc6defa6-85f4-4c93-9ced-742718e4b3f0">78,754,441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab03b72e1c442f393d5f68da2cd04dc_I20210331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfMTAtMTEtMS0xLTM3NDkx_5e15910e-be25-4c5e-bffc-8e550581027a">3,258,233</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i8cc494c450e145729b0695b37b951a0a_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dar&#233; Bioscience, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMy0xLTEtMS0zNzQ5MQ_bf8658ac-af77-46b4-99e9-0ec9dc54315e">8,398,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMy0zLTEtMS0zNzQ5MQ_f6593161-ad39-4577-95a5-de138d4da871">7,323,644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfNS0xLTEtMS0zNzQ5MQ_10712a74-87e1-48a3-bfff-45b8bb5d0c2f">5,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfNS0zLTEtMS0zNzQ5MQ_35830973-bb9b-405d-824b-11e6ba8cc95d">6,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfNi0xLTEtMS0zNzQ5MQ_653f6193-8dcf-4d70-b300-f71f3f975970">532,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfNi0zLTEtMS0zNzQ5MQ_74a674ae-7c63-49e9-8ef1-3a7fec4c1a5c">365,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash operating lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" sign="-" name="dare:NonCashLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfNy0xLTEtMS0zNzQ5MQ_1105b432-3923-4df5-8565-76a6cc63faa7">9,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" sign="-" name="dare:NonCashLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfNy0zLTEtMS0zNzQ5MQ_aff36155-16c1-455d-8d9b-ed525d9e2d17">24,224</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on extinguishment of notes payable and accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfOS0xLTEtMS0zNzQ5MQ_b6e6d6a1-bb52-4629-ae58-fbfc58fd8db8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfOS0zLTEtMS0zNzQ5MQ_50b12372-256b-4060-b1c7-45b63cf86c26">369,887</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTEtMS0xLTEtMzc0OTE_5999d859-7a10-44ef-b44d-7155714fcfb2">584,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTEtMy0xLTEtMzc0OTE_2e808ad4-459e-4b16-9680-411c02b6ed6e">158,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTItMS0xLTEtMzc0OTE_4ca15624-2c6f-4f52-8103-443f4ac3b834">4,293,814</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTItMy0xLTEtMzc0OTE_d396c580-50bd-4ab9-bcda-358ac0d2b4d9">217,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" sign="-" name="dare:IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTQtMS0xLTEtMzc0OTE_42aa408d-c7b1-4567-8ee9-4b9b93249d51">87,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="dare:IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTQtMy0xLTEtMzc0OTE_252eb7ff-686a-4ad0-894f-1aeff3efe709">128,086</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTUtMS0xLTEtMzc0OTE_184cd36e-ac40-4821-a36f-4784535b3462">727,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTUtMy0xLTEtMzc0OTE_a754b62d-6449-4607-85a1-cb82ec3d3cbb">450,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTYtMS0xLTEtMzc0OTE_a7ce3c43-8aae-4cbf-9e73-f824a2b78259">401,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTYtMy0xLTEtMzc0OTE_b036ac00-3705-4b08-8f87-f24c9a577de3">837,191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred grant funding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="dare:IncreaseDecreaseInDeferredGrantFunding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTctMS0xLTEtMzc0OTE_cdd73bb2-9784-40a0-94dc-4ba481fce65a">811,620</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="dare:IncreaseDecreaseInDeferredGrantFunding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTctMy0xLTEtMzc0OTE_b205b2e6-8c2d-49e9-a8c3-bf024d7eb060">892,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTktMS0xLTEtMzc0OTE_8400c6bd-239b-4fc2-9ddf-81f7d52e8043">12,343,473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTktMy0xLTEtMzc0OTE_70d31648-c5fa-4277-b612-2474bde893d2">8,377,015</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjEtMS0xLTEtMzc0OTE_b36408ff-ff3d-4115-8116-9d4c36f3b9b6">4,553</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjEtMy0xLTEtMzc0OTE_c950e68e-2e19-478b-8b24-6857999fae6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjItMS0xLTEtMzc0OTE_0beb9ffe-beb3-4a61-9246-20ef5accefe4">4,553</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjItMy0xLTEtMzc0OTE_0513c638-098b-4073-bcd0-913590648d2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="dare:NetProceedsFromIssuanceOfCommonStockAndWarrants" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjQtMS0xLTEtMzc0OTE_c071cd33-34f3-41e9-a51a-2714f8d9c703">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="dare:NetProceedsFromIssuanceOfCommonStockAndWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjQtMy0xLTEtMzc0OTE_42bc697f-822c-4a3a-858e-f5878554f030">11,324,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="dare:ProceedsFromIssuanceOfCommonStockAndWarrants" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjUtMS0xLTEtMzc0OTE_c8255b0b-0f81-4085-a7e3-def01fe469a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="dare:ProceedsFromIssuanceOfCommonStockAndWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjUtMy0xLTEtMzc0OTE_44a33c88-5383-4504-ad75-08e5d8ea6ae5">50,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjgtMS0xLTEtMzc0OTE_279b1dbb-2f9e-4ed8-b96a-1a380742b6e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjgtMy0xLTEtMzc0OTE_36f0d40b-f312-4539-b7bc-c594bff73323">11,374,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjktMS0xLTEtMzc0OTE_ba149b16-57dd-41b9-9ea0-6c0e5c0f6e6d">9,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjktMy0xLTEtMzc0OTE_599ef1fb-70ed-4792-8b20-678b64147c3e">6,841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMzAtMS0xLTEtMzc0OTE_c9db7134-663d-48c5-ae4e-a8b324dc99ae">12,357,176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMzAtMy0xLTEtMzc0OTE_35eac2c4-e836-4439-9136-3877eb8238b4">2,990,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMzEtMS0xLTEtMzc0OTE_14fe3530-ed38-4793-b864-692083793f3b">51,674,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0526bb23c864be7babc6b325d2ae2b3_I20201231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMzEtMy0xLTEtMzc0OTE_8581a302-9fe8-4b96-aa07-11ddaf3a9ae1">4,669,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMzItMS0xLTEtMzc0OTE_c586b08b-da42-4504-8e4b-c38633e98028">39,316,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab03b72e1c442f393d5f68da2cd04dc_I20210331" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMzItMy0xLTEtMzc0OTE_fd2b3b9b-9f90-42cc-8424-776b1189f394">7,660,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forgiveness of Paycheck Protection Program note payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="dare:ForgivenessOfPaycheckProtectionProgramNotePayable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMzMtMS0xLTEtMzg3MzQ_e5d9d136-9213-449f-ac6b-3481f79bbefa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="dare:ForgivenessOfPaycheckProtectionProgramNotePayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMzMtMy0xLTEtMzg3MzQ_e3ff3d3b-7e0b-42bf-a9c3-99402062b192">369,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMzQtMS0xLTEtMzc0OTE_96cf839f-4924-4909-baf3-76b57dec546f">1,043,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMzQtMy0xLTEtMzc0OTE_762906c7-daac-4ef3-82b5-3a14291c59d5">308,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i8cc494c450e145729b0695b37b951a0a_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dar&#233; Bioscience, Inc. and Subsidiaries</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div id="i8cc494c450e145729b0695b37b951a0a_34"></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNC9mcmFnOmJkYWQzNmVkZDE5MDQ0OWFiNmEyYzk0MTBmMTk2OThjL3RleHRyZWdpb246YmRhZDM2ZWRkMTkwNDQ5YWI2YTJjOTQxMGYxOTY5OGNfMTQ5MDM_c820155c-4e31-4a53-9a1d-0e7cc750555c" continuedAt="icf0b7e69b90140549684b6409e99c48a" escape="true">ORGANIZATION AND DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="icf0b7e69b90140549684b6409e99c48a"><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dar&#233; Bioscience, Inc. is a biopharmaceutical company committed to advancing innovative products for women&#8217;s health. Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries operate <ix:nonFraction unitRef="segment" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNC9mcmFnOmJkYWQzNmVkZDE5MDQ0OWFiNmEyYzk0MTBmMTk2OThjL3RleHRyZWdpb246YmRhZDM2ZWRkMTkwNDQ5YWI2YTJjOTQxMGYxOTY5OGNfMzg0ODI5MDc2NjgyMw_0fd5afba-f65d-49d9-8f82-39acfec9ccf1">one</ix:nonFraction> segment. In this report, the &#8220;Company&#8221; refers collectively to Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company began assembling its diverse portfolio in 2017 through acquisitions, exclusive in-licenses and other collaborations. The Company's programs target unmet needs in women's health in the areas of contraception, fertility, and vaginal and sexual health, and aim to expand treatment options, enhance outcomes and improve ease of use for women. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any revenue. The Company&#8217;s primary operations have consisted of, and are expected to continue to consist primarily of, research and development activities to advance its product candidates through clinical development and regulatory approval.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's first product, XACIATO&#8482; (clindamycin phosphate vaginal gel, 2%), was approved by the FDA in December 2021, as a single-dose prescription medication for the treatment of bacterial vaginosis in female patients 12 years of age and older. In March 2022, the Company entered into an exclusive global license agreement with an affiliate of Organon &amp; Co., Organon International GmbH, or Organon, to commercialize XACIATO. XACIATO is expected to be available commercially in the United States in the fourth quarter of 2022.   </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's portfolio includes drug and drug/device product candidates and potential product candidates in various stages of development, from pre-clinical to advanced clinical development.</span></div></ix:continuation><div id="i8cc494c450e145729b0695b37b951a0a_37"></div><div style="margin-top:18pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMzg0ODI5MDczMzAwNw_2e3b9a9e-b530-469f-b21a-1fe0b5a1c183" continuedAt="i41adbfa408ed48d9af856cbf3e0352b0" escape="true">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i41adbfa408ed48d9af856cbf3e0352b0" continuedAt="i7258c4f3695546cd96a2e27e50154931"><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMzg0ODI5MDczMzAwNQ_8e587e65-c130-4459-8689-2a81529e0f9b" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#8217;s opinion, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, or the 2021 10-K.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dare:GoingConcernPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMzg0ODI5MDczMzAwNg_84686727-90b7-46c3-925e-7744e82e5c3c" continuedAt="i777a191c907b41f58729029488f27011" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The Company has a history of losses from operations, expects negative cash flows from its operations to continue for the foreseeable future, and expects that its net losses will continue for at least the next several years as it develops and seeks to bring to market its existing product candidates and to potentially acquire, license and develop additional product candidates. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and reclassification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of the Company's ability to continue as a going concern.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7258c4f3695546cd96a2e27e50154931" continuedAt="iec90939a53e9401f89ff38944cabdbc1"><ix:continuation id="i777a191c907b41f58729029488f27011" continuedAt="i53bdf7413d8f49c7b8a64493a0261d2f"><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company had an accumulated deficit of approximately $<ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTA5OTUxMTYzOTA4NA_774231ba-3bdd-4f32-8857-39f626447788">118.5</ix:nonFraction> million, cash and cash equivalents of approximately $<ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTA5OTUxMTYzOTEzMg_8f18f492-189b-4570-b433-788d5034e541">39.3</ix:nonFraction> million, and working capital of approximately $<ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="-5" name="dare:WorkingCapitalIncreaseDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTA5OTUxMTYzOTE3NA_0586e054-fa13-49b3-a2d4-129d10060fa9">31.4</ix:nonFraction> million. For the three months ended March&#160;31, 2022, the Company incurred a net loss of approximately $<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMjE5OTAyMzMzMTE2Nw_6f5ae751-3687-4f87-b2fa-6fd2306961a2">8.4</ix:nonFraction> million and had negative cash flow from operations of approximately $<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTA5OTUxMTYzOTMwOA_68121f7c-ad90-4738-a55e-3c1c612a4a31">12.3</ix:nonFraction> million.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects its primary uses of capital to be staff-related expenses, the cost of clinical trials and regulatory activities related to its product candidates, costs associated with contract manufacturing services and third-party clinical research and development services, payments due to third-parties under the Company's in-license and acquisition agreements including upon the occurrence of commercial milestones for XACIATO and development milestones for the Company&#8217;s product candidates, legal expenses, other regulatory expenses and general overhead costs. The Company&#8217;s future funding requirements could also include significant costs related to commercialization of its product candidates, if approved, depending on the type, nature and terms of commercial collaborations the Company establishes.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects its expenses, and in particular its research and development expenses, to increase significantly in 2022 compared to 2021 as the Company continues to develop and seek to bring to market its product candidates, with a focus on its product candidates that have reached the human clinical study development phase. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has one FDA-approved product, XACIATO, and has generated no revenue. Commercial launch of XACIATO in the U.S. by the Company's licensee, Organon, is expected in the fourth quarter of 2022. Under the terms of its license agreement with Organon, the Company will receive a $<ix:nonFraction unitRef="usd" contextRef="ib8e755817cb04a57a08c4f99adb8ffd6_D20220101-20220331" decimals="-5" name="dare:UpfrontLicenseFeeAmountPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTY0OTI2NzQ3OTQ0OA_5be3749c-3ef2-41a2-9a57-90865d40810d">10.0</ix:nonFraction>&#160;million non-refundable and non-creditable payment following the effective date of the license agreement and will be entitled to receive tiered double-digit royalties based on net sales and up to $<ix:nonFraction unitRef="usd" contextRef="ib8e755817cb04a57a08c4f99adb8ffd6_D20220101-20220331" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTY0OTI2NzQ3OTQ2MQ_eae2e1f0-bbee-46c1-aabf-ff7aa0b6a776">182.5</ix:nonFraction>&#160;million in milestone payments as follows: $<ix:nonFraction unitRef="usd" contextRef="ib8e755817cb04a57a08c4f99adb8ffd6_D20220101-20220331" decimals="-5" name="dare:MilestonePaymentsContingentAmountFirstCommercialSaleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTY0OTI2NzQ3OTQ1Nw_8d2a81c2-a5c0-455a-89fd-15287eedd442">2.5</ix:nonFraction>&#160;million following the first commercial sale of a licensed product in the United States; and up to $<ix:nonFraction unitRef="usd" contextRef="i1c840e118dda4da0839c1173ced12675_I20220331" decimals="-5" name="dare:MilestonePaymentsContingentAmountSalesBasedMilestonesAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTY0OTI2NzQ3OTQ2NQ_a989e32d-958b-4a59-a948-78597e174dbc">180.0</ix:nonFraction>&#160;million in tiered commercial sales milestones and regulatory milestones. The Company has devoted significant resources to building its portfolio of product candidates and to research and development activities related to these product candidates. The Company or its licensees must obtain regulatory approvals to market and sell any of its product candidates in the future and to market and sell XACIATO anywhere outside the U.S. The Company will need to generate sufficient safety and efficacy data on each of its product candidates in order to apply for regulatory approvals and for such assets to be attractive assets to potential strategic collaborators to license or to acquire, and for the Company to generate revenue through license fees, royalties on net revenues and commercial milestones related to such product candidates.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on the Company's current operating plan estimates, the Company does not have sufficient cash to satisfy its working capital needs and other liquidity requirements over at least the next <ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dare:PeriodofInsufficientCashandLiquidityRequirements" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTA5OTUxMTY0MTg4OQ_9147acdf-a9ce-4468-bc96-ea35a69a86e2">12</ix:nonNumeric> months from the date of issuance of the accompanying financial statements. The Company will need to raise substantial additional capital to continue to fund its operations and to successfully execute its current strategy. The Company may continue to seek to raise capital through the sale of shares of its common stock under its ATM sales agreement or through other types of equity transactions. However, when the Company can effect such sales and the amount of shares the Company can sell depends on a variety of factors including, among others, market conditions, the trading price of its common stock, its determination as to the appropriate sources of funding for its operations, and the number of authorized shares of common stock that are available for issuance, which is approximately <ix:nonFraction unitRef="shares" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="-6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTA5OTUxMTYzNTA1Nzg_55299eec-58b6-476c-b217-1c088c86212d">27</ix:nonFraction>&#160;million as of the date hereof. For the foreseeable future, the Company will evaluate and may pursue a variety of capital raising options on an on-going basis, including equity and debt financings, government or other grant funding, collaborations and strategic alliances or other similar types of arrangements, to cover its operating expenses, and the cost of any license or other acquisition of new product candidates or technologies. The amount and timing of the Company's capital needs have been and will continue to depend highly on many factors, including the product development programs the Company chooses to pursue, the pace and results of its clinical development efforts, and the nature and extent of expansion of its product candidate portfolio, if any. If the Company raises capital through collaborations, strategic alliances or other similar types of arrangements, it may have to relinquish, on terms that are not favorable to the Company, rights to some of its technologies or product candidates the Company would otherwise seek to develop or commercialize. </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iec90939a53e9401f89ff38944cabdbc1" continuedAt="i30843129bfa340b29df58be89cd3e2be"><ix:continuation id="i53bdf7413d8f49c7b8a64493a0261d2f"><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company and its stockholders. In addition, equity or debt financings may have a dilutive effect on the holdings of the Company's existing stockholders, and debt financings may subject the Company to restrictive covenants, operational restrictions and security interests in its assets. If the Company cannot raise capital when needed, on favorable terms or at all, the Company will not be able to continue development of its product candidates, will need to reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If the Company becomes unable to continue as a going concern, the Company may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its condensed consolidated financial statements, and stockholders may lose all or part of their investment in the Company's common stock. The Company's condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are described in Note 1 to the consolidated financial statements included in the 2021 10-K. Since the date of those consolidated financial statements, there have been no material changes to the Company&#8217;s significant accounting policies.</span></div></ix:continuation><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTAxNzY_c1900e9c-777f-41dd-9a97-e76dd27860d5" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTAxODY_e2b8270e-bc28-4da0-be66-36b6c40af6bc" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following tables present the classification within the fair value hierarchy of financial assets and liabilities that are remeasured on a recurring basis as of March&#160;31, 2022 and December&#160;31, 2021. There were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 2) or using unobservable inputs (Level 3) as of March&#160;31, 2022 or December&#160;31, 2021.</span></div><div style="margin-top:8pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:485.25pt"><tr><td style="width:1.0pt"></td><td style="width:216.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d128dda6aad45f6928caa2a8b0ac74d_I20220331" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RhYmxlOjE3ZWJiYjY5YjgwNzQ5ZWViN2VhODdkM2ZkYWJkMGFlL3RhYmxlcmFuZ2U6MTdlYmJiNjliODA3NDllZWI3ZWE4N2QzZmRhYmQwYWVfNC0xLTEtMS0zNzQ5MQ_e745cb34-a600-460d-ba04-3c93777bba29">36,330,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if261222bb7c7445a96aa0768ee93bdf6_I20220331" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RhYmxlOjE3ZWJiYjY5YjgwNzQ5ZWViN2VhODdkM2ZkYWJkMGFlL3RhYmxlcmFuZ2U6MTdlYmJiNjliODA3NDllZWI3ZWE4N2QzZmRhYmQwYWVfNC0zLTEtMS0zNzQ5MQ_e5f18ba8-17d6-4f7c-b4f7-16cad609dbd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa56362091f34c8cb0ef0c7d93a4dea5_I20220331" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RhYmxlOjE3ZWJiYjY5YjgwNzQ5ZWViN2VhODdkM2ZkYWJkMGFlL3RhYmxlcmFuZ2U6MTdlYmJiNjliODA3NDllZWI3ZWE4N2QzZmRhYmQwYWVfNC01LTEtMS0zNzQ5MQ_1dc54f21-2d49-40ae-ab9c-857b58c4daa7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i753c4d96be1e4ba3967076ff69f73d0d_I20220331" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RhYmxlOjE3ZWJiYjY5YjgwNzQ5ZWViN2VhODdkM2ZkYWJkMGFlL3RhYmxlcmFuZ2U6MTdlYmJiNjliODA3NDllZWI3ZWE4N2QzZmRhYmQwYWVfNC03LTEtMS0zNzQ5MQ_3d006eef-5d0c-4ba7-a4a8-dad5b2150cbe">36,330,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id64ecf9188364d48a0817d2f74ce0032_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RhYmxlOjE3ZWJiYjY5YjgwNzQ5ZWViN2VhODdkM2ZkYWJkMGFlL3RhYmxlcmFuZ2U6MTdlYmJiNjliODA3NDllZWI3ZWE4N2QzZmRhYmQwYWVfOS0xLTEtMS0zNzQ5MQ_1bec6aa0-43f1-4d3d-b69b-7f008b3593ab">49,666,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36a1700da3be4028993f5fe8ba965b06_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RhYmxlOjE3ZWJiYjY5YjgwNzQ5ZWViN2VhODdkM2ZkYWJkMGFlL3RhYmxlcmFuZ2U6MTdlYmJiNjliODA3NDllZWI3ZWE4N2QzZmRhYmQwYWVfOS0zLTEtMS0zNzQ5MQ_4c46fafa-7b32-40d2-a4be-be8063cad3a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieae613e2bfc34e51b675c0145659b974_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RhYmxlOjE3ZWJiYjY5YjgwNzQ5ZWViN2VhODdkM2ZkYWJkMGFlL3RhYmxlcmFuZ2U6MTdlYmJiNjliODA3NDllZWI3ZWE4N2QzZmRhYmQwYWVfOS01LTEtMS0zNzQ5MQ_44e90ab6-5258-4898-b1ee-9f7b353b8f6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a58ac7dc95d43f7af582f30cbdc5d98_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RhYmxlOjE3ZWJiYjY5YjgwNzQ5ZWViN2VhODdkM2ZkYWJkMGFlL3RhYmxlcmFuZ2U6MTdlYmJiNjliODA3NDllZWI3ZWE4N2QzZmRhYmQwYWVfOS03LTEtMS0zNzQ5MQ_c8a012d4-36fa-443f-bcf6-9ce32601f0d6">49,666,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Represents cash held in money market funds.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i30843129bfa340b29df58be89cd3e2be"><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTAxNzg_0b1ff99c-ddb9-40c8-8b50-a72eab6f76c2" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract, assesses whether each good or service is distinct, and determines those that are</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company develops estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration and licensing agreements under which it out-licenses certain rights to its products or product candidates to third parties. The terms of these arrangements typically include payment of one or more of the following to the Company: non-refundable, up-front license fees; development, regulatory and/or commercial milestone payments; and royalties on net sales of licensed products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license&#160;to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from non-refundable, upfront fees allocated to the&#160;license when the&#160;license&#160;is transferred to the customer and the customer is able to use and benefit from the&#160;license. For licenses bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. To date, the Company has not recognized any license fee revenue. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of product for commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The evaluation is based on the degree the Company controls the specified product at any time before transfer to the customer. Revenues are recognized on a gross basis if the Company is in the capacity of principal and on a net basis if the Company is in the capacity of an agent. To date, the Company has not recognized any revenue associated with product supply arrangements. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestones.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement in which the Company is a licensor and that includes developmental, regulatory or commercial milestones, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments not within the Company's control, such as where achievement of the specified milestone depends on activities of a third party or regulatory approval, are not considered probable of being achieved until the specified milestone occurs. To date, the Company has not recognized any milestone revenue.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i8cc494c450e145729b0695b37b951a0a_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzg0ODI5MDc0MDMzOA_1fa57158-8a49-4967-8864-7f6429b58dc2" continuedAt="i057ca0ad77b2472e83eff07c7395f444" escape="true">STRATEGIC AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="i057ca0ad77b2472e83eff07c7395f444" continuedAt="ifae2cce3e2f64fc6b3434f4e24b72afc"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Agreements for Product Commercialization</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organon Exclusive License Agreement</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company entered into an exclusive license agreement with Organon pursuant to which Organon will obtain exclusive worldwide rights to develop, manufacture and commercialize XACIATO and other future intravaginal or urological products for human use formulated with clindamycin that rely on intellectual property controlled by the Company. The effective date of the agreement will occur following the satisfaction of closing conditions that include receipt of all applicable approvals, or the expiration or termination of all applicable waiting periods, required under applicable antitrust laws, including the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.  </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other terms of the Organon license agreement:</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Upfront Payment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company will receive a $<ix:nonFraction unitRef="usd" contextRef="ib8e755817cb04a57a08c4f99adb8ffd6_D20220101-20220331" decimals="-5" name="dare:UpfrontLicenseFeeAmountPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTY0OTI2NzQ5NDI3NQ_5be3749c-3ef2-41a2-9a57-90865d40810d">10.0</ix:nonFraction> million non-refundable and non-creditable payment following the effective date of the agreement.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will be entitled to receive tiered double-digit royalties based on net sales and up to $<ix:nonFraction unitRef="usd" contextRef="ib8e755817cb04a57a08c4f99adb8ffd6_D20220101-20220331" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTY0OTI2NzQ5NDI5OA_eae2e1f0-bbee-46c1-aabf-ff7aa0b6a776">182.5</ix:nonFraction> million in milestone payments as follows: $<ix:nonFraction unitRef="usd" contextRef="ib8e755817cb04a57a08c4f99adb8ffd6_D20220101-20220331" decimals="-5" name="dare:MilestonePaymentsContingentAmountFirstCommercialSaleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTY0OTI2NzQ5NDI4Mg_8d2a81c2-a5c0-455a-89fd-15287eedd442">2.5</ix:nonFraction> million following the first commercial sale of a licensed product in the United States; and up to $<ix:nonFraction unitRef="usd" contextRef="i1c840e118dda4da0839c1173ced12675_I20220331" decimals="-5" name="dare:MilestonePaymentsContingentAmountSalesBasedMilestonesAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTY0OTI2NzQ5NDI5MA_a989e32d-958b-4a59-a948-78597e174dbc">180.0</ix:nonFraction> million in tiered commercial sales milestones and regulatory milestones. Royalty payments will be subject to customary reductions and offsets. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalty period for each licensed product will continue on a country-by-country basis from the first commercial sale of the licensed product in the country until the expiration of the later of (i) the date that no valid patent claim would be infringed in the absence of the license granted under the agreement by the sale of the licensed product in the country, (ii) <ix:nonNumeric contextRef="ib8e755817cb04a57a08c4f99adb8ffd6_D20220101-20220331" name="dare:MilestonePaymentsTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTY0OTI2NzQ5NDM0MQ_2d39210e-0863-40da-99f2-b836decd1959">10</ix:nonNumeric> years after the end of the month in which the first commercial sale of the licensed product in the country occurred, and (iii) the expiration of regulatory market exclusivity for the licensed product in that country.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Interactions and Product Supply.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will be responsible for regulatory interactions and for providing product supply on an interim basis until Organon assumes such responsibilities. Until such time, Organon will purchase all of its product requirements of XACIATO from the Company at a transfer price equal to the Company's manufacturing costs plus a single-digit percentage markup. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unless terminated earlier, the agreement will expire on a product-by-product and country-by-country basis upon expiration of the applicable royalty period for each licensed product. In addition to customary termination rights for both parties, following the first anniversary of the effective date of the agreement, Organon may terminate the agreement in its entirety or on a country-by-country basis at any time in Organon's sole discretion on 120 days' advance written notice.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The terms of the agreement provide Organon exclusive worldwide rights of first negotiation for specified potential future products of the Company.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Bayer HealthCare License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company entered into a license agreement with Bayer, regarding the further development and commercialization of Ovaprene in the U.S. The Company received a $<ix:nonFraction unitRef="usd" contextRef="ie39ad353b32c4dc891e544e148bc9b66_D20200101-20200131" decimals="-5" name="dare:UpfrontLicenseFeePaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzAy_cb039012-c8db-45d4-b15a-f59ebc0027f9">1.0</ix:nonFraction> million upfront non-refundable license fee payment from Bayer, and Bayer agreed to support the Company in development and regulatory activities by providing the equivalent of two experts to advise the Company in clinical, regulatory, preclinical, commercial, CMC and product supply matters. Bayer, in its sole discretion, has the right to make the license effective by paying the Company an additional $<ix:nonFraction unitRef="usd" contextRef="ie39ad353b32c4dc891e544e148bc9b66_D20200101-20200131" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzg4_d84d6796-45e5-4f53-b56a-7d4b1bee9db9">20.0</ix:nonFraction> million, referred to as the Clinical Trial and Manufacturing Activities Fee. Such license would be exclusive with regard to the commercialization of Ovaprene for human contraception in the U.S. and co-exclusive with the Company with regard to development.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifae2cce3e2f64fc6b3434f4e24b72afc" continuedAt="ib63df90f671a4f5899aacd7daa50f794"><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded there was one significant performance obligation related to the $<ix:nonFraction unitRef="usd" contextRef="ie39ad353b32c4dc891e544e148bc9b66_D20200101-20200131" decimals="-5" name="dare:UpfrontLicenseFeePaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTA5OTUxMTYzMzQxNzI_cb039012-c8db-45d4-b15a-f59ebc0027f9">1.0</ix:nonFraction> million upfront payment: a distinct license to commercialize Ovaprene effective upon the receipt of the $<ix:nonFraction unitRef="usd" contextRef="ie39ad353b32c4dc891e544e148bc9b66_D20200101-20200131" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTA5OTUxMTYzMzQyNzI_d84d6796-45e5-4f53-b56a-7d4b1bee9db9">20.0</ix:nonFraction> million fee. The $<ix:nonFraction unitRef="usd" contextRef="ie39ad353b32c4dc891e544e148bc9b66_D20200101-20200131" decimals="-5" name="dare:UpfrontLicenseFeePaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTA5OTUxMTYzMzQyODU_cb039012-c8db-45d4-b15a-f59ebc0027f9">1.0</ix:nonFraction> million upfront payment will be recorded as license revenue at the earlier of (1) the point in time the&#160;Company receives the $<ix:nonFraction unitRef="usd" contextRef="ie39ad353b32c4dc891e544e148bc9b66_D20200101-20200131" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTA5OTUxMTYzMzQ0MDY_d84d6796-45e5-4f53-b56a-7d4b1bee9db9">20.0</ix:nonFraction> million fee, the license&#160;is transferred to Bayer and Bayer is able to use and benefit from the&#160;license and (2) the termination of the agreement. As of March&#160;31, 2022, neither of the foregoing had occurred. The $<ix:nonFraction unitRef="usd" contextRef="ie39ad353b32c4dc891e544e148bc9b66_D20200101-20200131" decimals="-5" name="dare:UpfrontLicenseFeePaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTA5OTUxMTYzMzQ2MDE_cb039012-c8db-45d4-b15a-f59ebc0027f9">1.0</ix:nonFraction> million payment is recorded as long-term deferred license revenue in the Company's condensed consolidated balance sheet at March&#160;31, 2022 and December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other terms of the Bayer license agreement:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone &amp; Royalty Payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company will be entitled to receive (a) a milestone payment in the low double-digit millions upon the first commercial sale of Ovaprene in the U.S. and escalating milestone payments based on annual net sales of Ovaprene during a calendar year, totaling up to $<ix:nonFraction unitRef="usd" contextRef="ie39ad353b32c4dc891e544e148bc9b66_D20200101-20200131" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfOTcw_56015707-8cb8-4d4a-b058-3aac3d059c4a">310.0</ix:nonFraction> million if all such milestones, including first commercial sale, are achieved, (b) tiered royalties starting in the low double digits based on annual net sales of Ovaprene during a calendar year, subject to customary royalty reductions and offsets, and (c) a percentage of sublicense revenue.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Efforts.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company is responsible for the pivotal trial for Ovaprene and for its development and regulatory activities and has product supply obligations. After payment of the Clinical Trial and Manufacturing Activities Fee, Bayer will be responsible for the commercialization of Ovaprene for human contraception in the U.S.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial term of the agreement, which is subject to automatic renewal terms, continues until the later of (a) the expiration of any valid claim covering the manufacture, use, sale or import of Ovaprene in the U.S.; or (b) <ix:nonNumeric contextRef="ie39ad353b32c4dc891e544e148bc9b66_D20200101-20200131" name="dare:LicenseAgreementInitialTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTk4MA_ac5a9d5d-a289-46aa-bf35-4b9012a5d761">15</ix:nonNumeric> years from the first commercial sale of Ovaprene in the U.S. In addition to customary termination rights for both parties, Bayer may terminate the agreement at any time on 90 days' notice and the agreement will automatically terminate if the Company does not receive the Clinical Trial and Manufacturing Activities Fee if and when due.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Strategic Agreements for Pipeline Development</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Hammock/MilanaPharm Assignment and License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into (a) an Assignment Agreement with Hammock Pharmaceuticals, Inc., or the Assignment Agreement, and (b) a First Amendment to License Agreement with TriLogic Pharma, LLC and MilanaPharm LLC, or the License Amendment. Both agreements relate to the Exclusive License Agreement among Hammock, TriLogic and MilanaPharm dated as of January 9, 2017, or the MilanaPharm License Agreement. Under the Assignment Agreement and the MilanaPharm License Agreement, as amended by the License Amendment, the Company acquired an exclusive, worldwide license under certain intellectual property to, among other things, develop and commercialize products for the diagnosis, treatment and prevention of human diseases or conditions in or through any intravaginal or urological applications. The licensed intellectual property relates to the hydrogel drug delivery platform of TriLogic and MilanaPharm known as TRI-726. In XACIATO, this proprietary technology is formulated with clindamycin for the treatment of bacterial vaginosis. Each of the Assignment Agreement and License Amendment was amended in December 2019 and the License Agreement was further amended in September 2021 and March 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other terms of the License Amendment, as amended:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A total of $<ix:nonFraction unitRef="usd" contextRef="i8b96da1d703849ca87cb722301f4332a_D20191201-20191231" decimals="0" name="dare:LicenseFee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzczNQ_dd0c16d7-e0b2-456c-be5d-b1e071e1954f">235,000</ix:nonFraction> in license fees were payable to MilanaPharm, the final installment of which was $<ix:nonFraction unitRef="usd" contextRef="ia36cb4e021c8477c9cdd5cd2270d26f0_D20200101-20201231" decimals="0" name="dare:LicenseFeeToBePaidUponContingency" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzg4OQ_ca9f5ef2-9d0f-4c9c-ac46-6f5de82eaa57">110,000</ix:nonFraction> paid in 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company paid MilanaPharm $<ix:nonFraction unitRef="usd" contextRef="id7e84f1a2279490fb994ed669d2a5794_D20191201-20191231" decimals="-3" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzk1MA_84826cb6-9482-4e41-ac3f-3ccb0a17f624">300,000</ix:nonFraction> in the aggregate upon achievement of certain clinical and regulatory development milestones, $<ix:nonFraction unitRef="usd" contextRef="ie1a197ace83745b5af0af06d9e6a03ef_I20201231" decimals="-3" name="dare:AssetAcquisitionContingentConsideration" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfNDA0Ng_b173c65e-08f2-400d-acc0-ab9858dfc1df">50,000</ix:nonFraction> of which was paid in 2020 and $<ix:nonFraction unitRef="usd" contextRef="ica0953b3410b4366b3dd008e5682c91c_D20210101-20211231" decimals="-3" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTA5OTUxMTYzMzc0MTM_54a96e65-ce72-4065-97ba-0b359220109f">250,000</ix:nonFraction> of which was paid in 2021. The Company may also pay MilanaPharm up to $<ix:nonFraction unitRef="usd" contextRef="ie54bf079d17049f89f976bde3354e8eb_D20220101-20220331" decimals="-3" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTA5OTUxMTYzMzc0MDk_2029c24f-1485-40c1-bfb2-29d268bc0325">500,000</ix:nonFraction> upon the first commercial sale in the United States of the first licensed product for each vaginal use and urological use, and up to $<ix:nonFraction unitRef="usd" contextRef="i1377eee01ae54f288857d7190cc24095_D20220101-20220331" decimals="-3" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTA5OTUxMTYzMzc0MjQ_1af0f308-0231-4bb4-857e-4fa0c699c0df">250,000</ix:nonFraction> upon the first commercial sale in the United States of successive licensed products for vaginal or urological use. In addition, upon achievement of $<ix:nonFraction unitRef="usd" contextRef="i96570265e6d94bafb524501622be0afa_D20220101-20220331" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTA5OTUxMTYzMzc0MzI_e1c38da8-83a0-429f-84d6-1332cae793f3">50.0</ix:nonFraction> million in cumulative worldwide net sales of licensed products, the Company must pay $<ix:nonFraction unitRef="usd" contextRef="i52d0dedfaf874adfb961664b9bce5b92_D20210101-20210331" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTA5OTUxMTYzMzc0NTA_e9b34fc8-1b99-4d77-837e-f78c94e18d44">1.0</ix:nonFraction> million to MilanaPharm. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Sublicense Income.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will pay MilanaPharm a low double-digit percentage of all income received by the Company or its affiliates in connection with any sublicense granted to a third party for use outside of the United States, subject to certain exclusions.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib63df90f671a4f5899aacd7daa50f794" continuedAt="ifc965433eac7438db2ab7d97455653d9"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the royalty term, the Company will pay MilanaPharm high single-digit to low double-digit royalties based on annual worldwide net sales of licensed products and processes. The royalty term, which is determined on a country-by-country basis and licensed product-by-product basis (or process-by-process basis), begins with the first commercial sale of a licensed product or process in a country and terminates on the latest of (1) the expiration date of the last valid claim of the licensed patent rights that cover the method of use of such product or process in such country, or (2) <ix:nonNumeric contextRef="id84a19a7b61f49aab03e5421a920942c_D20220101-20220331" name="dare:RoyaltyAgreementTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjE5OTAyMzMxNTk1MA_c141befc-4495-4fb3-a307-51f5d72079f4">10</ix:nonNumeric> years following the first commercial sale of such product or process in such country. Royalty payments are subject to reduction in certain circumstances, including as a result of generic competition, patent prosecution expenses incurred by the Company, or payments to third parties for rights or know-how required for the Company to exercise the licenses granted to it under the MilanaPharm License Agreement or that are strategically important or could add value to a licensed product or process in a manner expected to materially generate or increase sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Efforts. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company must use commercially reasonable efforts and resources to (1) develop and commercialize at least one licensed product or process in the United States and at least one licensed product or process in at least one of Canada, the United Kingdom, France, Germany, Italy or Spain, and (2) continue to commercialize that product or process following the first commercial sale of a licensed product or process in the applicable jurisdiction.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unless earlier terminated, the license term continues until (1) on a licensed product-by-product (or process-by-process basis) and country-by-country basis, the date of expiration of the royalty term with respect to such licensed product in such country, and (2) the expiration of all applicable royalty terms under the MilanaPharm License Agreement with respect to all licensed products and processes in all countries. Upon expiration of the term with respect to any licensed product or process in a country (but not upon earlier termination of the MilanaPharm License Agreement), the licenses granted to the Company under the MilanaPharm License Agreement will convert automatically to an exclusive, fully paid-up, royalty-free, perpetual, non-terminable and irrevocable right and license under the licensed intellectual property.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to customary termination rights for all parties, MilanaPharm may terminate the license granted to the Company solely with respect to a licensed product or process in a country if, after having launched such product or process in such country, (1) the Company or its affiliates or sublicensees discontinue the sale of such product or process in such country and MilanaPharm notifies the Company of such termination within <ix:nonNumeric contextRef="i8b96da1d703849ca87cb722301f4332a_D20191201-20191231" name="dare:LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfNzQzOQ_eb79e9da-d6bc-42f1-ae74-712ee63e0983">60</ix:nonNumeric> days of having first been notified by the Company of such discontinuation, or (2) the Company or its affiliates or sublicensees (A) discontinue all commercially reasonable marketing efforts to sell, and discontinue all sales of, such product or process in such country for nine months or more, (B) fail to resume such commercially reasonable marketing efforts within <ix:nonNumeric contextRef="i8b96da1d703849ca87cb722301f4332a_D20191201-20191231" name="dare:LicenseAgreementTerminationPeriodDueToPerformanceFailure" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfNzgwNA_ffa2a415-94d3-483d-a09a-eef52492c45b">120</ix:nonNumeric> days of having been notified of such failure by MilanaPharm, (C) fail to reasonably demonstrate a strategic justification for the discontinuation and failure to resume to MilanaPharm, and (D) MilanaPharm gives <ix:nonNumeric contextRef="i8b96da1d703849ca87cb722301f4332a_D20191201-20191231" name="dare:LicenseAgreementNoticePeriodOfTermination" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfODAxMg_1ea58c61-fa16-40e8-8c3d-f187a601ecbf">90</ix:nonNumeric> days&#8217; notice to the Company. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other terms of the Assignment Agreement, as amended:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assignment; Technology Transfer</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Hammock assigned and transferred to the Company all of its right, title and interest in and to the MilanaPharm License Agreement and agreed to cooperate to transfer to the Company all of the data, materials and the licensed technology in its possession pursuant to a technology transfer plan to be agreed upon by the parties, with a goal for the Company to independently practice the licensed intellectual property as soon as commercially practical in order to develop and commercialize the licensed products and processes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fees</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A total of $<ix:nonFraction unitRef="usd" contextRef="i45bf9ce3d7014dd4a8cc904a8d6fdfe3_D20191201-20191231" decimals="0" name="dare:LicenseFee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfODY5OA_369c471c-d93c-4938-9219-fca885c043d1">512,500</ix:nonFraction> in fees were payable to Hammock, the final installment of which was $<ix:nonFraction unitRef="usd" contextRef="i24bd5f0c2d834a5386e1ac19b19670c4_D20200101-20201231" decimals="0" name="dare:LicenseFeeToBePaidUponContingency" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfODg0Mw_5e318eb8-fc17-4b9b-a12a-53edb99eaf16">137,500</ix:nonFraction> paid in 2020. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company will pay Hammock up to $<ix:nonFraction unitRef="usd" contextRef="ib3040a789d9a4c049500fc9df1a161d5_D20191201-20191231" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfODkxNg_8ff9088d-8913-4186-8515-4e23cacc4329">1.1</ix:nonFraction> million in the aggregate upon achievement of certain clinical and regulatory development milestones, $<ix:nonFraction unitRef="usd" contextRef="ie890f0c1b2d94ab1b54648bda60c9b9e_D20200101-20201231" decimals="0" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzg0ODI5MDc0MDI2Nw_a1995f13-8569-4bb1-90db-ed0722ed2edc">100,000</ix:nonFraction> of which was paid in 2020 and $<ix:nonFraction unitRef="usd" contextRef="ie4e5b11922fb45baae7deef39cf719d8_D20210101-20211231" decimals="0" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzg0ODI5MDc0MDI3Nw_f9f6b703-024a-4a81-abe5-a00c243c7d4a">750,000</ix:nonFraction> of which was paid in 2021. The remaining milestone does not relate to a bacterial vaginosis product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Assignment Agreement will terminate upon the later of (1) completion of the parties' technology transfer plan, and (2) payment to Hammock of the last of the milestone payments.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifc965433eac7438db2ab7d97455653d9" continuedAt="ic7a613ca1c394712ba3c4261bbfb5c78"><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADVA-Tec License Agreement </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a license agreement with ADVA-Tec, Inc., under which the Company was granted the exclusive right to develop and commercialize Ovaprene for human contraceptive use worldwide. The Company must use commercially reasonable efforts to develop and commercialize Ovaprene and must meet certain minimum spending amounts per year, including $<ix:nonFraction unitRef="usd" contextRef="id40ce46b765846a5aa2e57368b8b8e2e_D20170301-20170331" decimals="-5" name="dare:ResearchAndDevelopmentMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzg0ODI5MDc0MDI4Nw_76d49942-8929-4c1d-a65a-8e67436189d1">2.5</ix:nonFraction>&#160;million per year to cover such activities until a final PMA is filed, or until the first commercial sale of Ovaprene, whichever occurs first. ADVA-Tec will conduct certain research and development work as necessary to allow the Company to seek a PMA from the FDA and will provide the Company with clinical trial and commercial supplies of Ovaprene, either directly or through a CMO, on commercially reasonable terms.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the license agreement, in addition to an exclusive license to ADVA-Tec's and its affiliates' intellectual property rights for all uses of Ovaprene as a human contraceptive device, the Company has a right of first refusal to license these patents and patent applications for additional indications.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other terms of the ADVA-Tec license agreement:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will pay to ADVA-Tec: (1) up to $<ix:nonFraction unitRef="usd" contextRef="i3cba105a870f4df89d49f7bf4d41b3b3_D20170301-20170331" decimals="-5" name="dare:ResearchAndDevelopmentMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfOTg3Nw_28e69737-5b60-4724-ad2a-e349e0e98218">14.6</ix:nonFraction> million in the aggregate based on the achievement of specified development and regulatory milestones, $<ix:nonFraction unitRef="usd" contextRef="i2502d37404a542acb2be44f30462a6db_D20210101-20211231" decimals="0" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzg0ODI5MDc0MDMwMw_9f4b767a-615b-4014-8b85-8eefc79dbc63">200,000</ix:nonFraction> of which was paid in 2021; and (2) up to $<ix:nonFraction unitRef="usd" contextRef="i3c82657d880d4e1fa411c307e0109b6c_D20170301-20170331" decimals="-5" name="dare:ResearchAndDevelopmentMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfOTk4OA_bfe4da5e-6449-453e-b231-e95f10c02095">20.0</ix:nonFraction> million in the aggregate based on the achievement of certain worldwide net sales milestones.  The remaining development and regulatory milestones include: the FDA's approval to commence a pivotal clinical trial; successful completion of such pivotal clinical trial; the FDA's acceptance of a PMA filing for Ovaprene; the FDA's approval of the PMA for Ovaprene; CE Marking of Ovaprene in at least three designated European countries; obtaining regulatory approval in at least three designated European countries; and obtaining regulatory approval in Japan.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. After the commercial launch of Ovaprene, the Company will pay to ADVA-Tec royalties based on aggregate annual net sales of Ovaprene in specified regions, at a royalty rate that will vary between <ix:nonFraction unitRef="number" contextRef="i33b5825a9b744e5d8bdf4464e25fdeca_D20170301-20170331" decimals="INF" name="dare:PercentageOfRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTAyODk_e408b0f1-952d-4775-9d17-c30df998de2e">1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i2c11228dbbd544df9e87f818ade25d08_D20170301-20170331" decimals="INF" name="dare:PercentageOfRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTAyOTY_2c6ffc3a-eb0a-4a1d-9adb-5f1c84469ddf">10</ix:nonFraction>% and will increase based on various net sales thresholds. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Unless earlier terminated, the license the Company received under the agreement continues on a country-by-country basis until the later of the life of the licensed patents or the Company's last commercial sale of Ovaprene. In addition to customary termination rights for both parties: (A) the Company may terminate the agreement with or without cause in whole or on a country-by-country basis upon 60 days prior written notice; and (B) ADVA-Tec may terminate the agreement if the Company develops or commercializes any non-hormonal ring-based vaginal contraceptive device competitive to Ovaprene or if the Company fails to: (1) in certain limited circumstances, commercialize Ovaprene in certain designated countries within <ix:nonNumeric contextRef="i3c82657d880d4e1fa411c307e0109b6c_D20170301-20170331" name="dare:MilestonePaymentsTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjE5OTAyMzMxNTk2Mw_25e2485b-9aa6-4bd1-ab38-c4cf0308b829">three years</ix:nonNumeric> of the first commercial sale of Ovaprene; (2) satisfy the annual spending obligation described above, (3) use commercially reasonable efforts to complete all necessary pre-clinical and clinical studies required to support and submit a PMA, (4) conduct clinical trials as set forth in the development plan to which the Company and ADVA-Tec agree, and as may be modified by a joint research committee, unless such failure is caused by events outside of the Company&#8217;s reasonable control, or (5) enroll a patient in the first non-significant risk medical device study or clinical trial as allowed by an institutional review board within six months of the production and release of Ovaprene, unless such failure is caused by events outside of the Company&#8217;s reasonable control.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SST License and Collaboration Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a license and collaboration agreement with Strategic Science &amp;&#160;Technologies-D,&#160;LLC and Strategic Science &amp; Technologies, LLC, referred to collectively as SST, under which the Company received an exclusive, royalty-bearing, sublicensable license to develop and commercialize, in all countries and geographic territories of the world, for all indications for women related to female sexual dysfunction and/or female reproductive health, including the treatment of female sexual arousal disorder, or the Field of Use, SST&#8217;s topical formulation of Sildenafil Cream, 3.6% as it existed as of the effective date of the agreement, or any other topically applied pharmaceutical product containing sildenafil or a salt thereof as a pharmaceutically active ingredient, alone or with other active ingredients, but specifically excluding any product containing ibuprofen or any salt derivative of ibuprofen, or the Licensed Products.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic7a613ca1c394712ba3c4261bbfb5c78" continuedAt="i7121330724114afabbb36258569987d8"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other terms of the SST license and collaboration agreement:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invention Ownership.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company retains rights to inventions made by its employees, SST retains rights to inventions made by its employees, and each party owns a <ix:nonFraction unitRef="number" contextRef="ib4370da4fa5342028ed801f0a9fa0408_D20180201-20180228" decimals="INF" name="dare:PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTMwNzc_2bfb6e8a-a8e7-4db9-a5bd-fdb010f94c3f">50</ix:nonFraction>% undivided interest in all joint inventions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Development Committee.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The parties will collaborate through a joint development committee that will determine the strategic objectives for, and generally oversee, the development efforts of both parties under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company must use commercially reasonable efforts to develop the Licensed Products in the Field of Use in accordance with a development plan in the agreement, and to commercialize the Licensed Products in the Field of Use. The Company is responsible for all reasonable internal and external costs and expenses incurred by SST in its performance of the development activities it must perform under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SST will be eligible to receive tiered royalties based on percentages of annual net sales of Licensed Products in the single digits to the mid double digits, subject to customary royalty reductions and offsets, and a percentage of sublicense revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SST will be eligible to receive payments (1) ranging from $<ix:nonFraction unitRef="usd" contextRef="ic670d6c2f83e480aaccaa11002b3fd82_D20180201-20180228" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTQxMjk_38aa2243-4c24-4dc9-865c-007da3c25ccc">0.5</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="iaac673f0f7dd48318f3456c2bd5051e6_D20180201-20180228" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTQxMzU_4461c913-eaf3-4b30-926c-0053ca1bf086">18.0</ix:nonFraction> million in the aggregate on achieving certain clinical and regulatory milestones in the U.S. and worldwide, and (2) between $<ix:nonFraction unitRef="usd" contextRef="i4e73b75602364a808872b80c92bb1c3d_D20180201-20180228" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTQyNTQ_be55f95b-dbef-4cea-ac00-6dc7a453e8f8">10.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i88690cf0663d46c2a1f6398cdafd4e30_D20180201-20180228" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTQyNjA_46265100-4c7f-4f32-a446-353018a5cfd8">100.0</ix:nonFraction> million in the aggregate upon achieving certain commercial sales milestones. If the Company enters into strategic development or distribution partnerships related to the Licensed Products, additional milestone payments would be due to SST.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s license continues on a country-by-country basis until the later of 10 years from the date of the first commercial sale of such Licensed Product or the expiration of the last valid claim of patent rights covering the Licensed Product in the Field of Use. Upon expiration (but not termination) of the agreement in a particular country, the Company will have a fully paid-up license under the licensed intellectual property to develop and commercialize the applicable Licensed Products in the applicable country on a non-exclusive basis.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Termination.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to customary termination rights for both parties: (1) prior to receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including NDA approval, the Company may terminate the agreement without cause upon 90 days prior written notice; (2) following receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including NDA approval, the Company may terminate the agreement without cause upon 180 days prior written notice; and (3) SST may terminate the agreement with respect to the applicable Licensed Product(s) in the applicable country(ies) upon 30 days&#8217; notice if the Company fails to use commercially reasonable efforts to perform development activities in substantial accordance with the development plan and do not cure such failure within 60 days of receipt of SST's notice thereof.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Catalent JNP License Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018,&#160;the Company entered into an exclusive license agreement with Catalent JNP, Inc. (formerly known as Juniper Pharmaceuticals, Inc., and which the Company refers to as Catalent), under which Catalent granted the Company (a) an exclusive, royalty-bearing worldwide license under certain patent rights, either owned by or exclusively licensed to Catalent, to make, have made, use, have used, sell, have sold, import and have imported products and processes, and (b) a non-exclusive, royalty-bearing worldwide license to use certain technological information owned by Catalent to make, have made, use, have used, sell, have sold, import and have imported products and processes. The Company is entitled to sublicense the rights granted to it under this agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Upfront Fee.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company paid a $<ix:nonFraction unitRef="usd" contextRef="ia6e9a4923f614a9492dd0238e4cca80f_D20180401-20180430" decimals="0" name="dare:UpfrontLicenseFeePaid" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTY4NTU_4ea2c031-f235-4ce8-ae08-fff6cb1bf945">250,000</ix:nonFraction> non-creditable upfront license fee to Catalent in connection with the execution of the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annual Maintenance Fee.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will pay an annual license maintenance fee to Catalent on each anniversary of the date of the agreement, the amount of which will be $<ix:nonFraction unitRef="usd" contextRef="ia6e9a4923f614a9492dd0238e4cca80f_D20180401-20180430" decimals="0" name="dare:PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTcxMjU_e93b1f67-5075-4cbf-89e4-95e561fcfb80">50,000</ix:nonFraction> for the first two years and $<ix:nonFraction unitRef="usd" contextRef="ia6e9a4923f614a9492dd0238e4cca80f_D20180401-20180430" decimals="0" name="dare:PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTcxNTY_2a7b1d35-a476-4e54-9f6c-322fcd83c9da">100,000</ix:nonFraction> thereafter, and which will be creditable against royalties and other payments due to Catalent in the same calendar year but may not be carried forward to any other year. The Company made the first payments in April 2019.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7121330724114afabbb36258569987d8" continuedAt="i0a60bf04c0914bee9a6e43218315efb4"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company must make potential future development and sales milestone payments of (1) up to $<ix:nonFraction unitRef="usd" contextRef="ic39a296e2a1e45a29ed3a2a13c728ab9_D20180401-20180430" decimals="-5" name="dare:MaximumPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTc0NDI_f7a019af-e9e6-4875-b367-1290b2714cd8">13.5</ix:nonFraction> million in the aggregate upon achieving certain clinical and regulatory milestones, $<ix:nonFraction unitRef="usd" contextRef="i18e026cd749c470d865e295625b2d49f_D20210701-20210930" decimals="-5" name="dare:MilestonePaymentsContingentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTc1MjE_87212a04-3e27-4627-b283-1343899743de">1.0</ix:nonFraction>&#160;million of which became payable in the third quarter of 2021, and in accordance with the license agreement, the amount payable was offset by the $<ix:nonFraction unitRef="usd" contextRef="i130fa20b36a240b182234edcc27974bf_D20210701-20210930" decimals="0" name="us-gaap:CostMaintenance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTc2NjE_bc903b3e-5aff-4e32-816d-467390e42387">100,000</ix:nonFraction> annual maintenance fee, resulting in a net amount of $<ix:nonFraction unitRef="usd" contextRef="i05dcf861082b438c816582ce5fd7e46e_I20220331" decimals="0" name="dare:MilestonePaymentsContingentAmountPayableNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTc3MTc_62e33fb3-5f6e-4355-8217-700adab30f74">900,000</ix:nonFraction> paid during the third quarter of 2021, and (2) up to $<ix:nonFraction unitRef="usd" contextRef="idb8485972ede4668ac56f750cad9b2ea_D20180401-20180430" decimals="-5" name="dare:MaximumPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTc3NzM_749b2c94-6b4d-4033-97be-b3a4df229c9b">30.3</ix:nonFraction> million in the aggregate upon achieving certain commercial sales milestones for each product or process covered by the licenses granted under the agreement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the royalty term, the Company will pay Catalent mid-single-digit to low double-digit royalties based on worldwide net sales of products and processes covered by the licenses granted under the agreement. In lieu of such royalty payments, the Company will pay Catalent a low double-digit percentage of all sublicense income the Company receives for the sublicense of rights under the agreement to a third party. The royalty term, which is determined on a country-by-country basis and product-by-product basis (or process-by-process basis), begins with the first commercial sale of a product or process in a country and terminates on the latest of (1) the expiration date of the last valid claim within the licensed patent rights with respect to such product or process in such country, (2) 10 years following the first commercial sale of such product or process in such country, and (3) when one or more generic products for such product or process are commercially available in such country, except that if there is no such generic product by the 10th year following the first commercial sale in such country, then the royalty term will terminate on the 10-year anniversary of the first commercial sale in such country.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Efforts. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company must use commercially reasonable efforts to develop and make at least one product or process available to the public, which efforts include achieving specific diligence requirements by specific dates specified in the agreement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the term of the agreement will continue on a country-by-country basis until the later of (1) the expiration date of the last valid claim within such country, or (2) 10 years from the date of first commercial sale of a product or process in such country. Upon expiration (but not early termination) of the agreement, the licenses granted thereunder will convert automatically to fully-paid irrevocable licenses. Catalent may terminate the agreement (1) upon 30 days&#8217; notice for the Company&#8217;s uncured breach of any payment obligation under the agreement, (2) if the Company fails to maintain required insurance, (3) immediately upon the Company&#8217;s insolvency or the making of an assignment for the benefit of the Company&#8217;s creditors or if a bankruptcy petition is filed for or against the Company, which petition is not dismissed within 90 days, or (4) upon 60 days&#8217; notice for any uncured material breach by the Company of any of the Company&#8217;s other obligations under the agreement. The Company may terminate the agreement on a country-by-country basis for any reason by giving 180 days&#8217; notice (or 90 days&#8217; notice if such termination occurs prior to receipt of marketing approval in the United States). If Catalent terminates the agreement for the reason described in clause (4) above or if the Company terminates the agreement, Catalent will have full access including the right to use and reference all product data generated during the term of the agreement that is owned by the Company.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adare Development and Option Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Company entered into an exclusive development and option agreement with Adare Pharma Solutions (formerly known as Adare Pharmaceuticals and Orbis Biosciences, and which the Company refers to as Adare), for the development of long-acting injectable etonogestrel contraceptive with 6- and 12-month durations (now known as ADARE-204 and ADARE-214, respectively). The agreement provides the Company with an option to negotiate an exclusive license agreement for the programs if the Company funds the conduct of specified development work by Adare. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MBI Acquisition</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company acquired Dare MB Inc. (formerly, Microchips Biotech, Inc.), or MBI, to secure the rights to develop a long-acting reversible contraception method that a woman can turn on or off herself, according to her own needs. This candidate is now known as DARE-LARC1. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing of the acquisition, the Company issued an aggregate of approximately <ix:nonFraction unitRef="shares" contextRef="if0d7024baebb42f3921f362b71af0807_D20191101-20191130" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzg0ODI5MDc0MDMxMw_c4c6d13f-6e59-44b9-a2aa-edea96be102a">3.0</ix:nonFraction>&#160;million shares of its common stock to the holders of shares of MBI's capital stock outstanding immediately prior to the effective time of the merger. The transaction was valued at $<ix:nonFraction unitRef="usd" contextRef="id9429fbf089249aeb34b9943fccfb3aa_I20191130" decimals="-5" name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjIzNDE_eabb490e-8179-476d-a2fa-e691368f02a9">2.4</ix:nonFraction> million, based on the fair value of the approximately <ix:nonFraction unitRef="shares" contextRef="if0d7024baebb42f3921f362b71af0807_D20191101-20191130" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzg0ODI5MDc0MDMyNg_ea4759d5-22bc-4e8c-9ec4-e2e631627746">3.0</ix:nonFraction>&#160;million shares issued at $<ix:nonFraction unitRef="usdPerShare" contextRef="id9429fbf089249aeb34b9943fccfb3aa_I20191130" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjIzOTY_7d6b5e62-dfa1-4aa3-a890-3d2b23640ac9">0.79</ix:nonFraction> per share, which was the closing price per share of the Company's common stock on the date of closing. The shares were issued in exchange for MBI&#8217;s cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="id9429fbf089249aeb34b9943fccfb3aa_I20191130" decimals="-5" name="dare:BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjI1NzY_eaccb52c-1bde-4416-9d74-2eb6c31fa05a">6.1</ix:nonFraction> million, less net liabilities of $<ix:nonFraction unitRef="usd" contextRef="id9429fbf089249aeb34b9943fccfb3aa_I20191130" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjI2MDQ_27aa31bc-0122-421e-9da2-27551e0f33ec">3.5</ix:nonFraction> million and transaction costs of $<ix:nonFraction unitRef="usd" contextRef="i4550db8657fb446599597be07760a4e9_I20191130" decimals="0" name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjI2MzI_4f4a7ca3-8398-4c57-bf1c-28b48ed729ee">202,000</ix:nonFraction>, which was allocated based on the relative fair value of the assets acquired and the liabilities assumed.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0a60bf04c0914bee9a6e43218315efb4" continuedAt="icaab3fc5cad84aa68c64aa66792d39df"><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also agreed to pay the following additional consideration to the former MBI stockholders: (a) up to $<ix:nonFraction unitRef="usd" contextRef="id246537752c543dc90f3ce1157fa81db_D20191101-20191130" decimals="-5" name="dare:ResearchAndDevelopmentMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjI4NDk_44b36914-d166-404c-b018-b56c5fe45678">46.5</ix:nonFraction> million contingent upon the achievement of specified funding, product development and regulatory milestones; (b) up to $<ix:nonFraction unitRef="usd" contextRef="i4871de07797e4ead9c91bde6f6f1da64_I20191130" decimals="-5" name="dare:AssetAcquisitionContingentConsiderationCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjI5NjM_80752dbf-c1d2-4c95-956a-8533653761df">55.0</ix:nonFraction> million contingent upon the achievement of specified amounts of aggregate net sales of products incorporating the intellectual property acquired by the Company in the merger; (c) tiered royalty payments ranging from low single-digit to low double-digit percentages of annual net sales of such products, subject to customary provisions permitting royalty reductions and offset; and (d)&#160;a percentage of sublicense revenue related to such products. The Company agreed to use commercially reasonable efforts to achieve specified development and regulatory objectives relating to DARE-LARC1. In June 2021, a total of $<ix:nonFraction unitRef="usd" contextRef="i0088c2d5b3d841d79733a7ba7eb77c3f_I20210630" decimals="-4" name="us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjM1NzA_94c69993-d5a8-4288-ab17-cda52b96c25f">1.25</ix:nonFraction>&#160;million of that potential additional consideration became payable upon the achievement of certain of the funding and product development milestone events, $<ix:nonFraction unitRef="usd" contextRef="id9429fbf089249aeb34b9943fccfb3aa_I20191130" decimals="-5" name="dare:AssetAcquisitionContingentConsiderationCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjM3MjA_7d324695-7e7d-4a55-95fd-59df2edaf9b0">1.0</ix:nonFraction> million of which was recorded as contingent consideration on the Company's consolidated balance sheets upon the completion of the MBI acquisition and $<ix:nonFraction unitRef="usd" contextRef="id046ca48ded64152a085f277ffdbdbd8_I20220331" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjM4NjU_9a67a436-6fe9-495c-8e1c-1550a1f65855">250,000</ix:nonFraction> of which was expensed in 2021. In July 2021, the Company&#8217;s board of directors elected to make these milestone payments in shares of the Company&#8217;s common stock, to the extent permissible under the terms of the merger agreement with MBI, and, in September 2021, the Company issued approximately <ix:nonFraction unitRef="shares" contextRef="i3b39b4e982ff415dacb98beb58f1a039_D20210901-20210930" decimals="0" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjQyMTg_eda7055a-81ca-4b93-988d-681ed83e8bc3">700,000</ix:nonFraction> shares of its common stock to former stockholders of MBI and paid $<ix:nonFraction unitRef="usd" contextRef="i3b39b4e982ff415dacb98beb58f1a039_D20210901-20210930" decimals="0" name="dare:PaymentsToStockholdersRepresentativeInBusinessCombination" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjQyODc_e50254d8-3235-4c13-9c98-8bac6b572bbe">75,000</ix:nonFraction> in cash to the stockholders&#8217; representative in accordance with the terms of the merger agreement in satisfaction of the $<ix:nonFraction unitRef="usd" contextRef="i4e1024a3a3274602a0b50c48b9aa2f4a_D20210601-20210630" decimals="-4" name="dare:PaymentOfAdditionalConsiderationInBusinessCombination" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjQ0MTA_99e6e2f5-99bc-4dd4-91ef-1479437123e2">1.25</ix:nonFraction>&#160;million in milestone payments associated with milestones achieved in June 2021. See Note 7.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pear Tree Acquisition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company completed its acquisition of Pear Tree Pharmaceuticals, Inc., or Pear Tree. The Company acquired Pear Tree to secure the rights to develop a proprietary vaginal formulation of tamoxifen, now known as DARE-VVA1, as a potential treatment for vulvar and vaginal atrophy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company must make contingent payments to certain Pear Tree licensors and former stockholders of Pear Tree that become payable upon achievement of specified clinical, regulatory and commercial milestones, which may be paid, in the Company&#8217;s sole discretion, in cash or shares of the Company&#8217;s common stock.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="icaab3fc5cad84aa68c64aa66792d39df" continuedAt="i7901bb712cda419383a626e9f4c0f5e2">Royalty Payments</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7901bb712cda419383a626e9f4c0f5e2">. Subject to royalty reductions and offsets, (a) the former stockholders of Pear Tree will be eligible to receive tiered royalties based on percentages of net sales of certain products and a percentage of sublicense revenue and (b) certain Pear Tree licensors will be eligible to receive royalties based on percentages of net sales of certain products and a percentage of sublicense revenue.</ix:continuation> </span></div><div id="i8cc494c450e145729b0695b37b951a0a_46"></div><div style="margin-top:18pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfNTc0Nw_feb5a245-c979-4d74-9d92-d40fa116ff63" continuedAt="i572e37c89ea84569aacd8bbd00f4a7f6" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="i572e37c89ea84569aacd8bbd00f4a7f6" continuedAt="i5f98ece9a0244f7cb38f3e48258e169e"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">October 2021 ATM Sales Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into a sales agreement with SVB Leerink LLC to sell shares of its common stock from time to time through an "at-the-market," or ATM, equity offering program under which SVB Leerink acts as the Company's agent. The Company agreed to pay a commission equal to <ix:nonFraction unitRef="number" contextRef="i8375b393afa24fd4b4172cd82f83fced_D20210401-20210430" decimals="2" name="dare:PercentageOfAggregateCommission" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNTc0Ng_772c5f73-e87b-44ee-94e0-11697a4a2804">3</ix:nonFraction>% of the gross proceeds of any common stock sold under the agreement, plus certain legal expenses. Shares of the Company's common stock sold under the agreement will be issued pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-254862) and the base prospectus included therein, originally filed with the SEC on March 30, 2021, and declared effective on April 7, 2021, and the prospectus supplement dated October 13, 2021 relating to the offering of up to $<ix:nonFraction unitRef="usd" contextRef="i027223a9458b44d887cea8de9f1d3556_I20210430" decimals="-5" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNTc1MA_bf14221e-668e-4d12-b3b3-24e7a29e51dc">50.0</ix:nonFraction> million in shares of the Company's common stock under this sales agreement, and any subsequent prospectus supplement filed with the SEC related to this ATM equity offering program.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, the Company sold no shares under this agreement.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5f98ece9a0244f7cb38f3e48258e169e" continuedAt="i2ed52237d25e4c55a908962a3376cb33"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">April 2021 ATM Sales Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into a sales agreement with SVB Leerink LLC to sell shares of its common stock from time to time through an ATM, equity offering program under which SVB Leerink acts as the Company's agent. Under the sales agreement, the Company may issue and sell up to $<ix:nonFraction unitRef="usd" contextRef="i027223a9458b44d887cea8de9f1d3556_I20210430" decimals="-5" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNTg1OQ_bf14221e-668e-4d12-b3b3-24e7a29e51dc">50.0</ix:nonFraction> million of shares of its common stock. The Company agreed to pay a commission equal to <ix:nonFraction unitRef="number" contextRef="i8375b393afa24fd4b4172cd82f83fced_D20210401-20210430" decimals="2" name="dare:PercentageOfAggregateCommission" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNTg2Nw_772c5f73-e87b-44ee-94e0-11697a4a2804">3</ix:nonFraction>% of the gross proceeds of any common stock sold under the agreement, plus certain legal expenses. Any shares of the Company's common stock sold under the agreement will be issued pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-254862) and the base prospectus included therein, originally filed with the SEC on March 30, 2021, and declared effective on April 7, 2021, and the prospectus supplement dated April 7, 2021 filed with the SEC on April 8, 2021.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, the Company sold no shares under this agreement.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 ATM Sales Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018 the Company entered into a common stock sales agreement with H.C. Wainwright &amp; Co., LLC, or Wainwright, relating to the offering and sale of shares of its common stock from time to time in an ATM equity offering program through Wainwright, acting as sales agent. Under the agreement, Wainwright was entitled to a commission at a fixed commission rate equal to <ix:nonFraction unitRef="number" contextRef="iba344274a14c460b96e230f0cbc5d2bb_D20180101-20180131" decimals="INF" name="dare:PercentageOfAggregateCommission" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTg1OA_a285b093-a1a3-46cc-936b-8fbeaf59616b">3.0</ix:nonFraction>% of the gross proceeds per share sold under the agreement. In March 2021, the Company provided notice to Wainwright to terminate the agreement, and the agreement terminated in April 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Line</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into a purchase agreement, or the Purchase Agreement, and a registration rights agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park. Under the terms and subject to the conditions of the Purchase Agreement, the Company had the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park was obligated to purchase up to&#160;$<ix:nonFraction unitRef="usd" contextRef="i06ac362092d24b6bb3af02efaf7065e2_I20210430" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNjYzNA_269120b5-5001-44e5-9c20-ea776a9bdd3e">15.0</ix:nonFraction> million&#160;of the Company&#8217;s common stock. The Company incurred legal, accounting, and other fees related to the Purchase Agreement of approximately $<ix:nonFraction unitRef="usd" contextRef="i860c63444c524b589d982ed7ae48fd65_I20210430" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNjcyOA_d76633c4-5caf-46de-99e5-382853b2cf4f">374,000</ix:nonFraction>. These costs were amortized and expensed as shares were sold under the Purchase Agreement. As of December 31, 2021, the Company had sold and Lincoln Park had purchased $<ix:nonFraction unitRef="usd" contextRef="i06ac362092d24b6bb3af02efaf7065e2_I20210430" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNzU2NA_269120b5-5001-44e5-9c20-ea776a9bdd3e">15.0</ix:nonFraction> million of the Company's common stock under the Purchase Agreement, there were <ix:nonFraction unitRef="usd" contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231" decimals="INF" name="dare:DeferredOfferingCostsUnamortizedPortion" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzODM2OQ_e8c2fe68-be5d-4228-bea3-9f16bfc8d2aa">no</ix:nonFraction> unamortized costs, and no more shares of common stock may be sold by the Company to Lincoln Park under the Purchase Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company closed an underwritten public offering in connection with which the Company issued to the investors in that offering warrants exercisable through February 2023 and that initially had an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i10618bb6d8c14b5885277741ae4a3091_I20180228" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNzU3NQ_8b338965-cb11-4e69-80cd-491e71a2d21c">3.00</ix:nonFraction> per share.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrants include a price-based anti-dilution provision, which provides that, subject to certain limited exceptions, the exercise price of the warrants will be reduced each time the Company issues or sells (or is deemed to issue or sell) securities for a net consideration per share less than the exercise price of those warrants in effect immediately prior to such issuance or sale. In addition, subject to certain exceptions, if the Company issues, sells or enters into any agreement to issue or sell securities at a price which varies or may vary with the market price of the shares of the Company&#8217;s common stock, the warrant holders have the right to substitute such variable price for the exercise price of the warrant then in effect. These warrants are exercisable only for cash, unless a registration statement covering the shares issued upon exercise of the warrants is not effective, in which case the warrants may be exercised on a cashless basis. A registration statement covering the shares issued upon exercise of the warrants is currently effective. The Company estimated the fair value of the warrants as of February 15, 2018 to be approximately $<ix:nonFraction unitRef="usd" contextRef="i7d4b21210fae4311928f3d408e82529a_I20180215" decimals="-5" name="dare:EstimatedFairValueOfWarrantsRecordedInEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNzU3OQ_ce705af4-0afa-426f-abc8-6b4df774e1cc">3.0</ix:nonFraction> million which was recorded in equity as of the grant date. The Company early adopted ASU 2017-11 as of January 1, 2018 and recorded the fair value of the warrants as equity. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019 and July 2020, in accordance with the price-based anti-dilution provision discussed above, the exercise price of these warrants was automatically reduced to $<ix:nonFraction unitRef="usdPerShare" contextRef="if840484cdcd14e6c9fa54cfcf591c465_D20190401-20190430" decimals="2" name="us-gaap:WarrantExercisePriceDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfNTQ5NzU1ODE0ODg3Nw_b1b60632-46a4-4851-a5ac-e00197b03cd9">0.98</ix:nonFraction> per share and to $<ix:nonFraction unitRef="usdPerShare" contextRef="i32d71d006cd64f2da751eaec03afcb7e_D20200701-20200731" decimals="2" name="us-gaap:WarrantExercisePriceDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfNTQ5NzU1ODE0ODg5MA_77d32c51-c9eb-4b1e-93ef-2127d6f3a91a">0.96</ix:nonFraction> per share, respectively, and as a result of the triggering of the anti-dilution provision, $<ix:nonFraction unitRef="usd" contextRef="if840484cdcd14e6c9fa54cfcf591c465_D20190401-20190430" decimals="-5" name="dare:DeemedDividendFromTriggerOfRoundDownProvisionFeature" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfNTMxNw_b053d27d-85f1-46da-b281-70a46db894ad">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i32d71d006cd64f2da751eaec03afcb7e_D20200701-20200731" decimals="0" name="dare:DeemedDividendFromTriggerOfRoundDownProvisionFeature" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfNTQ5NzU1ODE0ODkwNA_607a41b7-ee96-4a10-8306-1893b12175eb">6,863</ix:nonFraction>, respectively, was recorded to additional paid-in capital.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="INF" name="dare:NumberOfCommonStockWarrantsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfNTQ5NzU1ODE0ODkxMQ_d765d306-fecd-4f68-ad7f-5bea47e1f82f">no</ix:nonFraction> warrants were exercised. During the three months ended March&#160;31, 2021, warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="INF" name="dare:NumberOfCommonStockWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNzcxNw_65259f20-92b7-4352-abc4-de7df2069cf9">52,500</ix:nonFraction> shares of common stock were exercised for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNzcyMQ_1cc7be67-55ab-40e7-90ce-cdd04f6e4fd4">50,000</ix:nonFraction>. <ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfNTc1MA_df6c5d78-828a-40c3-906e-78e1c401f44a" continuedAt="if84edef8396d4b47bba526bfa74486f8" escape="true">As of March&#160;31, 2022, the Company had the following warrants outstanding:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:1pt;text-align:center"><ix:continuation id="i2ed52237d25e4c55a908962a3376cb33"><ix:continuation id="if84edef8396d4b47bba526bfa74486f8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:169.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:19.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:18.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:118.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:18.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:157.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying<br/>Outstanding Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b97f0e3d65145168bade1be8778dd8a_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RhYmxlOmNmNGQ4N2ZhYjYzODQ3ZjNhNWU5N2UyYWJjZWVlZGRiL3RhYmxlcmFuZ2U6Y2Y0ZDg3ZmFiNjM4NDdmM2E1ZTk3ZTJhYmNlZWVkZGJfMy0wLTEtMS0zNzQ5MQ_2e987df5-5d73-4815-96ff-5fcf3aad8c84">6,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9b97f0e3d65145168bade1be8778dd8a_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RhYmxlOmNmNGQ4N2ZhYjYzODQ3ZjNhNWU5N2UyYWJjZWVlZGRiL3RhYmxlcmFuZ2U6Y2Y0ZDg3ZmFiNjM4NDdmM2E1ZTk3ZTJhYmNlZWVkZGJfMy0zLTEtMS0zNzQ5MQ_dca4a184-85ca-4395-813e-fb6954f57a87">10.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3314d2bef75a49b1a150ea0c2b067414_D20220101-20220331" name="dare:ClassOfWarrantOrRightsWarrantsExpirationDate" format="ixt:date-month-day-year" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RhYmxlOmNmNGQ4N2ZhYjYzODQ3ZjNhNWU5N2UyYWJjZWVlZGRiL3RhYmxlcmFuZ2U6Y2Y0ZDg3ZmFiNjM4NDdmM2E1ZTk3ZTJhYmNlZWVkZGJfMy01LTEtMS0zNzQ5MQ_7ae3cb12-95e7-4998-b185-9f9ea8cfac6d">04/04/2026</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea4b068280ea4864aa871809e542b4c1_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RhYmxlOmNmNGQ4N2ZhYjYzODQ3ZjNhNWU5N2UyYWJjZWVlZGRiL3RhYmxlcmFuZ2U6Y2Y0ZDg3ZmFiNjM4NDdmM2E1ZTk3ZTJhYmNlZWVkZGJfNC0wLTEtMS0zNzQ5MQ_89fc51df-d55c-47b1-b83c-399520ad0137">1,374,515</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea4b068280ea4864aa871809e542b4c1_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RhYmxlOmNmNGQ4N2ZhYjYzODQ3ZjNhNWU5N2UyYWJjZWVlZGRiL3RhYmxlcmFuZ2U6Y2Y0ZDg3ZmFiNjM4NDdmM2E1ZTk3ZTJhYmNlZWVkZGJfNC0zLTEtMS0zNzQ5MQ_fa43a1f6-1b62-4d57-b555-9352bc9a1bfd">0.96</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc86055f4ef84234810f28d2d776d7ae_D20220101-20220331" name="dare:ClassOfWarrantOrRightsWarrantsExpirationDate" format="ixt:date-month-day-year" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RhYmxlOmNmNGQ4N2ZhYjYzODQ3ZjNhNWU5N2UyYWJjZWVlZGRiL3RhYmxlcmFuZ2U6Y2Y0ZDg3ZmFiNjM4NDdmM2E1ZTk3ZTJhYmNlZWVkZGJfNC01LTEtMS0zNzQ5MQ_d545a40e-97b5-4411-b731-abc93787e015">02/15/2023</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RhYmxlOmNmNGQ4N2ZhYjYzODQ3ZjNhNWU5N2UyYWJjZWVlZGRiL3RhYmxlcmFuZ2U6Y2Y0ZDg3ZmFiNjM4NDdmM2E1ZTk3ZTJhYmNlZWVkZGJfNS0wLTEtMS0zNzQ5MQ_936925db-b9fb-466d-bece-ac79b588cfb7">1,381,015</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></ix:continuation></ix:continuation></div><div id="i8cc494c450e145729b0695b37b951a0a_43"></div><div style="margin-top:18pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMjI1NA_b04d5d29-b15c-4e28-922b-36961018ae27" continuedAt="ic2b9151d4abd4a9686f214922f0a78aa" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="ic2b9151d4abd4a9686f214922f0a78aa" continuedAt="ief0c024db1b749f2b26e2bcfdbbcaaab"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2014 Employee Stock Purchase Plan, or the ESPP, became effective in April 2014, but no offering period has been initiated thereunder since January 2017. There was <ix:nonFraction unitRef="usd" contextRef="idf23d7941e8f4965a9fcb43805fcc930_D20220101-20220331" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMjQ0_3bbbbad5-7705-480b-a8de-6591575ef6ea"><ix:nonFraction unitRef="usd" contextRef="ia882bdf1215042478edd6c0cd729a9d8_D20210101-20210331" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMjQ0_5d3c74b8-e6c6-43cf-a990-db288d1eebbd">no</ix:nonFraction></ix:nonFraction> stock-based compensation related to the ESPP for the three months ended March&#160;31, 2022 or March&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated 2014 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains the Amended and Restated 2014 Stock Incentive Plan, or the Amended 2014 Plan, which provides for the grant of options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to employees, officers and directors, and consultants and advisors. There were <ix:nonFraction unitRef="shares" contextRef="ide7f913a931341588fd2f90818d1cee0_I20180731" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfNjc0_2c54b71c-370b-4293-a49a-6c9d1df8175f">2,046,885</ix:nonFraction> shares of common stock authorized for issuance under the Amended 2014 Plan when it was approved by the Company's stockholders in July 2018. The number of authorized shares increases annually on the first day of each fiscal year until, and including, the fiscal year ending December 31, 2024 by the least of (i) <ix:nonFraction unitRef="shares" contextRef="ide7f913a931341588fd2f90818d1cee0_I20180731" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfOTg4_60880fe9-8b99-431f-8a06-0fd572738e2b">2,000,000</ix:nonFraction>, (ii) <ix:nonFraction unitRef="number" contextRef="ia0d3fa77cb2945be89df99f83cc05ff3_D20180701-20180731" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfOTk3_aeaf4323-af72-4068-a29a-345fece861fc">4</ix:nonFraction>% of the number of outstanding shares of common stock on such date, or (iii) an amount determined by the Company&#8217;s board of directors. On January 1, 2022, the number of authorized shares increased by <ix:nonFraction unitRef="shares" contextRef="i409dea6286e3437c8531176fdea88602_D20210101-20210101" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMTE5Ng_f87f3665-dc9d-4a3b-97b4-3c39ef5c95b0">2,000,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="i20fdc0f111514e9491d559f7b5252a54_I20210101" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMTIwMg_9134e70a-c995-4857-92e5-94c450673e32">2,201,855</ix:nonFraction>.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Stock Option Activity</span></div><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMjI0OA_4555de9a-4513-4bd0-aefa-a3194a6c5d6f" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes stock option activity under the Amended 2014 Plan and related information for the three months ended March&#160;31, 2022. The exercise price of all options granted during the three months ended March&#160;31, 2022 was equal to the market value of the Company&#8217;s common stock on the date of grant. As of March&#160;31, 2022, unamortized stock-based compensation expense of approximately $<ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMTY3Ng_52cdbb9e-041c-4993-8222-995bdca7b20b">5.3</ix:nonFraction>&#160;million will be amortized over a weighted average period of <ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dare:WeightedAverageAmortizationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMTczMQ_7def18e5-a518-4390-a7f5-166c06997e9b">2.98</ix:nonNumeric> years. At March&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="if170fdedc89840ffbe1185f85069788b_I20220331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMTc0Mg_82ab4198-0c91-48e1-8ebe-4f8c12fa01de">642,175</ix:nonFraction> shares of common stock were available for future awards granted under the Amended 2014 Plan.</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:376.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5bcbbadf58fc412c9319a78f2b9da62f_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfMS0xLTEtMS0zNzQ5MQ_e95c7f7d-b1dc-4c6a-93de-603735f8ae6e">4,717,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5bcbbadf58fc412c9319a78f2b9da62f_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfMS0zLTEtMS0zNzQ5MQ_f3f4ad40-6acb-4df9-9516-406db70e29fc">1.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf2231aefe254fee96b7aeae2d91ae6e_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfMi0xLTEtMS0zNzQ5MQ_88e4c68a-3a65-4b8a-bc55-23ef31b35139">1,759,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idf2231aefe254fee96b7aeae2d91ae6e_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfMi0zLTEtMS0zNzQ5MQ_5be37296-ada5-43b8-9b20-43152e4113ba">1.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf2231aefe254fee96b7aeae2d91ae6e_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfMy0xLTEtMS0zNzQ5MQ_597d8755-4218-4255-8f86-b7c542d442e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idf2231aefe254fee96b7aeae2d91ae6e_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfMy0zLTEtMS0zNzQ5MQ_08f03225-f234-4c08-84e2-35b73f5da292">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idf2231aefe254fee96b7aeae2d91ae6e_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfNC0xLTEtMS0zNzQ5MQ_01b01dad-a8b2-40f7-af86-c9e96600bd7b">200,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idf2231aefe254fee96b7aeae2d91ae6e_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfNC0zLTEtMS0zNzQ5MQ_be9b89e6-964d-4321-8d57-6e45d764dc28">1.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf2231aefe254fee96b7aeae2d91ae6e_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfNS0xLTEtMS0zNzQ5MQ_939d62f5-4027-416f-a2f9-db772297e97f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idf2231aefe254fee96b7aeae2d91ae6e_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfNS0zLTEtMS0zNzQ5MQ_c1a2f83c-54aa-465d-bf92-452033ab2608">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if170fdedc89840ffbe1185f85069788b_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfNi0xLTEtMS0zNzQ5MQ_df29fe62-438d-4aca-a38f-3989a2ef5ae0">6,277,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if170fdedc89840ffbe1185f85069788b_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfNi0zLTEtMS0zNzQ5MQ_04fc7efb-42d6-4316-8858-74bf312cd2b8">1.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if170fdedc89840ffbe1185f85069788b_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfNy0xLTEtMS0zNzQ5MQ_21699bc3-245a-4eaa-8291-091d46c36237">2,597,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if170fdedc89840ffbe1185f85069788b_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfNy0zLTEtMS0zNzQ5MQ_cbe8966b-e79f-45cf-a562-ff60eee1a8f3">1.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMjI1Mg_dc2f7f9e-d233-4b72-b66b-2748393dc874" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense related to stock options granted to employees and directors recognized in the condensed consolidated statements of operations is as follows:</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:376.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied5f9449859d4a96a3953aabaec51ac8_D20220101-20220331" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOjk4ZjA5ZGU0ZGY4NDQ3ZjA5NjVkNjVkMGY5MzBhZTlmL3RhYmxlcmFuZ2U6OThmMDlkZTRkZjg0NDdmMDk2NWQ2NWQwZjkzMGFlOWZfMi0xLTEtMS0zNzQ5MQ_37775cf7-d144-464f-9465-864ea25bb536">174,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29bec700eba84708bf53a7ae61f8afcc_D20210101-20210331" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOjk4ZjA5ZGU0ZGY4NDQ3ZjA5NjVkNjVkMGY5MzBhZTlmL3RhYmxlcmFuZ2U6OThmMDlkZTRkZjg0NDdmMDk2NWQ2NWQwZjkzMGFlOWZfMi0zLTEtMS0zNzQ5MQ_4613bc8a-5cb2-4a4d-bf50-f45873ea26de">115,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibafd6f2e17734e039ee794c367b91ef1_D20220101-20220331" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOjk4ZjA5ZGU0ZGY4NDQ3ZjA5NjVkNjVkMGY5MzBhZTlmL3RhYmxlcmFuZ2U6OThmMDlkZTRkZjg0NDdmMDk2NWQ2NWQwZjkzMGFlOWZfMy0xLTEtMS0zNzQ5MQ_055dd0d7-efdd-4d77-8dc4-546d70917d95">357,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia79e904977c04b448a641740a5804fd5_D20210101-20210331" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOjk4ZjA5ZGU0ZGY4NDQ3ZjA5NjVkNjVkMGY5MzBhZTlmL3RhYmxlcmFuZ2U6OThmMDlkZTRkZjg0NDdmMDk2NWQ2NWQwZjkzMGFlOWZfMy0zLTEtMS0zNzQ5MQ_b51fb7ab-9d9b-4137-b03f-16ff8515c99d">250,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if248f08c609e432db641de162429b03e_D20220101-20220331" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOjk4ZjA5ZGU0ZGY4NDQ3ZjA5NjVkNjVkMGY5MzBhZTlmL3RhYmxlcmFuZ2U6OThmMDlkZTRkZjg0NDdmMDk2NWQ2NWQwZjkzMGFlOWZfNC0xLTEtMS0zNzQ5MQ_1a0a03c0-6a04-430d-81d6-4788ffbd89fb">532,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a8c036f5354223a3849ead24935854_D20210101-20210331" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOjk4ZjA5ZGU0ZGY4NDQ3ZjA5NjVkNjVkMGY5MzBhZTlmL3RhYmxlcmFuZ2U6OThmMDlkZTRkZjg0NDdmMDk2NWQ2NWQwZjkzMGFlOWZfNC0zLTEtMS0zNzQ5MQ_43c3427a-938b-429b-8e21-e1fc5c119d8e">365,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ief0c024db1b749f2b26e2bcfdbbcaaab"><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMjI1NQ_6430c2ee-6874-437b-9907-b270ee14731a" escape="true"><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the three months ended March&#160;31, 2022 are as follows:</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:442.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:45pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmQ0NGZlMzk3OGY4NTQ2MGU4MWM2Y2IxYzU0NmUyMGQ1L3RhYmxlcmFuZ2U6ZDQ0ZmUzOTc4Zjg1NDYwZTgxYzZjYjFjNTQ2ZTIwZDVfMS0yLTEtMS0zNzQ5MQ_51533d08-1409-4d51-acb9-8765fff8caf9">6.02</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmQ0NGZlMzk3OGY4NTQ2MGU4MWM2Y2IxYzU0NmUyMGQ1L3RhYmxlcmFuZ2U6ZDQ0ZmUzOTc4Zjg1NDYwZTgxYzZjYjFjNTQ2ZTIwZDVfMi0yLTEtMS0zNzQ5MQ_83dbfe75-c0ce-4c43-aa4e-f526c9f529d8">1.65</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmQ0NGZlMzk3OGY4NTQ2MGU4MWM2Y2IxYzU0NmUyMGQ1L3RhYmxlcmFuZ2U6ZDQ0ZmUzOTc4Zjg1NDYwZTgxYzZjYjFjNTQ2ZTIwZDVfMy0yLTEtMS0zNzQ5MQ_b64e912f-9c71-4a6a-a52f-3d9132faa9f1">122</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="2" name="dare:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmQ0NGZlMzk3OGY4NTQ2MGU4MWM2Y2IxYzU0NmUyMGQ1L3RhYmxlcmFuZ2U6ZDQ0ZmUzOTc4Zjg1NDYwZTgxYzZjYjFjNTQ2ZTIwZDVfNC0yLTEtMS0zNzQ5MQ_e13e7aa7-f6c3-4b12-920f-362b210840b7">0.0</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmQ0NGZlMzk3OGY4NTQ2MGU4MWM2Y2IxYzU0NmUyMGQ1L3RhYmxlcmFuZ2U6ZDQ0ZmUzOTc4Zjg1NDYwZTgxYzZjYjFjNTQ2ZTIwZDVfNS0yLTEtMS0zNzQ5MQ_b20e1fd4-0e22-4689-9cee-59e733077262">0.0</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of options granted</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmQ0NGZlMzk3OGY4NTQ2MGU4MWM2Y2IxYzU0NmUyMGQ1L3RhYmxlcmFuZ2U6ZDQ0ZmUzOTc4Zjg1NDYwZTgxYzZjYjFjNTQ2ZTIwZDVfNi0yLTEtMS0zNzQ5MQ_25963115-d4c0-4d23-8d8b-fee397daef79">1.38</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i8cc494c450e145729b0695b37b951a0a_49"></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMzIwMg_11688a93-8850-48f7-8fc1-513914357068" continuedAt="i6e0afc3b2e2d43698d37d74be602665a" escape="true">LEASED PROPERTIES</ix:nonNumeric></span></div><ix:continuation id="i6e0afc3b2e2d43698d37d74be602665a" continuedAt="i9ff01c47cc314c47a981b1a3c7985835"><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease for its corporate headquarters (<ix:nonFraction unitRef="sqft" contextRef="ia70cb47052db467ab271c5cebe1a8cb5_I20180701" decimals="0" name="us-gaap:NetRentableArea" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfNzk_74dbba02-3d73-4f0e-83dc-70a944a944a6">3,169</ix:nonFraction> square feet of office space) commenced on July 1, 2018. In February 2022, the Company entered into an amendment to extend the term of the lease for <ix:nonNumeric contextRef="i10a03a7421004d2d9b8fe72bbc336117_I20220228" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMjI0_86740e7f-9687-4bf6-bcc7-9504f4ffe752">two years</ix:nonNumeric> such that the term now expires on August 31, 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MBI, a wholly owned subsidiary the Company acquired in November 2019, leases general office space in Lexington, Massachusetts and warehouse space in Billerica, Massachusetts. The Lexington lease commenced on July 1, 2013. In February 2022, the Company entered into an amendment to extend the term of the lease for <ix:nonNumeric contextRef="i8152258bc79f4460a437ec7e86255593_I20220228" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfNTg3_5f8f640c-6ed3-4f99-b137-bbd0704bdca1">three years</ix:nonNumeric> such that the term now expires on December 31, 2025, subject to the landlord's right to terminate the lease on December 31, 2023. The Billerica lease commenced on October 1, 2016 and terminated on March 31, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under</span><span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the terms of each lease, the lessee pays base annual rent (subject to an annual fixed percentage increase), plus property taxes, and other normal and necessary expenses, such as utilities, repairs, and maintenance. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. The leases do not require material variable lease payments, residual value guarantees or restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The leases do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. The Company uses an incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="ie288d155ad8e4f839c40e7b4157edee1_I20191231" decimals="2" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMTc4NA_860db538-6b41-4d5b-af3a-388ef04cf4e3">7</ix:nonFraction>% for operating leases that commenced prior to January 2019 (and all of the Company's operating leases commenced prior to such date). The depreciable lives of operating leases and leasehold improvements are limited by the expected lease term.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, the Company reported operating lease <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMzIwMw_e12ce3aa-c3f3-4f18-b044-bf8fda01a7e9">ROU assets</span> of approximately $<ix:nonFraction unitRef="usd" contextRef="i715e356f19e949be97608ee8258262cb_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMjEwMA_32e16cb8-32c3-44c4-8071-9b5d6f6cfdaf">1.2</ix:nonFraction> million in other non-current assets, and approximately $<ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMjEzNg_1c220bae-f134-4e6c-a6ef-c3901ca641b5">294,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMjE0Mw_ee181927-9c97-40d1-b1fa-78155def5fd9">913,000</ix:nonFraction>, respectively, in current portion of lease liabilities and lease liabilities long-term on the condensed consolidated balance sheet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease costs were approximately $<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMjMyNQ_2edecc1b-8b7e-4a27-9716-27eda28120f5">169,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMjMzMg_36a547ed-cf8c-4c63-90a1-ac18bb5450cc">135,000</ix:nonFraction> for the three months ended&#160;March&#160;31, 2022 and March&#160;31, 2021, respectively. Operating lease costs consist of monthly lease payments expense, common area maintenance and other repair and maintenance costs and are included in general and administrative expenses in the condensed consolidated statements of operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities was approximately $<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMjc5MA_0615ed0f-c810-44f8-a35d-b0b300a56017">123,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMjc5Nw_f7e23bae-7853-4d48-9a33-b6fd88e447d4">112,000</ix:nonFraction>&#160;for the three months ended&#160;March&#160;31, 2022 and March&#160;31, 2021, respectively. These amounts are included in operating activities in the condensed consolidated statements of cash flows. Further, at March&#160;31, 2022, operating leases had a weighted average remaining lease term of <ix:nonNumeric contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMzEwMg_2bdeaef0-bf5a-40e7-9ff4-fa38eedf6526">3.13</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9ff01c47cc314c47a981b1a3c7985835"><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMzIwNg_706de8ca-da05-419d-ab37-57067e88cf33" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, future minimum lease payments under the Company's operating leases are as follows:</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:445.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RhYmxlOjY0NTgxNzNkY2Q5MDRlNDY4OWUxMDY3M2Y4N2NkNmQ2L3RhYmxlcmFuZ2U6NjQ1ODE3M2RjZDkwNGU0Njg5ZTEwNjczZjg3Y2Q2ZDZfMS0xLTEtMS0zNzQ5MQ_074aca47-2633-42ed-80ef-cf9687a44f70">288,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RhYmxlOjY0NTgxNzNkY2Q5MDRlNDY4OWUxMDY3M2Y4N2NkNmQ2L3RhYmxlcmFuZ2U6NjQ1ODE3M2RjZDkwNGU0Njg5ZTEwNjczZjg3Y2Q2ZDZfMi0xLTEtMS0zNzQ5MQ_b9e596c9-bb5a-4129-8ca8-319f7c72446c">422,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RhYmxlOjY0NTgxNzNkY2Q5MDRlNDY4OWUxMDY3M2Y4N2NkNmQ2L3RhYmxlcmFuZ2U6NjQ1ODE3M2RjZDkwNGU0Njg5ZTEwNjczZjg3Y2Q2ZDZfMy0xLTEtMS0zOTM4OA_a628ec06-0947-43dc-a09c-5167a681e2b7">384,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RhYmxlOjY0NTgxNzNkY2Q5MDRlNDY4OWUxMDY3M2Y4N2NkNmQ2L3RhYmxlcmFuZ2U6NjQ1ODE3M2RjZDkwNGU0Njg5ZTEwNjczZjg3Y2Q2ZDZfNC0xLTEtMS0zOTM4OA_9014055c-2dec-4c8f-b167-32405dd33876">297,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RhYmxlOjY0NTgxNzNkY2Q5MDRlNDY4OWUxMDY3M2Y4N2NkNmQ2L3RhYmxlcmFuZ2U6NjQ1ODE3M2RjZDkwNGU0Njg5ZTEwNjczZjg3Y2Q2ZDZfMy0xLTEtMS0zNzQ5MQ_65379c65-5393-423f-a124-553c3195a7ec">1,391,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RhYmxlOjY0NTgxNzNkY2Q5MDRlNDY4OWUxMDY3M2Y4N2NkNmQ2L3RhYmxlcmFuZ2U6NjQ1ODE3M2RjZDkwNGU0Njg5ZTEwNjczZjg3Y2Q2ZDZfNC0xLTEtMS0zNzQ5MQ_d61068ed-acdd-4322-9bea-197fe92e3f1b">183,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="0" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RhYmxlOjY0NTgxNzNkY2Q5MDRlNDY4OWUxMDY3M2Y4N2NkNmQ2L3RhYmxlcmFuZ2U6NjQ1ODE3M2RjZDkwNGU0Njg5ZTEwNjczZjg3Y2Q2ZDZfNS0xLTEtMS0zNzQ5MQ_550c9951-e865-48de-bf3e-e37437d8d50d">1,208,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i8cc494c450e145729b0695b37b951a0a_52"></div><div style="margin-top:18pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="us-gaap:CommitmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMzgzOA_3d2f885a-0c41-4cf3-9d33-87d4c099d016" continuedAt="ieb3be5f631fe4304a399dd32510ed700" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="ieb3be5f631fe4304a399dd32510ed700" continuedAt="i8ba2b48ee5004ddd8d8a4094b743cbe7"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CRADA with NICHD for the Pivotal Phase 3 Study of Ovaprene</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a Cooperative Research and Development Agreement, or the CRADA, with the U.S. Department of Health and Human Services, as represented by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or NICHD, for the conduct of a multi-center, non-comparative, pivotal Phase 3 clinical study of Ovaprene, or the Ovaprene Phase 3. The Ovaprene Phase 3 will be conducted within NICHD&#8217;s Contraceptive Clinical Trial Network with NICHD contractor Health Decisions Inc., a contract research organization, providing clinical coordination and data collection and management services for the Ovaprene Phase 3. The Company and NICHD will each provide medical oversight and final data review and analysis for the Ovaprene Phase 3 and will work together to prepare the final report of the results of the Ovaprene Phase 3. The Company is responsible for providing clinical supplies of Ovaprene, coordinating interactions with the FDA, preparing and submitting supportive regulatory documentation, and providing a total of $<ix:nonFraction unitRef="usd" contextRef="ifa2f7c9e3aba42cea0f0485646d7bae0_I20210731" decimals="-5" name="dare:ResearchAndDevelopmentAgreementCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMTE2OQ_dcc85168-af8d-47ef-ac29-d7bbee4bbf4c">5.5</ix:nonFraction>&#160;million in payments to NICHD to be applied toward the costs of conducting the Ovaprene Phase 3. NICHD will be responsible for the other costs related to the conduct of the Ovaprene Phase 3. In accordance with the payment schedule under the CRADA, the Company has made aggregate payments of $<ix:nonFraction unitRef="usd" contextRef="i39725376a360492eb4ee1a813cb8c93c_D20210701-20210731" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMTQ0Mg_b0f8438b-2465-4d0f-ba75-f8404b626164">5.0</ix:nonFraction> million of the total amount payable to NICHD, $<ix:nonFraction unitRef="usd" contextRef="i0417ba5df1e4483f9533526585cde1af_D20220101-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfODI0NjMzNzIxMjcwNg_ba5d1b9b-f884-4a0a-8dca-68bf3bf20c37">3.5</ix:nonFraction>&#160;million of which was paid during the first quarter of 2022. At March&#160;31, 2022, the remaining amount of the Company's payment obligation under the CRADA was $<ix:nonFraction unitRef="usd" contextRef="i4de0e117c45544bba3f02be2df728a46_I20220331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMTU0Mw_55d946ad-59d7-4e53-bddb-905968dad9d5">0.5</ix:nonFraction>&#160;million. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3 above, in connection with the acquisition of MBI, the Company agreed to pay additional consideration of up to $<ix:nonFraction unitRef="usd" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="-5" name="dare:PaymentOfAdditionalConsiderationInBusinessCombination" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMTcwNQ_e2fbf94e-cfb7-4cf1-b558-8f6dd726990b">46.5</ix:nonFraction>&#160;million to the former stockholders of MBI contingent upon the achievement of specified funding, product development and regulatory milestones. In June 2021, $<ix:nonFraction unitRef="usd" contextRef="i0088c2d5b3d841d79733a7ba7eb77c3f_I20210630" decimals="-4" name="us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMTg2OA_4d4d251c-e6fc-4709-9a39-15e87e18b285">1.25</ix:nonFraction>&#160;million of that potential additional consideration became payable upon the achievement of certain of the funding and product development milestone events, $<ix:nonFraction unitRef="usd" contextRef="i0088c2d5b3d841d79733a7ba7eb77c3f_I20210630" decimals="-5" name="dare:AssetAcquisitionContingentConsiderationCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMjAxOA_0bc6205d-95e6-41c0-bfa0-5b1c1a630293">1.0</ix:nonFraction> million of which was previously recorded as contingent consideration on the Company's consolidated balance sheets upon the completion of the MBI acquisition and $<ix:nonFraction unitRef="usd" contextRef="i328c1592bccd48bd90299695bcc0f38e_I20211231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMjE3NA_2492b5e5-1ad8-440e-a1cd-19e344d8d9ca">250,000</ix:nonFraction> of which was expensed in 2021. In July 2021, the Company&#8217;s board of directors elected to make these milestone payments in shares of the Company&#8217;s common stock, to the extent permissible under the terms of the merger agreement with MBI, and, in September 2021, the Company issued approximately <ix:nonFraction unitRef="shares" contextRef="i3b39b4e982ff415dacb98beb58f1a039_D20210901-20210930" decimals="0" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMjUyNw_eda7055a-81ca-4b93-988d-681ed83e8bc3">700,000</ix:nonFraction> shares of its common stock to former stockholders of MBI and paid $<ix:nonFraction unitRef="usd" contextRef="i3b39b4e982ff415dacb98beb58f1a039_D20210901-20210930" decimals="0" name="dare:PaymentsToStockholdersRepresentativeInBusinessCombination" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMjU5Ng_e50254d8-3235-4c13-9c98-8bac6b572bbe">75,000</ix:nonFraction> to the stockholders&#8217; representative in accordance with the terms of the merger agreement in satisfaction of the $<ix:nonFraction unitRef="usd" contextRef="i4e1024a3a3274602a0b50c48b9aa2f4a_D20210601-20210630" decimals="-4" name="dare:PaymentOfAdditionalConsiderationInBusinessCombination" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMjcxMQ_99e6e2f5-99bc-4dd4-91ef-1479437123e2">1.25</ix:nonFraction>&#160;million in milestone payments associated with milestones achieved in June 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><ix:continuation id="i8ba2b48ee5004ddd8d8a4094b743cbe7" continuedAt="i5b51d3fb85004cb7bb85eed3d1c4123b"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Payable</span></ix:continuation></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5b51d3fb85004cb7bb85eed3d1c4123b">In April 2020, due to the economic uncertainty resulting from the impact of the COVID-19 pandemic on the Company's operations and to support its ongoing operations and retain all employees, the Company applied for and received a loan of $<ix:nonFraction unitRef="usd" contextRef="i1668c60b90eb40c1b26a55cdec6001a8_D20200401-20200430" decimals="0" name="dare:CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMzAzNg_634c72e2-481e-4278-b958-6a9f542552c9">367,285</ix:nonFraction> under the Paycheck Protection Program, or the PPP, of the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, administered by the U.S. Small Business Administration, or the SBA. Under the terms of the PPP, the loan proceeds could be used for "qualifying expenses" and, subject to specified limitations in the CARES Act and under the terms of the PPP, certain amounts of the loan, including accrued interest, may be forgiven if used for qualifying expenses. In January 2021, the Company was notified that the principal balance of its PPP loan and all accrued interest, which together totaled $<ix:nonFraction unitRef="usd" contextRef="i2bda66626a774b0baba97582a51cae04_I20210131" decimals="0" name="dare:NotesPayableCurrentPlusAccruedInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMzY0NA_d0fde9b3-0b0a-402b-8e5e-b3e2418fcccf">369,887</ix:nonFraction>, were fully forgiven by the SBA. The Company recorded a gain on extinguishment of note payable and debt forgiveness income with respect to such loan forgiveness in the first quarter of 2021.</ix:continuation> </span></div><div id="i8cc494c450e145729b0695b37b951a0a_55"></div><div style="margin-top:18pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="dare:GrantAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfNDI5MQ_593f79a6-ec67-42f0-ab09-8e883165d3fb" continuedAt="i752d502cae7747639b6fd1671738258f" escape="true">GRANT AWARDS</ix:nonNumeric></span></div><ix:continuation id="i752d502cae7747639b6fd1671738258f" continuedAt="i9ab351a2872246dc950be6170c476638"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NICHD Non-Dilutive Grant Funding</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received notices of awards and non-dilutive grant funding from NICHD to support the development of Ovaprene, DARE-PTB1 and DARE-LARC1. NICHD issues notices of awards to the Company for a specified amount, and the Company must incur and track expenses eligible for reimbursement under the award and submit a detailed accounting of such expenses to receive payment. If the Company receives payments under the award, the amounts of such payments are recognized in the statements of operations as a reduction to research and development activities as the related costs are incurred to meet those obligations over the period. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ovaprene</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2018 through 2021, the Company received approximately $<ix:nonFraction unitRef="usd" contextRef="ia85f04efe0484874ad1aa6775fdee9cf_D20180101-20181231" decimals="-5" name="dare:ProceedsFromAwardOfGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfNzQ1_098564c3-651d-4f73-93cf-718e14c69dae">1.9</ix:nonFraction> million of non-dilutive grant funding from NICHD for clinical development efforts supporting Ovaprene. All funds under the final notice of award had been disbursed as of December 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DARE-PTB1</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company received a notice of award of a grant from NICHD to support the development of DARE-PTB1. The award in the amount of $<ix:nonFraction unitRef="usd" contextRef="i8dab52c413224c10ab210ce9f3988ef2_D20200801-20200831" decimals="-3" name="dare:ProceedsFromAwardOfGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMTM2MA_ecf880cb-7982-4a8b-b053-cecf7579fe1b">300,000</ix:nonFraction> was for the "Phase I" segment of the project outlined in the Company's grant application, which is ongoing. Additional potential funding of up to approximately $<ix:nonFraction unitRef="usd" contextRef="ie5c7aa9a64ff4a88b42de5c106336b62_I20200831" decimals="-5" name="dare:AdditionalPotentialFundingRelatedToGrantAward" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMTU0Ng_f3d91a71-6390-4cbe-a04e-8a9330672aa5">2.0</ix:nonFraction> million for the "Phase II" segment of the project outlined in the grant application is contingent upon satisfying specified requirements, including, assessment of the results of the Phase I segment, determination that the Phase I goals were achieved, and availability of funds. There is no guarantee the Company will receive any Phase II award.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded credits to research and development expense for costs related to the NICHD award of approximately $<ix:nonFraction unitRef="usd" contextRef="i18d65ffa0cea435eacda2d0f47db2080_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMTY0OTI2NzQ1MDA1OA_751a1cd3-1916-4b3b-a0f7-f8eaaa0a4ab5">17,000</ix:nonFraction> during the three months ended March&#160;31, 2022. At March&#160;31, 2022, the Company recorded a receivable of approximately $<ix:nonFraction unitRef="usd" contextRef="i2a168cd74d64472ca8597b5ad0dc79dd_I20220331" decimals="-3" name="dare:ReceivableForExpensesEligibleForReimbursement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMTY0OTI2NzQ1MDA2Mw_d7de227a-416f-44b5-83aa-1e96cb643989">19,000</ix:nonFraction> for expenses incurred through such date that it believes are eligible for reimbursement under the grant.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DARE-LARC1</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company received a notice of award of a grant from NICHD to support the development of DARE-LARC1. The award in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="i33bd9119af634fbe93377ca5a92bc751_D20210901-20210930" decimals="-3" name="dare:ProceedsFromAwardOfGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMjQwMA_328ab36c-d38c-4ff8-8134-cdbe2fc2a611">300,000</ix:nonFraction> is to be used to explore device insertion and removal in non-clinical studies, which is to occur during the period of September 2021 through August 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded credits to research and development expense of approximately $<ix:nonFraction unitRef="usd" contextRef="i316cb86d094b4f0ca01c73b2980e9033_D20220101-20220331" decimals="0" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMTY0OTI2NzQ1MDA3NQ_c10503b0-5d12-439b-be98-8864c05d2e8e">165,000</ix:nonFraction> for costs related to the NICHD award during the three months ended March&#160;31, 2022. At March&#160;31, 2022, the Company recorded a receivable of approximately $<ix:nonFraction unitRef="usd" contextRef="i45c466b7177d4d4c87ff8c12edc1f3ce_I20220331" decimals="-3" name="dare:ReceivableForExpensesEligibleForReimbursement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMTY0OTI2NzQ1MDA4MA_e3fd26f1-4ee4-4392-b7dc-78494941e7f5">173,000</ix:nonFraction> for expenses incurred through such date that it believes is eligible for reimbursement under the grant. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9ab351a2872246dc950be6170c476638"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DARE-LARC1 Non-Dilutive Grant Funding</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MBI Grant Agreement </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's wholly-owned subsidiary, MBI, was awarded $<ix:nonFraction unitRef="usd" contextRef="i316cb86d094b4f0ca01c73b2980e9033_D20220101-20220331" decimals="-5" name="us-gaap:BusinessDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMzA2NQ_2e95f632-18d3-4147-bef2-a2ebcb70f6cc">5.4</ix:nonFraction>&#160;million to support the development of DARE-LARC1 under a grant agreement with the Bill &amp; Melinda Gates Foundation, or the Foundation. The funding period under this agreement ended on June 30, 2021. Expenses eligible for funding were incurred, tracked and reported to the Foundation. MBI received aggregate payments under this agreement of approximately $<ix:nonFraction unitRef="usd" contextRef="i316cb86d094b4f0ca01c73b2980e9033_D20220101-20220331" decimals="-5" name="us-gaap:BusinessDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMTY0OTI2NzQ1MDE1MQ_2e95f632-18d3-4147-bef2-a2ebcb70f6cc">5.4</ix:nonFraction>&#160;million. At June 30, 2021, all payments under this agreement associated with research and development expenses for DARE-LARC1 had been incurred and reported to the Foundation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 DARE-LARC1 Grant Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into an agreement with the Foundation, or the 2021 DARE-LARC1 Grant Agreement, under which the Company was awarded up to $<ix:nonFraction unitRef="usd" contextRef="iaeedb8a01d9247389d7cf8d46e7e6514_I20210630" decimals="-4" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMzY5MA_8b7d1dc5-9c8b-45cf-a0a3-9b419159fa6a">48.95</ix:nonFraction>&#160;million to support the development of DARE-LARC1. The 2021 DARE-LARC1 Grant Agreement will support technology development and preclinical activities over the period of June 30, 2021 to November 1, 2026, to advance DARE-LARC1 in non-clinical proof of principle studies. The Company received an initial payment of $<ix:nonFraction unitRef="usd" contextRef="i010eed1efee345f4bd75243e4aa2a9c3_D20210701-20210731" decimals="-4" name="dare:ProceedsFromAwardOfGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMzk5Nw_85cb04b5-cc4c-4461-97d7-0d54702b0efd">11.45</ix:nonFraction>&#160;million in July 2021. Additional payments are contingent upon the DARE-LARC1 program&#8217;s achievement of specified development and reporting milestones. At March&#160;31, 2022, approximately $<ix:nonFraction unitRef="usd" contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331" decimals="-5" name="dare:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMTA5OTUxMTYzNjU1OA_c9376d96-f953-4ad2-8097-5fb3f659d8ec">9.7</ix:nonFraction> million of deferred grant funding liability under this agreement was recorded in the Company's condensed consolidated balance sheet.</span></div></ix:continuation><div id="i8cc494c450e145729b0695b37b951a0a_61"></div><div style="margin-top:18pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82MS9mcmFnOjJlYjJhNzM2ZmJlNTQ5MGJhNjJlMDUxODE5M2QzODU1L3RleHRyZWdpb246MmViMmE3MzZmYmU1NDkwYmE2MmUwNTE4MTkzZDM4NTVfODQ2_dcc3a8a9-bc1d-437a-bec5-808038701bd4" continuedAt="i23379ceb5d2a470094dfaf8cd0eccca1" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i23379ceb5d2a470094dfaf8cd0eccca1"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes basic net loss per share using the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under outstanding options and warrants to purchase shares of the Company&#8217;s common stock. Common share equivalents are excluded from the diluted net loss per share calculation if their effect is anti-dilutive.</span></div><ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82MS9mcmFnOjJlYjJhNzM2ZmJlNTQ5MGJhNjJlMDUxODE5M2QzODU1L3RleHRyZWdpb246MmViMmE3MzZmYmU1NDkwYmE2MmUwNTE4MTkzZDM4NTVfODQ5_5f9dc5a2-5b51-49a5-acd1-358173ffce66" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect:</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:367.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Potentially dilutive securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie858a3b9009b46719e1b0cd4afebc54a_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82MS9mcmFnOjJlYjJhNzM2ZmJlNTQ5MGJhNjJlMDUxODE5M2QzODU1L3RhYmxlOjZjYzBmMTVlMjJhODRmMDZiOWJmZTk0MDAyODk2OTMyL3RhYmxlcmFuZ2U6NmNjMGYxNWUyMmE4NGYwNmI5YmZlOTQwMDI4OTY5MzJfMi0yLTEtMS0zNzQ5MQ_bb0609ba-ae24-4bd7-8e85-d44a94bfafcc">6,277,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4385c5c549b145f4b28516d3328b7fae_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82MS9mcmFnOjJlYjJhNzM2ZmJlNTQ5MGJhNjJlMDUxODE5M2QzODU1L3RhYmxlOjZjYzBmMTVlMjJhODRmMDZiOWJmZTk0MDAyODk2OTMyL3RhYmxlcmFuZ2U6NmNjMGYxNWUyMmE4NGYwNmI5YmZlOTQwMDI4OTY5MzJfMi00LTEtMS0zNzQ5MQ_99afb26e-593a-4c41-a07e-a0d87777f880">4,311,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3581e3652c314104b3dfff05b889fd6e_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82MS9mcmFnOjJlYjJhNzM2ZmJlNTQ5MGJhNjJlMDUxODE5M2QzODU1L3RhYmxlOjZjYzBmMTVlMjJhODRmMDZiOWJmZTk0MDAyODk2OTMyL3RhYmxlcmFuZ2U6NmNjMGYxNWUyMmE4NGYwNmI5YmZlOTQwMDI4OTY5MzJfMy0yLTEtMS0zNzQ5MQ_d113534a-cd18-4cfb-97dd-b9cb01f52164">1,381,015</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13cb5e160bd84532b3e28a94c5995894_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82MS9mcmFnOjJlYjJhNzM2ZmJlNTQ5MGJhNjJlMDUxODE5M2QzODU1L3RhYmxlOjZjYzBmMTVlMjJhODRmMDZiOWJmZTk0MDAyODk2OTMyL3RhYmxlcmFuZ2U6NmNjMGYxNWUyMmE4NGYwNmI5YmZlOTQwMDI4OTY5MzJfMy00LTEtMS0zNzQ5MQ_ea2fac58-7f1a-4cbd-b9b4-2c9e2f5e862a">1,856,143</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82MS9mcmFnOjJlYjJhNzM2ZmJlNTQ5MGJhNjJlMDUxODE5M2QzODU1L3RhYmxlOjZjYzBmMTVlMjJhODRmMDZiOWJmZTk0MDAyODk2OTMyL3RhYmxlcmFuZ2U6NmNjMGYxNWUyMmE4NGYwNmI5YmZlOTQwMDI4OTY5MzJfNC0yLTEtMS0zNzQ5MQ_4473c806-8b67-48f7-9c19-49b181951d22">7,658,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82MS9mcmFnOjJlYjJhNzM2ZmJlNTQ5MGJhNjJlMDUxODE5M2QzODU1L3RhYmxlOjZjYzBmMTVlMjJhODRmMDZiOWJmZTk0MDAyODk2OTMyL3RhYmxlcmFuZ2U6NmNjMGYxNWUyMmE4NGYwNmI5YmZlOTQwMDI4OTY5MzJfNC00LTEtMS0zNzQ5MQ_ac0bbb7e-f1e7-42b4-81e0-c337fbd1815a">6,167,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i8cc494c450e145729b0695b37b951a0a_64"></div><div style="margin-top:18pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82NC9mcmFnOjNmYjI4ZDNjM2E2MjRkYTY5MTRlYTY5N2I1NGVkMDI1L3RleHRyZWdpb246M2ZiMjhkM2MzYTYyNGRhNjkxNGVhNjk3YjU0ZWQwMjVfMTE5MA_f088db69-8c4a-45f2-9fe2-75b6ade8d475" continuedAt="ie57e666bfe614e148518a17216d889ea" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="ie57e666bfe614e148518a17216d889ea"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of Common Stock</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Between April 1, 2022 and May&#160;10, 2022, the Company sold an aggregate of approximately <ix:nonFraction unitRef="shares" contextRef="i4b95783721914c71aa6fe27dd4fcf58c_D20220401-20220510" decimals="-3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82NC9mcmFnOjNmYjI4ZDNjM2E2MjRkYTY5MTRlYTY5N2I1NGVkMDI1L3RleHRyZWdpb246M2ZiMjhkM2MzYTYyNGRhNjkxNGVhNjk3YjU0ZWQwMjVfMTA5OTUxMTYzMDgyOQ_362909ba-2a19-4b16-9601-10dcbe485070">751,000</ix:nonFraction> shares of common stock for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i4b95783721914c71aa6fe27dd4fcf58c_D20220401-20220510" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82NC9mcmFnOjNmYjI4ZDNjM2E2MjRkYTY5MTRlYTY5N2I1NGVkMDI1L3RleHRyZWdpb246M2ZiMjhkM2MzYTYyNGRhNjkxNGVhNjk3YjU0ZWQwMjVfMTA5OTUxMTYzMDg5Nw_51a3e38c-0d82-4733-bcfc-b350511c6239">1.2</ix:nonFraction> million under its ATM equity offering program. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commencement of Phase 1/2 Clinical Study of DARE-HRT1</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2022, the Company announced commencement of its Phase 1/2 clinical study of DARE-HRT1. The open-label study will evaluate the pharmacokinetics (PK) of two versions of DARE-HRT1 in approximately 20 healthy, post-menopausal women over approximately three consecutive months of use. The study will also collect safety, usability, acceptability and symptom-relief data. The study is being conducted by the Company's wholly owned subsidiary in Australia.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i8cc494c450e145729b0695b37b951a0a_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and notes thereto included in this Quarterly Report on Form 10-Q and our audited financial statements and notes thereto for the year ended December&#160;31, 2021 included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, or our 2021 10-K, filed with the Securities and Exchange Commission, or SEC, on March 31, 2022. Past operating results are not necessarily indicative of results that may occur in future periods.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> The following discussion includes forward-looking statements.&#160;See &#8220;CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS,&#8221; above. Forward-looking statements are not guarantees of future performance and our actual results may differ materially from those currently anticipated and from historical results depending upon a variety of factors, including, but not limited to, those discussed in Part I, Item 1A. Risk Factors of our 2021 10-K, and in our subsequent filings with the SEC, including any discussed in Part II, Item 1A of this report under the heading &#8220;Risk Factors,&#8221; which are incorporated herein by reference.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this report, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Dar&#233;&#8221; or the &#8220;Company&#8221; refer collectively to Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires. All information presented in this report is based on our fiscal year. Unless otherwise stated, references to particular years, quarters, months or periods refer to our fiscal years ending December 31 and the associated quarters, months and periods of those fiscal years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dar&#233; Bioscience</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a registered trademark of Dar&#233; Bioscience, Inc. and XACIATO&#8482; is a trademark of Dar&#233; Bioscience, Inc. with registration pending. Ovaprene</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a registered trademark licensed to Dar&#233; Bioscience, Inc. All other trademarks, service marks or trade names appearing in this report are the property of their respective owners. Use or display by us of other parties&#8217; trademarks, service marks or trade names is not intended to and does not imply a relationship with, or endorsements or sponsorship of, us by the trademark, service mark or trade name owners.</span></div><div id="i8cc494c450e145729b0695b37b951a0a_70"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company committed to advancing innovative products for women&#8217;s health. We are driven by a mission to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility and vaginal and sexual health. Our business strategy is to in-license or otherwise acquire the rights to differentiated product candidates in our areas of focus, some of which have existing clinical proof-of-concept data, to take those candidates through mid to late-stage clinical development or regulatory approval, and to establish and leverage strategic collaborations to achieve commercialization. We and our wholly owned subsidiaries operate in one business segment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first product, XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%), was approved by the FDA in December 2021, as a single-dose prescription medication for the treatment of bacterial vaginosis in female patients 12 years of age and older. In March 2022, we entered into an exclusive global license agreement with an affiliate of Organon &amp; Co., Organon International GmbH, or Organon, to commercialize XACIATO. XACIATO is expected to be available commercially in the United States in the fourth quarter of 2022.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product pipeline includes diverse programs that target unmet needs in women's health in the areas of contraception, fertility and vaginal and sexual health and aim to expand treatment options, enhance outcomes and improve ease of use for women. We are primarily focused on progressing the development of our existing product candidates. We are also exploring opportunities to expand our portfolio by leveraging assets to which we hold rights or obtaining rights to new assets, with continued focus solely on women's health. Our current portfolio includes two product candidates in advanced clinical development:</span></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Ovaprene</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a hormone-free, monthly contraceptive; and</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Sildenafil Cream, 3.6%</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a proprietary cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder, or FSAD.</span></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio also includes four product candidates in Phase 1 clinical development or that we believe are Phase 1-ready:</span></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-HRT1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a combination bio-identical estradiol and progesterone intravaginal ring, or IVR, for the treatment of menopausal symptoms, including vasomotor symptoms, as part of hormone therapy following menopause;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-VVA1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy as an option for women with hormone-receptor positive breast cancer;</span></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-FRT1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an intravaginal ring containing bio-identical progesterone for broader luteal phase support as part of an in vitro fertilization treatment plan; and</span></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-PTB1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our portfolio includes these pre-clinical stage potential product candidates:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">DARE-LARC1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a contraceptive implant delivering levonorgestrel with a woman-centered design that has the potential to be a long-acting, yet convenient and user-controlled contraceptive option;</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">ADARE-204 and ADARE-214</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, injectable formulations of etonogestrel designed to provide contraception over 6-month and 12-month periods, respectively; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-RH1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a novel approach to non-hormonal contraception for both men and women by targeting the CatSper ion channel.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary operations have consisted of research and development activities to advance our portfolio of product candidates through clinical development and regulatory approval. We expect our research and development expenses will continue to represent the majority of our operating expenses for at least the next twelve months. For the remainder of 2022, we expect to continue to focus our resources on advancement of Ovaprene and Sildenafil Cream, 3.6%, and our other product candidates that have reached the human clinical study development phase. In addition, we expect to incur significant research and development expenses for the DARE-LARC1 program for the next several years, but we also expect such expenses will be supported by non-dilutive funding provided under a grant agreement we entered into in June 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to several risks common to biopharmaceutical companies, including dependence on key employees, dependence on third-party collaborators and service providers, competition from other companies, the need to develop commercially viable products in a timely and cost-effective manner, and the need to obtain adequate additional capital to fund the development of product candidates. We are also subject to several risks common to other companies in the industry, including rapid technology change, regulatory approval of products, uncertainty of market acceptance of products, success of third parties in the marketing, sale and distribution of our products, competition from substitute products and larger companies, compliance with government regulations, protection of proprietary technology, and product liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic remains an evolving and uncertain risk to our business, operating results, financial condition and stock price. To date, we believe the pandemic contributed to a slower than expected initial pace of enrollment in our Phase 2b clinical study of Sildenafil Cream, 3.6% and delays in commencement of clinical studies and nonclinical testing for more than one of our earlier stage clinical programs, but has not had a material adverse effect on our business as a whole. Continued uncertainty regarding the duration and impact of the pandemic on the U.S. and global economies, healthcare systems, workplace environments and capital markets, preclude any prediction as to the ultimate effect of the pandemic on our business. See the risk factor in Part I, Item 1A of our 2021 10-K titled, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 pandemic has negatively impacted our business and, in the future, may materially and adversely affect our business, financial condition and results and stock price, including by increasing the cost and timelines for our clinical development programs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">XACIATO</span></div><div style="margin-bottom:10pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we entered into an exclusive license agreement with Organon pursuant to which Organon will obtain exclusive worldwide rights to develop, manufacture and commercialize XACIATO. The effective date of the agreement will occur following the satisfaction of closing conditions that include receipt of all applicable approvals, or the expiration or termination of all applicable waiting periods, required under applicable antitrust laws, including the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. We will receive a $10.0 million non-refundable and non-creditable payment from Organon following the effective date of the agreement, which is expected to occur in the second quarter of 2022, and we are entitled to receive a $2.5 million milestone payment following the first commercial sale of a licensed product in the United States. XACIATO is expected to be available commercially in the U.S. in the fourth quarter of 2022. We will also be eligible to receive future potential milestone payments of up to $180.0 million and tiered double-digit royalties based on net sales.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, we will be responsible for regulatory interactions and for providing product supply on an interim basis until Organon assumes such responsibilities. Until such time, Organon will purchase all of its product requirements of XACIATO from us at a transfer price equal to our manufacturing costs plus a single-digit percentage markup. We will fulfill our commercial supply obligations through the contract manufacturer that provided clinical supplies of XACIATO for our pivotal Phase 3 DARE-BVFREE clinical study of XACIATO. We will not be responsible for other costs of commercializing XACIATO. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Our Pipeline: Clinical-Stage Programs</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Ovaprene</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we initiated an Investigational Device Exemption, or IDE, review process with the FDA for a multi-center, non-comparative, pivotal Phase 3 clinical study of the safety and efficacy of Ovaprene to prevent pregnancy. Our IDE submission was subsequently converted to an IDE pre-submission so that the FDA could engage in a collaborative discussion with us regarding items that must be addressed prior to enrollment of any subjects in the Phase 3 study. This process is ongoing and we believe it will allow us to finalize the protocol and design of the study as the registration study to support a future PMA submission. Based on communications with the FDA, in terms of study sample size and duration, we expect that at least 200 subjects completing 12 months of Ovaprene use will be adequate. We are targeting commencement of the Phase 3 study during 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The planned Phase 3 clinical study will be conducted under our Cooperative Research and Development Agreement, or CRADA, with the U.S. Department of Health and Human Services, as represented by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or the NICHD, part of the National Institutes of Health, and within NICHD&#8217;s Contraceptive Clinical Trial Network. We and NICHD will each provide medical oversight and final data review and analysis for the study and will work together to prepare the final report of the results of the study. We are responsible for providing clinical supplies of Ovaprene, coordinating interactions with the FDA, preparing and submitting supportive regulatory documentation, and providing a total of $5.5&#160;million in payments to NICHD to be applied toward the costs of conducting the Phase 3 study of which a total of $5.0 million has been paid. NICHD will be responsible for the other costs related to the conduct of the Phase 3 study and will manage the payment of expenses to contract research organization Health Decisions Inc., the clinical sites, and other parties involved with the study. If the Phase 3 study is successful, we expect the data to support a pre-market approval submission to the FDA, as well as regulatory filings in Europe and other countries worldwide, to allow for marketing approvals of Ovaprene.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Sildenafil Cream, 3.6%</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ongoing Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% in women with FSAD is designed to evaluate Sildenafil Cream, 3.6% compared to placebo cream over 12 weeks of dosing in the participants&#8217; home setting following both a non-drug and placebo run-in period. The primary efficacy endpoint of the study is a composite endpoint that includes patient-reported improvement in genital sensations of arousal and reduction in distress associated with FSAD. The study is expected to randomize 400 to 590 subjects into the double-blind dosing period at 40 to 50 clinical sites in the U.S. to ensure a total of 300 (150:150) to 440 (220:220) subjects complete the 12-week double-blind dosing period. The final size of the study will be determined by a single interim analysis for unblinded sample size re-estimation, based on the study&#8217;s adaptive design. An adaptive design implemented in accordance with the FDA&#8217;s Guidance for Industry on adaptive designs for clinical trials of drugs mitigates the risk of the study being underpowered if the true treatment effect and variability are significantly different from estimates based on published data but are still clinically meaningful. We anticipate that the planned interim analysis will be conducted in 2022, after which we should be able to provide an updated timeframe for announcement of topline data from this trial. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">DARE-HRT1</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we announced initiation of our Phase 1/2 clinical study of DARE-HRT1. The open-label study will evaluate the pharmacokinetics (PK) of two versions of DARE-HRT1 (estradiol 80 &#181;g/progesterone 4 mg IVR and estradiol 160 &#181;g/progesterone 8 mg IVR) in approximately 20 healthy, post-menopausal women over approximately three consecutive months of use. The study will also collect safety, usability, acceptability and symptom-relief data. The study is being conducted by our wholly owned subsidiary in Australia. In 2021, we reported positive topline data from a Phase 1 clinical study that evaluated the PK of the same two versions of DARE-HRT1 over 28 days. We anticipate reporting topline data from the Phase 1/2 study in the fourth quarter of 2022. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">DARE-VVA1</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we announced initiation of our Phase 1/2 clinical study of DARE-VVA1. The randomized, multi-center, double-blind, parallel-arm, placebo-controlled, dose-ranging study is designed to evaluate the safety, tolerability, PK, and pharmacodynamics (PD) of DARE-VVA1 in postmenopausal participants with moderate to severe VVA and is being conducted by our wholly owned Australian subsidiary. We expect the study will enroll approximately 40 postmenopausal women with VVA, including a cohort of women with a history of hormone-receptor positive breast cancer, at approximately three study sites. Eligible participants will be randomly allocated to one of the five treatment groups (approximately 8 participants per group) that will evaluate four dose levels (1 mg, 5 mg, 10 mg, and 20 mg) and a placebo. Following a screening visit, DARE-VVA1 will be self-administered intravaginally once a day for the first two weeks, and then twice a week for the following six weeks for a total treatment period of 56 days. In each treatment group, participants will have serial blood sampling for PK analysis and undergo safety evaluations and preliminary assessments of effectiveness. Following the completion of the treatment period, participants will attend a safety follow-up visit. The primary endpoints of the study will evaluate the safety and tolerability of DARE-VVA1 by vaginal administration and determine the plasma PK of DARE-VVA1 after intravaginal application. Secondary endpoints will evaluate the preliminary efficacy and PD of DARE-VVA1 in terms of the most bothersome symptom and changes in vaginal cytology and pH. We anticipate reporting topline data from the study in the second half of 2022. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">DARE-FRT1 and DARE-PTB1</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting development activities in preparation for Phase 1 clinical studies of DARE-FRT1 and DARE-PTB1. We do not expect to commence clinical development of these product candidates in 2022.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> currently anticipated timelines and aggregate costs for the development of our product candidates could be delayed and could increase as a result of the COVID-19 pandemic, or otherwise. See the risk factor titled,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 pandemic has negatively impacted our business and, in the future, may materially and adversely affect our business, financial condition and results and stock price, including by increasing the cost and timelines for our clinical development programs, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Part I, Item 1A, Risk Factors of our 2021 10-K. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i8cc494c450e145729b0695b37b951a0a_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Events</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global License Agreement with Organon to Commercialize XACIATO</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we entered into an exclusive license agreement with Organon, pursuant to which Organon will obtain exclusive worldwide rights to develop, manufacture and commercialize XACIATO. See &#8220;Strategic Agreements for Product Commercialization &#8211; Organon License Agreement&#8220; in Part I, Item 1. Business of our 2021 10-K for a description of the terms of the license agreement. As discussed above, we will receive a $10.0 million non-refundable and non-creditable payment from Organon following the effective date of the agreement, which is expected to occur in the second quarter of 2022, and we are entitled to receive a $2.5 million milestone payment following the first commercial sale of a licensed product in the United States, which is expected to occur in the fourth quarter of 2022. We currently cannot predict with any reasonable certainty the timing or amount of other potential payments from Organon under the license agreement in future periods. </span></div><div style="margin-bottom:10pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initiation of Phase 1/2 Clinical Study of DARE-HRT1</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As discussed above, in April 2022, we announced initiation of our Phase 1/2 clinical study of DARE-HRT1 in Australia. </span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i8cc494c450e145729b0695b37b951a0a_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have not generated any revenue.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may generate revenue from royalties and commercial milestones based on the net sales of XACIATO, from product sales of other approved products, if any, and from license fees, milestone payments, research and development payments in connection with strategic collaborations. Our ability to generate such revenue, with respect to XACIATO, will depend on the extent to which its commercialization is successful, and with respect to our product candidates, will depend on their successful clinical development, the receipt of regulatory approvals to market such product candidates and the eventual successful commercialization of products. If the commercialization of XACIATO is not successful or we fail to complete the development of product candidates in a timely manner, or to receive regulatory approval for such product candidates, our ability to generate future revenue and our results of operations would be materially adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include research and development costs for our product candidates and transaction costs related to our acquisitions. We recognize all research and development expenses as they are incurred. Research and development expenses consist primarily of:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">expenses incurred under agreements with clinical trial sites and consultants that conduct research and development and regulatory affairs activities on our behalf;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">laboratory and vendor expenses related to the execution of nonclinical studies and clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">contract manufacturing expenses, primarily for the production of clinical supplies; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">transaction costs related to acquisitions of companies, technologies and related intellectual property, and other assets;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">milestone payments due to third parties under acquisition and in-licensing arrangements we incur, or the incurrence of which we deem probable; and</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">internal costs associated with activities performed by our research and development organization and generally benefit multiple programs.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, our research and development expenses consisted primarily of costs associated with the continued development of XACIATO, Ovaprene and Sildenafil Cream, 3.6% and during the first quarter of 2022, our research and development expenses consisted primarily of costs associated with the continued development of Ovaprene and Sildenafil Cream 3.6%. We expect research and development expenses to increase in the future as we continue to invest in the development of and seek regulatory approval for our clinical-stage and Phase 1-ready product candidates and as any other potential product candidates we may develop are advanced into and through clinical trials in the pursuit of regulatory approvals. Such activities will require a significant increase in investment in regulatory support, clinical supplies, inventory build-up related costs, and the payment of success-based milestones to licensors. In addition, we continue to evaluate opportunities to acquire or in-license other product candidates and technologies, which may result in higher research and development expenses due to, among other factors, license fee and/or milestone payments.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may not obtain regulatory approval for any product candidate on a timely or cost-effective basis, or at all. The probability of success of our product candidates may be affected by numerous factors, including clinical results and data, competition, intellectual property rights, manufacturing capability and commercial viability. As a result, we cannot accurately determine the duration and completion costs of development projects or when and to what extent we will generate revenue from the commercialization of any of our product candidates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Fees</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees consist of up-front license fees and annual license fees due under our in-licensing arrangements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist of personnel costs, facility expenses, expenses for outside professional services, including legal, audit and accounting services. Personnel costs consist of salaries, benefits and stock-based compensation. Facility expenses consist of rent and other related costs. </span></div><div id="i8cc494c450e145729b0695b37b951a0a_79"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of financial condition and results of operations is based on our interim condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Preparing these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses, and related disclosures. On an ongoing basis, we evaluate these estimates and judgments. We base our estimates on historical experience and on various assumptions we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. For a description of critical accounting policies that affect our significant judgments and estimates used in the preparation of our unaudited condensed consolidated interim financial statements, refer to Item 7 in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and Note 1 to our financial statements contained in our 2021 10-K, and Note 2 to our unaudited condensed consolidated financial statements contained in this report.</span></div><div id="i8cc494c450e145729b0695b37b951a0a_82"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Three Months Ended March&#160;31, 2022 and 2021 (Unaudited)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our condensed consolidated results of operations for the periods indicated, together with the changes in those items in dollars:</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:225.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,569,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,940,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,805,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,728,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,400,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,400,449)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,693,534)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(706,915)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on extinguishment of note payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369,887)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,398,670)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,323,644)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,075,026)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,841)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,407,820)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,330,485)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,077,335)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not recognize any revenues for either of the three months ended March&#160;31, 2022 or 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and administrative expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of approximately $0.6 million in general and administrative expenses&#160;for the three months ended March&#160;31, 2022 as compared to the three months ended March&#160;31, 2021 was primarily attributable to increases in (i) professional services expense of approximately $351,000, (ii) stock-based compensation expense of approximately 108,000, (iii) personnel costs of approximately $101,000, and (iv) commercial-readiness expenses of approximately $92,000. Such increases were partially offset by a decrease in rent and facilities expenses of $80,000 attributable to the allocation of a portion of rent and facilities expense included in general and administrative in 2021 to research and development in 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect an increase in general and administrative expenses of approximately 20% in 2022 compared to 2021 primarily due to increased personnel expenses and other general corporate overhead. Our general and administrative expenses in 2021 were approximately $8.4 million. Our 2022 general and administrative expenses will include costs related to commercial-readiness activities and obtaining commercial supplies of XACIATO from our contract manufacturer. Following commercial launch of XACIATO, we expect our general and administrative expenses will include payments by us to a third-party licensor, including royalty payments at rates in the high single-digit to low double-digits based on annual net sales of XACIATO. In 2022, in connection with commercialization of XACIATO in the U.S., these payments may include a milestone payment in the mid six-figures and royalty payments on net sales at a high single digit royalty rate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of approximately $0.1&#160;million in research and development expenses for the three months ended March&#160;31, 2022 as compared to the three months ended March&#160;31, 2021 was primarily attributable to increased costs for two of our clinical-stage product candidates, Sildenafil Cream 3.6% and Ovaprene, with approximately $1.6&#160;million related to the ongoing Sildenafil Cream, 3.6% Phase 2b RESPOND clinical trial and manufacturing and regulatory affairs activities for Ovaprene. Also contributing to the increase were increases in (a) personnel costs of approximately $248,000, (b) rent and facilities expenses of $171,000 attributable to the allocation of a portion of rent and facilities expense included in general and administrative in 2021 to research and development in 2022, and (c) stock-based compensation expense of approximately $59,000. Such increases were partially offset by (i) a decrease in development costs of approximately $873,000 as a result of the completion of the Phase 3 clinical trial for XACIATO in December 2020, (ii) a decrease in costs related to development activities for our Phase 1 and Phase 1-ready programs of approximately $843,000, and (iii) a decrease in costs related to development activities for our preclinical programs of approximately $271,000.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously reported, we expect research and development expenses to increase significantly in 2022 as we continue to develop our product candidates. Our research and development expenses in 2021 were approximately $30.6 million. If we advance our programs as currently planned, our research and development expenses for 2022 could be more than double our research and development expenses for 2021. Our 2022 research and development expenses could include up to $4.0 million in milestone payments payable by us to third parties under license and acquisition agreements related to certain of our product candidates, up to $1.0 million of which we may elect to pay in shares of our common stock. As discussed below in the section titled &#8220;Liquidity and Capital Resources,&#8221; we will need to raise substantial additional capital to continue to fund our operations and successfully execute our current operating plan. The pace and extent of our research and development activities and, therefore, our research and development spend, will depend on our cash resources. We expect our research and development spend to vary across our fiscal quarters. In regard to Sildenafil Cream, 3.6%, we anticipate that the costs of the Phase 2b RESPOND clinical trial will be approximately $20.0 million, approximately $9.5 million of which was recorded in prior fiscal years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License fees</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the three months ended March&#160;31, 2022 and March&#160;31, 2021, we accrued $25,000 of the $100,000 annual license maintenance fee payable under our license agreement related to DARE-HRT1.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further discussion of these license fees, see Note 3 to our unaudited condensed consolidated financial statements contained in this report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $1,776 in other income for the three months ended March&#160;31, 2022 as compared to the three months ended March&#160;31, 2021 was primarily due to an increase in interest earned on cash balances in the current period. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on extinguishment of note payable</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $369,887 recorded as a gain on extinguishment of note payable and debt forgiveness income in the first quarter of 2021 represents the forgiveness of all the principal and accrued interest of the loan we obtained under the Paycheck Protection Program, or the PPP, of the Coronavirus Aid, Relief, and Economic Security Act, administered by the U.S. Small Business Administration.</span></div><div id="i8cc494c450e145729b0695b37b951a0a_85"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan of Operations and Future Funding Requirements</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared the accompanying condensed consolidated financial statements on a going concern basis, which assumes that we will realize our assets and satisfy our liabilities in the normal course of business. We have a history of losses from operations, we expect negative cash flows from our operations to continue for the foreseeable future, and we expect that our net losses will continue for at least the next several years as we develop and seek to bring to market our existing product candidates and as we seek to potentially acquire, license and develop additional product candidates. These circumstances raise substantial doubt about our ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and reclassification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of our ability to remain a going concern.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, our accumulated deficit was approximately $118.5 million, our cash and cash equivalents were approximately $39.3 million, and our working capital was approximately $31.4 million. We incurred a loss from operations of approximately $8.4 million, and had negative cash flow from operations of approximately $12.3 million during the three months ended March&#160;31, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our primary uses of capital to be staff-related expenses, the cost of clinical trials and regulatory activities related to our product candidates, costs associated with contract manufacturing services and third-party clinical research and development services, payments to third-parties upon the occurrence of commercial milestones for XACIATO and development milestones for our product candidates pursuant to terms of the agreements under which we acquired or in-licensed rights to those programs, legal expenses, other regulatory expenses and general overhead costs. Our future funding requirements could also include significant costs related to commercialization of our product candidates, if approved, depending on the type, nature and terms of commercial collaborations we establish.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, we expect our expenses, and in particular our research and development expenses, to increase significantly in 2022 compared to 2021 as we continue to develop and seek to bring to market our product candidates, with a focus on our product candidates that have reached the human clinical study development phase. Under the terms of our license agreement with Organon, Organon will purchase all of its product requirements of XACIATO from us at a price equal to our manufacturing costs plus a single digit percentage markup. As a result, we do not anticipate our costs of providing XACIATO commercial supplies will have a material impact on our cash resources and requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan estimates, we do not have sufficient cash to satisfy our working capital needs and other liquidity requirements over at least the next 12 months from the date of issuance of the accompanying condensed consolidated financial statements. Historically, the cash used to fund our operations has come from a variety of sources and predominantly from sales of shares of our common stock. During the three months ended March&#160;31, 2022, we did not generate any proceeds from sales of our common stock. Subsequent to March&#160;31, 2022 and through May&#160;10, 2022 we received approximately $1.2 million in net proceeds from ATM sales of shares of our common stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to raise substantial additional capital to continue to fund our operations and to successfully execute our current business strategy. During 2022, we may receive up to $12.5 million under our license agreement for XACIATO and up to $8.0 million in additional funding for pre-clinical development of DARE-LARC1 under our June 2021 grant agreement, and we will continue to seek to raise capital through the sale of shares of our common stock under our ATM sales agreements, however, when we effect such sales and the amount of shares we can sell depends on a variety of factors including, among others, market conditions, the trading price of our common stock, our determination as to the appropriate sources of funding for our operations, and the number of authorized shares of common stock available for issuance, which is approximately 27 million as of the date hereof. For the foreseeable future, we will evaluate and may pursue a variety of capital raising options on an on-going basis, including equity and debt financings, government or other grant funding, collaborations and strategic alliances or other similar types of arrangements, to cover our operating expenses, and the cost of any license or other acquisition of new product candidates or technologies. The amount and timing of our capital needs have been and will continue to depend highly on many factors, including the product development programs we choose to pursue, the pace and results of our clinical development efforts, and the nature and extent of expansion of our product candidate portfolio, if any. If we raise capital through collaborations, strategic alliances or other similar types of arrangements, we may have to relinquish, on terms that are not favorable to us, rights to some of our technologies or product candidates we would otherwise seek to develop or commercialize.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to us and our stockholders. In addition, equity or debt financings may have a dilutive effect on the holdings of our existing stockholders, and debt financings may subject us to restrictive covenants, operational restrictions and security interests in our assets. If we cannot raise capital when needed, on favorable terms or at all, we will not be able to continue development of our product candidates, will need to reevaluate our planned operations and may need to delay, scale back or eliminate some or all of our development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If we become unable to continue as a going concern, we may have to liquidate our assets, and might realize significantly less than the values at which they are carried on our financial statements, and stockholders may lose all or part of their investment in our common stock. See the risk factor in Part I, Item 1A of our 2021 10-K titled </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We will need to raise additional capital to continue our operations and execute our business strategy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the periods indicated:</span></div><div style="margin-bottom:7pt;margin-top:10pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:520.50pt"><tr><td style="width:1.0pt"></td><td style="width:378.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,343,473)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,377,015)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,553)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,374,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,841)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,357,176)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,684&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net cash used in operating activities</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the three months ended March&#160;31, 2022 included the net loss of $8.4 million, decreased by non-cash stock-based compensation expense of approximately $0.5 million. Components providing operating cash were an increase in accrued expenses of approximately $0.4 million and an increase in accounts payable of approximately $0.7 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components reducing operating cash were an increase in prepaid expenses of approximately $4.3 million, a decrease in deferred grant funding of approximately $0.8 million, and an increase in other receivables of approximately $0.6 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the three months ended March&#160;31, 2021 included the net loss of $7.3 million, decreased by non-cash stock-based compensation expense of approximately $0.4 million and increased by the non-cash gain on the extinguishment of the note payable and accrued interest of approximately $0.4 million related to our PPP loan. Components providing operating cash were an increase in accounts payable of approximately $0.5 million, a decrease in prepaid expenses of approximately $0.2 million, and a decrease in other receivables of approximately $0.2 million. Components reducing operating cash were a decrease in deferred grant funding of approximately $0.9 million and a decrease in accrued expenses of approximately $0.8 million, and an increase in other non-current assets of approximately $0.1 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net cash used in investing activities</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities for three months ended March&#160;31, 2022 was approximately $4,600. </span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No cash was provided by or used in investing activities for the three months ended March&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by financing activities </span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No cash was provided by financing activities for the three months ended March&#160;31, 2022. </span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the three months ended March&#160;31, 2021 consisted of approximately $11.4&#160;million in the aggregate from sales of shares of our common stock under our ATM sales agreement and our equity line after fees and expenses and upon the exercise of warrants during the period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Royalty Agreements</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We agreed to make royalty and milestone payments under the license and development agreements related to XACIATO, Ovaprene, and Sildenafil Cream, 3.6%, and under other agreements related to our other clinical and preclinical candidates.&#160;For further discussion of these potential payments, see Note 3 to our unaudited condensed consolidated financial statements contained in this report.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Contracts</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with various third parties for research studies, clinical trials, testing and other services. These contracts generally provide for termination upon notice, and we do not believe that our non-cancelable obligations under these agreements are material.</span></div><div id="i8cc494c450e145729b0695b37b951a0a_88"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i8cc494c450e145729b0695b37b951a0a_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under SEC rules and regulations, as a smaller reporting company we are not required to provide the information required by this item.</span></div><div id="i8cc494c450e145729b0695b37b951a0a_94"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an evaluation performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) were effective as of March&#160;31, 2022 at the reasonable assurance level.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the fiscal quarter to which this report relates that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i8cc494c450e145729b0695b37b951a0a_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i8cc494c450e145729b0695b37b951a0a_100"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-bottom:10pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in various claims and legal proceedings. Regardless of outcome, litigation and other legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. As of the date of filing this report, there is no material pending legal proceeding to which we are a party or to which any of our property is subject, and management is not aware of any contemplated proceeding by any governmental authority against us.</span></div><div id="i8cc494c450e145729b0695b37b951a0a_103"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investment in shares of our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described in our 2021 10-K, in addition to other information in this report, before investing in our common stock. The occurrence of any of these risks could have a material adverse effect on our business, financial condition, results of operations and growth prospects. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment. There have been no material changes from the risk factors disclosed in Part I, Item 1A. Risk Factors in our 2021 10-K.</span></div><div id="i8cc494c450e145729b0695b37b951a0a_106"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;None.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;None.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;None</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div id="i8cc494c450e145729b0695b37b951a0a_109"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i8cc494c450e145729b0695b37b951a0a_112"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i8cc494c450e145729b0695b37b951a0a_115"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;None.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i8cc494c450e145729b0695b37b951a0a_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incorporated by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Exhibit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">File No.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Filed Herewith</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ex101_10q033122.htm">Exclusive license agreement by and between Organon International GmbH and Dar&#233; Bioscience, Inc., dated as of March 31, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ex102_10q033122.htm">Consent, Waiver and Stand-By License Agreement, dated March 30, 2022, by and among TriLogic Pharma, LLC, and MilanaPharm LLC, Dare Bioscience, Inc., and Organon International GmbH.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ex_102noneedirectorcomppol.htm">Amended &amp; Restated Non-Employee Director Compensation Policy (as amended through January 2022)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit311_20220331.htm">Certification of principal executive officer pursuant to Rule&#160;13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit312_20220331.htm">Certification of principal financial officer pursuant to Rule&#160;13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit321_20220331.htm">Certification of principal executive officer pursuant to 18&#160;U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit322_20220331.htm">Certification of principal financial officer pursuant to 18&#160;U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Label Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(10). The omitted information is not material and is the type that we treat as private or confidential.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or compensatory plan or arrangement</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith. This certification is being furnished solely to accompany this report pursuant to U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated herein by reference into any filing of the registrant whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i8cc494c450e145729b0695b37b951a0a_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:45.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dar&#233; Bioscience, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 12, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Sabrina Martucci Johnson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sabrina Martucci Johnson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 12, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Lisa Walters-Hoffert</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisa Walters-Hoffert</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex101_10q033122.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3b0a00aea3d943e089d5be06d8c23680_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.  IN THIS EXHIBIT, &#8220;&#91;***&#93;&#8221; INDICATES WHERE SUCH INFORMATION HAS BEEN OMITTED.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">EXCLUSIVE LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">by and between</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">ORGANON INTERNATIONAL GMBH</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">and</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">DAR&#201; BIOSCIENCE, INC.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXCLUSIVE LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Exclusive License Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is entered as of March 31, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Execution Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) by and between Organon International GmbH, a limited liability company organized and existing under the laws of Switzerland (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Organon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and Dar&#233; Bioscience, Inc., a corporation organized and existing under the laws of Delaware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dar&#233;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RECITALS&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Dar&#233; has developed or Controls Dar&#233; Know-How (as hereinafter defined) and Dar&#233; Patents (as hereinafter defined)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Organon and Dar&#233; desire to enter into a collaboration to develop, manufacture, commercialize and otherwise exploit Licensed Products (as hereinafter defined) upon the terms and conditions set forth herein&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Organon desires to obtain an exclusive license under the Dar&#233; Patents and Dar&#233; Know-How, and Dar&#233; desires to grant such a license, all upon the terms and conditions set forth herein&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> until Organon establishes the capability to manufacture or have manufactured the Licensed Products, the Parties desire Dar&#233; to supply Licensed Products to Organon for its resale and distribution upon the terms and conditions of the Supply and Distribution Agreement (as hereinafter defined). </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOW, THEREFORE,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, Dar&#233; and Organon hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:13.66pt">DEFINITIONS.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as applicable, the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C. &#167;&#167; 301 et seq., or the Public Health Service Act, 42 U.S.C. &#167;&#167; 262 et seq., as amended from time to time.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Adverse Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any untoward medical occurrence in a human clinical trial subject or in a patient who is administered a Licensed Product, whether or not having a causal relationship with such Licensed Product, including, without limitation, any unfavorable and unintended sign (including, without limitation, abnormal laboratory findings of clinical concern), symptom or disease temporally associated with the use of such Licensed Product.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Person that controls, is controlled by or is under common control with a Party, but only for so long as such control exists.  For the purposes of this definition, the word &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under common control with&#8221;) means the actual power, either directly or indirectly through one or more intermediaries, to direct the management and policies of such Person, whether by the ownership of more than fifty percent (50%) of the voting stock of such entity, or by contract or otherwise.  The Parties acknowledge that in the case of certain entities organized under the laws of certain countries outside of the United States, the maximum percentage ownership permitted by law for a foreign investor may be equal to or less than fifty percent (50%), and that in such case such lower percentage shall be substituted in the preceding sentence, provided that such foreign investor has the power to direct the management or policies of such entity.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">has the meaning given such term in the preamble to this document.</font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">2</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.4.1.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Antibiotic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the active pharmaceutical ingredient of a product that has received Marketing Authorization in the United States as of the Effective Date, that is indicated for use in bacterial vaginosis on its label, and that is within the &#91;***&#93; drug class.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Anti-Corruption Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Applicable Laws regarding corruption, bribery, ethical business conduct, money laundering, political contributions, gifts and gratuities, or lawful expenses to Public Officials or private persons, agency relationships, commissions, lobbying, books and records, and financial controls, including the United States Foreign Corrupt Practices Act, 15 U.S.C. &#167; 78-dd-1, et seq., the United Kingdom Bribery Act 2010, the Criminal Law and Anti-Unfair Competition Law of the People&#8217;s Republic of China, and laws implementing the Convention on Combating Bribery of Foreign Public Officials in International Business Transactions&#59; each as may be amended or supplemented from time to time.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Antitrust Clearance Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the earliest date on which all applicable waiting periods and approvals required under Antitrust Laws with respect to the transactions contemplated under this Agreement have expired or have been terminated (in the case of waiting periods) or been received (in the case of approvals), in each case, without the imposition of any conditions. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Antitrust Filing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means filings by the Parties with the United States Federal Trade Commission and the United States Department of Justice and any applicable Governmental Authority in each other country or jurisdiction where antitrust clearance is required under any Antitrust Laws with respect to the transactions contemplated under this Agreement, together with all required documentary attachments thereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Antitrust Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any and all Applicable Laws, including HSR Act, designed to prohibit, restrict, or regulate actions for the purpose or effect of monopolization or restraint of trade.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means applicable laws, statutes, ordinances, rules, regulations, guidances and orders of any Governmental Authority (including court orders) having jurisdiction over or related to the subject item.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Assignment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.2.4.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a day, other than a Saturday or a Sunday, on which banking institutions in New York, New York are open for business.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means each successive period of twelve (12) months commencing on January 1 and ending on December 31.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party, the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.16.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">any Exchange Act Person becomes the Owner, directly or indirectly, of securities of such Party representing more than &#91;***&#93;% of the combined voting power of such Party&#8217;s then outstanding securities, other than by virtue of a merger, consolidation or similar transaction&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.16.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) such Party or an Affiliate of such Party and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of such Party (or such Affiliate of such Party) immediately prior thereto do not Own, </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">3</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">directly or indirectly, outstanding voting securities representing more than &#91;***&#93;% of the combined outstanding voting power of the surviving Person in such merger, consolidation or similar transaction or more than &#91;***&#93;% of the combined outstanding voting power of a parent of the surviving Person in such merger, consolidation or similar transaction&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.16.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of such Party (or the direct or indirect parent entity of such Party) to an Exchange Act Person.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means a Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial, or post-Marketing Authorization human clinical trial. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Closing Condition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 11.4.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clindamycin Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) a thermosetting vaginal gel formulated with clindamycin phosphate two percent (2%) that is the subject of the Dar&#233; Marketing Authorization, &#91;***&#93; and (b) any other product formulated with clindamycin &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 10.6.10.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Licensed Product that contains (a) clindamycin &#91;***&#93; together with (b) &#91;***&#93;, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means with respect to a product in a country, any and all activities that are undertaken after receipt of Marketing Authorization for the product in such country and that relate to the pricing or reimbursement (including obtaining and maintaining the establishment of prices for such product that can be charged or reimbursed in regulatory jurisdictions where the applicable Regulatory Authorities approve or determine the price or reimbursement of pharmaceutical products but that are not necessary for obtaining Marketing Authorization), marketing, promoting, distributing, importing for sale, offering for sale, selling, or otherwise disposing of the product in such country, including post-Marketing Authorization human clinical trials that are voluntarily undertaken and are not mandated by a Regulatory Authority as a condition of receiving or maintaining Marketing Authorization.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has correlative meaning. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, (a) with respect to the efforts to be expended by Dar&#233; to accomplish a specified objective, such efforts to accomplish such objective that are substantially equivalent to that which &#91;***&#93; would normally use to accomplish that objective under similar circumstances (b) with respect to the efforts to be expended by Organon with respect to an objective relating to a Licensed Product, such efforts to accomplish such objective that are substantially equivalent to those efforts and resources commonly used by &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">for another pharmaceutical product that is at a similar stage in its development or product life and is of similar market potential as the Licensed Product, taking into account &#91;***&#93;, and (c) with respect to the efforts to be expended by each Party under Section 11.2.3, each Party shall comply, as promptly as possible, with any reasonable requests for information by the applicable Governmental Authorities.  Commercially Reasonable Efforts shall be determined, with regard to subparts (a) and (b) in this Section 1.23, on a country-by-country basis, and it is anticipated that the level of effort will be different for different countries. &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Competing Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.8.1(c).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Competitive Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a particular Licensed Product in a country, a product sold by Dar&#233;, its Affiliate or any Third Party (other than a Sublicensee) in such country that (a) is &#91;***&#93;, (b) contains clindamycin, (c) is for treatment or prevention of bacterial vaginosis, (d) is the subject of a Marketing Authorization granted in such country after the Effective Date, and (e) has a &#91;***&#93;.</font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">4</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any item of or right under Dar&#233; Patents or Dar&#233; Know-How, the tangible possession of such items, or the legal authority or right (whether by ownership or license, other than pursuant to this Agreement), or the ability of a Party to grant access to, or a license or sublicense of, or right to use, such items or right, in each case as provided for herein and as applicable, without violating the terms of any agreement or other arrangement with any Third Party existing at the time such Party would be required hereunder to grant the other Party such right to use, access or license or sublicense, and without requiring consent from a Third Party. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Convicted Individual</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Convicted Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.2.14.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">&#8220;Covered Recipient</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.4.4.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dar&#233;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning given such term in the preamble to this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dar&#233; Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.1. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dar&#233; Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all information and materials, including discoveries, improvements, processes, methods, protocols, formulas, data, inventions (including Dar&#233;&#8217;s rights in Joint Agreement Information and Inventions), know-how, Gel Know-How, and trade secrets, patentable or otherwise, which during the term of this Agreement (a) are Controlled by Dar&#233; or any of its Affiliates, subject to Section 3.8, (b) are not generally known in the public domain and (c) are necessary or reasonably useful to Organon for Exploitation of a Clindamycin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Product in the Field&#59; and in each case of (a) through (c), excluding information and materials, including discoveries, improvements, processes, methods, protocols, formulas, data, inventions, know-how, Gel Know-How, and trade secrets, patentable or otherwise, that is or are solely necessary or reasonably useful for the Exploitation of an active or therapeutic ingredient other than clindamycin. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dar&#233; Marketing Authorizations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) NDA 215650 approved by the FDA to Dar&#233; on December 7, 2021 for XACIATO, and (b) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dar&#233; Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Patents that are Controlled by Dar&#233; or any of its Affiliates at any time during the term of this Agreement, subject to Section 3.8, that are necessary or reasonably useful to Organon for Exploitation of a Clindamycin Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in the Field.  Dar&#233; Patents include (a) the Patents set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, (b) all Patents that claim priority to, or claim to a common priority as, any such Patents, in whole or in part, as of the Effective Date or at any time hereafter, and (c) all Patents licensed to Dar&#233; under the DTM Upstream License Agreement&#59; and in the case of (a) and (b), excluding any Patents that are Controlled by Dar&#233; or any of its Affiliates &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dar&#233; Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Regulatory Materials Controlled by Dar&#233; and its Affiliates related to the Dar&#233; Marketing Authorizations.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Data Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.7.1(a).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Debarred Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.2.14.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Debarred Individual</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.2.14.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) pre-clinical and clinical research and drug development activities, (b) formulation, protocol design, test method development and stability testing, toxicology, pharmacokinetic, qualification and validation, manufacturing scale-up and process development and manufacturing of products for use in Clinical Trials, (c) conducting Clinical Trials, statistical analysis and report writing using data generated from Clinical Trials, preparation and submission of Regulatory Materials, seeking, obtaining and maintaining Marketing Authorizations (excluding pricing or governmental reimbursement approvals not necessary to legally market, distribute, </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">5</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">offer for sale or sell a product in a country), regulatory affairs with respect to the foregoing, including communicating with Regulatory Authorities, and satisfying post-marketing approval commitments, and (d) all other activities necessary or useful or otherwise requested or required by a Regulatory Authority or as a condition or in support of obtaining or maintaining any Marketing Authorization (excluding pricing or governmental reimbursement approvals not necessary to legally market, distribute, offer for sale or sell a product in a country). &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has correlative meaning.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 12.7.1.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DTM Upstream License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Exclusive License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> effective as of January 9, 2017, among Hammock Pharmaceuticals, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Hammock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; now Dar&#233; by assignment to Dar&#233; effective as of December 5, 2018), TriLogic Pharma, LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TriLogic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and MilanaPharm LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MilanaPharm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), as amended by that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">First Amendment to License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> effective as of December 5, 2018, and that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Amendment No. 2 to License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> effective December 3, 2019, and that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Second Amendment to License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> effective as of September 21, 2021.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 11.1.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Excluded Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 12.7.2.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Excluded Individual</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Excluded Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.2.14.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exchange Act Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Person or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act of 1934, as amended), whether or not their securities are listed for trading on a securities exchange, except that &#8220;Exchange Act Person&#8221; shall not, with respect to a potential Change in Control of a Party include (a) such Party or any subsidiary of such Party, (b) any employee benefit plan of such Party or any subsidiary of such Party or any trustee or other fiduciary holding securities under an employee benefit plan of such Party or any subsidiary of such Party, (c) an underwriter temporarily holding securities pursuant to an offering of such securities, or (d) a Person Owned, directly or indirectly, by the stockholders of such Party in substantially the same proportions as their Ownership of stock of such Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exploit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means to use, research, Develop, Manufacture, Commercialize or otherwise exploit.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exploitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has correlative meaning. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Facility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the facility(s) where any Licensed Product or active pharmaceutical ingredient therein is approved to be Manufactured by Dar&#233; or its Affiliate or its contract manufacturer under the Dar&#233; Marketing Authorizations as applicable, including &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the United States Food and Drug Administration and any successor governmental authority having substantially the same function. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the treatment, prevention, or supportive care of any human diseases, disorders, conditions, symptoms, or state of health or wellness in or through any intravaginal or urological applications, pathways or routes of administration.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means, with respect to any Licensed Product in a country, the first sale, by a Related Party, for monetary value to a Third Party for use or consumption of such Licensed Product in such country after Marketing Authorization of the Licensed Product in such country, excluding, however, any sale or other distribution for use in a Clinical Trial, reasonable and customary promotional use (including samples), other Development purposes, early access programs (such as pursuant to treatment INDs or protocols, named patient programs or compassionate use programs) or any similar use.</font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">6</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gel Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all information and materials, including discoveries, improvements, processes, methods, protocols, formulas, data, inventions, know-how and trade secrets, patentable or otherwise, which are in the possession and Control of Dar&#233; relating to the exploitation of thermosetting gel.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.51</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gel Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any compound or product, including any drug or device, (a) that is or contains a gel component that is the same or substantially similar to the gel component of any Licensed Product or (b) for which any Regulatory Authority relies, in whole or in part, on the Marketing Authorization, or on safety or efficacy data submitted in support of the Marketing Authorization, of any Licensed Product.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the applicable then-current standards for laboratory activities for pharmaceuticals or biologicals, as set forth in the Act and any regulations or guidance documents promulgated thereunder, including 21 C.F.R. part 58, as amended from time to time, together with any similar standards of good laboratory practice as are required by any Regulatory Authority in the Territory.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the applicable then-current standards for Manufacturing activities for pharmaceuticals, biologicals, or devices, as set forth in the Act and any regulations or guidance documents promulgated thereunder, as amended from time to time, together with any similar standards of good manufacturing practice as are required by any Regulatory Authority in the Territory.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any&#58; (a) nation, principality, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature&#59; (b) federal, state, local, municipal, foreign or other government&#59; (c) governmental or quasigovernmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, representative, organization, unit, body or entity and any court or other tribunal)&#59; (d) multinational or supranational organization or body&#59; or (e) individual, entity, or body, including any court, exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GxP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, collectively, all applicable good practice quality guidelines and regulations, encompassing such internationally recognized standards as GMP, Good Clinical Practice (GCP), GLP, Good Distribution Practice (GDP), and Good Review Practice (GRP), in each case (a) as such terms are defined from time to time by the FDA and other applicable Governmental Authorities pursuant to its regulations, guidelines or otherwise and (b) applicable from time to time to the Development or Manufacturing of a Licensed Product or any intermediate thereof pursuant to Applicable Law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">HSR Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and any rules or regulations promulgated thereunder.&#160;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an investigational new drug application filed with the FDA or the equivalent application or filing filed with any equivalent agency or Governmental Authority outside the United States (including any supra-national entity such as in the European Union) for approval to commence Clinical Trials in such jurisdiction such as a clinical trial application or a clinical trial notification, and including all regulations at Title 21 of the Code of Federal Regulations Part 312 et seq. and equivalent foreign regulations.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.58</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.3.1.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.3.1.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any and all information and data, including all Organon Know-How, all Dar&#233; Know-How, and all other scientific, Development, regulatory, Manufacturing, and </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">7</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercialization information or data, whether communicated in writing or orally or by any other method, which is provided by one Party to the other Party in connection with this Agreement.  Dar&#233;&#8217;s Information includes information and data relating to TriLogic or MilanaPharm in the DTM Upstream License Agreement and the terms of the DTM Upstream License Agreement. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Invention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, whether or not patentable, any process, method, composition of matter, article of Manufacture, discovery or finding that is conceived or reduced to practice by or on behalf of at least one representative of Dar&#233; or at least one representative of Organon in performing Development activities pursuant to this Agreement.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint Agreement Information and Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all protocols, formulas, data, Inventions, know-how and trade secrets, patentable or otherwise, that are developed, created, made, discovered, invented, conceived, reduced to practice or otherwise result from the activities conducted by or on behalf of at least one representative of Dar&#233; together with at least one representative of Organon in performing research or Development activities pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Patents that claim or cover Joint Agreement Information and Inventions.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Knowledge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party, the actual knowledge of the officers of such Party after reasonable investigation, including through direct or indirect reports of any such officer, except in such cases indicated in this Agreement where no investigation is required.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) the thermosetting vaginal gel formulated with clindamycin phosphate two percent (2%) that is the subject of the Dar&#233; Marketing Authorization, &#91;***&#93; and (b) any other product formulated with clindamycin &#91;***&#93;, including any Combination Product, and (ii) that is Developed, Manufactured, Commercialized or otherwise Exploited using any Dar&#233; Know-How or the Development, Manufacture, Commercialization or Exploitation of which would, but for the rights granted under this Agreement, infringe a Dar&#233; Patent.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Legacy Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.2.2.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.67</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.1.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all activities related to the synthesis, making, having made, production, processing, purifying, formulating, filling, finishing, packaging, labelling, shipping, and holding of a product or any intermediate thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial production and analytic development, product characterization, supply chain, stability testing, quality assurance testing and release, investigations, risk assessments, corrective actions, and quality control.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufactured</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has a correlative meaning. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 4.2.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 4.2.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.71</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Marketing Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) approval or other authorization of an NDA in the United States, and in any other jurisdiction, all approvals from the relevant Regulatory Authority necessary to legally market, distribute, offer for sale or sell a product in the Field in the Territory, including all applicable pricing and governmental reimbursement approvals in regulatory jurisdiction where the applicable Regulatory Authorities must approve or determine the price or reimbursement of all of the product in a country and (b) any other required approvals or authorizations from the relevant Regulatory Authority related to marketing, promoting, distributing, importing for sale, offering for sale, selling, or otherwise disposing of the product in such country (including any required pricing and governmental reimbursement approvals).  </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">8</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.72</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MilanaPharm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 1.40.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.73</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a New Drug Application, Biologics License Application, any other Marketing Authorization, filing pursuant to Section 510(k) of the Act or a Premarket Approval (PMA) premarketing authorization, or similar application or submission for Marketing Authorization filed with a Regulatory Authority to obtain marketing approval for a biological, pharmaceutical or medical device product in that country or in that group of countries.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.74</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.7.1(a).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the gross invoice price (&#91;***&#93;) of a Licensed Product sold by a Related Party to the first Third Party in a country after the First Commercial Sale of Licensed Product in such country, after deducting&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.75.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.75.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.75.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.75.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.75.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Deductions shall be calculated in accordance with the Related Party&#8217;s standard accounting standards consistently applied by the Related Party for the country(ies) in which the sales occur.  Deductions for a single sale that includes Licensed Products with products that are not Licensed Products shall be &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, Net Sales shall not be imputed to transfers of Licensed Products, as applicable, for use in any Clinical Trial, non-clinical development activities with respect to Licensed Products by or on behalf of the Parties, for bona fide charitable purposes or for compassionate or other similar use or for reasonable and customary quantities of Licensed Product samples.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The following provisions (a) through (c) regarding Combination Products apply only to any given Combination Product where &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If (i) a Licensed Product is sold by a Related Party in a country in the form of a Combination Product, (ii) the Licensed Product is sold by such Related Party in such country in a form &#91;***&#93; and (iii) the Other Product is also sold in such country &#91;***&#93;, then Net Sales for such Combination Product will be calculated by multiplying actual Net Sales of such Combination Product by the fraction A&#47;(A+B) where &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is &#91;***&#93;, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">If (i) a Licensed Product is sold by a Related Party in a country in the form of a Combination Product, (ii) the Licensed Product is sold by such Related Party in such country in a form &#91;***&#93;, and (iii) such Other Products in the Combination Product are </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> sold as a separate product in such country &#91;***&#93;, then Net Sales for such Combination Product will be calculated by multiplying actual Net Sales of such Combination Product by the fraction A&#47;C where &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is &#91;***&#93;, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">If a Licensed Product is sold by a Related Party in a country only in the form of a Combination Product, then Net Sales for such Combination Product will be calculated by multiplying actual Net Sales of such Combination Product by the fraction D&#47;E where &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is &#91;***&#93; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is &#91;***&#93;. If a Licensed Product &#91;***&#93;.  </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">9</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If a Related Party sells a Licensed Product to a customer who also purchases other products or services from such Related Party, the Related Party shall not manipulate the discount or price of any Licensed Product solely to increase sales or prices of such other products or services.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.76</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Non-compete Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a product, including any drug or device, that &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.77</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Non-Identifiable Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.6.1.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.78</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Organon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning given such term in the preamble to this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.79</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Organon Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.2.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.80</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Organon Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all information and materials, including discoveries, improvements, processes, methods, protocols, formulas, data, inventions (including Organon&#8217;s rights in Joint Agreement Information and Inventions), know-how and trade secrets, patentable or otherwise, which during the term of this Agreement are owned by Organon or any of its Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.81</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Organon Marketing Authorizations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 10.6.7(a).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.82</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Organon Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Patents that are Controlled by Organon or any of its Affiliates and that claim or cover a Licensed Product.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.83</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Own</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">,&#8221; to have &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Owned</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">,&#8221; to be the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Owner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; of, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; of securities by a Person means such Person has acquired, directly or indirectly (including through ownership of securities or any contract, arrangement, understanding, relationship or otherwise), or such Person, directly or indirectly, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.84</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Organon or Dar&#233;, individually, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Organon and Dar&#233;, collectively.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.85</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any patent, utility model, or certificate of invention, or other indicia of ownership of an invention recognized by any Governmental Authority of competent jurisdiction, any application for any of the foregoing, and any and all pre-grant and post-grant forms of any of the foregoing, including all continuations, continuations-in-part, divisionals, provisionals, and extensions, and including any counterparts or foreign equivalents of any of the foregoing issued by or filed in any country or other jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.86</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning given to it in Section 10.3.3.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.87</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any individual, partnership, joint venture, limited liability company, corporation, firm, trust, association, unincorporated organization, Governmental Authority or agency, or any other entity not specifically listed herein.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.88</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.6.1.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.89</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Phase&#160;I Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a human clinical trial in any country that would satisfy the requirements of 21 C.F.R. &#167; 312.21(a).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Phase&#160;II Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a human clinical trial in any country that would satisfy the requirements of 21 C.F.R. &#167; 312.21(b).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.91</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Phase&#160;III Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a human clinical trial in any country that would satisfy the requirements of 21 C.F.R. &#167; 312.21(c).</font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">10</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.92</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Privacy Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Applicable Laws regarding the collection, use, transfer, storage, protection, deletion, processing (both by computer and manually), combination, or other use of Clinical Trial subject or patient data (sometimes referred to as protected health information) or other personal data.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.93</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.5.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.94</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product-Specific Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 9.1.1.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.95</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any of the Trademarks XACIATO or BIVVIE, in any and all words, stylizations, or design formats, and all transliterations or local language character adaptations thereof, alone or in combination with other words or elements, whether or not registered with a Governmental Authority. Product Trademarks include the Trademark registrations and applications for Trademark registration set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.95</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.96</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Public Official</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) any elected or appointed officer, employee or representative of any regional, federal, state, provincial, county or municipal Governmental Authority, agency or other division&#59; (b) any officer, employee or representative of any commercial enterprise that is owned or controlled by a Governmental Authority, including any state-owned or controlled veterinary, laboratory research or medical facility&#59; (c) any political party officer, candidate for public office, or political party employees or individuals acting for or on behalf of a political party or candidate for public office&#59; (d) any officer, employee or representative of any public international organization, such as the African Union, the International Monetary Fund, the United Nations or the World Bank&#59; and (e) any person acting in an official capacity for any Governmental Authority, enterprise or organization identified above.  For clarity, healthcare providers employed by government-owned or -controlled hospitals, or a person serving on a healthcare committee that advises a Governmental Authority, will be considered Public Officials.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.97</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any applicable regulatory Governmental Authority involved in granting approvals for the Manufacturing, Commercialization, reimbursement or pricing of a Licensed Product in the Territory, including, in the United States, the FDA.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.98</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a particular Licensed Product in a country in the Territory, any exclusivity (including for clarity new biologic exclusivity, new use or indication exclusivity, new formulation exclusivity, orphan drug exclusivity, pediatric exclusivity, or any applicable data exclusivity) conferred by the Regulatory Authority in such country which confers an exclusive commercialization period during which any Related Party has the exclusive right to market and sell the Licensed Product in such country, excluding any rights conferred by or based on any Patents.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.99</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means applications, submissions, notifications (or waivers), registrations, copies of licenses, approvals and permits, or other filings or documents that are made to or with a Regulatory Authority and that are necessary or reasonably desirable in order to develop, seek, obtain or maintain a Marketing Authorization for, Exploiting a product or maintaining a Marketing Authorization for a product in a particular country or regulatory jurisdiction.  Regulatory Materials include INDs, NDAs, copies of applications for Marketing Authorization and all materials that support a Marketing Authorization (but not the Marketing Authorization itself), including all correspondence and reports to or received from Regulatory Authorities (including official minutes and official contact reports relating to any communication with Regulatory Authorities), specifications of INDs, labelling requirements, specifications for animal studies and all supporting documents with respect thereto, including all regulatory drug lists, advertising and promotion documents, adverse event files, and all data relied on in connection with the foregoing and related to a product.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.100</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 6.2.3.</font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">11</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.101</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Related Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means each of Organon, its Affiliates, and their respective Sublicensees, as applicable. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.102</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Required Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 11.2.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.103</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Released Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.7.1(b).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.104</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Data Sets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.6.2.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.105</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Restricted Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any product &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.106</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reversion License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 10.6.6(a).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.107</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reversion Royalty Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 10.6.6(b).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.108</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ROFN Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.7.1.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.109</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ROFR Activity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.7.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.110</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ROFR Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any product, including any drug or device, that (1) (a) includes &#91;***&#93; and (b) &#91;***&#93;&#59; or (2) is &#91;***&#93;&#59; or (3) includes &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.111</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 6.3.1(a).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.112</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 6.3.1(d).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.113</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Safety Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 10.5.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.114</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sales Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 6.2.2.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.115</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sales Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 6.2.2.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.116</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Serious Adverse Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an Adverse Event occurring at any dose of a drug that (a) results in death or poses a threat to life&#59; (b) requires or prolongs hospitalization&#59; (c) results in persistent or significant disability or incapacity&#59; (d) is medically significant&#59; or (e) results in a congenital anomaly or birth defect.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.117</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standby Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Consent, Waiver and Stand-by License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> executed as of the Execution Date among Dar&#233;, Organon, Trilogic and MilanaPharm.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.118</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Statement of Use</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.2.4.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.119</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Person to which Organon or any of its Affiliates grants a sublicense under any of the rights licensed&#47;sublicensed to Organon under Section 3.1&#59; except for contract manufacturers and distributors of the Licensed Products.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.120</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.121</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Supply and Distribution Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 4.1.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.122</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 6.7.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.123</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all of the countries in the world, and their territories and possessions.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.124</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third-Party Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.1.</font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">12</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.125</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an entity other than Organon and its Affiliates, and Dar&#233; and its Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.126</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 6.3.2(a).  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.127</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means trademarks, service marks, assumed business names, trade names, commercial names, certification marks, collective marks, and other proprietary rights to any words, names, slogans, symbols, logos, devices or combinations thereof used to identify, distinguish and indicate the source or origin of goods or services, including without limitation the associated registrations, renewals, applications for registration, equivalents and counterparts of the foregoing.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.128</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transition Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning ascribed to it in Section 10.6.14.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.129</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TriLogic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 1.40.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.130</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the United States of America, excluding its territories and possessions. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.131</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.132</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">USPTO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.2.4.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.133</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Valid Patent Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a claim in an issued, unexpired Patent within the Dar&#233; Patents that (a) has not been finally cancelled, withdrawn, abandoned or rejected by any Governmental Authority of competent jurisdiction, (b) has not been revoked, held invalid, or declared unpatentable or unenforceable &#91;***&#93;, (c) has not been rendered unenforceable through disclaimer or otherwise, and (d) is not lost through an interference proceeding.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:13.66pt">REGULATORY, PHARMACOVIGILANCE, EXCLUSIVITY GOVERNANCE, AND DATA. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Assignment and Disclosure of Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon request by Organon, Dar&#233; hereby assigns all right, title and interest in the Dar&#233; Marketing Authorizations and Dar&#233; Regulatory Materials to Organon.  Promptly after requested by Organon, Dar&#233; will cooperate with Organon as reasonably requested to effect an orderly transition of Control of the Dar&#233; Marketing Authorizations, and will use Commercially Reasonable Efforts to assist Organon in all interactions with the applicable Regulatory Authorities and other Development activities related to the Licensed Products from Dar&#233; to Organon.  Upon and after such request by Organon, Organon shall be the holder of all Marketing Authorizations for Licensed Products in the Field in the Territory and shall have the sole right to maintain such Marketing Authorizations and responsibility for interactions with Regulatory Authorities with respect to the Licensed Products in the Field in the Territory&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Dar&#233; will hold the Dar&#233; Marketing Authorizations after such request until they are officially transferred to Organon by the applicable Regulatory Authority. Upon and after the Execution Date, Dar&#233; will not assign or otherwise grant to any Person other than Organon any rights, title or interest in or to any of the Dar&#233; Marketing Authorizations and Dar&#233; Regulatory Materials.   </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Within &#91;***&#93; after the Effective Date, Dar&#233; will provide to Organon the Dar&#233; Marketing Authorizations and original and electronic copies of the Dar&#233; Regulatory Materials.  Thereafter, Dar&#233; will provide to Organon the original and an electronic copy of all updates to the Dar&#233; Marketing Authorizations and Dar&#233; Regulatory Materials within &#91;***&#93; after receipt or filing, as applicable. </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">13</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Adverse Event Reporting&#59; Global Safety Database&#59; Transition to Organon&#59; Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Adverse Event Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  On and after the assignment and transfer of the Dar&#233; Marketing Authorizations to Organon hereunder, Organon shall be solely responsible for the collection, review, assessment, tracking, submission, and filing of information related to Adverse Events and Serious Adverse Events associated with all Licensed Products, in accordance with 21 C.F.R. &#167;&#167; 312.32 and 314.80 and comparable regulations, guidance, and directives governing such events associated with Licensed Products.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Legacy Adverse Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  No later than &#91;***&#93; after the Effective Date, Dar&#233; and its Affiliates shall provide Organon an electronic copy of the CIOMS I form or XML files, or an agreeable format, for all legacy data of Adverse Events and Serious Adverse Events for all Licensed Products, and for all Gel Products Exploited by or on behalf of Dar&#233;, its Affiliates or their respective licensee&#47;sublicensee, in the Territory (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Legacy Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that is within Dar&#233; or its Affiliate&#8217;s possession and Control, for inclusion in Organon&#8217;s safety database for the Licensed Products.  Dar&#233; and its Affiliates shall keep Legacy Data up-to-date until the completion of transfer and processing of all Legacy Data by the Parties.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Global Database Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon completion of processing of all Legacy Data, Organon will assume the role of global safety database holder for the Licensed Products (even if before transfer of the Dar&#233; Marketing Authorizations).  Between the Execution Date and such time as Organon assumes such role, Dar&#233; shall continue to be the global safety database holder for the Licensed Products and shall continue to maintain such global safety database and, subject to Section 2.2.1, shall be responsible for the collection, review, assessment, tracking, submission, and filing of information related to Adverse Events and Serious Adverse Events associated with all Licensed Products, in accordance with 21 C.F.R. &#167;&#167; 312.32 and 314.80 and comparable regulations, guidance, and directives governing such events associated with Licensed Products.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Transition to Organon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to Section 2.2.5, as applicable, starting with the Execution Date and until completion of assignment and transfer to Organon of all Dar&#233; Marketing Authorizations and Dar&#233; Regulatory Materials with respect to Licensed Products, Dar&#233; shall, at its own cost&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">promptly notify Organon of any information of which Dar&#233; becomes aware concerning any newly known Adverse Events or Serious Adverse Events with respect to any Licensed Product and any such notice will&#58; (i) be provided in English in the form of a processed CIOMS I&#59; and (ii) be provided within &#91;***&#93; of such Adverse Event where such Adverse Event is a Serious Adverse Event and within &#91;***&#93; otherwise&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">be responsible for documenting and reporting any newly known Adverse Events or Serious Adverse Events in the Territory with respect to each Licensed Product in conformance with all Applicable Laws, and responding to safety issues and to all requests of Regulatory Authorities related to each Licensed Product in the Territory&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">be responsible for submission or filing of any other information or reports to Regulatory Authorities with respect to each Licensed Product in conformance with all Applicable Laws&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">promptly notify Organon of any information of which Dar&#233; becomes aware concerning any Adverse Events or Serious Adverse Events with respect to any Gel Product Exploited by or on behalf of Dar&#233;, its Affiliate or their respective licensee&#47;sublicensee where the Adverse Event is not attributed to the active ingredient in such Gel Product, and any such notice will&#58; (i)&#160;be provided in </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">14</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">English in the form of a processed CIOMS I&#59; and (ii) be provided within &#91;***&#93; of such Adverse Event where such Adverse Event is a Serious Adverse Event and within &#91;***&#93; otherwise&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">be responsible for documenting and reporting any Adverse Events and Serious Adverse Events in the Territory with respect to each Gel Product Exploited by or on behalf of Dar&#233;, its Affiliate or their respective licensee&#47;sublicensee that is not attributed to the active ingredient in the Gel Product, in conformance with all Applicable Laws, and responding to safety issues and to all requests of Regulatory Authorities related to each such Gel Product in the Territory.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Agency Correspondence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding anything in this Agreement to the contrary and to the extent permitted in accordance with Applicable Law, </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Between the Execution Date and the Effective Date, Organon shall have the right to review and comment on, prior to submission, any correspondence between Dar&#233; and any Regulatory Authority that affects or relates to any Licensed Product or Gel Product Exploited by or on behalf of Dar&#233;, its Affiliate or their respective licensee&#47;sublicensee.  Dar&#233; shall consider in good faith Organon&#8217;s comments and not refuse to implement any proposed comments to the correspondence for submission reasonably requested by Organon provided, however, that if Dar&#233; objects to implementation of any revisions required by Organon, then the &#91;***&#93; of each Party shall promptly meet, at mutually convenient time, to discuss and address the refusal, and to consider a revised correspondence for submission by Dar&#233; to the Regulatory Authority&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however, that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Dar&#233; shall have the final decision authority with respect to the proposed correspondence so discussed.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">After the Effective Date and until the completion of transfer of all Dar&#233; Marketing Authorizations to Organon, Organon shall have the right to review and approve, prior to submission, such approval not to be unreasonably withheld, any correspondence between Dar&#233; and any Regulatory Authority that affects or relates to any Licensed Product, or to any or Gel Product Exploited by or on behalf of Dar&#233;, its Affiliate or their respective licensee&#47;sublicensee.  If Organon notifies Dar&#233; that Organon does not approve any correspondence promptly after receiving the proposed correspondence, the Parties&#8217; &#91;***&#93; shall promptly meet, at mutually convenient time, to discuss and address the objection, and to consider a revised correspondence for submission by Dar&#233; to the Regulatory Authority.  As between the Parties, Dar&#233; shall have the final decision authority with respect to the proposed correspondence so discussed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however, that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, upon and after &#91;***&#93; assumes the role of global safety database holder for the Licensed Products pursuant to Section 2.2.3, Organon shall have the final decision authority on the data, reports, and submissions related to Adverse Events and Serious Adverse Events for Licensed Products to be included in any such correspondence. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Organon shall have the right to perform any audit or investigation, in each case, with respect to any Licensed Product sold anywhere in the Territory prior to the date upon which all Dar&#233; Marketing Authorizations have been transferred to Organon.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  No later than &#91;***&#93; before Dar&#233;, its Affiliates or any of its or their sublicensees, &#91;***&#93; Dar&#233; will provide notice of such to Organon. Upon Organon&#8217;s request, the Parties shall promptly, but no later than the date that any Clinical Trial relating to a Gel Product commences, negotiate and enter into a pharmacovigilance agreement for the Licensed Product and such Gel Product that sets forth the responsibilities of each Party with respect to pharmacovigilance matters relating to the </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">15</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licensed Products and the Gel Products in the Territory until the termination or expiration of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Development and Commercialization Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement, including Section 3.4&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Development Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  As between the Parties, subject to Section 2.1 and Section 2.2 and the other terms of this Agreement, Organon shall have the exclusive right, but not the obligation, to conduct all Development involving any Licensed Product after the Effective Date.  Without limiting the foregoing, upon and after the Execution Date, except as provided in Sections 2.1 and 2.2, Dar&#233; shall not, and shall cause its Affiliates not to, without the advance, written consent or request of Organon, anywhere in the world&#58; (a) conduct any Clinical Trials involving a Licensed Product, (b) seek, obtain or maintain any Marketing Authorization involving a Licensed Product, (c) generate any new Regulatory Materials involving a Licensed Product, (d) except to the extent required by Applicable Law and with notice to Organon, communicate with any Regulatory Authority regarding any Licensed Product, Dar&#233; Marketing Authorizations or Dar&#233; Regulatory Materials, or (e) assign, license, sublicense or otherwise grant or convey any rights under any of the Product Trademarks, Dar&#233; Know-How or Dar&#233; Patents for any Licensed Product for Exploitation in the Field.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Commercialization Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon and after the Execution Date, and subject to the terms of this Agreement, as between the Parties, Organon shall have the sole right and responsibility, but not the obligation (other than Organon&#8217;s diligence obligation under Section 3.4.1), at its sole cost and expense, to Commercialize Licensed Products or Restricted Products &#91;***&#93; in the Territory and to conduct market access activities relating to the Licensed Products or Restricted Products that are not Non-compete Products, including&#58; (a) developing and executing a commercial launch and pre-launch plan, (b) negotiating reimbursement approvals with Governmental Authorities, (c) marketing, advertising and promoting, (d) distributing and performing related services, (e) handling order processing, invoicing and collecting inventory and receivables, (f) determining pricing and terms of sale of Licensed Products or Restricted Products that are not Non-compete Products, (g) providing customer support, and (h) assign, license, sublicense or otherwise grant or convey any rights under any of the Product Trademarks, Dar&#233; Know-How or Dar&#233; Patents for any Licensed Product or Restricted Product that are not Non-compete Products for Exploitation in the Field. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Medical Affairs Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the terms of this Agreement, including Section&#160;3.8, as between the Parties, Organon shall have the exclusive right to conduct medical affairs relating to Licensed Products or Restricted Products that are not Non-compete Products.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">***&#93;, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however, that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> upon termination of this Agreement in any country within the Territory, the Parties&#8217; obligation under this Section 2.3.4 also terminates with respect to such country.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Appointment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party shall appoint an employee who shall oversee interactions between the Parties for all matters related to this Agreement (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Such persons shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information, and shall serve as the day-to-day primary point of contact for any matters arising under this Agreement (but communications between them are not substitutes for notices required to be provided in accordance with Section 12.5).  The Alliance Managers shall have such other responsibilities as the Parties may mutually agree in writing.  Unless designated by a Party otherwise before the Effective Date, the Alliance Manager for Organon shall be </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">16</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; and for Dar&#233; shall be &#91;***&#93;. Each Party may designate different Alliance Managers by notice in writing to the other Party.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Responsibilities of the Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Alliance Managers shall have the responsibility of creating and maintaining a constructive and amicable work environment between the Parties.  Without limiting the generality of the foregoing, each Alliance Manager shall&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">&#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">&#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Transfer of Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Within &#91;***&#93; after the Effective Date and within &#91;***&#93; from Organon&#8217;s reasonable written request at any time thereafter throughout the term of this Agreement, Dar&#233; shall transfer to Organon a copy of all preclinical and clinical data in Dar&#233;&#8217;s Control that relates to (a) &#91;***&#93; and (b) &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  During the term of this Agreement, &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Dar&#233; shall not provide to Organon any data that identifies or could be used to identify an individual natural person within the Dar&#233; Know-How and Product Data (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), except to the limited extent required by Applicable Law.  If Dar&#233; is required to provide to Organon any Personal Data, then each Party will abide by all Applicable Laws with respect to its disclosure and use of such Personal Data.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Organon Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Organon and its Affiliates may use Non-Identifiable Data received from Dar&#233; to create data sets (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Data Sets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) for Organon&#8217;s and its Affiliates&#8217; internal research purposes, and may use and disclose the Research Data Sets for medical research, including research unrelated to the Licensed Products, and any filings of medical research study results with regulatory Governmental Authorities worldwide.  For purposes of this section, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Non-Identifiable Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Personal Data that has been de-identified such that it meets the Health Insurance Portability and Accountability Act safe harbor for de-identification of protected health information set forth at 45 C.F.R. &#167; 164.514.  Organon will&#58; (a) &#91;***&#93;&#59; (b) use appropriate safeguards to prevent &#91;***&#93;&#59; (c) not use the Research Data Sets to identify any study subject or contact any study subject&#59; and (d) use and disclose Research Data Sets in compliance with Applicable Laws.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:13.66pt">LICENSES AND OWNERSHIP OF IP.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Patents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Subject to the terms of this Agreement, Dar&#233; hereby grants to Organon an exclusive license (even as to Dar&#233;) in the Territory under all rights in the Dar&#233; Patents and all of Dar&#233;&#8217;s rights in Joint Patents, with the right to grant and authorize sublicenses, to Exploit Licensed Products in the Field.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Know-How.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Subject to the terms of this Agreement, Dar&#233; hereby grants to Organon an exclusive license (even as to Dar&#233;) in the Territory under all rights in the Dar&#233; Know-How and all of Dar&#233;&#8217;s rights in Joint Agreement Information and Inventions, with the right to grant and authorize sublicenses, to Exploit Licensed Products in the Field. </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">17</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Sublicenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The foregoing licenses include the right to further sublicense, provided that such further sublicenses (a) are in writing, (b) shall refer to and be subject and subordinate to the applicable terms of this Agreement, and are consistent with the terms and requirements of this Agreement, and (c) disclaim any representations or warranties of Dar&#233; and licensors under the DTM Upstream License Agreement.  Organon will promptly notify Dar&#233; upon execution of each sublicense, in each case within &#91;***&#93; and shall furnish Dar&#233; with a true copy of each sublicense and of any amendment thereto, each of which may be redacted by Organon for competitively sensitive or financial information or information unrelated to the obligations of Organon to Dar&#233; hereunder.  Organon shall remain liable to Dar&#233; for the performance of all of Organon&#8217;s obligations under this Agreement, and will be liable for any act or failure to act by any Sublicensee that if committed (or not committed) by such Sublicensee would be a breach of any of Organon&#8217;s obligations under this Agreement as though the same were a breach by Organon itself. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Marking</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Organon will use Commercially Reasonable Efforts to mark or virtually mark (including by listing applicable Patents on a website for Licensed Products) and require all Sublicensees to mark or virtually mark all Licensed Products with appropriate patent numbers. This Section 3.1.4 shall expire, on a Dar&#233; Patent-by-Dar&#233; Patent basis, upon expiration or cancellation of such Dar&#233; Patent.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Dar&#233; hereby grants to Organon an exclusive license (even as to Dar&#233;) in the Territory to the Product Trademarks, with the right to grant and authorize sublicenses (pursuant to Section 3.1.3), for purposes of using the Product Trademarks in connection with the Development and Commercialization of any Licensed Product.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Dar&#233; hereby grants to Organon a non-exclusive license in the Territory to use Dar&#233;&#8217;s corporate name and corporate logo (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Corporate Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to the extent that Organon is required to use Corporate Trademarks under Applicable Laws in connection with the Exploitation of the Licensed Products.  Organon will &#91;***&#93;, and Organon will not &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Use of Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Organon will use the Corporate Trademarks as permitted under Section 3.2.1, and Dar&#233; shall have the right to reasonably verify that such use is, in accordance with all applicable Marketing Authorizations and Applicable Law.  In the case of Product Trademarks, until the Assignment Date as defined in accordance with Section 3.2.4, (a) Organon will use the Product Trademarks, and Dar&#233; shall have the right to reasonably verify that such use is, in accordance with all applicable Marketing Authorizations and Applicable Law&#59; and (b) Dar&#233; will exclusively own and retain all rights to such Product Trademark together with all goodwill associated therewith throughout the Territory.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Dar&#233; will not use any Product Trademark, or any other Trademark selected by Organon for use in connection with the sale of any Licensed Product, to Develop or Commercialize any product or service other than Licensed Products.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Domain Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Within &#91;***&#93; after the Effective Date, Dar&#233; will transfer to Organon the Control of any and all (a) Internet domain names registered to Dar&#233; that include any Product Trademark in the domain and (b) social media account identifiers that include any Product Trademark in its handle.  Other than such Internet domain names and social </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">18</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">media account handles, Dar&#233; will not register or maintain any Internet domain name that includes any Product Trademark in the domain or social media account that includes any Product Trademark in its handle.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Assignment of Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As of the date of Notice of Acceptance of Statement of Use issued from the United States Patent and Trademark Office (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">USPTO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) for a Product Trademark having an application for registration filed with the USPTO, Dar&#233; agrees to assign to Organon, effective as of the filing date of the accepted Statement of Use under 37 C.F.R. &#167; 2.88 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Statement of Use</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59;&#8221; each such Statement of Use filing date, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Assignment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) all right, title and interest in and to each such Product Trademark throughout the Territory, including all applications and registrations therefor, and the goodwill of the business symbolized by each such Product Trademark or associated with the use of each such Product Trademark.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Selection and Registrations of Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Subject to Section 3.2.5(b), as between the Parties, Organon shall have the sole right and responsibility to select, file, prosecute, register and maintain any Product Trademark or any other Trademark for use in connection with the Exploitation of any Licensed Product or Restricted Product using counsel of Organon&#8217;s choice. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Until the Assignment Date for a Product Trademark, Dar&#233; will prosecute, register, maintain and enforce, as applicable, all Product Trademarks&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, within &#91;***&#93; after the Effective Date, Dar&#233; will instruct its legal representatives to take instruction from Organon with respect to the filing, prosecution, registration (including the defense against any and all oppositions) and maintenance of all Product Trademarks still owned in the name of Dar&#233;.  Organon shall keep Dar&#233; advised of the status of such registrations and applications for registration of the Product Trademarks that are still owned in Dar&#233;&#8217;s name and, upon Dar&#233;&#8217;s request, shall provide advance copies of any papers related to such filing, prosecution (including the defense against any and all oppositions), registration and maintenance of such Product Trademarks.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Dar&#233; shall give notice to Organon promptly upon becoming aware of any infringement of any Product Trademark or any other use of any Product Trademark, whether or not such use is as a Trademark. As between the Parties, following the Assignment Date for a Product Trademark, Organon shall have the sole right to enforce such Product Trademark. Organon shall have the sole right to enforce any other Trademark selected by Organon for use in connection with the sale of any Licensed Product, anywhere in the world.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">In case at any time after the Effective Date, as applicable, any further action is necessary or desirable to carry out the purposes of this Section 3.2, Dar&#233; will take such further action as Organon may reasonably request as will be deemed necessary to (i) transfer, convey and assign to Organon all of the rights, titles, interests, remedies, powers and privileges in the Product Trademarks, and (ii) otherwise effect the transactions contemplated by this Section 3.2, including (1) obtaining all necessary actions or non-actions, consents, and the making of all necessary registrations and filings and the taking of all steps as may be necessary to obtain an approval or waiver from, or to avoid an action or proceeding by, any Governmental Authority or Third Party and (2) executing and delivering any additional instruments necessary to consummate the transactions contemplated by, and to fully carry out the purpose of, this Section 3.2.  In case at any time after the Assignment Date with respect to a Product Trademark any further action </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">19</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">is necessary or desirable to carry out the purposes of this Section 3.2, Organon will fully record or otherwise further document the assignment of such Product Trademark in the name of Organon.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">After the Effective Date, Dar&#233; will, without further compensation to Dar&#233;, but at the expense of Organon, and upon request of Organon, cooperate in all lawful acts as may be necessary to (i) file, prosecute, register (including with respect to filing any statement of use), maintain, abandon, or renew in any country any Trademark registration with respect to any Product Trademark, or (ii) enforce Organon&#8217;s rights in or defend against challenges to the validity or enforceability of any Product Trademark in the name under which it is registered in the respective jurisdiction. Without limiting the generality of the foregoing, after the first use in commerce of any Product Trademark, Dar&#233; will take all actions necessary to file, or facilitate the filing of, a Statement of Use with the USPTO in connection with such Product Trademark.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Information Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Dar&#233; Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Within &#91;***&#93; after the Effective Date, Dar&#233; will deliver to Organon a complete and accurate copy of all of the items of Dar&#233; Know-How that were made available to Organon through the electronic data room during the due diligence leading to the execution of this Agreement, and disclose and deliver to Organon any additional Dar&#233; Know-How, including all of the Gel Know-How, requested by Organon within &#91;***&#93; after the Effective Date. Thereafter, Dar&#233; shall use Commercially Reasonable Efforts on an ongoing basis during the term of this Agreement to disclose to Organon in English and in writing or in an electronic format all Dar&#233; Know-How not previously disclosed promptly after such Dar&#233; Know-How first arises. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In connection the disclosure of Dar&#233; Know-How hereunder, Dar&#233; shall, in a timely manner, use Commercially Reasonable Efforts to assist Organon in the use and understanding of such Dar&#233; Know-How, &#91;***&#93;.  Without limiting the generality of the foregoing, if &#91;***&#93;  Organon shall reimburse Dar&#233; for its documented and verifiable out-of-pocket costs and expenses charged by a Third Party for providing the assistance described in this Section 3.3.2, provided such costs are pre-approved by Organon. &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Development and Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Organon shall use Commercially Reasonable Efforts to (a) upon and after completion of the assignment and transfer of the Dar&#233; Marketing Authorizations to Organon, maintain a Marketing Authorization for &#91;***&#93; Licensed Product in the United States, (b) effect a First Commercial Sale of a Licensed Product within &#91;***&#93;, (c) after the First Commercial Sale of a Licensed Product within the United States, Commercialize &#91;***&#93; Licensed Product on an ongoing basis within the United States, (d) evaluate in good faith whether to seek and obtain Marketing Authorization for &#91;***&#93; Licensed Product &#91;***&#93;, and (e) Commercialize &#91;***&#93; Licensed Product on an ongoing basis in each of &#91;***&#93;.  In the event that Organon is unable to effect a First Commercial Sale of a Licensed Product within the time frame of foregoing subpart (b), the Parties&#8217; &#91;***&#93; shall promptly meet, at mutually convenient time, to discuss and address the circumstances leading to the delay, and agree to a reasonable extension of time for effecting the First Commercial Sale by mutual agreement. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Subcontracting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Organon will have the right to engage any Third Party subcontractor to perform any or all of its obligations hereunder, including contract research organizations, contract manufacturing organizations and similar service providers.  The applicable provisions of each agreement between Organon and a Third Party subcontractor shall be materially consistent with the corresponding provisions of this Agreement and shall include confidentiality and non-use provisions at least as stringent as those set forth in </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">20</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Article 5. Organon&#8217;s engagement of any subcontractor pursuant to this Section 3.4.2 shall not relieve Organon of its obligations under this Agreement and Organon shall be fully responsible for any acts or omissions of its subcontractors, including compliance by such subcontractors with Anti-Corruption Laws, Privacy Laws and GxP standards, as applicable, and for compliance with all provisions of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  With respect to each Licensed Product, Organon shall provide to Dar&#233; &#91;***&#93; a summary report, which shall summarize the results of the development work and regulatory activities performed during the preceding &#91;***&#93; and summarize the activities planned for the &#91;***&#93;.  Such reports shall be prepared by Organon and provided to Dar&#233; between &#91;***&#93; and shall include status or results of any Clinical Trials conducted in the preceding year, when applicable. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Sunshine Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Parties acknowledge and agree that any direct or indirect payment or transfer of value, as defined in the Physician Payments Sunshine Act (42 U.S.C. &#167; 1320a-7h) and its implementing regulations (42 C.F.R. &#167; 403.900 et seq.), including any compensation, reimbursement for expenses, meals, travel, and medical journal reprints to any teaching hospital in the United States or any physician, physician assistant, nurse practitioner, clinical nurse specialist, certified registered nurse anesthetist, or certified nurse-midwife who is not a bona fide employee of a Party that is licensed to practice in the United States (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Covered Recipient</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is subject to transparency reporting requirements, including disclosure on the federal Open Payments website.  The Parties shall comply with such law in their performance of this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Excused Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In addition to the provisions of Article 7, the obligations of Organon with respect to any Licensed Product under Section 3.4 are expressly conditioned upon (a) the absence of any Serious Adverse Event demonstrated, through pharmacovigilance surveillance, where such Serious Adverse Event was not known at the time of Marketing Authorization, and (b) the ability to have the Licensed Product Manufactured and delivered to Organon in sufficient quantities&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> in each case Organon notifies Dar&#233; promptly upon becoming aware of any such condition and uses Commercially Reasonable Efforts to overcome such condition as promptly as possible. The obligations of Organon under Section 3.4 with respect to any Licensed Product shall be delayed or suspended so long as any such condition or event exists.  If the obligations of Organon with respect to any Licensed Product under Section 3.4 are suspended or delayed pursuant to this Section 3.5 for &#91;***&#93;, then the Parties&#8217; &#91;***&#93; shall promptly meet, at a mutually convenient time, to discuss and address the circumstances leading to the delay.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">New Information and Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The ownership of the entire right, title and interest in any new inventions or discoveries conceived or works created by the Parties during the term of this Agreement shall be allocated consistent with inventorship.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For the purposes of determining ownership under this Section 3.6, (a) inventorship shall be determined in accordance with United States patent laws (regardless of where the applicable activities occurred and whether or not any subject matter is patentable or patented) and (b) authorship shall be determined in accordance with United States copyright laws (regardless of where the applicable activities occurred).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Disclosure.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Each Party shall promptly disclose in writing to the other Party the development, creation, making, conception or reduction to practice of any Joint Agreement Information and Inventions. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Upon Dar&#233; becoming aware of the existence of any Other Technology Patent (as defined in the DTM Upstream License Agreement), or upon Control by Dar&#233; </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">21</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">after the Effective Date of any information, materials, discoveries, improvements, processes, methods, protocols, formulas, data, inventions, know-how, or trade secrets not generally known in the public domain and not already disclosed to Organon, in each case that could reasonably be deemed necessary or reasonably useful for Exploitation of Licensed Products in the Field, Dar&#233; will promptly disclose in writing to Organon such Other Technology Patent or such other information, materials, discoveries, improvements, processes, methods, protocols, formulas, data, inventions, know-how, or trade secrets, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Exploitation of Joint Agreement Information and Inventions and Joint Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the licenses granted under this Agreement and the other terms and conditions of this Agreement, each Party shall have the non-exclusive right to exploit its interest in Joint Agreement Information and Inventions and Joint Patents, and to grant licenses under its interest in Joint Agreement Information and Inventions and Joint Patents, as it deems appropriate, without the consent of, and without accounting to, the other Party&#59; provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that for clarity, the foregoing joint ownership rights shall not be construed as granting, conveying or creating any license or other rights to the other Party&#8217;s intellectual property. Each Party will grant and hereby does grant to the other Party all further permissions, consents, and waivers with respect to, and all licenses under, the Joint Agreement Information and Inventions and Joint Patents, throughout the world, necessary to provide the other Party with full rights of use and Exploitation of the Joint Agreement Information and Inventions and Joint Patents.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Right of First Refusal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Dar&#233; hereby grants to Organon the exclusive right of first refusal in the event that either (a) Dar&#233; or any of its Affiliates &#91;***&#93;, or (b) Dar&#233; or its Affiliate &#91;***&#93; (any of the foregoing, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ROFR Activity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), as follows. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">First Negotiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon determining to engage in a ROFR Activity, Dar&#233; will notify Organon in writing of such determination and identify &#91;***&#93; and &#91;***&#93;.  Organon will have an exclusive right, exercisable &#91;***&#93; after receipt of any such written notice from Dar&#233; &#91;***&#93;, to notify Dar&#233; in writing as to whether Organon desires to negotiate exclusively for the rights to such ROFR Product in such jurisdictions (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ROFN Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If Organon provides a ROFN Exercise Notice to Dar&#233; &#91;***&#93;, then (i) upon Organon&#8217;s request, Dar&#233; will (A) within &#91;***&#93; after Organon&#8217;s request, provide Organon with &#91;***&#93;&#59; and (ii) Organon will have the exclusive right for &#91;***&#93; to request, by notice, to enter into an agreement or an amendment to this Agreement, as applicable, with respect to the exploitation by Organon of such ROFR Product in such jurisdiction(s).  If Organon notifies Dar&#233; within &#91;***&#93; that Organon wishes to enter into such agreement or amendment, then the Parties will &#91;***&#93; for &#91;***&#93; to execute such agreement or amendment (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">If, with respect to a ROFR Product in the applicable jurisdiction(s), &#91;***&#93;, such ROFR Product shall &#91;***&#93; and, subject to Section 3.7.2, Dar&#233; shall &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Most Favorable Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Dar&#233; may not, during &#91;***&#93;, transfer, license, sublicense, assign, grant, or otherwise dispose of any rights to a Third Party with respect to the ROFR Product in the applicable jurisdiction(s) that were the subject of the ROFR Activity that triggered the Negotiation Period (other than the grant of express or implied licenses&#47;sublicenses to an agent or a consultant, contract manufacturing organization, contract research organization, distributors, or other similar type contractor acting for or on behalf of Dar&#233; or its Affiliates) upon terms that on the whole are more favorable to such Third Party than the most favorable terms on the whole offered by Dar&#233; in writing to Organon during the Negotiation Period.  </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">22</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Effects of Change of Control.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Acquisition by Dar&#233;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If Dar&#233; acquires a Third Party that becomes an Affiliate through merger, acquisition, consolidation or similar transaction or series of related transactions, and any such transaction(s) do&#47;does not result in a Change of Control of Dar&#233;, then&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">all know-how, patent rights, technology, information, materials, intellectual property rights or other items that are owned or in-licensed or controlled by the new Affiliate when such Person becomes an Affiliate of Dar&#233; constitute Dar&#233; Know-How or Dar&#233; Patents (to the extent otherwise falling within either of such definitions).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">if the new Affiliate is engaged in Commercialization of any ROFR Product, or is engaged in Development of &#91;***&#93;, when such Person becomes an Affiliate of Dar&#233;, then, &#91;***&#93;, each product that is the subject of such Development or Commercialization &#91;***&#93; for purposes of Section 3.7 &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">if the new Affiliate is engaged in Development, Manufacture, Commercialization or other Exploitation of &#91;***&#93; or Commercialization of any &#91;***&#93; when such Person becomes an Affiliate of Dar&#233;, then Dar&#233; and its new Affiliate will have &#91;***&#93; to wind down or divest to a Third Party all rights, title, and interests in and to such &#91;***&#93;, and during such &#91;***&#93; period, such new Affiliate&#8217;s conduct of such &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Acquisition of Dar&#233;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If a Third Party becomes an Affiliate of Dar&#233; through merger, acquisition, consolidation, or other similar transaction or series of related transactions, and any such transaction(s) do&#47;does result in a Change of Control of Dar&#233;, then&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">notwithstanding the definitions of Dar&#233; Know-How or Dar&#233; Patents, none of the know-how, patent rights, technology, information, materials, intellectual property rights or other items that are owned or in-licensed or controlled by such new Affiliate when such Person becomes an Affiliate of Dar&#233; constitute Dar&#233; Know-How or Dar&#233; Patents.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">if (i) such new Affiliate is engaged in any Development, Manufacturing, Commercialization or other Exploitation of a product that would constitute &#91;***&#93; when such Person becomes an Affiliate of Dar&#233; and (ii) Dar&#233; is not engaged in any of such activities for such product at or before such time, then, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">if such new Affiliate is engaged in &#91;***&#93; when such Person becomes an Affiliate of Dar&#233;, then (i) &#91;***&#93;, subject to Section 6.3.1(c), and (ii) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Acquisition by Organon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If Organon acquires a Third Party that becomes an Affiliate through merger, acquisition, consolidation or similar transaction or series of related transactions, and any such transaction(s) do&#47;does not result in a Change of Control of Organon, and if the new Affiliate is engaged in Commercialization of a Non-compete Product, then Organon will notify Dar&#233; thereof within &#91;***&#93;, and can elect to either (a) wind down or divest to a Third Party all rights, title, and interest in and to such Commercialization activities within &#91;***&#93;, and during such &#91;***&#93; period, such new Affiliate&#8217;s conduct of such Commercialization activities will not constitute a breach of Organon&#8217;s obligations under Section 2.3.4&#59; or (b) treat such Non-compete Product as a Licensed Product for purposes of the calculation of Net Sales and Section 6.3 of this Agreement (in which case for the avoidance of doubt such Net Sales shall be calculated from the time of the closing of the transaction).  Organon will notify Dar&#233; of Organon&#8217;s election prior to expiration of the foregoing &#91;***&#93; period.  Organon&#8217;s failure to notify Dar&#233; of a Change of Control transaction within the foregoing &#91;***&#93; period &#91;***&#93; shall not be deemed a material breach of this Agreement.</font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">23</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Acquisition of Organon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If (a) a Third Party becomes an Affiliate of Organon through merger, acquisition, consolidation, or other similar transactions or series of related transactions, and any such transaction(s) do&#47;does result in a Change of Control of Organon and (b) the new Affiliate is engaged in Commercialization of a Non-compete Product when such Person becomes an Affiliate of Organon, then the new Affiliate may continue with Commercialization of the Non-compete Product without such Affiliate&#8217;s conduct of such activities constituting a breach of Organon&#8217;s obligations under Section 2.3.4.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">No Implied Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as specifically set forth in this Agreement, neither Party shall acquire any license or other right, title or interest, by implication, estoppel or otherwise, in any Information or Inventions or other information disclosed to it under this Agreement or under any Patents or other intellectual property rights Controlled by the other Party or any of its Affiliates, and each Party reserves all such other right, title and interest in and to such Information, Inventions, other information, Patents or other intellectual property rights.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:13.66pt">MANUFACTURING.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Interim Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Prior to the completion of the Manufacturing Technology Transfer pursuant to Section 4.2, Dar&#233; will, either by itself or through a contract manufacturer(s), Manufacture and supply the Licensed Products to Organon and its Affiliates and Sublicensees until &#91;***&#93;.  During such time, Dar&#233; appoints Organon as Dar&#233;&#8217;s exclusive distributor of the Licensed Products, and Organon or its Affiliate(s) will purchase all of Organon and its Affiliates&#8217; requirements of such Licensed Products from Dar&#233; for use by Organon and its Affiliates and Sublicensees pursuant to a supply and distribution agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Supply and Distribution Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The Parties will use Commercially Reasonable Efforts to enter into the Supply and Distribution Agreement promptly after the Effective Date and prior to &#91;***&#93;. The terms of the Supply and Distribution Agreement will be consistent with the terms for it specified in this Agreement, including those in this Section 4.1 and the terms set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (as applicable to Manufacture and supply of the Licensed Product), and other terms customary for supply arrangements between Persons in a similar relationship as the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Form of Product and Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Neither Dar&#233; nor its contract manufacture(s) may initiate any changes with respect to the Manufacture of any Licensed Product that could reasonably be expected to affect the quality, performance, or requirements of the FDA in the Dar&#233; Marketing Authorization, in each case, of such Licensed Product as Manufactured by Dar&#233; or its contract manufacturer(s), without the prior written consent of Organon or as otherwise set forth in the Quality Agreement (as referenced in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">). Dar&#233; will Manufacture and supply the Licensed Products &#91;***&#93; in the Dar&#233; Marketing Authorization and Change Being Effected Day Zero (CBE0), in each case, pursuant to this Section 4.1 at a transfer price equal to Dar&#233;&#8217;s Manufacturing costs plus &#91;***&#93; percent (&#91;***&#93;%). All Manufacturing activities by or on behalf of Dar&#233; and its contract manufacturer(s) will at all times be in compliance with GMP and in compliance with Applicable Laws, and Facilities in which Licensed Product are Manufactured will at all times be in compliance with Applicable Laws. Organon hereby grants back to Dar&#233; a nonexclusive, royalty-free license to Manufacture the Licensed Products solely for supply to Organon under the terms of the Supply and Distribution Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Inventory Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. At Organon&#8217;s request, Dar&#233; shall, after the Effective Date, transfer, assign and deliver to Organon all Licensed Products in Dar&#233;&#8217;s (or its Affiliates&#8217; or its contract manufacturers&#8217;) inventory. Dar&#233; hereby represents to Organon that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 4.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> sets forth a complete and accurate list of the total quantities of such inventory as of the Execution Date (and indicating whether such inventory is GMP or non-GMP).  On the Effective Date, Dar&#233; shall deliver to Organon an update of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 4.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> reflecting the information therein as of the Effective Date.  Dar&#233; shall make available to Organon documentation demonstrating that all such inventory to be provided to Organon was Manufactured in accordance with GMPs.  Dar&#233; shall and hereby does, represent to </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">24</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Organon that, to Dar&#233;&#8217;s Knowledge, such inventory was Manufactured in accordance with GMPs, Applicable Laws and the specifications therefor. In furtherance of and without limiting the foregoing, Dar&#233; shall provide to Organon, &#91;***&#93;, supporting documentation within its Control with respect to such inventory and the Certificates of Analysis with respect to such inventory. Organon may, within &#91;***&#93; of receipt of the Certificates of Analysis, notify Dar&#233; if Organon elects to take possession of less than the inventory remaining because Organon or its Affiliates reasonably believes that any such inventory was not (and at all times up until delivery of such inventory to Organon hereunder did not remain) Manufactured or stored in accordance with all Applicable Laws (including, as applicable, GMPs), and the specifications therefor, or that such inventory were adulterated or misbranded or could not be introduced into interstate commerce.  If Organon elects to take possession of less than the remaining inventory, Organon shall so notify Dar&#233; and Dar&#233; shall transfer, assign and deliver to Organon only such inventory as requested by Organon. Except as otherwise set forth in this Section 4.1.2, Organon shall accept all such inventory transferred, assigned and delivered to Organon on an as-is basis. Deliveries shall be made at Organon&#8217;s expense Ex Works (Incoterms 2020). </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Governmental Authority Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Dar&#233; shall promptly notify Organon of any information Dar&#233; receives regarding any threatened or pending action by any Governmental Authority, including any Governmental Authority non-approval or regulatory action, that may impact the Manufacture of Licensed Product by Dar&#233; or its Affiliate or its contract manufacturer.  Upon receipt of such information, Dar&#233; shall consult with Organon in an effort to arrive at a mutually acceptable procedure for taking appropriate action.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Governmental Authority Inspection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Dar&#233; shall promptly notify Organon of any proposed visit or inspection of a Facility directly related to, and&#47;or which could potentially impact, Manufacture of Licensed Product by any Governmental Authority, and agrees to use Commercially Reasonable Efforts to permit one or more qualified representatives of Organon to be present if requested by Organon. Dar&#233; shall notify Organon of any unannounced visits or inspections of a Facility as soon as reasonably practical upon becoming aware of the same. If Organon is not present during such a visit or inspection, Dar&#233; shall, &#91;***&#93;. Dar&#233; shall, &#91;***&#93;. Organon will &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Audit and Inspection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. &#91;***&#93;.  Organon shall have access to Dar&#233;&#8217;s contract manufacturer&#8217;s Facilities &#91;***&#93; to observe the Licensed Product and its components manufacturing services and to audit its compliance with cGMP and Applicable Laws in the manufacture of Licensed Products and components of Licensed Products.  Organon&#8217;s access and audits shall in no way give Organon the right to any of the contract manufacturer&#8217;s confidential or proprietary information. Furthermore, such audits shall normally be limited in frequency to &#91;***&#93; and limited to a maximum number of &#91;***&#93; of Organon, each of which are deemed representatives of Organon, but &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Without limiting Dar&#233;&#8217;s obligations under Section 3.3, &#91;***&#93;, Dar&#233; will, &#91;***&#93;, transfer to Organon or its designated contract manufacturer, all Dar&#233; Know-How relating to the Manufacture of Licensed Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) necessary or useful to allow Organon or its designated contract manufacturer to implement the Manufacturing Process at facilities designated by Organon (such transfer and implementation, as more fully described in this Section 4.2, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Dar&#233; shall provide &#91;***&#93;, all assistance reasonably requested by Organon to enable Organon (or its Affiliate(s) or designated contract manufacturer(s), as applicable) to implement the Manufacturing Process at the facilities designated by Organon.  If requested by Organon, such assistance shall include &#91;***&#93;.  Without limitation to the foregoing, in connection with the Manufacturing Technology Transfer&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#91;***&#93;&#59; </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">25</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">&#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">&#91;***&#93;.   </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:13.66pt">CONFIDENTIALITY AND PUBLICITY.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Nondisclosure Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All Information disclosed by one Party to the other Party hereunder shall be maintained in confidence by the receiving Party and shall not be disclosed to any Third Party or used for any purpose except as set forth herein without the prior written consent of the disclosing Party, except to the extent that such Information&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">is known by the receiving Party at the time of its receipt, and not through a prior disclosure by the disclosing Party, as documented by the receiving Party&#8217;s business records&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">is in the public domain by use or publication before its receipt from the disclosing Party, or thereafter enters the public domain through no fault of the receiving Party&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">is subsequently disclosed to the receiving Party by a Third Party who may lawfully do so and is not under an obligation of confidentiality to the disclosing Party&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">is developed by the receiving Party independently of Information received from the disclosing Party, as documented by the receiving Party&#8217;s business records&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">is deemed necessary by the receiving Party to be disclosed to its Affiliates, licensees and sublicensees, agent(s), consultant(s), or other Third Parties for any and all purposes such Party and its Affiliates deem necessary or advisable in the ordinary course of business in accordance with this Agreement on the condition that such Third Parties have a need to know such Information so that the receiving Party may exercise its rights and perform its obligations hereunder and agree to be bound by confidentiality and non-use obligations that substantially are no less stringent than those confidentiality and non-use provisions contained in this Agreement&#59; provided, however, that the term of confidentiality for such Third Parties shall be no less than &#91;***&#93;, and the receiving Party shall be liable and responsible for such Persons&#8217; compliance with the terms of this Article 5&#59; or </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">is deemed necessary by counsel to the receiving Party to be disclosed to such Party&#8217;s attorneys, insurers, independent accountants or financial advisors for the sole purpose of enabling such attorneys, insurers, independent accountants or financial advisors to provide advice and services to the receiving Party, on the condition that such attorneys, insurers, independent accountants and financial advisors agree to be bound by confidentiality and non-use obligations that substantially are no less stringent than those confidentiality and non-use provisions contained in this Agreement&#59; provided, however, that the term of confidentiality for such attorneys, insurers, independent accountants and financial advisors shall be no less than &#91;***&#93;, and the receiving Party shall be liable and responsible for such Persons&#8217; compliance with the terms of this Article. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any combination of features or disclosures shall not be deemed to fall within the foregoing exclusions merely because individual features are published or available to the general public or in the rightful possession of the receiving Party unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the receiving Party.</font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">26</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Mandatory and Permitted Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Section 5.1 shall not apply to Information that the receiving Party is required by Applicable Law, or similar requirements to disclose, provided that the receiving Party provides the disclosing Party with prompt notice thereof such that the disclosing Party may seek a protective order or other appropriate remedy with respect to such Information, including, without limitation, confidential treatment to the extent available under any Applicable Law, and the receiving Party shall provide the disclosing Party with reasonable cooperation in order to obtain such a protective order or other remedy, including confidential treatment, and discloses only that portion of the confidential Information that it is legally compelled to disclose.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Additionally, notwithstanding Section 5.1, Organon may disclose the information of Dar&#233; as is deemed necessary by Organon to be disclosed to a Governmental Authority to exercise Organon&#8217;s or its Affiliate&#8217;s rights or perform its obligations with respect to Patents under Article 9 or to seek, obtain or maintain Marketing Authorizations for Licensed Products.    </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Information that is disclosed pursuant to this Section 5.2 shall remain otherwise subject to the confidentiality and non-use provisions of Section 5.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Dar&#233; Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Dar&#233; will use Commercially Reasonable Efforts to keep all Dar&#233; Know-How confidential as if the Dar&#233; Know-How were first disclosed by Organon to Dar&#233;. For the avoidance of doubt, Dar&#233; may disclose Dar&#233; Know-How as permitted in this Article 5, and otherwise to Third Parties as if Dar&#233; were a receiving Party of the Dar&#233; Know-How.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Disclosure to DTM Upstream Licensors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Organon acknowledges and agrees that Dar&#233; may disclose Information of Organon, and the terms of this Agreement, to MilanaPharm or TriLogic as necessary to comply with the DTM Upstream License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Publicity&#47;Use of Names.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  No disclosure of the existence, or the terms, of this Agreement may be made by either Party, and no Party shall use the name, Trademark, trade name or logo of the other Party, its Affiliates or their respective employee(s), and Organon may not use the name, trade name or logo of any Dar&#233; licensor, in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except as may be required by Applicable Law. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Announcements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Promptly following the Execution Date, the Parties shall issue an initial press release having the content specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Following such initial press release, Dar&#233; agrees &#91;***&#93;.  Organon will have the right without obtaining Dar&#233;&#8217;s consent to make public announcements concerning the Development, Commercialization or other Exploitation of Licensed Products under this Agreement.  The Parties agree that after a press release (including the initial press release or any subsequent press release, such as on or after the Effective Date) or other public announcement has been issued in accordance with this Section 5.6, each Party may make subsequent public disclosures of the information contained in such press release or other public announcement without the further approval of the other Party, so long as the information in such press release or other public announcement remains true and correct.  Notwithstanding anything to the contrary set forth in this Agreement, each Party may issue a press release or public announcement as required, in the reasonable judgment of such Party, by Applicable Law, including by the rules or regulations of the United States Securities and Exchange Commission or similar regulatory agency in a country other than the United States or of any stock exchange or listing entity.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Required Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If either Party is required to disclose the terms of this Agreement in submissions to the U.S. Securities and Exchange Commission or other equivalent Governmental Authority, it will &#91;***&#93;.  The requirements of this Section 5.7 shall not apply if the substance of the description of or reference to this Agreement contained in the proposed filing or disclosure has been included in any previous filing or disclosure made by either Party or otherwise approved by the other Party and such information remains accurate as of such time.</font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">27</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Publications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to Organon&#8217;s obligations under Section 2.6, and notwithstanding anything to the contrary in this Article 5, Organon shall have the right to disclose, publish or present all Information, including preclinical and clinical data, relating to the Licensed Products.  Dar&#233; shall not disclose, publish or present any preclinical and clinical data relating to the Licensed Products to any Third Party without first submitting such disclosure, publication or presentation to Organon for review.  Organon shall have &#91;***&#93; to review such disclosure, publication or presentation to determine whether the Information proposed to be disclosed contains any of Organon&#8217;s confidential Information or confidential Dar&#233; Know-How and issue notice of such to Dar&#233;. If notification is not received by Dar&#233; within such &#91;***&#93; period, Dar&#233; will be free to proceed with such disclosure, publication or presentation.  If due to a valid business reason or a reasonable belief by Organon that the disclosure, publication or presentation contains (a) confidential Information of Organon or confidential Dar&#233; Know-How, or (b) subject matter for which a patentable invention should be sought, then prior to the expiration of the &#91;***&#93;, Organon will so notify Dar&#233;, and the Dar&#233; will then (x) at the request of Organon delete any confidential Information of Organon or confidential Dar&#233; Know-How, or (y) delay public disclosure, publication or presentation of such Information for &#91;***&#93; to permit the preparation and filing of a patent application on the subject matter to be disclosed, published, or presented or other protective action to be taken.  The determination of authorship for any paper will be in accordance with accepted scientific practice.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:13.66pt">PAYMENTS&#59; ROYALTIES AND REPORTS.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">License Fee and Development Milestone.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In partial consideration for the licenses and other rights granted to Organon herein under the Dar&#233; Patents and Dar&#233; Know-How, upon the terms and conditions contained herein, Organon shall pay to Dar&#233; $10,000,000 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) within &#91;***&#93; after the Effective Date, and such amount is non-refundable and non-creditable.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Milestone Payments. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Organon shall pay to Dar&#233; the following milestone payments corresponding to the following milestone events during the term of this Agreement&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">First Commercial Sale Milestone.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Organon shall pay to Dar&#233; $2,500,000 for the First Commercial Sale in the United States of a Licensed Product.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Sales Milestones.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Organon shall pay to Dar&#233; each of the following amounts in Table 6.2.2 below (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sales Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) &#91;***&#93; as a result of the &#91;***&#93; of the corresponding event (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sales Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:0.12pt;padding-left:37.54pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.294%"><tr><td style="width:1.0%"></td><td style="width:22.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Table 6.2.2 Sales Milestone Events and Payments</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Milestone Event No.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">One Time Milestone Event Description</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">One Time Milestone Payment</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$&#91;***&#93;</font></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">$&#91;***&#93;</font></td></tr></table></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">28</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Regulatory Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Organon shall pay to Dar&#233; $&#91;***&#93; upon &#91;***&#93; (any such event described by foregoing clauses (a) and (b), a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however, that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Notifications of Sales Milestones and Regulatory Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Organon shall notify Dar&#233; in writing within &#91;***&#93; after the end of a Calendar Quarter in which the Sales Milestone Event first occurs.  The Sales Milestone Payment for each such event shall be due and payable &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Organon shall notify Dar&#233; in writing within &#91;***&#93; following the achievement of each Regulatory Milestone, and shall make the appropriate milestone payment within &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Each milestone payment shall be payable only upon the initial achievement of the applicable corresponding milestone and no amounts shall be due hereunder for subsequent or repeated achievement of such milestone.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Royalties.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Royalties Payable By Organon.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Subject to the terms and conditions of this Agreement, Organon shall pay Dar&#233; royalties, calculated on all Licensed Products and on a tiered basis, as set forth in this Section 6.3.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Patent Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the provisions of Section 6.3.1(b) through Section 6.3.1(e), Organon shall pay Dar&#233; royalties (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) in an amount equal to the following percentage of Net Sales during a Royalty Period&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">&#91;***&#93; of the aggregate of such Net Sales in each Calendar Year up to and including &#91;***&#93; of such Net Sales&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">&#91;***&#93; of the aggregate of such Net Sales in each Calendar Year greater than &#91;***&#93; of such Net Sales up to and including &#91;***&#93; of such Net Sales&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">&#91;***&#93; of the aggregate of such Net Sales in each Calendar Year greater than &#91;***&#93; of such Net Sales up to and including &#91;***&#93; of such Net Sales&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">&#91;***&#93; of the aggregate of such Net Sales in each Calendar Year greater than &#91;***&#93; of such Net Sales up to and including &#91;***&#93; of such Net Sales&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#91;***&#93; of the aggregate of such Net Sales in each Calendar Year greater than &#91;***&#93; of such Net Sales.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.57pt">Know-How Royalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  On a Licensed Product-by-Licensed Product and country-by-country basis, if during any Calendar Quarter within the applicable Royalty Period for such Licensed Product in such country, no Valid Patent Claim exists that would be infringed, in the absence of the license granted under Section 3.1, by the sale of such Licensed Product in such country, &#91;***&#93;, then, commencing the first Calendar Quarter thereafter and for all Calendar Quarters thereafter, Organon shall pay royalties at rates equal to &#91;***&#93; of the applicable royalty rate determined according to Section 6.3.1(a).  Such royalties shall be calculated after first calculating royalties under Section 6.3.1(a). </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">29</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  On a Licensed Product-by-Licensed Product and country-by-country basis during the Royalty Period, if (i) &#91;***&#93; in such country and Regulatory Exclusivity for such Licensed Product has expired (or otherwise does not exist) and (ii) if &#91;***&#93; during &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Competition Analysis Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is &#91;***&#93; during such Competition Analysis Period and (iii) aggregate Net Sales of such Licensed Product in such Competition Analysis Period is &#91;***&#93; during the &#91;***&#93;, then commencing &#91;***&#93; after the Competition Analysis Period and each Calendar Quarter thereafter, the royalty rates set forth in Section 6.3.1(a) for such Licensed Product in such country during such next Calendar Quarter shall be reduced in such country by &#91;***&#93;. For purposes of the foregoing, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.57pt">Royalty Period and Application to Tiers and Sales Milestone Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Royalties due pursuant to Section 6.3.1(a) through Section 6.3.1(c) and Sales Milestone Events shall be calculated based on Net Sales of all Licensed Products during a Royalty Period throughout the Territory, provided that the determination of whether the royalty rate shall be reduced under Section 6.3.1(b) or Section 6.3.1(c) shall be determined on a country-by-country and Licensed Product-by-Licensed Product basis.  Royalties on each Licensed Product at the applicable rates set forth above shall continue on a country-by-country and Licensed Product-by-Licensed Product basis from the First Commercial Sale of such Licensed Product in such country until the expiration of the later of&#58; (i) the date that no Valid Patent Claim would be infringed, in the absence of the license granted hereunder, by the sale of such Licensed Product in such country occurred&#59; (ii) for a period of ten (10) years after the end of the month in which the First Commercial Sale of such Licensed Product in such country occurred&#59; and (iii) expiration of Regulatory Exclusivity (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Net Sales and Royalty Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All Net Sales calculations and associated royalties are subject to the following conditions&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">that only one royalty shall be due with respect to the same unit of Licensed Product&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">that no Net Sales calculations will be performed for the purposes of Sales Milestone Events and no royalties shall be due upon the sale or other transfer among Related Parties where the Licensed Product will not be used or consumed by such Related Party(ies), but in such cases the Net Sales calculation and associated royalty shall be due and calculated upon Organon&#8217;s or its Related Party&#8217;s Net Sales to the first independent Third Party that is not a Related Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Third Party Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">In the event that Organon obtains (after the Effective Date) a license under, or other rights to, Patents or know-how or other intellectual property from any Third Party(ies) that Organon reasonably determines add value, are strategically important or are useful, or are reasonably necessary or required, in order to Exploit Licensed Product(s) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), &#91;***&#93; of the amounts actually paid (including milestone payments, royalties or other license fees) under such Third Party Licenses by Organon or its Related Parties as consideration for the acquisition or exploitation of such Third Party License in connection with the Exploiting of Licensed Product(s) for a Calendar Quarter shall be creditable against the royalty payments due Dar&#233; by Organon with respect to the sale of such Licensed Product in such Calendar Quarter.  Amounts payable by Organon to TriLogic or MilanaPharm pursuant to the Standby Agreement shall not be subject to offset pursuant to this Section&#160;6.3.2.</font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">30</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Notwithstanding the foregoing provisions of this Section 6.3.2, in no event shall the royalties owed by Organon to Dar&#233; for any Calendar Quarter be reduced by more than &#91;***&#93; pursuant to this Section 6.3.2 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however, that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> if Organon is not able to fully recover the amounts paid by Organon or its Related Parties under any Third Party License as a result of the foregoing restriction, then Organon shall be entitled to carry forward such right of offset to one or more future Calendar Quarter(s) with respect to such excess amount until the amounts have been fully offset). At the reasonable request of Organon, Dar&#233; shall provide reasonable assistance to Organon (or its Related Parties) in obtaining any such Third Party Licenses or otherwise taking reasonable action with respect Patents or know-how or other intellectual property of any Third Party(ies) that may be necessary or useful in order to Exploit Licensed Product(s) or any components of Licensed Product(s).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Floor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary, in no event will the royalty rate that otherwise would be applicable under Section 6.3.1(a) to a Licensed Product in a country in a Calendar Quarter be reduced by more than &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Reports&#59; Payment of Royalty.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  During the term of this Agreement, on a country-by-country and Licensed Product-by-Licensed Product basis, following the month in which the First Commercial Sale of a Licensed Product occurs in a country, Organon shall furnish to Dar&#233; a &#91;***&#93; written report for such and each subsequent &#91;***&#93; showing (a) &#91;***&#93;. Reports shall be due &#91;***&#93;.  Royalties shall be due and payable on the date such royalty report is due.  Each Related Party shall keep complete and accurate books and records pertaining to Net Sales in sufficient detail to calculate all amounts payable hereunder with respect thereto and to verify compliance with its obligations under this Agreement.  Such books and records shall be retained until &#91;***&#93; after the end of the Calendar Year to which such books and records pertain.   </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon the written request of Dar&#233; and not more than &#91;***&#93;, Organon shall permit an independent certified public accounting firm of nationally recognized standing selected by Dar&#233; and reasonably acceptable to Organon to have access during normal business hours to such of the records of Organon and its Affiliates as may be reasonably necessary to verify the accuracy of the royalty reports hereunder for any Calendar Year ending not more than &#91;***&#93; prior to the date of such request.  Any records or accounting information received from Organon shall be Organon&#8217;s confidential Information, and the accounting firm will sign a confidentiality agreement in form and substance that is reasonably satisfactory to Organon prior to beginning any audit.  The accounting firm shall disclose to Dar&#233; only whether the royalty reports are correct or incorrect and the amount of any discrepancy.  Such disclosure by the accounting firm will be deemed confidential Information hereunder.  No other Information of Organon or its Affiliate shall be provided to Dar&#233; by the accounting firm without Organon&#8217;s prior written consent.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Discrepancy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If such accounting firm correctly identifies an underpayment made during such period, Organon shall pay Dar&#233; the amount of the underpayment within &#91;***&#93; after the date Dar&#233; delivers to Organon such accounting firm&#8217;s written report that correctly identifies such discrepancy, or as otherwise agreed upon by the Parties.  If such accounting firm identifies an overpayment made during an audited period, such overpayment will be creditable towards Organon&#8217;s future payments hereunder.  The fees charged by such accounting firm shall be paid by Dar&#233;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that if such audit uncovers an underpayment of royalties by Organon that exceeds &#91;***&#93;, then the fees of such accounting firm shall be paid by Organon.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Sublicensee Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Organon shall include in each sublicense granted by it pursuant to this Agreement a provision requiring the Sublicensee to make reports to </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">31</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Organon, to keep and maintain records of sales made pursuant to such sublicense and to grant access to such records by Dar&#233;&#8217;s independent accountant to the same extent required of Organon under this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Dar&#233; shall treat all financial information subject to review under this Section 6.5 or under any sublicense agreement as the confidential Information of Organon in accordance with Article 5.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Payment&#59; Currency Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All payments to be made by Organon to Dar&#233; under this Agreement shall be made in United States dollars and may be paid by check made to the order of Dar&#233; or bank wire transfer in immediately available funds to such bank account in the United States as may be designated in writing by Dar&#233; from time to time.  In the case of sales outside the United States, the rate of exchange to be used in computing the monthly amount of currency equivalent in United States dollars due Dar&#233; shall be made at the rate of exchange utilized by Organon in its worldwide accounting system from time to time, consistently applied.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Income Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Dar&#233; shall be liable for all income and other taxes (including interest) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) imposed upon its income.  If Applicable Laws, rules or regulations require the withholding of Taxes, Organon shall make such withholding payments and shall subtract the amount thereof from the payments due hereunder.  Organon shall submit to Dar&#233; appropriate proof of payment of the withheld Taxes as well as the official receipts within a reasonable period of time.  Organon shall provide Dar&#233; reasonable assistance in order to allow Dar&#233; to obtain the benefit of any present or future treaty against double taxation which may apply to the payments due hereunder.  Each Party will provide the other with reasonable assistance to enable the recovery, as permitted by Applicable Law, of withholding taxes, VAT, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or VAT. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Late Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Organon may not offset, deduct or withhold any amounts payable hereunder except pursuant to Section 6.7, Section 10.3.2 and as permitted under the Standby Agreement.  Any payments or portions thereof due hereunder that are not paid when due (including any underpayment of Royalties) will accrue interest under this Agreement at a rate of &#91;***&#93; per annum or the maximum applicable legal rate, if less, calculated on the total number of days payment is delinquent.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:13.66pt">REPRESENTATIONS AND WARRANTIES&#59; COVENANTS.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Representations and Warranties of Each Party.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Each Party represents and warrants to the other Party that as of the Execution Date, and unless also limited to just the Execution Date, then again as of the Effective Date&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">such Party is duly organized and validly existing under the laws of the state or jurisdiction of its organization and has full corporate right, power and authority to enter into this Agreement and to perform its obligations hereunder&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by the necessary corporate actions of such Party.  This Agreement has been duly executed by such Party.  This Agreement and any other documents contemplated hereby constitute valid and legally binding obligations of such Party enforceable against it in accordance with their respective terms, except to the extent that enforcement of the rights and remedies created thereby is subject to bankruptcy, insolvency, reorganization, moratorium and other similar laws of general application affecting the rights and remedies of creditors&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">the execution, delivery and performance by such Party of this Agreement and any other agreements and instruments contemplated hereunder will not (a) in any respect violate any statute, regulation, judgment, order, decree or other restriction of any Governmental </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">32</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Authority to which such Party is subject, (b) violate any provision of the corporate charter, by-laws or other organizational documents of such Party, or (c) constitute a material violation or breach by such Party of any provision of any material contract, agreement or instrument to which such Party is a party or to which such Party is otherwise bound.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Dar&#233; Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Dar&#233; represents and warrants to Organon that as of the Execution Date, and unless also limited to just the Execution Date, then again as of the Effective Date&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> sets forth a true, correct and complete list of Dar&#233; Patents, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.95</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> sets forth a true, correct and complete list of all Product Trademarks, existing as of the Execution Date&#59; and (b) the Dar&#233; Patents, Product Trademarks, and Dar&#233; Know-How constitute all intellectual property owned by or licensed to Dar&#233; (or any of its Affiliates) that are necessary or useful for Exploitation of the Licensed Products in the Field&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">all Patents within the Dar&#233; Patents and Trademarks within the Product Trademarks are subsisting and in full force and effect, and, to Dar&#233;&#8217;s Knowledge, the issued Dar&#233; Patents are not invalid or unenforceable, in whole or in part&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">it has the full right, power and authority and sufficient resources to perform the activities hereunder and to grant the licenses granted hereunder (including under Article 3)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">it has not (a) assigned, transferred, conveyed, licensed or otherwise encumbered its right, title and interest in or to Dar&#233; Patents, Dar&#233; Know-How or Product Trademarks or (b) otherwise granted any rights, covenant not to sue, or immunity from suit to any Person&#59; in each case of (a) and (b) that would conflict with the rights granted to Organon hereunder&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Dar&#233;&#8217;s right, title and interest in the Dar&#233; Patents, Dar&#233; Know-How and Product Trademarks is free and clear of any liens, charges, restrictions and encumbrances (other than restrictions and encumbrances of the DTM Upstream License Agreement and other than Joint Agreement Information and Inventions and Joint Patents), and no Third Party (including any Governmental Authority or subdivision thereof), has or shall have any claim of ownership whatsoever with respect to the Dar&#233; Patents and Dar&#233; Know-How (other than ownership by the licensors under the DTM Upstream License Agreement) and Product Trademarks&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">to Dar&#233;&#8217;s Knowledge, but without any further inquiry or investigation, the Manufacture, use, sale, offer for sale, or importation of the Licensed Product in the form that is the subject of the Dar&#233; Marketing Authorization as of the Execution Date, does not and will not infringe, misappropriate, or otherwise violate any intellectual property rights that exist as of the Execution Date (and again as of the Effective Date) of any Person&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">neither it nor any of its Affiliates has received any written notification from a Third Party that the Exploitation of any Licensed Product or component thereof, or the use of any Product Trademark, infringes or misappropriates or will infringe or misappropriate the Patents or other intellectual property rights of any Person, and Dar&#233; has no Knowledge that any Person has any basis for any such claim&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">there are no claims, judgments or settlements against or owed by Dar&#233; (or any of its Affiliates) or, to Dar&#233;&#8217;s Knowledge, threatened claims or litigation, in each case relating to the Dar&#233; Patents, Product Trademarks, or Dar&#233; Know-How&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Dar&#233; has disclosed to Organon all reasonably relevant information Controlled by Dar&#233; regarding (a) the Licensed Products, including the Facilities at which the Licensed Products may be Manufactured by Dar&#233; or its contract manufacturer(s), and (b) the Dar&#233; </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">33</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Patents and Dar&#233; Know-How licensed under this Agreement, including (i) any licenses and binding agreements related to the Dar&#233; Patents, Product Trademarks, and Dar&#233; Know-How to which Dar&#233; is a party, and (ii) and safety or efficacy information related to the Licensed Products or any component thereof of which Dar&#233; has Knowledge, and none of the foregoing information disclosed by Dar&#233; to Organon is not Controlled by Dar&#233;&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">Dar&#233; has disclosed to Organon the existence of any patent opinions or results of freedom to operate or patentability searches of which Dar&#233; is aware that are related to the Dar&#233; Patents and Dar&#233; Know-How licensed under this Agreement&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.2.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">Dar&#233; has disclosed to Organon all material information and data and all material correspondences to&#47;from any Regulatory Authority related to Licensed Products and Facilities at which Licensed Products may be Manufactured by Dar&#233; or its contract manufacturer(s) Controlled by Dar&#233;, regardless of whether such data and information would have a positive, negative or neutral impact on the potential commercial, scientific or strategic value or attractiveness of the Licensed Products&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.2.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">Dar&#233; has obtained all necessary consents, approvals and authorizations of all Governmental Authorities and other Persons required to be obtained by it as of the Effective Date, as applicable, in connection with the execution, delivery and performance of this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.2.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">except for the Regulatory Materials and Marketing Authorizations assigned by Dar&#233; to Organon pursuant to Section 2.1, neither Dar&#233; nor any of its Affiliates has obtained, or filed for, any Marketing Authorizations, pricing or reimbursement approvals from any Governmental Authority (whether or not required to legally market, distribute, offer for sale or sell a product), INDs or NDAs for any Licensed Products, ROFR Products, Restricted Products, Competitive Products or Non-Compete Products&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">Dar&#233; and its Affiliates have not ever been, nor are they currently, the subject of a proceeding that could lead to Dar&#233; or its Affiliates becoming a Debarred Entity, Excluded Entity or Convicted Entity and it and its Affiliates will not, to its Knowledge, use in any capacity, in connection with the obligations to be performed under this Agreement, any person who is a Debarred Individual, Excluded Individual or a Convicted Individual, where for purposes of this provision, the following definitions shall apply&#58; (a) a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Debarred Individual</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is an individual who has been debarred by the FDA pursuant to 21 U.S.C. &#167;335a (a) or (b) from providing services in any capacity to a Person that has an approved or pending drug or biological product application, (b) a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Debarred Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is a corporation, partnership or association that has been debarred by the FDA pursuant to 21 U.S.C. &#167;335a (a) or (b) from submitting or assisting in the submission of any abbreviated drug application, or a subsidiary or affiliate of a Debarred Entity, (c) an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Excluded Individual</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Excluded Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is (i) an individual or entity, as applicable, who has been excluded, debarred, suspended or is otherwise ineligible to participate in federal health care programs such as Medicare or Medicaid by the Office of the Inspector General (OIG&#47;HHS) of the U.S. Department of Health and Human Services, or (ii) is an individual or entity, as applicable, who has been excluded, debarred, suspended or is otherwise ineligible to participate in U.S. federal procurement and non-procurement programs, including those produced by the U.S. General Services Administration (GSA), and (d) a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Convicted Individual</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Convicted Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is an individual or entity, as applicable, who has been convicted of a criminal offense that falls within the ambit of 21 U.S.C. &#167;335a (a) or 42 U.S.C. &#167;1320a-7(a), but has not yet been excluded, debarred, suspended or otherwise declared ineligible&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.2.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">all research and development (including non-clinical studies and Clinical Trials) performed by Dar&#233;, and, to Dar&#233;&#8217;s Knowledge, on behalf of Dar&#233;, related to the Licensed Products prior to the Effective Date has been conducted in accordance with all Applicable Laws&#59; </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">34</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.2.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">all information, data and statements provided by Dar&#233;, and, to Dar&#233;&#8217;s Knowledge, on behalf of Dar&#233;, to each Regulatory Authority in connection with the Licensed Product were, and remain, true and accurate and complete in all material respects and there have been no material omissions from such information, data or statements, and Dar&#233; has not disclosed, failed to disclose, or cause to be disclosed, any information, data or statements that would reasonably be expected to cause the information, data and statements that has been disclosed to any Regulatory Authority to be misleading in any material respect&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.2.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">all information and data provided by or on behalf of Dar&#233; to Organon on or before the Effective Date in contemplation of this Agreement was and is, to Dar&#233;&#8217;s Knowledge, true and accurate and complete in all material respects, and Dar&#233; has not knowingly disclosed, failed to disclose, or cause to be disclosed, any information or data that would reasonably be expected to cause the information and data that has been disclosed to be misleading in any material respect.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Dar&#233; Upstream License Agreements Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Dar&#233; represents and warrants to Organon that as of the Execution Date, and unless also limited to just the Execution Date, then again as of the Effective Date&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">except for the DTM Upstream License Agreement, there are no agreements (including any licenses), written or oral, granting any licenses or other rights to (or from) Dar&#233; (or any of its Affiliates) relating to the Licensed Products or the Dar&#233; Know-How or Dar&#233; Patents&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">with respect to the DTM Upstream License Agreement, (a) it is in full force and effect&#59; (b) neither Dar&#233; nor any of its Affiliates is in breach thereof&#59; (c) neither Dar&#233; nor any of its Affiliates has received any notice of breach or notice of threatened breach thereof&#59; and (d) neither Dar&#233; nor any of its Affiliates has received any notice from the counterparty to such DTM Upstream License Agreement of intent to reduce the scope of the field thereof or render any of the licenses thereunder non-exclusive&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Dar&#233; has provided to Organon as of the Effective date a true, correct and complete (but with commercial information redacted) copy of each of the DTM Upstream License Agreement, including any and all amendments, restatements, side letters, and other modifications thereto, as such DTM Upstream License Agreement is in effect as of the Effective Date&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">that the payments required to be paid by Organon pursuant to this Agreement are sufficient to satisfy Dar&#233;&#8217;s obligation under Section 2.1.3(ii) of the DTM Upstream License Agreement&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">to Dar&#233;&#8217;s Knowledge, Hammock has retained no right, title or interest in or to any intellectual property rights or Information under the DTM Upstream License Agreement relating to any (a) product that would constitute at any time Licensed Product, ROFR Product or Competitive Product, (b) Dar&#233; Patents, Joint Patents, or Dar&#233; Know-How, (c)&#160;Dar&#233; Marketing Authorizations or Dar&#233; Regulatory Materials, (d) any intellectual property rights licensed under the DTM Upstream License Agreement, and (e) any Technology and Data (as defined in the Assignment Agreement between Dar&#233; and Hammock, effective December 5, 2018)&#59; and to Dar&#233;&#8217;s Knowledge, there is no Hammock Data (as defined in the DTM Upstream License Agreement).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each of the following provisions are effective as of the Execution Date and remain in effect during the term of this Agreement unless otherwise noted.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party hereby covenants to the other Party that, in the performance of its obligations under this Agreement, such covenanting Party shall comply, and shall cause its and its Affiliates&#8217; and sublicensees&#8217; and its and their </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">35</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">employees and subcontractors to comply, with all Applicable Laws, including (a) all Anti-Corruption Laws, (b) all Privacy Laws, (c) all current governmental regulations concerning GxP, as applicable, and (d) national and international pharmaceutical industry codes of practice.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">No Kickback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party hereby covenants to the other Party that such covenanting Party and its Affiliates&#8217; employees and contractors shall not, in connection with the performance of its obligations under this Agreement, directly or indirectly through Third Parties, pay, promise, or offer to pay, or authorize the payment of, any money or give any promise or offer to give, or authorize the giving of anything of value to a Public Official or other person for purpose of obtaining or retaining business for or with, or directing business to, any person, and shall not directly or indirectly promise, offer, or provide any corrupt payment, gratuity, emolument, bribe, kickback, illicit gift, or hospitality or other illegal or unethical benefit to a Public Official or any other person in connection with the performance of its obligations under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Notice of Violation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party hereby covenants to the other Party that such covenanting Party shall immediately notify the other Party if such Party has any information or suspicion that there may be a violation of any Anti-Corruption Laws, any Privacy Laws, or any other Applicable Laws in connection with its performance of this Agreement or its or its Affiliates&#8217; or sublicensees&#8217; Exploitation of any Licensed Product.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Organon Policies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Organon hereby covenants to Dar&#233; that (a) Organon and its Affiliates shall maintain and enforce a compliance and ethics program containing adequate systems, policies and procedures for the detection, investigation, documentation, and remediation of any allegations, reports or findings related to a potential violation of Applicable Laws, including Anti-Corruption Laws, with respect to the Licensed Products and payments and activities under this Agreement, (b) such policies and procedures will set out rules governing interactions with healthcare providers, Public Officials, the engagement of Third Parties, and where appropriate, conducting due diligence, and the investigation, documentation and remediation of any allegations, reports or findings related to a potential violation of Applicable Laws, and (c) Organon shall comply and shall cause its and its Affiliates&#8217; employees and contractors to comply with all such policies and procedures in connection with the performance of its obligations under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Dar&#233; Policies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Dar&#233; hereby covenants to Organon that Dar&#233; shall maintain a &#8220;Code of Business Conduct and Ethics&#8221; approved by its Board of Directors of a scope substantially equivalent to, and in any event no less stringent than, Dar&#233;&#8217;s Code of Business Conduct and Ethics that is in effect as of the Execution Date and, in the performance of its obligations under this Agreement, Dar&#233; shall comply and shall require its and its Affiliates&#8217; employees and contractors to comply with such Code of Business Conduct and Ethics.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">No Encumbrances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Dar&#233; will not enter into any assignment, transfer, license, conveyance or encumbrance of, or otherwise assign, transfer, license, convey or encumber, its right, title, or interest in or to the Dar&#233; Patents, Joint Patents or Dar&#233; Know-How or grant to any Person any such right, title, or interest, in each case that conflicts with the rights and licenses granted, or to be granted, to Organon under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Upstream Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Dar&#233; further covenants and agrees that Dar&#233; (a) shall satisfy all of its obligations under (including making all payments), and take all reasonable and lawful steps to maintain in full force and effect, the DTM Upstream License Agreement in all manner necessary to prevent any adverse effect on the rights of Organon under this Agreement&#59; (b) will not assign (except an assignment to a party to which this Agreement has been assigned as permitted under Section 12.2), amend, restate, amend and restate, terminate in whole or in part, or otherwise modify the DTM Upstream License Agreement without the prior written consent of Organon, in all manner necessary to </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">36</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">prevent an adverse effect on the rights of Organon under this Agreement&#59; and (c) will provide Organon with prompt notice of any claim of a breach under the DTM Upstream License Agreement or notice of termination of the DTM Upstream License Agreement, made by either Dar&#233; or the counterparty to such DTM Upstream License Agreements (or any party acting on behalf of such counterparty).  For the purposes of clarity, Dar&#233; (and not Organon) shall be responsible for all of the financial and other obligations of Dar&#233; (or any of its Affiliates) under the DTM Upstream License Agreement, including any and all financial obligations thereunder with respect to Net Sales of the Related Parties or other payments due or made by Organon under this Agreement.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Patent Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Between the Execution Date and the Effective Date Dar&#233; will (a) diligently prepare, file, prosecute and maintain the Dar&#233; Patents licensed to Organon under this Agreement, (b) keep Organon informed of all material actions taken or intended to be taken in connection with the preparation, filing, prosecution and maintenance of such Dar&#233; Patents and (c) consult with Organon and reasonably consider Organon&#8217;s reasonable requests with respect to the preparation, filing, prosecution and maintenance of such Dar&#233; Patents.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.4.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Trademark Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Between the Execution Date and the Assignment Date, Dar&#233; will (a) diligently prepare, file, prosecute, register and maintain the Product Trademarks, (b) keep Organon informed of all material actions taken or intended to be taken in connection with the preparation, filing, prosecution, registration, and maintenance of Product Trademark, and (c) consult with Organon and reasonably consider Organon&#8217;s reasonable requests with respect to the preparation, filing, prosecution, registration, and maintenance of Product Trademarks.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Disclaimers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED (AND EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES NOT EXPRESSLY PROVIDED IN THIS AGREEMENT), INCLUDING WITH RESPECT TO ANY PATENTS, PATENT APPLICATIONS, KNOW-HOW, PRODUCTS AND MATERIALS, INCLUDING WARRANTIES OF VALIDITY OR ENFORCEABILITY OF ANY PATENTS OR THAT PATENTS WILL ISSUE UPON APPLICATIONS, OR THE TITLE, QUALITY, COMPLETENESS, ACCURACY, MERCHANTABILITY, FITNESS FOR A PARTICULAR USE OR PURPOSE, PERFORMANCE AND NONINFRINGEMENT OF ANY THIRD PARTY PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:13.66pt">INDEMNIFICATION.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Indemnification by Organon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Organon shall indemnify Dar&#233; and its Affiliates and their respective licensors (including TriLogic and MilanaPharm), directors, officers, employees, and agents (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dar&#233; Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and defend each of them (subject to Section 9.5) and hold each of them harmless from and against any and all liabilities, damages, expenses, fines, penalties, costs and losses, including reasonable legal expenses and attorneys&#8217; fees (and excluding any multiplier of attorneys&#8217; fees or similar penalty payable to Dar&#233; Indemnitees based upon a contingency fee arrangement with their attorneys) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), to which any Dar&#233; Indemnitee may become subject as a result of any claim, demand, action, or other proceeding by any Third Party (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third-Party Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to the extent such Losses arise out of or relate to&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">the Exploitation of any Licensed Product by or on behalf of Organon or its Affiliates or Sublicensees&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">the negligence or willful misconduct of any Organon Indemnitee&#59; </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">37</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">use or disclosure of Research Data Sets and Non-Identifiable Data&#59; or </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">the breach by Organon of any warranty, representation, covenant, or agreement made by Organon in this Agreement, </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">except, in each case (a) thru (d), to the extent such Losses arise out of any activities set forth in Section 8.2 for which Dar&#233; is obligated to indemnify any Organon Indemnitee under Section 8.2. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Indemnification by Dar&#233;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Dar&#233; shall indemnify Organon and its Affiliates and their respective directors, officers, employees, and agents (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Organon Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and defend each of them (subject to Section 9.5) and hold each of them harmless from and against any and all Losses (and excluding any multiplier of attorneys&#8217; fees or similar penalty payable to Organon Indemnitees based upon a contingency fee arrangement with their attorneys) to which any Organon Indemnitee may become subject as a result of any Third-Party Claim to the extent such Losses arise out of or relate to&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">the Exploitation of any Licensed Product by or on behalf of, or for, Dar&#233;, its Affiliates, or its or their sublicensees anywhere in the world&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">the negligence or willful misconduct of any Dar&#233; Indemnitee&#59; or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">the breach by Dar&#233; of any warranty, representation, covenant, or agreement made by Dar&#233; in this Agreement,</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">except, in each case (a) thru (c), to the extent such Losses arise out of any activities set forth in Section 8.1 for which Organon is obligated to indemnify any Dar&#233; Indemnitee under Section 8.1. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Indemnification Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Defense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Party claiming indemnity under this Article 8 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) from a Third-Party Claim shall give written notice to the Party from whom indemnity is being sought (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) promptly after learning of such Third-Party Claim&#59; provided, however, that failure to promptly notify the Indemnifying Party shall not relieve it of its obligations under this Article 8, unless such failure materially prejudices the Indemnifying Party&#8217;s ability to defend the Third-Party Claim. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to Section 9.5, the Indemnified Party&#58; (a) shall allow the Indemnifying Party to control the defense and settlement of the Third-Party Claim&#59; (b) shall provide the Indemnifying Party with reasonable assistance, at the Indemnifying Party&#8217;s request and expense, in connection with the defense of the Third-Party Claim for which indemnity is being sought&#59; and (c) may participate in and monitor such defense with counsel of its own choice at its own expense. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Indemnifying Party shall not settle any Third-Party Claim without the prior written consent of the Indemnified Party, which shall not be unreasonably withheld, conditioned or delayed, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that no consent is necessary if the settlement involves only the payment of money (which will be paid by the Indemnifying Party), no admission of wrong-doing or fault by the Indemnified Party, and no restriction on the future actions or activities of the Indemnified Party.  Subject to Section 9.5, so long as the Indemnifying Party is actively defending the Third-Party Claim in good faith, the Indemnified Party shall not settle such Third-Party Claim without the prior written consent of the Indemnifying Party, which shall not be unreasonably withheld, conditioned or delayed. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Control by Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If the Indemnifying Party does not assume and conduct the defense of the Third-Party Claim as provided in Section 8.3.1 or if the Indemnified </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">38</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Party has the right to control such defense under Section 9.5, (a) the Indemnified Party may defend against and consent to the entry of any judgment, or enter into any settlement with respect to, the Third-Party Claim in any manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith), and (b) the Indemnifying Party will remain responsible to indemnify and hold harmless the Indemnified Party as provided in this Article 8. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party, at its own expense, shall maintain insurance (or self-insurance), including commercial general liability insurance, product liability insurance and other appropriate insurance, in amounts &#91;***&#93;.  Each Party shall maintain such insurance for the period commencing on the Effective Date until &#91;***&#93; after expiration or termination of this Agreement.  Each Party shall provide a certificate of insurance evidencing such coverage to the other Party upon request.  It is understood that such insurance shall not be construed to create any limit of either Party&#8217;s obligations or liabilities with respect to its indemnification obligations under this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  EXCEPT FOR (A) DAMAGES THAT ARE CAUSED BY (I) A PARTY&#8217;S WILLFUL MISCONDUCT OR FRAUD, (II) A PARTY&#8217;S BREACH OF ITS OBLIGATIONS UNDER ARTICLE 5, (III) DAR&#201;&#8217;S FAILURE TO ASSIGN THE DAR&#201; MARKETING AUTHORIZATIONS AND DAR&#201; REGULATORY MATERIALS TO ORGANON AND FAILURE TO COOPERATE WITH ORGANON FOR PURPOSES OF EFFECTING AN ORDERLY TRANSITION OF CONTROL OF DAR&#201; MARKETING AUTHORIZATIONS IN BREACH OF SECTION 2.1, OR (IV) DAR&#201;&#8217;S BREACH OF SECTION 2.3, THE FIRST SENTENCE OF SECTION 2.5, THE FIRST SENTENCE OF SECTION 3.3.1, OR THE FIRST SENTENCE OF SECTION 4.2 (AND IN EACH CASE WHERE SUCH BREACH IS NOT CURED WITHIN &#91;***&#93; OF RECEIPT OF NOTICE FROM ORGANON DESCRIBING THE BREACH), AND (B) AMOUNTS PAYABLE PURSUANT TO INDEMNIFICATION UNDER SECTION 8.1 OR SECTION 8.2, NEITHER PARTY SHALL BE LIABLE IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY, OR OTHERWISE FOR &#91;***&#93; SUFFERED BY THE OTHER PARTY (OR ITS AFFILIATES OR (SUB)LICENSEES), &#91;***&#93;. DAMAGES CAUSED BY A PARTY&#8217;S INFRINGEMENT OF THE OTHER PARTY&#8217;S INTELLECTUAL PROPERTY RIGHTS ARE NOT LIMITED BY THIS SECTION&#160;8.5.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:13.66pt">PATENT PROVISIONS.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Filing, Prosecution and Maintenance of Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Product-Specific Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  As between the Parties, after the Effective Date, &#91;***&#93; shall have the first right, but not the obligation, to prepare, file, prosecute, and maintain (a) the Dar&#233; Patents that are set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 9.1.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and all Patents that claim priority thereto, whether existing as of the Effective Date or first existing thereafter, (b) Dar&#233; Patents first Controlled by Dar&#233; or its Affiliates after the Effective Date that &#91;***&#93;, (c) Dar&#233; Patents first Controlled by Dar&#233; or its Affiliates after the Effective Date that &#91;***&#93;, and (d) Dar&#233; Patents first Controlled by Dar&#233; or its Affiliates after the Effective Date that &#91;***&#93;&#59; and in each of foregoing clauses (b) through (e), within the Field and to the extent not otherwise the subject of foregoing clause (a) (each of the Dar&#233; Patents described in foregoing clauses (a)&#8211;(d), collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product-Specific Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), &#91;***&#93;. Product-Specific Patents include the Patents set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 9.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and all Patents that claim priority to or have common priority with any such Patents, in whole or in part, as of the Effective Date or at any time hereafter. &#91;***&#93; shall give &#91;***&#93; at least &#91;***&#93; to review the text of any new patent application filed within the Product-Specific Patents &#91;***&#93;, and shall supply &#91;***&#93; with a copy of the application and other material filings as filed, together with notice of its filing date and serial number.  &#91;***&#93; shall keep &#91;***&#93; regularly advised of the status of the Product-Specific Patents, including upon &#91;***&#93; request.  &#91;***&#93; shall promptly give notice to &#91;***&#93; of the grant, lapse, or invalidation of any Product-</font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">39</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Specific Patents.  &#91;***&#93; shall give notice to &#91;***&#93; of any desire to cease prosecution or maintenance, or abandonment, of Product-Specific Patents &#91;***&#93; in the Territory, and shall permit &#91;***&#93; to continue prosecution or maintenance of such Product-Specific Patents &#91;***&#93;. If &#91;***&#93; elects to continue prosecution or maintenance of such Product-Specific Patents, &#91;***&#93; shall execute documents in a timely manner as may be reasonably necessary to allow &#91;***&#93; to continue such prosecution or maintenance.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Joint Patents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  &#91;***&#93; shall have the first right, but not the obligation, to prepare, file, prosecute, and maintain patents and patent applications claiming Joint Agreement Information and Inventions.  &#91;***&#93; shall give &#91;***&#93; at least &#91;***&#93; to review the text of any patent application and a reasonable opportunity to review any other material filing before submission, &#91;***&#93;, and shall supply &#91;***&#93; with a copy of the application and other material filings as filed, together with notice of its filing date and serial number.  &#91;***&#93; shall keep &#91;***&#93; regularly advised of the status of the Joint Patents&#91;***&#93;.  &#91;***&#93; shall promptly give notice to &#91;***&#93; of the grant, lapse, or invalidation of any Joint Patents.  &#91;***&#93; shall give notice to Dar&#233; of any desire to cease prosecution or maintenance, or abandonment, of Joint Patents &#91;***&#93; in the Territory, and shall permit &#91;***&#93; to continue prosecution or maintenance of such Joint Patents &#91;***&#93;.  If &#91;***&#93; elects to continue prosecution or maintenance of such Joint Patents, &#91;***&#93; shall execute documents in a timely manner as may be reasonably necessary to allow &#91;***&#93; to continue such prosecution or maintenance. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Patent Term Extension.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Parties shall cooperate fully with each other to provide necessary information and assistance, as the other Party may reasonably request, in obtaining patent term extension or supplemental protection certificates or their equivalents in any country in the Territory where applicable to Product-Specific Patents and Joint Patents.  &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Other Cooperation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Parties agree to cooperate fully and provide any information and assistance that either may reasonably request for the filing, prosecution and maintenance of Dar&#233; Patents and Joint Patents.  The Parties will, and will cause their Affiliates to, cooperate and implement reasonable patent filing and prosecution strategies (including filing divisionals, continuations, or otherwise) so that, to the extent reasonably feasible, Dar&#233; Patents and Joint Patents are pursued in mutually exclusive patent applications of the other Party&#8217;s Patents.  Such prosecution strategies will include the obligation of each Party to refrain from the use of statements that disparage the other Party&#8217;s Patents. The Parties further agree to take reasonable actions to maximize the protections available under the safe harbor provisions of 35 U.S.C. &#167; 102(c) for U.S. patents and patent applications.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Filing, Prosecution and Maintenance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  With respect to all filing, prosecution and maintenance activities under this Section 9.1, the filing or prosecuting Party shall be responsible &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Inventor Remuneration.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Dar&#233; shall comply with all applicable country-specific inventor remuneration laws and regulations associated with Dar&#233; Owned Patents when inventor remuneration obligations are triggered by an employee of Dar&#233; or its Affiliates, or a Third Party acting on behalf of Dar&#233; or its Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  As between the Parties, &#91;***&#93; shall have the exclusive right to file Patent applications &#91;***&#93;  and to prosecute, maintain, seek patent term extensions and abandon such Patents, and to conduct or defend against any interference, derivation proceeding, opposition, reexamination requested by a Third Party, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">inter partes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> review, post-grant review or similar contested administrative proceeding involving a Third Party relating to any of the foregoing&#91;***&#93;.</font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">40</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  As between the Parties, with respect to &#91;***&#93; shall have the exclusive right to file Patent applications and to prosecute, maintain, seek patent term extensions and abandon Patents, and to conduct or defend against any interference, derivation proceeding, opposition, reexamination requested by a Third Party, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">inter partes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> review, post-grant review or similar contested administrative proceeding relating to any of the foregoing&#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.1.9&#160;&#160;&#160;&#160;Decision Not to Prosecute.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  In the event that &#91;***&#93; decides not to prepare, file, prosecute, or maintain any Product-Specific Patent in any country or jurisdiction, &#91;***&#93; shall provide reasonable prior written notice to &#91;***&#93; of such intention (which notice shall, in any event, be given no later than &#91;***&#93; prior to the next deadline for any action that may be taken with respect to such Product-Specific Patent in such country or jurisdiction).  &#91;***&#93; shall thereupon have the option, in its sole discretion, to assume the control and direction of the preparation, filing, prosecution, and maintenance of such Product-Specific Patent at its expense in such country or jurisdiction.  If &#91;***&#93; exercises this option, it shall promptly notify &#91;***&#93; thereof, and provide written instructions to &#91;***&#93; to transfer control of such Product-Specific Patent to counsel instructed by &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Interference, Derivation, Opposition, Reexamination, Reissue, Supplemental Examination, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Inter Partes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Review and Post-Grant Review Proceedings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Third Party Initiated Proceedings. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Each Party shall, within &#91;***&#93; after learning of such event, inform the other Party of any request for, or filing or declaration of, any interference, derivation proceeding, opposition, reexamination requested by a Third Party, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">inter partes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> review, post-grant review or similar contested administrative proceeding involving a Third Party relating to Dar&#233; Patents or Joint Patents.  &#91;***&#93; shall have the first right, but not the obligation, to control such proceedings with respect to Product-Specific Patents, and Joint Patents, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Party Initiated Proceedings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  &#91;***&#93; shall have the first right, but not the obligation, to initiate a reexamination, supplemental examination, reissue or similar administrative proceeding relating to Product-Specific Patents or Joint Patents &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Cooperation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  In connection with any administrative proceeding under Sections 9.2.1 or 9.2.2, Organon and Dar&#233; shall cooperate fully and provide each other with any information or assistance that either may reasonably request.  &#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt"> &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Enforcement and Defense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Notice&#59; &#91;***&#93; First Right.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Parties shall give notice to each other promptly upon becoming aware of either (a) any infringement of Dar&#233; Patents or Joint Patents, or (b) any misappropriation or misuse of Dar&#233; Know-How.  With respect to Product-Specific Patents and Joint Patents, &#91;***&#93;.  After the Effective Date, &#91;***&#93; shall have the first right, but not the obligation, to initiate and prosecute such legal action within the Field at its own expense and in the name of &#91;***&#93; and to control the defense of any declaratory judgment action relating to Product-Specific Patents or Joint Patents&#91;***&#93;.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Backup Right.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  &#91;***&#93; shall promptly inform &#91;***&#93; if &#91;***&#93; elects not to exercise its first right under Section 9.3.1 to initiate and prosecute legal action, and &#91;***&#93; shall thereafter have the right, at its own cost and expense, to either initiate and prosecute such action or to control the defense of such declaratory judgment action &#91;***&#93;.  &#91;***&#93; shall have the right to be represented by counsel of its own choice &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Joinder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  For any action to enforce any infringement of Product-Specific Patents or Joint Patents against a Third Party, in the event that a Party is unable, as a matter of law, to </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">41</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">initiate or prosecute such action solely in its own name, the other Party will &#91;***&#93;  join such action voluntarily and will execute and cause its Affiliates to execute all documents necessary for the Party to initiate litigation to prosecute and maintain such action under this Section 9.3.  In connection with any action or potential action, Organon and Dar&#233; will cooperate fully and will provide each other with any information or assistance that either may reasonably request&#91;***&#93;.  Each Party shall keep the other informed of developments in any action or proceeding.  In connection with any defense pursuant to this Section 9.3.3, the controlling Party shall (a) &#91;***&#93;, (b) keep the other Party reasonably informed of material steps taken in the course of such defense, and (c)&#160;provide copies of all documents filed in connection with such defense.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Recoveries.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Any recovery obtained by either or both Organon and Dar&#233; in connection with or as a result of any action contemplated by this Section 9.3, whether by settlement or otherwise, shall be shared in order as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">&#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">the amount of any recovery remaining shall then &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Generic Certification.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Each Party shall inform the other Party of any notice of certification regarding any Dar&#233; Patents or Joint Patents it has received pursuant to either 21 U.S.C. &#167;&#167; 355(b)(2)(A)(iv) or (j)(2)(A)(vii)(IV), or its successor provisions or any similar provisions in a country in the Territory other than the United States, and shall provide a copy of such notice of certification within &#91;***&#93; after its receipt.  &#91;***&#93; has the first right, but not the obligation, to initiate and prosecute any legal action as a result of such notice of certification with respect to Product-Specific Patents or Joint Patents&#59; provided, however, that &#91;***&#93; shall inform &#91;***&#93; of such decision to initiate such action within &#91;***&#93;after its receipt of the notice of certification, after which time, &#91;***&#93;.  Regardless of which Party has the right to initiate and prosecute such action, both Parties shall, as soon as practicable after receiving notice of such notice of certification, convene and consult with each other regarding the appropriate course of conduct for such action.  The non-initiating Party shall &#91;***&#93;.  Dar&#233;&#8217;s and Organon&#8217;s rights and obligations with respect to the prosecution of any legal action as a result of such notice of certification and any recovery obtained as a result of such legal action shall be as defined in Sections 9.3.3 and 9.3.4.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Organon Patents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  As between the Parties, Organon shall have the exclusive right to enforce any of the rights in the Organon Patents and Organon Know-How, in each case in its sole discretion.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Other Dar&#233; Patents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  As between the Parties, Dar&#233; shall have the exclusive right to enforce any of the rights in the Dar&#233; Patents that are not Product-Specific Patents or Joint Patents, in each case in its sole discretion.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Orange Book Listings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  After the Effective Date, &#91;***&#93; will &#91;***&#93; determine which, if any, of the Product-Specific Patents should be listed in any governmental registers in any country requiring or permitting a listing of patents covering a Licensed Product which has received Marketing Authorization in such country, including, but not limited to, the Orange Book and the Canadian Patent Register.  &#91;***&#93;make any such filings and listings, and will have &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Infringement of Third Party Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If any claim, suit, or proceeding is brought by a Third Party against either Party, its Affiliates, Sublicensees or its or its Affiliates&#8217; sublicensees, as applicable, alleging patent infringement by such Party, its Affiliates, Sublicensees or its or its Affiliates&#8217; </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">42</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">sublicensees caused by the Exploitation of a Licensed Product, such Party shall promptly notify the other Party in writing.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Control and Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  As between the Parties, each Party shall have the right to defend itself against any such claim, suit, or proceeding that names such Party, its Affiliates, Sublicensees or its or its Affiliates&#8217; sublicensees as a defendant.  The other Party shall provide such defendant Party with such reasonable assistance in such defense, at the defendant Party&#8217;s expense, as the defendant Party may request.  The defendant Party shall keep the other Party reasonably informed of all material developments in connection with any such claim, suit, or proceeding.  However, if such claim, suit or proceeding is subject to a Party&#8217;s obligation to indemnify and hold harmless the other Party in accordance with Sections 8.1 or 8.2, then this Section 9.5.2 shall not apply to such claim, suit or proceeding, and the provisions of Sections 8.1 or 8.2 shall apply.  &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.16pt">TERM AND TERMINATION.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Term and Expiration.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  This Agreement shall be effective as of the Effective Date and unless terminated earlier pursuant to Section 10.2, Section 10.3, Section 10.4 or Section 10.5, this Agreement shall expire on a Licensed Product-by-Licensed Product and country-by-country basis, upon the expiration of the Royalty Period for such Licensed Product in such country, at which point Organon&#8217;s license to the applicable Dar&#233; Patents and Dar&#233; Know-How in the applicable country pursuant to Section 3.1 shall become fully paid-up, irrevocable, perpetual, and survive termination for any reason.   </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Termination by Organon for Convenience.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Following the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) anniversary of the Effective Date, Organon shall have the right to terminate this Agreement in its entirety or on a country-by-country basis at any time in its sole discretion by giving one hundred twenty (120) days&#8217; advance written</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> notice to Dar&#233;.  Any termination by Organon under this Section 10.2 can be effected only through a written notice specifically referring to this Section 10.2.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Material Breach&#59; Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Termination for Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be terminated at any time during the term of this Agreement upon written notice by either Party if the other Party is in material breach of this Agreement and has not cured such breach within &#91;***&#93; after notice requesting cure of the breach&#59; provided, however, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Organon&#8217;s Alternative Remedy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Organon has the right to terminate this Agreement under Section 10.3.1 (either as a result of resolution of a Dispute pursuant to Section 12.7, or because Dar&#233; does not dispute Organon&#8217;s ability to do so), then in lieu of Organon terminating this Agreement pursuant to Section 10.3.1 &#91;***&#93;, Organon may, upon notice to Dar&#233;, &#91;***&#93; have this Agreement continue in full force as modified by this Section 10.3.2, in which case, effective as of the date Organon delivers such waiver notice to Dar&#233; to exercise this alternative remedy&#58; (i) any milestone payments payable by Organon to Dar&#233; shall be reduced by &#91;***&#93;%&#59; (ii) the royalty rates payable by Organon to Dar&#233; pursuant to Section 6.3.1 shall be replaced with the royalty rates set forth in clauses (a) through (d) below&#59; (iii) Organon shall be entitled &#91;***&#93;, and (iv) all other provisions of this Agreement shall remain in full force and effect without change. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#91;***&#93; of the aggregate of such Net Sales in each Calendar Year up to and including &#91;***&#93; of such Net Sales&#59;</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> NTD&#58; This time period has been publicly disclosed, including in Dar&#233;&#8217;s 8-K filed 3&#47;31&#47;2022.</font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">43</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">&#91;***&#93; of the aggregate of such Net Sales in each Calendar Year greater than &#91;***&#93; of such Net Sales up to and including $50,000,000 of such Net Sales&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;***&#93; of the aggregate of such Net Sales in each Calendar Year greater than &#91;***&#93; of such Net Sales up to and including &#91;***&#93; of such Net Sales&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">&#91;***&#93; of the aggregate of such Net Sales in each Calendar Year greater than &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If Organon notifies Dar&#233; that Organon believes it has the right to terminate this Agreement under Section 10.3.1 (whether or not it is at such time electing to do so), then, upon and after such notice, Organon may &#91;***&#93;.  If such right to terminate is confirmed, then &#91;***&#93;.  If such right to terminate is determined to be incorrect, then &#91;***&#93;.   </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Termination for Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Dar&#233; may terminate this Agreement &#91;***&#93; if Organon or its Affiliate individually or in association with any other Person, asserts&#91;***&#93; a Patent Challenge with respect to  &#91;***&#93; other than (a) as permitted in accordance with Section 9.2.2 or (b) as part of a defense or counterclaim to any action brought or threatened by Dar&#233; against Organon or any of its Affiliates.  If a Sublicensee individually or in association with any other Person, asserts, voluntarily assists or directs a Patent Challenge with respect to &#91;***&#93; and either (i) Organon does not &#91;***&#93; or (ii) such Patent Challenge with respect to such &#91;***&#93; is not stopped and withdrawn within &#91;***&#93; of commencement, then Dar&#233; may terminate this Agreement with respect to &#91;***&#93;.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Termination for Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be terminated at any time during the term of this Agreement immediately upon written notice by either Party, in the event the other Party files for protection under bankruptcy Applicable Laws, makes an assignment for the benefit of creditors, appoints or suffers appointment of a receiver or trustee over its property, files a petition under any bankruptcy or insolvency act or has any such petition filed against it which is not discharged within &#91;***&#93; of the filing thereof. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Termination for Safety</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be terminated on a Licensed Product-by-Licensed Product basis at any time during the term of this Agreement immediately upon written notice by Organon, if Organon reasonably believes in good faith, after due inquiry and in a manner consistent with Organon&#8217;s then-current decision-making process with respect to such a determination (where a reasonable summary of such inquiry and Organon&#8217;s conclusions are included in such notice), that Development or commercialization of such Licensed Product should be terminated due to there being a Serious Adverse Event related to such Licensed Product (where such adverse effect was not included in the FDA-approved label for such Licensed Product at the time the Marketing Authorization was obtained for such Licensed Product) that is based upon and demonstrated by (a) preclinical safety data, including data from animal toxicology studies, (b) the observation of one or more Serious Adverse Events in humans after such Licensed Product has been administered to humans, such as during a Clinical Trial of such Licensed Product, or (c) with respect to such Licensed Product, (i) any other safety concern required to be reported under 21 C.F.R. &#167; 312.32(c)(1)(iii) or the equivalent in any non U.S. jurisdiction, or (ii) a material toxicity or material drug safety issue or any other evidence of a Serious Adverse Event reasonably related to a Licensed Product (any of the foregoing reasons, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Safety Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  If the Parties reasonably disagree as to the existence of a Safety Reason, the Parties&#8217; &#91;***&#93; shall promptly meet, at a mutually convenient time, to discuss and address the disagreement and possible resolution.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Effects of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">General Consequences</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon termination of this Agreement in its entirety, or upon termination for a specific country pursuant to Section 10.2, except for the licenses that are fully paid-up and except for the surviving provisions set forth in this Section 10.6 or </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">44</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 10.7, the provisions of this Agreement are of no further force or effect as of the effective date of such termination and the terms of this Section 10.6 shall apply.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon termination of this Agreement in its entirety, either Party may request in writing, and the other Party shall either promptly return to the requesting Party, or as soon as reasonably practicable delete or destroy, all of the requesting Party&#8217;s Information in such other Party&#8217;s Control to which such other Party does not retain rights under the surviving provisions of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> such other Party may keep one copy of such materials for legal archival purposes subject to continuing confidentiality obligations, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">further provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, if any license to Organon is deemed fully paid up at the time of such termination, then Organon shall be entitled to retain Dar&#233;&#8217;s Information necessary or reasonably useful for the Exploitation of such license. Notwithstanding the foregoing, such other Party also shall be permitted to retain such additional copies of or any computer records or files containing such confidential Information that (a) it is required by Applicable Law to retain (the disclosure of which shall continue to be governed by the provisions of Article 5), or (b) have been created solely by such Party&#8217;s automatic archiving and back-up procedures, to the extent created and retained in a manner consistent with such other Party&#8217;s standard archiving and back-up procedures, but not for any other use or purpose.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Sublicenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event of termination of this Agreement under Section 10.2 or by Dar&#233; under Section 10.3 or Section 10.4, at the request of Organon received by Dar&#233; by notice within &#91;***&#93; after the effective date of such termination, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> such Sublicensee is not then in default of its obligations under its sublicense agreement with Organon, Dar&#233; shall consider in good faith whether or not to enter into a license with such Sublicensee granting such Sublicensee rights under the Dar&#233; Know-How and Dar&#233; Patents (or the subset of the Dar&#233; Know-How and Dar&#233; Patents that were sublicensed to such Sublicensee), that do not conflict with the remaining rights granted to Organon hereunder, on commercially reasonable terms, and subject to the requirements of the DTM Upstream License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Commercial Inventory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event of termination of this Agreement for a specific country or termination of this Agreement in its entirety, Organon, its Affiliates and its and their Sublicensees and distributors shall be entitled, during the &#91;***&#93; period immediately following the effective date of such termination, to finish work-in-progress and to sell any Licensed Product remaining in inventory in accordance with the terms of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, for a period of &#91;***&#93; ending on the last day of such &#91;***&#93; period, Organon will offer to sell to Dar&#233; inventories of any Licensed Products that are not Combination Products and that can be sold legally and solely in such terminated country(ies) and that remain in Organon&#8217;s and its Affiliates&#8217; and their contract manufacturers&#8217; inventory at the end of such &#91;***&#93; period at &#91;***&#93;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided further that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, if the Parties cannot agree upon a price or Dar&#233; elects not to purchase the entire remaining inventory of such Licensed Product, Organon and its Affiliates can continue selling such inventories of Licensed Product that can be sold legally solely in such terminated country for &#91;***&#93; period. For the avoidance of doubt, such sales constitute Net Sales and are subject to Royalties if the sales are not to Dar&#233; or its Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">License to Organon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event of termination of this Agreement for any reason in a particular country, effective as of the date of such termination, the licenses granted by Dar&#233; to Organon under Section 3.1 and Section 3.2 shall automatically terminate in such country if not fully paid up before the date of such termination, except that Dar&#233; grants to Organon, its Affiliates and Sublicensees (as the case may be) nonexclusive licenses or rights of reference to any Dar&#233; Know-How, Dar&#233; Patents and Product Trademarks in such country that are reasonably necessary for Organon, its Affiliates or Sublicensees to exercise its rights or fulfill its obligations set forth in this Section 10.6.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.6.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Reversion License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">45</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">In the event of termination of this Agreement under Section 10.2 or by Dar&#233; under Section 10.3, Organon shall, and hereby does, grant to Dar&#233;, effective on the effective date of termination, an exclusive (even as to Organon and its Affiliates), royalty-bearing license, with the right to sublicense through multiple tiers, under the Organon Patents that claim inventions conceived or reduced to practice during the term of this Agreement, Joint Patents and Organon Know-How created or conceived during the term of this Agreement to Exploit Licensed Products in the Field in the portion of the Territory terminated, which Licensed Products are or have been made or sold in the portion of the Territory terminated during the term of this Agreement, as such Licensed Products exist as of the effective date of termination (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reversion License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  In all cases, the Reversion License excludes any Organon Patents to the extent that such Patent claims or covers the composition of any Other Product in a Combination Product. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The royalty(ies) to be paid by Dar&#233; to Organon under the Reversion License shall &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reversion Royalty Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the Reversion Royalty Dispute shall be resolved in accordance with Section 12.7. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">In connection with the negotiation and execution of a Reversion License, with respect to any Organon Patent or Organon Know-How that is licensed by Organon from Third Parties and sublicensed to Dar&#233;, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.6.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Assignment of Regulatory Materials&#59; Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event of termination of this Agreement by Organon under Section 10.2, or by Dar&#233; under Sections 10.3.1 or 10.3.3, or by either Party under Section 10.4, or by Organon under Section 10.5 but where the Safety Reason does not result in either a recall of the Licensed Product or the withdrawal of Marketing Authorization of the Licensed Product, in each case as required by a Regulatory Authority, then Organon shall promptly&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">where permitted by Applicable Law, assign and transfer (or cause to be assigned and transferred) to Dar&#233; or its designee (and, if in Organon&#8217;s possession or control, provide copies of) all (i) Dar&#233; Marketing Authorizations and Dar&#233; Regulatory Materials and (ii) Marketing Authorizations that are Controlled by Organon, and obtained during the term of this Agreement and solely relating to Licensed Products (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Organon Marketing Authorizations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and Regulatory Materials that are Controlled by Organon and solely relating to Organon Marketing Authorizations, in each case within this clause (a), solely relating to the Licensed Products in the Field and in the portion of the Territory terminated and that are the subject of the license granted in Section 10.6.6&#59; and </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">if this Agreement is terminated in its entirety, assign to Dar&#233; or its designee all of Organon&#8217;s and its Affiliates&#8217; rights, title, and interest in and to all Product Trademarks that are in actual use in the portion of the Territory terminated at the time of such termination as a Trademark solely in connection with the sale of Licensed Products in the Field and all Internet domain names and social media accounts that incorporate any such Product Trademarks, in each case, that are solely used in connection with the sale of Licensed Products in the Field in the portion of the Territory terminated, including the goodwill symbolized by, or associated with the use of, such Product Trademarks.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.6.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Joint Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event of termination of this Agreement by Organon under Section 10.3 or Section&#160;10.4, Dar&#233; will assign, and hereby does assign, to Organon all of Dar&#233;&#8217;s right, title and interest in and to the Joint Patents. In the event of any other termination of this Agreement, the Parties shall confer to determine how ownership of the Joint Patents will be addressed, subject to Section 10.6.14.</font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">46</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.6.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event of termination of this Agreement in its entirety under Section 10.2 or by Dar&#233; under Section 10.3 or Section 10.4, the Parties shall negotiate in good faith with respect to the transition of the then-current Manufacturing Process from Organon (or its Affiliates or designated contract manufacturer) to Dar&#233;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.6.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:3pt">Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If this Agreement is terminated by Organon under Section 10.4 due to the rejection of this Agreement by or on behalf of Dar&#233; under Section 365 of the United States Bankruptcy Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), all licenses and rights to licenses granted under or pursuant to this Agreement by Dar&#233; to Organon are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the Code, licenses of rights to &#8220;intellectual property&#8221; as defined under Section 101(35A) of the Code.  The Parties agree that Organon, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Code, and that upon commencement of a bankruptcy proceeding by or against Dar&#233; under the Code, Organon shall be entitled to a complete duplicate of or complete access to (as Organon deems appropriate), any such intellectual property and all embodiments of such intellectual property.  Such intellectual property and all embodiments thereof shall be promptly delivered to Organon (a) upon any such commencement of a bankruptcy proceeding upon written request therefore by Organon, unless Dar&#233; elects to continue to perform all of its obligations under this Agreement or (b) if not delivered under clause (a) above, upon the rejection of this Agreement by or on behalf of Dar&#233; upon written request therefore by Organon.  Unless required by Applicable Law, Dar&#233; will not reject any license hereunder in bankruptcy proceedings outside of the United States.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.6.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:3pt">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as otherwise expressly provided herein, termination of this Agreement as permitted herein shall not limit remedies that may otherwise be available in law or equity, all of which are cumulative.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.6.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:3pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.6.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:3pt">Patent Matters.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  If &#91;***&#93; has assumed the prosecution or enforcement of any of the Product-Specific Patents, then upon termination of this Agreement for any reason, &#91;***&#93; shall ensure that the prosecution and enforcement of such Patents in each country of the Territory that was terminated is transferred to &#91;***&#93; in a prompt and orderly fashion such that no deadline is missed in respect of such prosecution or enforcement and that the scope of such Patents is not limited or restricted as a consequence of such transfer.  &#91;***&#93; will cooperate with &#91;***&#93; and provide &#91;***&#93; with reasonable assistance in the transfer of all prosecution, maintenance, defense and enforcement activities, filings and documents with respect to such Patents. After any such transfer, if &#91;***&#93; has retained any right to prosecute or enforce any Product-Specific Patents anywhere in the Territory, &#91;***&#93; will keep &#91;***&#93; reasonably informed of any prosecution and enforcement conducted by or on behalf of &#91;***&#93; with respect to any Product-Specific Patents, including by&#58; &#91;***&#93;. If this Agreement is terminated by Organon pursuant to Section 10.3 or Section 10.4, then &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.6.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:3pt">Transition Plan.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If this Agreement is terminated in its entirety or in a country by Organon under Section 10.2, or by Dar&#233; under Sections 10.3.1 or 10.3.3, or by either Party under Section 10.4, or by Organon under Section 10.5 but where the Safety Reason does not result in either a recall of the Licensed Product or the withdrawal of Marketing Authorization of the Licensed Product, in each case as required by a Regulatory Authority, then the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Parties will promptly discuss in good faith the terms and conditions of a written plan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transition Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) pursuant to which they will effectuate and coordinate an orderly transition of the relevant obligations and rights to Dar&#233; as reasonably necessary for Dar&#233; to Develop, Manufacture, Commercialize and otherwise Exploit Licensed Products that are not Combination Products after such termination in a manner consistent with Applicable Law and standards of ethical conduct and as promptly as </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">47</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">possible.  The Transition Plan shall be subject to Section 10.6 and is expected to address at least&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">&#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination.  Any expiration or termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement prior to expiration or termination, including the obligation to make payments under Article 6, which obligation accrued prior to such expiration or termination.  Organon will provide a final royalty report and royalty payment in accordance with Section 6.4 within &#91;***&#93; after the end of the Calendar Quarter in which expiration or termination occurs, and the obligation of Related Parties to keep books and records under Section 6.4 shall survive termination for the period specified therein.  The provisions of Article 5 shall survive the expiration or termination of this Agreement and shall continue in effect for &#91;***&#93;.  In addition, the provisions of Article 1, Article 8, Article 9 (with respect to &#91;***&#93;) and Article 12, and Sections 2.6, 3.9, 6.5 through 6.8 (with respect to payment obligations accruing hereunder), 7.5, 10.6, and 10.7 shall survive any expiration or termination of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.16pt">EFFECTIVENESS. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except for the Parties&#8217; obligations under Article 5 and this Article 11 or other provisions specified to occur, be effective or based on the Execution Date or &#8220;during the term of this Agreement&#8221;, all of which will be effective as of the Execution Date, the other provisions of this Agreement will become effective on &#91;***&#93; after all of the Closing Conditions have been met or if Organon waives such Closing Conditions by notice to Dar&#233; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the Effective Date will not occur (a) if either Party exercises its termination right under Section 11.3 or under Article 10 prior to the Antitrust Clearance Date, (b) if and for so long as there is in force any Applicable Law (i) enjoining or prohibiting the consummation of the transactions contemplated by this Agreement or (ii) imposing any conditions in connection with such effectiveness, or (c) there is any action, proceeding, or investigation brought by a Governmental Authority pending that would reasonably be expected to lead to any of the foregoing that would be material in the context of the transactions contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Filings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Each Party will, unless otherwise agreed by the Parties, within &#91;***&#93; following the Execution Date, file those Antitrust Filings required under the applicable Antitrust Laws (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Required Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Parties will reasonably cooperate with one another to the extent necessary in the preparation and execution of all such documents that are required to be filed pursuant to the Required Filings.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party will be responsible for &#91;***&#93; associated with any such Required Filing, including premerger filing fees incurred by each Party associated with any such Required Filing. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Waiting Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  With respect to the Required Filings, the Parties will use Commercially Reasonable Efforts to obtain any necessary approvals or consents under such applicable Antitrust Law, &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Communications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To the extent permitted under Applicable Law and by the applicable Governmental Authorities, the Parties will (a) provide each other reasonable advance </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">48</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">written notice of any meetings or telephone conferences with a Governmental Authority under the HSR Act relating to the transactions contemplated by this Agreement, and (b) permit each other to attend and participate in those meetings and telephone conferences.  Each Party will (i) provide the other with reasonable opportunity to review and comment on any written submissions, and will consider comments in good faith, and (ii) keep the other Party apprised of the status of any communications with, and any inquiries or requests for information from, any Governmental Authority under the HSR Act, regardless of whether such other Party declines to participate in any meetings or telephone conferences&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> neither Party will be obligated to disclose any commercially sensitive or privileged information, and to the extent the Parties agree to share information of this nature, such exchange and review will be limited to the Parties&#8217; outside counsel only.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Not Required</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any provision to the contrary set forth in this Agreement, nothing in this Agreement (including this Section 11.2) will require either Party or any of its Affiliates to &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Outside Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement will terminate at the election of either Party, immediately upon written notice to the other Party, (a) if any Governmental Authority &#91;***&#93; injunction under applicable Antitrust Laws against the Parties to enjoin the transactions contemplated by this Agreement&#59; or (b) in the event that the Antitrust Clearance Date has not occurred on or prior to &#91;***&#93;, and the Parties have not agreed in writing to extend the Antitrust Clearance Date.  In the event of such termination, this Agreement will be of no further force and effect, except for the Parties&#8217; continued obligations under Article 5, which shall survive such termination. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Closing Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Unless waived by Organon, this Agreement will not become effective until each of the following conditions (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Closing Condition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) have been met&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Antitrust</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  the occurrence of the Antitrust Clearance Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59; and </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Bring Down</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  all representations and warranties of Dar&#233; in this Agreement shall be true and correct as of the Effective Date, Dar&#233; will have, up through the Effective Date, complied with all of its obligations set forth in Section 7.4 and Dar&#233; will have delivered to Organon a certificate executed by an officer of Dar&#233; certifying the accuracy of the foregoing.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.16pt">MISCELLANEOUS.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement, except for the obligation to make payment, to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, potentially including embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting by any Governmental Authority or the other Party.  The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Either Party may, without consent of the other Party, assign this Agreement in its entirety and all of its rights and obligations hereunder to an Affiliate or in connection with the transfer or sale of all or substantially all of its assets related to the subject matter of this Agreement.  Except as provided in the preceding sentence, this Agreement may not be assigned, </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">49</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">nor may any right or obligation hereunder be assigned, by either Party without the consent of the other Party.  Any attempted assignment not in accordance with this Section 12.2 shall be void.  Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Use of Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party shall have the right to exercise its rights and perform its obligations under this Agreement either itself or through any of its Affiliates, and each Party&#8217;s Affiliates will have the benefit of all rights (including all licenses) of such Party under this Agreement.  Accordingly, in this Agreement &#8220;Dar&#233;&#8221; will be interpreted to mean &#8220;Dar&#233; or its Affiliates&#8221; and &#8220;Organon&#8221; will be interpreted to mean &#8220;Organon or its Affiliates&#8221; where necessary to give each Party&#8217;s Affiliates the benefit of the rights provided to the applicable Party in this Agreement&#59; provided, however, that in any event each Party will remain responsible hereunder for the acts and omissions of its respective Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties.  The Parties shall in such an instance use reasonable efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All notices which are required or permitted hereunder shall be in writing and sufficient if sent by internationally-recognized commercial courier, addressed as follows&#58;</font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">50</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.12pt;padding-left:41.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.269%"><tr><td style="width:1.0%"></td><td style="width:28.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.004%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">if to Dar&#233;, to&#58;</font></td><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dar&#233; Bioscience, Inc.</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3655 Nobel Drive, Suite 260</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">San Diego, CA 92122</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; Sabrina Johnson, CEO</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:31pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">With a copy to, which shall not constitute notice&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mintz Levin</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3580 Carmel Mountain Rd. #300</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">San Diego, CA 92130</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; Tali Tuchin</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">if to Organon, to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Organon International GmBH</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weystrasse 20, 6006 Lucerne, Switzerland</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; General Counsel</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-and-</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Organon LLC</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30 Hudson Street, Floor 33</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">New Jersey, NJ, USA 07302</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58;  SVP, Business Development</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-and-</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Via electronic mail to&#58;</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Organon LLC</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30 Hudson Street, Floor 33</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">New Jersey, NJ, USA 07302</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58;  General Counsel</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">With a copy to, which shall not constitute notice&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Jones Day</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4655 Executive Drive, Suite 1500</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">San Diego, CA 92121-3134</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58;  Thomas Briggs and Jonn Beeson</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div></td></tr></table></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">51</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith.  Any such notice shall be deemed to have been given upon receipt.  The Parties hereby agree that, to the extent permitted by Applicable Law, any notice provided in accordance with this Section 12.5 shall constitute due service of process with respect to any legal proceeding between the Parties arising hereunder and that compliance with the Hague Convention for the Service of Process, if otherwise applicable, shall not be required.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without reference to any rules of conflict of laws or venue.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">The Parties shall negotiate in good faith and use reasonable efforts to settle any dispute, controversy or claim arising from or related to this Agreement or the breach thereof (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Any Party shall give the other Party written notice of any Dispute not resolved in the normal course of business.  Within &#91;***&#93; from the date of delivery of such notice, the receiving Party shall submit to the other Party a written response.  The notice and response shall include (a) a statement of that Party&#8217;s position and a summary of arguments supporting that position, and (b) the name and title of the executive who will represent that Party and of any other person who will accompany the executive.  Within &#91;***&#93; from the date of delivery of the initial notice, the executives of both Parties shall meet at a mutually acceptable time and place, and thereafter as often as they reasonably deem necessary, to attempt to resolve the Dispute.  These executives shall have the authority to settle the Dispute and shall be at a higher level of management than the persons with direct responsibility for administration of this Agreement.  All negotiations pursuant to this paragraph are confidential and shall be treated as compromise and settlement negotiations for purposes of applicable rules of evidence.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">If the Parties do not fully settle following the procedure in Section 12.7.1, and a Party wishes to pursue the matter, each dispute, controversy or claim arising from or related to this Agreement or the breach thereof that is not an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Excluded Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall be brought in the federal court for the District of Delaware, if federal jurisdiction is available, or, alternatively, in the state courts in Wilmington, Delaware.  Each of the Parties hereby submits to the exclusive jurisdiction of such courts for the purpose of any such litigation&#59; provided, that a final judgment in any such litigation shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">  Each party irrevocably and unconditionally agrees not to assert (a) any objection which it may ever have to the laying of venue of any such litigation in such courts, (b) any claim that any such litigation brought in any such court has been brought in an inconvenient forum, and (c) any claim that such court does not have jurisdiction with respect to such litigation.  EACH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT TO A TRIAL BY JURY AND AGREES THAT ANY OF THEM MAY FILE A COPY OF THIS PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY AND BARGAINED-FOR AGREEMENT AMONG THE PARTIES IRREVOCABLY TO WAIVE ITS RIGHT TO TRIAL BY JURY IN ANY LITIGATION.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">DTM Upstream License Agreement Licensors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Organon acknowledges that neither TriLogic nor MilanaPharm provides any representations, warranties, indemnities or has any liabilities to Organon pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Entire Agreement&#59; Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement, together with the Schedules hereto, contains the entire understanding of the Parties with respect to the subject matter hereof and the licenses granted hereunder.  Any other express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, with respect to the subject matter hereof and the licenses granted hereunder are superseded by the terms of this Agreement.  The </font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">52</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedules to this Agreement are incorporated herein by reference and shall be deemed a part of this Agreement.  This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representative(s) of both Parties hereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.25pt">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The captions to the several Articles, Sections and subsections hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading the several Articles and Sections hereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.25pt">Independent Contractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  It is expressly agreed that Dar&#233; and Organon shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency.  Neither Dar&#233; nor Organon shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.25pt">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as specifically provided in this Agreement, each Party will be responsible for its own costs and expenses associated with its negotiation, execution, delivery and performance of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.25pt">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The waiver by either Party hereto of any right hereunder, or of any failure of the other Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party whether of a similar nature or otherwise.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.25pt">Waiver of Rule of Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement.  Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.25pt">Certain Conventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any reference in this Agreement to an Article, Section, subsection, paragraph, clause or Schedule shall be deemed to be a reference to an Article, Section, subsection, paragraph, clause or Schedule, of or to, as the case may be, this Agreement, unless otherwise indicated.  Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days.  Unless the context of this Agreement otherwise requires, (a) words of any gender include any other gender, (b) words such as &#8220;herein&#8221;, &#8220;hereof&#8221;, and &#8220;hereunder&#8221; refer to this Agreement as a whole and not merely to the particular provision in which such words appear, (c) words using the singular shall include the plural, and vice versa, (d) each use of the word &#8220;including&#8221; is not limiting and is deemed to be followed by the words &#8220;without limitation&#8221;, (e) the words &#8220;shall&#8221; and &#8220;will&#8221; have the same meaning unless the context dictates otherwise, (f) use of the words &#8220;or,&#8221; &#8220;either&#8221; or &#8220;any&#8221; will not be exclusive, and (g) the word &#8220;or&#8221; will be interpreted in the inclusive sense commonly associated with the term &#8220;and&#47;or.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.25pt">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be signed in any number of counterparts (including by facsimile or electronic transmission), each of which shall be deemed an original, but all of which shall constitute one and the same instrument.  After facsimile or electronic transmission, the Parties agree to execute and exchange documents with original signatures.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.25pt">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  From time to time, each Party will execute, acknowledge and deliver to each other any further documents, assurances and other matters, and will take any other action consistent with the terms and conditions of this Agreement, that may reasonably be requested by a Party and necessary or desirable to carry out the purpose of this Agreement.</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#91;SIGNATURES ON FOLLOWING PAGE&#93;</font></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">53</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div><div id="i3b0a00aea3d943e089d5be06d8c23680_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties have executed this Agreement by their duly authorized representatives as of the Execution Date.</font></div><div style="margin-bottom:0.12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.830%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">ORGANON INTERNATIONAL GMBH</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">DAR&#201; BIOSCIENCE, INC.</font></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BY&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Thomas Morlet</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BY&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Sabrina Johnson</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">NAME&#58;&#160;&#160;&#160;&#160; Thomas Morlet</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">NAME&#58; Sabrina Johnson</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">TITLE&#58; Managing Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TITLE&#58; Chief Executive Officer</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421791v2</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex102_10q033122.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7463834712be46a1b67f686b11e09594_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.  IN THIS EXHIBIT, &#8220;&#91;***&#93;&#8221; INDICATES WHERE SUCH INFORMATION HAS BEEN OMITTED.</font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONSENT, WAIVER AND STAND-BY LICENSE AGREEMENT</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This CONSENT, WAIVER AND STAND-BY LICENSE AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), dated March 30, 2022 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Execution Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), is by and among TriLogic Pharma, LLC, a limited liability company organized under the laws of Delaware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TriLogic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), MilanaPharm LCC, a limited liability company organized under the laws of Delaware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MilanaPharm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Dar&#233; Bioscience, Inc., a corporation organized and existing under the laws of Delaware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dar&#233;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and Organon International GmbH, a limited liability company organized and existing under the laws of Switzerland (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Organon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RECITALS&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;TriLogic, MilanaPharm and Hammock Pharmaceuticals, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Hammock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) entered into that Exclusive License Agreement effective as of January 9, 2017 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Original License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Hammock assigned to Dar&#233; Hammock&#8217;s entire right, title and interest in the Original License Agreement pursuant to that Assignment Agreement between Hammock and Dar&#233; effective as of December 5, 2018. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Dar&#233;, TriLogic and MilanaPharm amended the Original License Agreement pursuant to that First Amendment to License Agreement effective as of December 5, 2018, that Amendment No. 2 to License Agreement effective as of December 3, 2019 and that Second Amendment to License Agreement effective as of September 21, 2021 (the Original License Agreement, as amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DTM Upstream License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Dar&#233; desires to sublicense to Organon, and Organon desires to receive a sublicense from Dar&#233;, under rights granted to Dar&#233;  in the DTM Upstream License Agreement as set forth in the Exclusive License Agreement between Dar&#233; and Organon being entered as of the Execution Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dar&#233;-Organon Sublicense Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), a redacted copy of which is attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">E.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As a condition to entering into the Dar&#233;-Organon Sublicense Agreement&#58; (i) Organon requested Dar&#233; to obtain from TriLogic and MilanaPharm consent to the Dar&#233;-Organon Sublicense Agreement as a sublicense under the DTM Upstream License Agreement, including waivers of any requirements for such sublicensing to the extent not satisfied by the Dar&#233;-Organon Sublicense Agreement, (ii) Organon requested TriLogic and MilanaPharm to provide Organon certain assurances regarding Organon&#8217;s rights and obligations should the DTM Upstream License Agreement be terminated, and (iii) Dar&#233; requested TriLogic and MilanaPharm to further amend the Original License Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;TriLogic and MilanaPharm have agreed to provide such consent, waivers, assurances and amendments to the extent set forth below.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, Dar&#233;, TriLogic, MilanaPharm and Organon hereby agree as follows&#58;</font></div><div style="height:76.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.527%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421817v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt">DEFINITIONS.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Person or entity that controls, is controlled by or is under common control with a Party, but only for so long as such control exists.  For the purposes of this definition, the word &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under common control with&#8221;) means the actual power, either directly or indirectly through one or more intermediaries, to direct the management and policies of such Person or entity, whether by the ownership of more than 50% of the voting stock of such entity, or by contract or otherwise.  The Parties acknowledge that in the case of certain entities organized under the laws of certain countries outside of the United States, the maximum percentage ownership permitted by law for a foreign investor may be less than 50%, and that in such case such lower percentage shall be substituted in the preceding sentence, provided that such foreign investor has the power to direct the management or policies of such entity.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Effective Date of the Dar&#233;-Organon Sublicense Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, collectively, TriLogic, MilanaPharm, Dar&#233; and Organon.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means one of TriLogic, MilanaPharm, Dar&#233; and Organon.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any individual, partnership, joint venture, limited liability company, corporation, firm, trust, association, unincorporated organization, governmental authority or agency, or any other entity not specifically listed herein.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt">CONSENT TO SUBLICENSE, WAIVERS AND COOPERATION.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Consent to Dar&#233;-Organon Sublicense Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. TriLogic and MilanaPharm each consent to the Dar&#233;-Organon Sublicense Agreement as a sublicense under the DTM Upstream License Agreement and agree that, notwithstanding anything to the contrary in the DTM Upstream License Agreement, the terms of this Agreement together with the provisions of the Dar&#233;-Organon Sublicense Agreement satisfy all of the obligations of Dar&#233; related to sublicensing under the DTM Upstream License Agreement, including those specified in Section 2.1.3 (Sublicensing) of or elsewhere in the DTM Upstream License Agreement.  To the extent that any provision of this Agreement or the Dar&#233;-Organon Sublicense Agreement conflicts with or otherwise could&#47;would be deemed not to satisfy any right of TriLogic or MilanaPharm or any obligation of Dar&#233; regarding a grant of a sublicense under the DTM Upstream License Agreement, each of TriLogic and MilanaPharm hereby waives each such right or obligation, including any such right or obligation specified in Section 2.1.3 (Sublicensing) or elsewhere in the DTM Upstream License Agreement.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Waivers Of Certain Obligations of Dar&#233; under DTM Upstream License Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  To the extent that Organon&#8217;s performance of its obligations under the Dar&#233;-Organon Sublicense Agreement would not otherwise satisfy any of Dar&#233;&#8217;s obligations to TriLogic or MilanaPharm under the DTM Upstream License Agreement, then, effective as of the Effective Date, TriLogic and MilanaPharm each hereby waive such obligation(s) of Dar&#233;.  Without limiting the foregoing, as of the Effective Date, TriLogic and MilanaPharm each hereby waive Dar&#233;&#8217;s obligation under&#58;  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Section 2.1.3(iii)(b) of the DTM Upstream License Agreement to include copies of Sections 4.5 (Royalty Records), 4.6 (Review), 9.1 (Indemnification by Hammock) and Articles 5 (Confidentiality) and 11 (Insurance) of the DTM Upstream License Agreement in the Dar&#233;-Organon Sublicense Agreement and </font></div><div style="height:76.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.527%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421817v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">waive Organon&#8217;s, but not Dar&#233;&#8217;s, obligation to comply with the provisions of such Section and Articles&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Section 2.1.3(vi)(b) of the DTM Upstream License Agreement to require that further sublicenses of rights granted to Organon under the Dar&#233;-Organon Sublicense Agreement be consistent with the terms and requirements of the DTM Upstream License Agreement and include all provisions that Dar&#233; is required to include in a sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#59; provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Dar&#233;-Organon Sublicense Agreement will require that further sublicenses of the rights granted to Organon under the Dar&#233;-Organon Sublicense Agreement will be consistent with the license set forth in Section 2.3 (Further Sublicensing by Organon) of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Section 3.2 (Diligence) of the DTM Upstream License Agreement to use commercially reasonable efforts and resources to develop and commercialize and continue to commercialize a Licensed Product (as defined in the DTM Upstream License Agreement) in the Field (as defined in the DTM Upstream License Agreement) in at least one of Canada or any country in the EU Major Market (as defined in the DTM Upstream License Agreement)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Section 3.4 (Hammock Data) of the DTM Upstream License Agreement to disclose to TriLogic or MilanaPharm any Data (as defined in the DTM Upstream License Agreement) disclosed by Organon to Dar&#233; or obtained by Dar&#233; on behalf of Organon&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Section 3.6 (Reports) of the DTM Upstream License Agreement to provide MilanaPharm reports on the regulatory activities performed by Organon or by Dar&#233; on behalf of Organon in connection with the Dar&#233;-Organon Sublicense Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Dar&#233; shall be required to deliver to MilanaPharm a copy of all such reports or other notifications relating to regulatory activities prepared by it or received by it from Organon or any other source relating to the Licensed Products within &#91;***&#93; of any such report becoming available to it&#59; and </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Section 12.5 (Discontinuation of Sales) of the DTM Upstream License Agreement to notify MilanaPharm in the event that the sale of a Licensed Product (as defined in the DTM Upstream License Agreement) is discontinued indefinitely in a country after being launched in such country and TriLogic and MilanaPharm each waive their right under Section 12.5 (Discontinuation of Sales) of the DTM Upstream License Agreement to terminate the license granted under Section 2.1.1 (Grant of License) of the DTM Upstream License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Further Sublicensing by Organon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Without limiting the generality of Sections 2.1 (Consent to Dar&#233;-Organon Sublicense Agreement) and 2.2 (Waiver of Certain Obligations of Dar&#233; under DTM Upstream License Agreement) of this Agreement, as of the Effective Date, TriLogic and MilanaPharm hereby grant Dar&#233; the right to allow Organon to grant further sublicenses of Organon&#8217;s rights under the Dar&#233;-Organon Sublicense Agreement where such sublicenses are consistent with the terms and conditions of the Dar&#233;-Organon Sublicense Agreement and with the terms and conditions of the DTM Upstream License as amended by and with the waivers provided in this Agreement with respect to such sublicenses to the same extent as to Organon.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Patent Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As of the Effective Date&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Organon, upon notice to TriLogic and MilanaPharm, shall have the first right, but not the obligation, to initiate and prosecute any legal action to terminate an infringement of the Licensed Patents (as defined in the DTM Upstream License Agreement) within the Field (as defined in the Dar&#233;-Organon Sublicense </font></div><div style="height:76.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.527%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421817v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Agreement), and to control the defense against challenges to the validity or enforceability of such Licensed Patents within such Field, at its own expense and in its own name, in which case Organon shall keep TriLogic and MilanaPharm updated with respect to any such action, including providing copies of all material documents received, prepared and filed in connection with any such action, and shall consult with TriLogic and MilanaPharm to determine a course of action with respect to any defense of the validity and&#47;or enforceability of any such Licensed Patents in such Field and shall consider in good faith all reasonable comments, requests, and suggestions provided by TriLogic and MilanaPharm with respect thereto.  Subject to Organon&#8217;s obligations to Dar&#233; under the Dar&#233;-Organon Sublicense Agreement, Organon shall have the right to enter into a settlement of any matter under this Section 2.4.1 (Patent Control), without MilanaPharm&#8217;s and TriLogic&#8217;s consent, so long as (a) such settlement does not involve any express statement or admission of any fault of, breach of contract by, or violation of applicable law by, MilanaPharm, (b) MilanaPharm is not liable under such settlement agreement to pay any monetary damages or other payments, for which Organon shall agree not to seek any indemnification from MilanaPharm, and does not include any requirement that MilanaPharm take or refrain from taking any actions other than compliance with any nondisclosure obligations related to the terms of such settlement contained in the settlement agreement, (c) such settlement includes a release of MilanaPharm on the same terms as such release applies to Organon, (d) such settlement agreement includes a reasonable confidentiality obligation by the third party claimant or defendant of the terms of the settlement, and (e) to the extent MilanaPharm is not a direct signatory of such settlement agreement, MilanaPharm is designated as an express third party beneficiary of the settlement agreement, entitled to enforce the applicable terms of such settlement agreement&#894; in any other event, TriLogic and MilanaPharm&#8217;s consent shall be required (such consent not to be unreasonably withheld, conditioned or delayed).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Each of TriLogic and MilanaPharm will fully cooperate with Organon and provide any information and assistance that Organon may reasonably request for the filing, prosecution, maintenance and defense of, and in connection with all administrative proceedings contemplated by Sections 9.2.1 (Third Party Initiated Proceedings) and 9.2.2 (Party Initiated Proceedings) of the Dar&#233;-Organon Sublicense Agreement with respect to, all Patents (as defined in the Dar&#233;-Organon Sublicense Agreement) that Organon has the right to file, prosecute, maintain and defend under the Dar&#233;-Organon Sublicense Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">In the event that Organon is unable, as a matter of law, to initiate, prosecute or maintain, in its own name, any action to enforce any intellectual property rights that are exclusively licensed to Organon pursuant to the Dar&#233;-Organon Sublicense Agreement and any of TriLogic or MilanaPharm have any right, title or interest in or to such intellectual property rights, then each of TriLogic and MilanaPharm will, at Organon&#8217;s expense, join such action voluntarily and will execute and cause its Affiliates to execute all documents where necessary for Organon to initiate, prosecute or maintain such action. In connection with any such action or potential action, each of TriLogic and MilanaPharm that has any right, title or interest in or to the intellectual property rights that are the subject of, or otherwise involved in, such action or potential action, will, at Organon&#8217;s expense, cooperate fully with Organon and will provide Organon with any information or assistance that Organon may reasonably request, including cooperating with regard to any pre-litigation review of such intellectual property rights. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">All recoveries in connection with an enforcement contemplated by Section 2.4.1 (Patent Control) of this Agreement will be shared in the manner contemplated by Section 9.3.4 (Recoveries) of the Dar&#233;-Organon Sublicense Agreement. </font></div><div style="height:76.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.527%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421817v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Proof of Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon MilanaPharm or TriLogic&#8217;s request, Dar&#233; will exercise its rights under Sections 8.4 and 5.4 of the Dar&#233;-Organon Sublicense Agreement to obtain a copy of Organon&#8217;s certificate of insurance evidencing insurance (or self-insurance) and Dar&#233; will provide such copy to MilanaPharm or TriLogic, respectively.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt">AMENDMENTS.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Net Sales, Royalties and Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Effective as of the Effective Date, and during the term of this Agreement and solely as applied to &#8220;Licensed Products&#8221; as defined in the Dar&#233;-Organon Sublicense Agreement&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Section 1.24 (&#8220;Net Sales&#8221;) of the DTM Upstream License Agreement is deleted in its entirety and replaced with Section 1.75 (&#8220;Net Sales&#8221;) of the Dar&#233;-Organon Sublicense Agreement. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All definitions of the Dar&#233;-Organon Sublicense Agreement on which Section 1.75 (&#8220;Net Sales&#8221;) of the Dar&#233;-Organon Sublicense Agreement depends and that correspond to definitions of the DTM Upstream License Agreement, replace such definitions of the DTM Upstream License Agreement. All other definitions of the Dar&#233;-Organon Sublicense Agreement on which Section 1.75 (&#8220;Net Sales&#8221;) of the Dar&#233;-Organon Sublicense Agreement depends are added in alphabetical order to Article 1 (Definitions) of the DTM Upstream License Agreement and all Section references in Article 1 (Definitions) of the DTM Upstream License Agreement are updated accordingly.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Royalty Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Section 4.3.1 (Royalty Rate) of the DTM Upstream License Agreement is hereby amended by &#91;***&#93; the Percentage of Annual Net Sales for each category of Annual Net Sales by &#91;***&#93; (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Percentage of Annual Net Sales shall be &#91;***&#93; for Annual Net Sales &#91;***&#93;&#59; the Percentage of Annual Net Sales shall be &#91;***&#93; for the portion of Annual Net Sales equal to or greater than &#91;***&#93; but less than &#91;***&#93;, etc.).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Royalty Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Section 4.4.1 (Payment of Royalties) of the DTM Upstream License Agreement is deleted in its entirety and replaced as follows&#58; &#8220;Dar&#233; shall make royalty payments owed to MilanaPharm hereunder in arrears, &#91;***&#93; after receipt of the corresponding payment(s) from Dar&#233;&#8217;s Sublicensee(s).  Each royalty payment shall be accompanied by a report for each country in which sales of Licensed Products occurred in the Calendar Quarter covered by such statement, containing information sufficient to calculate the royalty payable on a country-by-country basis, including all amounts included in the calculation of Net Sales, the aggregate of deductions taken in such calculation, amounts from all Affiliates and Sublicensees.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Competition&#59; Third Party Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Effective as of the Effective Date, and during the term of this Agreement and solely as applied to &#8220;Licensed Products&#8221; as defined in the Dar&#233;-Organon Sublicense Agreement&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Section 6.3.1(c) (Competition) of the Dar&#233;-Organon Sublicense Agreement is added after Section 4.3.3(iii) (Generic Competition) of the DTM Upstream License Agreement as new Section 4.3.3(iv) (Generic Competition) of the DTM Upstream License Agreement. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All definitions of the Dar&#233;-Organon Sublicense Agreement on which Section 6.3.1(c) (Competition) of the Dar&#233;-Organon Sublicense Agreement depends and that correspond to definitions of the DTM Upstream License Agreement, replace such definitions of the DTM Upstream License Agreement. All other definitions of the Dar&#233;-Organon Sublicense Agreement on which Section 6.3.1(c) </font></div><div style="height:76.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.527%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421817v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Competition) of the Dar&#233;-Organon Sublicense Agreement depends are added in alphabetical order to Article 1 (Definitions) of the DTM Upstream License Agreement and all Section references in Article 1 (Definitions) of the DTM Upstream License Agreement are updated accordingly.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Section 4.3.4(ii) (Third Party Offset) of the DTM Upstream License Agreement is deleted in its entirety and replaced with Section 6.3.2 (Third Party Licenses) from the Dar&#233;-Organon Sublicense Agreement. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All definitions of the Dar&#233;-Organon Sublicense Agreement on which Section 6.3.2 (Third Party Licenses) of the Dar&#233;-Organon Sublicense Agreement depends and that correspond to definitions of the DTM Upstream License Agreement, replace such definitions of the DTM Upstream License Agreement. All other definitions of the Dar&#233;-Organon Sublicense Agreement on which Section 6.3.2 (Third Party Licenses) of the Dar&#233;-Organon Sublicense Agreement depends are added in alphabetical order to Article 1 (Definitions) of the DTM Upstream License Agreement and all Section references in Article 1 (Definitions) of the DTM Upstream License Agreement are updated accordingly.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">The following is added immediately after Section 4.3.4 (Third Party Payments) of the DTM Upstream License Agreement as new Section 4.3.5 (Floor) of the DTM Upstream License Agreement&#58; &#8220;Notwithstanding anything to the contrary in this Agreement&#58; (a) in no event will the royalty rate that otherwise would be applicable under Section 4.3.1 (Royalty Rate) of this Agreement be &#91;***&#93; through application of the provisions of Section 4.3.3(vi) (Generic Competition), or Section 4.3.4 (Third Party Payments) of this Agreement&#59; and (b) the application of clauses (a) through (c) of Section 1.24 (&#8220;Net Sales&#8221;) of this Agreement will not &#91;***&#93; the royalty rate payable on Licensed Products &#91;***&#93; of Net Sales of Licensed Products if clauses (a) through (c) of Section 1.24 (&#8220;Net Sales&#8221;) of this Agreement were not applied.&#8221; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any right that TriLogic or MilanaPharm have to terminate the DTM Upstream License Agreement with respect to &#8220;Licensed Products&#8221; as defined in the Dar&#233;-Organon Sublicense Agreement must be exercised jointly by TriLogic and MilanaPharm.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Termination for Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Section 12.2 (Termination for Breach) of the DTM Upstream License Agreement as applied to &#8220;Licensed Products&#8221; as defined in the Dar&#233;-Organon Sublicense Agreement is hereby amended to replace all references therein to &#8220;sixty (60)&#8221; days with &#91;***&#93;.  All other provisions of such Section 12.2 shall remain as written.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt">ACKNOWLEDGEMENT OF RIGHTS OF DAR&#201; UNDER AND MAINTENANCE OF DTM UPSTREAM LICENSE AGREEMENT&#59; COMMERCIALIZATION DISCUSSION </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each of TriLogic and MilanaPharm represent to Organon that, as of the Execution Date&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">the DTM Upstream License Agreement, inclusive of the amendments described in Recital C of this Agreement, and that License Agreement between TriLogic and MilanaPharm dated April 5, 2013 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TriLogic-MilanaPharm Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) constitute the entire agreement between any two or more of TriLogic, MilanaPharm and Dar&#233; related to the rights licensed to Dar&#233; thereunder, and no other amendments or agreements have been entered into in connection with the DTM Upstream License Agreement or the rights licensed thereunder&#59;</font></div><div style="height:76.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.527%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421817v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">the DTM Upstream License Agreement is in full force and effect and, to the best of their knowledge, Dar&#233; is not in breach of any of its provisions and there are no facts or circumstances that would result in Dar&#233; being in breach of the DTM Upstream License Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">the TriLogic-MilanaPharm Agreement is in full force and effect and neither TriLogic nor MilanaPharm is in breach of any of its provisions&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">neither TriLogic nor MilanaPharm, and, to the best of their knowledge, Dar&#233; or any other Person has granted to any Person any rights that are inconsistent with or affect the rights granted to Dar&#233; under the DTM Upstream License Agreement&#59; and.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt;text-decoration:underline">Schedule 4.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> to this Agreement sets forth a complete and accurate list of all Licensed Patents (as defined in the DTM Upstream License Agreement).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Maintain DTM Upstream License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each of TriLogic, MilanaPharm and Dar&#233; agree not to waive or amend the DTM Upstream License Agreement, without the prior written consent of Organon (which shall not be unreasonably withheld, conditioned or delayed), in any manner that would have a materially adverse effect upon the rights that are granted to Organon under the Dar&#233;-Organon Sublicense Agreement, including Organon&#8217;s rights under the Licensed Intellectual Property (as defined in the DTM Upstream License Agreement).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Assignment of DTM Upstream License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each of TriLogic, MilanaPharm and Dar&#233; agree not to provide consent to any other Party to the DTM Upstream License Agreement to assign such agreement in those cases where any such consent is required. If TriLogic, MilanaPharm or Dar&#233; assign any right title or interest in and to any of the Licensed Intellectual Property (as defined in the DTM Upstream License Agreement) or any right or obligation under the DTM Upstream License Agreement to any Person, the assigning Party will cause such Person to be bound in writing to the terms and conditions of this Agreement and take assignment thereof subject to all of the rights and obligations of Organon under this Agreement and the Dar&#233;-Organon Sublicense Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Commercialization Discussion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If Organon&#8217;s and Dar&#233;&#8217;s Chief Executive Officers meet in accordance with the last sentence of Section 3.4.1 (Diligence) of the Dar&#233;-Organon Sublicense Agreement to discuss a delay in the Commercialization (as defined in the Dar&#233;-Organon Sublicense Agreement) of a Licensed Product(s), then Organon and Dare will permit MilanaPharm&#8217;s Chief Executive Officer to meet with them, at a mutually convenient time, to discuss and address the circumstances leading to such delay.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt">GRANT OF STAND-BY LICENSE TO ORGANON. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Effective as of the Stand-by License Time, immediately, automatically, and without any need for further action by any Party, TriLogic and MilanaPharm hereby grant to Organon all rights and licenses granted by TriLogic and MilanaPharm to Dar&#233; under the DTM Upstream License Agreement that were the subject of termination of the DTM Upstream License Agreement, on the same terms and conditions as such rights and licenses were granted to Dar&#233; under the DTM Upstream License Agreement immediately prior to the Stand-by License Time as modified by Section 5.2 (Amendments) of this Agreement, including all obligations of Dar&#233; thereunder going forward from the Stand-by License Time (such license, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TMO License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). For the avoidance of doubt&#58; (a) the foregoing does not waive any obligation of (i) Dar&#233; to MilanaPharm or TriLogic or (ii) Organon to Dar&#233;, in each case of (i) and (ii), that has accrued prior to the Stand-by License Time&#59; and (b) Organon will have no obligation to pay any amount to MilanaPharm or TriLogic arising from Dar&#233;&#8217;s breach of the DTM Upstream License Agreement nor cure such breach. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Stand-by License Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the termination of the </font></div><div style="height:76.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.527%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421817v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DTM Upstream License Agreement, or part thereof, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">for any reason, including in connection with any laws governing an insolvency, reorganization, bankruptcy, liquidation or winding up of TriLogic, MilanaPharm or Dar&#233; or any breach of the DTM Upstream License Agreement. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The TMO License is granted upon the terms and conditions of the DTM Upstream License Agreement except as stated below or as otherwise mutually agreed in writing by TriLogic, MilanaPharm and Organon&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Sections 3.4 (Hammock Data), 3.6 (Reports), 4.2.2 (Out-License Milestone Payment), 4.2.3 (Foreign Sublicense Income), 11 (Insurance) and 12.5 (Discontinuation of Sales) from the DTM Upstream License Agreement are not included as part of terms and conditions of the TMO License.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">The obligations of Dar&#233; that are waived under Section 2.2 (Waiver of Certain Obligations of Dar&#233; under DTM Upstream License Agreement) of this Agreement shall continue to be irrevocably waived under the TMO License to the extent of such waiver.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">The terms and conditions of the DTM Upstream License Agreement that are amended by Article 3 (Amendments) of this Agreement are amended in the TMO License </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis&#59; provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the first sentence of Section 4.4.1 (Payment of Royalties) of the DTM Upstream License Agreement will be replaced with the following&#58; &#8220;Organon shall make royalty payments owed to MilanaPharm hereunder in arrears, within &#91;***&#93; after the end of the Calendar Quarter in which they become due.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">To the extent there is any other inconsistency between a right or obligation of Organon under the Dar&#233;-Organon Sublicense Agreement and the corresponding right or obligation of Dar&#233; under the DTM Upstream License Agreement, the right or obligation of Organon in the Dar&#233;-Organon Sublicense Agreement is included in the TMO License in substitution for the corresponding right or obligation under the DTM Upstream License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Restatement of TMO License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon request of any of TriLogic, MilanaPharm or Organon, such Parties will use commercially reasonable efforts to promptly restate the TMO License in a separate agreement that further documents the TMO License with the terms and conditions contemplated by Sections 5.1 (License Grant) and 5.2 (Amendments) of this Agreement or as may be otherwise mutually agreed by such Parties.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Offset of Payments by Organon Under a TMO License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Organon can offset from any payments that Organon is obligated to pay Dar&#233; under the Dar&#233;-Organon Sublicense Agreement any and all payments that Organon is obligated to make to MilanaPharm or TriLogic under the TMO License against.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">If any amount owed by Organon under the TMO License for any particular period or milestone event is less than the amount that Organon owes to Dar&#233; for the same period or event under the Dar&#233;-Organon Sublicense Agreement, then Organon may pay to Dar&#233; &#91;***&#93; otherwise in accordance with the applicable terms of the Dar&#233;-Organon Sublicense Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">If any amount owed by Organon under the TMO License for any particular period or milestone event is more than the amount that Organon owes to Dar&#233; for </font></div><div style="height:76.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.527%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421817v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the same period or milestone event under the Dar&#233;-Organon Sublicense Agreement, then Organon &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt">TERMINATION.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement automatically terminates upon termination of the Dar&#233;-Organon Sublicense Agreement for any reason, including if the Effective Date does not occur within the time specified under Article 11 therein, or upon expiration of the Dar&#233;-Organon Sublicense Agreement.  Except as provided in the preceding sentence, this Agreement may not be terminated for any reason other than mutual written agreement of all of the Parties.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The provisions of Articles 7 (Confidentiality) &#8211; 9 (Miscellaneous) of this Agreement and this Section 6.2 (Survival) survive termination of this Agreement for any reason and remain in effect if and as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt">CONFIDENTIALITY.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Terms of this Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The existence and the terms and conditions of this Agreement will be considered the confidential information of each Party. Any confidential information of Organon provided by Dar&#233; to MilanaPharm or TriLogic in accordance with the Dar&#233;-Organon Sublicense Agreement will remain the confidential information of Organon. No disclosure of (a) the existence, or the terms or conditions, of this Agreement may be made by any Party, without the prior express written permission of all of the other Parties, or (b) the confidential information of Organon provided by Dar&#233; to MilanaPharm or TriLogic in accordance with the Dar&#233;-Organon Sublicense Agreement may be made without the prior express written permission of Organon, except, in each case of (a) and (b), as may be required by applicable laws. Without limiting the generality of the foregoing, no Party shall use the name, trademark, trade name or logo of any other Party, its Affiliates or their respective employee(s) in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the express written permission of such Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Required Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If any Party is required to disclose the terms of this Agreement or other confidential information of another Party in submissions to the U.S. Securities and Exchange Commission or other equivalent governmental authority, it will (a) consult with the Party(ies) whose confidential information is required to be disclosed as to which information to redact from such confidential information&#59; and (b) to the extent permitted under all applicable laws, redact all sensitive, material and non-public information, from such confidential information.  The requirements of this Section 7.2 (Required Disclosure) shall not apply if the substance of the description of or reference to the applicable confidential information contained in the proposed filing or disclosure has been included in any previous filing or disclosure made by any Party or otherwise approved by all of the other Parties and such information remains accurate as of such time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt">NOTICES.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All notices which are required or permitted hereunder shall be in writing and sufficient if sent by internationally-recognized commercial courier, addressed as follows&#58;</font></div><div style="height:76.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.527%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421817v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.12pt;padding-left:41.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.004%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">if to TriLogic, to&#58;</font></td><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TriLogic Pharma, LLC </font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">219 S 8th Street</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Opelika, AL 36801</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; James A.H. Harwick</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:31pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">With a copy to, which shall not constitute notice&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dentons Sirote PC</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2311 Highland Avenue South</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Birmingham, Alabama 35205</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; Peter J. Hardin</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Facsimile No.&#58; 205-212-3805</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:28pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">if to MilanaPharm, to&#58;</font></td><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MilanaPharm LLC</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">219 S 8th Street</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Opelika, AL 36801</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; James A.H. Harwick</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">With a copy to, which shall not constitute notice&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dentons Sirote PC</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2311 Highland Avenue South</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Birmingham, Alabama 35205</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; Peter J. Hardin</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">if to Dar&#233;, to&#58;</font></td><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dar&#233; Bioscience, Inc.</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3655 Nobel Drive, Suite 260</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">San Diego, CA 92122</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; Sabrina Johnson, CEO</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:31pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">With a copy to, which shall not constitute notice&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mintz Levin</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3580 Carmel Mountain Rd. #300</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">San Diego, CA 92130</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; Tali Tuchin</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:76.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.527%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421817v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.12pt;padding-left:41.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">if to Organon, to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Organon International GmBH</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weystrasse 20, 6006 Lucerne, Switzerland</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; General Counsel</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-and-</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Organon LLC</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30 Hudson Street, Floor 33</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">New Jersey, NJ, USA 07302</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58;  SVP, Business Development</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-and-</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Via electronic mail to&#58;</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Organon LLC</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30 Hudson Street, Floor 33</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">New Jersey, NJ, USA 07302</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58;  General Counsel</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">With a copy to, which shall not constitute notice&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Jones Day</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4655 Executive Drive, Suite 1500</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">San Diego, CA 92121-3134</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58;  Thomas Briggs and Jonn Beeson</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party(ies) in writing in accordance herewith.  Any such notice shall be deemed to have been given upon receipt.  The Parties hereby agree that, to the extent permitted by applicable law, any notice provided in accordance with this Article 8 (Notices) shall constitute due service of process with respect to any legal proceeding between the Parties arising hereunder and that compliance with the Hague Convention for the Service of Process, if otherwise applicable, shall not be required.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt">MISCELLANEOUS.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. No Party can assign this Agreement, in whole or in part, without the prior written consent of each other Party hereto, except that, without such consent (a) any Party may assign its respective interest under this Agreement to its Affiliate in a transaction or series of transactions in which such Affiliates is also the assignee of the assigning Party&#8217;s interest in (i) the Licensed Intellectual Property and the DTM Upstream License Agreement, in the case of TriLogic or MilanaPharm, (ii) the DTM Upstream License Agreement and the Dar&#233;-Organon Sublicense Agreement in the case of Dar&#233;, or (iii) the Dar&#233;-Organon Sublicense Agreement in the case of Organon, and (b) any Party may assign its respective interest under this Agreement to the successors or assignees of at least substantially all of the assets of its business to which this Agreement relates.</font></div><div style="height:76.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.527%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421817v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties.  The Parties shall in such an instance use reasonable efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Relationship of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement shall not constitute any Party as the joint venturer, legal representative or agent of any other Party hereto.  No Party hereto shall have the right or authority to assume or create any obligation on the part of any among the Parties with respect to their collective subject matter.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Specific Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties agree that if any of the terms and conditions of this Agreement were not performed in accordance with the terms and conditions herein and, accordingly, each Party &#91;***&#93; entitled to obtain an injunction to prevent any breaches and to obtain specific performance of the terms and conditions herein in addition to any other remedy available at law or in equity.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event of any conflict between this Agreement, on the hand, and the DTM Upstream License Agreement or the Dar&#233;-Organon Sublicense Agreement, on the other hand, the terms and conditions of this Agreement shall prevail.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Entire Agreement&#59; Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement, the DTM Upstream License Agreement and the Dar&#233;-Organon Sublicense Agreement, contain the entire understanding of the Parties with respect to the subject matter hereof.  Any other express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, with respect to the subject matter hereof and the licenses granted hereunder are superseded by the terms of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representative(s) of all Parties hereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without reference to any rules of conflict of laws or venue.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">The Parties shall negotiate in good faith and use reasonable efforts to settle any dispute, controversy or claim arising from or related to this Agreement or the breach thereof (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Any Party shall give the other Party(ies) to the Dispute written notice of any Dispute not resolved in the normal course of business.  Within &#91;***&#93;, the receiving Party shall submit to the other Party(ies) a written response.  The notice and response shall include (A) a statement of &#91;***&#93;, and (B) the name and title of the executive who will represent that Party and of any other person who will accompany the executive.  Within &#91;***&#93;, the executives of the disputing Parties shall meet at a mutually acceptable time and place, and thereafter as often as they reasonably deem necessary, to attempt to resolve the Dispute.  These executives shall have the authority to settle the Dispute and shall be at a higher level of management than the persons with direct responsibility for administration of this Agreement.  All negotiations pursuant to this paragraph are confidential and shall be treated as compromise and settlement negotiations for purposes of applicable rules of evidence.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">If the Parties do not fully settle following the procedure in Section 9.8.1, and a Party wishes to pursue the matter, each dispute, controversy or claim arising from </font></div><div style="height:76.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.527%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421817v2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or related to this Agreement or the breach thereof shall be brought in the federal court for the District of Delaware, if federal jurisdiction is available, or, alternatively, in the state courts in Wilmington, Delaware.  Each of the Parties hereby submits to the exclusive jurisdiction of such courts for the purpose of any such litigation&#59; provided, that a final judgment in any such litigation shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">  Each Party irrevocably and unconditionally agrees not to assert (a) any objection which it may ever have to the laying of venue of any such litigation in such courts, (b) any claim that any such litigation brought in any such court has been brought in an inconvenient forum, and (c) any claim that such court does not have jurisdiction with respect to such litigation.  EACH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT TO A TRIAL BY JURY AND AGREES THAT ANY OF THEM MAY FILE A COPY OF THIS PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY AND BARGAINED-FOR AGREEMENT AMONG THE PARTIES IRREVOCABLY TO WAIVE ITS RIGHT TO TRIAL BY JURY IN ANY LITIGATION.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The captions to the several Articles, Sections and subsections hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading the several Articles and Sections hereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The waiver by any Party hereto of any right hereunder, or of any failure of any other Party to perform, or of any breach by any other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such any other Party whether of a similar nature or otherwise.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Waiver of Rule of Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement.  Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party(ies) shall not apply.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Certain Conventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any reference in this Agreement to an Article, Section, subsection, paragraph, clause or Schedule shall be deemed to be a reference to an Article, Section, subsection, paragraph, clause or Schedule, of or to, as the case may be, this Agreement, unless otherwise indicated.  Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days.  Unless the context of this Agreement otherwise requires, (a) words of any gender include any other gender, (b) words such as &#8220;herein&#8221;, &#8220;hereof&#8221;, and &#8220;hereunder&#8221; refer to this Agreement as a whole and not merely to the particular provision in which such words appear, (c) words using the singular shall include the plural, and vice versa, (d) each use of the word &#8220;including&#8221; is not limiting and is deemed to be followed by the words &#8220;without limitation&#8221;, (e) the words &#8220;shall&#8221; and &#8220;will&#8221; have the same meaning unless the context dictates otherwise, and (f) use of the words &#8220;or,&#8221; &#8220;either&#8221; or &#8220;any&#8221; will not be exclusive.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement may be executed in any number of counterparts (including by facsimile or electronic transmission) each of which shall be deemed and original but all of which together shall constitute one and the same instrument.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#60;signature page follows&#62;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:76.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.527%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:113%">NAI-1530421817v2</font></div></td></tr></table></div></div></div><div id="i7463834712be46a1b67f686b11e09594_4"></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties have executed this Agreement by their duly authorized representatives as of the Execution Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">TRILOGIC PHARMA, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MILANAPHARM, LLC</font></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BY&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; James A. H. Harwick</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BY&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; James A. H. Harwick</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NAME&#58;&#160;&#160;&#160;&#160;James A. H. Harwick</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NAME&#58;&#160;&#160;&#160;&#160;James A. H. Harwick</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">TITLE&#58;&#160;&#160;&#160;&#160;Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">TITLE&#58;&#160;&#160;&#160;&#160;Chief Executive Officer</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">DAR&#201; BIOSCIENCE, INC.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">ORGANON INTERNATIONAL GMBH</font></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BY&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Sabrina Johnson</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BY&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Thomas Morlet</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">NAME&#58;&#160;&#160;&#160;&#160;SABRINA JOHNSON</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">NAME&#58;&#160;&#160;&#160;&#160;Thomas Morlet</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">TITLE&#58;&#160;&#160;&#160;&#160;Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">TITLE&#58;&#160;&#160;&#160;&#160;Managing Officer</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ex_102noneedirectorcomppol.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i35194f02100941af8c1da90c70ee3f24_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAR&#201; BIOSCIENCE, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;text-indent:41.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The board of directors (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of Dar&#233; Bioscience,&#160;Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) has approved this amended and restated non-employee director compensation policy (this &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).&#160;&#160;</font></div><div style="margin-bottom:12pt;text-indent:41.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Compensation</font></div><div style="margin-bottom:12pt;text-indent:41.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this Policy, the Company will pay its non-employee directors retainers in cash, unless a director elects to receive his or her retainer for a given calendar year in the form of awards of unrestricted shares of the Company&#8217;s common stock, as described below.&#160; Each non-employee director will receive a retainer for service on the Board and for service on each committee of which the director is a member. The chairmen of the Board and of each committee will receive higher retainers for such service. The amounts of the retainers are as follows&#58;</font></div><div style="margin-bottom:0.08pt;padding-left:3.19pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:47.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.456%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#160;</font></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Annual Retainer ($)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ccecff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Board of Directors</font></td><td colspan="3" style="background-color:#ccecff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160; Chairman</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">65,000</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160; Member</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">40,000</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Committees of the Board of Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160; Audit</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chair</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">20,000</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Member</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,500</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160; Compensation</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chair</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">15,000</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Member</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,500</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160; Nominating and Corporate Governance</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chair</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10,000</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Member</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4,000</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160; Clinical Advisory</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chair</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">20,000</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Member</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10,000</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;text-indent:41.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These retainers are payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment shall be prorated for any portion of such quarter during which the director was not serving.&#160; The Company will also reimburse its non-employee directors for reasonable travel and other expenses incurred in connection with attending Board and committee meetings.</font></div><div style="margin-bottom:12pt;text-indent:41.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each non-employee director may elect to receive up to 100% of these retainers in the form of awards of unrestricted shares of the Company&#8217;s common stock, issued on the first trading day of the quarter following the quarter to which the retainer relates, for a number of shares of the Company&#8217;s common stock equal to (x) the amount of the cash retainer that would otherwise have been payable to such director on the date of grant divided by (y) the fair market value of the Company&#8217;s common stock on the date of grant.&#160;&#160;Directors wishing to make this election for a given calendar year must make the election on or before the last day of the prior calendar year, except that the election with respect to calendar year 2016 and in any year in which a director is newly elected must be made on or before June 30th&#160;of such year or such other date as determined by the Board.</font></div><div style="margin-bottom:12pt;text-indent:41.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Compensation</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> As amended through January 2022.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:41.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Grants</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each director elected to the Board at the Company&#8217;s annual meeting of stockholders in fiscal year 2022 will receive an option to purchase 57,000 shares of the Company&#8217;s common stock (each, an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Each director newly elected to the Board thereafter will receive an Initial Grant. Each Initial Grant will vest as to one-third of the shares of the Company&#8217;s common stock underlying such option on each anniversary of the grant date until the third anniversary of the grant date, subject to the director&#8217;s continued service as a director, and will become exercisable in full upon a Change in Control (as defined below).&#160; </font></div><div style="margin-bottom:12pt;text-indent:41.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Grants</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On the date of each annual meeting of stockholders, beginning with the annual meeting of stockholders held in 2022, each director who has served on the Board for at least six months will receive an option to purchase 38,000 shares of the Company&#8217;s common stock (each, an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annual</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, however, that if a director is up for election at such annual meeting of stockholders, such director will receive the Annual Grant only if such director is elected at such annual meeting. Each Annual Grant will vest in full on the earlier of the first anniversary of the date of grant or immediately prior to the Company&#8217;s first annual meeting of stockholders occurring after the date of grant, subject to the director&#8217;s continued service as a director, and will become exercisable in full upon a Change in Control.</font></div><div style="margin-bottom:12pt;text-indent:41.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The exercise price of each option granted under this Policy will equal the fair market value of the Company&#8217;s common stock on the date of grant.</font></div><div style="margin-bottom:12pt;text-indent:41.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For purposes of this Policy, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the occurrence, in a single transaction or in a series of related transactions occurring after the date of grant of the applicable equity award, of any one or more of the following events&#58; (1) any person or persons acting together becomes the owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting power of the Company&#8217;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction&#59; (2) there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not own, directly or indirectly, either (A) outstanding voting securities representing more than fifty percent (50%) of the combined outstanding voting power of the surviving entity in such merger, consolidation or similar transaction or (B) more than fifty percent (50%) of the combined outstanding voting power of the parent of the surviving entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their ownership of the outstanding voting securities of the Company immediately prior to such transaction&#59; or (3) there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company during any twelve month period, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company to an entity, more than fifty percent (50%) of the combined voting power of the voting securities of which are owned by stockholders of the Company in substantially the same proportions as their ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition.  Notwithstanding the above, to the extent that any interpretation of this definition would otherwise cause the option on or following a Change in Control to constitute deferred compensation that is subject to Section 409A of the Internal Revenue Code, and not otherwise exempt from complying with the provisions of the statute, then a Change in Control shall only be deemed to occur if the Change in Control also qualifies as a change in the ownership or effective control of a corporation, or a change in the ownership of a substantial portion of a corporation&#8217;s assets as defined in Treasury Regulation Section 1.409A-3(i)(5).  No Change in Control will be deemed to occur because of a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">4839-9777-0351, v. 3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>exhibit311_20220331.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9d26f9c8dce74c229c77a796b24eda09_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1 </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Sabrina Martucci Johnson, certify that&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Quarterly Report on Form 10-Q of Dar&#233; Bioscience, Inc.&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;  May&#160;12, 2022 </font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.150%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sabrina Martucci Johnson</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sabrina Martucci Johnson</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal executive officer)</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>exhibit312_20220331.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ieea35d5803b9412ea2e461b958e465bf_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2 </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Lisa Walters-Hoffert, certify that&#58; </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Quarterly Report on Form 10-Q of Dar&#233; Bioscience, Inc.&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;12, 2022 </font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.150%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lisa Walters-Hoffert</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisa Walters-Hoffert</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>exhibit321_20220331.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1c16deea4999466ba81105b75a2ffabe_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Dar&#233; Bioscience, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended March&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Sabrina Martucci Johnson, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that, to her knowledge on the date hereof&#58; </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;12, 2022 </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.903%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sabrina Martucci Johnson</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sabrina Martucci Johnson</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal executive officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>exhibit322_20220331.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i901dff32e9d44dcebef7d6fa6dab46d3_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Dar&#233; Bioscience, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended March&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Lisa Walters-Hoffert, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that, to her knowledge on the date hereof&#58; </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;12, 2022 </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.903%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lisa Walters-Hoffert</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisa Walters-Hoffert</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>dare-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:fd319a35-eb86-476b-85ca-f1b0e0a14df0,g:c97ede0a-3f8a-49b3-9abb-a622ab8bee13-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dare="http://darebioscience.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://darebioscience.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dare-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dare-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dare-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dare-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://darebioscience.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://darebioscience.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" roleURI="http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityUnaudited" roleURI="http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusiness" roleURI="http://darebioscience.com/role/OrganizationandDescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusinessDetails" roleURI="http://darebioscience.com/role/OrganizationandDescriptionofBusinessDetails">
        <link:definition>2402401 - Disclosure - Organization and Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails" roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails">
        <link:definition>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Financial Assets and Liabilities Remeasured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StrategicAgreements" roleURI="http://darebioscience.com/role/StrategicAgreements">
        <link:definition>2108103 - Disclosure - Strategic Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StrategicAgreementsDetails" roleURI="http://darebioscience.com/role/StrategicAgreementsDetails">
        <link:definition>2409404 - Disclosure - Strategic Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://darebioscience.com/role/StockholdersEquity">
        <link:definition>2110104 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://darebioscience.com/role/StockholdersEquityTables">
        <link:definition>2311302 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetails" roleURI="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails">
        <link:definition>2412405 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails" roleURI="http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails">
        <link:definition>2413406 - Disclosure - Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://darebioscience.com/role/StockBasedCompensation">
        <link:definition>2114105 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://darebioscience.com/role/StockBasedCompensationTables">
        <link:definition>2315303 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>2416407 - Disclosure - Stock Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails" roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails">
        <link:definition>2417408 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails" roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails">
        <link:definition>2418409 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails" roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails">
        <link:definition>2419410 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedProperties" roleURI="http://darebioscience.com/role/LeasedProperties">
        <link:definition>2120106 - Disclosure - Leased Properties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedPropertiesTables" roleURI="http://darebioscience.com/role/LeasedPropertiesTables">
        <link:definition>2321304 - Disclosure - Leased Properties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedPropertiesAdditionalInformationDetails" roleURI="http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails">
        <link:definition>2422411 - Disclosure - Leased Properties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedPropertiesFutureMinimumLeasePaymentsDetails" roleURI="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails">
        <link:definition>2423412 - Disclosure - Leased Properties - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedPropertiesFutureMinimumLeasePaymentsDetails_1" roleURI="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>2423412 - Disclosure - Leased Properties - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://darebioscience.com/role/CommitmentsandContingencies">
        <link:definition>2124107 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://darebioscience.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2425413 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantAwards" roleURI="http://darebioscience.com/role/GrantAwards">
        <link:definition>2126108 - Disclosure - Grant Awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantAwardsDetails" roleURI="http://darebioscience.com/role/GrantAwardsDetails">
        <link:definition>2427414 - Disclosure - Grant Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://darebioscience.com/role/NetLossPerShare">
        <link:definition>2128109 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://darebioscience.com/role/NetLossPerShareTables">
        <link:definition>2329305 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails" roleURI="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails">
        <link:definition>2430415 - Disclosure - Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://darebioscience.com/role/SubsequentEvents">
        <link:definition>2131110 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://darebioscience.com/role/SubsequentEventsDetails">
        <link:definition>2432416 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="dare_SignificantAccountingPoliciesLineItems" abstract="true" name="SignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dare_DeferredOfferingCostsUnamortizedPortion" abstract="false" name="DeferredOfferingCostsUnamortizedPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_EstimatedFairValueOfWarrantsRecordedInEquity" abstract="false" name="EstimatedFairValueOfWarrantsRecordedInEquity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_NICHDMember" abstract="true" name="NICHDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_April2021AtTheMarketSalesAgreementMember" abstract="true" name="April2021AtTheMarketSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived" abstract="false" name="CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_DARELARC1Member" abstract="true" name="DARELARC1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_MilestonePaymentsTerm" abstract="false" name="MilestonePaymentsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dare_JuniperPharmaceuticalsInc.Member" abstract="true" name="JuniperPharmaceuticalsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_ResearchAndDevelopmentMilestonePayment" abstract="false" name="ResearchAndDevelopmentMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_SignificantAccountingPoliciesTable" abstract="true" name="SignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" abstract="false" name="PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dare_PeriodofInsufficientCashandLiquidityRequirements" abstract="false" name="PeriodofInsufficientCashandLiquidityRequirements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dare_UpfrontLicenseFeeAmountPaid" abstract="false" name="UpfrontLicenseFeeAmountPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_LincolnParkMember" abstract="true" name="LincolnParkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_ForgivenessOfPaycheckProtectionProgramNotePayable" abstract="false" name="ForgivenessOfPaycheckProtectionProgramNotePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_GrantDAREFRT1Member" abstract="true" name="GrantDAREFRT1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_WorkingCapitalIncreaseDeficit" abstract="false" name="WorkingCapitalIncreaseDeficit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct" abstract="false" name="LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dare_UpfrontLicenseFeePaid" abstract="false" name="UpfrontLicenseFeePaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_MilestonePaymentsContingentAmount" abstract="false" name="MilestonePaymentsContingentAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_MilestonePaymentsContingentAmountPayableNet" abstract="false" name="MilestonePaymentsContingentAmountPayableNet" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_AssignmentAgreementMember" abstract="true" name="AssignmentAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_NotesPayableCurrentPlusAccruedInterest" abstract="false" name="NotesPayableCurrentPlusAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" abstract="true" name="AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_ResearchAndDevelopmentAgreementCommitmentAmount" abstract="false" name="ResearchAndDevelopmentAgreementCommitmentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" abstract="false" name="BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" abstract="true" name="StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_LicenseAgreementInitialTerm" abstract="false" name="LicenseAgreementInitialTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dare_AdditionalPotentialFundingRelatedToGrantAward" abstract="false" name="AdditionalPotentialFundingRelatedToGrantAward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" abstract="true" name="UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" abstract="false" name="IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_ADVATecAgreementMember" abstract="true" name="ADVATecAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_WeightedAverageAmortizationPeriod" abstract="false" name="WeightedAverageAmortizationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" abstract="false" name="PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_PurchaseAgreementMember" abstract="true" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_MicrochipsBiotechInc.Member" abstract="true" name="MicrochipsBiotechInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_StockholdersEquityTable" abstract="true" name="StockholdersEquityTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember" abstract="true" name="LicensedProductOrProcessForVaginalOrUrologicalUseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_NumberOfCommonStockWarrantsExercised" abstract="false" name="NumberOfCommonStockWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dare_DeferredGrantFundingCurrent" abstract="false" name="DeferredGrantFundingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_CRADAMember" abstract="true" name="CRADAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_PaymentsToStockholdersRepresentativeInBusinessCombination" abstract="false" name="PaymentsToStockholdersRepresentativeInBusinessCombination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_IncreaseDecreaseInDeferredGrantFunding" abstract="false" name="IncreaseDecreaseInDeferredGrantFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_AssetAcquisitionContingentConsideration" abstract="false" name="AssetAcquisitionContingentConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_LicenseAndCollaborationAgreementMember" abstract="true" name="LicenseAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_ClinicalAndRegulatoryMilestonesMember" abstract="true" name="ClinicalAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_PercentageOfAggregateCommission" abstract="false" name="PercentageOfAggregateCommission" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dare_BayerHealthcareLicenseAgreementMember" abstract="true" name="BayerHealthcareLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_RoyaltyAgreementTerm" abstract="false" name="RoyaltyAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature" abstract="false" name="DeemedDividendFromTriggerOfRoundDownProvisionFeature" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" abstract="true" name="WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_LicenseFeeToBePaidUponContingency" abstract="false" name="LicenseFeeToBePaidUponContingency" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_ProceedsFromIssuanceOfCommonStockAndWarrants" abstract="false" name="ProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_PercentageOfRoyaltyRate" abstract="false" name="PercentageOfRoyaltyRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dare_ATMEquityOfferingProgramMember" abstract="true" name="ATMEquityOfferingProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" abstract="false" name="NetProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount" abstract="false" name="MilestonePaymentsContingentAmountFirstCommercialSaleAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_MilanaPharmMember" abstract="true" name="MilanaPharmMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_GoingConcernPolicyTextBlock" abstract="false" name="GoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dare_ClassOfWarrantOrRightsWarrantsExpirationDate" abstract="false" name="ClassOfWarrantOrRightsWarrantsExpirationDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="dare_MBIMember" abstract="true" name="MBIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" abstract="true" name="UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_GrantAwardTextBlock" abstract="false" name="GrantAwardTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dare_UponAchievingCertainDevelopmentMilestonesMember" abstract="true" name="UponAchievingCertainDevelopmentMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_LicenseAgreementNoticePeriodOfTermination" abstract="false" name="LicenseAgreementNoticePeriodOfTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dare_HammockPharmaceuticalsInc.Member" abstract="true" name="HammockPharmaceuticalsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount" abstract="false" name="MilestonePaymentsContingentAmountSalesBasedMilestonesAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_NonCashLeaseExpense" abstract="false" name="NonCashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_UponAchievingCertainCommercialMilestonesMember" abstract="true" name="UponAchievingCertainCommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_SalesMilestonesMember" abstract="true" name="SalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" abstract="false" name="LicenseAgreementTerminationPeriodDueToPerformanceFailure" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dare_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dare_PaymentOfAdditionalConsiderationInBusinessCombination" abstract="false" name="PaymentOfAdditionalConsiderationInBusinessCombination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_UponReachingCertainWorldwideNetSalesMilestonesMember" abstract="true" name="UponReachingCertainWorldwideNetSalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandAndFourteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_OrganonMember" abstract="true" name="OrganonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_LicenseFee" abstract="false" name="LicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_GrantDAREPTB1Member" abstract="true" name="GrantDAREPTB1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_ProceedsFromAwardOfGrant" abstract="false" name="ProceedsFromAwardOfGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" abstract="false" name="PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dare_MaximumPotentialMilestonePayments" abstract="false" name="MaximumPotentialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" abstract="true" name="WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_CatalentAndMilanaPharmMember" abstract="true" name="CatalentAndMilanaPharmMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dare_ReceivableForExpensesEligibleForReimbursement" abstract="false" name="ReceivableForExpensesEligibleForReimbursement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_AssetAcquisitionContingentConsiderationCurrent" abstract="false" name="AssetAcquisitionContingentConsiderationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_StockholdersEquityLineItems" abstract="true" name="StockholdersEquityLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>dare-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:fd319a35-eb86-476b-85ca-f1b0e0a14df0,g:c97ede0a-3f8a-49b3-9abb-a622ab8bee13-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://darebioscience.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="dare-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d87fe31b-6ae3-440b-9ea0-677dcfcb759c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5945f1ea-e08f-4040-be39-fa2399ddb2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d87fe31b-6ae3-440b-9ea0-677dcfcb759c" xlink:to="loc_us-gaap_PreferredStockValue_5945f1ea-e08f-4040-be39-fa2399ddb2d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8ada2ba3-8234-48d0-896a-f6d10c43d3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d87fe31b-6ae3-440b-9ea0-677dcfcb759c" xlink:to="loc_us-gaap_CommonStockValue_8ada2ba3-8234-48d0-896a-f6d10c43d3dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8ab0623e-5620-4855-9061-a881c119246f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d87fe31b-6ae3-440b-9ea0-677dcfcb759c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8ab0623e-5620-4855-9061-a881c119246f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5c6da6d4-d693-4636-86d6-1c81a258bb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d87fe31b-6ae3-440b-9ea0-677dcfcb759c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5c6da6d4-d693-4636-86d6-1c81a258bb9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8c7097b8-0111-4a04-bd32-286c74f45341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d87fe31b-6ae3-440b-9ea0-677dcfcb759c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8c7097b8-0111-4a04-bd32-286c74f45341" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0fceda62-376c-4f20-8e4a-d08caaac1d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_35c72272-8c3f-4fd0-b676-44000ed3caf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0fceda62-376c-4f20-8e4a-d08caaac1d2a" xlink:to="loc_us-gaap_AssetsCurrent_35c72272-8c3f-4fd0-b676-44000ed3caf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7e3a5a08-4cfc-4f0a-bc94-44763a3468b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0fceda62-376c-4f20-8e4a-d08caaac1d2a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7e3a5a08-4cfc-4f0a-bc94-44763a3468b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_11cdaa7a-dfa8-4763-ad3b-a15a2e1b5174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0fceda62-376c-4f20-8e4a-d08caaac1d2a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_11cdaa7a-dfa8-4763-ad3b-a15a2e1b5174" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b6050570-a9b4-4bd9-a298-1c0ab7019705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_7ad3fb07-858d-43ad-a853-75987f73553b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b6050570-a9b4-4bd9-a298-1c0ab7019705" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_7ad3fb07-858d-43ad-a853-75987f73553b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_48a47e55-d852-4c53-a816-01c7cb1637f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b6050570-a9b4-4bd9-a298-1c0ab7019705" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_48a47e55-d852-4c53-a816-01c7cb1637f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6d57cd3f-aae3-4230-b94f-6551c9a08761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b6050570-a9b4-4bd9-a298-1c0ab7019705" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6d57cd3f-aae3-4230-b94f-6551c9a08761" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bb572eed-f4d1-4536-bf63-54c2ddced042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredGrantFundingCurrent_7c533330-f943-431a-b892-8859e4a1edef" xlink:href="dare-20220331.xsd#dare_DeferredGrantFundingCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb572eed-f4d1-4536-bf63-54c2ddced042" xlink:to="loc_dare_DeferredGrantFundingCurrent_7c533330-f943-431a-b892-8859e4a1edef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ce527eae-8468-465c-92d7-b4d2ca78b330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb572eed-f4d1-4536-bf63-54c2ddced042" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ce527eae-8468-465c-92d7-b4d2ca78b330" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_fdc70e64-5d15-4879-9815-fd028bc9dc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb572eed-f4d1-4536-bf63-54c2ddced042" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_fdc70e64-5d15-4879-9815-fd028bc9dc4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3c81303f-f10b-409a-b02e-582334050cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb572eed-f4d1-4536-bf63-54c2ddced042" xlink:to="loc_us-gaap_AccountsPayableCurrent_3c81303f-f10b-409a-b02e-582334050cc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0966d78a-4b85-4ccb-afe5-59aaea8806d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_52b6ef69-31c8-4faa-aa64-4f4f4870bc86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0966d78a-4b85-4ccb-afe5-59aaea8806d2" xlink:to="loc_us-gaap_Liabilities_52b6ef69-31c8-4faa-aa64-4f4f4870bc86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_eea92f83-dcaa-4d41-a2a0-5a5d0913e0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0966d78a-4b85-4ccb-afe5-59aaea8806d2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_eea92f83-dcaa-4d41-a2a0-5a5d0913e0d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_02de2913-9f97-4da3-a5c7-e9324ddaa121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0966d78a-4b85-4ccb-afe5-59aaea8806d2" xlink:to="loc_us-gaap_StockholdersEquity_02de2913-9f97-4da3-a5c7-e9324ddaa121" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_11d287cb-8f79-4a03-a2a5-72cd1b8c90a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a5ecb2d1-8695-4829-aaa2-3c3c6caa8ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_11d287cb-8f79-4a03-a2a5-72cd1b8c90a8" xlink:to="loc_us-gaap_LiabilitiesCurrent_a5ecb2d1-8695-4829-aaa2-3c3c6caa8ef6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c8158b3e-bc39-4db3-8421-9f97bd39b593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_11d287cb-8f79-4a03-a2a5-72cd1b8c90a8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c8158b3e-bc39-4db3-8421-9f97bd39b593" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9c4f1f4c-d379-4096-8072-958cef49c300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_11d287cb-8f79-4a03-a2a5-72cd1b8c90a8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9c4f1f4c-d379-4096-8072-958cef49c300" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="dare-20220331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e71d3ed5-72d8-46b1-bb7d-89f3c89b3044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9a682462-2486-4846-a7ae-65cefcf78a40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e71d3ed5-72d8-46b1-bb7d-89f3c89b3044" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9a682462-2486-4846-a7ae-65cefcf78a40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_247f4a41-6014-4e9b-bdda-12ed5891435f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e71d3ed5-72d8-46b1-bb7d-89f3c89b3044" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_247f4a41-6014-4e9b-bdda-12ed5891435f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseFee_b17c20ab-b2b3-4a4c-b7e3-e2cc5bc30651" xlink:href="dare-20220331.xsd#dare_LicenseFee"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e71d3ed5-72d8-46b1-bb7d-89f3c89b3044" xlink:to="loc_dare_LicenseFee_b17c20ab-b2b3-4a4c-b7e3-e2cc5bc30651" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_61f01fb8-0da4-4360-81f0-39dc755e235a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b5f0b3bd-0a8a-4aad-b295-6daa722ce136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_61f01fb8-0da4-4360-81f0-39dc755e235a" xlink:to="loc_us-gaap_OperatingExpenses_b5f0b3bd-0a8a-4aad-b295-6daa722ce136" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_318438c5-4c34-4318-84a1-0de82f889534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3e20163a-df68-41b1-b2c9-085caf1f7d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_318438c5-4c34-4318-84a1-0de82f889534" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3e20163a-df68-41b1-b2c9-085caf1f7d7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6ec01c6f-6f17-418f-b20c-ff0d69bd0a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_318438c5-4c34-4318-84a1-0de82f889534" xlink:to="loc_us-gaap_OperatingIncomeLoss_6ec01c6f-6f17-418f-b20c-ff0d69bd0a2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c8cfdcc9-2f29-45c7-8966-a1d052bd1214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_318438c5-4c34-4318-84a1-0de82f889534" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c8cfdcc9-2f29-45c7-8966-a1d052bd1214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_58a3afe9-6ebe-45f6-afd4-02aeecd5a276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_860511b4-7e22-4b2a-8ef4-12a906b1c193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_58a3afe9-6ebe-45f6-afd4-02aeecd5a276" xlink:to="loc_us-gaap_NetIncomeLoss_860511b4-7e22-4b2a-8ef4-12a906b1c193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_83d326ec-6b3c-479e-af85-1dfa9252b512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_58a3afe9-6ebe-45f6-afd4-02aeecd5a276" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_83d326ec-6b3c-479e-af85-1dfa9252b512" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="dare-20220331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b569ab53-94d1-401f-8855-97f4a666d26b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_ed38b2b9-1d28-4c24-bf3f-b9a4c4c21815" xlink:href="dare-20220331.xsd#dare_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b569ab53-94d1-401f-8855-97f4a666d26b" xlink:to="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_ed38b2b9-1d28-4c24-bf3f-b9a4c4c21815" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_9c2d43a2-46db-4c37-94e8-a891f97711dc" xlink:href="dare-20220331.xsd#dare_NetProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b569ab53-94d1-401f-8855-97f4a666d26b" xlink:to="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_9c2d43a2-46db-4c37-94e8-a891f97711dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a4e1262a-ccab-48df-9c10-866becca6619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5ec8ea0-4157-4331-b9dd-868748565a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a4e1262a-ccab-48df-9c10-866becca6619" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5ec8ea0-4157-4331-b9dd-868748565a44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51ef7685-9f82-4175-8c0a-c8636121cf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a4e1262a-ccab-48df-9c10-866becca6619" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51ef7685-9f82-4175-8c0a-c8636121cf9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5fe19edb-dbb3-447e-bc9d-3073480988df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a4e1262a-ccab-48df-9c10-866becca6619" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5fe19edb-dbb3-447e-bc9d-3073480988df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7856d432-d8b2-493a-af95-b01d19e250aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a4e1262a-ccab-48df-9c10-866becca6619" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7856d432-d8b2-493a-af95-b01d19e250aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_394c8460-fb3a-4be5-8766-1e6aeef24cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_2a4a6487-67ad-4934-b900-b292c33d43ad" xlink:href="dare-20220331.xsd#dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_394c8460-fb3a-4be5-8766-1e6aeef24cd8" xlink:to="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_2a4a6487-67ad-4934-b900-b292c33d43ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_16d7a25d-4a12-4dd9-823a-d309975a6a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_394c8460-fb3a-4be5-8766-1e6aeef24cd8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_16d7a25d-4a12-4dd9-823a-d309975a6a4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_90cbfe85-906a-46c9-b1bc-19d02d915cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_394c8460-fb3a-4be5-8766-1e6aeef24cd8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_90cbfe85-906a-46c9-b1bc-19d02d915cb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_3e180f91-6eae-4c8e-a517-499d97380768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_394c8460-fb3a-4be5-8766-1e6aeef24cd8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_3e180f91-6eae-4c8e-a517-499d97380768" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_IncreaseDecreaseInDeferredGrantFunding_fd301106-3b6d-4df2-8e55-42d62f88f088" xlink:href="dare-20220331.xsd#dare_IncreaseDecreaseInDeferredGrantFunding"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_394c8460-fb3a-4be5-8766-1e6aeef24cd8" xlink:to="loc_dare_IncreaseDecreaseInDeferredGrantFunding_fd301106-3b6d-4df2-8e55-42d62f88f088" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_54382ed4-b1d4-43a4-85a5-3a6298a70b52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_394c8460-fb3a-4be5-8766-1e6aeef24cd8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_54382ed4-b1d4-43a4-85a5-3a6298a70b52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NonCashLeaseExpense_87470b5f-fec0-4679-9634-08987ef3bc56" xlink:href="dare-20220331.xsd#dare_NonCashLeaseExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_394c8460-fb3a-4be5-8766-1e6aeef24cd8" xlink:to="loc_dare_NonCashLeaseExpense_87470b5f-fec0-4679-9634-08987ef3bc56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_f6fe3d00-7e33-40c6-b08d-08d11f8da065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_394c8460-fb3a-4be5-8766-1e6aeef24cd8" xlink:to="loc_us-gaap_Depreciation_f6fe3d00-7e33-40c6-b08d-08d11f8da065" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e483bd0e-12c1-412e-8664-31a943d8d64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_394c8460-fb3a-4be5-8766-1e6aeef24cd8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e483bd0e-12c1-412e-8664-31a943d8d64b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b2e12b08-6347-4bdd-bca4-871dfbeaf24c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_394c8460-fb3a-4be5-8766-1e6aeef24cd8" xlink:to="loc_us-gaap_ShareBasedCompensation_b2e12b08-6347-4bdd-bca4-871dfbeaf24c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f1351060-84a0-4e01-8326-abded1b7166c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_394c8460-fb3a-4be5-8766-1e6aeef24cd8" xlink:to="loc_us-gaap_NetIncomeLoss_f1351060-84a0-4e01-8326-abded1b7166c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_43553f2a-c198-4a6c-a73d-8a36e21205eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0242f397-83d4-4820-98a1-1839b4ded0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_43553f2a-c198-4a6c-a73d-8a36e21205eb" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0242f397-83d4-4820-98a1-1839b4ded0cb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#LeasedPropertiesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_55470eea-f047-45af-a0a6-612068cb204f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_54d3c5d2-9177-43e8-90c1-921f4f5c075a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_55470eea-f047-45af-a0a6-612068cb204f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_54d3c5d2-9177-43e8-90c1-921f4f5c075a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5dfb2786-29a8-4799-a525-e0d9ba6af8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_55470eea-f047-45af-a0a6-612068cb204f" xlink:to="loc_us-gaap_OperatingLeaseLiability_5dfb2786-29a8-4799-a525-e0d9ba6af8ae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="dare-20220331.xsd#LeasedPropertiesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f6264705-5342-457d-9b98-5fa49c1e9ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2ee76a8d-ef56-4936-a096-2f40cd6d0ead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f6264705-5342-457d-9b98-5fa49c1e9ce2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2ee76a8d-ef56-4936-a096-2f40cd6d0ead" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8cf69ece-a103-473a-81f1-6628c75e7333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f6264705-5342-457d-9b98-5fa49c1e9ce2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8cf69ece-a103-473a-81f1-6628c75e7333" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5ed55e37-8102-47d7-af71-904c528640db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f6264705-5342-457d-9b98-5fa49c1e9ce2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5ed55e37-8102-47d7-af71-904c528640db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ccc46e8b-ffe6-4a19-add4-c0f80bdcd844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f6264705-5342-457d-9b98-5fa49c1e9ce2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ccc46e8b-ffe6-4a19-add4-c0f80bdcd844" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>dare-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:fd319a35-eb86-476b-85ca-f1b0e0a14df0,g:c97ede0a-3f8a-49b3-9abb-a622ab8bee13-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="dare-20220331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended" id="i6bfac079d6d145cfba1c95a521ba2cd7_CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c8ca5018-d279-4fb7-acca-65dc2f88e455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c8ca5018-d279-4fb7-acca-65dc2f88e455" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3134b506-88a4-4e96-b7c3-4edfce9603b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:to="loc_us-gaap_SharesOutstanding_3134b506-88a4-4e96-b7c3-4edfce9603b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b279ab90-01b9-4c1b-85f1-274965ea6400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:to="loc_us-gaap_StockholdersEquity_b279ab90-01b9-4c1b-85f1-274965ea6400" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c9e7b9e4-5269-4a07-8ee9-1dd095b18a01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c9e7b9e4-5269-4a07-8ee9-1dd095b18a01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_25b46119-c81d-4d89-bb03-2cf17a824b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_25b46119-c81d-4d89-bb03-2cf17a824b78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1d49dc77-7147-4b2b-b40e-29456ad09c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1d49dc77-7147-4b2b-b40e-29456ad09c3a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_e1accce4-bc0b-446d-88c8-24f40374dd40" xlink:href="dare-20220331.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:to="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_e1accce4-bc0b-446d-88c8-24f40374dd40" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_bd3edb3b-0dfb-4d01-b228-303c71f72f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_bd3edb3b-0dfb-4d01-b228-303c71f72f2d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_474f859c-2040-4aa3-8b2a-5abe431c501c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:to="loc_us-gaap_NetIncomeLoss_474f859c-2040-4aa3-8b2a-5abe431c501c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_93b9b149-d30a-4b87-a283-fd6b72547e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_93b9b149-d30a-4b87-a283-fd6b72547e5e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_63b056a1-3932-4007-adbf-33cde9c5ae40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3a9b5304-5c40-47b5-8579-f266687acd46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4ff5721d-529a-49ac-9566-dc3023e52b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c8ca5018-d279-4fb7-acca-65dc2f88e455" xlink:to="loc_us-gaap_StatementTable_4ff5721d-529a-49ac-9566-dc3023e52b6c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2ff1c311-355e-4dc4-a677-eb810c46ef3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4ff5721d-529a-49ac-9566-dc3023e52b6c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2ff1c311-355e-4dc4-a677-eb810c46ef3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2ff1c311-355e-4dc4-a677-eb810c46ef3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2ff1c311-355e-4dc4-a677-eb810c46ef3c" xlink:to="loc_us-gaap_EquityComponentDomain_2ff1c311-355e-4dc4-a677-eb810c46ef3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d057ee64-8609-4dc6-ba55-8046605dfd23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2ff1c311-355e-4dc4-a677-eb810c46ef3c" xlink:to="loc_us-gaap_EquityComponentDomain_d057ee64-8609-4dc6-ba55-8046605dfd23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_adf055fa-56c9-408f-87bf-29c5f1002922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d057ee64-8609-4dc6-ba55-8046605dfd23" xlink:to="loc_us-gaap_CommonStockMember_adf055fa-56c9-408f-87bf-29c5f1002922" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_296eaa62-236c-4366-9940-a632c3f5742d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d057ee64-8609-4dc6-ba55-8046605dfd23" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_296eaa62-236c-4366-9940-a632c3f5742d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8520a420-6c43-4f5d-911c-7b7702769bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d057ee64-8609-4dc6-ba55-8046605dfd23" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8520a420-6c43-4f5d-911c-7b7702769bb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6ddf373d-cb9a-43b9-a1a2-83e64b107243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d057ee64-8609-4dc6-ba55-8046605dfd23" xlink:to="loc_us-gaap_RetainedEarningsMember_6ddf373d-cb9a-43b9-a1a2-83e64b107243" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i4f7938a6dc7448bfb9ee25a82c8408e1_BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:href="dare-20220331.xsd#dare_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_29caebe2-a344-4cf3-b679-4b1033aae8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_29caebe2-a344-4cf3-b679-4b1033aae8f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e9778099-b3f4-4c13-97ca-eb0a9cddf6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e9778099-b3f4-4c13-97ca-eb0a9cddf6f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WorkingCapitalIncreaseDeficit_1a14777f-37bf-4509-a48b-af36ed3dc1cb" xlink:href="dare-20220331.xsd#dare_WorkingCapitalIncreaseDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_dare_WorkingCapitalIncreaseDeficit_1a14777f-37bf-4509-a48b-af36ed3dc1cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_528aad66-d38f-487f-90cf-34645d380851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_us-gaap_NetIncomeLoss_528aad66-d38f-487f-90cf-34645d380851" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b9e986b4-0dcc-4d11-b6b6-22e8be3b39ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b9e986b4-0dcc-4d11-b6b6-22e8be3b39ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UpfrontLicenseFeeAmountPaid_aea70dcb-0402-44da-8c2d-7c9cced4037f" xlink:href="dare-20220331.xsd#dare_UpfrontLicenseFeeAmountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_dare_UpfrontLicenseFeeAmountPaid_aea70dcb-0402-44da-8c2d-7c9cced4037f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmount_33b36967-8c99-416a-a778-d05f53a637b5" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsContingentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_dare_MilestonePaymentsContingentAmount_33b36967-8c99-416a-a778-d05f53a637b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_07d20379-f137-40b6-8dfc-febaefb10bc7" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_07d20379-f137-40b6-8dfc-febaefb10bc7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount_77f8655d-53fd-4986-8793-daed015cbef3" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount_77f8655d-53fd-4986-8793-daed015cbef3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PeriodofInsufficientCashandLiquidityRequirements_97fdda6d-0b80-4009-985b-3fbc5f87deae" xlink:href="dare-20220331.xsd#dare_PeriodofInsufficientCashandLiquidityRequirements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_dare_PeriodofInsufficientCashandLiquidityRequirements_97fdda6d-0b80-4009-985b-3fbc5f87deae" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_007d7a33-ca03-478b-9f28-bb2f3efd3b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_007d7a33-ca03-478b-9f28-bb2f3efd3b29" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UpfrontLicenseFeePaid_db3b3315-ed35-43ff-b3e6-f245972eb683" xlink:href="dare-20220331.xsd#dare_UpfrontLicenseFeePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_dare_UpfrontLicenseFeePaid_db3b3315-ed35-43ff-b3e6-f245972eb683" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f6f29f25-1603-45d8-bc12-4b2b50a13827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f6f29f25-1603-45d8-bc12-4b2b50a13827" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesTable_92118821-34ce-4791-8e8e-d8adf7c7a376" xlink:href="dare-20220331.xsd#dare_SignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_dare_SignificantAccountingPoliciesTable_92118821-34ce-4791-8e8e-d8adf7c7a376" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c7738d8a-f7ab-4959-8cde-e9858e2c23a6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_SignificantAccountingPoliciesTable_92118821-34ce-4791-8e8e-d8adf7c7a376" xlink:to="loc_srt_CounterpartyNameAxis_c7738d8a-f7ab-4959-8cde-e9858e2c23a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7738d8a-f7ab-4959-8cde-e9858e2c23a6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c7738d8a-f7ab-4959-8cde-e9858e2c23a6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7738d8a-f7ab-4959-8cde-e9858e2c23a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_873ea665-7783-4b21-9341-8c01a1568b64" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c7738d8a-f7ab-4959-8cde-e9858e2c23a6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_873ea665-7783-4b21-9341-8c01a1568b64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_OrganonMember_9c2be024-5957-422c-aa65-912858fc7f4b" xlink:href="dare-20220331.xsd#dare_OrganonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_873ea665-7783-4b21-9341-8c01a1568b64" xlink:to="loc_dare_OrganonMember_9c2be024-5957-422c-aa65-912858fc7f4b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails" xlink:type="extended" id="i464fb1ee84444308bfae7e03d56fec62_BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c6f66a6-753f-4d4a-8cfd-10785e229223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ab1b2c6e-d971-419e-acbd-b4f4f587c9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c6f66a6-753f-4d4a-8cfd-10785e229223" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ab1b2c6e-d971-419e-acbd-b4f4f587c9cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d88e43bb-9595-46f9-81a5-c2a2f637a314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c6f66a6-753f-4d4a-8cfd-10785e229223" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d88e43bb-9595-46f9-81a5-c2a2f637a314" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b14d906-4c1e-4a05-b601-687bda59c5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d88e43bb-9595-46f9-81a5-c2a2f637a314" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b14d906-4c1e-4a05-b601-687bda59c5ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4b14d906-4c1e-4a05-b601-687bda59c5ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b14d906-4c1e-4a05-b601-687bda59c5ea" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4b14d906-4c1e-4a05-b601-687bda59c5ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_91ea6c91-df01-408d-93fb-3c704878226d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b14d906-4c1e-4a05-b601-687bda59c5ea" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_91ea6c91-df01-408d-93fb-3c704878226d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_dd64a0bc-0112-4e3d-bffd-20ba4596cff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_91ea6c91-df01-408d-93fb-3c704878226d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_dd64a0bc-0112-4e3d-bffd-20ba4596cff2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beb18af6-5283-4afd-9527-c3d7bf7f78c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d88e43bb-9595-46f9-81a5-c2a2f637a314" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beb18af6-5283-4afd-9527-c3d7bf7f78c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_beb18af6-5283-4afd-9527-c3d7bf7f78c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beb18af6-5283-4afd-9527-c3d7bf7f78c2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_beb18af6-5283-4afd-9527-c3d7bf7f78c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bbaa160f-f5f7-470d-90b4-5a2ec737005f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beb18af6-5283-4afd-9527-c3d7bf7f78c2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bbaa160f-f5f7-470d-90b4-5a2ec737005f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6845b954-7f94-49e3-8169-8875dbd3fd79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bbaa160f-f5f7-470d-90b4-5a2ec737005f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6845b954-7f94-49e3-8169-8875dbd3fd79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8979259b-e14b-4944-8a7a-eb2009c61693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bbaa160f-f5f7-470d-90b4-5a2ec737005f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8979259b-e14b-4944-8a7a-eb2009c61693" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_06b1fa56-9d79-437b-b5f8-6c8d83c267af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bbaa160f-f5f7-470d-90b4-5a2ec737005f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_06b1fa56-9d79-437b-b5f8-6c8d83c267af" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StrategicAgreementsDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#StrategicAgreementsDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StrategicAgreementsDetails" xlink:type="extended" id="i390c60afca5e4e7d988c40c9bd47f404_StrategicAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UpfrontLicenseFeeAmountPaid_c0d9e5c1-cce9-4b1c-9d78-1b62c396e197" xlink:href="dare-20220331.xsd#dare_UpfrontLicenseFeeAmountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_UpfrontLicenseFeeAmountPaid_c0d9e5c1-cce9-4b1c-9d78-1b62c396e197" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmount_8c6dcfff-edc3-40d3-b260-fb842af90c4d" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsContingentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_MilestonePaymentsContingentAmount_8c6dcfff-edc3-40d3-b260-fb842af90c4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_db2be150-70f0-4121-96d4-28448cefd045" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_db2be150-70f0-4121-96d4-28448cefd045" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount_00f2e8f5-459c-4c0a-b489-58a9fbd1c7e9" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount_00f2e8f5-459c-4c0a-b489-58a9fbd1c7e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsTerm_216da86d-1488-4e13-af46-fa5c5645e3c8" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_MilestonePaymentsTerm_216da86d-1488-4e13-af46-fa5c5645e3c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UpfrontLicenseFeePaid_d2a0bf84-6122-4043-9ff1-d582df6f477e" xlink:href="dare-20220331.xsd#dare_UpfrontLicenseFeePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_UpfrontLicenseFeePaid_d2a0bf84-6122-4043-9ff1-d582df6f477e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5d9b4b3e-bb67-4747-8350-a2c68f57cc6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5d9b4b3e-bb67-4747-8350-a2c68f57cc6b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementInitialTerm_7912033d-aa4f-457b-9fe3-65cb33d7dad4" xlink:href="dare-20220331.xsd#dare_LicenseAgreementInitialTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_LicenseAgreementInitialTerm_7912033d-aa4f-457b-9fe3-65cb33d7dad4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseFee_50c51cfb-1574-464f-9976-91c09f99898f" xlink:href="dare-20220331.xsd#dare_LicenseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_LicenseFee_50c51cfb-1574-464f-9976-91c09f99898f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseFeeToBePaidUponContingency_a1f8cc42-e1f6-4b12-9d30-5e2d17ecff4c" xlink:href="dare-20220331.xsd#dare_LicenseFeeToBePaidUponContingency"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_LicenseFeeToBePaidUponContingency_a1f8cc42-e1f6-4b12-9d30-5e2d17ecff4c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsideration_57610b2e-1909-4285-9875-ac8cd4c0bfa1" xlink:href="dare-20220331.xsd#dare_AssetAcquisitionContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_AssetAcquisitionContingentConsideration_57610b2e-1909-4285-9875-ac8cd4c0bfa1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_RoyaltyAgreementTerm_190cbded-ea2e-4bc0-ad2e-ac0b58a75773" xlink:href="dare-20220331.xsd#dare_RoyaltyAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_RoyaltyAgreementTerm_190cbded-ea2e-4bc0-ad2e-ac0b58a75773" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct_6a1b882f-088a-4688-88d0-450906cd36d7" xlink:href="dare-20220331.xsd#dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct_6a1b882f-088a-4688-88d0-450906cd36d7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_b76499bb-4a30-48a2-a384-8e4b1a403b4e" xlink:href="dare-20220331.xsd#dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_b76499bb-4a30-48a2-a384-8e4b1a403b4e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTermination_1ac5a7ea-84f4-4c52-8e84-055c98610fee" xlink:href="dare-20220331.xsd#dare_LicenseAgreementNoticePeriodOfTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_LicenseAgreementNoticePeriodOfTermination_1ac5a7ea-84f4-4c52-8e84-055c98610fee" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ResearchAndDevelopmentMilestonePayment_f3a2db04-cd2d-460b-ac89-520268d26068" xlink:href="dare-20220331.xsd#dare_ResearchAndDevelopmentMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_ResearchAndDevelopmentMilestonePayment_f3a2db04-cd2d-460b-ac89-520268d26068" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfRoyaltyRate_54776b69-f761-4bea-a071-bc589d9726b5" xlink:href="dare-20220331.xsd#dare_PercentageOfRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_PercentageOfRoyaltyRate_54776b69-f761-4bea-a071-bc589d9726b5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_c5362064-bcea-4c1c-87f4-5f5d3180704e" xlink:href="dare-20220331.xsd#dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_c5362064-bcea-4c1c-87f4-5f5d3180704e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_6b57a5e8-89a4-40c8-8601-8dc33a1bc0e6" xlink:href="dare-20220331.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_6b57a5e8-89a4-40c8-8601-8dc33a1bc0e6" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_5ca28c21-0022-4e58-93de-365b3be871ff" xlink:href="dare-20220331.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_5ca28c21-0022-4e58-93de-365b3be871ff" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MaximumPotentialMilestonePayments_36170272-118e-49cd-8982-2c6740ffa5e9" xlink:href="dare-20220331.xsd#dare_MaximumPotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_MaximumPotentialMilestonePayments_36170272-118e-49cd-8982-2c6740ffa5e9" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostMaintenance_0ece14c2-32c7-4573-9216-671f3a060d26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostMaintenance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_us-gaap_CostMaintenance_0ece14c2-32c7-4573-9216-671f3a060d26" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountPayableNet_a21f8f17-b76b-48b7-becf-a3767155964b" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsContingentAmountPayableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_MilestonePaymentsContingentAmountPayableNet_a21f8f17-b76b-48b7-becf-a3767155964b" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_785176f8-02e6-462d-a9f0-e7d0a4243c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_785176f8-02e6-462d-a9f0-e7d0a4243c4c" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_3b9e2257-efb5-49c7-95e2-5dfe7cb1e207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_39462533-9aaf-4b98-a1fe-ddbf35b30441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_39462533-9aaf-4b98-a1fe-ddbf35b30441" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_7f0267dd-a6db-4304-9661-85909101d1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_7f0267dd-a6db-4304-9661-85909101d1fd" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1f9739cb-2aee-412d-8def-65e1389112fd" xlink:href="dare-20220331.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1f9739cb-2aee-412d-8def-65e1389112fd" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_295bf075-4d5f-4ed6-a723-9b05ae139aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_295bf075-4d5f-4ed6-a723-9b05ae139aaf" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsiderationCurrent_c9b09dce-ec9f-4906-bf07-3358279f6279" xlink:href="dare-20220331.xsd#dare_AssetAcquisitionContingentConsiderationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_AssetAcquisitionContingentConsiderationCurrent_c9b09dce-ec9f-4906-bf07-3358279f6279" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_d2a02f99-0c7e-487e-ad6e-776c47eb5ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_d2a02f99-0c7e-487e-ad6e-776c47eb5ed9" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f473be8c-2f90-434b-b61e-62543fa7f9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f473be8c-2f90-434b-b61e-62543fa7f9ae" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PaymentsToStockholdersRepresentativeInBusinessCombination_147aeaac-e4ef-4e1c-857e-5079b36e81c6" xlink:href="dare-20220331.xsd#dare_PaymentsToStockholdersRepresentativeInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_PaymentsToStockholdersRepresentativeInBusinessCombination_147aeaac-e4ef-4e1c-857e-5079b36e81c6" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PaymentOfAdditionalConsiderationInBusinessCombination_a937b562-287b-4c2f-b9cb-5dac41f6620c" xlink:href="dare-20220331.xsd#dare_PaymentOfAdditionalConsiderationInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_PaymentOfAdditionalConsiderationInBusinessCombination_a937b562-287b-4c2f-b9cb-5dac41f6620c" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e45eba88-e39c-4a1c-8003-cb3f72069f78" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_srt_CounterpartyNameAxis_e45eba88-e39c-4a1c-8003-cb3f72069f78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e45eba88-e39c-4a1c-8003-cb3f72069f78_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e45eba88-e39c-4a1c-8003-cb3f72069f78" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e45eba88-e39c-4a1c-8003-cb3f72069f78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6afa8524-853a-4fbc-91a1-f915c52d2f13" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e45eba88-e39c-4a1c-8003-cb3f72069f78" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6afa8524-853a-4fbc-91a1-f915c52d2f13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_OrganonMember_3549bdd8-924f-44a2-bc25-cb4e3a063aba" xlink:href="dare-20220331.xsd#dare_OrganonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6afa8524-853a-4fbc-91a1-f915c52d2f13" xlink:to="loc_dare_OrganonMember_3549bdd8-924f-44a2-bc25-cb4e3a063aba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilanaPharmMember_cdf3faed-ab12-4070-9655-7b9f9daf72b4" xlink:href="dare-20220331.xsd#dare_MilanaPharmMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6afa8524-853a-4fbc-91a1-f915c52d2f13" xlink:to="loc_dare_MilanaPharmMember_cdf3faed-ab12-4070-9655-7b9f9daf72b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CatalentAndMilanaPharmMember_ce05dc16-b6c9-46aa-bca3-8a35999fb1d6" xlink:href="dare-20220331.xsd#dare_CatalentAndMilanaPharmMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6afa8524-853a-4fbc-91a1-f915c52d2f13" xlink:to="loc_dare_CatalentAndMilanaPharmMember_ce05dc16-b6c9-46aa-bca3-8a35999fb1d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_148d6e12-ba52-4717-82e6-6599e7789d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_us-gaap_TypeOfArrangementAxis_148d6e12-ba52-4717-82e6-6599e7789d7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_148d6e12-ba52-4717-82e6-6599e7789d7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_148d6e12-ba52-4717-82e6-6599e7789d7f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_148d6e12-ba52-4717-82e6-6599e7789d7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b8eea63-1406-4e41-9b82-ee6a47fd94a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_148d6e12-ba52-4717-82e6-6599e7789d7f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b8eea63-1406-4e41-9b82-ee6a47fd94a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BayerHealthcareLicenseAgreementMember_c1afc7c1-b595-419a-b8d1-113dd8f2f036" xlink:href="dare-20220331.xsd#dare_BayerHealthcareLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b8eea63-1406-4e41-9b82-ee6a47fd94a4" xlink:to="loc_dare_BayerHealthcareLicenseAgreementMember_c1afc7c1-b595-419a-b8d1-113dd8f2f036" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_22642995-dbc3-46de-a4ae-5c0f8cac023e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b8eea63-1406-4e41-9b82-ee6a47fd94a4" xlink:to="loc_us-gaap_LicensingAgreementsMember_22642995-dbc3-46de-a4ae-5c0f8cac023e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssignmentAgreementMember_62bf4955-3da9-4bd6-8626-bbb8d09b6182" xlink:href="dare-20220331.xsd#dare_AssignmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b8eea63-1406-4e41-9b82-ee6a47fd94a4" xlink:to="loc_dare_AssignmentAgreementMember_62bf4955-3da9-4bd6-8626-bbb8d09b6182" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAndCollaborationAgreementMember_6b459b4f-a88f-486b-9d47-dd8db8d7f50f" xlink:href="dare-20220331.xsd#dare_LicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b8eea63-1406-4e41-9b82-ee6a47fd94a4" xlink:to="loc_dare_LicenseAndCollaborationAgreementMember_6b459b4f-a88f-486b-9d47-dd8db8d7f50f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_JuniperPharmaceuticalsInc.Member_900215d8-6a05-458e-bfac-a87d8c9eda8d" xlink:href="dare-20220331.xsd#dare_JuniperPharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b8eea63-1406-4e41-9b82-ee6a47fd94a4" xlink:to="loc_dare_JuniperPharmaceuticalsInc.Member_900215d8-6a05-458e-bfac-a87d8c9eda8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e137612b-1853-4982-807a-a3c6af6cf3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e137612b-1853-4982-807a-a3c6af6cf3c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e137612b-1853-4982-807a-a3c6af6cf3c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e137612b-1853-4982-807a-a3c6af6cf3c5" xlink:to="loc_us-gaap_RelatedPartyDomain_e137612b-1853-4982-807a-a3c6af6cf3c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_241f493d-9cde-4418-af4c-5b625d3bc8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e137612b-1853-4982-807a-a3c6af6cf3c5" xlink:to="loc_us-gaap_RelatedPartyDomain_241f493d-9cde-4418-af4c-5b625d3bc8b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilanaPharmMember_b2c1a38c-c7cd-4c98-b3d4-28f840eb3b51" xlink:href="dare-20220331.xsd#dare_MilanaPharmMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_241f493d-9cde-4418-af4c-5b625d3bc8b8" xlink:to="loc_dare_MilanaPharmMember_b2c1a38c-c7cd-4c98-b3d4-28f840eb3b51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_HammockPharmaceuticalsInc.Member_1a01c141-c1c0-4feb-b80c-980190680800" xlink:href="dare-20220331.xsd#dare_HammockPharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_241f493d-9cde-4418-af4c-5b625d3bc8b8" xlink:to="loc_dare_HammockPharmaceuticalsInc.Member_1a01c141-c1c0-4feb-b80c-980190680800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_e38b555f-0564-42c3-a7ab-71e32f8dcbc5" xlink:href="dare-20220331.xsd#dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_241f493d-9cde-4418-af4c-5b625d3bc8b8" xlink:to="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_e38b555f-0564-42c3-a7ab-71e32f8dcbc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_4d5220cf-dce4-4f6e-a643-34a3bc254194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_4d5220cf-dce4-4f6e-a643-34a3bc254194" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_4d5220cf-dce4-4f6e-a643-34a3bc254194_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_4d5220cf-dce4-4f6e-a643-34a3bc254194" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_4d5220cf-dce4-4f6e-a643-34a3bc254194_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c18a23c2-379f-4dd2-8942-2e243f283ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_4d5220cf-dce4-4f6e-a643-34a3bc254194" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c18a23c2-379f-4dd2-8942-2e243f283ef9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainDevelopmentMilestonesMember_cd160fcb-62df-4c00-8017-e17d371b0ef4" xlink:href="dare-20220331.xsd#dare_UponAchievingCertainDevelopmentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_c18a23c2-379f-4dd2-8942-2e243f283ef9" xlink:to="loc_dare_UponAchievingCertainDevelopmentMilestonesMember_cd160fcb-62df-4c00-8017-e17d371b0ef4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainCommercialMilestonesMember_7c31e85d-686a-49ee-ad4d-c4c8f9d3e136" xlink:href="dare-20220331.xsd#dare_UponAchievingCertainCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_c18a23c2-379f-4dd2-8942-2e243f283ef9" xlink:to="loc_dare_UponAchievingCertainCommercialMilestonesMember_7c31e85d-686a-49ee-ad4d-c4c8f9d3e136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember_89fc343b-b551-4e8b-909d-4c86b02043cf" xlink:href="dare-20220331.xsd#dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_c18a23c2-379f-4dd2-8942-2e243f283ef9" xlink:to="loc_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember_89fc343b-b551-4e8b-909d-4c86b02043cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_796046f8-bc7a-4c87-b901-f44fe2f95a9e" xlink:href="dare-20220331.xsd#dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_c18a23c2-379f-4dd2-8942-2e243f283ef9" xlink:to="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_796046f8-bc7a-4c87-b901-f44fe2f95a9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c0ccef61-083d-46fc-b345-8e546e615aed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_srt_RangeAxis_c0ccef61-083d-46fc-b345-8e546e615aed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c0ccef61-083d-46fc-b345-8e546e615aed_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c0ccef61-083d-46fc-b345-8e546e615aed" xlink:to="loc_srt_RangeMember_c0ccef61-083d-46fc-b345-8e546e615aed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fe6ec243-89eb-416c-ae60-c60938fc4f62" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c0ccef61-083d-46fc-b345-8e546e615aed" xlink:to="loc_srt_RangeMember_fe6ec243-89eb-416c-ae60-c60938fc4f62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_206daf29-fc19-4ce1-80d1-c9d9093fe05f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fe6ec243-89eb-416c-ae60-c60938fc4f62" xlink:to="loc_srt_MaximumMember_206daf29-fc19-4ce1-80d1-c9d9093fe05f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_60d5cc85-ab23-4f69-bb9a-c2164235e742" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fe6ec243-89eb-416c-ae60-c60938fc4f62" xlink:to="loc_srt_MinimumMember_60d5cc85-ab23-4f69-bb9a-c2164235e742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7bf75df6-0045-4281-b32f-46651dd01f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7bf75df6-0045-4281-b32f-46651dd01f44" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7bf75df6-0045-4281-b32f-46651dd01f44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7bf75df6-0045-4281-b32f-46651dd01f44" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7bf75df6-0045-4281-b32f-46651dd01f44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2bfaafc0-1022-4224-9630-bba597120bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7bf75df6-0045-4281-b32f-46651dd01f44" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2bfaafc0-1022-4224-9630-bba597120bb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ADVATecAgreementMember_987ae5e5-7691-4da8-95ad-bdce30439bee" xlink:href="dare-20220331.xsd#dare_ADVATecAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2bfaafc0-1022-4224-9630-bba597120bb0" xlink:to="loc_dare_ADVATecAgreementMember_987ae5e5-7691-4da8-95ad-bdce30439bee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ClinicalAndRegulatoryMilestonesMember_d9bf088b-b1b4-4337-b156-a0e13027ac39" xlink:href="dare-20220331.xsd#dare_ClinicalAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2bfaafc0-1022-4224-9630-bba597120bb0" xlink:to="loc_dare_ClinicalAndRegulatoryMilestonesMember_d9bf088b-b1b4-4337-b156-a0e13027ac39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SalesMilestonesMember_10793da0-b7a5-449c-891f-09690f5f419d" xlink:href="dare-20220331.xsd#dare_SalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2bfaafc0-1022-4224-9630-bba597120bb0" xlink:to="loc_dare_SalesMilestonesMember_10793da0-b7a5-449c-891f-09690f5f419d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7a4f8d42-d085-40ad-b33c-550c7f270e92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7a4f8d42-d085-40ad-b33c-550c7f270e92" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_7a4f8d42-d085-40ad-b33c-550c7f270e92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7a4f8d42-d085-40ad-b33c-550c7f270e92" xlink:to="loc_us-gaap_ProjectMember_7a4f8d42-d085-40ad-b33c-550c7f270e92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_6ff619c6-b612-4808-80a2-01b37c6520c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7a4f8d42-d085-40ad-b33c-550c7f270e92" xlink:to="loc_us-gaap_ProjectMember_6ff619c6-b612-4808-80a2-01b37c6520c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_5f48a18b-4a2d-4bb6-9db9-ef9321ead8d3" xlink:href="dare-20220331.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_6ff619c6-b612-4808-80a2-01b37c6520c2" xlink:to="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_5f48a18b-4a2d-4bb6-9db9-ef9321ead8d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_d7364c88-9122-4e8d-9b68-606130654c1f" xlink:href="dare-20220331.xsd#dare_UponReachingCertainWorldwideNetSalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_6ff619c6-b612-4808-80a2-01b37c6520c2" xlink:to="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_d7364c88-9122-4e8d-9b68-606130654c1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3ef8dc84-8a36-4089-a81c-f97789df0e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3ef8dc84-8a36-4089-a81c-f97789df0e15" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ef8dc84-8a36-4089-a81c-f97789df0e15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3ef8dc84-8a36-4089-a81c-f97789df0e15" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ef8dc84-8a36-4089-a81c-f97789df0e15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_878dcd58-7b8c-4788-98f7-5dd4257e4424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3ef8dc84-8a36-4089-a81c-f97789df0e15" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_878dcd58-7b8c-4788-98f7-5dd4257e4424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MicrochipsBiotechInc.Member_99a93cf6-e42b-4087-bfd5-84b66a52354f" xlink:href="dare-20220331.xsd#dare_MicrochipsBiotechInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_878dcd58-7b8c-4788-98f7-5dd4257e4424" xlink:to="loc_dare_MicrochipsBiotechInc.Member_99a93cf6-e42b-4087-bfd5-84b66a52354f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_79ff3115-290f-4994-8ef6-bd0b3b2b0e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_us-gaap_StatementClassOfStockAxis_79ff3115-290f-4994-8ef6-bd0b3b2b0e78" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_79ff3115-290f-4994-8ef6-bd0b3b2b0e78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_79ff3115-290f-4994-8ef6-bd0b3b2b0e78" xlink:to="loc_us-gaap_ClassOfStockDomain_79ff3115-290f-4994-8ef6-bd0b3b2b0e78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ea8211c8-d9aa-43ba-a86d-4587e1845f56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_79ff3115-290f-4994-8ef6-bd0b3b2b0e78" xlink:to="loc_us-gaap_ClassOfStockDomain_ea8211c8-d9aa-43ba-a86d-4587e1845f56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_308e2b72-27d5-4a21-b296-554b1ff12df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ea8211c8-d9aa-43ba-a86d-4587e1845f56" xlink:to="loc_us-gaap_CommonStockMember_308e2b72-27d5-4a21-b296-554b1ff12df1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_29e5f211-d7db-448d-a26b-e85cf6bcec5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_29e5f211-d7db-448d-a26b-e85cf6bcec5e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_29e5f211-d7db-448d-a26b-e85cf6bcec5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_29e5f211-d7db-448d-a26b-e85cf6bcec5e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_29e5f211-d7db-448d-a26b-e85cf6bcec5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f61ac2e6-98d1-4f12-94fc-542281e6a76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_29e5f211-d7db-448d-a26b-e85cf6bcec5e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f61ac2e6-98d1-4f12-94fc-542281e6a76b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_268bf69c-b9eb-476c-9c19-0b507a1d3d55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f61ac2e6-98d1-4f12-94fc-542281e6a76b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_268bf69c-b9eb-476c-9c19-0b507a1d3d55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_f1cf9c3e-c92f-49c9-9edb-c0559abcf2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_f1cf9c3e-c92f-49c9-9edb-c0559abcf2bd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_f1cf9c3e-c92f-49c9-9edb-c0559abcf2bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_f1cf9c3e-c92f-49c9-9edb-c0559abcf2bd" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_f1cf9c3e-c92f-49c9-9edb-c0559abcf2bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_a5b9cf6b-2153-4b53-8184-ed8ec1097ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_f1cf9c3e-c92f-49c9-9edb-c0559abcf2bd" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_a5b9cf6b-2153-4b53-8184-ed8ec1097ca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_923632ad-35dd-4f22-a185-6a7da6f0d6db" xlink:href="dare-20220331.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_a5b9cf6b-2153-4b53-8184-ed8ec1097ca7" xlink:to="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_923632ad-35dd-4f22-a185-6a7da6f0d6db" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended" id="i65263d62e1404b3d90148c35fd891eba_StockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:href="dare-20220331.xsd#dare_StockholdersEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfAggregateCommission_5c43370c-74bd-49c7-a813-b2e39b576dc2" xlink:href="dare-20220331.xsd#dare_PercentageOfAggregateCommission"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_dare_PercentageOfAggregateCommission_5c43370c-74bd-49c7-a813-b2e39b576dc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6be9b6f8-4224-46e9-be46-5586ebdfddf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_us-gaap_CommonStockValue_6be9b6f8-4224-46e9-be46-5586ebdfddf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_6ef9fe9d-dc42-4457-aa36-1320932dd534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_us-gaap_PurchaseObligation_6ef9fe9d-dc42-4457-aa36-1320932dd534" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_3e16d3c3-5fb9-478a-a126-8f49f891cd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_us-gaap_DeferredOfferingCosts_3e16d3c3-5fb9-478a-a126-8f49f891cd2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredOfferingCostsUnamortizedPortion_1edeb3c9-4a65-4f96-bbdb-cb3e56ce88d5" xlink:href="dare-20220331.xsd#dare_DeferredOfferingCostsUnamortizedPortion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_dare_DeferredOfferingCostsUnamortizedPortion_1edeb3c9-4a65-4f96-bbdb-cb3e56ce88d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_47abec84-8f7c-412f-90b8-7943bcc9923c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_47abec84-8f7c-412f-90b8-7943bcc9923c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_2202ef67-2030-4db4-b482-cff72b44eec5" xlink:href="dare-20220331.xsd#dare_EstimatedFairValueOfWarrantsRecordedInEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_2202ef67-2030-4db4-b482-cff72b44eec5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease_006a7d0d-8bc2-4a3d-9644-5288fbcd066c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_us-gaap_WarrantExercisePriceDecrease_006a7d0d-8bc2-4a3d-9644-5288fbcd066c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature_2d0d3f84-e856-4241-bdb3-f720da291208" xlink:href="dare-20220331.xsd#dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature_2d0d3f84-e856-4241-bdb3-f720da291208" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NumberOfCommonStockWarrantsExercised_f35bf81a-3c56-4c19-83b7-24641cab3abf" xlink:href="dare-20220331.xsd#dare_NumberOfCommonStockWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_dare_NumberOfCommonStockWarrantsExercised_f35bf81a-3c56-4c19-83b7-24641cab3abf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_0756096c-c1c5-4518-9241-974b8d5c8718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_0756096c-c1c5-4518-9241-974b8d5c8718" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockholdersEquityTable_87f13757-e094-460a-bff5-d40af98a5654" xlink:href="dare-20220331.xsd#dare_StockholdersEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_dare_StockholdersEquityTable_87f13757-e094-460a-bff5-d40af98a5654" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a2052cfa-29ef-4167-ac56-78cc4a74782c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_StockholdersEquityTable_87f13757-e094-460a-bff5-d40af98a5654" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a2052cfa-29ef-4167-ac56-78cc4a74782c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a2052cfa-29ef-4167-ac56-78cc4a74782c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a2052cfa-29ef-4167-ac56-78cc4a74782c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a2052cfa-29ef-4167-ac56-78cc4a74782c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce0a251c-1d0b-408b-9302-be3bdb186724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a2052cfa-29ef-4167-ac56-78cc4a74782c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce0a251c-1d0b-408b-9302-be3bdb186724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_April2021AtTheMarketSalesAgreementMember_4ffc19d4-ca59-40f7-9c64-328ef24a0766" xlink:href="dare-20220331.xsd#dare_April2021AtTheMarketSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce0a251c-1d0b-408b-9302-be3bdb186724" xlink:to="loc_dare_April2021AtTheMarketSalesAgreementMember_4ffc19d4-ca59-40f7-9c64-328ef24a0766" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PurchaseAgreementMember_f180f46d-0795-4e42-a5e4-7624ea72f631" xlink:href="dare-20220331.xsd#dare_PurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce0a251c-1d0b-408b-9302-be3bdb186724" xlink:to="loc_dare_PurchaseAgreementMember_f180f46d-0795-4e42-a5e4-7624ea72f631" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d1c79c9d-d693-43b3-89ae-31d04e226ba3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_StockholdersEquityTable_87f13757-e094-460a-bff5-d40af98a5654" xlink:to="loc_dei_LegalEntityAxis_d1c79c9d-d693-43b3-89ae-31d04e226ba3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d1c79c9d-d693-43b3-89ae-31d04e226ba3_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d1c79c9d-d693-43b3-89ae-31d04e226ba3" xlink:to="loc_dei_EntityDomain_d1c79c9d-d693-43b3-89ae-31d04e226ba3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_31762fba-1233-4bf3-8021-3dfd64cce1bc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d1c79c9d-d693-43b3-89ae-31d04e226ba3" xlink:to="loc_dei_EntityDomain_31762fba-1233-4bf3-8021-3dfd64cce1bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LincolnParkMember_a312122c-5ca1-4e39-8691-b341b48acfaf" xlink:href="dare-20220331.xsd#dare_LincolnParkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_31762fba-1233-4bf3-8021-3dfd64cce1bc" xlink:to="loc_dare_LincolnParkMember_a312122c-5ca1-4e39-8691-b341b48acfaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6ed57a30-a281-4f48-b0fd-7bb14d9f4f7c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_StockholdersEquityTable_87f13757-e094-460a-bff5-d40af98a5654" xlink:to="loc_srt_CounterpartyNameAxis_6ed57a30-a281-4f48-b0fd-7bb14d9f4f7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ed57a30-a281-4f48-b0fd-7bb14d9f4f7c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6ed57a30-a281-4f48-b0fd-7bb14d9f4f7c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ed57a30-a281-4f48-b0fd-7bb14d9f4f7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b214d93-b4ee-4669-aee0-dae94849f88c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6ed57a30-a281-4f48-b0fd-7bb14d9f4f7c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b214d93-b4ee-4669-aee0-dae94849f88c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LincolnParkMember_d5a0f758-9f31-4ae0-8d09-2fe98a8f6eea" xlink:href="dare-20220331.xsd#dare_LincolnParkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b214d93-b4ee-4669-aee0-dae94849f88c" xlink:to="loc_dare_LincolnParkMember_d5a0f758-9f31-4ae0-8d09-2fe98a8f6eea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1d68adcb-0dda-4fc5-a48c-f787054a81dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_StockholdersEquityTable_87f13757-e094-460a-bff5-d40af98a5654" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1d68adcb-0dda-4fc5-a48c-f787054a81dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1d68adcb-0dda-4fc5-a48c-f787054a81dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1d68adcb-0dda-4fc5-a48c-f787054a81dc" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1d68adcb-0dda-4fc5-a48c-f787054a81dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_b13d8cd5-0834-4bc5-89ae-1483ad6f991f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1d68adcb-0dda-4fc5-a48c-f787054a81dc" xlink:to="loc_us-gaap_TypeOfAdoptionMember_b13d8cd5-0834-4bc5-89ae-1483ad6f991f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201711Member_ad22e0fd-a5f5-464d-bed0-6b513e59325f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201711Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_b13d8cd5-0834-4bc5-89ae-1483ad6f991f" xlink:to="loc_us-gaap_AccountingStandardsUpdate201711Member_ad22e0fd-a5f5-464d-bed0-6b513e59325f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails" xlink:type="extended" id="ib1f672dfba99434fab924469dea4508c_StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_adc2c5e4-5d47-4b23-941a-fb0515716929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_018270b8-70ac-45d2-92ee-3dbadcf9083e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_adc2c5e4-5d47-4b23-941a-fb0515716929" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_018270b8-70ac-45d2-92ee-3dbadcf9083e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b3f1e59e-7e69-4c70-bac1-89bf6e1c830a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_adc2c5e4-5d47-4b23-941a-fb0515716929" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b3f1e59e-7e69-4c70-bac1-89bf6e1c830a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_db25d950-7ead-49f9-a903-5c56f7f330f6" xlink:href="dare-20220331.xsd#dare_ClassOfWarrantOrRightsWarrantsExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_adc2c5e4-5d47-4b23-941a-fb0515716929" xlink:to="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_db25d950-7ead-49f9-a903-5c56f7f330f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_3e78249d-9924-4e66-a320-cdc6d5bad9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_adc2c5e4-5d47-4b23-941a-fb0515716929" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_3e78249d-9924-4e66-a320-cdc6d5bad9f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_0a92eb6a-d89e-4f22-93da-3b65e133de42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_3e78249d-9924-4e66-a320-cdc6d5bad9f2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_0a92eb6a-d89e-4f22-93da-3b65e133de42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0a92eb6a-d89e-4f22-93da-3b65e133de42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0a92eb6a-d89e-4f22-93da-3b65e133de42" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0a92eb6a-d89e-4f22-93da-3b65e133de42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_138bd33a-54c9-43cb-8b22-fe9927194144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0a92eb6a-d89e-4f22-93da-3b65e133de42" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_138bd33a-54c9-43cb-8b22-fe9927194144" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_f2fcc27c-ff39-4d53-b786-c07f72312138" xlink:href="dare-20220331.xsd#dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_138bd33a-54c9-43cb-8b22-fe9927194144" xlink:to="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_f2fcc27c-ff39-4d53-b786-c07f72312138" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_32804fdc-2d99-4062-96c6-75df10dc0a7b" xlink:href="dare-20220331.xsd#dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_138bd33a-54c9-43cb-8b22-fe9927194144" xlink:to="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_32804fdc-2d99-4062-96c6-75df10dc0a7b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="i72d6ede81e6643c48123f98e891d7c13_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced03f59-b52a-4b38-87cf-92920c2dd6de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_869b2224-291b-42a5-a1ca-d119d7d9906c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced03f59-b52a-4b38-87cf-92920c2dd6de" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_869b2224-291b-42a5-a1ca-d119d7d9906c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_24b253db-93ed-4244-b82f-2053fe070b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced03f59-b52a-4b38-87cf-92920c2dd6de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_24b253db-93ed-4244-b82f-2053fe070b9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_68d266ae-d088-4352-b416-e11c5432cd55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced03f59-b52a-4b38-87cf-92920c2dd6de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_68d266ae-d088-4352-b416-e11c5432cd55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_181a111e-6c73-4132-903c-d077e1145d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced03f59-b52a-4b38-87cf-92920c2dd6de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_181a111e-6c73-4132-903c-d077e1145d3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_dd0f32d0-eeb6-4286-945b-bcfcc61cded5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced03f59-b52a-4b38-87cf-92920c2dd6de" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_dd0f32d0-eeb6-4286-945b-bcfcc61cded5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_d44335eb-2ce9-4eb8-8070-a378fce628a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced03f59-b52a-4b38-87cf-92920c2dd6de" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_d44335eb-2ce9-4eb8-8070-a378fce628a8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_6538ac5c-7c5f-4d19-8412-c0960f587176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced03f59-b52a-4b38-87cf-92920c2dd6de" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_6538ac5c-7c5f-4d19-8412-c0960f587176" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WeightedAverageAmortizationPeriod_d94070c3-7b01-4029-8471-f2e57b591efb" xlink:href="dare-20220331.xsd#dare_WeightedAverageAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced03f59-b52a-4b38-87cf-92920c2dd6de" xlink:to="loc_dare_WeightedAverageAmortizationPeriod_d94070c3-7b01-4029-8471-f2e57b591efb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ddd936e-71c2-491c-a51b-78ea32c9f54c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced03f59-b52a-4b38-87cf-92920c2dd6de" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ddd936e-71c2-491c-a51b-78ea32c9f54c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4405985f-55ff-4003-9479-3525445cf274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ddd936e-71c2-491c-a51b-78ea32c9f54c" xlink:to="loc_us-gaap_PlanNameAxis_4405985f-55ff-4003-9479-3525445cf274" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4405985f-55ff-4003-9479-3525445cf274_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4405985f-55ff-4003-9479-3525445cf274" xlink:to="loc_us-gaap_PlanNameDomain_4405985f-55ff-4003-9479-3525445cf274_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_090d40a3-a70b-4dec-8951-8f0060003958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4405985f-55ff-4003-9479-3525445cf274" xlink:to="loc_us-gaap_PlanNameDomain_090d40a3-a70b-4dec-8951-8f0060003958" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_8c523685-947b-463f-9f37-879f4b031276" xlink:href="dare-20220331.xsd#dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_090d40a3-a70b-4dec-8951-8f0060003958" xlink:to="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_8c523685-947b-463f-9f37-879f4b031276" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_7d6ca70b-d36e-46c3-b183-f9a9c5a750f4" xlink:href="dare-20220331.xsd#dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_090d40a3-a70b-4dec-8951-8f0060003958" xlink:to="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_7d6ca70b-d36e-46c3-b183-f9a9c5a750f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1dcd1bfc-4f16-4afc-bc48-5401d9179e18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ddd936e-71c2-491c-a51b-78ea32c9f54c" xlink:to="loc_us-gaap_AwardTypeAxis_1dcd1bfc-4f16-4afc-bc48-5401d9179e18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1dcd1bfc-4f16-4afc-bc48-5401d9179e18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1dcd1bfc-4f16-4afc-bc48-5401d9179e18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1dcd1bfc-4f16-4afc-bc48-5401d9179e18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5aead4a5-a722-48aa-a175-46b28b72222b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1dcd1bfc-4f16-4afc-bc48-5401d9179e18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5aead4a5-a722-48aa-a175-46b28b72222b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_71714223-d543-4dcd-b728-239d2fbb57d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5aead4a5-a722-48aa-a175-46b28b72222b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_71714223-d543-4dcd-b728-239d2fbb57d7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails" xlink:type="extended" id="ifa8f41fb85fc4e2684b885299a589672_StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed20a188-008f-4817-b477-4ed992cdba23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_027b9787-bbd9-428f-8e3a-69940410e36e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed20a188-008f-4817-b477-4ed992cdba23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_027b9787-bbd9-428f-8e3a-69940410e36e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7f5c384a-116e-452c-8024-926b07535184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_027b9787-bbd9-428f-8e3a-69940410e36e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7f5c384a-116e-452c-8024-926b07535184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ca1e0b0c-d60c-4a0f-a81a-6b33dc42a3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_027b9787-bbd9-428f-8e3a-69940410e36e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ca1e0b0c-d60c-4a0f-a81a-6b33dc42a3d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6d357a30-ee98-4208-afb0-137886514e36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_027b9787-bbd9-428f-8e3a-69940410e36e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6d357a30-ee98-4208-afb0-137886514e36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4b7373a9-f558-40d7-bf1d-4c33d8459454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_027b9787-bbd9-428f-8e3a-69940410e36e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4b7373a9-f558-40d7-bf1d-4c33d8459454" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_ae30f306-2b3b-4182-b820-208d2d589e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_027b9787-bbd9-428f-8e3a-69940410e36e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_ae30f306-2b3b-4182-b820-208d2d589e88" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cc5cb835-b8f0-483c-b4f5-d919274a54dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a5d479ae-26fe-40a1-9c7c-5c2e441ba86d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed20a188-008f-4817-b477-4ed992cdba23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a5d479ae-26fe-40a1-9c7c-5c2e441ba86d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7974e481-0bcd-44a8-b827-33971a2996f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed20a188-008f-4817-b477-4ed992cdba23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7974e481-0bcd-44a8-b827-33971a2996f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_26160193-f531-4c98-871e-fade9fab1d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7974e481-0bcd-44a8-b827-33971a2996f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_26160193-f531-4c98-871e-fade9fab1d2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9fa0cdb3-5da5-44bf-9352-be5321d1c1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7974e481-0bcd-44a8-b827-33971a2996f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9fa0cdb3-5da5-44bf-9352-be5321d1c1ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9804ad02-6d47-4fa7-ac62-163d96bd3ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7974e481-0bcd-44a8-b827-33971a2996f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9804ad02-6d47-4fa7-ac62-163d96bd3ea0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_93e2bf31-d2de-47d0-ae66-7330dddde710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7974e481-0bcd-44a8-b827-33971a2996f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_93e2bf31-d2de-47d0-ae66-7330dddde710" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_166f08d6-e45f-45af-8e6d-323e22d8fb35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7974e481-0bcd-44a8-b827-33971a2996f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_166f08d6-e45f-45af-8e6d-323e22d8fb35" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d2bd41a6-f109-48aa-94bb-5db9b7420ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fa476db6-19f0-4a38-9189-91e42a126d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed20a188-008f-4817-b477-4ed992cdba23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fa476db6-19f0-4a38-9189-91e42a126d6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36d10670-d97c-428c-9298-57c3d2118ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed20a188-008f-4817-b477-4ed992cdba23" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36d10670-d97c-428c-9298-57c3d2118ad0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_eb3aa727-6495-4fc1-96e7-5bd2c02e6e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36d10670-d97c-428c-9298-57c3d2118ad0" xlink:to="loc_us-gaap_PlanNameAxis_eb3aa727-6495-4fc1-96e7-5bd2c02e6e7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_eb3aa727-6495-4fc1-96e7-5bd2c02e6e7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_eb3aa727-6495-4fc1-96e7-5bd2c02e6e7f" xlink:to="loc_us-gaap_PlanNameDomain_eb3aa727-6495-4fc1-96e7-5bd2c02e6e7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ed3fd5be-db34-4a08-9b70-5d4f0df88489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_eb3aa727-6495-4fc1-96e7-5bd2c02e6e7f" xlink:to="loc_us-gaap_PlanNameDomain_ed3fd5be-db34-4a08-9b70-5d4f0df88489" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_58b7144b-26fa-47c9-a63c-62687406e3d2" xlink:href="dare-20220331.xsd#dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ed3fd5be-db34-4a08-9b70-5d4f0df88489" xlink:to="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_58b7144b-26fa-47c9-a63c-62687406e3d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_60628e9c-ff70-4525-a532-5b6df44e3da3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36d10670-d97c-428c-9298-57c3d2118ad0" xlink:to="loc_us-gaap_AwardTypeAxis_60628e9c-ff70-4525-a532-5b6df44e3da3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60628e9c-ff70-4525-a532-5b6df44e3da3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_60628e9c-ff70-4525-a532-5b6df44e3da3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60628e9c-ff70-4525-a532-5b6df44e3da3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46a4cab3-b39b-4a16-b560-3a4e2ef56e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_60628e9c-ff70-4525-a532-5b6df44e3da3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46a4cab3-b39b-4a16-b560-3a4e2ef56e3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2e1e2331-7638-4c14-aed4-6fd847477337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46a4cab3-b39b-4a16-b560-3a4e2ef56e3e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2e1e2331-7638-4c14-aed4-6fd847477337" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="extended" id="i98947da446f4461fb9eca8c57cec206b_StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_05451db2-c474-4499-8f93-7dcd4aedd195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_43c60559-6ad1-440f-b722-4e900f8d0f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_05451db2-c474-4499-8f93-7dcd4aedd195" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_43c60559-6ad1-440f-b722-4e900f8d0f37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_967930db-eb00-453f-ad2d-0d8aff82e890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_05451db2-c474-4499-8f93-7dcd4aedd195" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_967930db-eb00-453f-ad2d-0d8aff82e890" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_64dc9a47-d29d-418a-ac46-d8b570067b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_967930db-eb00-453f-ad2d-0d8aff82e890" xlink:to="loc_us-gaap_AwardTypeAxis_64dc9a47-d29d-418a-ac46-d8b570067b0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_64dc9a47-d29d-418a-ac46-d8b570067b0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_64dc9a47-d29d-418a-ac46-d8b570067b0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_64dc9a47-d29d-418a-ac46-d8b570067b0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf2689f-2cbe-430c-b472-f5b7d23120cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_64dc9a47-d29d-418a-ac46-d8b570067b0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf2689f-2cbe-430c-b472-f5b7d23120cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_956f521b-15e0-4709-ae0b-a5db97042734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf2689f-2cbe-430c-b472-f5b7d23120cb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_956f521b-15e0-4709-ae0b-a5db97042734" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_30352fe4-27ad-4c99-b59b-6c7c6b508875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_967930db-eb00-453f-ad2d-0d8aff82e890" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_30352fe4-27ad-4c99-b59b-6c7c6b508875" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_30352fe4-27ad-4c99-b59b-6c7c6b508875_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_30352fe4-27ad-4c99-b59b-6c7c6b508875" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_30352fe4-27ad-4c99-b59b-6c7c6b508875_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f358386c-0bab-4564-b564-749c0412125b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_30352fe4-27ad-4c99-b59b-6c7c6b508875" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f358386c-0bab-4564-b564-749c0412125b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5f885258-67c1-4faf-8371-e2e91a603d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f358386c-0bab-4564-b564-749c0412125b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5f885258-67c1-4faf-8371-e2e91a603d86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4608b055-f763-4b3f-8db8-7c0156871f16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f358386c-0bab-4564-b564-749c0412125b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4608b055-f763-4b3f-8db8-7c0156871f16" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#LeasedPropertiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails" xlink:type="extended" id="ib6fb35ce889940e0b1ffd89f46a40166_LeasedPropertiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_aa6a0b45-8678-44d4-9920-835820a1e6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetRentableArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_NetRentableArea_aa6a0b45-8678-44d4-9920-835820a1e6fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_38adb60c-af21-4d86-ac74-01d0a46d2814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_38adb60c-af21-4d86-ac74-01d0a46d2814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_f47edc93-51f9-4f3b-9c85-23390419014d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_f47edc93-51f9-4f3b-9c85-23390419014d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_58adcc33-cfb2-46ea-a909-d990bf2623d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_58adcc33-cfb2-46ea-a909-d990bf2623d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_52ebe99e-f458-4f44-a884-93cc7a9aea01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_52ebe99e-f458-4f44-a884-93cc7a9aea01" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_febeb1c5-fcad-424a-ae53-24770af1309a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_febeb1c5-fcad-424a-ae53-24770af1309a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_20c93805-255d-493e-a0e3-caa5430ff56b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_20c93805-255d-493e-a0e3-caa5430ff56b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_a5e4622a-ddb1-4f6a-8f33-c3f7efbf4c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_OperatingLeaseCost_a5e4622a-ddb1-4f6a-8f33-c3f7efbf4c17" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5c7db6a2-9e7a-4246-9a57-b5d894322157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_OperatingLeasePayments_5c7db6a2-9e7a-4246-9a57-b5d894322157" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_172ebeba-df38-4e9f-a98b-e471ec120600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_172ebeba-df38-4e9f-a98b-e471ec120600" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_07485b02-7463-4912-b464-b7d68bdba64a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_07485b02-7463-4912-b464-b7d68bdba64a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ce64e6c4-48bc-4028-9b52-b5065f34b24a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_07485b02-7463-4912-b464-b7d68bdba64a" xlink:to="loc_dei_LegalEntityAxis_ce64e6c4-48bc-4028-9b52-b5065f34b24a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ce64e6c4-48bc-4028-9b52-b5065f34b24a_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_ce64e6c4-48bc-4028-9b52-b5065f34b24a" xlink:to="loc_dei_EntityDomain_ce64e6c4-48bc-4028-9b52-b5065f34b24a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ec9971a0-b0ce-46e2-a334-279af7d9e77d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_ce64e6c4-48bc-4028-9b52-b5065f34b24a" xlink:to="loc_dei_EntityDomain_ec9971a0-b0ce-46e2-a334-279af7d9e77d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MBIMember_3babcf68-6dd1-4c3d-b573-bc03ad58c7f6" xlink:href="dare-20220331.xsd#dare_MBIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ec9971a0-b0ce-46e2-a334-279af7d9e77d" xlink:to="loc_dare_MBIMember_3babcf68-6dd1-4c3d-b573-bc03ad58c7f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_bdf98773-238a-4c67-a695-75788393561b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_07485b02-7463-4912-b464-b7d68bdba64a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_bdf98773-238a-4c67-a695-75788393561b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bdf98773-238a-4c67-a695-75788393561b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bdf98773-238a-4c67-a695-75788393561b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bdf98773-238a-4c67-a695-75788393561b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b9c91854-8d2b-40d8-ab0b-c1e7ae097c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bdf98773-238a-4c67-a695-75788393561b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b9c91854-8d2b-40d8-ab0b-c1e7ae097c2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_61f50404-99e6-4183-b4ac-b640c2218d63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b9c91854-8d2b-40d8-ab0b-c1e7ae097c2b" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_61f50404-99e6-4183-b4ac-b640c2218d63" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i3d9b510a55844277975e53edfb796311_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:href="dare-20220331.xsd#dare_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ResearchAndDevelopmentAgreementCommitmentAmount_d4dd201c-e5b5-49d9-abbb-2a60ef1a63ab" xlink:href="dare-20220331.xsd#dare_ResearchAndDevelopmentAgreementCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_dare_ResearchAndDevelopmentAgreementCommitmentAmount_d4dd201c-e5b5-49d9-abbb-2a60ef1a63ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_f50efd11-bd05-4775-b749-68af07dfc06d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_f50efd11-bd05-4775-b749-68af07dfc06d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_3586686b-c67a-41ec-b9be-3f2e6193ca45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_3586686b-c67a-41ec-b9be-3f2e6193ca45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PaymentOfAdditionalConsiderationInBusinessCombination_4c95dcd9-3b42-41d4-a744-37f764892f5e" xlink:href="dare-20220331.xsd#dare_PaymentOfAdditionalConsiderationInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_dare_PaymentOfAdditionalConsiderationInBusinessCombination_4c95dcd9-3b42-41d4-a744-37f764892f5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_74d7c53e-c3a4-45b4-adb5-8dc3bcf182a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_74d7c53e-c3a4-45b4-adb5-8dc3bcf182a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsiderationCurrent_eb74092a-4440-4f4f-a35f-2971a39699d6" xlink:href="dare-20220331.xsd#dare_AssetAcquisitionContingentConsiderationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_dare_AssetAcquisitionContingentConsiderationCurrent_eb74092a-4440-4f4f-a35f-2971a39699d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5f3909f2-0689-475e-8c58-b7601a4974bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5f3909f2-0689-475e-8c58-b7601a4974bb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_345621f0-203a-4baa-a96c-75ee92cf1e09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_345621f0-203a-4baa-a96c-75ee92cf1e09" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PaymentsToStockholdersRepresentativeInBusinessCombination_1fe116ef-8603-4555-a3e5-c7d74f62c432" xlink:href="dare-20220331.xsd#dare_PaymentsToStockholdersRepresentativeInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_dare_PaymentsToStockholdersRepresentativeInBusinessCombination_1fe116ef-8603-4555-a3e5-c7d74f62c432" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived_31ab1052-e108-4b6b-8ed9-57082258d98a" xlink:href="dare-20220331.xsd#dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived_31ab1052-e108-4b6b-8ed9-57082258d98a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NotesPayableCurrentPlusAccruedInterest_2aa77f7d-5348-44d8-a226-d69e9a367c16" xlink:href="dare-20220331.xsd#dare_NotesPayableCurrentPlusAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_dare_NotesPayableCurrentPlusAccruedInterest_2aa77f7d-5348-44d8-a226-d69e9a367c16" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommitmentsAndContingenciesTable_21f282ae-6b8a-4c27-97bd-713f239a24b0" xlink:href="dare-20220331.xsd#dare_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_dare_CommitmentsAndContingenciesTable_21f282ae-6b8a-4c27-97bd-713f239a24b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7444de76-5993-4abf-9dd6-2dc919484906" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_CommitmentsAndContingenciesTable_21f282ae-6b8a-4c27-97bd-713f239a24b0" xlink:to="loc_srt_CounterpartyNameAxis_7444de76-5993-4abf-9dd6-2dc919484906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7444de76-5993-4abf-9dd6-2dc919484906_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7444de76-5993-4abf-9dd6-2dc919484906" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7444de76-5993-4abf-9dd6-2dc919484906_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6cba302c-1b06-4f7a-a1b2-d31c180dfe8f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7444de76-5993-4abf-9dd6-2dc919484906" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6cba302c-1b06-4f7a-a1b2-d31c180dfe8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NICHDMember_b96375e5-402c-4614-b08c-edb1d7ebac71" xlink:href="dare-20220331.xsd#dare_NICHDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6cba302c-1b06-4f7a-a1b2-d31c180dfe8f" xlink:to="loc_dare_NICHDMember_b96375e5-402c-4614-b08c-edb1d7ebac71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CRADAMember_95317c48-8f72-40e0-a454-2e35aca9d9f7" xlink:href="dare-20220331.xsd#dare_CRADAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6cba302c-1b06-4f7a-a1b2-d31c180dfe8f" xlink:to="loc_dare_CRADAMember_95317c48-8f72-40e0-a454-2e35aca9d9f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3654326c-9677-4284-a65c-c1e0e3a236b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_CommitmentsAndContingenciesTable_21f282ae-6b8a-4c27-97bd-713f239a24b0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3654326c-9677-4284-a65c-c1e0e3a236b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3654326c-9677-4284-a65c-c1e0e3a236b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3654326c-9677-4284-a65c-c1e0e3a236b5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3654326c-9677-4284-a65c-c1e0e3a236b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32cb513c-4582-4c06-a44b-6a46260bc81a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3654326c-9677-4284-a65c-c1e0e3a236b5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32cb513c-4582-4c06-a44b-6a46260bc81a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MicrochipsBiotechInc.Member_27e82a44-7215-4e13-b27e-3c4699306dbb" xlink:href="dare-20220331.xsd#dare_MicrochipsBiotechInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32cb513c-4582-4c06-a44b-6a46260bc81a" xlink:to="loc_dare_MicrochipsBiotechInc.Member_27e82a44-7215-4e13-b27e-3c4699306dbb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAwardsDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#GrantAwardsDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/GrantAwardsDetails" xlink:type="extended" id="i0cb81cc4761c476684e44d1bd5a6209a_GrantAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_af4794bb-f048-4edd-bc11-9b774aac6e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ProceedsFromAwardOfGrant_c795589c-a6ee-4990-bdc9-72bb289ce485" xlink:href="dare-20220331.xsd#dare_ProceedsFromAwardOfGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_af4794bb-f048-4edd-bc11-9b774aac6e46" xlink:to="loc_dare_ProceedsFromAwardOfGrant_c795589c-a6ee-4990-bdc9-72bb289ce485" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdditionalPotentialFundingRelatedToGrantAward_620e516d-2a39-4bfd-8c1a-a54c8c248245" xlink:href="dare-20220331.xsd#dare_AdditionalPotentialFundingRelatedToGrantAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_af4794bb-f048-4edd-bc11-9b774aac6e46" xlink:to="loc_dare_AdditionalPotentialFundingRelatedToGrantAward_620e516d-2a39-4bfd-8c1a-a54c8c248245" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_237d6f45-4d97-41ae-885c-33d9df48ee48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_af4794bb-f048-4edd-bc11-9b774aac6e46" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_237d6f45-4d97-41ae-885c-33d9df48ee48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ReceivableForExpensesEligibleForReimbursement_b4a506c8-8474-4a8b-a323-0cdd91ff28fa" xlink:href="dare-20220331.xsd#dare_ReceivableForExpensesEligibleForReimbursement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_af4794bb-f048-4edd-bc11-9b774aac6e46" xlink:to="loc_dare_ReceivableForExpensesEligibleForReimbursement_b4a506c8-8474-4a8b-a323-0cdd91ff28fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDevelopment_ee0499ea-2642-49de-afeb-63c2a92d0cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_af4794bb-f048-4edd-bc11-9b774aac6e46" xlink:to="loc_us-gaap_BusinessDevelopment_ee0499ea-2642-49de-afeb-63c2a92d0cd9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_2e213a11-e2a7-4f63-a623-0182a1305748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_af4794bb-f048-4edd-bc11-9b774aac6e46" xlink:to="loc_us-gaap_GrantsReceivable_2e213a11-e2a7-4f63-a623-0182a1305748" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredGrantFundingCurrent_6e734ed5-dc0e-4232-a1df-ff995c9ac2dc" xlink:href="dare-20220331.xsd#dare_DeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_af4794bb-f048-4edd-bc11-9b774aac6e46" xlink:to="loc_dare_DeferredGrantFundingCurrent_6e734ed5-dc0e-4232-a1df-ff995c9ac2dc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4dde34e4-7a04-49b6-a683-e5399e23241c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_af4794bb-f048-4edd-bc11-9b774aac6e46" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4dde34e4-7a04-49b6-a683-e5399e23241c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cdd5b84f-d604-4bf8-9e2a-8db93587338d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4dde34e4-7a04-49b6-a683-e5399e23241c" xlink:to="loc_srt_ProductOrServiceAxis_cdd5b84f-d604-4bf8-9e2a-8db93587338d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cdd5b84f-d604-4bf8-9e2a-8db93587338d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cdd5b84f-d604-4bf8-9e2a-8db93587338d" xlink:to="loc_srt_ProductsAndServicesDomain_cdd5b84f-d604-4bf8-9e2a-8db93587338d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7aeb3469-ae39-43bd-93f3-bfcb20cc71b5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cdd5b84f-d604-4bf8-9e2a-8db93587338d" xlink:to="loc_srt_ProductsAndServicesDomain_7aeb3469-ae39-43bd-93f3-bfcb20cc71b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantDAREFRT1Member_d14cc211-1c43-4c9b-ba9e-c95188fc321d" xlink:href="dare-20220331.xsd#dare_GrantDAREFRT1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7aeb3469-ae39-43bd-93f3-bfcb20cc71b5" xlink:to="loc_dare_GrantDAREFRT1Member_d14cc211-1c43-4c9b-ba9e-c95188fc321d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantDAREPTB1Member_cc1d3350-f74a-4c94-8b85-f85c0ef31a87" xlink:href="dare-20220331.xsd#dare_GrantDAREPTB1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7aeb3469-ae39-43bd-93f3-bfcb20cc71b5" xlink:to="loc_dare_GrantDAREPTB1Member_cc1d3350-f74a-4c94-8b85-f85c0ef31a87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DARELARC1Member_e8454e96-b8c7-4a4c-a381-5a33ec961eae" xlink:href="dare-20220331.xsd#dare_DARELARC1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7aeb3469-ae39-43bd-93f3-bfcb20cc71b5" xlink:to="loc_dare_DARELARC1Member_e8454e96-b8c7-4a4c-a381-5a33ec961eae" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails" xlink:type="extended" id="iaf88c083aa1f4da7ab7e0916e9e098a0_NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cf247043-4ab7-455a-a06d-a386dd2a0efe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9e5c99ed-0f4c-45b1-a8c2-2ae6de76521b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cf247043-4ab7-455a-a06d-a386dd2a0efe" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9e5c99ed-0f4c-45b1-a8c2-2ae6de76521b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7b56e56d-cad3-4f55-9b92-849510e29742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cf247043-4ab7-455a-a06d-a386dd2a0efe" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7b56e56d-cad3-4f55-9b92-849510e29742" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9cee82c-8ac0-4bd4-bc0a-1550a378e70b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7b56e56d-cad3-4f55-9b92-849510e29742" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9cee82c-8ac0-4bd4-bc0a-1550a378e70b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c9cee82c-8ac0-4bd4-bc0a-1550a378e70b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9cee82c-8ac0-4bd4-bc0a-1550a378e70b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c9cee82c-8ac0-4bd4-bc0a-1550a378e70b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_813cd389-bc7e-4012-8054-125bd57c5cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9cee82c-8ac0-4bd4-bc0a-1550a378e70b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_813cd389-bc7e-4012-8054-125bd57c5cbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d80d5c32-a7eb-4783-98c2-b0d67f0c4efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_813cd389-bc7e-4012-8054-125bd57c5cbe" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d80d5c32-a7eb-4783-98c2-b0d67f0c4efd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_24b39d0a-3ba0-46c1-834c-d58224760d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_813cd389-bc7e-4012-8054-125bd57c5cbe" xlink:to="loc_us-gaap_WarrantMember_24b39d0a-3ba0-46c1-834c-d58224760d9d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/SubsequentEventsDetails" xlink:type="extended" id="ie8bd18cf1c594122aa00c3c98285cc9f_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_c677582a-da1c-4ee4-acc1-650702f56eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d1c024a3-fff5-47fa-be02-e52be3286202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c677582a-da1c-4ee4-acc1-650702f56eb3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d1c024a3-fff5-47fa-be02-e52be3286202" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4492fd9d-510d-44aa-911c-7f5d8858df61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c677582a-da1c-4ee4-acc1-650702f56eb3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4492fd9d-510d-44aa-911c-7f5d8858df61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_93f3b798-a09e-4cb0-9da9-4c33d01b824f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_c677582a-da1c-4ee4-acc1-650702f56eb3" xlink:to="loc_us-gaap_SubsequentEventTable_93f3b798-a09e-4cb0-9da9-4c33d01b824f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_21503170-7a75-4c4c-88b2-f22959a5a146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_93f3b798-a09e-4cb0-9da9-4c33d01b824f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_21503170-7a75-4c4c-88b2-f22959a5a146" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_21503170-7a75-4c4c-88b2-f22959a5a146_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_21503170-7a75-4c4c-88b2-f22959a5a146" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_21503170-7a75-4c4c-88b2-f22959a5a146_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_02ee0e81-1e00-45f7-b47a-e620c47d7621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_21503170-7a75-4c4c-88b2-f22959a5a146" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_02ee0e81-1e00-45f7-b47a-e620c47d7621" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d4aa9a4d-1dc3-4c70-b441-9ec25c8387e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_02ee0e81-1e00-45f7-b47a-e620c47d7621" xlink:to="loc_us-gaap_SubsequentEventMember_d4aa9a4d-1dc3-4c70-b441-9ec25c8387e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9125d405-3828-4857-a46d-9cf86c2cfde8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_93f3b798-a09e-4cb0-9da9-4c33d01b824f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9125d405-3828-4857-a46d-9cf86c2cfde8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9125d405-3828-4857-a46d-9cf86c2cfde8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9125d405-3828-4857-a46d-9cf86c2cfde8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9125d405-3828-4857-a46d-9cf86c2cfde8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_314ab2be-414e-4703-bcb4-5286f368641b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9125d405-3828-4857-a46d-9cf86c2cfde8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_314ab2be-414e-4703-bcb4-5286f368641b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ATMEquityOfferingProgramMember_f3e4979d-b02e-47e4-8686-ee5aa6db18e0" xlink:href="dare-20220331.xsd#dare_ATMEquityOfferingProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_314ab2be-414e-4703-bcb4-5286f368641b" xlink:to="loc_dare_ATMEquityOfferingProgramMember_f3e4979d-b02e-47e4-8686-ee5aa6db18e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>dare-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:fd319a35-eb86-476b-85ca-f1b0e0a14df0,g:c97ede0a-3f8a-49b3-9abb-a622ab8bee13-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_04b46a38-1def-4444-9f31-c5e02d65acc9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercises, gross</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_1eac05be-53a7-4fc4-82c9-599b61f4ce63_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_29819248-98df-4084-9084-0e090e9695aa_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5980c141-0676-4182-aa6d-5a6427905679_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ed31c14e-db1a-4b5f-8c74-047ebed1e74b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_62da93b3-15e6-4ee0-a708-beb4fadefe3a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_07f788bd-c02e-4d24-991c-100b01961908_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6de6e1c8-3a1d-4aa1-abcd-5e83e2b6c96b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_8c403ae8-52b9-4485-a648-8e64b1ef0e2f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_17493382-ea58-41ec-b0fb-926003c346c8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_52369e98-2c75-4aa6-8c83-2166cc2a6dcc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8235df99-c63a-4cad-8bc7-7f5f7c37662b_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MicrochipsBiotechInc.Member_1a0a4672-a03f-4e1b-a8d7-b298ce4cd7d3_terseLabel_en-US" xlink:label="lab_dare_MicrochipsBiotechInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Microchips Biotech, Inc.</link:label>
    <link:label id="lab_dare_MicrochipsBiotechInc.Member_label_en-US" xlink:label="lab_dare_MicrochipsBiotechInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Microchips Biotech, Inc. [Member]</link:label>
    <link:label id="lab_dare_MicrochipsBiotechInc.Member_documentation_en-US" xlink:label="lab_dare_MicrochipsBiotechInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Microchips Biotech, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MicrochipsBiotechInc.Member" xlink:href="dare-20220331.xsd#dare_MicrochipsBiotechInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MicrochipsBiotechInc.Member" xlink:to="lab_dare_MicrochipsBiotechInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_f54c853c-cc33-4d86-a7bf-5814f7a4095f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_061294eb-8980-4fe0-b486-8836cacafe01_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal, accounting and other fees related to purchase agreement</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_fddd3a39-c4ee-4dd0-849b-d149c13b245d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_fd114d83-0fb1-4b11-b3c4-9135c6fe5ece_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3386f987-90ad-48bd-9654-ed6e69deda3f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostMaintenance_58e091ff-880c-4845-b3eb-1e0a56e5b08d_terseLabel_en-US" xlink:label="lab_us-gaap_CostMaintenance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual maintenance fee</link:label>
    <link:label id="lab_us-gaap_CostMaintenance_label_en-US" xlink:label="lab_us-gaap_CostMaintenance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Maintenance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostMaintenance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostMaintenance" xlink:to="lab_us-gaap_CostMaintenance" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_DARELARC1Member_8cfadd15-5c2e-4e45-96cc-f773c0176c8f_terseLabel_en-US" xlink:label="lab_dare_DARELARC1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARE-LARC1</link:label>
    <link:label id="lab_dare_DARELARC1Member_label_en-US" xlink:label="lab_dare_DARELARC1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARE-LARC1 [Member]</link:label>
    <link:label id="lab_dare_DARELARC1Member_documentation_en-US" xlink:label="lab_dare_DARELARC1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARE-LARC1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DARELARC1Member" xlink:href="dare-20220331.xsd#dare_DARELARC1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_DARELARC1Member" xlink:to="lab_dare_DARELARC1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ClinicalAndRegulatoryMilestonesMember_0721b36b-24b9-4036-a005-bf3a0660ed5a_terseLabel_en-US" xlink:label="lab_dare_ClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical and Regulatory Milestones</link:label>
    <link:label id="lab_dare_ClinicalAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_dare_ClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_dare_ClinicalAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_dare_ClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical And Regulatory Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ClinicalAndRegulatoryMilestonesMember" xlink:href="dare-20220331.xsd#dare_ClinicalAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ClinicalAndRegulatoryMilestonesMember" xlink:to="lab_dare_ClinicalAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_59892486-4655-4226-aef0-550dae447b8a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_4cc91210-395f-441d-8d84-feeee54a4f83_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_535ac9fa-f3ed-4ee0-93db-36f0f016dd07_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cece1a3c-3192-4989-98cd-71ebef4c084b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_a6e8fd9f-eaf8-4b22-9e73-ee425adc3634_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_67cd5f81-8239-4ba2-b80f-e04b0772b246_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_46e32622-0296-49ed-a824-de74b052222b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_79e6d9ad-3685-4cac-887e-3be7d0b96f27_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3b53f0a1-1c85-4f32-8888-98684c8ccd28_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AdditionalPotentialFundingRelatedToGrantAward_dd17cd1d-a98d-4d62-b5ae-5dbd3e182eb5_terseLabel_en-US" xlink:label="lab_dare_AdditionalPotentialFundingRelatedToGrantAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional potential grant funding</link:label>
    <link:label id="lab_dare_AdditionalPotentialFundingRelatedToGrantAward_label_en-US" xlink:label="lab_dare_AdditionalPotentialFundingRelatedToGrantAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Potential Funding Related To Grant Award</link:label>
    <link:label id="lab_dare_AdditionalPotentialFundingRelatedToGrantAward_documentation_en-US" xlink:label="lab_dare_AdditionalPotentialFundingRelatedToGrantAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Potential Funding Related To Grant Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdditionalPotentialFundingRelatedToGrantAward" xlink:href="dare-20220331.xsd#dare_AdditionalPotentialFundingRelatedToGrantAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AdditionalPotentialFundingRelatedToGrantAward" xlink:to="lab_dare_AdditionalPotentialFundingRelatedToGrantAward" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_NumberOfCommonStockWarrantsExercised_b443a8b3-e023-434e-816c-8183293d2518_terseLabel_en-US" xlink:label="lab_dare_NumberOfCommonStockWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Common Stock Warrants Exercised</link:label>
    <link:label id="lab_dare_NumberOfCommonStockWarrantsExercised_label_en-US" xlink:label="lab_dare_NumberOfCommonStockWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Common Stock Warrants Exercised</link:label>
    <link:label id="lab_dare_NumberOfCommonStockWarrantsExercised_documentation_en-US" xlink:label="lab_dare_NumberOfCommonStockWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Common Stock Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NumberOfCommonStockWarrantsExercised" xlink:href="dare-20220331.xsd#dare_NumberOfCommonStockWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NumberOfCommonStockWarrantsExercised" xlink:to="lab_dare_NumberOfCommonStockWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_87fc34b1-d07a-4e27-ad7b-20c9535641ac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_1de420a7-1c21-463e-acd7-8d35d770bddf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_43557beb-423e-46d9-a8d3-eb1b6aacc12a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_LicenseAndCollaborationAgreementMember_f168cfb7-a162-464d-9be1-8fb547f9287b_terseLabel_en-US" xlink:label="lab_dare_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreement</link:label>
    <link:label id="lab_dare_LicenseAndCollaborationAgreementMember_label_en-US" xlink:label="lab_dare_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_dare_LicenseAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_dare_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAndCollaborationAgreementMember" xlink:href="dare-20220331.xsd#dare_LicenseAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAndCollaborationAgreementMember" xlink:to="lab_dare_LicenseAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_af436471-cd6a-4a66-88c5-056373af58da_terseLabel_en-US" xlink:label="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Two Thousand Fourteen Stock Incentive Plan</link:label>
    <link:label id="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_label_en-US" xlink:label="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" xlink:href="dare-20220331.xsd#dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" xlink:to="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cae25d04-638a-4604-8612-67e2ae7b307b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MilestonePaymentsContingentAmount_5daf2090-160c-4232-b6eb-79a1a842127a_terseLabel_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment paid in common stock</link:label>
    <link:label id="lab_dare_MilestonePaymentsContingentAmount_label_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Amount</link:label>
    <link:label id="lab_dare_MilestonePaymentsContingentAmount_documentation_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments, contingent amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmount" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsContingentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MilestonePaymentsContingentAmount" xlink:to="lab_dare_MilestonePaymentsContingentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e277b4dd-5a25-4190-906f-d7a203902b9b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_65417bbc-4b09-4d7d-9c28-4243e8ecce13_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_9fa33b74-d742-4c5d-aa58-82336791d216_terseLabel_en-US" xlink:label="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Reaching Certain Worldwide Net Sales Milestones</link:label>
    <link:label id="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_label_en-US" xlink:label="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Reaching Certain Worldwide Net Sales Milestones [Member]</link:label>
    <link:label id="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_documentation_en-US" xlink:label="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon reaching certain worldwide net sales milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:href="dare-20220331.xsd#dare_UponReachingCertainWorldwideNetSalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:to="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_70640131-31e3-42cb-a6c5-841f5065a220_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3eb2d4f9-85cf-4b08-944e-c88669476358_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled/forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e11e5fd5-224f-412f-9167-9f6fa577cc90_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ba981d46-ae5e-46ef-b7d1-0f5e137b30a9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_de43054d-b670-4839-a9dc-d3d8fd372c5f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDevelopment_23daff1a-26d1-4991-9615-c5585efccf19_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business development</link:label>
    <link:label id="lab_us-gaap_BusinessDevelopment_label_en-US" xlink:label="lab_us-gaap_BusinessDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDevelopment" xlink:to="lab_us-gaap_BusinessDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3b8bc444-b25d-4203-9ef3-df95025fc678_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_HammockPharmaceuticalsInc.Member_840ca044-c45a-4269-98cf-b26c725086b2_terseLabel_en-US" xlink:label="lab_dare_HammockPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hammock Pharmaceuticals, Inc</link:label>
    <link:label id="lab_dare_HammockPharmaceuticalsInc.Member_label_en-US" xlink:label="lab_dare_HammockPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hammock Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_dare_HammockPharmaceuticalsInc.Member_documentation_en-US" xlink:label="lab_dare_HammockPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hammock Pharmaceuticals, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_HammockPharmaceuticalsInc.Member" xlink:href="dare-20220331.xsd#dare_HammockPharmaceuticalsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_HammockPharmaceuticalsInc.Member" xlink:to="lab_dare_HammockPharmaceuticalsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_30a7d498-81d0-446a-8684-0f3429d93c80_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2d529dff-5c4f-48b9-b0e8-a418deef1e68_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_f48ac31f-8c08-41b7-a582-fc07069f5f74_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_01765714-86de-4a33-8b3e-4726526cb47b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits recorded to research and development expense for costs related to award</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_54a913b1-9d5d-4c83-95f1-359040ddb5f3_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a34ef413-6e9c-4724-968f-55185c04c1db_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_fa591bd7-48a6-4ce8-bd0c-f7b47f7cef03_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MilestonePaymentsTerm_0c5a9bef-33a6-4acc-a751-c6c2ca501fd6_terseLabel_en-US" xlink:label="lab_dare_MilestonePaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments term</link:label>
    <link:label id="lab_dare_MilestonePaymentsTerm_label_en-US" xlink:label="lab_dare_MilestonePaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Term</link:label>
    <link:label id="lab_dare_MilestonePaymentsTerm_documentation_en-US" xlink:label="lab_dare_MilestonePaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsTerm" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MilestonePaymentsTerm" xlink:to="lab_dare_MilestonePaymentsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UponAchievingCertainDevelopmentMilestonesMember_6a083953-6364-4cef-aca6-979e8a7ca938_terseLabel_en-US" xlink:label="lab_dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Development Milestones</link:label>
    <link:label id="lab_dare_UponAchievingCertainDevelopmentMilestonesMember_label_en-US" xlink:label="lab_dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Development Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievingCertainDevelopmentMilestonesMember_documentation_en-US" xlink:label="lab_dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Development Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:href="dare-20220331.xsd#dare_UponAchievingCertainDevelopmentMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:to="lab_dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_53deaf8b-e824-42d1-9298-1023f501224a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_0ae0877f-512b-4f1d-945b-ce484e9aefa6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_40e8bab6-98c6-49cb-8dca-2db0f240e91d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ebd3e84-b33d-4285-a60a-5e74e78e50a0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_83b4305e-4cdf-4bae-a57a-a191070fea8e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from the exercise of warrants</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_abbf23c2-2e80-4463-8a28-cccde3334a22_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_ab96d26b-ecd8-47af-95f7-c3a68816bdd1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_deef6d99-e142-471b-8571-8093829315b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_599b8754-d7f5-42bd-8a3c-659a909fb762_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MaximumPotentialMilestonePayments_2f95a42a-5062-4250-b5db-9ad689ba5b8e_terseLabel_en-US" xlink:label="lab_dare_MaximumPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential milestone payments</link:label>
    <link:label id="lab_dare_MaximumPotentialMilestonePayments_label_en-US" xlink:label="lab_dare_MaximumPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Potential Milestone Payments</link:label>
    <link:label id="lab_dare_MaximumPotentialMilestonePayments_documentation_en-US" xlink:label="lab_dare_MaximumPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Potential Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MaximumPotentialMilestonePayments" xlink:href="dare-20220331.xsd#dare_MaximumPotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MaximumPotentialMilestonePayments" xlink:to="lab_dare_MaximumPotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_dd38b6a8-e4b9-475b-ab86-8c7c65d2cb28_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_315f3bd3-1238-43cc-8286-405f084201dc_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_adca5da1-cb34-48df-bf23-172c0d7dfec4_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_44b48cfe-360b-43c8-9375-68458ae4324f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Warrants Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_dab668b1-b142-4a29-9f18-c9887d5b9d2e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_d4a7386b-f24c-4a3b-8225-ceeb48f68847_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_92a76b89-9666-4f04-8408-34d0e322e5c0_terseLabel_en-US" xlink:label="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of common stock warrants</link:label>
    <link:label id="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_label_en-US" xlink:label="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants</link:label>
    <link:label id="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_documentation_en-US" xlink:label="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock and warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:href="dare-20220331.xsd#dare_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_751fb1e8-6c28-4eb2-a8cb-a4b83cfd146c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_2fbc0a6d-0c46-4d50-b09f-2c3bbba5e203_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_de25210e-e4f0-4d72-b78f-f9fc2ae85a70_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value of options granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_5e5e9c5d-3ec8-4dae-93a8-e24a3b4fccca_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_89c13f07-0d9f-4a70-8315-1bf0a65c872e_terseLabel_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual license maintenance fee, payments in year one</link:label>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_label_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Annual License Maintenance Fee, Payments In Year One</link:label>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_documentation_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Annual License Maintenance Fee, Payments In Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" xlink:href="dare-20220331.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" xlink:to="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MBIMember_8ba24905-37c2-47ab-bc9a-65832df48600_terseLabel_en-US" xlink:label="lab_dare_MBIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MBI</link:label>
    <link:label id="lab_dare_MBIMember_label_en-US" xlink:label="lab_dare_MBIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MBI [Member]</link:label>
    <link:label id="lab_dare_MBIMember_documentation_en-US" xlink:label="lab_dare_MBIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MBI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MBIMember" xlink:href="dare-20220331.xsd#dare_MBIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MBIMember" xlink:to="lab_dare_MBIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_GrantDAREPTB1Member_d566694f-03d9-4517-985f-3ad9dadaaf33_terseLabel_en-US" xlink:label="lab_dare_GrantDAREPTB1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, DARE-PTB1</link:label>
    <link:label id="lab_dare_GrantDAREPTB1Member_label_en-US" xlink:label="lab_dare_GrantDAREPTB1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, DARE-PTB1 [Member]</link:label>
    <link:label id="lab_dare_GrantDAREPTB1Member_documentation_en-US" xlink:label="lab_dare_GrantDAREPTB1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, DARE-PTB1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantDAREPTB1Member" xlink:href="dare-20220331.xsd#dare_GrantDAREPTB1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_GrantDAREPTB1Member" xlink:to="lab_dare_GrantDAREPTB1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bdc19432-31c3-47b6-9c8d-27d51ee266c9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7583e11d-bb4b-49bd-b609-80034b5b10f3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f4c3fe99-caf5-4adf-ab61-1e6244de01a6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1a818103-5d6c-4f61-ac9a-1f808e8689a9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_CatalentAndMilanaPharmMember_3d246bda-fae4-4fa2-9ba9-cc39b42d7552_terseLabel_en-US" xlink:label="lab_dare_CatalentAndMilanaPharmMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Catalent and MilanaPharm</link:label>
    <link:label id="lab_dare_CatalentAndMilanaPharmMember_label_en-US" xlink:label="lab_dare_CatalentAndMilanaPharmMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Catalent and MilanaPharm [Member]</link:label>
    <link:label id="lab_dare_CatalentAndMilanaPharmMember_documentation_en-US" xlink:label="lab_dare_CatalentAndMilanaPharmMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Catalent and MilanaPharm</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CatalentAndMilanaPharmMember" xlink:href="dare-20220331.xsd#dare_CatalentAndMilanaPharmMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CatalentAndMilanaPharmMember" xlink:to="lab_dare_CatalentAndMilanaPharmMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4b5fcc7c-d994-4140-9c70-adc2439c89c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b35ffe31-c50e-4854-bc04-b01d7a626cb6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_6819aac7-632b-4c14-aab4-2c96dabaf538_terseLabel_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual license maintenance fee payments, thereafter</link:label>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_label_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Annual License Maintenance Fee Payments, Thereafter</link:label>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_documentation_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Annual License Maintenance Fee Payments, Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:href="dare-20220331.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:to="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d97a019c-aa16-4b74-b8b9-284ea7a7642e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_4e4e7beb-9047-4eb3-95c1-44813a597207_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4739219b-3a4f-41f1-b3a3-7766dc88ee5c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_5d902be3-e4b6-41ba-9919-d86c32a0fb1b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_6d5610c8-9c97-431b-9e82-8279c0d223a0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4019b586-211c-4a2f-8492-61d2da8e943e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ccd1b794-75fe-4f06-affd-d6e2fbb47f79_terseLabel_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_documentation_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="dare-20220331.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_c37e033d-b0a3-4731-b7fe-3431c5fe01de_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d48308c2-2489-4bf8-8c2a-d2bdf6d2d238_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6ef25ee8-1b3d-4eee-835f-de23707e33ce_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ac4d24fd-9309-44d0-8591-814f81e94c82_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_78f080d0-b7b0-41c7-9a32-22c490658a70_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_c728f2f0-c1ff-45d6-95b6-f3018b465970_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2be027e8-e0a9-45e3-b9a8-6cb2ebe3193b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_2fda0c3b-9c37-4bb9-9f67-03de25438079_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f6c93b26-928a-463b-b774-83a62ebe9701_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_76439d51-d80f-4764-aac6-38ee29c347d0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred license revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_b98058d7-6777-46cf-80b2-16287f8083e2_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_75a5a8fd-f80a-41e8-bbae-7398e93b19db_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember_a49f4fdf-f1dd-418a-a5d8-7a8244f90815_terseLabel_en-US" xlink:label="lab_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensed Product or Process for Vaginal or Urological Use</link:label>
    <link:label id="lab_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember_label_en-US" xlink:label="lab_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensed Product or Process for Vaginal or Urological Use [Member]</link:label>
    <link:label id="lab_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember_documentation_en-US" xlink:label="lab_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensed Product or Process for Vaginal or Urological Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember" xlink:href="dare-20220331.xsd#dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember" xlink:to="lab_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d149af48-23bd-4eb4-a229-adc0a15ace94_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5a45df79-8f34-40e0-afbe-baa56d988dea_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6fd3d399-5903-48e7-b96f-10b4acfafb76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_57b55fce-4d93-4365-a88e-199d2383e68b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTermination_37c9fcc6-5fa0-4cee-94f9-32e46b117ebb_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain clinical and regulatory development milestone payments</link:label>
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTermination_label_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Notice Period Of Termination</link:label>
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTermination_documentation_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Notice Period Of Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTermination" xlink:href="dare-20220331.xsd#dare_LicenseAgreementNoticePeriodOfTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementNoticePeriodOfTermination" xlink:to="lab_dare_LicenseAgreementNoticePeriodOfTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b9e7493d-2a40-42ff-bb6f-4107bef4d167_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_144bed80-87d0-4e77-a381-c5eaac1df19c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_99aff6e2-6a67-42d3-96de-6b364445216d_terseLabel_en-US" xlink:label="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_label_en-US" xlink:label="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Warrants Expiration Date</link:label>
    <link:label id="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_documentation_en-US" xlink:label="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or rights warrants expiration date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:href="dare-20220331.xsd#dare_ClassOfWarrantOrRightsWarrantsExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:to="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_a2301fa5-a4a2-466b-b824-1393d8edcf19_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_1e6bca88-f4ea-4326-9209-26a4c5ffc105_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_bce84558-4527-4895-9e6a-0221a8c9cbef_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_779d266a-1059-40b0-983b-66f538375bdd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_LicenseAgreementInitialTerm_249e1c22-63df-4bc9-b53c-032a27558566_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementInitialTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial term of license agreement</link:label>
    <link:label id="lab_dare_LicenseAgreementInitialTerm_label_en-US" xlink:label="lab_dare_LicenseAgreementInitialTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial Term</link:label>
    <link:label id="lab_dare_LicenseAgreementInitialTerm_documentation_en-US" xlink:label="lab_dare_LicenseAgreementInitialTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementInitialTerm" xlink:href="dare-20220331.xsd#dare_LicenseAgreementInitialTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementInitialTerm" xlink:to="lab_dare_LicenseAgreementInitialTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_47888a2e-7dad-47fd-b9cf-ad9771dd2851_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1ddbf9bc-4d94-4304-b35a-ffd79c5f69ba_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PercentageOfRoyaltyRate_75995de3-ae11-40a5-9226-92f126301c69_terseLabel_en-US" xlink:label="lab_dare_PercentageOfRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalty rate</link:label>
    <link:label id="lab_dare_PercentageOfRoyaltyRate_label_en-US" xlink:label="lab_dare_PercentageOfRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Royalty Rate</link:label>
    <link:label id="lab_dare_PercentageOfRoyaltyRate_documentation_en-US" xlink:label="lab_dare_PercentageOfRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalty rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfRoyaltyRate" xlink:href="dare-20220331.xsd#dare_PercentageOfRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PercentageOfRoyaltyRate" xlink:to="lab_dare_PercentageOfRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_30a798a2-9369-475c-93ed-1e59d9b77006_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9ae89514-e30d-4fce-a57e-c04c09c6e939_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_cd31c99d-f072-4590-abbf-4c2635e83f0e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_6fa03863-5936-48b7-b2b5-8922835eeea2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_SalesMilestonesMember_ab9c4eff-d5cf-4723-86ea-9b517a0311dd_terseLabel_en-US" xlink:label="lab_dare_SalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones</link:label>
    <link:label id="lab_dare_SalesMilestonesMember_label_en-US" xlink:label="lab_dare_SalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones [Member]</link:label>
    <link:label id="lab_dare_SalesMilestonesMember_documentation_en-US" xlink:label="lab_dare_SalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SalesMilestonesMember" xlink:href="dare-20220331.xsd#dare_SalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SalesMilestonesMember" xlink:to="lab_dare_SalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_JuniperPharmaceuticalsInc.Member_1ff33486-f533-4c65-9d37-38f8f101db7b_terseLabel_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juniper Pharmaceuticals, Inc</link:label>
    <link:label id="lab_dare_JuniperPharmaceuticalsInc.Member_label_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juniper Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_dare_JuniperPharmaceuticalsInc.Member_documentation_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juniper Pharmaceuticals, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_JuniperPharmaceuticalsInc.Member" xlink:href="dare-20220331.xsd#dare_JuniperPharmaceuticalsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_JuniperPharmaceuticalsInc.Member" xlink:to="lab_dare_JuniperPharmaceuticalsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_GrantDAREFRT1Member_7f6a4b5d-841e-40a2-ac11-8a40220e17a0_terseLabel_en-US" xlink:label="lab_dare_GrantDAREFRT1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, DARE-FRT1</link:label>
    <link:label id="lab_dare_GrantDAREFRT1Member_label_en-US" xlink:label="lab_dare_GrantDAREFRT1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, DARE-FRT1 [Member]</link:label>
    <link:label id="lab_dare_GrantDAREFRT1Member_documentation_en-US" xlink:label="lab_dare_GrantDAREFRT1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, DARE-FRT1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantDAREFRT1Member" xlink:href="dare-20220331.xsd#dare_GrantDAREFRT1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_GrantDAREFRT1Member" xlink:to="lab_dare_GrantDAREFRT1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_dbac04fb-c2c0-46bb-9034-535691720824_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term of operating lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_b2914035-291e-4194-af74-0fd92475bd88_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_DeferredOfferingCostsUnamortizedPortion_7bf125fd-220b-4863-b10a-43096b210239_terseLabel_en-US" xlink:label="lab_dare_DeferredOfferingCostsUnamortizedPortion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized costs related to legal, accounting, and other fees</link:label>
    <link:label id="lab_dare_DeferredOfferingCostsUnamortizedPortion_label_en-US" xlink:label="lab_dare_DeferredOfferingCostsUnamortizedPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs, Unamortized Portion</link:label>
    <link:label id="lab_dare_DeferredOfferingCostsUnamortizedPortion_documentation_en-US" xlink:label="lab_dare_DeferredOfferingCostsUnamortizedPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs, Unamortized Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredOfferingCostsUnamortizedPortion" xlink:href="dare-20220331.xsd#dare_DeferredOfferingCostsUnamortizedPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_DeferredOfferingCostsUnamortizedPortion" xlink:to="lab_dare_DeferredOfferingCostsUnamortizedPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_e574f9a0-3dbb-44d9-8b96-47eba54406a5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ResearchAndDevelopmentAgreementCommitmentAmount_07960678-cc2b-432d-a650-edd785861186_terseLabel_en-US" xlink:label="lab_dare_ResearchAndDevelopmentAgreementCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total payment</link:label>
    <link:label id="lab_dare_ResearchAndDevelopmentAgreementCommitmentAmount_label_en-US" xlink:label="lab_dare_ResearchAndDevelopmentAgreementCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Agreement, Commitment, Amount</link:label>
    <link:label id="lab_dare_ResearchAndDevelopmentAgreementCommitmentAmount_documentation_en-US" xlink:label="lab_dare_ResearchAndDevelopmentAgreementCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Agreement, Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ResearchAndDevelopmentAgreementCommitmentAmount" xlink:href="dare-20220331.xsd#dare_ResearchAndDevelopmentAgreementCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ResearchAndDevelopmentAgreementCommitmentAmount" xlink:to="lab_dare_ResearchAndDevelopmentAgreementCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a649049d-0625-44ae-87a7-aacb59c42738_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_IncreaseDecreaseInDeferredGrantFunding_6c6d617a-9e90-408d-9678-22ba60667aa2_negatedTerseLabel_en-US" xlink:label="lab_dare_IncreaseDecreaseInDeferredGrantFunding" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding</link:label>
    <link:label id="lab_dare_IncreaseDecreaseInDeferredGrantFunding_label_en-US" xlink:label="lab_dare_IncreaseDecreaseInDeferredGrantFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Deferred Grant Funding</link:label>
    <link:label id="lab_dare_IncreaseDecreaseInDeferredGrantFunding_documentation_en-US" xlink:label="lab_dare_IncreaseDecreaseInDeferredGrantFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Deferred Grant Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_IncreaseDecreaseInDeferredGrantFunding" xlink:href="dare-20220331.xsd#dare_IncreaseDecreaseInDeferredGrantFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_IncreaseDecreaseInDeferredGrantFunding" xlink:to="lab_dare_IncreaseDecreaseInDeferredGrantFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_e0c90a58-a36a-4513-9397-1cdab38d627f_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_e84d53c8-738c-404f-99bf-4352d5536345_terseLabel_en-US" xlink:label="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_label_en-US" xlink:label="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Proceeds From Issuance Of Common Stock And Warrants</link:label>
    <link:label id="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_documentation_en-US" xlink:label="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock and warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:href="dare-20220331.xsd#dare_NetProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PaymentsToStockholdersRepresentativeInBusinessCombination_54b7b41c-52f1-4881-9705-36b56223f070_terseLabel_en-US" xlink:label="lab_dare_PaymentsToStockholdersRepresentativeInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid to stockholders' representative</link:label>
    <link:label id="lab_dare_PaymentsToStockholdersRepresentativeInBusinessCombination_label_en-US" xlink:label="lab_dare_PaymentsToStockholdersRepresentativeInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Stockholders' Representative in Business Combination</link:label>
    <link:label id="lab_dare_PaymentsToStockholdersRepresentativeInBusinessCombination_documentation_en-US" xlink:label="lab_dare_PaymentsToStockholdersRepresentativeInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Stockholders' Representative in Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PaymentsToStockholdersRepresentativeInBusinessCombination" xlink:href="dare-20220331.xsd#dare_PaymentsToStockholdersRepresentativeInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PaymentsToStockholdersRepresentativeInBusinessCombination" xlink:to="lab_dare_PaymentsToStockholdersRepresentativeInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2ffc4bc5-2501-435c-ad15-7f6544726ba3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ed1c333-89e7-49cc-97ac-69c646b38dc1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_0ec9569e-8c05-4ddf-a69e-2711f4092f7d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e4ef2737-18c5-41a6-8f33-84737ccf1170_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_GoingConcernPolicyTextBlock_0801989c-a8ee-4e16-997d-76230d03ecd9_terseLabel_en-US" xlink:label="lab_dare_GoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Going Concern</link:label>
    <link:label id="lab_dare_GoingConcernPolicyTextBlock_label_en-US" xlink:label="lab_dare_GoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Going Concern [Policy Text Block]</link:label>
    <link:label id="lab_dare_GoingConcernPolicyTextBlock_documentation_en-US" xlink:label="lab_dare_GoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Going Concern</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GoingConcernPolicyTextBlock" xlink:href="dare-20220331.xsd#dare_GoingConcernPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_GoingConcernPolicyTextBlock" xlink:to="lab_dare_GoingConcernPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_bfb3cac2-9dd3-44a8-a28c-8f69028c209e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7a252825-9ccb-4d14-95ed-ef0f52ca7f84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase number of outstanding shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UponAchievingCertainCommercialMilestonesMember_1c1c851a-5c32-4573-a64c-2024207dfdd1_terseLabel_en-US" xlink:label="lab_dare_UponAchievingCertainCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Commercial Milestones</link:label>
    <link:label id="lab_dare_UponAchievingCertainCommercialMilestonesMember_label_en-US" xlink:label="lab_dare_UponAchievingCertainCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Commercial Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievingCertainCommercialMilestonesMember_documentation_en-US" xlink:label="lab_dare_UponAchievingCertainCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Commercial Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainCommercialMilestonesMember" xlink:href="dare-20220331.xsd#dare_UponAchievingCertainCommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievingCertainCommercialMilestonesMember" xlink:to="lab_dare_UponAchievingCertainCommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_f5215f5e-b2f6-4861-b620-0ce86642b1b9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_5f29ea48-2c75-4ff5-a253-ab04319b5009_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_34d571e7-def6-4226-8b5a-29c11adbae5a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6c6a9ce1-307f-424a-9924-b2d95c2127e1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PercentageOfAggregateCommission_d3e15f7a-5b79-4748-9be4-f124e2fe94e9_terseLabel_en-US" xlink:label="lab_dare_PercentageOfAggregateCommission" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission percent</link:label>
    <link:label id="lab_dare_PercentageOfAggregateCommission_label_en-US" xlink:label="lab_dare_PercentageOfAggregateCommission" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Aggregate Commission</link:label>
    <link:label id="lab_dare_PercentageOfAggregateCommission_documentation_en-US" xlink:label="lab_dare_PercentageOfAggregateCommission" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of aggregate commission.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfAggregateCommission" xlink:href="dare-20220331.xsd#dare_PercentageOfAggregateCommission"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PercentageOfAggregateCommission" xlink:to="lab_dare_PercentageOfAggregateCommission" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AssetAcquisitionContingentConsiderationCurrent_160bdde0-29f2-406f-b55c-68276b7d23ce_terseLabel_en-US" xlink:label="lab_dare_AssetAcquisitionContingentConsiderationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of contingent consideration</link:label>
    <link:label id="lab_dare_AssetAcquisitionContingentConsiderationCurrent_label_en-US" xlink:label="lab_dare_AssetAcquisitionContingentConsiderationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Current</link:label>
    <link:label id="lab_dare_AssetAcquisitionContingentConsiderationCurrent_documentation_en-US" xlink:label="lab_dare_AssetAcquisitionContingentConsiderationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsiderationCurrent" xlink:href="dare-20220331.xsd#dare_AssetAcquisitionContingentConsiderationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AssetAcquisitionContingentConsiderationCurrent" xlink:to="lab_dare_AssetAcquisitionContingentConsiderationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct_2bf31ae5-a93d-4d9a-8798-a25c65d20a96_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement termination periodic discontinued sale of product</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct_label_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Termination Periodic Discontinued Sale Of Product</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct_documentation_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Termination Periodic Discontinued Sale Of Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct" xlink:href="dare-20220331.xsd#dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct" xlink:to="lab_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_754cbd4f-62d7-47b1-a6ec-255440d10795_negatedLabel_en-US" xlink:label="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_label_en-US" xlink:label="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Other Non Current Assets And Deferred Charges</link:label>
    <link:label id="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_documentation_en-US" xlink:label="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in other non-current assets and deferred charges.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" xlink:href="dare-20220331.xsd#dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" xlink:to="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_88416241-c650-437c-b629-b55a8eb641d1_terseLabel_en-US" xlink:label="lab_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential additional consideration payable</link:label>
    <link:label id="lab_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_label_en-US" xlink:label="lab_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Payment Arrangement, Maximum Potential Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:to="lab_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_93e68078-dfa3-435f-8c1c-a455de650c5e_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PurchaseAgreementMember_da7ad3dc-0f08-4328-b3ae-d26180029fce_terseLabel_en-US" xlink:label="lab_dare_PurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement</link:label>
    <link:label id="lab_dare_PurchaseAgreementMember_label_en-US" xlink:label="lab_dare_PurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement [Member]</link:label>
    <link:label id="lab_dare_PurchaseAgreementMember_documentation_en-US" xlink:label="lab_dare_PurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PurchaseAgreementMember" xlink:href="dare-20220331.xsd#dare_PurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PurchaseAgreementMember" xlink:to="lab_dare_PurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_46dd05ad-220b-4b83-ad0f-8712490230ea_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_bef433f8-2502-4258-b481-11cf6f1e2ad1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_bff0d595-c54c-474b-a787-f4b631af7dd4_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_CRADAMember_a96c8fe6-7b8a-4322-8fd5-e7e898be6197_terseLabel_en-US" xlink:label="lab_dare_CRADAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CRADA</link:label>
    <link:label id="lab_dare_CRADAMember_label_en-US" xlink:label="lab_dare_CRADAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CRADA [Member]</link:label>
    <link:label id="lab_dare_CRADAMember_documentation_en-US" xlink:label="lab_dare_CRADAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CRADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CRADAMember" xlink:href="dare-20220331.xsd#dare_CRADAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CRADAMember" xlink:to="lab_dare_CRADAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature_0d3483c5-de1b-4fe0-ab03-e74386ac122a_terseLabel_en-US" xlink:label="lab_dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend from trigger of down round provision feature</link:label>
    <link:label id="lab_dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature_label_en-US" xlink:label="lab_dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed Dividend From Trigger Of Round Down Provision Feature</link:label>
    <link:label id="lab_dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature_documentation_en-US" xlink:label="lab_dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed Dividend From Trigger Of Round Down Provision Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature" xlink:href="dare-20220331.xsd#dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature" xlink:to="lab_dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c20f9dc0-f04f-43f1-b55f-52dfe7bba77b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ccc35070-93c7-4648-8713-0b7f1c2fa8d7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5db2607b-7ca3-4100-b78b-4d2086d893f2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_81ab55f1-59b9-4c56-8d91-477878d37519_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_23650d48-0c99-4bed-a624-1ac6e8cc7376_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_2bf468cd-b39f-4f37-8bec-9f1b04675e06_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_bea86379-6d49-4b40-bc6a-b2ccacd06c5a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_a7af9720-e5b6-408e-9ce9-d76dce9287b1_terseLabel_en-US" xlink:label="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Clinical and Regulatory Development Milestones</link:label>
    <link:label id="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_label_en-US" xlink:label="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Clinical And Regulatory Development Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_documentation_en-US" xlink:label="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Clinical And Regulatory Development Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:href="dare-20220331.xsd#dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:to="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_3b864970-f74e-4c00-9b4e-f225d5941245_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_108c5919-d837-4cff-ad23-53a94b0d6444_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b61c244e-bc27-49bb-af69-bddb7d250bb2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ForgivenessOfPaycheckProtectionProgramNotePayable_c01f4e82-bc99-470f-9d22-e66a74825c87_terseLabel_en-US" xlink:label="lab_dare_ForgivenessOfPaycheckProtectionProgramNotePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness of Paycheck Protection Program note payable</link:label>
    <link:label id="lab_dare_ForgivenessOfPaycheckProtectionProgramNotePayable_label_en-US" xlink:label="lab_dare_ForgivenessOfPaycheckProtectionProgramNotePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness of Paycheck Protection Program Note Payable</link:label>
    <link:label id="lab_dare_ForgivenessOfPaycheckProtectionProgramNotePayable_documentation_en-US" xlink:label="lab_dare_ForgivenessOfPaycheckProtectionProgramNotePayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness of Paycheck Protection Program Note Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ForgivenessOfPaycheckProtectionProgramNotePayable" xlink:href="dare-20220331.xsd#dare_ForgivenessOfPaycheckProtectionProgramNotePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ForgivenessOfPaycheckProtectionProgramNotePayable" xlink:to="lab_dare_ForgivenessOfPaycheckProtectionProgramNotePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_3c37009e-d0dd-4fee-9cb8-07e19e5f6024_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_ef8b0bb5-3682-41d0-ad4d-7804a50e93a9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8bc00c6-e5bd-43e2-aa52-3da32bfdd108_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ATMEquityOfferingProgramMember_e00a2f81-728e-46e0-8bba-d6a8f0d95abc_terseLabel_en-US" xlink:label="lab_dare_ATMEquityOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Equity Offering Program</link:label>
    <link:label id="lab_dare_ATMEquityOfferingProgramMember_label_en-US" xlink:label="lab_dare_ATMEquityOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Equity Offering Program [Member]</link:label>
    <link:label id="lab_dare_ATMEquityOfferingProgramMember_documentation_en-US" xlink:label="lab_dare_ATMEquityOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Equity Offering Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ATMEquityOfferingProgramMember" xlink:href="dare-20220331.xsd#dare_ATMEquityOfferingProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ATMEquityOfferingProgramMember" xlink:to="lab_dare_ATMEquityOfferingProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_NotesPayableCurrentPlusAccruedInterest_e5ac0dd0-efd0-4a0e-ae56-b67847fa5f98_terseLabel_en-US" xlink:label="lab_dare_NotesPayableCurrentPlusAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable including accrued interest</link:label>
    <link:label id="lab_dare_NotesPayableCurrentPlusAccruedInterest_label_en-US" xlink:label="lab_dare_NotesPayableCurrentPlusAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current, Plus Accrued Interest</link:label>
    <link:label id="lab_dare_NotesPayableCurrentPlusAccruedInterest_documentation_en-US" xlink:label="lab_dare_NotesPayableCurrentPlusAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current, Plus Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NotesPayableCurrentPlusAccruedInterest" xlink:href="dare-20220331.xsd#dare_NotesPayableCurrentPlusAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NotesPayableCurrentPlusAccruedInterest" xlink:to="lab_dare_NotesPayableCurrentPlusAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount_abc772d3-7cd3-4a34-b552-8b34aa790adc_terseLabel_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales based milestones amount</link:label>
    <link:label id="lab_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount_label_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Amount, Sales Based Milestones Amount</link:label>
    <link:label id="lab_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount_documentation_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Amount, Sales Based Milestones Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount" xlink:to="lab_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_fbe6a77b-b1c2-4ffd-86a4-08b9fb702a0a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5700931f-d7d5-41b5-893e-c5f8fcb5ff8f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_LicenseFeeToBePaidUponContingency_45821e10-72e5-4ae7-ad18-465ca3106d00_terseLabel_en-US" xlink:label="lab_dare_LicenseFeeToBePaidUponContingency" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee to be paid upon contingency</link:label>
    <link:label id="lab_dare_LicenseFeeToBePaidUponContingency_label_en-US" xlink:label="lab_dare_LicenseFeeToBePaidUponContingency" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fee, To Be Paid Upon Contingency</link:label>
    <link:label id="lab_dare_LicenseFeeToBePaidUponContingency_documentation_en-US" xlink:label="lab_dare_LicenseFeeToBePaidUponContingency" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fee, To Be Paid Upon Contingency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseFeeToBePaidUponContingency" xlink:href="dare-20220331.xsd#dare_LicenseFeeToBePaidUponContingency"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseFeeToBePaidUponContingency" xlink:to="lab_dare_LicenseFeeToBePaidUponContingency" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_59bf900c-662c-4717-8ece-9570a7ed0009_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_75813fe5-837f-4c6b-b9b2-ff20a7efb112_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_96438206-706a-4f98-b075-ba151a1b8904_terseLabel_en-US" xlink:label="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of rights to inventions by employees under license agreement</link:label>
    <link:label id="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_label_en-US" xlink:label="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Rights To Inventions By Employees Under License Agreement</link:label>
    <link:label id="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_documentation_en-US" xlink:label="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of rights to inventions by employees under license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" xlink:href="dare-20220331.xsd#dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" xlink:to="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_6584880b-d3c3-4ce2-8e7e-eef8a4fe795c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_a6191743-7eef-4d38-b15f-61dd210b1ec3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition transaction value</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8582941d-3a9c-4b27-b302-c9c952bb4ee0_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_StockholdersEquityLineItems_2f661a8e-15e3-4495-ac88-c957ea087c53_terseLabel_en-US" xlink:label="lab_dare_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Line Items]</link:label>
    <link:label id="lab_dare_StockholdersEquityLineItems_label_en-US" xlink:label="lab_dare_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Line Items]</link:label>
    <link:label id="lab_dare_StockholdersEquityLineItems_documentation_en-US" xlink:label="lab_dare_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockholdersEquityLineItems" xlink:href="dare-20220331.xsd#dare_StockholdersEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_StockholdersEquityLineItems" xlink:to="lab_dare_StockholdersEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_937d0ae7-ae03-47e3-964b-7c6532e9c683_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_31b5ed69-3999-449f-8d9b-1013c19b2ba7_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_BayerHealthcareLicenseAgreementMember_29537617-e431-47b3-8232-d30399ada792_terseLabel_en-US" xlink:label="lab_dare_BayerHealthcareLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Healthcare License Agreement</link:label>
    <link:label id="lab_dare_BayerHealthcareLicenseAgreementMember_label_en-US" xlink:label="lab_dare_BayerHealthcareLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Healthcare License Agreement [Member]</link:label>
    <link:label id="lab_dare_BayerHealthcareLicenseAgreementMember_documentation_en-US" xlink:label="lab_dare_BayerHealthcareLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Healthcare License Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BayerHealthcareLicenseAgreementMember" xlink:href="dare-20220331.xsd#dare_BayerHealthcareLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BayerHealthcareLicenseAgreementMember" xlink:to="lab_dare_BayerHealthcareLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2829c48c-a7dc-4ce2-9216-1d413598d7fc_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_82827a6c-45e8-4232-8038-40691d001614_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7db87254-1127-4c4d-a296-d0a90ef3b688_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_80169b08-62cc-49c4-a8f7-db337686b8c9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_StockholdersEquityTable_15a8df8a-a1bf-49d1-b350-3cc1a39e92ff_terseLabel_en-US" xlink:label="lab_dare_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Table]</link:label>
    <link:label id="lab_dare_StockholdersEquityTable_label_en-US" xlink:label="lab_dare_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Table]</link:label>
    <link:label id="lab_dare_StockholdersEquityTable_documentation_en-US" xlink:label="lab_dare_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockholdersEquityTable" xlink:href="dare-20220331.xsd#dare_StockholdersEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_StockholdersEquityTable" xlink:to="lab_dare_StockholdersEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ba118d2d-3bc3-487e-8bc5-6e2d6fed08ff_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_3c98ef80-6ace-46b8-8757-856476a1fafd_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f70a2b2c-206a-4998-a7db-a6f2d532c759_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_6e716c12-44ed-4e64-9023-3180d9a80837_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetRentableArea_52a9dec3-a66c-415f-9241-4878b89a3c17_terseLabel_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Square footage of office space</link:label>
    <link:label id="lab_us-gaap_NetRentableArea_label_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Rentable Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetRentableArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetRentableArea" xlink:to="lab_us-gaap_NetRentableArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_e77a7da9-9dc1-406d-a1e6-0f0fb9bd0d10_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b8b58e10-0385-444f-9e61-4ce6b4d451e3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_a1d8a3b1-0fd9-4225-a9e4-d8f2d4517961_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_73e79793-a0a5-4c31-9e1c-3d14f1a8f2fe_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_08812c8c-f14d-418e-ba7f-aaab27f324c2_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_02087a83-9796-46c2-bf72-8c26dcb371cd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_265d78cc-b607-4e51-a2c3-ee852386e6d5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_8ef011bb-7848-43dc-8be9-0ea863cb82c6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_a4168ca7-64e0-4643-a5bb-f50e65197185_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement termination period due to performance failure</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_label_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Termination Period Due To Performance Failure</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_documentation_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, termination period due to performance failure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" xlink:href="dare-20220331.xsd#dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" xlink:to="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_288771a2-7e16-42eb-bb58-07c5f27a1951_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_f7bc4af1-22f1-41d9-8ed1-4712b1a3ff4f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_b245c477-f180-4be9-96fc-174c6fde080c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MilanaPharmMember_d1f427ae-3424-4a75-9edc-a34b84f186a7_terseLabel_en-US" xlink:label="lab_dare_MilanaPharmMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MilanaPharm</link:label>
    <link:label id="lab_dare_MilanaPharmMember_label_en-US" xlink:label="lab_dare_MilanaPharmMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MilanaPharm [Member]</link:label>
    <link:label id="lab_dare_MilanaPharmMember_documentation_en-US" xlink:label="lab_dare_MilanaPharmMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MilanaPharm [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilanaPharmMember" xlink:href="dare-20220331.xsd#dare_MilanaPharmMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MilanaPharmMember" xlink:to="lab_dare_MilanaPharmMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_101efcd7-a2c6-4bce-893f-880cb28d9005_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_17b7b9fb-4cd2-423f-aee0-06ffcdf2102e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2565d0f9-f556-4dc4-b90e-fe69a625c60f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_521928e4-4db2-453f-ad9c-3a209f10e732_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_35666954-e449-42c0-837c-2ffc2a3f2450_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_2adbe2bc-4fbb-435c-b4c0-83e78034b573_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_755c5e2e-c50a-442a-9f1a-dff13e94256f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MilestonePaymentsContingentAmountPayableNet_aab8ee8e-9b3a-464f-8d48-0cf11ed20692_terseLabel_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmountPayableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount payable</link:label>
    <link:label id="lab_dare_MilestonePaymentsContingentAmountPayableNet_label_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmountPayableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Amount Payable, Net</link:label>
    <link:label id="lab_dare_MilestonePaymentsContingentAmountPayableNet_documentation_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmountPayableNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Amount Payable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountPayableNet" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsContingentAmountPayableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MilestonePaymentsContingentAmountPayableNet" xlink:to="lab_dare_MilestonePaymentsContingentAmountPayableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_683edc0c-a69b-435e-a55c-693e0f47d6e8_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_781a3e41-72bd-4220-9786-a7cee215f191_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_20131926-745b-4131-928c-c3cfaad5b22e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UpfrontLicenseFeeAmountPaid_c26af894-48bf-41d9-9264-2c055fa36a25_terseLabel_en-US" xlink:label="lab_dare_UpfrontLicenseFeeAmountPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront license fee paid</link:label>
    <link:label id="lab_dare_UpfrontLicenseFeeAmountPaid_label_en-US" xlink:label="lab_dare_UpfrontLicenseFeeAmountPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront License Fee, Amount Paid</link:label>
    <link:label id="lab_dare_UpfrontLicenseFeeAmountPaid_documentation_en-US" xlink:label="lab_dare_UpfrontLicenseFeeAmountPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront License Fee, Amount Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UpfrontLicenseFeeAmountPaid" xlink:href="dare-20220331.xsd#dare_UpfrontLicenseFeeAmountPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UpfrontLicenseFeeAmountPaid" xlink:to="lab_dare_UpfrontLicenseFeeAmountPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_98b7025d-929d-4599-8f28-550049ecf601_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AssetAcquisitionContingentConsideration_a32259ef-caa6-4b83-a414-edc6e7513476_terseLabel_en-US" xlink:label="lab_dare_AssetAcquisitionContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, contingent consideration</link:label>
    <link:label id="lab_dare_AssetAcquisitionContingentConsideration_label_en-US" xlink:label="lab_dare_AssetAcquisitionContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_dare_AssetAcquisitionContingentConsideration_documentation_en-US" xlink:label="lab_dare_AssetAcquisitionContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsideration" xlink:href="dare-20220331.xsd#dare_AssetAcquisitionContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AssetAcquisitionContingentConsideration" xlink:to="lab_dare_AssetAcquisitionContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_75b172d7-f0af-4c88-8c79-d1f57693d9a7_terseLabel_en-US" xlink:label="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring on February 15, 2023</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_label_en-US" xlink:label="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_documentation_en-US" xlink:label="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:href="dare-20220331.xsd#dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:to="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4670da47-c848-48bd-ae22-a3dec51fbfbc_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7e327b36-93c2-42dd-a5a7-46b4ffd58ed9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_27311236-2a07-4456-9cdf-0eb1fdfc2ab1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_da55a9a1-af3b-456a-a421-d13c765e5f50_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_438b43ec-b8ee-47b0-b403-d58020078594_terseLabel_en-US" xlink:label="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring on April 4, 2026</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_label_en-US" xlink:label="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring On April Four Two Thousand Twenty Six [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_documentation_en-US" xlink:label="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expiring on april four two thousand twenty six.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:href="dare-20220331.xsd#dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:to="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_74cc1dbf-366d-44cc-bec1-8b517d86b0e9_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a95983ec-bcb4-4e43-bb0a-97b24b85f396_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_86722d42-db72-4dbd-8725-1756b96b288f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7d99f1ee-69f7-41fd-bc63-e5b4813156ee_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 120,000,000 shares authorized; 83,944,119 shares issued and outstanding at March&#160;31, 2022 and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_338eb25e-03eb-449f-9844-8eb7826f353e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issues shares</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_CommitmentsAndContingenciesTable_cb823ea9-26a6-49c3-9359-bef1e4961b70_terseLabel_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_dare_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_dare_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommitmentsAndContingenciesTable" xlink:href="dare-20220331.xsd#dare_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CommitmentsAndContingenciesTable" xlink:to="lab_dare_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_cbbf20d8-a853-43dc-81b6-ec3b13ed8674_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_dc8b7178-1e0b-4190-8d18-4af591299010_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_9233e823-74b4-4f82-9a3f-064ebd37ff5a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_3169d28a-09de-473d-ac77-d5afdd0e29aa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased Properties</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a4096936-fed3-40e5-84d9-cc38a215d986_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_afee327c-a293-4036-ae56-2e952724e4cd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2870d71d-6c0f-4349-b2b0-9e6c593988cc_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_82caccfa-45a4-4ac4-bf01-10d1e6570847_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a90b3940-89ac-4a5b-b480-a16f896c9e61_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_a6f2ca3a-fab0-4924-8fc9-af4fa16ab4f6_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201711Member_99c137ec-718c-405d-bc05-16470e20d756_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201711Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2017-11</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201711Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201711Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2017-11 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201711Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201711Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201711Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201711Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9fe1b0b3-04a4-42c3-a62f-edd63b8e6127_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_CommitmentsAndContingenciesLineItems_950fea3a-1c47-4147-95c5-791ae098fdcf_terseLabel_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_dare_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_dare_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommitmentsAndContingenciesLineItems" xlink:href="dare-20220331.xsd#dare_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems" xlink:to="lab_dare_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_GrantAwardTextBlock_2110f296-a658-45b5-91da-5d5ffcbe802f_terseLabel_en-US" xlink:label="lab_dare_GrantAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Awards</link:label>
    <link:label id="lab_dare_GrantAwardTextBlock_label_en-US" xlink:label="lab_dare_GrantAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Award [Text Block]</link:label>
    <link:label id="lab_dare_GrantAwardTextBlock_documentation_en-US" xlink:label="lab_dare_GrantAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Award [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantAwardTextBlock" xlink:href="dare-20220331.xsd#dare_GrantAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_GrantAwardTextBlock" xlink:to="lab_dare_GrantAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_d6b90148-f6db-4a2a-99c0-50b2135fab95_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_NICHDMember_40cf795f-3d49-47b6-bea3-52a89f5bce07_terseLabel_en-US" xlink:label="lab_dare_NICHDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NICHD</link:label>
    <link:label id="lab_dare_NICHDMember_label_en-US" xlink:label="lab_dare_NICHDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NICHD [Member]</link:label>
    <link:label id="lab_dare_NICHDMember_documentation_en-US" xlink:label="lab_dare_NICHDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NICHD</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NICHDMember" xlink:href="dare-20220331.xsd#dare_NICHDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NICHDMember" xlink:to="lab_dare_NICHDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_WorkingCapitalIncreaseDeficit_8859ecf1-2edc-41d5-bb98-0a1d9da01e03_terseLabel_en-US" xlink:label="lab_dare_WorkingCapitalIncreaseDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_dare_WorkingCapitalIncreaseDeficit_label_en-US" xlink:label="lab_dare_WorkingCapitalIncreaseDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital Increase (Deficit)</link:label>
    <link:label id="lab_dare_WorkingCapitalIncreaseDeficit_documentation_en-US" xlink:label="lab_dare_WorkingCapitalIncreaseDeficit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital Increase (Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WorkingCapitalIncreaseDeficit" xlink:href="dare-20220331.xsd#dare_WorkingCapitalIncreaseDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WorkingCapitalIncreaseDeficit" xlink:to="lab_dare_WorkingCapitalIncreaseDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_44f3e2c2-af5a-48c5-bd4b-8f55d36c22cc_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_ad59d2b1-7eb2-47ea-a254-5121a7b406e2_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_7c652853-74f6-44a8-900c-4f727f544b78_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_25727046-cf21-4766-a526-32eb1d9d5d95_terseLabel_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First commercial sale amount</link:label>
    <link:label id="lab_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_label_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Amount, First Commercial Sale Amount</link:label>
    <link:label id="lab_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_documentation_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Amount, First Commercial Sale Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount" xlink:to="lab_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3c7660c8-ed86-4253-b9ac-96e95394b4c3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_551de416-cea0-4918-9cec-a827255319e8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c3aa63e3-19ed-4f94-a684-ccd4d9d7810c_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_94402069-532c-4cc5-8d8f-fd466b2a56a1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8e6afa19-bb6b-492b-922f-2192dfea2934_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2e19c9f7-377f-45bf-ab95-25d1c717a4bc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_cc778545-6361-4d3d-8470-5a3a31c3912e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_70340dc2-9f0f-4de4-8dc9-a1a8b0319574_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_2037c432-8ce2-4d5f-9093-63ce820d59e4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares underlying outstanding warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_RoyaltyAgreementTerm_29d2ee25-a619-4f8f-92bc-cfe466a4b4de_terseLabel_en-US" xlink:label="lab_dare_RoyaltyAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty agreement term</link:label>
    <link:label id="lab_dare_RoyaltyAgreementTerm_label_en-US" xlink:label="lab_dare_RoyaltyAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Term</link:label>
    <link:label id="lab_dare_RoyaltyAgreementTerm_documentation_en-US" xlink:label="lab_dare_RoyaltyAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_RoyaltyAgreementTerm" xlink:href="dare-20220331.xsd#dare_RoyaltyAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_RoyaltyAgreementTerm" xlink:to="lab_dare_RoyaltyAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived_1c1ace85-56f6-4bea-8132-e7b0c113afdf_terseLabel_en-US" xlink:label="lab_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan under paycheck protection program</link:label>
    <link:label id="lab_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived_label_en-US" xlink:label="lab_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</link:label>
    <link:label id="lab_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived_documentation_en-US" xlink:label="lab_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived" xlink:href="dare-20220331.xsd#dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived" xlink:to="lab_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e08112b5-d294-43fa-96ff-a306eade96c9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accreted interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1ac416c6-b6fd-4511-b386-1607a4ae9a56_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_7fb26db7-babd-41db-aa81-9c8780c542fa_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d765e75a-1460-4f84-8ced-9fa25528e7e4_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock for net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0009a55b-f6e3-4286-a7c4-742726f6bc5f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_dfe4c146-28e2-4a68-a4f9-f115f0d0f32a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8a742972-a8ee-4d09-8416-d6c711934695_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_196354d0-daa3-4bb4-bc75-431d45025383_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8004ca4f-925c-41c6-a1ba-88d91ae8dbf9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_28e4d302-2441-418c-92ce-7c01da9a3408_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_eaaffad1-f22d-4a06-bce5-e6a49320a8df_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued to microchips capital stock holders (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1bec86d5-d316-4048-86c7-1e488fbfcf8d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_21828d3a-3903-4737-83b9-bafa1a3685e8_terseLabel_en-US" xlink:label="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Fourteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and fourteen employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:href="dare-20220331.xsd#dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:to="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_3b850e69-1c1e-46fa-985c-01eded0d9776_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b669ea6d-cd79-4b56-a4cf-25ff88880a56_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from grant for notice of award</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_70b6cf2c-8c5a-476f-9f21-9dcff082fcea_terseLabel_en-US" xlink:label="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achievement of Specified Development and Regulatory Milestones</link:label>
    <link:label id="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achievement Of Specified Development And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon achievement of specified development and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:href="dare-20220331.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:to="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_ef936d50-f639-4997-91b5-523264d48cf1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other cost</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_4128ee60-70ff-4bdb-9f3c-1c90de6d4a3f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6e8ba040-8630-4c15-a187-aff52b130bba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity for Amended 2014 Plan and Related Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a7664aec-bb05-4e7f-9415-2eca838e73a4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_ee385023-f83f-4436-9810-2c82caa69e6e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_11a7bff2-1eb8-49a0-bd2c-a9b11a8e8b6a_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_00de63bf-4d18-48f5-917c-17efbef5b7ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_83bdbbcc-6210-4385-a85a-16a324a1341d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_1648c4d7-0f59-4cc9-83ad-2f1e42ecd5ba_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8355e4f0-935c-4d10-bea5-e52d09d9b2d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_4c83ee71-6e76-4cf1-ae3f-9c53e1eaaeda_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_032cb553-b302-4c8f-a55e-2ec982c4488b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_WeightedAverageAmortizationPeriod_fc9383a8-f679-45e1-ab07-eca594845b80_terseLabel_en-US" xlink:label="lab_dare_WeightedAverageAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average amortization period</link:label>
    <link:label id="lab_dare_WeightedAverageAmortizationPeriod_label_en-US" xlink:label="lab_dare_WeightedAverageAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Amortization Period</link:label>
    <link:label id="lab_dare_WeightedAverageAmortizationPeriod_documentation_en-US" xlink:label="lab_dare_WeightedAverageAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WeightedAverageAmortizationPeriod" xlink:href="dare-20220331.xsd#dare_WeightedAverageAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WeightedAverageAmortizationPeriod" xlink:to="lab_dare_WeightedAverageAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_02c72297-2319-4f35-88c6-82397a53fabf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_0c9dd4c4-6a37-4d73-92a5-7bfed00207e1_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligation to purchase common stock</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_14e6cc2d-1f17-4b24-a0d8-b8b8e8e759cb_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_a6a15328-c0ba-4b60-a536-e1a44d7bf1da_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d4da0c0b-9fcb-461d-a6b8-fa81e03964cb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1c8c525a-64c9-4bb4-ab28-4bbd65dc0dff_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_dca2b302-956e-4a9d-86d5-d9d0ec10d88b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_867164fe-641f-4834-a4a2-c30d73ef7856_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7d7c794e-6ae2-4853-ae9b-f59dcde126fc_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_99188050-e148-4d35-a87b-f36a45ee6803_terseLabel_en-US" xlink:label="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of warrants recorded in equity</link:label>
    <link:label id="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_label_en-US" xlink:label="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value Of Warrants Recorded In Equity</link:label>
    <link:label id="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_documentation_en-US" xlink:label="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value Of Warrants Recorded In Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:href="dare-20220331.xsd#dare_EstimatedFairValueOfWarrantsRecordedInEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:to="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_abba6576-5aa0-4314-9d2a-5de11eebab73_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6bba211c-d798-4f4a-93af-550146a66fa1_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b95c41ab-5342-4c74-a2ae-84421ac3830e_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2bfe35c1-f226-41fc-9915-98008e142570_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_bca0dce0-5c51-423b-aebd-41e93973e67c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_19f4d7fc-5e1d-44b3-93a6-c542f10023dc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_LincolnParkMember_a234ca20-28c2-441b-beff-8df0dd907f19_terseLabel_en-US" xlink:label="lab_dare_LincolnParkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park</link:label>
    <link:label id="lab_dare_LincolnParkMember_label_en-US" xlink:label="lab_dare_LincolnParkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park [Member]</link:label>
    <link:label id="lab_dare_LincolnParkMember_documentation_en-US" xlink:label="lab_dare_LincolnParkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LincolnParkMember" xlink:href="dare-20220331.xsd#dare_LincolnParkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LincolnParkMember" xlink:to="lab_dare_LincolnParkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1a906921-02f5-4a2c-a5a7-edb2c32ab860_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_62b5fa58-508c-431b-a06d-fc8f4d4bac80_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_571ebb56-ee5f-4146-aaa8-6d9523be8fea_terseLabel_en-US" xlink:label="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company</link:label>
    <link:label id="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_label_en-US" xlink:label="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Science And Technologies D Limited Liability Company And Strategic Science Technologies Limited Liability Company [Member]</link:label>
    <link:label id="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_documentation_en-US" xlink:label="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:href="dare-20220331.xsd#dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:to="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_NonCashLeaseExpense_07a52cc0-2c5c-43b6-8f27-43ac25b7784e_terseLabel_en-US" xlink:label="lab_dare_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease cost</link:label>
    <link:label id="lab_dare_NonCashLeaseExpense_label_en-US" xlink:label="lab_dare_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:label id="lab_dare_NonCashLeaseExpense_documentation_en-US" xlink:label="lab_dare_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NonCashLeaseExpense" xlink:href="dare-20220331.xsd#dare_NonCashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NonCashLeaseExpense" xlink:to="lab_dare_NonCashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_380c5f21-4982-4ff7-8af3-3803ad77f502_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e53325d0-5b83-4796-890d-632cf22a18db_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_cbf9995b-1451-4740-a3b9-a0000b80a3e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_b461d9de-630e-421d-b60b-8aed6d9b4560_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_432100a5-9422-4e18-a573-e4a1c0346311_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_2d8977cb-3eb0-4e4b-b684-6810ea1a8ce2_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_4eb7706a-b0eb-48fa-9cc3-8ebb56f018e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual percentage increase in outstanding number of common stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7cc6a62e-37b0-4282-a668-a174d89f055c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_709dba97-d219-4d76-99b4-72cf4c116fdf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_fd6fd14d-b0ac-4cbc-96cf-6f2ba19c7954_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow from operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ResearchAndDevelopmentMilestonePayment_5e8d3800-aa8d-4bbd-bcbd-8e6dbbb6fcc6_terseLabel_en-US" xlink:label="lab_dare_ResearchAndDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_dare_ResearchAndDevelopmentMilestonePayment_label_en-US" xlink:label="lab_dare_ResearchAndDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Milestone Payment</link:label>
    <link:label id="lab_dare_ResearchAndDevelopmentMilestonePayment_documentation_en-US" xlink:label="lab_dare_ResearchAndDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ResearchAndDevelopmentMilestonePayment" xlink:href="dare-20220331.xsd#dare_ResearchAndDevelopmentMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ResearchAndDevelopmentMilestonePayment" xlink:to="lab_dare_ResearchAndDevelopmentMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6595715b-a30d-4a8b-8308-99eea39283b8_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_1d4113e3-2aef-4e55-9ee5-062ce786da30_terseLabel_en-US" xlink:label="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_label_en-US" xlink:label="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate</link:label>
    <link:label id="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_documentation_en-US" xlink:label="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by Share-based payment award fair value assumptions forfeiture rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:href="dare-20220331.xsd#dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:to="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_DeferredGrantFundingCurrent_27b1dba8-5426-4eb6-a4d2-19890a382322_terseLabel_en-US" xlink:label="lab_dare_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding</link:label>
    <link:label id="lab_dare_DeferredGrantFundingCurrent_label_en-US" xlink:label="lab_dare_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding Current</link:label>
    <link:label id="lab_dare_DeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_dare_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredGrantFundingCurrent" xlink:href="dare-20220331.xsd#dare_DeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_DeferredGrantFundingCurrent" xlink:to="lab_dare_DeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_8240693f-f05f-49a9-94b3-11e44a2f196d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_aba650f3-de3c-40d1-9f85-3dd732d76207_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d02a4f67-f8f6-4244-bdb4-0a9e5f51d5d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_SignificantAccountingPoliciesLineItems_5ced6380-1c3b-4f97-af6e-85076c02e28b_terseLabel_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_dare_SignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_dare_SignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesLineItems" xlink:href="dare-20220331.xsd#dare_SignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems" xlink:to="lab_dare_SignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_de7e6c47-e19a-4f89-a0d4-137596575c86_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PeriodofInsufficientCashandLiquidityRequirements_bfaa9653-d1df-497b-9aa4-d6684677308b_terseLabel_en-US" xlink:label="lab_dare_PeriodofInsufficientCashandLiquidityRequirements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of insufficient cash and liquidity requirements</link:label>
    <link:label id="lab_dare_PeriodofInsufficientCashandLiquidityRequirements_label_en-US" xlink:label="lab_dare_PeriodofInsufficientCashandLiquidityRequirements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of Insufficient Cash and Liquidity Requirements</link:label>
    <link:label id="lab_dare_PeriodofInsufficientCashandLiquidityRequirements_documentation_en-US" xlink:label="lab_dare_PeriodofInsufficientCashandLiquidityRequirements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of Insufficient Cash and Liquidity Requirements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PeriodofInsufficientCashandLiquidityRequirements" xlink:href="dare-20220331.xsd#dare_PeriodofInsufficientCashandLiquidityRequirements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PeriodofInsufficientCashandLiquidityRequirements" xlink:to="lab_dare_PeriodofInsufficientCashandLiquidityRequirements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_e5426bd3-f12d-4097-aa0e-c2a9059f079a_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_35ee9617-b8a2-44d7-905e-bd2239de20fe_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9353fa34-a1a2-4a3c-a848-d51c554c35e7_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_3f85103c-3233-45b5-bfcb-1588f33df0ec_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_711e73b6-6710-45d7-be42-3e98367272e5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_9c9583bd-1dc4-48e1-a171-ccbb996da6e6_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_bd2f4df7-a8b9-4926-b5ad-e32f35097c56_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantsReceivable_025b4769-6e50-4bfa-bc0c-f4dc171508e6_verboseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial payment</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_label_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable" xlink:to="lab_us-gaap_GrantsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_cae4694d-f103-4423-a693-7c4fd50909c5_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7448ca59-fb63-472d-badc-5b8436e194d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ADVATecAgreementMember_c9b7c0aa-d9ac-4c61-acd9-1bfe37db477e_terseLabel_en-US" xlink:label="lab_dare_ADVATecAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVA Tec Agreement</link:label>
    <link:label id="lab_dare_ADVATecAgreementMember_label_en-US" xlink:label="lab_dare_ADVATecAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A D V A Tec Agreement [Member]</link:label>
    <link:label id="lab_dare_ADVATecAgreementMember_documentation_en-US" xlink:label="lab_dare_ADVATecAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVA Tec agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ADVATecAgreementMember" xlink:href="dare-20220331.xsd#dare_ADVATecAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ADVATecAgreementMember" xlink:to="lab_dare_ADVATecAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d65cd621-796b-4d29-9de2-bb2fcd2892ad_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantExercisePriceDecrease_7f1df39f-2eed-457d-90b2-34c3d806de5f_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantExercisePriceDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant, exercise price, decrease (in usd per share)</link:label>
    <link:label id="lab_us-gaap_WarrantExercisePriceDecrease_label_en-US" xlink:label="lab_us-gaap_WarrantExercisePriceDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant, Exercise Price, Decrease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantExercisePriceDecrease" xlink:to="lab_us-gaap_WarrantExercisePriceDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AssignmentAgreementMember_ae02d47e-5a0c-48ae-b9de-0a20b9e1e682_terseLabel_en-US" xlink:label="lab_dare_AssignmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement</link:label>
    <link:label id="lab_dare_AssignmentAgreementMember_label_en-US" xlink:label="lab_dare_AssignmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement [Member]</link:label>
    <link:label id="lab_dare_AssignmentAgreementMember_documentation_en-US" xlink:label="lab_dare_AssignmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssignmentAgreementMember" xlink:href="dare-20220331.xsd#dare_AssignmentAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AssignmentAgreementMember" xlink:to="lab_dare_AssignmentAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_247e1840-d05b-41da-9fb5-a9884d569181_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, right-of-use asset, statement of financial position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9a0c11f3-06fe-421e-9781-e618c0135b3f_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2a514a09-a4ec-42fb-b8ce-f1f68860fa0e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f2ac2fd2-674b-4716-a70e-6e0c85357cf5_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7f8af314-fdf0-403c-81f1-026604e8df3b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_63e90d16-cd82-4a4d-9917-42e61681baab_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_ba9c922e-0788-4eee-8c77-351723864132_terseLabel_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from the exercise of warrants (in shares)</link:label>
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_label_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares</link:label>
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_documentation_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:href="dare-20220331.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:to="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5bf32326-b4c1-4e8f-90e3-9242986875f7_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_April2021AtTheMarketSalesAgreementMember_8ed1ece8-bece-4740-be02-15eb6f2bf028_terseLabel_en-US" xlink:label="lab_dare_April2021AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 2021 At The Market Sales Agreement</link:label>
    <link:label id="lab_dare_April2021AtTheMarketSalesAgreementMember_label_en-US" xlink:label="lab_dare_April2021AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 2021 At The Market Sales Agreement [Member]</link:label>
    <link:label id="lab_dare_April2021AtTheMarketSalesAgreementMember_documentation_en-US" xlink:label="lab_dare_April2021AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 2021 At The Market Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_April2021AtTheMarketSalesAgreementMember" xlink:href="dare-20220331.xsd#dare_April2021AtTheMarketSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_April2021AtTheMarketSalesAgreementMember" xlink:to="lab_dare_April2021AtTheMarketSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_c22cb2f4-0165-44a0-87fb-2ee3eab153b3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7236834b-8c18-47dd-ab13-d90fea5d138a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a4f24352-23df-49f6-80c8-e9c4a179cea4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_LicenseFee_0ae8a6a1-513d-498d-9923-9c9b7c540aca_terseLabel_en-US" xlink:label="lab_dare_LicenseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fees</link:label>
    <link:label id="lab_dare_LicenseFee_a6151757-047b-45a6-bb8b-10c6ca904692_verboseLabel_en-US" xlink:label="lab_dare_LicenseFee" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee</link:label>
    <link:label id="lab_dare_LicenseFee_label_en-US" xlink:label="lab_dare_LicenseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fee</link:label>
    <link:label id="lab_dare_LicenseFee_documentation_en-US" xlink:label="lab_dare_LicenseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseFee" xlink:href="dare-20220331.xsd#dare_LicenseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseFee" xlink:to="lab_dare_LicenseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_3d10b44f-e461-4217-a0ea-1eb99052417d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_SignificantAccountingPoliciesTable_e5f84bb2-76de-414e-8773-79d339c6f289_terseLabel_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_dare_SignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_dare_SignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesTable" xlink:href="dare-20220331.xsd#dare_SignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SignificantAccountingPoliciesTable" xlink:to="lab_dare_SignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_a361be3e-d847-464e-9abc-9285723e555f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expenses</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_3b18ddac-a056-410b-afdf-eb16ca468a28_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_76544510-1ec1-432a-a3ed-f1c557557e52_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UpfrontLicenseFeePaid_62cae679-f0c6-4bd8-b68b-0657fa9ec84b_terseLabel_en-US" xlink:label="lab_dare_UpfrontLicenseFeePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront license fee paid</link:label>
    <link:label id="lab_dare_UpfrontLicenseFeePaid_label_en-US" xlink:label="lab_dare_UpfrontLicenseFeePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront License Fee Paid</link:label>
    <link:label id="lab_dare_UpfrontLicenseFeePaid_documentation_en-US" xlink:label="lab_dare_UpfrontLicenseFeePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront License Fee Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UpfrontLicenseFeePaid" xlink:href="dare-20220331.xsd#dare_UpfrontLicenseFeePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UpfrontLicenseFeePaid" xlink:to="lab_dare_UpfrontLicenseFeePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_97075368-2a55-4928-9b7a-cf4348396151_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on extinguishment of note payable</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_c9873825-8c1e-49d4-ad1a-f5b508c7fdee_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on extinguishment of notes payable and accrued interest</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ReceivableForExpensesEligibleForReimbursement_6c9dc840-ca07-4072-96be-0b7468764702_terseLabel_en-US" xlink:label="lab_dare_ReceivableForExpensesEligibleForReimbursement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable for expenses eligible for reimbursement</link:label>
    <link:label id="lab_dare_ReceivableForExpensesEligibleForReimbursement_label_en-US" xlink:label="lab_dare_ReceivableForExpensesEligibleForReimbursement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable For Expenses Eligible For Reimbursement</link:label>
    <link:label id="lab_dare_ReceivableForExpensesEligibleForReimbursement_documentation_en-US" xlink:label="lab_dare_ReceivableForExpensesEligibleForReimbursement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable For Expenses Eligible For Reimbursement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ReceivableForExpensesEligibleForReimbursement" xlink:href="dare-20220331.xsd#dare_ReceivableForExpensesEligibleForReimbursement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ReceivableForExpensesEligibleForReimbursement" xlink:to="lab_dare_ReceivableForExpensesEligibleForReimbursement" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ProceedsFromAwardOfGrant_20a7eb5b-b9d8-4872-9260-8683da5e5208_terseLabel_en-US" xlink:label="lab_dare_ProceedsFromAwardOfGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount awarded for grant</link:label>
    <link:label id="lab_dare_ProceedsFromAwardOfGrant_label_en-US" xlink:label="lab_dare_ProceedsFromAwardOfGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Award Of Grant</link:label>
    <link:label id="lab_dare_ProceedsFromAwardOfGrant_documentation_en-US" xlink:label="lab_dare_ProceedsFromAwardOfGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Award Of Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ProceedsFromAwardOfGrant" xlink:href="dare-20220331.xsd#dare_ProceedsFromAwardOfGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ProceedsFromAwardOfGrant" xlink:to="lab_dare_ProceedsFromAwardOfGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_OrganonMember_3fd48573-6732-4d16-b267-b63685c5eacf_terseLabel_en-US" xlink:label="lab_dare_OrganonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organon</link:label>
    <link:label id="lab_dare_OrganonMember_label_en-US" xlink:label="lab_dare_OrganonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organon [Member]</link:label>
    <link:label id="lab_dare_OrganonMember_documentation_en-US" xlink:label="lab_dare_OrganonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organon</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_OrganonMember" xlink:href="dare-20220331.xsd#dare_OrganonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_OrganonMember" xlink:to="lab_dare_OrganonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_bb3bbcce-4466-4be5-bdbb-a391c417f7a3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination shares issued (in usd per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_45b65c7f-7062-414f-8663-f747424620f8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PaymentOfAdditionalConsiderationInBusinessCombination_6f157c8f-a55d-4485-87f2-d6711bb4ad4d_terseLabel_en-US" xlink:label="lab_dare_PaymentOfAdditionalConsiderationInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of additional consideration</link:label>
    <link:label id="lab_dare_PaymentOfAdditionalConsiderationInBusinessCombination_label_en-US" xlink:label="lab_dare_PaymentOfAdditionalConsiderationInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Additional Consideration in Business Combination</link:label>
    <link:label id="lab_dare_PaymentOfAdditionalConsiderationInBusinessCombination_documentation_en-US" xlink:label="lab_dare_PaymentOfAdditionalConsiderationInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Additional Consideration in Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PaymentOfAdditionalConsiderationInBusinessCombination" xlink:href="dare-20220331.xsd#dare_PaymentOfAdditionalConsiderationInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PaymentOfAdditionalConsiderationInBusinessCombination" xlink:to="lab_dare_PaymentOfAdditionalConsiderationInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25bcd6d5-1451-4949-b8c0-6f335a860cbc_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>dare-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:fd319a35-eb86-476b-85ca-f1b0e0a14df0,g:c97ede0a-3f8a-49b3-9abb-a622ab8bee13-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://darebioscience.com/role/CoverPage" xlink:type="simple" xlink:href="dare-20220331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ee70f197-a22b-47d4-a44f-5849598c8036" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_DocumentType_ee70f197-a22b-47d4-a44f-5849598c8036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_83c7f465-9c5d-49f4-bb73-345b18fc87ad" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_DocumentQuarterlyReport_83c7f465-9c5d-49f4-bb73-345b18fc87ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ffda6a3a-dda4-4ab1-931b-cc20a900e955" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_DocumentPeriodEndDate_ffda6a3a-dda4-4ab1-931b-cc20a900e955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_257aba55-efc3-4294-abcb-c8233b36b112" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_DocumentTransitionReport_257aba55-efc3-4294-abcb-c8233b36b112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_dff65b4d-1263-46be-aec5-2b215721a0cc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_EntityRegistrantName_dff65b4d-1263-46be-aec5-2b215721a0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c15b2ef7-0557-4f43-a120-4397802d48f7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c15b2ef7-0557-4f43-a120-4397802d48f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_cff518f7-a216-4c76-9e22-2895d76999e0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_EntityFileNumber_cff518f7-a216-4c76-9e22-2895d76999e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ecc0e8ab-f498-4fa7-a321-3c79c7a829fb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_EntityTaxIdentificationNumber_ecc0e8ab-f498-4fa7-a321-3c79c7a829fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_457eae23-ea43-46b5-96a6-90d132d3abf3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_EntityAddressAddressLine1_457eae23-ea43-46b5-96a6-90d132d3abf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_0026e7ca-8bd7-45a1-a35d-35c095184245" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_EntityAddressAddressLine2_0026e7ca-8bd7-45a1-a35d-35c095184245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_6a0f95c2-82b2-42c1-baf1-cd43aed72262" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_EntityAddressCityOrTown_6a0f95c2-82b2-42c1-baf1-cd43aed72262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_16255cb8-8c13-47ce-a07f-dcc1ebabc00c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_EntityAddressStateOrProvince_16255cb8-8c13-47ce-a07f-dcc1ebabc00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_358817ab-d05e-42f7-be85-fb364d110fd5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_CityAreaCode_358817ab-d05e-42f7-be85-fb364d110fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6c76e775-a985-41b3-a7cf-09cec3a47f25" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_LocalPhoneNumber_6c76e775-a985-41b3-a7cf-09cec3a47f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_959fd265-38fe-4a15-b366-6d5def65bc26" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_EntityAddressPostalZipCode_959fd265-38fe-4a15-b366-6d5def65bc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_18276464-03d5-4c54-a993-11b2be45c16f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_Security12bTitle_18276464-03d5-4c54-a993-11b2be45c16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_fc0f21dc-9e88-45d5-be65-95ce88a9b115" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_TradingSymbol_fc0f21dc-9e88-45d5-be65-95ce88a9b115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_88e6c923-ddb9-4233-a238-f1e63e6a4a32" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_EntityCurrentReportingStatus_88e6c923-ddb9-4233-a238-f1e63e6a4a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_1135d840-086d-4f9c-9fc2-4f1827d9517f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_EntityInteractiveDataCurrent_1135d840-086d-4f9c-9fc2-4f1827d9517f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_94a4366f-fe4a-48e2-8535-1c261c877b14" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_EntityFilerCategory_94a4366f-fe4a-48e2-8535-1c261c877b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_91440540-cd76-4d78-8b67-556a573eee7c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_EntitySmallBusiness_91440540-cd76-4d78-8b67-556a573eee7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_fb92cda5-93ff-4b7c-bfb5-ee40b0692e0e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_EntityEmergingGrowthCompany_fb92cda5-93ff-4b7c-bfb5-ee40b0692e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_42c8412c-0a9d-4b22-82da-d4636056e83e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_EntityShellCompany_42c8412c-0a9d-4b22-82da-d4636056e83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c224e070-9cbf-45df-9982-248a13c86c30" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c224e070-9cbf-45df-9982-248a13c86c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_71f28bbd-f0a3-41f3-936d-a267829c0aa8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_AmendmentFlag_71f28bbd-f0a3-41f3-936d-a267829c0aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f4a679cc-524d-479d-be0e-d04f9710e787" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_DocumentFiscalYearFocus_f4a679cc-524d-479d-be0e-d04f9710e787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ba3ad81e-3525-4ea5-8882-aaaa8599ce1a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ba3ad81e-3525-4ea5-8882-aaaa8599ce1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ebde3a64-0b31-4066-b14d-eaf63b566d2b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_EntityCentralIndexKey_ebde3a64-0b31-4066-b14d-eaf63b566d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_537c18d7-cb2d-4929-bc1d-2b2a07d39121" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74fc0e43-b309-46b3-a647-c2ae45997303" xlink:to="loc_dei_CurrentFiscalYearEndDate_537c18d7-cb2d-4929-bc1d-2b2a07d39121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="dare-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_98972a2a-c428-4403-979c-bce5c75b5c57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3fa9555d-6c7e-43e3-98f3-b1df041cc9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98972a2a-c428-4403-979c-bce5c75b5c57" xlink:to="loc_us-gaap_AssetsAbstract_3fa9555d-6c7e-43e3-98f3-b1df041cc9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_5eb1b616-6d6c-4314-af48-21c122fb92d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa9555d-6c7e-43e3-98f3-b1df041cc9bc" xlink:to="loc_us-gaap_AssetsCurrentAbstract_5eb1b616-6d6c-4314-af48-21c122fb92d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2b607efe-0733-42c6-a631-8d6d83fdeeec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5eb1b616-6d6c-4314-af48-21c122fb92d2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2b607efe-0733-42c6-a631-8d6d83fdeeec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_56cd5a01-0dab-46b8-934f-fc727eae35a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5eb1b616-6d6c-4314-af48-21c122fb92d2" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_56cd5a01-0dab-46b8-934f-fc727eae35a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_167b302c-0b22-49b8-a29f-f3791bbfb864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5eb1b616-6d6c-4314-af48-21c122fb92d2" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_167b302c-0b22-49b8-a29f-f3791bbfb864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_83ee65da-fb7b-4b6e-b462-14d48f231c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5eb1b616-6d6c-4314-af48-21c122fb92d2" xlink:to="loc_us-gaap_AssetsCurrent_83ee65da-fb7b-4b6e-b462-14d48f231c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a034d301-e358-4575-bba8-5bd480e43f04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa9555d-6c7e-43e3-98f3-b1df041cc9bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a034d301-e358-4575-bba8-5bd480e43f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_27c4b62b-aa21-4081-98ae-779276ce4918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa9555d-6c7e-43e3-98f3-b1df041cc9bc" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_27c4b62b-aa21-4081-98ae-779276ce4918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_62c6551d-f5df-4c54-9e06-f2f989425c54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa9555d-6c7e-43e3-98f3-b1df041cc9bc" xlink:to="loc_us-gaap_Assets_62c6551d-f5df-4c54-9e06-f2f989425c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a398d5c6-835e-4810-83d0-7bb7b9d7ccad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98972a2a-c428-4403-979c-bce5c75b5c57" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a398d5c6-835e-4810-83d0-7bb7b9d7ccad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_48410e82-e32a-4ffc-ab70-b427e75e0f55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a398d5c6-835e-4810-83d0-7bb7b9d7ccad" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_48410e82-e32a-4ffc-ab70-b427e75e0f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6711fd04-4f85-4a2f-a4fd-cde3478312bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_48410e82-e32a-4ffc-ab70-b427e75e0f55" xlink:to="loc_us-gaap_AccountsPayableCurrent_6711fd04-4f85-4a2f-a4fd-cde3478312bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_984963ac-27aa-4c92-85c1-08957500b161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_48410e82-e32a-4ffc-ab70-b427e75e0f55" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_984963ac-27aa-4c92-85c1-08957500b161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredGrantFundingCurrent_fae13696-90a2-4b37-93ff-84c561f79f86" xlink:href="dare-20220331.xsd#dare_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_48410e82-e32a-4ffc-ab70-b427e75e0f55" xlink:to="loc_dare_DeferredGrantFundingCurrent_fae13696-90a2-4b37-93ff-84c561f79f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_fa79a54b-c34d-417a-a8f3-79e654e1007a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_48410e82-e32a-4ffc-ab70-b427e75e0f55" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_fa79a54b-c34d-417a-a8f3-79e654e1007a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ecc5c31d-e3a4-45bb-9dea-0abbf9629026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_48410e82-e32a-4ffc-ab70-b427e75e0f55" xlink:to="loc_us-gaap_LiabilitiesCurrent_ecc5c31d-e3a4-45bb-9dea-0abbf9629026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_830d9f04-f45f-4d74-9454-1c7cb4cf1b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a398d5c6-835e-4810-83d0-7bb7b9d7ccad" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_830d9f04-f45f-4d74-9454-1c7cb4cf1b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_918fd918-bb27-4c82-a812-7c6aa98144d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a398d5c6-835e-4810-83d0-7bb7b9d7ccad" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_918fd918-bb27-4c82-a812-7c6aa98144d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_696e795c-aaa2-442a-beac-c060825ffd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a398d5c6-835e-4810-83d0-7bb7b9d7ccad" xlink:to="loc_us-gaap_Liabilities_696e795c-aaa2-442a-beac-c060825ffd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b32ff092-637a-4faa-b222-08edf9baeb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a398d5c6-835e-4810-83d0-7bb7b9d7ccad" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b32ff092-637a-4faa-b222-08edf9baeb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a6454bf8-bae6-4c66-a13c-61b207bd9280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a398d5c6-835e-4810-83d0-7bb7b9d7ccad" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a6454bf8-bae6-4c66-a13c-61b207bd9280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_07633cc1-fea6-4291-a806-43e0015d8ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a6454bf8-bae6-4c66-a13c-61b207bd9280" xlink:to="loc_us-gaap_PreferredStockValue_07633cc1-fea6-4291-a806-43e0015d8ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_15f902be-fef6-4434-bebf-438b82a0a003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a6454bf8-bae6-4c66-a13c-61b207bd9280" xlink:to="loc_us-gaap_CommonStockValue_15f902be-fef6-4434-bebf-438b82a0a003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dbb9482b-4ff9-418a-b6d1-ba3a8e45c513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a6454bf8-bae6-4c66-a13c-61b207bd9280" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dbb9482b-4ff9-418a-b6d1-ba3a8e45c513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c2cc33c1-5be5-4314-af79-b035a6156342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a6454bf8-bae6-4c66-a13c-61b207bd9280" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c2cc33c1-5be5-4314-af79-b035a6156342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34aa9dc9-1249-4799-b79c-f0e3bf87ee07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a6454bf8-bae6-4c66-a13c-61b207bd9280" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34aa9dc9-1249-4799-b79c-f0e3bf87ee07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8345cd1b-0ebe-4dea-acf4-2cb5816fd339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a6454bf8-bae6-4c66-a13c-61b207bd9280" xlink:to="loc_us-gaap_StockholdersEquity_8345cd1b-0ebe-4dea-acf4-2cb5816fd339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_285dfef7-978b-4624-9d19-9335ce5063b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a398d5c6-835e-4810-83d0-7bb7b9d7ccad" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_285dfef7-978b-4624-9d19-9335ce5063b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="dare-20220331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_958c8966-ab42-4fa3-ad51-9ce16f41f4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_125996d5-7fd3-4313-893c-f5fc889f6699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_958c8966-ab42-4fa3-ad51-9ce16f41f4bb" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_125996d5-7fd3-4313-893c-f5fc889f6699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_083f2d57-3ad8-43d3-a334-f3af02f9e9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_958c8966-ab42-4fa3-ad51-9ce16f41f4bb" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_083f2d57-3ad8-43d3-a334-f3af02f9e9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f4a81573-11cf-4096-9533-843189637ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_958c8966-ab42-4fa3-ad51-9ce16f41f4bb" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f4a81573-11cf-4096-9533-843189637ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_56fd2ae6-a86b-4826-9e91-31509585f691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_958c8966-ab42-4fa3-ad51-9ce16f41f4bb" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_56fd2ae6-a86b-4826-9e91-31509585f691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c761c5a5-a219-4833-b618-161ec1e2f36a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_958c8966-ab42-4fa3-ad51-9ce16f41f4bb" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c761c5a5-a219-4833-b618-161ec1e2f36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e087c7cd-4212-406f-9f17-dbf2b8395dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_958c8966-ab42-4fa3-ad51-9ce16f41f4bb" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e087c7cd-4212-406f-9f17-dbf2b8395dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_870a4510-37e0-47af-a112-1cc9f765da0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_958c8966-ab42-4fa3-ad51-9ce16f41f4bb" xlink:to="loc_us-gaap_CommonStockSharesIssued_870a4510-37e0-47af-a112-1cc9f765da0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1d969e16-057e-4fe9-8e2b-f77b3a985d54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_958c8966-ab42-4fa3-ad51-9ce16f41f4bb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1d969e16-057e-4fe9-8e2b-f77b3a985d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="dare-20220331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_aec709a4-b680-45e0-87df-fe0fe9b3a8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_21529ff6-7098-4148-9314-fc00aac5004a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aec709a4-b680-45e0-87df-fe0fe9b3a8ff" xlink:to="loc_us-gaap_OperatingExpensesAbstract_21529ff6-7098-4148-9314-fc00aac5004a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4b1a0229-a488-41cb-aa04-a0b4c524c269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_21529ff6-7098-4148-9314-fc00aac5004a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4b1a0229-a488-41cb-aa04-a0b4c524c269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_10790e46-c6f1-4890-b479-4904695825aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_21529ff6-7098-4148-9314-fc00aac5004a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_10790e46-c6f1-4890-b479-4904695825aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseFee_38a754e3-2d1d-432f-b560-7bb11e515704" xlink:href="dare-20220331.xsd#dare_LicenseFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_21529ff6-7098-4148-9314-fc00aac5004a" xlink:to="loc_dare_LicenseFee_38a754e3-2d1d-432f-b560-7bb11e515704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_bc81e183-12dc-4f39-9df2-dbdb71b99956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_21529ff6-7098-4148-9314-fc00aac5004a" xlink:to="loc_us-gaap_OperatingExpenses_bc81e183-12dc-4f39-9df2-dbdb71b99956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cf2034d2-5c70-4514-b90a-55e451dc3f39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aec709a4-b680-45e0-87df-fe0fe9b3a8ff" xlink:to="loc_us-gaap_OperatingIncomeLoss_cf2034d2-5c70-4514-b90a-55e451dc3f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2a596e64-cb20-4c6e-9ef4-a7e535b7b926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aec709a4-b680-45e0-87df-fe0fe9b3a8ff" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2a596e64-cb20-4c6e-9ef4-a7e535b7b926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_058a0b82-a4f6-489a-8844-7f1899090fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aec709a4-b680-45e0-87df-fe0fe9b3a8ff" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_058a0b82-a4f6-489a-8844-7f1899090fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6b36310b-650d-4c87-84ae-96496ea06de5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aec709a4-b680-45e0-87df-fe0fe9b3a8ff" xlink:to="loc_us-gaap_NetIncomeLoss_6b36310b-650d-4c87-84ae-96496ea06de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e8e51431-8b2a-42ea-8594-b8e3aaa8bc06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aec709a4-b680-45e0-87df-fe0fe9b3a8ff" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e8e51431-8b2a-42ea-8594-b8e3aaa8bc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_bf8e1a49-569e-488b-958e-6e7ab84e1fde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aec709a4-b680-45e0-87df-fe0fe9b3a8ff" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_bf8e1a49-569e-488b-958e-6e7ab84e1fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_45b06f4d-cec0-421d-a32b-5169bbf0ccc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aec709a4-b680-45e0-87df-fe0fe9b3a8ff" xlink:to="loc_us-gaap_EarningsPerShareBasic_45b06f4d-cec0-421d-a32b-5169bbf0ccc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1d8bc664-7244-4340-b2e5-ffdb5064a310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aec709a4-b680-45e0-87df-fe0fe9b3a8ff" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1d8bc664-7244-4340-b2e5-ffdb5064a310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3955b885-e2b0-44e3-bf14-c2a003bb23cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aec709a4-b680-45e0-87df-fe0fe9b3a8ff" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3955b885-e2b0-44e3-bf14-c2a003bb23cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b2b16b92-c65c-4462-a583-baec87b0f42e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3955b885-e2b0-44e3-bf14-c2a003bb23cd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b2b16b92-c65c-4462-a583-baec87b0f42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_044aef12-483a-4516-b42a-8f55af7bd165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3955b885-e2b0-44e3-bf14-c2a003bb23cd" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_044aef12-483a-4516-b42a-8f55af7bd165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="dare-20220331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6abc6f09-d618-48c5-981b-9fe60b19fc72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4ff5721d-529a-49ac-9566-dc3023e52b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6abc6f09-d618-48c5-981b-9fe60b19fc72" xlink:to="loc_us-gaap_StatementTable_4ff5721d-529a-49ac-9566-dc3023e52b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2ff1c311-355e-4dc4-a677-eb810c46ef3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4ff5721d-529a-49ac-9566-dc3023e52b6c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2ff1c311-355e-4dc4-a677-eb810c46ef3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d057ee64-8609-4dc6-ba55-8046605dfd23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2ff1c311-355e-4dc4-a677-eb810c46ef3c" xlink:to="loc_us-gaap_EquityComponentDomain_d057ee64-8609-4dc6-ba55-8046605dfd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_adf055fa-56c9-408f-87bf-29c5f1002922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d057ee64-8609-4dc6-ba55-8046605dfd23" xlink:to="loc_us-gaap_CommonStockMember_adf055fa-56c9-408f-87bf-29c5f1002922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_296eaa62-236c-4366-9940-a632c3f5742d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d057ee64-8609-4dc6-ba55-8046605dfd23" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_296eaa62-236c-4366-9940-a632c3f5742d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8520a420-6c43-4f5d-911c-7b7702769bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d057ee64-8609-4dc6-ba55-8046605dfd23" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8520a420-6c43-4f5d-911c-7b7702769bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6ddf373d-cb9a-43b9-a1a2-83e64b107243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d057ee64-8609-4dc6-ba55-8046605dfd23" xlink:to="loc_us-gaap_RetainedEarningsMember_6ddf373d-cb9a-43b9-a1a2-83e64b107243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c8ca5018-d279-4fb7-acca-65dc2f88e455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4ff5721d-529a-49ac-9566-dc3023e52b6c" xlink:to="loc_us-gaap_StatementLineItems_c8ca5018-d279-4fb7-acca-65dc2f88e455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c8ca5018-d279-4fb7-acca-65dc2f88e455" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3134b506-88a4-4e96-b7c3-4edfce9603b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:to="loc_us-gaap_SharesOutstanding_3134b506-88a4-4e96-b7c3-4edfce9603b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b279ab90-01b9-4c1b-85f1-274965ea6400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:to="loc_us-gaap_StockholdersEquity_b279ab90-01b9-4c1b-85f1-274965ea6400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c9e7b9e4-5269-4a07-8ee9-1dd095b18a01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c9e7b9e4-5269-4a07-8ee9-1dd095b18a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_25b46119-c81d-4d89-bb03-2cf17a824b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_25b46119-c81d-4d89-bb03-2cf17a824b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1d49dc77-7147-4b2b-b40e-29456ad09c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1d49dc77-7147-4b2b-b40e-29456ad09c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_e1accce4-bc0b-446d-88c8-24f40374dd40" xlink:href="dare-20220331.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:to="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_e1accce4-bc0b-446d-88c8-24f40374dd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_bd3edb3b-0dfb-4d01-b228-303c71f72f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_bd3edb3b-0dfb-4d01-b228-303c71f72f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_474f859c-2040-4aa3-8b2a-5abe431c501c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:to="loc_us-gaap_NetIncomeLoss_474f859c-2040-4aa3-8b2a-5abe431c501c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_93b9b149-d30a-4b87-a283-fd6b72547e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_93b9b149-d30a-4b87-a283-fd6b72547e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_63b056a1-3932-4007-adbf-33cde9c5ae40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:to="loc_us-gaap_SharesOutstanding_63b056a1-3932-4007-adbf-33cde9c5ae40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3a9b5304-5c40-47b5-8579-f266687acd46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a40d76e-c0e3-40c1-b0fe-3f230033485b" xlink:to="loc_us-gaap_StockholdersEquity_3a9b5304-5c40-47b5-8579-f266687acd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="dare-20220331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_135d0590-8d4e-4fc4-b822-13deec2003dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_268ad11b-1899-4ffc-afa1-75030a9fba26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_135d0590-8d4e-4fc4-b822-13deec2003dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_268ad11b-1899-4ffc-afa1-75030a9fba26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_07e24ee7-2828-4d73-b82b-80d1a332dafc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_268ad11b-1899-4ffc-afa1-75030a9fba26" xlink:to="loc_us-gaap_NetIncomeLoss_07e24ee7-2828-4d73-b82b-80d1a332dafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ef86e41-3fb4-4d08-9305-afa50b4a877f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_268ad11b-1899-4ffc-afa1-75030a9fba26" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ef86e41-3fb4-4d08-9305-afa50b4a877f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_f412dc73-5365-465c-9d33-fa9b5a84663f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ef86e41-3fb4-4d08-9305-afa50b4a877f" xlink:to="loc_us-gaap_Depreciation_f412dc73-5365-465c-9d33-fa9b5a84663f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4d08b1f3-500a-4a05-83a2-8e27da781468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ef86e41-3fb4-4d08-9305-afa50b4a877f" xlink:to="loc_us-gaap_ShareBasedCompensation_4d08b1f3-500a-4a05-83a2-8e27da781468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NonCashLeaseExpense_a70cb8a2-f537-44cc-921e-22e78ac5100e" xlink:href="dare-20220331.xsd#dare_NonCashLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ef86e41-3fb4-4d08-9305-afa50b4a877f" xlink:to="loc_dare_NonCashLeaseExpense_a70cb8a2-f537-44cc-921e-22e78ac5100e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_73e007fc-c0df-4e7f-9e2e-e916737c37ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ef86e41-3fb4-4d08-9305-afa50b4a877f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_73e007fc-c0df-4e7f-9e2e-e916737c37ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6d89648c-90c6-4d59-b56a-534ccba79cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ef86e41-3fb4-4d08-9305-afa50b4a877f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6d89648c-90c6-4d59-b56a-534ccba79cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_e0c0d3c9-9046-4d66-aa6e-6c05c03269b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6d89648c-90c6-4d59-b56a-534ccba79cd2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_e0c0d3c9-9046-4d66-aa6e-6c05c03269b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_0a3d1153-0379-41fb-8dd2-c54194569e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6d89648c-90c6-4d59-b56a-534ccba79cd2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_0a3d1153-0379-41fb-8dd2-c54194569e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_e57060e7-3b85-4a8c-84f1-ada5b43deb4e" xlink:href="dare-20220331.xsd#dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6d89648c-90c6-4d59-b56a-534ccba79cd2" xlink:to="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_e57060e7-3b85-4a8c-84f1-ada5b43deb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c3b5957b-2270-414c-a37b-52ff9fbfbe01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6d89648c-90c6-4d59-b56a-534ccba79cd2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c3b5957b-2270-414c-a37b-52ff9fbfbe01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d192a69b-f40e-4273-a176-ea3e4e13de4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6d89648c-90c6-4d59-b56a-534ccba79cd2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d192a69b-f40e-4273-a176-ea3e4e13de4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_IncreaseDecreaseInDeferredGrantFunding_305d151c-acfb-49e6-a8da-3b3da3aa36d6" xlink:href="dare-20220331.xsd#dare_IncreaseDecreaseInDeferredGrantFunding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6d89648c-90c6-4d59-b56a-534ccba79cd2" xlink:to="loc_dare_IncreaseDecreaseInDeferredGrantFunding_305d151c-acfb-49e6-a8da-3b3da3aa36d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39c811b3-1fdf-4b71-ac04-6ab031e2b2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_268ad11b-1899-4ffc-afa1-75030a9fba26" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39c811b3-1fdf-4b71-ac04-6ab031e2b2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_96e743d5-0732-411a-9084-cd71074967f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_135d0590-8d4e-4fc4-b822-13deec2003dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_96e743d5-0732-411a-9084-cd71074967f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a1151299-f841-4846-b568-1607cc37be16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_96e743d5-0732-411a-9084-cd71074967f9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a1151299-f841-4846-b568-1607cc37be16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e7deb76-7b58-4441-a342-61173f78e90b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_96e743d5-0732-411a-9084-cd71074967f9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e7deb76-7b58-4441-a342-61173f78e90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_201ab8f2-0839-4d80-b757-a81906ea8443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_135d0590-8d4e-4fc4-b822-13deec2003dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_201ab8f2-0839-4d80-b757-a81906ea8443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_c82eb6f2-56ef-4afc-a87c-1dc1b09a9acc" xlink:href="dare-20220331.xsd#dare_NetProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_201ab8f2-0839-4d80-b757-a81906ea8443" xlink:to="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_c82eb6f2-56ef-4afc-a87c-1dc1b09a9acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_94f51f4c-eb3a-418a-8d8d-afc6ca61ab53" xlink:href="dare-20220331.xsd#dare_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_201ab8f2-0839-4d80-b757-a81906ea8443" xlink:to="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_94f51f4c-eb3a-418a-8d8d-afc6ca61ab53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_07a9caef-5f71-4028-81d7-aa604aaf1c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_201ab8f2-0839-4d80-b757-a81906ea8443" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_07a9caef-5f71-4028-81d7-aa604aaf1c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7ef311c0-364f-43af-be37-f08389bae0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_135d0590-8d4e-4fc4-b822-13deec2003dc" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7ef311c0-364f-43af-be37-f08389bae0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5370d0e7-682b-4477-8a46-3336ce6e8fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_135d0590-8d4e-4fc4-b822-13deec2003dc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5370d0e7-682b-4477-8a46-3336ce6e8fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e066c8a3-f5dc-4864-9662-8ce6d76363d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_135d0590-8d4e-4fc4-b822-13deec2003dc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e066c8a3-f5dc-4864-9662-8ce6d76363d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a47927fc-b2de-4968-a340-eaef930b3f29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_135d0590-8d4e-4fc4-b822-13deec2003dc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a47927fc-b2de-4968-a340-eaef930b3f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1cb84d39-5db6-427d-8cfd-004ee0155420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_135d0590-8d4e-4fc4-b822-13deec2003dc" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_1cb84d39-5db6-427d-8cfd-004ee0155420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ForgivenessOfPaycheckProtectionProgramNotePayable_56778591-35dc-49cf-bc1a-fcbdb45cfda6" xlink:href="dare-20220331.xsd#dare_ForgivenessOfPaycheckProtectionProgramNotePayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1cb84d39-5db6-427d-8cfd-004ee0155420" xlink:to="loc_dare_ForgivenessOfPaycheckProtectionProgramNotePayable_56778591-35dc-49cf-bc1a-fcbdb45cfda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a4227ecc-47fd-44f3-b2ea-23a10a2cd3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1cb84d39-5db6-427d-8cfd-004ee0155420" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a4227ecc-47fd-44f3-b2ea-23a10a2cd3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="dare-20220331.xsd#OrganizationandDescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36b72ee8-c23f-4dcb-b36d-250fa630f574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6df9ec26-1205-4505-a4c7-b2ace49eb49a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36b72ee8-c23f-4dcb-b36d-250fa630f574" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6df9ec26-1205-4505-a4c7-b2ace49eb49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#OrganizationandDescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_232a1096-36a6-4a1a-929e-95917f454198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_af63b17f-bd14-4205-80d5-6756a52fdf01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_232a1096-36a6-4a1a-929e-95917f454198" xlink:to="loc_us-gaap_NumberOfOperatingSegments_af63b17f-bd14-4205-80d5-6756a52fdf01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="dare-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_77889d03-2bd7-4e80-afac-a62d97217faa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_99b7945d-453f-4836-be48-dd7dc667d218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_77889d03-2bd7-4e80-afac-a62d97217faa" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_99b7945d-453f-4836-be48-dd7dc667d218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="dare-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_18183f1b-78c3-43d5-ae54-f8271df20e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_271ce98e-4151-4d6f-9603-59d0a3e4e145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18183f1b-78c3-43d5-ae54-f8271df20e60" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_271ce98e-4151-4d6f-9603-59d0a3e4e145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GoingConcernPolicyTextBlock_a7c90ae4-08fe-4ced-a98d-bd50369cb0e9" xlink:href="dare-20220331.xsd#dare_GoingConcernPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18183f1b-78c3-43d5-ae54-f8271df20e60" xlink:to="loc_dare_GoingConcernPolicyTextBlock_a7c90ae4-08fe-4ced-a98d-bd50369cb0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_d261354a-2e2d-4bf3-aacb-a555cbeee7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18183f1b-78c3-43d5-ae54-f8271df20e60" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_d261354a-2e2d-4bf3-aacb-a555cbeee7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_173d67dd-4951-486f-a0f9-4cceb78c3cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18183f1b-78c3-43d5-ae54-f8271df20e60" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_173d67dd-4951-486f-a0f9-4cceb78c3cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="dare-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_584cf88e-0916-4477-8144-ddd81e340b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_88beefb5-01d8-4ab1-a635-2541b1c214b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_584cf88e-0916-4477-8144-ddd81e340b4b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_88beefb5-01d8-4ab1-a635-2541b1c214b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6d665c01-f0f3-458b-af6d-8bfd5ca46183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesTable_92118821-34ce-4791-8e8e-d8adf7c7a376" xlink:href="dare-20220331.xsd#dare_SignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6d665c01-f0f3-458b-af6d-8bfd5ca46183" xlink:to="loc_dare_SignificantAccountingPoliciesTable_92118821-34ce-4791-8e8e-d8adf7c7a376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c7738d8a-f7ab-4959-8cde-e9858e2c23a6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesTable_92118821-34ce-4791-8e8e-d8adf7c7a376" xlink:to="loc_srt_CounterpartyNameAxis_c7738d8a-f7ab-4959-8cde-e9858e2c23a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_873ea665-7783-4b21-9341-8c01a1568b64" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c7738d8a-f7ab-4959-8cde-e9858e2c23a6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_873ea665-7783-4b21-9341-8c01a1568b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_OrganonMember_9c2be024-5957-422c-aa65-912858fc7f4b" xlink:href="dare-20220331.xsd#dare_OrganonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_873ea665-7783-4b21-9341-8c01a1568b64" xlink:to="loc_dare_OrganonMember_9c2be024-5957-422c-aa65-912858fc7f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:href="dare-20220331.xsd#dare_SignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesTable_92118821-34ce-4791-8e8e-d8adf7c7a376" xlink:to="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_29caebe2-a344-4cf3-b679-4b1033aae8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_29caebe2-a344-4cf3-b679-4b1033aae8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e9778099-b3f4-4c13-97ca-eb0a9cddf6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e9778099-b3f4-4c13-97ca-eb0a9cddf6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WorkingCapitalIncreaseDeficit_1a14777f-37bf-4509-a48b-af36ed3dc1cb" xlink:href="dare-20220331.xsd#dare_WorkingCapitalIncreaseDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_dare_WorkingCapitalIncreaseDeficit_1a14777f-37bf-4509-a48b-af36ed3dc1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_528aad66-d38f-487f-90cf-34645d380851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_us-gaap_NetIncomeLoss_528aad66-d38f-487f-90cf-34645d380851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b9e986b4-0dcc-4d11-b6b6-22e8be3b39ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b9e986b4-0dcc-4d11-b6b6-22e8be3b39ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UpfrontLicenseFeeAmountPaid_aea70dcb-0402-44da-8c2d-7c9cced4037f" xlink:href="dare-20220331.xsd#dare_UpfrontLicenseFeeAmountPaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_dare_UpfrontLicenseFeeAmountPaid_aea70dcb-0402-44da-8c2d-7c9cced4037f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmount_33b36967-8c99-416a-a778-d05f53a637b5" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsContingentAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_dare_MilestonePaymentsContingentAmount_33b36967-8c99-416a-a778-d05f53a637b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_07d20379-f137-40b6-8dfc-febaefb10bc7" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_07d20379-f137-40b6-8dfc-febaefb10bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount_77f8655d-53fd-4986-8793-daed015cbef3" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount_77f8655d-53fd-4986-8793-daed015cbef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PeriodofInsufficientCashandLiquidityRequirements_97fdda6d-0b80-4009-985b-3fbc5f87deae" xlink:href="dare-20220331.xsd#dare_PeriodofInsufficientCashandLiquidityRequirements"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_dare_PeriodofInsufficientCashandLiquidityRequirements_97fdda6d-0b80-4009-985b-3fbc5f87deae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_007d7a33-ca03-478b-9f28-bb2f3efd3b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_007d7a33-ca03-478b-9f28-bb2f3efd3b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UpfrontLicenseFeePaid_db3b3315-ed35-43ff-b3e6-f245972eb683" xlink:href="dare-20220331.xsd#dare_UpfrontLicenseFeePaid"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_dare_UpfrontLicenseFeePaid_db3b3315-ed35-43ff-b3e6-f245972eb683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f6f29f25-1603-45d8-bc12-4b2b50a13827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_4c97f183-a678-433f-93f1-583ca8450889" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f6f29f25-1603-45d8-bc12-4b2b50a13827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3797bdf7-e750-40ed-8d91-d19f5c5ba871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d88e43bb-9595-46f9-81a5-c2a2f637a314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3797bdf7-e750-40ed-8d91-d19f5c5ba871" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d88e43bb-9595-46f9-81a5-c2a2f637a314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b14d906-4c1e-4a05-b601-687bda59c5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d88e43bb-9595-46f9-81a5-c2a2f637a314" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b14d906-4c1e-4a05-b601-687bda59c5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_91ea6c91-df01-408d-93fb-3c704878226d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b14d906-4c1e-4a05-b601-687bda59c5ea" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_91ea6c91-df01-408d-93fb-3c704878226d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_dd64a0bc-0112-4e3d-bffd-20ba4596cff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_91ea6c91-df01-408d-93fb-3c704878226d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_dd64a0bc-0112-4e3d-bffd-20ba4596cff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beb18af6-5283-4afd-9527-c3d7bf7f78c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d88e43bb-9595-46f9-81a5-c2a2f637a314" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beb18af6-5283-4afd-9527-c3d7bf7f78c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bbaa160f-f5f7-470d-90b4-5a2ec737005f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beb18af6-5283-4afd-9527-c3d7bf7f78c2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bbaa160f-f5f7-470d-90b4-5a2ec737005f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6845b954-7f94-49e3-8169-8875dbd3fd79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bbaa160f-f5f7-470d-90b4-5a2ec737005f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6845b954-7f94-49e3-8169-8875dbd3fd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8979259b-e14b-4944-8a7a-eb2009c61693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bbaa160f-f5f7-470d-90b4-5a2ec737005f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8979259b-e14b-4944-8a7a-eb2009c61693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_06b1fa56-9d79-437b-b5f8-6c8d83c267af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bbaa160f-f5f7-470d-90b4-5a2ec737005f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_06b1fa56-9d79-437b-b5f8-6c8d83c267af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c6f66a6-753f-4d4a-8cfd-10785e229223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d88e43bb-9595-46f9-81a5-c2a2f637a314" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c6f66a6-753f-4d4a-8cfd-10785e229223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ab1b2c6e-d971-419e-acbd-b4f4f587c9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c6f66a6-753f-4d4a-8cfd-10785e229223" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ab1b2c6e-d971-419e-acbd-b4f4f587c9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StrategicAgreements" xlink:type="simple" xlink:href="dare-20220331.xsd#StrategicAgreements"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StrategicAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3fd4d9c5-3668-402c-8d4b-c64c85c27d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_08b0cb0f-c560-4a79-b536-b461a235fdfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3fd4d9c5-3668-402c-8d4b-c64c85c27d14" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_08b0cb0f-c560-4a79-b536-b461a235fdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StrategicAgreementsDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#StrategicAgreementsDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StrategicAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8b649afa-0bce-4543-9482-d63df6820468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8b649afa-0bce-4543-9482-d63df6820468" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e45eba88-e39c-4a1c-8003-cb3f72069f78" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_srt_CounterpartyNameAxis_e45eba88-e39c-4a1c-8003-cb3f72069f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6afa8524-853a-4fbc-91a1-f915c52d2f13" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e45eba88-e39c-4a1c-8003-cb3f72069f78" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6afa8524-853a-4fbc-91a1-f915c52d2f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_OrganonMember_3549bdd8-924f-44a2-bc25-cb4e3a063aba" xlink:href="dare-20220331.xsd#dare_OrganonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6afa8524-853a-4fbc-91a1-f915c52d2f13" xlink:to="loc_dare_OrganonMember_3549bdd8-924f-44a2-bc25-cb4e3a063aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilanaPharmMember_cdf3faed-ab12-4070-9655-7b9f9daf72b4" xlink:href="dare-20220331.xsd#dare_MilanaPharmMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6afa8524-853a-4fbc-91a1-f915c52d2f13" xlink:to="loc_dare_MilanaPharmMember_cdf3faed-ab12-4070-9655-7b9f9daf72b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CatalentAndMilanaPharmMember_ce05dc16-b6c9-46aa-bca3-8a35999fb1d6" xlink:href="dare-20220331.xsd#dare_CatalentAndMilanaPharmMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6afa8524-853a-4fbc-91a1-f915c52d2f13" xlink:to="loc_dare_CatalentAndMilanaPharmMember_ce05dc16-b6c9-46aa-bca3-8a35999fb1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_148d6e12-ba52-4717-82e6-6599e7789d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_us-gaap_TypeOfArrangementAxis_148d6e12-ba52-4717-82e6-6599e7789d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b8eea63-1406-4e41-9b82-ee6a47fd94a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_148d6e12-ba52-4717-82e6-6599e7789d7f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b8eea63-1406-4e41-9b82-ee6a47fd94a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BayerHealthcareLicenseAgreementMember_c1afc7c1-b595-419a-b8d1-113dd8f2f036" xlink:href="dare-20220331.xsd#dare_BayerHealthcareLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b8eea63-1406-4e41-9b82-ee6a47fd94a4" xlink:to="loc_dare_BayerHealthcareLicenseAgreementMember_c1afc7c1-b595-419a-b8d1-113dd8f2f036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_22642995-dbc3-46de-a4ae-5c0f8cac023e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b8eea63-1406-4e41-9b82-ee6a47fd94a4" xlink:to="loc_us-gaap_LicensingAgreementsMember_22642995-dbc3-46de-a4ae-5c0f8cac023e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssignmentAgreementMember_62bf4955-3da9-4bd6-8626-bbb8d09b6182" xlink:href="dare-20220331.xsd#dare_AssignmentAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b8eea63-1406-4e41-9b82-ee6a47fd94a4" xlink:to="loc_dare_AssignmentAgreementMember_62bf4955-3da9-4bd6-8626-bbb8d09b6182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAndCollaborationAgreementMember_6b459b4f-a88f-486b-9d47-dd8db8d7f50f" xlink:href="dare-20220331.xsd#dare_LicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b8eea63-1406-4e41-9b82-ee6a47fd94a4" xlink:to="loc_dare_LicenseAndCollaborationAgreementMember_6b459b4f-a88f-486b-9d47-dd8db8d7f50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_JuniperPharmaceuticalsInc.Member_900215d8-6a05-458e-bfac-a87d8c9eda8d" xlink:href="dare-20220331.xsd#dare_JuniperPharmaceuticalsInc.Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b8eea63-1406-4e41-9b82-ee6a47fd94a4" xlink:to="loc_dare_JuniperPharmaceuticalsInc.Member_900215d8-6a05-458e-bfac-a87d8c9eda8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e137612b-1853-4982-807a-a3c6af6cf3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e137612b-1853-4982-807a-a3c6af6cf3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_241f493d-9cde-4418-af4c-5b625d3bc8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e137612b-1853-4982-807a-a3c6af6cf3c5" xlink:to="loc_us-gaap_RelatedPartyDomain_241f493d-9cde-4418-af4c-5b625d3bc8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilanaPharmMember_b2c1a38c-c7cd-4c98-b3d4-28f840eb3b51" xlink:href="dare-20220331.xsd#dare_MilanaPharmMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_241f493d-9cde-4418-af4c-5b625d3bc8b8" xlink:to="loc_dare_MilanaPharmMember_b2c1a38c-c7cd-4c98-b3d4-28f840eb3b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_HammockPharmaceuticalsInc.Member_1a01c141-c1c0-4feb-b80c-980190680800" xlink:href="dare-20220331.xsd#dare_HammockPharmaceuticalsInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_241f493d-9cde-4418-af4c-5b625d3bc8b8" xlink:to="loc_dare_HammockPharmaceuticalsInc.Member_1a01c141-c1c0-4feb-b80c-980190680800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_e38b555f-0564-42c3-a7ab-71e32f8dcbc5" xlink:href="dare-20220331.xsd#dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_241f493d-9cde-4418-af4c-5b625d3bc8b8" xlink:to="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_e38b555f-0564-42c3-a7ab-71e32f8dcbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_4d5220cf-dce4-4f6e-a643-34a3bc254194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_4d5220cf-dce4-4f6e-a643-34a3bc254194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c18a23c2-379f-4dd2-8942-2e243f283ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_4d5220cf-dce4-4f6e-a643-34a3bc254194" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c18a23c2-379f-4dd2-8942-2e243f283ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainDevelopmentMilestonesMember_cd160fcb-62df-4c00-8017-e17d371b0ef4" xlink:href="dare-20220331.xsd#dare_UponAchievingCertainDevelopmentMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_c18a23c2-379f-4dd2-8942-2e243f283ef9" xlink:to="loc_dare_UponAchievingCertainDevelopmentMilestonesMember_cd160fcb-62df-4c00-8017-e17d371b0ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainCommercialMilestonesMember_7c31e85d-686a-49ee-ad4d-c4c8f9d3e136" xlink:href="dare-20220331.xsd#dare_UponAchievingCertainCommercialMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_c18a23c2-379f-4dd2-8942-2e243f283ef9" xlink:to="loc_dare_UponAchievingCertainCommercialMilestonesMember_7c31e85d-686a-49ee-ad4d-c4c8f9d3e136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember_89fc343b-b551-4e8b-909d-4c86b02043cf" xlink:href="dare-20220331.xsd#dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_c18a23c2-379f-4dd2-8942-2e243f283ef9" xlink:to="loc_dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember_89fc343b-b551-4e8b-909d-4c86b02043cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_796046f8-bc7a-4c87-b901-f44fe2f95a9e" xlink:href="dare-20220331.xsd#dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_c18a23c2-379f-4dd2-8942-2e243f283ef9" xlink:to="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_796046f8-bc7a-4c87-b901-f44fe2f95a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c0ccef61-083d-46fc-b345-8e546e615aed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_srt_RangeAxis_c0ccef61-083d-46fc-b345-8e546e615aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fe6ec243-89eb-416c-ae60-c60938fc4f62" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c0ccef61-083d-46fc-b345-8e546e615aed" xlink:to="loc_srt_RangeMember_fe6ec243-89eb-416c-ae60-c60938fc4f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_206daf29-fc19-4ce1-80d1-c9d9093fe05f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fe6ec243-89eb-416c-ae60-c60938fc4f62" xlink:to="loc_srt_MaximumMember_206daf29-fc19-4ce1-80d1-c9d9093fe05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_60d5cc85-ab23-4f69-bb9a-c2164235e742" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fe6ec243-89eb-416c-ae60-c60938fc4f62" xlink:to="loc_srt_MinimumMember_60d5cc85-ab23-4f69-bb9a-c2164235e742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7bf75df6-0045-4281-b32f-46651dd01f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7bf75df6-0045-4281-b32f-46651dd01f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2bfaafc0-1022-4224-9630-bba597120bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7bf75df6-0045-4281-b32f-46651dd01f44" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2bfaafc0-1022-4224-9630-bba597120bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ADVATecAgreementMember_987ae5e5-7691-4da8-95ad-bdce30439bee" xlink:href="dare-20220331.xsd#dare_ADVATecAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2bfaafc0-1022-4224-9630-bba597120bb0" xlink:to="loc_dare_ADVATecAgreementMember_987ae5e5-7691-4da8-95ad-bdce30439bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ClinicalAndRegulatoryMilestonesMember_d9bf088b-b1b4-4337-b156-a0e13027ac39" xlink:href="dare-20220331.xsd#dare_ClinicalAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2bfaafc0-1022-4224-9630-bba597120bb0" xlink:to="loc_dare_ClinicalAndRegulatoryMilestonesMember_d9bf088b-b1b4-4337-b156-a0e13027ac39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SalesMilestonesMember_10793da0-b7a5-449c-891f-09690f5f419d" xlink:href="dare-20220331.xsd#dare_SalesMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2bfaafc0-1022-4224-9630-bba597120bb0" xlink:to="loc_dare_SalesMilestonesMember_10793da0-b7a5-449c-891f-09690f5f419d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7a4f8d42-d085-40ad-b33c-550c7f270e92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7a4f8d42-d085-40ad-b33c-550c7f270e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_6ff619c6-b612-4808-80a2-01b37c6520c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7a4f8d42-d085-40ad-b33c-550c7f270e92" xlink:to="loc_us-gaap_ProjectMember_6ff619c6-b612-4808-80a2-01b37c6520c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_5f48a18b-4a2d-4bb6-9db9-ef9321ead8d3" xlink:href="dare-20220331.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_6ff619c6-b612-4808-80a2-01b37c6520c2" xlink:to="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_5f48a18b-4a2d-4bb6-9db9-ef9321ead8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_d7364c88-9122-4e8d-9b68-606130654c1f" xlink:href="dare-20220331.xsd#dare_UponReachingCertainWorldwideNetSalesMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_6ff619c6-b612-4808-80a2-01b37c6520c2" xlink:to="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_d7364c88-9122-4e8d-9b68-606130654c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3ef8dc84-8a36-4089-a81c-f97789df0e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3ef8dc84-8a36-4089-a81c-f97789df0e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_878dcd58-7b8c-4788-98f7-5dd4257e4424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3ef8dc84-8a36-4089-a81c-f97789df0e15" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_878dcd58-7b8c-4788-98f7-5dd4257e4424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MicrochipsBiotechInc.Member_99a93cf6-e42b-4087-bfd5-84b66a52354f" xlink:href="dare-20220331.xsd#dare_MicrochipsBiotechInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_878dcd58-7b8c-4788-98f7-5dd4257e4424" xlink:to="loc_dare_MicrochipsBiotechInc.Member_99a93cf6-e42b-4087-bfd5-84b66a52354f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_79ff3115-290f-4994-8ef6-bd0b3b2b0e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_us-gaap_StatementClassOfStockAxis_79ff3115-290f-4994-8ef6-bd0b3b2b0e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ea8211c8-d9aa-43ba-a86d-4587e1845f56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_79ff3115-290f-4994-8ef6-bd0b3b2b0e78" xlink:to="loc_us-gaap_ClassOfStockDomain_ea8211c8-d9aa-43ba-a86d-4587e1845f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_308e2b72-27d5-4a21-b296-554b1ff12df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ea8211c8-d9aa-43ba-a86d-4587e1845f56" xlink:to="loc_us-gaap_CommonStockMember_308e2b72-27d5-4a21-b296-554b1ff12df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_29e5f211-d7db-448d-a26b-e85cf6bcec5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_29e5f211-d7db-448d-a26b-e85cf6bcec5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f61ac2e6-98d1-4f12-94fc-542281e6a76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_29e5f211-d7db-448d-a26b-e85cf6bcec5e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f61ac2e6-98d1-4f12-94fc-542281e6a76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_268bf69c-b9eb-476c-9c19-0b507a1d3d55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f61ac2e6-98d1-4f12-94fc-542281e6a76b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_268bf69c-b9eb-476c-9c19-0b507a1d3d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_f1cf9c3e-c92f-49c9-9edb-c0559abcf2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_f1cf9c3e-c92f-49c9-9edb-c0559abcf2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_a5b9cf6b-2153-4b53-8184-ed8ec1097ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_f1cf9c3e-c92f-49c9-9edb-c0559abcf2bd" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_a5b9cf6b-2153-4b53-8184-ed8ec1097ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_923632ad-35dd-4f22-a185-6a7da6f0d6db" xlink:href="dare-20220331.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_a5b9cf6b-2153-4b53-8184-ed8ec1097ca7" xlink:to="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_923632ad-35dd-4f22-a185-6a7da6f0d6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f15e90c-2bcf-4978-852f-7cd9588bdb74" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UpfrontLicenseFeeAmountPaid_c0d9e5c1-cce9-4b1c-9d78-1b62c396e197" xlink:href="dare-20220331.xsd#dare_UpfrontLicenseFeeAmountPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_UpfrontLicenseFeeAmountPaid_c0d9e5c1-cce9-4b1c-9d78-1b62c396e197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmount_8c6dcfff-edc3-40d3-b260-fb842af90c4d" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsContingentAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_MilestonePaymentsContingentAmount_8c6dcfff-edc3-40d3-b260-fb842af90c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_db2be150-70f0-4121-96d4-28448cefd045" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount_db2be150-70f0-4121-96d4-28448cefd045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount_00f2e8f5-459c-4c0a-b489-58a9fbd1c7e9" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount_00f2e8f5-459c-4c0a-b489-58a9fbd1c7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsTerm_216da86d-1488-4e13-af46-fa5c5645e3c8" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_MilestonePaymentsTerm_216da86d-1488-4e13-af46-fa5c5645e3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UpfrontLicenseFeePaid_d2a0bf84-6122-4043-9ff1-d582df6f477e" xlink:href="dare-20220331.xsd#dare_UpfrontLicenseFeePaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_UpfrontLicenseFeePaid_d2a0bf84-6122-4043-9ff1-d582df6f477e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5d9b4b3e-bb67-4747-8350-a2c68f57cc6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5d9b4b3e-bb67-4747-8350-a2c68f57cc6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementInitialTerm_7912033d-aa4f-457b-9fe3-65cb33d7dad4" xlink:href="dare-20220331.xsd#dare_LicenseAgreementInitialTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_LicenseAgreementInitialTerm_7912033d-aa4f-457b-9fe3-65cb33d7dad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseFee_50c51cfb-1574-464f-9976-91c09f99898f" xlink:href="dare-20220331.xsd#dare_LicenseFee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_LicenseFee_50c51cfb-1574-464f-9976-91c09f99898f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseFeeToBePaidUponContingency_a1f8cc42-e1f6-4b12-9d30-5e2d17ecff4c" xlink:href="dare-20220331.xsd#dare_LicenseFeeToBePaidUponContingency"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_LicenseFeeToBePaidUponContingency_a1f8cc42-e1f6-4b12-9d30-5e2d17ecff4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsideration_57610b2e-1909-4285-9875-ac8cd4c0bfa1" xlink:href="dare-20220331.xsd#dare_AssetAcquisitionContingentConsideration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_AssetAcquisitionContingentConsideration_57610b2e-1909-4285-9875-ac8cd4c0bfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_RoyaltyAgreementTerm_190cbded-ea2e-4bc0-ad2e-ac0b58a75773" xlink:href="dare-20220331.xsd#dare_RoyaltyAgreementTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_RoyaltyAgreementTerm_190cbded-ea2e-4bc0-ad2e-ac0b58a75773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct_6a1b882f-088a-4688-88d0-450906cd36d7" xlink:href="dare-20220331.xsd#dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct_6a1b882f-088a-4688-88d0-450906cd36d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_b76499bb-4a30-48a2-a384-8e4b1a403b4e" xlink:href="dare-20220331.xsd#dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_b76499bb-4a30-48a2-a384-8e4b1a403b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTermination_1ac5a7ea-84f4-4c52-8e84-055c98610fee" xlink:href="dare-20220331.xsd#dare_LicenseAgreementNoticePeriodOfTermination"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_LicenseAgreementNoticePeriodOfTermination_1ac5a7ea-84f4-4c52-8e84-055c98610fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ResearchAndDevelopmentMilestonePayment_f3a2db04-cd2d-460b-ac89-520268d26068" xlink:href="dare-20220331.xsd#dare_ResearchAndDevelopmentMilestonePayment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_ResearchAndDevelopmentMilestonePayment_f3a2db04-cd2d-460b-ac89-520268d26068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfRoyaltyRate_54776b69-f761-4bea-a071-bc589d9726b5" xlink:href="dare-20220331.xsd#dare_PercentageOfRoyaltyRate"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_PercentageOfRoyaltyRate_54776b69-f761-4bea-a071-bc589d9726b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_c5362064-bcea-4c1c-87f4-5f5d3180704e" xlink:href="dare-20220331.xsd#dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_c5362064-bcea-4c1c-87f4-5f5d3180704e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_6b57a5e8-89a4-40c8-8601-8dc33a1bc0e6" xlink:href="dare-20220331.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_6b57a5e8-89a4-40c8-8601-8dc33a1bc0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_5ca28c21-0022-4e58-93de-365b3be871ff" xlink:href="dare-20220331.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_5ca28c21-0022-4e58-93de-365b3be871ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MaximumPotentialMilestonePayments_36170272-118e-49cd-8982-2c6740ffa5e9" xlink:href="dare-20220331.xsd#dare_MaximumPotentialMilestonePayments"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_MaximumPotentialMilestonePayments_36170272-118e-49cd-8982-2c6740ffa5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostMaintenance_0ece14c2-32c7-4573-9216-671f3a060d26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostMaintenance"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_us-gaap_CostMaintenance_0ece14c2-32c7-4573-9216-671f3a060d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmountPayableNet_a21f8f17-b76b-48b7-becf-a3767155964b" xlink:href="dare-20220331.xsd#dare_MilestonePaymentsContingentAmountPayableNet"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_MilestonePaymentsContingentAmountPayableNet_a21f8f17-b76b-48b7-becf-a3767155964b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_785176f8-02e6-462d-a9f0-e7d0a4243c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_785176f8-02e6-462d-a9f0-e7d0a4243c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_3b9e2257-efb5-49c7-95e2-5dfe7cb1e207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_39462533-9aaf-4b98-a1fe-ddbf35b30441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_39462533-9aaf-4b98-a1fe-ddbf35b30441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_7f0267dd-a6db-4304-9661-85909101d1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_7f0267dd-a6db-4304-9661-85909101d1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1f9739cb-2aee-412d-8def-65e1389112fd" xlink:href="dare-20220331.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1f9739cb-2aee-412d-8def-65e1389112fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_295bf075-4d5f-4ed6-a723-9b05ae139aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_295bf075-4d5f-4ed6-a723-9b05ae139aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsiderationCurrent_c9b09dce-ec9f-4906-bf07-3358279f6279" xlink:href="dare-20220331.xsd#dare_AssetAcquisitionContingentConsiderationCurrent"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_AssetAcquisitionContingentConsiderationCurrent_c9b09dce-ec9f-4906-bf07-3358279f6279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_d2a02f99-0c7e-487e-ad6e-776c47eb5ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_d2a02f99-0c7e-487e-ad6e-776c47eb5ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f473be8c-2f90-434b-b61e-62543fa7f9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f473be8c-2f90-434b-b61e-62543fa7f9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PaymentsToStockholdersRepresentativeInBusinessCombination_147aeaac-e4ef-4e1c-857e-5079b36e81c6" xlink:href="dare-20220331.xsd#dare_PaymentsToStockholdersRepresentativeInBusinessCombination"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_PaymentsToStockholdersRepresentativeInBusinessCombination_147aeaac-e4ef-4e1c-857e-5079b36e81c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PaymentOfAdditionalConsiderationInBusinessCombination_a937b562-287b-4c2f-b9cb-5dac41f6620c" xlink:href="dare-20220331.xsd#dare_PaymentOfAdditionalConsiderationInBusinessCombination"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a47004-b996-4b83-a130-3dffd2a9ed63" xlink:to="loc_dare_PaymentOfAdditionalConsiderationInBusinessCombination_a937b562-287b-4c2f-b9cb-5dac41f6620c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquity" xlink:type="simple" xlink:href="dare-20220331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_92adce2b-69ee-47a4-8221-479975abb2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_079e33cc-82eb-40ef-8092-51d7a0a2ff08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_92adce2b-69ee-47a4-8221-479975abb2a0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_079e33cc-82eb-40ef-8092-51d7a0a2ff08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="dare-20220331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_711102ef-d004-4b7d-a39a-cb08982af108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ee13a666-6a39-4e85-a6d9-de5d94237b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_711102ef-d004-4b7d-a39a-cb08982af108" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ee13a666-6a39-4e85-a6d9-de5d94237b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a9936415-184b-4f43-a61b-e4d61ab685b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockholdersEquityTable_87f13757-e094-460a-bff5-d40af98a5654" xlink:href="dare-20220331.xsd#dare_StockholdersEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a9936415-184b-4f43-a61b-e4d61ab685b6" xlink:to="loc_dare_StockholdersEquityTable_87f13757-e094-460a-bff5-d40af98a5654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a2052cfa-29ef-4167-ac56-78cc4a74782c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_87f13757-e094-460a-bff5-d40af98a5654" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a2052cfa-29ef-4167-ac56-78cc4a74782c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce0a251c-1d0b-408b-9302-be3bdb186724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a2052cfa-29ef-4167-ac56-78cc4a74782c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce0a251c-1d0b-408b-9302-be3bdb186724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_April2021AtTheMarketSalesAgreementMember_4ffc19d4-ca59-40f7-9c64-328ef24a0766" xlink:href="dare-20220331.xsd#dare_April2021AtTheMarketSalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce0a251c-1d0b-408b-9302-be3bdb186724" xlink:to="loc_dare_April2021AtTheMarketSalesAgreementMember_4ffc19d4-ca59-40f7-9c64-328ef24a0766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PurchaseAgreementMember_f180f46d-0795-4e42-a5e4-7624ea72f631" xlink:href="dare-20220331.xsd#dare_PurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce0a251c-1d0b-408b-9302-be3bdb186724" xlink:to="loc_dare_PurchaseAgreementMember_f180f46d-0795-4e42-a5e4-7624ea72f631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d1c79c9d-d693-43b3-89ae-31d04e226ba3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_87f13757-e094-460a-bff5-d40af98a5654" xlink:to="loc_dei_LegalEntityAxis_d1c79c9d-d693-43b3-89ae-31d04e226ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_31762fba-1233-4bf3-8021-3dfd64cce1bc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d1c79c9d-d693-43b3-89ae-31d04e226ba3" xlink:to="loc_dei_EntityDomain_31762fba-1233-4bf3-8021-3dfd64cce1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LincolnParkMember_a312122c-5ca1-4e39-8691-b341b48acfaf" xlink:href="dare-20220331.xsd#dare_LincolnParkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_31762fba-1233-4bf3-8021-3dfd64cce1bc" xlink:to="loc_dare_LincolnParkMember_a312122c-5ca1-4e39-8691-b341b48acfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6ed57a30-a281-4f48-b0fd-7bb14d9f4f7c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_87f13757-e094-460a-bff5-d40af98a5654" xlink:to="loc_srt_CounterpartyNameAxis_6ed57a30-a281-4f48-b0fd-7bb14d9f4f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b214d93-b4ee-4669-aee0-dae94849f88c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6ed57a30-a281-4f48-b0fd-7bb14d9f4f7c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b214d93-b4ee-4669-aee0-dae94849f88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LincolnParkMember_d5a0f758-9f31-4ae0-8d09-2fe98a8f6eea" xlink:href="dare-20220331.xsd#dare_LincolnParkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b214d93-b4ee-4669-aee0-dae94849f88c" xlink:to="loc_dare_LincolnParkMember_d5a0f758-9f31-4ae0-8d09-2fe98a8f6eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1d68adcb-0dda-4fc5-a48c-f787054a81dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_87f13757-e094-460a-bff5-d40af98a5654" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1d68adcb-0dda-4fc5-a48c-f787054a81dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_b13d8cd5-0834-4bc5-89ae-1483ad6f991f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1d68adcb-0dda-4fc5-a48c-f787054a81dc" xlink:to="loc_us-gaap_TypeOfAdoptionMember_b13d8cd5-0834-4bc5-89ae-1483ad6f991f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201711Member_ad22e0fd-a5f5-464d-bed0-6b513e59325f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201711Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_b13d8cd5-0834-4bc5-89ae-1483ad6f991f" xlink:to="loc_us-gaap_AccountingStandardsUpdate201711Member_ad22e0fd-a5f5-464d-bed0-6b513e59325f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:href="dare-20220331.xsd#dare_StockholdersEquityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_87f13757-e094-460a-bff5-d40af98a5654" xlink:to="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfAggregateCommission_5c43370c-74bd-49c7-a813-b2e39b576dc2" xlink:href="dare-20220331.xsd#dare_PercentageOfAggregateCommission"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_dare_PercentageOfAggregateCommission_5c43370c-74bd-49c7-a813-b2e39b576dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6be9b6f8-4224-46e9-be46-5586ebdfddf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_us-gaap_CommonStockValue_6be9b6f8-4224-46e9-be46-5586ebdfddf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_6ef9fe9d-dc42-4457-aa36-1320932dd534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_us-gaap_PurchaseObligation_6ef9fe9d-dc42-4457-aa36-1320932dd534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_3e16d3c3-5fb9-478a-a126-8f49f891cd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_us-gaap_DeferredOfferingCosts_3e16d3c3-5fb9-478a-a126-8f49f891cd2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredOfferingCostsUnamortizedPortion_1edeb3c9-4a65-4f96-bbdb-cb3e56ce88d5" xlink:href="dare-20220331.xsd#dare_DeferredOfferingCostsUnamortizedPortion"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_dare_DeferredOfferingCostsUnamortizedPortion_1edeb3c9-4a65-4f96-bbdb-cb3e56ce88d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_47abec84-8f7c-412f-90b8-7943bcc9923c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_47abec84-8f7c-412f-90b8-7943bcc9923c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_2202ef67-2030-4db4-b482-cff72b44eec5" xlink:href="dare-20220331.xsd#dare_EstimatedFairValueOfWarrantsRecordedInEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_2202ef67-2030-4db4-b482-cff72b44eec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease_006a7d0d-8bc2-4a3d-9644-5288fbcd066c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_us-gaap_WarrantExercisePriceDecrease_006a7d0d-8bc2-4a3d-9644-5288fbcd066c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature_2d0d3f84-e856-4241-bdb3-f720da291208" xlink:href="dare-20220331.xsd#dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature_2d0d3f84-e856-4241-bdb3-f720da291208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NumberOfCommonStockWarrantsExercised_f35bf81a-3c56-4c19-83b7-24641cab3abf" xlink:href="dare-20220331.xsd#dare_NumberOfCommonStockWarrantsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_dare_NumberOfCommonStockWarrantsExercised_f35bf81a-3c56-4c19-83b7-24641cab3abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_0756096c-c1c5-4518-9241-974b8d5c8718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_9c8a8c27-d29b-4ffd-8fce-bde8446717d5" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_0756096c-c1c5-4518-9241-974b8d5c8718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_080905b6-ab07-48de-9b39-b17ac8f30bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_3e78249d-9924-4e66-a320-cdc6d5bad9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_080905b6-ab07-48de-9b39-b17ac8f30bbb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_3e78249d-9924-4e66-a320-cdc6d5bad9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_0a92eb6a-d89e-4f22-93da-3b65e133de42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_3e78249d-9924-4e66-a320-cdc6d5bad9f2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_0a92eb6a-d89e-4f22-93da-3b65e133de42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_138bd33a-54c9-43cb-8b22-fe9927194144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0a92eb6a-d89e-4f22-93da-3b65e133de42" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_138bd33a-54c9-43cb-8b22-fe9927194144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_f2fcc27c-ff39-4d53-b786-c07f72312138" xlink:href="dare-20220331.xsd#dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_138bd33a-54c9-43cb-8b22-fe9927194144" xlink:to="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_f2fcc27c-ff39-4d53-b786-c07f72312138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_32804fdc-2d99-4062-96c6-75df10dc0a7b" xlink:href="dare-20220331.xsd#dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_138bd33a-54c9-43cb-8b22-fe9927194144" xlink:to="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_32804fdc-2d99-4062-96c6-75df10dc0a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_adc2c5e4-5d47-4b23-941a-fb0515716929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_3e78249d-9924-4e66-a320-cdc6d5bad9f2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_adc2c5e4-5d47-4b23-941a-fb0515716929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_018270b8-70ac-45d2-92ee-3dbadcf9083e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_adc2c5e4-5d47-4b23-941a-fb0515716929" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_018270b8-70ac-45d2-92ee-3dbadcf9083e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b3f1e59e-7e69-4c70-bac1-89bf6e1c830a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_adc2c5e4-5d47-4b23-941a-fb0515716929" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b3f1e59e-7e69-4c70-bac1-89bf6e1c830a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_db25d950-7ead-49f9-a903-5c56f7f330f6" xlink:href="dare-20220331.xsd#dare_ClassOfWarrantOrRightsWarrantsExpirationDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_adc2c5e4-5d47-4b23-941a-fb0515716929" xlink:to="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_db25d950-7ead-49f9-a903-5c56f7f330f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="dare-20220331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c721fbb4-f762-4405-bf83-c4e8916c34e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6c60a7d7-8928-4a99-8759-fe61da803ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c721fbb4-f762-4405-bf83-c4e8916c34e2" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6c60a7d7-8928-4a99-8759-fe61da803ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="dare-20220331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6dcf66da-bef1-4590-8a2b-d2417ce9f51c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_47408730-4086-4638-9dc1-70c7effef496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6dcf66da-bef1-4590-8a2b-d2417ce9f51c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_47408730-4086-4638-9dc1-70c7effef496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4f178077-9c61-406b-bd6c-c346ee1a2f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6dcf66da-bef1-4590-8a2b-d2417ce9f51c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4f178077-9c61-406b-bd6c-c346ee1a2f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2cf6e3ba-f98e-498c-bb3d-2b10ee1b3d95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6dcf66da-bef1-4590-8a2b-d2417ce9f51c" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2cf6e3ba-f98e-498c-bb3d-2b10ee1b3d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_03ac78b5-5503-4417-9b78-4f2670b309da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ddd936e-71c2-491c-a51b-78ea32c9f54c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_03ac78b5-5503-4417-9b78-4f2670b309da" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ddd936e-71c2-491c-a51b-78ea32c9f54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4405985f-55ff-4003-9479-3525445cf274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ddd936e-71c2-491c-a51b-78ea32c9f54c" xlink:to="loc_us-gaap_PlanNameAxis_4405985f-55ff-4003-9479-3525445cf274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_090d40a3-a70b-4dec-8951-8f0060003958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4405985f-55ff-4003-9479-3525445cf274" xlink:to="loc_us-gaap_PlanNameDomain_090d40a3-a70b-4dec-8951-8f0060003958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_8c523685-947b-463f-9f37-879f4b031276" xlink:href="dare-20220331.xsd#dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_090d40a3-a70b-4dec-8951-8f0060003958" xlink:to="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_8c523685-947b-463f-9f37-879f4b031276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_7d6ca70b-d36e-46c3-b183-f9a9c5a750f4" xlink:href="dare-20220331.xsd#dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_090d40a3-a70b-4dec-8951-8f0060003958" xlink:to="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_7d6ca70b-d36e-46c3-b183-f9a9c5a750f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1dcd1bfc-4f16-4afc-bc48-5401d9179e18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ddd936e-71c2-491c-a51b-78ea32c9f54c" xlink:to="loc_us-gaap_AwardTypeAxis_1dcd1bfc-4f16-4afc-bc48-5401d9179e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5aead4a5-a722-48aa-a175-46b28b72222b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1dcd1bfc-4f16-4afc-bc48-5401d9179e18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5aead4a5-a722-48aa-a175-46b28b72222b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_71714223-d543-4dcd-b728-239d2fbb57d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5aead4a5-a722-48aa-a175-46b28b72222b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_71714223-d543-4dcd-b728-239d2fbb57d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced03f59-b52a-4b38-87cf-92920c2dd6de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ddd936e-71c2-491c-a51b-78ea32c9f54c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced03f59-b52a-4b38-87cf-92920c2dd6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_869b2224-291b-42a5-a1ca-d119d7d9906c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced03f59-b52a-4b38-87cf-92920c2dd6de" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_869b2224-291b-42a5-a1ca-d119d7d9906c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_24b253db-93ed-4244-b82f-2053fe070b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced03f59-b52a-4b38-87cf-92920c2dd6de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_24b253db-93ed-4244-b82f-2053fe070b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_68d266ae-d088-4352-b416-e11c5432cd55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced03f59-b52a-4b38-87cf-92920c2dd6de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_68d266ae-d088-4352-b416-e11c5432cd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_181a111e-6c73-4132-903c-d077e1145d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced03f59-b52a-4b38-87cf-92920c2dd6de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_181a111e-6c73-4132-903c-d077e1145d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_dd0f32d0-eeb6-4286-945b-bcfcc61cded5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced03f59-b52a-4b38-87cf-92920c2dd6de" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_dd0f32d0-eeb6-4286-945b-bcfcc61cded5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_d44335eb-2ce9-4eb8-8070-a378fce628a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced03f59-b52a-4b38-87cf-92920c2dd6de" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_d44335eb-2ce9-4eb8-8070-a378fce628a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_6538ac5c-7c5f-4d19-8412-c0960f587176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced03f59-b52a-4b38-87cf-92920c2dd6de" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_6538ac5c-7c5f-4d19-8412-c0960f587176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WeightedAverageAmortizationPeriod_d94070c3-7b01-4029-8471-f2e57b591efb" xlink:href="dare-20220331.xsd#dare_WeightedAverageAmortizationPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced03f59-b52a-4b38-87cf-92920c2dd6de" xlink:to="loc_dare_WeightedAverageAmortizationPeriod_d94070c3-7b01-4029-8471-f2e57b591efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3c7ddde-4e7c-43bb-b9fb-be4d61240ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36d10670-d97c-428c-9298-57c3d2118ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3c7ddde-4e7c-43bb-b9fb-be4d61240ea0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36d10670-d97c-428c-9298-57c3d2118ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_eb3aa727-6495-4fc1-96e7-5bd2c02e6e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36d10670-d97c-428c-9298-57c3d2118ad0" xlink:to="loc_us-gaap_PlanNameAxis_eb3aa727-6495-4fc1-96e7-5bd2c02e6e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ed3fd5be-db34-4a08-9b70-5d4f0df88489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_eb3aa727-6495-4fc1-96e7-5bd2c02e6e7f" xlink:to="loc_us-gaap_PlanNameDomain_ed3fd5be-db34-4a08-9b70-5d4f0df88489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_58b7144b-26fa-47c9-a63c-62687406e3d2" xlink:href="dare-20220331.xsd#dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ed3fd5be-db34-4a08-9b70-5d4f0df88489" xlink:to="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_58b7144b-26fa-47c9-a63c-62687406e3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_60628e9c-ff70-4525-a532-5b6df44e3da3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36d10670-d97c-428c-9298-57c3d2118ad0" xlink:to="loc_us-gaap_AwardTypeAxis_60628e9c-ff70-4525-a532-5b6df44e3da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46a4cab3-b39b-4a16-b560-3a4e2ef56e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_60628e9c-ff70-4525-a532-5b6df44e3da3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46a4cab3-b39b-4a16-b560-3a4e2ef56e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2e1e2331-7638-4c14-aed4-6fd847477337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46a4cab3-b39b-4a16-b560-3a4e2ef56e3e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2e1e2331-7638-4c14-aed4-6fd847477337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed20a188-008f-4817-b477-4ed992cdba23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36d10670-d97c-428c-9298-57c3d2118ad0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed20a188-008f-4817-b477-4ed992cdba23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_027b9787-bbd9-428f-8e3a-69940410e36e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed20a188-008f-4817-b477-4ed992cdba23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_027b9787-bbd9-428f-8e3a-69940410e36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7f5c384a-116e-452c-8024-926b07535184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_027b9787-bbd9-428f-8e3a-69940410e36e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7f5c384a-116e-452c-8024-926b07535184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ca1e0b0c-d60c-4a0f-a81a-6b33dc42a3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_027b9787-bbd9-428f-8e3a-69940410e36e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ca1e0b0c-d60c-4a0f-a81a-6b33dc42a3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6d357a30-ee98-4208-afb0-137886514e36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_027b9787-bbd9-428f-8e3a-69940410e36e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6d357a30-ee98-4208-afb0-137886514e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4b7373a9-f558-40d7-bf1d-4c33d8459454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_027b9787-bbd9-428f-8e3a-69940410e36e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4b7373a9-f558-40d7-bf1d-4c33d8459454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_ae30f306-2b3b-4182-b820-208d2d589e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_027b9787-bbd9-428f-8e3a-69940410e36e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_ae30f306-2b3b-4182-b820-208d2d589e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cc5cb835-b8f0-483c-b4f5-d919274a54dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_027b9787-bbd9-428f-8e3a-69940410e36e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cc5cb835-b8f0-483c-b4f5-d919274a54dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a5d479ae-26fe-40a1-9c7c-5c2e441ba86d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed20a188-008f-4817-b477-4ed992cdba23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a5d479ae-26fe-40a1-9c7c-5c2e441ba86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7974e481-0bcd-44a8-b827-33971a2996f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed20a188-008f-4817-b477-4ed992cdba23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7974e481-0bcd-44a8-b827-33971a2996f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_26160193-f531-4c98-871e-fade9fab1d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7974e481-0bcd-44a8-b827-33971a2996f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_26160193-f531-4c98-871e-fade9fab1d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9fa0cdb3-5da5-44bf-9352-be5321d1c1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7974e481-0bcd-44a8-b827-33971a2996f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9fa0cdb3-5da5-44bf-9352-be5321d1c1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9804ad02-6d47-4fa7-ac62-163d96bd3ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7974e481-0bcd-44a8-b827-33971a2996f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9804ad02-6d47-4fa7-ac62-163d96bd3ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_93e2bf31-d2de-47d0-ae66-7330dddde710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7974e481-0bcd-44a8-b827-33971a2996f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_93e2bf31-d2de-47d0-ae66-7330dddde710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_166f08d6-e45f-45af-8e6d-323e22d8fb35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7974e481-0bcd-44a8-b827-33971a2996f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_166f08d6-e45f-45af-8e6d-323e22d8fb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d2bd41a6-f109-48aa-94bb-5db9b7420ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7974e481-0bcd-44a8-b827-33971a2996f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d2bd41a6-f109-48aa-94bb-5db9b7420ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fa476db6-19f0-4a38-9189-91e42a126d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed20a188-008f-4817-b477-4ed992cdba23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fa476db6-19f0-4a38-9189-91e42a126d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38bad835-4428-4229-ad40-bff22e9618cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_967930db-eb00-453f-ad2d-0d8aff82e890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38bad835-4428-4229-ad40-bff22e9618cd" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_967930db-eb00-453f-ad2d-0d8aff82e890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_64dc9a47-d29d-418a-ac46-d8b570067b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_967930db-eb00-453f-ad2d-0d8aff82e890" xlink:to="loc_us-gaap_AwardTypeAxis_64dc9a47-d29d-418a-ac46-d8b570067b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf2689f-2cbe-430c-b472-f5b7d23120cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_64dc9a47-d29d-418a-ac46-d8b570067b0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf2689f-2cbe-430c-b472-f5b7d23120cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_956f521b-15e0-4709-ae0b-a5db97042734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf2689f-2cbe-430c-b472-f5b7d23120cb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_956f521b-15e0-4709-ae0b-a5db97042734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_30352fe4-27ad-4c99-b59b-6c7c6b508875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_967930db-eb00-453f-ad2d-0d8aff82e890" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_30352fe4-27ad-4c99-b59b-6c7c6b508875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f358386c-0bab-4564-b564-749c0412125b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_30352fe4-27ad-4c99-b59b-6c7c6b508875" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f358386c-0bab-4564-b564-749c0412125b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5f885258-67c1-4faf-8371-e2e91a603d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f358386c-0bab-4564-b564-749c0412125b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5f885258-67c1-4faf-8371-e2e91a603d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4608b055-f763-4b3f-8db8-7c0156871f16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f358386c-0bab-4564-b564-749c0412125b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4608b055-f763-4b3f-8db8-7c0156871f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_05451db2-c474-4499-8f93-7dcd4aedd195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_967930db-eb00-453f-ad2d-0d8aff82e890" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_05451db2-c474-4499-8f93-7dcd4aedd195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_43c60559-6ad1-440f-b722-4e900f8d0f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_05451db2-c474-4499-8f93-7dcd4aedd195" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_43c60559-6ad1-440f-b722-4e900f8d0f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da171109-a858-43ca-a7ff-7f2c7e7c0dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c462149e-a4bf-4367-8b40-fd737fd3944d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da171109-a858-43ca-a7ff-7f2c7e7c0dcb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c462149e-a4bf-4367-8b40-fd737fd3944d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9fcf1f25-2518-4241-8e05-816d4097174a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da171109-a858-43ca-a7ff-7f2c7e7c0dcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9fcf1f25-2518-4241-8e05-816d4097174a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_02eac3c0-0fa1-46b1-bf08-298f54d7d119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da171109-a858-43ca-a7ff-7f2c7e7c0dcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_02eac3c0-0fa1-46b1-bf08-298f54d7d119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_2914919f-fff3-42fb-afe6-b4ec1bddc02e" xlink:href="dare-20220331.xsd#dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da171109-a858-43ca-a7ff-7f2c7e7c0dcb" xlink:to="loc_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_2914919f-fff3-42fb-afe6-b4ec1bddc02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d34820de-beef-402c-9d97-e85a1a176493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da171109-a858-43ca-a7ff-7f2c7e7c0dcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d34820de-beef-402c-9d97-e85a1a176493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_13ac71fd-5f83-42bf-91d8-deeb42d253bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da171109-a858-43ca-a7ff-7f2c7e7c0dcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_13ac71fd-5f83-42bf-91d8-deeb42d253bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedProperties" xlink:type="simple" xlink:href="dare-20220331.xsd#LeasedProperties"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedProperties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b6591feb-d455-46b4-a006-dac6f73d62d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_85e8734f-c785-4907-8d73-9fdc516576b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6591feb-d455-46b4-a006-dac6f73d62d6" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_85e8734f-c785-4907-8d73-9fdc516576b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesTables" xlink:type="simple" xlink:href="dare-20220331.xsd#LeasedPropertiesTables"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9ec724f5-efb7-48dc-a34e-8bc9b32570bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b6fe0ff1-55bf-4c80-9b7a-f2f5c76f7844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9ec724f5-efb7-48dc-a34e-8bc9b32570bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b6fe0ff1-55bf-4c80-9b7a-f2f5c76f7844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#LeasedPropertiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5e11df43-930a-4e46-886f-2bc1ff76b06d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_07485b02-7463-4912-b464-b7d68bdba64a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5e11df43-930a-4e46-886f-2bc1ff76b06d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_07485b02-7463-4912-b464-b7d68bdba64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ce64e6c4-48bc-4028-9b52-b5065f34b24a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_07485b02-7463-4912-b464-b7d68bdba64a" xlink:to="loc_dei_LegalEntityAxis_ce64e6c4-48bc-4028-9b52-b5065f34b24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ec9971a0-b0ce-46e2-a334-279af7d9e77d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_ce64e6c4-48bc-4028-9b52-b5065f34b24a" xlink:to="loc_dei_EntityDomain_ec9971a0-b0ce-46e2-a334-279af7d9e77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MBIMember_3babcf68-6dd1-4c3d-b573-bc03ad58c7f6" xlink:href="dare-20220331.xsd#dare_MBIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ec9971a0-b0ce-46e2-a334-279af7d9e77d" xlink:to="loc_dare_MBIMember_3babcf68-6dd1-4c3d-b573-bc03ad58c7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_bdf98773-238a-4c67-a695-75788393561b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_07485b02-7463-4912-b464-b7d68bdba64a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_bdf98773-238a-4c67-a695-75788393561b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b9c91854-8d2b-40d8-ab0b-c1e7ae097c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bdf98773-238a-4c67-a695-75788393561b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b9c91854-8d2b-40d8-ab0b-c1e7ae097c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_61f50404-99e6-4183-b4ac-b640c2218d63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b9c91854-8d2b-40d8-ab0b-c1e7ae097c2b" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_61f50404-99e6-4183-b4ac-b640c2218d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_07485b02-7463-4912-b464-b7d68bdba64a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_aa6a0b45-8678-44d4-9920-835820a1e6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetRentableArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_NetRentableArea_aa6a0b45-8678-44d4-9920-835820a1e6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_38adb60c-af21-4d86-ac74-01d0a46d2814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_38adb60c-af21-4d86-ac74-01d0a46d2814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_f47edc93-51f9-4f3b-9c85-23390419014d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_f47edc93-51f9-4f3b-9c85-23390419014d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_58adcc33-cfb2-46ea-a909-d990bf2623d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_58adcc33-cfb2-46ea-a909-d990bf2623d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_52ebe99e-f458-4f44-a884-93cc7a9aea01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_52ebe99e-f458-4f44-a884-93cc7a9aea01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_febeb1c5-fcad-424a-ae53-24770af1309a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_febeb1c5-fcad-424a-ae53-24770af1309a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_20c93805-255d-493e-a0e3-caa5430ff56b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_20c93805-255d-493e-a0e3-caa5430ff56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_a5e4622a-ddb1-4f6a-8f33-c3f7efbf4c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_OperatingLeaseCost_a5e4622a-ddb1-4f6a-8f33-c3f7efbf4c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5c7db6a2-9e7a-4246-9a57-b5d894322157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_OperatingLeasePayments_5c7db6a2-9e7a-4246-9a57-b5d894322157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_172ebeba-df38-4e9f-a98b-e471ec120600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bb3fad5-06d7-43e3-80c7-cde292f48d3d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_172ebeba-df38-4e9f-a98b-e471ec120600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#LeasedPropertiesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e888246a-e244-4613-92db-a11d3c762569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_67e94873-362f-4d20-acef-94df45baf8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e888246a-e244-4613-92db-a11d3c762569" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_67e94873-362f-4d20-acef-94df45baf8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f7dcf5f8-f5e1-47c6-b16e-abd5df6ab298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e888246a-e244-4613-92db-a11d3c762569" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f7dcf5f8-f5e1-47c6-b16e-abd5df6ab298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_14f8af57-d8a8-47ec-9572-833729f03c07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e888246a-e244-4613-92db-a11d3c762569" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_14f8af57-d8a8-47ec-9572-833729f03c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e37b6155-6562-40e1-87c5-4037e17e9a84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e888246a-e244-4613-92db-a11d3c762569" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e37b6155-6562-40e1-87c5-4037e17e9a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1b3c1032-919a-4aa1-be84-12c2d0e449fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e888246a-e244-4613-92db-a11d3c762569" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1b3c1032-919a-4aa1-be84-12c2d0e449fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_199f48b3-3ae2-4fa8-8aa8-ca5d605e6670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e888246a-e244-4613-92db-a11d3c762569" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_199f48b3-3ae2-4fa8-8aa8-ca5d605e6670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_20f4402a-c247-4498-b117-024844bdba57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e888246a-e244-4613-92db-a11d3c762569" xlink:to="loc_us-gaap_OperatingLeaseLiability_20f4402a-c247-4498-b117-024844bdba57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="dare-20220331.xsd#LeasedPropertiesFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="dare-20220331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_341f4341-3843-4806-96df-a17dfeb7ec3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_4b66b1ec-fbba-4769-a976-2321d200ee05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_341f4341-3843-4806-96df-a17dfeb7ec3d" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_4b66b1ec-fbba-4769-a976-2321d200ee05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a66551a-bf65-4dd3-8dc9-c10562a02f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommitmentsAndContingenciesTable_21f282ae-6b8a-4c27-97bd-713f239a24b0" xlink:href="dare-20220331.xsd#dare_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a66551a-bf65-4dd3-8dc9-c10562a02f5d" xlink:to="loc_dare_CommitmentsAndContingenciesTable_21f282ae-6b8a-4c27-97bd-713f239a24b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7444de76-5993-4abf-9dd6-2dc919484906" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_21f282ae-6b8a-4c27-97bd-713f239a24b0" xlink:to="loc_srt_CounterpartyNameAxis_7444de76-5993-4abf-9dd6-2dc919484906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6cba302c-1b06-4f7a-a1b2-d31c180dfe8f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7444de76-5993-4abf-9dd6-2dc919484906" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6cba302c-1b06-4f7a-a1b2-d31c180dfe8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NICHDMember_b96375e5-402c-4614-b08c-edb1d7ebac71" xlink:href="dare-20220331.xsd#dare_NICHDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6cba302c-1b06-4f7a-a1b2-d31c180dfe8f" xlink:to="loc_dare_NICHDMember_b96375e5-402c-4614-b08c-edb1d7ebac71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CRADAMember_95317c48-8f72-40e0-a454-2e35aca9d9f7" xlink:href="dare-20220331.xsd#dare_CRADAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6cba302c-1b06-4f7a-a1b2-d31c180dfe8f" xlink:to="loc_dare_CRADAMember_95317c48-8f72-40e0-a454-2e35aca9d9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3654326c-9677-4284-a65c-c1e0e3a236b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_21f282ae-6b8a-4c27-97bd-713f239a24b0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3654326c-9677-4284-a65c-c1e0e3a236b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32cb513c-4582-4c06-a44b-6a46260bc81a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3654326c-9677-4284-a65c-c1e0e3a236b5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32cb513c-4582-4c06-a44b-6a46260bc81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MicrochipsBiotechInc.Member_27e82a44-7215-4e13-b27e-3c4699306dbb" xlink:href="dare-20220331.xsd#dare_MicrochipsBiotechInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_32cb513c-4582-4c06-a44b-6a46260bc81a" xlink:to="loc_dare_MicrochipsBiotechInc.Member_27e82a44-7215-4e13-b27e-3c4699306dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:href="dare-20220331.xsd#dare_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_21f282ae-6b8a-4c27-97bd-713f239a24b0" xlink:to="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ResearchAndDevelopmentAgreementCommitmentAmount_d4dd201c-e5b5-49d9-abbb-2a60ef1a63ab" xlink:href="dare-20220331.xsd#dare_ResearchAndDevelopmentAgreementCommitmentAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_dare_ResearchAndDevelopmentAgreementCommitmentAmount_d4dd201c-e5b5-49d9-abbb-2a60ef1a63ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_f50efd11-bd05-4775-b749-68af07dfc06d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_f50efd11-bd05-4775-b749-68af07dfc06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_3586686b-c67a-41ec-b9be-3f2e6193ca45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_3586686b-c67a-41ec-b9be-3f2e6193ca45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PaymentOfAdditionalConsiderationInBusinessCombination_4c95dcd9-3b42-41d4-a744-37f764892f5e" xlink:href="dare-20220331.xsd#dare_PaymentOfAdditionalConsiderationInBusinessCombination"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_dare_PaymentOfAdditionalConsiderationInBusinessCombination_4c95dcd9-3b42-41d4-a744-37f764892f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_74d7c53e-c3a4-45b4-adb5-8dc3bcf182a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_74d7c53e-c3a4-45b4-adb5-8dc3bcf182a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsiderationCurrent_eb74092a-4440-4f4f-a35f-2971a39699d6" xlink:href="dare-20220331.xsd#dare_AssetAcquisitionContingentConsiderationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_dare_AssetAcquisitionContingentConsiderationCurrent_eb74092a-4440-4f4f-a35f-2971a39699d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5f3909f2-0689-475e-8c58-b7601a4974bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5f3909f2-0689-475e-8c58-b7601a4974bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_345621f0-203a-4baa-a96c-75ee92cf1e09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_345621f0-203a-4baa-a96c-75ee92cf1e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PaymentsToStockholdersRepresentativeInBusinessCombination_1fe116ef-8603-4555-a3e5-c7d74f62c432" xlink:href="dare-20220331.xsd#dare_PaymentsToStockholdersRepresentativeInBusinessCombination"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_dare_PaymentsToStockholdersRepresentativeInBusinessCombination_1fe116ef-8603-4555-a3e5-c7d74f62c432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived_31ab1052-e108-4b6b-8ed9-57082258d98a" xlink:href="dare-20220331.xsd#dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived_31ab1052-e108-4b6b-8ed9-57082258d98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NotesPayableCurrentPlusAccruedInterest_2aa77f7d-5348-44d8-a226-d69e9a367c16" xlink:href="dare-20220331.xsd#dare_NotesPayableCurrentPlusAccruedInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_fd96e7dd-069a-4ce0-9b2b-4412ae365992" xlink:to="loc_dare_NotesPayableCurrentPlusAccruedInterest_2aa77f7d-5348-44d8-a226-d69e9a367c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAwards" xlink:type="simple" xlink:href="dare-20220331.xsd#GrantAwards"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/GrantAwards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_78227a2b-0e24-49fb-88b0-66b094183834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantAwardTextBlock_fef50449-a544-478a-b6df-743a1950db5e" xlink:href="dare-20220331.xsd#dare_GrantAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_78227a2b-0e24-49fb-88b0-66b094183834" xlink:to="loc_dare_GrantAwardTextBlock_fef50449-a544-478a-b6df-743a1950db5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAwardsDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#GrantAwardsDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/GrantAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_e03565cc-855b-4d1b-8d33-5d6c4d7efdb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4dde34e4-7a04-49b6-a683-e5399e23241c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_e03565cc-855b-4d1b-8d33-5d6c4d7efdb6" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4dde34e4-7a04-49b6-a683-e5399e23241c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cdd5b84f-d604-4bf8-9e2a-8db93587338d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4dde34e4-7a04-49b6-a683-e5399e23241c" xlink:to="loc_srt_ProductOrServiceAxis_cdd5b84f-d604-4bf8-9e2a-8db93587338d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7aeb3469-ae39-43bd-93f3-bfcb20cc71b5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_cdd5b84f-d604-4bf8-9e2a-8db93587338d" xlink:to="loc_srt_ProductsAndServicesDomain_7aeb3469-ae39-43bd-93f3-bfcb20cc71b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantDAREFRT1Member_d14cc211-1c43-4c9b-ba9e-c95188fc321d" xlink:href="dare-20220331.xsd#dare_GrantDAREFRT1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7aeb3469-ae39-43bd-93f3-bfcb20cc71b5" xlink:to="loc_dare_GrantDAREFRT1Member_d14cc211-1c43-4c9b-ba9e-c95188fc321d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantDAREPTB1Member_cc1d3350-f74a-4c94-8b85-f85c0ef31a87" xlink:href="dare-20220331.xsd#dare_GrantDAREPTB1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7aeb3469-ae39-43bd-93f3-bfcb20cc71b5" xlink:to="loc_dare_GrantDAREPTB1Member_cc1d3350-f74a-4c94-8b85-f85c0ef31a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DARELARC1Member_e8454e96-b8c7-4a4c-a381-5a33ec961eae" xlink:href="dare-20220331.xsd#dare_DARELARC1Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7aeb3469-ae39-43bd-93f3-bfcb20cc71b5" xlink:to="loc_dare_DARELARC1Member_e8454e96-b8c7-4a4c-a381-5a33ec961eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_af4794bb-f048-4edd-bc11-9b774aac6e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4dde34e4-7a04-49b6-a683-e5399e23241c" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_af4794bb-f048-4edd-bc11-9b774aac6e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ProceedsFromAwardOfGrant_c795589c-a6ee-4990-bdc9-72bb289ce485" xlink:href="dare-20220331.xsd#dare_ProceedsFromAwardOfGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_af4794bb-f048-4edd-bc11-9b774aac6e46" xlink:to="loc_dare_ProceedsFromAwardOfGrant_c795589c-a6ee-4990-bdc9-72bb289ce485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdditionalPotentialFundingRelatedToGrantAward_620e516d-2a39-4bfd-8c1a-a54c8c248245" xlink:href="dare-20220331.xsd#dare_AdditionalPotentialFundingRelatedToGrantAward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_af4794bb-f048-4edd-bc11-9b774aac6e46" xlink:to="loc_dare_AdditionalPotentialFundingRelatedToGrantAward_620e516d-2a39-4bfd-8c1a-a54c8c248245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_237d6f45-4d97-41ae-885c-33d9df48ee48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_af4794bb-f048-4edd-bc11-9b774aac6e46" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_237d6f45-4d97-41ae-885c-33d9df48ee48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ReceivableForExpensesEligibleForReimbursement_b4a506c8-8474-4a8b-a323-0cdd91ff28fa" xlink:href="dare-20220331.xsd#dare_ReceivableForExpensesEligibleForReimbursement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_af4794bb-f048-4edd-bc11-9b774aac6e46" xlink:to="loc_dare_ReceivableForExpensesEligibleForReimbursement_b4a506c8-8474-4a8b-a323-0cdd91ff28fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDevelopment_ee0499ea-2642-49de-afeb-63c2a92d0cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDevelopment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_af4794bb-f048-4edd-bc11-9b774aac6e46" xlink:to="loc_us-gaap_BusinessDevelopment_ee0499ea-2642-49de-afeb-63c2a92d0cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_2e213a11-e2a7-4f63-a623-0182a1305748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_af4794bb-f048-4edd-bc11-9b774aac6e46" xlink:to="loc_us-gaap_GrantsReceivable_2e213a11-e2a7-4f63-a623-0182a1305748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredGrantFundingCurrent_6e734ed5-dc0e-4232-a1df-ff995c9ac2dc" xlink:href="dare-20220331.xsd#dare_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_af4794bb-f048-4edd-bc11-9b774aac6e46" xlink:to="loc_dare_DeferredGrantFundingCurrent_6e734ed5-dc0e-4232-a1df-ff995c9ac2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShare" xlink:type="simple" xlink:href="dare-20220331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fc474494-c2d6-4e30-8773-66ef6403731f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_35781715-9a35-4ee0-b769-94461c458a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc474494-c2d6-4e30-8773-66ef6403731f" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_35781715-9a35-4ee0-b769-94461c458a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="dare-20220331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_25cc3a06-ff34-4410-b4f3-d15175e64950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_55a39042-9ec9-4ad5-a623-f2db3a236f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_25cc3a06-ff34-4410-b4f3-d15175e64950" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_55a39042-9ec9-4ad5-a623-f2db3a236f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b7009d7e-9cbd-43ea-a026-0d70316addf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7b56e56d-cad3-4f55-9b92-849510e29742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b7009d7e-9cbd-43ea-a026-0d70316addf4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7b56e56d-cad3-4f55-9b92-849510e29742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9cee82c-8ac0-4bd4-bc0a-1550a378e70b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7b56e56d-cad3-4f55-9b92-849510e29742" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9cee82c-8ac0-4bd4-bc0a-1550a378e70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_813cd389-bc7e-4012-8054-125bd57c5cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9cee82c-8ac0-4bd4-bc0a-1550a378e70b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_813cd389-bc7e-4012-8054-125bd57c5cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d80d5c32-a7eb-4783-98c2-b0d67f0c4efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_813cd389-bc7e-4012-8054-125bd57c5cbe" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d80d5c32-a7eb-4783-98c2-b0d67f0c4efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_24b39d0a-3ba0-46c1-834c-d58224760d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_813cd389-bc7e-4012-8054-125bd57c5cbe" xlink:to="loc_us-gaap_WarrantMember_24b39d0a-3ba0-46c1-834c-d58224760d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cf247043-4ab7-455a-a06d-a386dd2a0efe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7b56e56d-cad3-4f55-9b92-849510e29742" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cf247043-4ab7-455a-a06d-a386dd2a0efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9e5c99ed-0f4c-45b1-a8c2-2ae6de76521b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cf247043-4ab7-455a-a06d-a386dd2a0efe" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9e5c99ed-0f4c-45b1-a8c2-2ae6de76521b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/SubsequentEvents" xlink:type="simple" xlink:href="dare-20220331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_c68a0871-93a6-493f-90c3-06b527054dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_ef605a69-7e23-46ff-836b-2603cd05af18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_c68a0871-93a6-493f-90c3-06b527054dd7" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_ef605a69-7e23-46ff-836b-2603cd05af18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="dare-20220331.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_bff35720-89d2-4e2d-865d-54c4c7d6ce5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_93f3b798-a09e-4cb0-9da9-4c33d01b824f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_bff35720-89d2-4e2d-865d-54c4c7d6ce5b" xlink:to="loc_us-gaap_SubsequentEventTable_93f3b798-a09e-4cb0-9da9-4c33d01b824f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_21503170-7a75-4c4c-88b2-f22959a5a146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_93f3b798-a09e-4cb0-9da9-4c33d01b824f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_21503170-7a75-4c4c-88b2-f22959a5a146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_02ee0e81-1e00-45f7-b47a-e620c47d7621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_21503170-7a75-4c4c-88b2-f22959a5a146" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_02ee0e81-1e00-45f7-b47a-e620c47d7621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d4aa9a4d-1dc3-4c70-b441-9ec25c8387e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_02ee0e81-1e00-45f7-b47a-e620c47d7621" xlink:to="loc_us-gaap_SubsequentEventMember_d4aa9a4d-1dc3-4c70-b441-9ec25c8387e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9125d405-3828-4857-a46d-9cf86c2cfde8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_93f3b798-a09e-4cb0-9da9-4c33d01b824f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9125d405-3828-4857-a46d-9cf86c2cfde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_314ab2be-414e-4703-bcb4-5286f368641b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9125d405-3828-4857-a46d-9cf86c2cfde8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_314ab2be-414e-4703-bcb4-5286f368641b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ATMEquityOfferingProgramMember_f3e4979d-b02e-47e4-8686-ee5aa6db18e0" xlink:href="dare-20220331.xsd#dare_ATMEquityOfferingProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_314ab2be-414e-4703-bcb4-5286f368641b" xlink:to="loc_dare_ATMEquityOfferingProgramMember_f3e4979d-b02e-47e4-8686-ee5aa6db18e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_c677582a-da1c-4ee4-acc1-650702f56eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_93f3b798-a09e-4cb0-9da9-4c33d01b824f" xlink:to="loc_us-gaap_SubsequentEventLineItems_c677582a-da1c-4ee4-acc1-650702f56eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d1c024a3-fff5-47fa-be02-e52be3286202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c677582a-da1c-4ee4-acc1-650702f56eb3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d1c024a3-fff5-47fa-be02-e52be3286202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4492fd9d-510d-44aa-911c-7f5d8858df61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c677582a-da1c-4ee4-acc1-650702f56eb3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4492fd9d-510d-44aa-911c-7f5d8858df61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>dare-20220331_g1.jpg
<TEXT>
begin 644 dare-20220331_g1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D="                  #VU@ !     -,M2% @(
M                                            $6-P<G0   %0
M,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M    %&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0
M  +$    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE
M87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (
M#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE
M='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V
M+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                                  !865H@
M    \U$  0    $6S%A96B                      6%E:(        &^B
M   X]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0
M +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M   6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                 &1E<V,         +DE%0R V,3DV
M-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M    +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@
M<U)'0@                            !D97-C         "Q2969E<F5N
M8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M   L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0                                  =FEE=P      $Z3^ !1?+@ 0
MSQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M      $                        "CP    )S:6<@     $-25"!C=7)V
M        !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0
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MBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____N  Y!9&]B90!DP
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M&?_:  P# 0 "$0,1 #\ W\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_?SS7_K7_LUG_LX_VP_(W^T3_P"D=%_ZL#^[_2/_ ,)_UM;^,']_/-?^M?\
MLUG_ +.7.Z)DKN9T?3<QDIOK.1RNJ:[DK]CVXH?K%V]B*=JU-[->.*"+W9Y7
M.[6-:QO7HB(G1"O&9T:=OF5Q;T5A1IUZD8K:\%&;26+Q;P2Z7B7_ --7=QF&
MG,OO[N7'=U[*A4G+!+BG.E&4GA%)+%MO!))="2/5GPGM@
M
M
M
M                                           BIYQ?A+YV^X]K]=HD
M3<]?LBS_ .02]*)-GAQ^W+37TE'T)F1HQ^-U   #8IRS^&S<_P"%5O[ :;U:
M ^<,H]U;_@B?S+<Z/JGJ7Y->?EE#9;<RP   -$_&'[M.//N-J7V!CRI>=?/%
MW\IJ^G(U4T=]4,J^C;;X&![D\PZ0
M
M
M
M                          $5/.+\)?.WW'M?KM$B;GK]D6?_ ""7I1)L
M\./VY::^DH^A,R-&/QNH   ;%.6?PV;G_"JW]@--ZM ?.&4>ZM_P1/YEN='U
M3U+\FO/RRALMN98   &B?C#]VG'GW&U+[ QY4O.OGB[^4U?3D:J:.^J&5?1M
MM\# ]R>8=(
M
M
M
M        "*GG%^$OG;[CVOUVB1-SU^R+/_D$O2B39X<?MRTU])1]"9D:,?C=
M0   V*<L_ALW/^%5O[ :;U: ^<,H]U;_ ((G\RW.CZIZE^37GY90V6W,L
M#1/QA^[3CS[C:E]@8\J7G7SQ=_*:OIR-5-'?5#*OHVV^!@>Y/,.D
M
M
M
M                                                  !%3SB_"7SM
M]Q[7Z[1(FYZ_9%G_ ,@EZ42;/#C]N6FOI*/H3,C1C\;J   &Q3EG\-FY_P *
MK?V TWJT!\X91[JW_!$_F6YT?5/4OR:\_+*&RVYE@   :)^,/W:<>?<;4OL#
M'E2\Z^>+OY35].1JIH[ZH95]&VWP,#W)YAT@
M
M
M
M                                  (J><7X2^=ON/:_7:)$W/7[(L_^
M02]*)-GAQ^W+37TE'T)F1HQ^-U   #8IRS^&S<_X56_L!IO5H#YPRCW5O^")
M_,MSH^J>I?DUY^64-EMS+    T3\8?NTX\^XVI?8&/*EYU\\7?RFKZ<C531W
MU0RKZ-MO@8'N3S#I
M
M
M
M               14\XOPE\[?<>U^NT2)N>OV19_\@EZ42;/#C]N6FOI*/H3
M,C1C\;J   &Q3EG\-FY_PJM_8#3>K0'SAE'NK?\ !$_F6YT?5/4OR:\_+*&R
MVYE@   :)^,/W:<>?<;4OL#'E2\Z^>+OY35].1JIH[ZH95]&VWP,#W)YAT@
M
M
M
M                                                         (J>
M<7X2^=ON/:_7:)$W/7[(L_\ D$O2B39X<?MRTU])1]"9D:,?C=0   V*<L_A
MLW/^%5O[ :;U: ^<,H]U;_@B?S+<Z/JGJ7Y->?EE#9;<RP   -$_&'[M.//N
M-J7V!CRI>=?/%W\IJ^G(U4T=]4,J^C;;X&![D\PZ0
M
M
M
M                                       $5/.+\)?.WW'M?KM$B;GK
M]D6?_()>E$FSPX_;EIKZ2CZ$S(T8_&Z@  !L4Y9_#9N?\*K?V TWJT!\X91[
MJW_!$_F6YT?5/4OR:\_+*&RVYE@   :)^,/W:<>?<;4OL#'E2\Z^>+OY35].
M1JIH[ZH95]&VWP,#W)YAT@
M
M
M
M                    (J><7X2^=ON/:_7:)$W/7[(L_P#D$O2B39X<?MRT
MU])1]"9D:,?C=0   V*<L_ALW/\ A5;^P&F]6@/G#*/=6_X(G\RW.CZIZE^3
M7GY90V6W,L   #1/QA^[3CS[C:E]@8\J7G7SQ=_*:OIR-5-'?5#*OHVV^!@>
MY/,.D
M
M
M
M   !%3SB_"7SM]Q[7Z[1(FYZ_9%G_P @EZ42;/#C]N6FOI*/H3,C1C\;J
M&Q3EG\-FY_PJM_8#3>K0'SAE'NK?\$3^9;G1]4]2_)KS\LH;+;F6   !HGXP
M_=IQY]QM2^P,>5+SKYXN_E-7TY&JFCOJAE7T;;? P/<GF'2
M
M
M
M                                              BIYQ?A+YV^X]K]
M=HD3<]?LBS_Y!+THDV>''[<M-?24?0F9&C'XW4   -BG+/X;-S_A5;^P&F]6
M@/G#*/=6_P"")_,MSH^J>I?DUY^64-EMS+    T3\8?NTX\^XVI?8&/*EYU\
M\7?RFKZ<C531WU0RKZ-MO@8'N3S#I
M
M
M
M                            14\XOPE\[?<>U^NT2)N>OV19_P#()>E$
MFSPX_;EIKZ2CZ$S(T8_&Z@  !L4Y9_#9N?\ "JW]@--ZM ?.&4>ZM_P1/YEN
M='U3U+\FO/RRALMN98   &B?C#]VG'GW&U+[ QY4O.OGB[^4U?3D:J:.^J&5
M?1MM\# ]R>8=(
M
M
M
M           "*GG%^$OG;[CVOUVB1-SU^R+/_D$O2B39X<?MRTU])1]"9D:,
M?C=0   V*<L_ALW/^%5O[ :;U: ^<,H]U;_@B?S+<Z/JGJ7Y->?EE#9;<RP
M  -$_&'[M.//N-J7V!CRI>=?/%W\IJ^G(U4T=]4,J^C;;X&![D\PZ0
M
M
M
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M;Y=94<OM$XVM"E"G!-MX0A%1BL7M>"2VO:^D^@?J/J
M
M
M
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MN83IUEOC).+7E3P:)GL[ZRS&WC>9?6I5[2:QC.G.,X279*+<7ZC/H'ZCZ@
M
M
M
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MTEQ13PJ0QZ*E.6$X=G%%)]#:/>'F'2@
M
M
M
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M6E._RZK3KV56/%"<)*49)]*DL4_U-Q](_2?6
M
M
M
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M_ALW/^%5O[ :;U: ^<,H]U;_ ((G\RW.CZIZE^37GY90V6W,L
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M0GC!=I.=)!
M
M
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MX*/::6O.+\)?.WW'M?KM$TYYZ_9%G_R"7I1,@_#C]N6FOI*/H3,C1C\;J
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MN$-L-T*ZBMM2ECN>]RI8N44G*+E%/AEH<(3>
M
M
M
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M[\F^;]#6UI'(\]G&&K:47MP48W,5[."6"51+\Y326YU(+AXHTYBD?D]
M
M
M
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M'.@
M    J]YY^:1Q3Q#OEW1-3U2[RO+A4=7V#/878Z.)P-++L?VRXC'7'8W+)F9J
M:(J6)8T9#'+^C:Y[FO1E6-?^*O2>CL_GD&46D\WG0V5:M*M&G2C4QVTX2X*G
M>./LY+",9>:G)J7#<OEEX,-;:[TS3U+G=]3R2G<>=0HUJ$ZM:=)K95G!5*7=
M*>^G&6,Y1\YJ*<>+BO\ OE=:_L$SG_>!0_ZJ'#_XT\L_L_7_ -;A_LY(?_\
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MYPD,
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MIOV-6-D.3?V4Z>^B;;X-&#//G[:-4?3=W\+(D<241*
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M,O/7GWJ7G1G?O[G:Z/MJK=I9I[([.%5J[6RI7E'';MC24I0I['.4YADS$"
M       &>OFG]\?+/\3-\_K3E2UVG?J_8?(Z'P<3+;F#]?<\^F+S^D5"X_Q2
M_#[QK_DS)_UAS!7W7'UKO/=Q^#@7VY*?9=E'[S4^'JDA3DR4P
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M5-QE3J)8X<7!449..[SHIQ3:3:;P.J'AG:
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M;B>'KD_:\GM T<KK1@]47O#7OZBVXUFO-HQETT[>+X(]#FZE18=XT1#(>)V
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M   &Q3EG\-FY_P *K?V TWJT!\X91[JW_!$_F6YT?5/4OR:\_+*&RVYE@
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MT=J-91F-3#3N83C">+\VE6?FTZW4D]D*KV+A:E)X4TBZ4KJ:"@
M                   &1KS@_%GSM]^;?ZG2,?N>OVNY_P#+Y>C$W4\./V&Z
M:^C8^G,BH1,38; O$#\+? /\*=-^QJQLAR;^RG3WT3;?!HP9Y\_;1JCZ;N_A
M9$CB2B)0
M    #\62R6.PV.O9?+WJ>+Q6+IV<ADLED+,-.C0HTX7V+=RY;L/C@K5:T$;G
MR2/<C6-15541#]%U=6UE;5+R\J0I6E*#G.<VHPA"*QE*4G@HQBDVVW@EM9]%
MG9W>87=*PL*52M>UJD84Z<(N4YSDU&,(1BFY2DVE&*3;;P1G:\[/F#Y#EZ7+
M<1\,W[6*XKBF?3V#:J[K%/*\B>TJMEK0(J0SX[3G2=?T3D2:^U$=+V1.6%<X
MN??B)N-8SK:/T54E2TFI<-:NL8U+S#?%;G"WQ]B_.JI)SP@W!ZM^&KPLVN@X
M4-=<P:4*^M914J%M+AG3L<=JE+?&I=)>R7F46VH<4TJBJA*DEW3LO!G _(OD
M-O-/0^.<0MZ[(C+.8RUERU\)K.']YD5C-9R]VN;6IP=_T6-1\]A_2.&.214:
MO::#T#J3F-GT,@TW1[RN\)5*DME*A3Q2=2K+HBL=B6,YOS81E)I' <R>9FD^
M56FZFIM65^[MUC&E2CYU:XJX-QI48>RE+#:WA""\^I*,$V:EO&3Q=X\\7])3
M6M1A7)[!DTAL;?NU^O#'FMFOQM7M1W9W_L_"TG.<E2DQ[HX&JKG.DF?+-)JQ
MRNY5:<Y69'^C,GCWN8U<'<7,TE5KS7DQX*4=O=TDVHK%MRG*4Y8N<XN<^JN<
MNHOTOGLNYRNCC&UM(2;HV\'Y<..K/!.K6:4IM))0IQA3C)4DXB$
M &>OFG]\?+/\3-\_K3E2UVG?J_8?(Z'P<3+;F#]?<\^F+S^D5"X_Q2_#[QK_
M ),R?]8<P5]UQ]:[SW<?@X%]N2GV791^\U/AZI(4Y,E,
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MT*Y%:\>L-)JPOI\6>9;PTJC;\Z=/!]S5?6VDX2>UN<')^N1+$X4FX
M                     &1KS@_%GSM]^;?ZG2,?N>OVNY_\OEZ,3=3PX_8;
MIKZ-CZ<R*A$Q-AL"\0/PM\ _PITW[&K&R')O[*=/?1-M\&C!GGS]M&J/IN[^
M%D2.)*(E
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MHZKYLZEJ:CU16<GBU0H1;[BVI-K"G1@W@E@EQS]?4DN*;;W=O.Y(Y
M     ,]?-/[X^6?XF;Y_6G*EKM._5^P^1T/@XF6W,'Z^YY],7G](J%Q_BE^'
MWC7_ "9D_P"L.8*^ZX^M=Y[N/P<"^W)3[+LH_>:GP]4D*<F2F
M                >/W/0-,Y#QD>(W77<;L5"&;ZQ7BOQ.]VK/T[5FIVX7Q6
MZ<KV?1<Z*1BN;Z+U3T/0R[-<QRFL[C+JTZ-5K!N+WKJ:>*:\J9X6H-,9!JJS
M5CJ&TI75K&7%%36V+ZX234H-K8W%K%;'L/PZ/Q=Q]QM%;BT?5<7KWU]6K=GJ
M,EENVFL7K'%/?N2V;TD$;O5L:R>VU5541%53]F99WFN<2C+,J\ZO#N3P27:H
MI)8];PQ9\VG-&Z7TE"<-.65&U[WU[BFYRPW)SDY3:71'BP70CWQY9TP
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MS2UG=ZQSV35:O+AI4DVX6]"+?=4(8X>;!/:TEQU)3J-<4Y'9#M#@
M "*GG%^$OG;[CVOUVB1-SU^R+/\ Y!+THDV>''[<M-?24?0F9&C'XW4   -B
MG+/X;-S_ (56_L!IO5H#YPRCW5O^")_,MSH^J>I?DUY^64-EMS+    T3\8?
MNTX\^XVI?8&/*EYU\\7?RFKZ<C531WU0RKZ-MO@8'N3S#I         #B'/_
M  YCN:-!NX![8(-BQR2Y/4LI)]!:.8CB5$KS2M17ICLHQ/9L-Z.1$5LG:KXF
M=.DTMJ"MIW-(W2Q=I/"-6/7#'>E^-'?'U5CA)D=<SM!6G,#3-3+)*,<UI8U+
M:H]G!52]:WO[NHO,FMJW3P<H1PH<R>,OX7)7\1E:DU#)XNY9Q^0I6&]D]2Y4
MF?!9KRM]>DD4T:M7XIU0L]1K4KBC&XH24J,XJ46MS36*:\J,U+RSNLONZMC>
MPE3O*-24)PEL<9Q;4HOM331^$_:?.   =U\<N4I.)N4\#GIYUCP&2D3 ;0Q7
M=L2X7)2Q,DMOZJC>N*M,BM)^54A5O5$<IS&KLD6>Y)5M8K&Z@N.GU\<4]G[)
M8Q]7'H)(Y4:SEHC6EMF=26&65GW-PL=G=5&DY/\ >Y*-3]BUN;+ZFN:YJ.:J
M.:Y$<US516N:J=45%3T5%0J^UAL>\TO336*VIG_0?Z
M         9&O.#\6?.WWYM_J=(Q^YZ_:[G_R^7HQ-U/#C]ANFOHV/IS(J$3$
MV&P+Q _"WP#_  ITW[&K&R')O[*=/?1-M\&C!GGS]M&J/IN[^%D2.)*(E
M                                                    !X_=^/\
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M?9=E'[S4^'JDA3DR4P
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M\:RL]4].U+$J)\>J_ A[,?&E>2FXY1D%.$$]DJUU*;:[8PHPX?)QR\I.V5>
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M; O$#\+? /\ "G3?L:L;(<F_LIT]]$VWP:,&>?/VT:H^F[OX61(XDHB4
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M6MKI73UU=W=.KEM.YJ2KNFY1G4K5Z:@N[A!)<-)2VK'SEMPW3,)J*_
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MD5_1J7;7YF>-.MLWX4YJ,I8=+@I1[3K1X1W
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M3=.K%QJ1>#3333ZFGM1,U"XH75&-Q:SA4MYK&,HM2C)/I4DVFNU,_2?@?N
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MWA=_QIHW_<WRA_LKIO\ W99?Q!<?\I;D_DKDC_7_ /ZP^0]YWW]C?ZJOV/\
MTTVW/[3^ROVC_K(_:'[-_;F0O?4?KWU&#WO:[?=]EG=U[&]+H>$/5.I]2_\
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M.NQWH^>5S(6*O17=RM:ONY%IW,]07'<6$/>UZZ<MD(>5]?5%8M]6&+.)UMS
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M,L   #1/QA^[3CS[C:E]@8\J7G7SQ=_*:OIR-5-'?5#*OHVV^!@>Y/,.D
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MG)MK$S:YE:NCKW7N;:QITYT:.87M2K"G)IRA!O"$9..";C!13:Z4=8.N.'
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MGL79%;HKLBDBXN0Z;R+3%BLNR"UHVMHL,5".#DULXIRVRG+VTW*7:>K/A/;
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M&6O>:F>:H4N*UKWTX47C_P"[T,*%#L6-*G"3PV<3;V[SOY(1%P
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MD^3%+*J5'6&K*2EFLTIV]O-;*">ZI4BUMK-;8Q:PI+:_?,.[L((H+1@
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MGX?^74-3YW+4V;4U+),OFN",ML:MS@I1BUTQI)JI)/8Y.FFI1<D7#$ %\0
M           0[\PN$H>1]%FW#"U&NW31ZEB[$Z)B^]F-=B1]C*8AZ,^E-/58
MCK-5.CG(]KXVIUF54D#E_J2649FLON9?]W7,DGCNA4>R,NQ/ULNS!OUI W/C
MEY3U9IN6>Y?!?\09="4U@MM6@L95*3PWN*QJ4][Q4H17OC94UQQO66XUW?7=
MUPSG?6\'D(K$M='K&S(4']8<EC)W(B](,C1DDA<O15;W]R='(BI.N;Y90SC+
M:V77'YNK!I/\66^,EVQE@_4PW%(M)ZDO=(ZBM-0V#??VU52<<<%.#V5*;[)P
M<HOJQQ6U(T(:[G\7M6!P^R86PEK$YW&T\KCYTZ(KZMV!EB+W&(J^W,QK^U[%
M^DQZ*U?5%*I7=K6L;JI9W*X:]*;C)=J>#]3J?2MIJ/E69V>=9;0S?+Y\=C<T
M8U(2ZXS2DL5T-8X-;T\4]J/LGSGW@                 &;7YMV>_:?DS@L
M2Q_6+6N*M;HOCZ.Z-N7\[M.8FD571LZNDJ7X$^BY[41B>J.[D3,[Q?7_ ,:Y
MH6]FGYEME-&.'MIU:]1O=TQG#<VMG7BC7+P,99\3Y/7-])>?>9W<33]K"C;4
MDM[W2A-[4GMZL&5<E5BYP  !8O\ *TU=-@\M<#DW1)*W2M,W3:%ZL>](UGQ\
M6HQRKVL<QBMDVIO17]K4<J=%[NU%LCX4\J68\WK>Z:Q5C97-?<]F,%;I]6^O
MO>"Q[<"I_C1SEY7R,NK-2P>8YA:6^]+'";NFMKQ>RV>*6+PQQ6&)IY-23&\
M            $5/.+\)?.WW'M?KM$B;GK]D6?_()>E$FSPX_;EIKZ2CZ$S(T
M8_&Z@  !L4Y9_#9N?\*K?V TWJT!\X91[JW_  1/YEN='U3U+\FO/RRALMN9
M8   &B?C#]VG'GW&U+[ QY4O.OGB[^4U?3D:J:.^J&5?1MM\# ]R>8=(
M         "A3R:PR8'GGDZBC48D^QOS/1.GJNQTZFPN=]'TZO=E.[\_KZ^I:
M'1MQ\:TO95.JCP?P;=/\DS/YOY>LMYEYQ;I8<5VZO\/"-?'U>\Q.%'3$;@
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MR3.ZY#Z1AJG75*XNX\66Y='XS-/=*<6E1@_+4:FT]DHTY)[R[<K@:'@
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M0>EJ&C=)V>GZ27>T:2=62]G6GYU67;C-M1VO"*BMR1TP\8Z\
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M=U2^[Y#-#Q^Z?A3S/3NJJ<?/K4+FTJ/#HI3IUJ*Q[>^KO#L>'278EX3.X
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MW$\'[:1IQX!-/0I9!J#5<HXU*]Y0M(O#<J%-UJB3W><[BFY+VL>M%+A28T(
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M_@PTQ_75_P#P5+]<?X^]7_V?RW^&K?K#_<Y<:_VR[Q_F# ?X0?X,-,?UU?\
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M4*C_  X$?^&2V577EU<26*I974P?5*5:A%?Y/$BWT@(O8
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MIL)YKIG,<KIQ4ZES87%)1>U2=2E."323>#;P>Q^0VQ&X1_.X
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MRZA+RNIWGJ>;47X3&WQH6=2UYZWE>?K;FPLZD?(J2I>KYU*75U=!8F6/*H@
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M<.4O,.3$+Z*VV.<6U9OI49PKV[6Y['*O'%8K:D\=F#TLFG)D&
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MIXUU&:OCZTE5C?9#KNC%NA.E4L*LL-D90E*XMXX]<U.Y:71W;ZR[<O(9T@
M                     %)'F=KC\!SYLMGVDBK;-CL%L=-$141[)<=%B;DJ
M*O\ *63*XBPJK^=5+(<O+M76EZ,,<9T9SIOU).27[6<3._G_ )3++.9EW6PX
M:5Y2HUX]J=-4Y/U:E*;)E> VU,RG&6Q:K),CK>J[.^S'%W)W18K8:L=BK]#^
M4B/R5&ZO7X+_ /81YS2L71SFC?)>]UZ.&/7*F\'_ )+@3]X9<ZC>:/N\EG+&
MO97CDEU4Z\5*.SMJ0JD[2,BR0                *"_(W:&;AS=R-F8I?>K
M-V"7#U)$_P"+?5UV"# 0OB1/1(IFXWO1?YW=W+ZJI:32-D\OTW:6\EA/NE-^
M6HW-X]JXL#,GFOG,<]YB9M?PEQ4E=.E%]#C02HIKL?=X]N..]EH_A=KC\!P+
MK]F:)(9MFRN<V.1G3H]637/V54ED_(JST,1$]JI_,<W\O5"%.8EVKK5%6$7C
M&C"%/[BXFO4E)KRXER_#]E,LLY:6M6:X:EY6K5VNG!S[N+?EA2BUV-$K3AB:
MP     "KSYAW^.>+?\F;5^M8,FKE/_-[WW=+\$RF_BG^<,F_>;GTJ)S+P0_?
M=:^XV>^T,&>SS.^K<?E,/1F<AX:_M$G]&UO3HER!7PON      0T\Z=?DR_"
M292)BN=JVV83+SO:G56U+D=W7Y&N_-&ZUF857_A:A(?+.[5OJ3N)/97H3BO*
ML)_@@R ?$AE<K[EW\=@MME?4:K?5&2G0?J<56'W$5W>*^TQ:ESOH5VS*D5/*
M9"QK=I5=VM=_2*E8Q5)'N^#6,REBN]57TZ-]>GQ)9UO8RO\ 3%U3@L:D(*HO
M^C:D_P#)4EZI5?DOG4,CYE99<59<-"M5E;RZO?X2IPQ[%4E!^H7N%8S28
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MV)56WV(ASQ!Z=EJGDMJ/*8+BK++9UX+>W.T<;J,5OVRE145VOH->1L081
M           BIYQ?A+YV^X]K]=HD3<]?LBS_ .02]*)-GAQ^W+37TE'T)F1H
MQ^-U   #8IRS^&S<_P"%5O[ :;U: ^<,H]U;_@B?S+<Z/JGJ7Y->?EE#9;<R
MP   -$_&'[M.//N-J7V!CRI>=?/%W\IJ^G(U4T=]4,J^C;;X&![D\PZ0
M        _P O>R)CY)'MCCC:Y\DCW(QC&,17.>]SE1K6M:G557T1#_4G)X+:
MV?Y*481<YM*"6+;V));VV9R-WS[MKW+;-G<Y[EV+9,WFT61.CT9E,E9NL:K4
M1$9V,F1$:B(C43HB=$+<Y;:JQR^A9+]RHPA^UBE^H90:BS-YWG]]G#;?QJ[K
M5=N_"I4E->3!/##HW'F#[3QP  "UKY?&$6OI&_[$K.U,MM&/P[7JC$5[<!BD
MN>BHGNN:UVQ+TZJK>O7IZ]Q!W-:YX\RM;3_-T)3_ &\L/)^Y_P#ML+K>%S+G
M2T[F>:M?G[R%+'9M[FGQ>7]W\F_#;B6#$4EH@     #.-\V?B274N=,'RE2K
M/;A^5=<KLO6$:OMMVW3X:N%O1.5K>R))M>7&/9W+W2/294Z]JF:_B[TA/*->
M4-5T(OXEFULN)]'QBW4:<EU+&CW+6.V3XWT,UH\#FN89YRVN=%W$U\?R2[DX
M1Z?BUTY58/K>%?XPGALBG372BJ@J:78+M?E(^0<5&_LWCGL=UD<>7DM;KQVL
M[T3OR<%9C=LU^%7=7/?9Q]6/(01IVM:E:VY>KGHA>/P@\Q(4+BZY;9E-*-9R
MN;/%^S45\8HKW4(JM"*P2X*SWR1G7XY^5D[FVL^;&4TVY4%&TOL%NIN3^+5W
MU*,Y2H3D\6^\H1W19>V7W,TP           "HSYK_D%6U'C;%\#X*]_^9^2)
M*N9VB."2/OQVB8FZLL$-E.OO0R;)GZ;&Q*WT?!1LL=Z/3K3[Q;\PZ63Z9I:
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MK4E-^63;P\BQP1JMDV5V^1Y1:Y-:?S:UMZ=*/1BJ<5%-]KPQ?6VS[Q\IZ0
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M)4=OJ=*+H>!K4:ROFU<Y%5:5+-,JJPBNNM0G"O'[E*-?9OZ=R9FY,T#7
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M\@EZ42;/#C]N6FOI*/H3,C1C\;J   &Q3EG\-FY_PJM_8#3>K0'SAE'NK?\
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MS&7LL%>+D9RREHO)GG6<0PU+?06*:VT*.R4:76IR>$ZN[!J$&L:;;F&1^3R
M                    9#?,KBMW#ODIRII\4#H,1-L4^SZW]!60KKVVM;L&
M.@K*O_&Q8OZ^^DKORR5G)\4,=^=.DWHSF;FV30CPV<KEUZ.S!=S<>_04>M4^
M-TL>N#-W/#_K5:^Y19)GTY*5_&T5O<;<7W]M[Q.4NIU.!5DOQ:D2,)%I,@
M!,#P8YS;P)Y%:?L62M?5M1V=S]&W5SG(R&'!;#/69!DYG.7MCBP6<KU+LKNB
MN]B"1C?5Y,G(?7BY?\R+/,KJ?#D]UC:W/4J59QPF^I4JJIU9/?P0DEO(&\27
M+:7,[E1?Y39PX\]LTKRTP6+=:@I-TUTMUJ,JM&*V+CG"3]::T#78PX
M      (J><7X2^=ON/:_7:)$W/7[(L_^02]*)-GAQ^W+37TE'T)F1HQ^-U
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MG3QR[*\WJU>JHK>DONQKUG_DGT9?X">9-2KAFN<9'1HX[Z4KJM+#W,[:@O\
M*]4B9R=\W?F/8X+-'C#1]5XU@F1[(\ODIY-XV*NGP9/4==IXK789%^*MGQUM
MJ?#JO3JL1:I\8>M,RIRH:6L;3+(2V*I-NZK+J<>*-.BGV2HU%T=KG'1O@2T!
ME-2%SK+,KW-ZD<&Z5-*SH2ZU+@E4KM=3A7I/I[%6/OO)._<I9V79>1-OS^Y9
MR5',2_G\E8OOKPN>K_JM&&5ZU\=28Y>K8*[(X6?S6H5=U!J;4&J[]YIJ.\N+
MV_?LZLW/!;^&">R$>J$%&*Z$BXNF-(Z8T7EL<GTI86N7Y;';P4:<8*3PPXIM
M+BJ3?3.;E-]+9XD\,Z(Z-Q7Q/OW-.YXS0N.-?M[#L63<KO:A3VZ>.I1N8VSE
MLQ?DZ5<7BJ?>GN3RN:WN<UC>Z1[&.Z32>D=0:WSNEI_35O.YS*KT+9&$5ZZI
M4F_-A3CCME)I8M)8R:3Y/6NM],<O=/UM3:MNH6N545AB]LZDWCPTJ4%YU2I+
M!\,(IO!.3PC&4EJ0\1?$?3/%C2EHTUKY[D//UZ[]XW5T"MDO31])&X7"ME:D
MU#6L?,J^VQ>DEF1/>F^EV,BU5Y/<G\EY49'W%#AN-1W$4[JYPVR:V]U2QVPH
MP?K5L<WY\]O#&.,//7GKJ#G3J'XS<<=KI2UG)6=ICL@GL[ZMALG<37KGMC3C
M[W3V<4IRZ)A()          !65Y3^)DJ2W^2>*<4LD<BS7-IT['Q)WQ/Z.EG
MS.O5(T17Q/5%=/3C17-<O?"U6JK&3+HC7<>&.3YY/!K!4ZLGOZ%"H^O\6;\D
MGCM=0.<_)":G5U;HJAC!XSN+6"VI[Y5:$5O3WSI16*?G033<8P*T'D+;N,=B
MK[-IV6GQ.3@3V9V(B24\A45[7S8[*4I/T-RE,K$[F.3JUR(]BM>UKDE#-,IL
M,ZM'9YA352B]JZXOHE%[TUUKR/%-HK/IG5.>Z/S6.;Y#7E0O([&M\9QQQ<*D
M'LG!X;4]J>$HM22:MEX9\R- Y#CJ8?<):VA[<]&1.COV$CUK*3]$;W8S+V'(
MRG),_P"%>VK'(KD8R29WJ07J'E]FN4N5QEZE=6&_S5[Y%>V@M^'XT<>MJ*+N
MZ Y^:8U3"%AGTH9;GKP6$Y86]1_Z.K+9%M[H5&GM48RJ,F(US7-1S51S7(CF
MN:J*US53JBHJ>BHJ$?-8;'O)Y336*VIG_0?Z    #R6X[WI_'^)ES>Y;#C=?
MQT;7JV2]81L]I[&JY8,?29WW<C:5J=4B@CDD7\C3[\ORS,,UKJVR^E.K6?XJ
MV+MD]T5VR:7:>'GVI,BTO8RS'/[JC:VJ3VSEMDUMX806,ZDNJ,(RD^HJ]YX\
MTLYN<5W5>,&7=7UF9'UKNP3*D&RYF!>YDD=3VGO3!8^=%_F.6U(WIU?$BOB6
M:=,<NK;+I1OLZX:]XMJIK;3@^W'U\EVKA3Z);)%..97B"S'4$*F2Z.52SR>6
M,9UWLN*JW-1P;[F#[&ZDEAC*"<H$2./..=MY2V6KK&HXV3(7[#FR6K+^YE#%
M4UD9'-D\K;[7MJTH%?\ 2=T5[UZ-8U[W-:O>9MF]ADEG*]OYJ%);E[*3Z(Q7
M2W]Q;VTL60=I;2F>:SS>&3Y%1=6ZD\92>R%.&*3J5);>&"QVO:V]D5*32=WW
M"/"6L\)ZLW"XA&W\U>[)]CV26!L5W,VV]ZQL1O=(M7&TD>K*]='*UB*KG*Z1
M[WNK;J34EYJ.]^,7'F6T=E.FGBH+]63WRET[E@DDM%.7?+S)^7F3++['"KF%
M3!U[AQPG5EMP73PTX8X0@G@EBWC.4I/M!SI(         !5Y\P[_ !SQ;_DS
M:OUK!DU<I_YO>^[I?@F4W\4_SADW[S<^E1.9>"'[[K7W&SWVA@SV>9WU;C\I
MAZ,SD/#7]HD_HVMZ=$N0*^%]P        "/'D)X_X/G#76-1\6*W3#03+K6?
M<UWMIWK[C\1EFQHY\^)MR)U[D1TE:1?<C1462.3K-*:JN=-7>.#GEU1KO(?E
MQZI+[DEL?0U%?-+EAEW,7*DL8T=06\7\7K=&W:Z57#:Z4GTK&5.7G1Q\Z,Z3
M]RTO9^/MANZQMF*M8;,X^3Z<$[5[)XN][8;M&PWK#<HV/;58IHU<QZ)Z+U14
M2QN7YC99K:1O;&<:EO-;UT/I4EO4ETI[49Z9_I_.-+YK4R?.Z$[?,*3VI[FL
M7A.$MTX2P\V<6T^ADT>"?-?,ZG%3U?E5E[9L!$D=>GM$*_6-DQ4*(K&LR3)7
MI^WZD?T?IJYMN-O<O6=>UB1WJ?ES;WTI7N1\-&Z>UTWLIR?M</6/LPX7L];M
M98'EMXA<PR2%/)M:JI>99'",;A>=<4UNPJ)OWZ*V;6U52QVU-D59WI^\ZAO^
M*9F]-V'&;#C7=J/FQ]A'R5I'M[FP7ZCTCN8ZUV^OM3QQR(GJK2&,PRR_RJO\
M6S"E.E6ZI+?VQ>Z2[8MKM+B9%J/(M3V2S'(+JC=6CWN$L7%OHG%X3A+VLXQE
MV'JSX3V@    ?RGG@JP2V;4T5:M7C?-/8GD9#!#%&U7R2RRR*V..-C455<JH
MB(GJ?E&,IR4()N;>"2VMOJ2/PJ5:=&G*M6E&%**;<FTDDM[;>Q)=+9"/F?S7
MTK38;>%XX=6WC:.V2%,G&Y[M3Q4R?1262Y&Z-^=>SKU;'4=[#D^,Z*G:LD:=
MY<YCF$HW&;\5M9;^']UDNK#V'EEM]KTE=^8'B%T]D%.>7Z3<,QSG!KO%C\6I
MOK<U@ZS6]1IO@?3436#JJVS;]JY#V*QL&T92]G\]DI&1>[-UD<C5>J5Z-"K$
MU(JM6-TBI%!"QK&]?1O55ZS?8V%CE-HK2RA&E:P6."^_*3>UOKDWCVE+,[SW
M.M59K/-,YK5+K,JS2Q>WI\V$(K9&*QPC"*26.Q;2R7Q6\3WZ[)C^2N4<<B9Y
MBQ7=6U2VUK_V(Y.V6OFLU#U<W]LIZ.KUG?\ ^&O1\B>_T;!#^M]=*[4\GR6?
M\E>*JU5[/H<(/\3\:7L]R\W;*VO)?DE+*I4M7:RI?]YK"=O;2P?==,:M5?YW
MIA3?YKUTEWN"IV(D3%J0                      4K_-]X9=D=?X^YVQ53
MOGUZ=_'^WRQL5TG[&RDT^4U6Y,YK42*ICLPMVNYSE7NER,34Z>O6D7C&T4[G
M+LNU]:0QJ6TG:7#2V]W-N="3ZHPJ=Y!M[Y5H)&AG@.Y@1M<TS7EI>SPI745>
MVJ;V=[34:=S!=<JE+NII+=&A-LH7*!&F@    -1WRZ/(]O.G!]'7\]D&V>1.
M*XJ.K;&V:1%N93",A?%JNQO1SG23.N8ZJM:Q*Y5?)<J2R.Z>XWKJIX;N92U[
MH6GEV85.+4>4J-"MB_.J4DL*%9]+XH1X)R>UU*<I/#B1C%XL.4LN6W,>KFF6
M4G#2F=2G<T,%YE.LVG<VZZ%P5)=Y3BL%&E4A%8\#+ BPQ5P          $5/
M.+\)?.WW'M?KM$B;GK]D6?\ R"7I1)L\./VY::^DH^A,R-&/QNH   ;%.6?P
MV;G_  JM_8#3>K0'SAE'NK?\$3^9;G1]4]2_)KS\LH;+;F6   !HGXP_=IQY
M]QM2^P,>5+SKYXN_E-7TY&JFCOJAE7T;;? P/<GF'2           @;YR\N,
MUK3ZO&&(M=N<W-K+>;]IZ))2U2K.OZ*3M<DD;LYD($B;TZM?!!.UWHY.LG\M
M,A=YF$LZN(_R:WV0QZ:K6_\ 81>/9*46MQ6GQ':YCE&0PT=8SPS',$I5L'MA
M;1>Y]*=::X5T.$*D7O14B3P4=    !<5X-<>.U7BVUM]ZNL64Y R*7HED8YD
MC=>Q"STL.US7+U1+%F2W8:Y.B213QKZHB*M?N9>;*^SN-A3>-&UA@_WR>#G]
MQ<,7U-,OIX<M*O)=&3SVXCPWF:5>-8K!]Q2QA26W\:3J33Z8SB^IDUB.2P@
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MCVFC^C]=Z/U]EBS?1V86U_8X+B=*:<Z;DL5&K3>%2C/#V%6$)+J.<G-G6
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MWM+KZ5TAD&B\L65:?H1HT-\I;ZE27X]2;VREU>QBO-@HQ22]Z>6=,
M   "M#S^P>:R^8XR=B</E,HV#&[.V=V.Q]NZV%TEK"JQ)5K0RI&KT:O3KTZ]
M%)CY67-M;V]XJ]2$&YT\.*26.R>[%E1/$[EV87]_D[L:%:LHT;C'NX2GAC*E
MACPIX8X;,3F_@]KNP8KF>U9R>"S..K+I6<B2Q?Q=VG LK[^%5L:2V((X^]R-
M543KU7HI[',F[M*^G8PHU:<Y_&8/",DWZV?0F<EX=,IS2RY@3K7EM<4:/Z/K
M+BG3G%8N=+!8R26.S<6[D"%Z           <OY2X?T;F#"?L;<<6DTM=)%Q6
M:I^W7S>%FE[>^3'7ECD5L<JL;[D,C9()>U.]BJUJI[629_F>07/QC+YX1?KH
M/;":7XT?P-8270]K..UGH33FN\N^(9]1XIQQ[NK'"-:DWO=.>#V/!<49)PE@
MN*+:353/+_B/R7QB^WD\74DW?4HG/D9F,'5FDR-*LU.[NS6$C]ZU42-J*KY8
M5GKM:G<Y[.O:DZY!KS)LZ4:->2MK]^PFUPM^TGL3[$^&70D]Y2'7?(W5VCY3
MO+.#S'(TVU5HQ;G"/75HK&4<.F47."2Q<HXX$<M?V;8]1R4>6UC.9;7LI#]%
MMW$7K./L]J.1SH9'UY(UE@>K?IQOZL>GHY%3T.NN[.TOZ+H7M*G5H/HE%27E
MV[GU-;5T$497F^;9'=J^R>YKVMY'V=*<H2\C<6L4^F+Q3W-,EII_G1S#K\<-
M;8(->W6M&B-=/DZ+L9EG,:G1K4O8:2I35>GQ=)5E>[XJJKU5>%S#EGI^Z;G:
M.K;3?1&7%'[D\7ZBDD3?D/B0UYE<(T<TC:YA1734AW=7#W=)QCY7*G)O>WB=
MRQOS#<-)$G[7XPR=69&HB_LW9JM^)[DZ(JI]:Q&-=&U?CT^GT^'5?B<S6Y3W
M"E_)[V$H^VIN+^].7ZA(]IXI\OE#^7Y/6A4P_<[B,TW^RI4\/O\ J[S]TOS"
MM32-RP<<[%)*B)V,ES.-AC<O5.O=*RO.YB=/S,=ZGZH\J+['SKRDH]D)/[V*
M_"?3/Q2Y(H-TLINW/H3JTTONJ,L/N,YILOS!=TNLDCU/1->P/<BM98S.1O;%
M/&G1J>XQE>+ 5TDZHJHCFR-3JB*CNG5?9L^5674VG?756KV0C&FOON;^XT<A
MF_BAU!<1<,DRVUML=TJLYUVNU**HQQ\JDEVX;8E[]S5RAR:KF;EN&4R=%9/<
M;AX7QX["1N145CDQ&.95H221=/HO>Q\B?WW55Z]WE>G,ER;;E]O"%3#U[\Z?
M[>6,MO4FEV$'ZFY@ZQU@W'/[^M6M\<>Z34**ZO>H*,&UT-IR[=Y_3C/A/DCE
MJXR#3M>L6*"3)#;V"\CJ.O8_U1'K9RDK%CD?$B]SH8&S6%3^3&I_F<ZCRC(J
M?%F%5*KABJ<?.J2\D>WKEA'K9^>D.7NK-;W"I9#:SE;<6$J\_,H0Z^*HU@VM
M[C!3GANBRUW@OQ0TKB):V?RKH]NWEC6/9F;==K<=A9NB]R:_0D[_ &96]>GU
MJ576%1.K/:1SF+!NIM<YCGW%:T,;?+'[!/SIK_22Z5[5>;U\6"9=CEOR3T]H
M9PS.]:OM2)8JK*/F4G_H(/'!]'>2QF_8\";B2M.&)K
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MC4YN/^3)2],A#./"U9SFYY#FU2G#HA<4E4?\)3E3^"9R2_X"<OUU<M'8./\
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M:F6"$5%H0
M
M
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MDHQ2Z$DDD?L/UG[P
M
M
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MU>J*GHJ%YHRC.*G!IQ:Q36U-/I1G1*,H2<)IJ:>#3V--;TUT-'^S_3\0
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M3"DFXQZ&W*>"X\#OQRQ)P
M
M
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M#^34I+;1IR6#JR36*JU$\(K?"FWCYTVH6 $5EGP
M
M
M
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M]<>P>$14\XOPE\[?<>U^NT2)N>OV19_\@EZ42;/#C]N6FOI*/H3,C1C\;J
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M&M5BU^;6^G!K&H\)OWO!5+2"%"Y8
M
M
M                                                        /Q9+
M&X[,XZ]B,O1IY3%92G9Q^2QN0K0W*-^C<A?7MT[E2PR2"S5LP2.9)&]JM>U5
M145%/T75K;7MM4L[RG"K:58.$X32E"<)+"491>*E&2;336#6QGT6=Y=Y?=TK
M^PJU*-[1J1G3J0DXSA.+4HSA*+3C*+2<9)IIK%&=+SD^7IE>&Y<IRIPS0R&=
MXH>Z:]GM>8LN0S7'??(^2:1O1CK.3TV%J_0L.]RQ28G2RKF-6P[-WGOX=+O1
M<ZNK-%4ZEQI)XRJT=LZMGB\6_P :=LNB;QG27YUN*[QZP>&_Q4V6OX4=%<P:
MM*VUNDH4:[PA2OL$DEOX:=V^FFL(5GMHI2?=*JDJ<78       ![#2>0=YXV
MS46Q:!MVQ:;FXNU$R6N9:[B;$L;555KV5J31-N5']51\,J/B>U51S5150]G(
M]19]IF]68Z>O+FROE[.C4E3;75+A:XHOIC+&+6QIH\'46EM-ZNR]Y5JBPM,P
MRZ7[G7I0JQ3_ !H\2?#)=$HX232:::+*.*OFT\Z:DRM0Y+US6.5<="UC'Y#M
M_H;M4B(J(KI,CB*MK 2]L:?#]EM>YWJYZ^I9G2?B\UYD\8V^I[:US:VCL<_Y
MM7?EG3C*D]G^@3;VN1436W@;Y;9[*=UI"[O,DNY-M0_G=LO)3JRC76W_ .8:
M2V*)(3FKYDG!7./CCRKHD>-W/3-XV34I\;C,3F\5#D<7=R+[%29*]+.82S=:
MD:MC=TDMP4TZM]43TZR+K?Q,:"UURUS;((TKVRSVZLW"%.K34X2FW%X1JTI2
MV;'MJ0ID5\O/"-S*Y<<VLDU+*ME^8:<L[Y5*E6C4=.I"FHR7%.C6C#;M7FTI
MU=^_>41E"#2T   V*<L_ALW/^%5O[ :;U: ^<,H]U;_@B?S+<Z/JGJ7Y->?E
ME#9;<RP   +6*7F]QEIFBZE@L3A]DVO-XC5-?QMID,$&&Q#+N/P]2K9A?D;[
MWW?H68E:CHZ<K%1%5%^'6#JG+;.<QS.O<UZE&A;5*\Y+%N<L)3;3X8[-SZ9I
MEU+;Q$Z/T_INQRVQH7=[F-"RH4Y)15*DIPI1C).I-N>R2PQC2DGOQW8QTWOS
MBY=VA)ZNM,Q.A8Z7N8U<5"F3S?M/:K7,ES&38^)C_7TDK5:TC5]4<BG799RU
MR&RPG>=Y=5E^,^&&/9".WU)2DB*=2^(S76<J5'*%0RRTEL][7>5<'T.K432?
M5*%.G)=#(C9G.9G8LA/EL_ELEF\I97K8R&6NV<A=F7JJ_I+-J269R(KEZ(J]
M$Z^AWEO;6]I25"UIPIT5NC%**7J+!$&W^8YAFMU*]S.O5N+R?KIU)RG-^64F
MW]\^6?O/C      "(JJB(BJJKT1$]555^"(GY54#?L6\LA\8/$6:W)C.1N5\
M<L5%BQWM=TJ]#^DO.Z1RU,KL<#U7VZ3>O='1>U'RJB+,B1_HY(@UIKV--3RC
M(IXU=U2M%^MZ'&F^OKFMB]CMVJV?)WD94KSHZKUM2PMEA.A:36V>YQJ5T]T.
MF-%K&3P=1*/FSL^1$1$1$1$1.B(GHB(GP1$_(B$+EQ4DE@MQ_P!
M
M
M
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MR(L=+NEGVJU3NM0QPE"ELE1MWT/;LJU8[^/UD)>L3<54<XR-2QH
M
M
M
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M)*/\JDDJE>>$JU3W4L%A'':H048+?ACBWUP\$[D
M
M
M
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M#_0
M
M
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ME"X[JMY?,V=.\C^J*U5:Y%1R*J*BIT5%3T5%1?5%12/&FG@]Y**::Q6X_P"
M   &Q3EG\-FY_P *K?V TWJT!\X91[JW_!$_F6YT?5/4OR:\_+*&RVYE@
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M18/2W*+06DG&ME]C"M?QW5KCWZICUQXEP0?;3A!G>CER2P
M
M
M
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MK"1IU]6*WK^3H7$R6O+)*]M7MTIRM7#AXMSX,,,<,-^&W# H3JK+J6K<MO\
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M><I>DV=]EN09%DT>')[*TM8_Z&C3I^A%;^D](?&>L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
)        ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512247921960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 10, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DAR&#201; BIOSCIENCE, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-4139823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3655 Nobel Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">926-7655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DARE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,711,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001401914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512248146056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 39,316,911<span></span>
</td>
<td class="nump">$ 51,674,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">1,729,851<span></span>
</td>
<td class="nump">1,145,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">6,770,426<span></span>
</td>
<td class="nump">2,476,612<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">47,817,188<span></span>
</td>
<td class="nump">55,296,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">25,366<span></span>
</td>
<td class="nump">26,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">1,344,028<span></span>
</td>
<td class="nump">485,120<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">49,186,582<span></span>
</td>
<td class="nump">55,807,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,830,866<span></span>
</td>
<td class="nump">2,103,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,537,856<span></span>
</td>
<td class="nump">3,136,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="nump">9,731,363<span></span>
</td>
<td class="nump">10,542,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">294,474<span></span>
</td>
<td class="nump">270,546<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,394,559<span></span>
</td>
<td class="nump">16,052,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred license revenue</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities long-term</a></td>
<td class="nump">913,113<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">18,307,672<span></span>
</td>
<td class="nump">17,052,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 120,000,000 shares authorized; 83,944,119 shares issued and outstanding at March&#160;31, 2022 and December&#160;31, 2021</a></td>
<td class="nump">8,394<span></span>
</td>
<td class="nump">8,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(164,123)<span></span>
</td>
<td class="num">(154,973)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">149,560,211<span></span>
</td>
<td class="nump">149,027,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(118,525,572)<span></span>
</td>
<td class="num">(110,126,902)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">30,878,910<span></span>
</td>
<td class="nump">38,754,321<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 49,186,582<span></span>
</td>
<td class="nump">$ 55,807,177<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512251721080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">83,944,119<span></span>
</td>
<td class="nump">83,944,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">83,944,119<span></span>
</td>
<td class="nump">83,944,119<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512246107992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 2,569,987<span></span>
</td>
<td class="nump">$ 1,940,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5,805,462<span></span>
</td>
<td class="nump">5,728,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFee', window );">License fees</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">8,400,449<span></span>
</td>
<td class="nump">7,693,534<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(8,400,449)<span></span>
</td>
<td class="num">(7,693,534)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">1,779<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">369,887<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,398,670)<span></span>
</td>
<td class="num">(7,323,644)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(9,150)<span></span>
</td>
<td class="num">(6,841)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (8,407,820)<span></span>
</td>
<td class="num">$ (7,330,485)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per common share - basic (in usd per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per common share - diluted (in usd per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">83,944,119<span></span>
</td>
<td class="nump">44,502,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">83,944,119<span></span>
</td>
<td class="nump">44,502,582<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512245947928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,596,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">$ (1,151,733)<span></span>
</td>
<td class="nump">$ 4,159<span></span>
</td>
<td class="nump">$ 70,366,293<span></span>
</td>
<td class="num">$ (91,388)<span></span>
</td>
<td class="num">$ (71,430,797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">365,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,664,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">11,324,140<span></span>
</td>
<td class="nump">$ 567<span></span>
</td>
<td class="nump">11,323,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares', window );">Issuance of common stock from the exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock from the exercise of warrants</a></td>
<td class="nump">50,400<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">50,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,323,644)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,323,644)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(6,841)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,841)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,312,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">3,258,233<span></span>
</td>
<td class="nump">$ 4,731<span></span>
</td>
<td class="nump">82,106,172<span></span>
</td>
<td class="num">(98,229)<span></span>
</td>
<td class="num">(78,754,441)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,944,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">38,754,321<span></span>
</td>
<td class="nump">$ 8,394<span></span>
</td>
<td class="nump">149,027,802<span></span>
</td>
<td class="num">(154,973)<span></span>
</td>
<td class="num">(110,126,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">532,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,398,670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,398,670)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(9,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,944,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 30,878,910<span></span>
</td>
<td class="nump">$ 8,394<span></span>
</td>
<td class="nump">$ 149,560,211<span></span>
</td>
<td class="num">$ (164,123)<span></span>
</td>
<td class="num">$ (118,525,572)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512245856152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,398,670)<span></span>
</td>
<td class="num">$ (7,323,644)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">5,227<span></span>
</td>
<td class="nump">6,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">532,409<span></span>
</td>
<td class="nump">365,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NonCashLeaseExpense', window );">Non-cash operating lease cost</a></td>
<td class="num">(9,758)<span></span>
</td>
<td class="num">(24,224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of notes payable and accrued interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(369,887)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(584,534)<span></span>
</td>
<td class="nump">158,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(4,293,814)<span></span>
</td>
<td class="nump">217,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges', window );">Other non-current assets</a></td>
<td class="nump">87,891<span></span>
</td>
<td class="num">(128,086)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">727,783<span></span>
</td>
<td class="nump">450,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">401,613<span></span>
</td>
<td class="num">(837,191)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_IncreaseDecreaseInDeferredGrantFunding', window );">Deferred grant funding</a></td>
<td class="num">(811,620)<span></span>
</td>
<td class="num">(892,123)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,343,473)<span></span>
</td>
<td class="num">(8,377,015)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(4,553)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(4,553)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,324,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from the exercise of common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,400<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,374,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(9,150)<span></span>
</td>
<td class="num">(6,841)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(12,357,176)<span></span>
</td>
<td class="nump">2,990,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">51,674,087<span></span>
</td>
<td class="nump">4,669,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">39,316,911<span></span>
</td>
<td class="nump">7,660,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ForgivenessOfPaycheckProtectionProgramNotePayable', window );">Forgiveness of Paycheck Protection Program note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">369,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 1,043,590<span></span>
</td>
<td class="nump">$ 308,533<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ForgivenessOfPaycheckProtectionProgramNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forgiveness of Paycheck Protection Program Note Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ForgivenessOfPaycheckProtectionProgramNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_IncreaseDecreaseInDeferredGrantFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Deferred Grant Funding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_IncreaseDecreaseInDeferredGrantFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in other non-current assets and deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NetProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512251551624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
<td class="text">ORGANIZATION AND DESCRIPTION OF BUSINESS<div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dar&#233; Bioscience, Inc. is a biopharmaceutical company committed to advancing innovative products for women&#8217;s health. Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries operate one segment. In this report, the &#8220;Company&#8221; refers collectively to Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company began assembling its diverse portfolio in 2017 through acquisitions, exclusive in-licenses and other collaborations. The Company's programs target unmet needs in women's health in the areas of contraception, fertility, and vaginal and sexual health, and aim to expand treatment options, enhance outcomes and improve ease of use for women. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any revenue. The Company&#8217;s primary operations have consisted of, and are expected to continue to consist primarily of, research and development activities to advance its product candidates through clinical development and regulatory approval.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's first product, XACIATO&#8482; (clindamycin phosphate vaginal gel, 2%), was approved by the FDA in December 2021, as a single-dose prescription medication for the treatment of bacterial vaginosis in female patients 12 years of age and older. In March 2022, the Company entered into an exclusive global license agreement with an affiliate of Organon &amp; Co., Organon International GmbH, or Organon, to commercialize XACIATO. XACIATO is expected to be available commercially in the United States in the fourth quarter of 2022.   </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's portfolio includes drug and drug/device product candidates and potential product candidates in various stages of development, from pre-clinical to advanced clinical development.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512251568072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#8217;s opinion, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, or the 2021 10-K.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The Company has a history of losses from operations, expects negative cash flows from its operations to continue for the foreseeable future, and expects that its net losses will continue for at least the next several years as it develops and seeks to bring to market its existing product candidates and to potentially acquire, license and develop additional product candidates. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and reclassification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of the Company's ability to continue as a going concern.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company had an accumulated deficit of approximately $118.5 million, cash and cash equivalents of approximately $39.3 million, and working capital of approximately $31.4 million. For the three months ended March&#160;31, 2022, the Company incurred a net loss of approximately $8.4 million and had negative cash flow from operations of approximately $12.3 million.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects its primary uses of capital to be staff-related expenses, the cost of clinical trials and regulatory activities related to its product candidates, costs associated with contract manufacturing services and third-party clinical research and development services, payments due to third-parties under the Company's in-license and acquisition agreements including upon the occurrence of commercial milestones for XACIATO and development milestones for the Company&#8217;s product candidates, legal expenses, other regulatory expenses and general overhead costs. The Company&#8217;s future funding requirements could also include significant costs related to commercialization of its product candidates, if approved, depending on the type, nature and terms of commercial collaborations the Company establishes.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects its expenses, and in particular its research and development expenses, to increase significantly in 2022 compared to 2021 as the Company continues to develop and seek to bring to market its product candidates, with a focus on its product candidates that have reached the human clinical study development phase. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has one FDA-approved product, XACIATO, and has generated no revenue. Commercial launch of XACIATO in the U.S. by the Company's licensee, Organon, is expected in the fourth quarter of 2022. Under the terms of its license agreement with Organon, the Company will receive a $10.0&#160;million non-refundable and non-creditable payment following the effective date of the license agreement and will be entitled to receive tiered double-digit royalties based on net sales and up to $182.5&#160;million in milestone payments as follows: $2.5&#160;million following the first commercial sale of a licensed product in the United States; and up to $180.0&#160;million in tiered commercial sales milestones and regulatory milestones. The Company has devoted significant resources to building its portfolio of product candidates and to research and development activities related to these product candidates. The Company or its licensees must obtain regulatory approvals to market and sell any of its product candidates in the future and to market and sell XACIATO anywhere outside the U.S. The Company will need to generate sufficient safety and efficacy data on each of its product candidates in order to apply for regulatory approvals and for such assets to be attractive assets to potential strategic collaborators to license or to acquire, and for the Company to generate revenue through license fees, royalties on net revenues and commercial milestones related to such product candidates.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on the Company's current operating plan estimates, the Company does not have sufficient cash to satisfy its working capital needs and other liquidity requirements over at least the next 12 months from the date of issuance of the accompanying financial statements. The Company will need to raise substantial additional capital to continue to fund its operations and to successfully execute its current strategy. The Company may continue to seek to raise capital through the sale of shares of its common stock under its ATM sales agreement or through other types of equity transactions. However, when the Company can effect such sales and the amount of shares the Company can sell depends on a variety of factors including, among others, market conditions, the trading price of its common stock, its determination as to the appropriate sources of funding for its operations, and the number of authorized shares of common stock that are available for issuance, which is approximately 27&#160;million as of the date hereof. For the foreseeable future, the Company will evaluate and may pursue a variety of capital raising options on an on-going basis, including equity and debt financings, government or other grant funding, collaborations and strategic alliances or other similar types of arrangements, to cover its operating expenses, and the cost of any license or other acquisition of new product candidates or technologies. The amount and timing of the Company's capital needs have been and will continue to depend highly on many factors, including the product development programs the Company chooses to pursue, the pace and results of its clinical development efforts, and the nature and extent of expansion of its product candidate portfolio, if any. If the Company raises capital through collaborations, strategic alliances or other similar types of arrangements, it may have to relinquish, on terms that are not favorable to the Company, rights to some of its technologies or product candidates the Company would otherwise seek to develop or commercialize. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company and its stockholders. In addition, equity or debt financings may have a dilutive effect on the holdings of the Company's existing stockholders, and debt financings may subject the Company to restrictive covenants, operational restrictions and security interests in its assets. If the Company cannot raise capital when needed, on favorable terms or at all, the Company will not be able to continue development of its product candidates, will need to reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If the Company becomes unable to continue as a going concern, the Company may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its condensed consolidated financial statements, and stockholders may lose all or part of their investment in the Company's common stock. The Company's condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are described in Note 1 to the consolidated financial statements included in the 2021 10-K. Since the date of those consolidated financial statements, there have been no material changes to the Company&#8217;s significant accounting policies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following tables present the classification within the fair value hierarchy of financial assets and liabilities that are remeasured on a recurring basis as of March&#160;31, 2022 and December&#160;31, 2021. There were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 2) or using unobservable inputs (Level 3) as of March&#160;31, 2022 or December&#160;31, 2021.</span></div><div style="margin-top:8pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:485.25pt"><tr><td style="width:1.0pt"/><td style="width:216.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:7.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:7.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:7.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,330,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,330,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,666,064&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,666,064&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Represents cash held in money market funds.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract, assesses whether each good or service is distinct, and determines those that are</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company develops estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration and licensing agreements under which it out-licenses certain rights to its products or product candidates to third parties. The terms of these arrangements typically include payment of one or more of the following to the Company: non-refundable, up-front license fees; development, regulatory and/or commercial milestone payments; and royalties on net sales of licensed products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license&#160;to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from non-refundable, upfront fees allocated to the&#160;license when the&#160;license&#160;is transferred to the customer and the customer is able to use and benefit from the&#160;license. For licenses bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. To date, the Company has not recognized any license fee revenue. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of product for commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The evaluation is based on the degree the Company controls the specified product at any time before transfer to the customer. Revenues are recognized on a gross basis if the Company is in the capacity of principal and on a net basis if the Company is in the capacity of an agent. To date, the Company has not recognized any revenue associated with product supply arrangements. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestones.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement in which the Company is a licensor and that includes developmental, regulatory or commercial milestones, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments not within the Company's control, such as where achievement of the specified milestone depends on activities of a third party or regulatory approval, are not considered probable of being achieved until the specified milestone occurs. To date, the Company has not recognized any milestone revenue.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512249794648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Strategic Agreements</a></td>
<td class="text">STRATEGIC AGREEMENTS<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Agreements for Product Commercialization</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organon Exclusive License Agreement</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company entered into an exclusive license agreement with Organon pursuant to which Organon will obtain exclusive worldwide rights to develop, manufacture and commercialize XACIATO and other future intravaginal or urological products for human use formulated with clindamycin that rely on intellectual property controlled by the Company. The effective date of the agreement will occur following the satisfaction of closing conditions that include receipt of all applicable approvals, or the expiration or termination of all applicable waiting periods, required under applicable antitrust laws, including the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.  </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other terms of the Organon license agreement:</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Upfront Payment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company will receive a $10.0 million non-refundable and non-creditable payment following the effective date of the agreement.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will be entitled to receive tiered double-digit royalties based on net sales and up to $182.5 million in milestone payments as follows: $2.5 million following the first commercial sale of a licensed product in the United States; and up to $180.0 million in tiered commercial sales milestones and regulatory milestones. Royalty payments will be subject to customary reductions and offsets. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalty period for each licensed product will continue on a country-by-country basis from the first commercial sale of the licensed product in the country until the expiration of the later of (i) the date that no valid patent claim would be infringed in the absence of the license granted under the agreement by the sale of the licensed product in the country, (ii) 10 years after the end of the month in which the first commercial sale of the licensed product in the country occurred, and (iii) the expiration of regulatory market exclusivity for the licensed product in that country.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Interactions and Product Supply.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will be responsible for regulatory interactions and for providing product supply on an interim basis until Organon assumes such responsibilities. Until such time, Organon will purchase all of its product requirements of XACIATO from the Company at a transfer price equal to the Company's manufacturing costs plus a single-digit percentage markup. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unless terminated earlier, the agreement will expire on a product-by-product and country-by-country basis upon expiration of the applicable royalty period for each licensed product. In addition to customary termination rights for both parties, following the first anniversary of the effective date of the agreement, Organon may terminate the agreement in its entirety or on a country-by-country basis at any time in Organon's sole discretion on 120 days' advance written notice.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The terms of the agreement provide Organon exclusive worldwide rights of first negotiation for specified potential future products of the Company.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Bayer HealthCare License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company entered into a license agreement with Bayer, regarding the further development and commercialization of Ovaprene in the U.S. The Company received a $1.0 million upfront non-refundable license fee payment from Bayer, and Bayer agreed to support the Company in development and regulatory activities by providing the equivalent of two experts to advise the Company in clinical, regulatory, preclinical, commercial, CMC and product supply matters. Bayer, in its sole discretion, has the right to make the license effective by paying the Company an additional $20.0 million, referred to as the Clinical Trial and Manufacturing Activities Fee. Such license would be exclusive with regard to the commercialization of Ovaprene for human contraception in the U.S. and co-exclusive with the Company with regard to development.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded there was one significant performance obligation related to the $1.0 million upfront payment: a distinct license to commercialize Ovaprene effective upon the receipt of the $20.0 million fee. The $1.0 million upfront payment will be recorded as license revenue at the earlier of (1) the point in time the&#160;Company receives the $20.0 million fee, the license&#160;is transferred to Bayer and Bayer is able to use and benefit from the&#160;license and (2) the termination of the agreement. As of March&#160;31, 2022, neither of the foregoing had occurred. The $1.0 million payment is recorded as long-term deferred license revenue in the Company's condensed consolidated balance sheet at March&#160;31, 2022 and December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other terms of the Bayer license agreement:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone &amp; Royalty Payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company will be entitled to receive (a) a milestone payment in the low double-digit millions upon the first commercial sale of Ovaprene in the U.S. and escalating milestone payments based on annual net sales of Ovaprene during a calendar year, totaling up to $310.0 million if all such milestones, including first commercial sale, are achieved, (b) tiered royalties starting in the low double digits based on annual net sales of Ovaprene during a calendar year, subject to customary royalty reductions and offsets, and (c) a percentage of sublicense revenue.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Efforts.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company is responsible for the pivotal trial for Ovaprene and for its development and regulatory activities and has product supply obligations. After payment of the Clinical Trial and Manufacturing Activities Fee, Bayer will be responsible for the commercialization of Ovaprene for human contraception in the U.S.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial term of the agreement, which is subject to automatic renewal terms, continues until the later of (a) the expiration of any valid claim covering the manufacture, use, sale or import of Ovaprene in the U.S.; or (b) 15 years from the first commercial sale of Ovaprene in the U.S. In addition to customary termination rights for both parties, Bayer may terminate the agreement at any time on 90 days' notice and the agreement will automatically terminate if the Company does not receive the Clinical Trial and Manufacturing Activities Fee if and when due.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Strategic Agreements for Pipeline Development</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Hammock/MilanaPharm Assignment and License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into (a) an Assignment Agreement with Hammock Pharmaceuticals, Inc., or the Assignment Agreement, and (b) a First Amendment to License Agreement with TriLogic Pharma, LLC and MilanaPharm LLC, or the License Amendment. Both agreements relate to the Exclusive License Agreement among Hammock, TriLogic and MilanaPharm dated as of January 9, 2017, or the MilanaPharm License Agreement. Under the Assignment Agreement and the MilanaPharm License Agreement, as amended by the License Amendment, the Company acquired an exclusive, worldwide license under certain intellectual property to, among other things, develop and commercialize products for the diagnosis, treatment and prevention of human diseases or conditions in or through any intravaginal or urological applications. The licensed intellectual property relates to the hydrogel drug delivery platform of TriLogic and MilanaPharm known as TRI-726. In XACIATO, this proprietary technology is formulated with clindamycin for the treatment of bacterial vaginosis. Each of the Assignment Agreement and License Amendment was amended in December 2019 and the License Agreement was further amended in September 2021 and March 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other terms of the License Amendment, as amended:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A total of $235,000 in license fees were payable to MilanaPharm, the final installment of which was $110,000 paid in 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company paid MilanaPharm $300,000 in the aggregate upon achievement of certain clinical and regulatory development milestones, $50,000 of which was paid in 2020 and $250,000 of which was paid in 2021. The Company may also pay MilanaPharm up to $500,000 upon the first commercial sale in the United States of the first licensed product for each vaginal use and urological use, and up to $250,000 upon the first commercial sale in the United States of successive licensed products for vaginal or urological use. In addition, upon achievement of $50.0 million in cumulative worldwide net sales of licensed products, the Company must pay $1.0 million to MilanaPharm. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Sublicense Income.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will pay MilanaPharm a low double-digit percentage of all income received by the Company or its affiliates in connection with any sublicense granted to a third party for use outside of the United States, subject to certain exclusions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the royalty term, the Company will pay MilanaPharm high single-digit to low double-digit royalties based on annual worldwide net sales of licensed products and processes. The royalty term, which is determined on a country-by-country basis and licensed product-by-product basis (or process-by-process basis), begins with the first commercial sale of a licensed product or process in a country and terminates on the latest of (1) the expiration date of the last valid claim of the licensed patent rights that cover the method of use of such product or process in such country, or (2) 10 years following the first commercial sale of such product or process in such country. Royalty payments are subject to reduction in certain circumstances, including as a result of generic competition, patent prosecution expenses incurred by the Company, or payments to third parties for rights or know-how required for the Company to exercise the licenses granted to it under the MilanaPharm License Agreement or that are strategically important or could add value to a licensed product or process in a manner expected to materially generate or increase sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Efforts. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company must use commercially reasonable efforts and resources to (1) develop and commercialize at least one licensed product or process in the United States and at least one licensed product or process in at least one of Canada, the United Kingdom, France, Germany, Italy or Spain, and (2) continue to commercialize that product or process following the first commercial sale of a licensed product or process in the applicable jurisdiction.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unless earlier terminated, the license term continues until (1) on a licensed product-by-product (or process-by-process basis) and country-by-country basis, the date of expiration of the royalty term with respect to such licensed product in such country, and (2) the expiration of all applicable royalty terms under the MilanaPharm License Agreement with respect to all licensed products and processes in all countries. Upon expiration of the term with respect to any licensed product or process in a country (but not upon earlier termination of the MilanaPharm License Agreement), the licenses granted to the Company under the MilanaPharm License Agreement will convert automatically to an exclusive, fully paid-up, royalty-free, perpetual, non-terminable and irrevocable right and license under the licensed intellectual property.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to customary termination rights for all parties, MilanaPharm may terminate the license granted to the Company solely with respect to a licensed product or process in a country if, after having launched such product or process in such country, (1) the Company or its affiliates or sublicensees discontinue the sale of such product or process in such country and MilanaPharm notifies the Company of such termination within 60 days of having first been notified by the Company of such discontinuation, or (2) the Company or its affiliates or sublicensees (A) discontinue all commercially reasonable marketing efforts to sell, and discontinue all sales of, such product or process in such country for nine months or more, (B) fail to resume such commercially reasonable marketing efforts within 120 days of having been notified of such failure by MilanaPharm, (C) fail to reasonably demonstrate a strategic justification for the discontinuation and failure to resume to MilanaPharm, and (D) MilanaPharm gives 90 days&#8217; notice to the Company. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other terms of the Assignment Agreement, as amended:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assignment; Technology Transfer</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Hammock assigned and transferred to the Company all of its right, title and interest in and to the MilanaPharm License Agreement and agreed to cooperate to transfer to the Company all of the data, materials and the licensed technology in its possession pursuant to a technology transfer plan to be agreed upon by the parties, with a goal for the Company to independently practice the licensed intellectual property as soon as commercially practical in order to develop and commercialize the licensed products and processes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fees</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A total of $512,500 in fees were payable to Hammock, the final installment of which was $137,500 paid in 2020. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company will pay Hammock up to $1.1 million in the aggregate upon achievement of certain clinical and regulatory development milestones, $100,000 of which was paid in 2020 and $750,000 of which was paid in 2021. The remaining milestone does not relate to a bacterial vaginosis product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Assignment Agreement will terminate upon the later of (1) completion of the parties' technology transfer plan, and (2) payment to Hammock of the last of the milestone payments.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADVA-Tec License Agreement </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a license agreement with ADVA-Tec, Inc., under which the Company was granted the exclusive right to develop and commercialize Ovaprene for human contraceptive use worldwide. The Company must use commercially reasonable efforts to develop and commercialize Ovaprene and must meet certain minimum spending amounts per year, including $2.5&#160;million per year to cover such activities until a final PMA is filed, or until the first commercial sale of Ovaprene, whichever occurs first. ADVA-Tec will conduct certain research and development work as necessary to allow the Company to seek a PMA from the FDA and will provide the Company with clinical trial and commercial supplies of Ovaprene, either directly or through a CMO, on commercially reasonable terms.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the license agreement, in addition to an exclusive license to ADVA-Tec's and its affiliates' intellectual property rights for all uses of Ovaprene as a human contraceptive device, the Company has a right of first refusal to license these patents and patent applications for additional indications.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other terms of the ADVA-Tec license agreement:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will pay to ADVA-Tec: (1) up to $14.6 million in the aggregate based on the achievement of specified development and regulatory milestones, $200,000 of which was paid in 2021; and (2) up to $20.0 million in the aggregate based on the achievement of certain worldwide net sales milestones.  The remaining development and regulatory milestones include: the FDA's approval to commence a pivotal clinical trial; successful completion of such pivotal clinical trial; the FDA's acceptance of a PMA filing for Ovaprene; the FDA's approval of the PMA for Ovaprene; CE Marking of Ovaprene in at least three designated European countries; obtaining regulatory approval in at least three designated European countries; and obtaining regulatory approval in Japan.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. After the commercial launch of Ovaprene, the Company will pay to ADVA-Tec royalties based on aggregate annual net sales of Ovaprene in specified regions, at a royalty rate that will vary between 1% and 10% and will increase based on various net sales thresholds. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Unless earlier terminated, the license the Company received under the agreement continues on a country-by-country basis until the later of the life of the licensed patents or the Company's last commercial sale of Ovaprene. In addition to customary termination rights for both parties: (A) the Company may terminate the agreement with or without cause in whole or on a country-by-country basis upon 60 days prior written notice; and (B) ADVA-Tec may terminate the agreement if the Company develops or commercializes any non-hormonal ring-based vaginal contraceptive device competitive to Ovaprene or if the Company fails to: (1) in certain limited circumstances, commercialize Ovaprene in certain designated countries within three years of the first commercial sale of Ovaprene; (2) satisfy the annual spending obligation described above, (3) use commercially reasonable efforts to complete all necessary pre-clinical and clinical studies required to support and submit a PMA, (4) conduct clinical trials as set forth in the development plan to which the Company and ADVA-Tec agree, and as may be modified by a joint research committee, unless such failure is caused by events outside of the Company&#8217;s reasonable control, or (5) enroll a patient in the first non-significant risk medical device study or clinical trial as allowed by an institutional review board within six months of the production and release of Ovaprene, unless such failure is caused by events outside of the Company&#8217;s reasonable control.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SST License and Collaboration Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a license and collaboration agreement with Strategic Science &amp;&#160;Technologies-D,&#160;LLC and Strategic Science &amp; Technologies, LLC, referred to collectively as SST, under which the Company received an exclusive, royalty-bearing, sublicensable license to develop and commercialize, in all countries and geographic territories of the world, for all indications for women related to female sexual dysfunction and/or female reproductive health, including the treatment of female sexual arousal disorder, or the Field of Use, SST&#8217;s topical formulation of Sildenafil Cream, 3.6% as it existed as of the effective date of the agreement, or any other topically applied pharmaceutical product containing sildenafil or a salt thereof as a pharmaceutically active ingredient, alone or with other active ingredients, but specifically excluding any product containing ibuprofen or any salt derivative of ibuprofen, or the Licensed Products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other terms of the SST license and collaboration agreement:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invention Ownership.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company retains rights to inventions made by its employees, SST retains rights to inventions made by its employees, and each party owns a 50% undivided interest in all joint inventions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Development Committee.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The parties will collaborate through a joint development committee that will determine the strategic objectives for, and generally oversee, the development efforts of both parties under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company must use commercially reasonable efforts to develop the Licensed Products in the Field of Use in accordance with a development plan in the agreement, and to commercialize the Licensed Products in the Field of Use. The Company is responsible for all reasonable internal and external costs and expenses incurred by SST in its performance of the development activities it must perform under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SST will be eligible to receive tiered royalties based on percentages of annual net sales of Licensed Products in the single digits to the mid double digits, subject to customary royalty reductions and offsets, and a percentage of sublicense revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SST will be eligible to receive payments (1) ranging from $0.5 million to $18.0 million in the aggregate on achieving certain clinical and regulatory milestones in the U.S. and worldwide, and (2) between $10.0 million to $100.0 million in the aggregate upon achieving certain commercial sales milestones. If the Company enters into strategic development or distribution partnerships related to the Licensed Products, additional milestone payments would be due to SST.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s license continues on a country-by-country basis until the later of 10 years from the date of the first commercial sale of such Licensed Product or the expiration of the last valid claim of patent rights covering the Licensed Product in the Field of Use. Upon expiration (but not termination) of the agreement in a particular country, the Company will have a fully paid-up license under the licensed intellectual property to develop and commercialize the applicable Licensed Products in the applicable country on a non-exclusive basis.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Termination.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to customary termination rights for both parties: (1) prior to receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including NDA approval, the Company may terminate the agreement without cause upon 90 days prior written notice; (2) following receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including NDA approval, the Company may terminate the agreement without cause upon 180 days prior written notice; and (3) SST may terminate the agreement with respect to the applicable Licensed Product(s) in the applicable country(ies) upon 30 days&#8217; notice if the Company fails to use commercially reasonable efforts to perform development activities in substantial accordance with the development plan and do not cure such failure within 60 days of receipt of SST's notice thereof.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Catalent JNP License Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018,&#160;the Company entered into an exclusive license agreement with Catalent JNP, Inc. (formerly known as Juniper Pharmaceuticals, Inc., and which the Company refers to as Catalent), under which Catalent granted the Company (a) an exclusive, royalty-bearing worldwide license under certain patent rights, either owned by or exclusively licensed to Catalent, to make, have made, use, have used, sell, have sold, import and have imported products and processes, and (b) a non-exclusive, royalty-bearing worldwide license to use certain technological information owned by Catalent to make, have made, use, have used, sell, have sold, import and have imported products and processes. The Company is entitled to sublicense the rights granted to it under this agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Upfront Fee.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company paid a $250,000 non-creditable upfront license fee to Catalent in connection with the execution of the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annual Maintenance Fee.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will pay an annual license maintenance fee to Catalent on each anniversary of the date of the agreement, the amount of which will be $50,000 for the first two years and $100,000 thereafter, and which will be creditable against royalties and other payments due to Catalent in the same calendar year but may not be carried forward to any other year. The Company made the first payments in April 2019.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company must make potential future development and sales milestone payments of (1) up to $13.5 million in the aggregate upon achieving certain clinical and regulatory milestones, $1.0&#160;million of which became payable in the third quarter of 2021, and in accordance with the license agreement, the amount payable was offset by the $100,000 annual maintenance fee, resulting in a net amount of $900,000 paid during the third quarter of 2021, and (2) up to $30.3 million in the aggregate upon achieving certain commercial sales milestones for each product or process covered by the licenses granted under the agreement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the royalty term, the Company will pay Catalent mid-single-digit to low double-digit royalties based on worldwide net sales of products and processes covered by the licenses granted under the agreement. In lieu of such royalty payments, the Company will pay Catalent a low double-digit percentage of all sublicense income the Company receives for the sublicense of rights under the agreement to a third party. The royalty term, which is determined on a country-by-country basis and product-by-product basis (or process-by-process basis), begins with the first commercial sale of a product or process in a country and terminates on the latest of (1) the expiration date of the last valid claim within the licensed patent rights with respect to such product or process in such country, (2) 10 years following the first commercial sale of such product or process in such country, and (3) when one or more generic products for such product or process are commercially available in such country, except that if there is no such generic product by the 10th year following the first commercial sale in such country, then the royalty term will terminate on the 10-year anniversary of the first commercial sale in such country.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Efforts. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company must use commercially reasonable efforts to develop and make at least one product or process available to the public, which efforts include achieving specific diligence requirements by specific dates specified in the agreement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the term of the agreement will continue on a country-by-country basis until the later of (1) the expiration date of the last valid claim within such country, or (2) 10 years from the date of first commercial sale of a product or process in such country. Upon expiration (but not early termination) of the agreement, the licenses granted thereunder will convert automatically to fully-paid irrevocable licenses. Catalent may terminate the agreement (1) upon 30 days&#8217; notice for the Company&#8217;s uncured breach of any payment obligation under the agreement, (2) if the Company fails to maintain required insurance, (3) immediately upon the Company&#8217;s insolvency or the making of an assignment for the benefit of the Company&#8217;s creditors or if a bankruptcy petition is filed for or against the Company, which petition is not dismissed within 90 days, or (4) upon 60 days&#8217; notice for any uncured material breach by the Company of any of the Company&#8217;s other obligations under the agreement. The Company may terminate the agreement on a country-by-country basis for any reason by giving 180 days&#8217; notice (or 90 days&#8217; notice if such termination occurs prior to receipt of marketing approval in the United States). If Catalent terminates the agreement for the reason described in clause (4) above or if the Company terminates the agreement, Catalent will have full access including the right to use and reference all product data generated during the term of the agreement that is owned by the Company.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adare Development and Option Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Company entered into an exclusive development and option agreement with Adare Pharma Solutions (formerly known as Adare Pharmaceuticals and Orbis Biosciences, and which the Company refers to as Adare), for the development of long-acting injectable etonogestrel contraceptive with 6- and 12-month durations (now known as ADARE-204 and ADARE-214, respectively). The agreement provides the Company with an option to negotiate an exclusive license agreement for the programs if the Company funds the conduct of specified development work by Adare. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MBI Acquisition</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company acquired Dare MB Inc. (formerly, Microchips Biotech, Inc.), or MBI, to secure the rights to develop a long-acting reversible contraception method that a woman can turn on or off herself, according to her own needs. This candidate is now known as DARE-LARC1. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing of the acquisition, the Company issued an aggregate of approximately 3.0&#160;million shares of its common stock to the holders of shares of MBI's capital stock outstanding immediately prior to the effective time of the merger. The transaction was valued at $2.4 million, based on the fair value of the approximately 3.0&#160;million shares issued at $0.79 per share, which was the closing price per share of the Company's common stock on the date of closing. The shares were issued in exchange for MBI&#8217;s cash and cash equivalents of $6.1 million, less net liabilities of $3.5 million and transaction costs of $202,000, which was allocated based on the relative fair value of the assets acquired and the liabilities assumed.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also agreed to pay the following additional consideration to the former MBI stockholders: (a) up to $46.5 million contingent upon the achievement of specified funding, product development and regulatory milestones; (b) up to $55.0 million contingent upon the achievement of specified amounts of aggregate net sales of products incorporating the intellectual property acquired by the Company in the merger; (c) tiered royalty payments ranging from low single-digit to low double-digit percentages of annual net sales of such products, subject to customary provisions permitting royalty reductions and offset; and (d)&#160;a percentage of sublicense revenue related to such products. The Company agreed to use commercially reasonable efforts to achieve specified development and regulatory objectives relating to DARE-LARC1. In June 2021, a total of $1.25&#160;million of that potential additional consideration became payable upon the achievement of certain of the funding and product development milestone events, $1.0 million of which was recorded as contingent consideration on the Company's consolidated balance sheets upon the completion of the MBI acquisition and $250,000 of which was expensed in 2021. In July 2021, the Company&#8217;s board of directors elected to make these milestone payments in shares of the Company&#8217;s common stock, to the extent permissible under the terms of the merger agreement with MBI, and, in September 2021, the Company issued approximately 700,000 shares of its common stock to former stockholders of MBI and paid $75,000 in cash to the stockholders&#8217; representative in accordance with the terms of the merger agreement in satisfaction of the $1.25&#160;million in milestone payments associated with milestones achieved in June 2021. See Note 7.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pear Tree Acquisition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company completed its acquisition of Pear Tree Pharmaceuticals, Inc., or Pear Tree. The Company acquired Pear Tree to secure the rights to develop a proprietary vaginal formulation of tamoxifen, now known as DARE-VVA1, as a potential treatment for vulvar and vaginal atrophy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company must make contingent payments to certain Pear Tree licensors and former stockholders of Pear Tree that become payable upon achievement of specified clinical, regulatory and commercial milestones, which may be paid, in the Company&#8217;s sole discretion, in cash or shares of the Company&#8217;s common stock.</span></div>Royalty Payments. Subject to royalty reductions and offsets, (a) the former stockholders of Pear Tree will be eligible to receive tiered royalties based on percentages of net sales of certain products and a percentage of sublicense revenue and (b) certain Pear Tree licensors will be eligible to receive royalties based on percentages of net sales of certain products and a percentage of sublicense revenue.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512251394808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">October 2021 ATM Sales Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into a sales agreement with SVB Leerink LLC to sell shares of its common stock from time to time through an "at-the-market," or ATM, equity offering program under which SVB Leerink acts as the Company's agent. The Company agreed to pay a commission equal to 3% of the gross proceeds of any common stock sold under the agreement, plus certain legal expenses. Shares of the Company's common stock sold under the agreement will be issued pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-254862) and the base prospectus included therein, originally filed with the SEC on March 30, 2021, and declared effective on April 7, 2021, and the prospectus supplement dated October 13, 2021 relating to the offering of up to $50.0 million in shares of the Company's common stock under this sales agreement, and any subsequent prospectus supplement filed with the SEC related to this ATM equity offering program.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, the Company sold no shares under this agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">April 2021 ATM Sales Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into a sales agreement with SVB Leerink LLC to sell shares of its common stock from time to time through an ATM, equity offering program under which SVB Leerink acts as the Company's agent. Under the sales agreement, the Company may issue and sell up to $50.0 million of shares of its common stock. The Company agreed to pay a commission equal to 3% of the gross proceeds of any common stock sold under the agreement, plus certain legal expenses. Any shares of the Company's common stock sold under the agreement will be issued pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-254862) and the base prospectus included therein, originally filed with the SEC on March 30, 2021, and declared effective on April 7, 2021, and the prospectus supplement dated April 7, 2021 filed with the SEC on April 8, 2021.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, the Company sold no shares under this agreement.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 ATM Sales Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018 the Company entered into a common stock sales agreement with H.C. Wainwright &amp; Co., LLC, or Wainwright, relating to the offering and sale of shares of its common stock from time to time in an ATM equity offering program through Wainwright, acting as sales agent. Under the agreement, Wainwright was entitled to a commission at a fixed commission rate equal to 3.0% of the gross proceeds per share sold under the agreement. In March 2021, the Company provided notice to Wainwright to terminate the agreement, and the agreement terminated in April 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Line</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into a purchase agreement, or the Purchase Agreement, and a registration rights agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park. Under the terms and subject to the conditions of the Purchase Agreement, the Company had the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park was obligated to purchase up to&#160;$15.0 million&#160;of the Company&#8217;s common stock. The Company incurred legal, accounting, and other fees related to the Purchase Agreement of approximately $374,000. These costs were amortized and expensed as shares were sold under the Purchase Agreement. As of December 31, 2021, the Company had sold and Lincoln Park had purchased $15.0 million of the Company's common stock under the Purchase Agreement, there were no unamortized costs, and no more shares of common stock may be sold by the Company to Lincoln Park under the Purchase Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company closed an underwritten public offering in connection with which the Company issued to the investors in that offering warrants exercisable through February 2023 and that initially had an exercise price of $3.00 per share.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrants include a price-based anti-dilution provision, which provides that, subject to certain limited exceptions, the exercise price of the warrants will be reduced each time the Company issues or sells (or is deemed to issue or sell) securities for a net consideration per share less than the exercise price of those warrants in effect immediately prior to such issuance or sale. In addition, subject to certain exceptions, if the Company issues, sells or enters into any agreement to issue or sell securities at a price which varies or may vary with the market price of the shares of the Company&#8217;s common stock, the warrant holders have the right to substitute such variable price for the exercise price of the warrant then in effect. These warrants are exercisable only for cash, unless a registration statement covering the shares issued upon exercise of the warrants is not effective, in which case the warrants may be exercised on a cashless basis. A registration statement covering the shares issued upon exercise of the warrants is currently effective. The Company estimated the fair value of the warrants as of February 15, 2018 to be approximately $3.0 million which was recorded in equity as of the grant date. The Company early adopted ASU 2017-11 as of January 1, 2018 and recorded the fair value of the warrants as equity. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019 and July 2020, in accordance with the price-based anti-dilution provision discussed above, the exercise price of these warrants was automatically reduced to $0.98 per share and to $0.96 per share, respectively, and as a result of the triggering of the anti-dilution provision, $0.8 million and $6,863, respectively, was recorded to additional paid-in capital.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, no warrants were exercised. During the three months ended March&#160;31, 2021, warrants to purchase 52,500 shares of common stock were exercised for gross proceeds of $50,000. As of March&#160;31, 2022, the Company had the following warrants outstanding:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:169.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:19.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:18.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:118.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:18.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:157.00pt"/><td style="width:1.0pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying<br/>Outstanding Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/04/2026</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374,515</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/15/2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,381,015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512251551064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2014 Employee Stock Purchase Plan, or the ESPP, became effective in April 2014, but no offering period has been initiated thereunder since January 2017. There was no stock-based compensation related to the ESPP for the three months ended March&#160;31, 2022 or March&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated 2014 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains the Amended and Restated 2014 Stock Incentive Plan, or the Amended 2014 Plan, which provides for the grant of options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to employees, officers and directors, and consultants and advisors. There were 2,046,885 shares of common stock authorized for issuance under the Amended 2014 Plan when it was approved by the Company's stockholders in July 2018. The number of authorized shares increases annually on the first day of each fiscal year until, and including, the fiscal year ending December 31, 2024 by the least of (i) 2,000,000, (ii) 4% of the number of outstanding shares of common stock on such date, or (iii) an amount determined by the Company&#8217;s board of directors. On January 1, 2022, the number of authorized shares increased by 2,000,000 to 2,201,855.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Stock Option Activity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes stock option activity under the Amended 2014 Plan and related information for the three months ended March&#160;31, 2022. The exercise price of all options granted during the three months ended March&#160;31, 2022 was equal to the market value of the Company&#8217;s common stock on the date of grant. As of March&#160;31, 2022, unamortized stock-based compensation expense of approximately $5.3&#160;million will be amortized over a weighted average period of 2.98 years. At March&#160;31, 2022, 642,175 shares of common stock were available for future awards granted under the Amended 2014 Plan.</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:376.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,717,602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,277,282&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,597,775&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense related to stock options granted to employees and directors recognized in the condensed consolidated statements of operations is as follows:</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:376.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,613&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,911&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the three months ended March&#160;31, 2022 are as follows:</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:442.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:45pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of options granted</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.38</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512251572200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leased Properties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leased Properties</a></td>
<td class="text">LEASED PROPERTIES<div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease for its corporate headquarters (3,169 square feet of office space) commenced on July 1, 2018. In February 2022, the Company entered into an amendment to extend the term of the lease for two years such that the term now expires on August 31, 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MBI, a wholly owned subsidiary the Company acquired in November 2019, leases general office space in Lexington, Massachusetts and warehouse space in Billerica, Massachusetts. The Lexington lease commenced on July 1, 2013. In February 2022, the Company entered into an amendment to extend the term of the lease for three years such that the term now expires on December 31, 2025, subject to the landlord's right to terminate the lease on December 31, 2023. The Billerica lease commenced on October 1, 2016 and terminated on March 31, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under</span><span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the terms of each lease, the lessee pays base annual rent (subject to an annual fixed percentage increase), plus property taxes, and other normal and necessary expenses, such as utilities, repairs, and maintenance. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. The leases do not require material variable lease payments, residual value guarantees or restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The leases do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. The Company uses an incremental borrowing rate of 7% for operating leases that commenced prior to January 2019 (and all of the Company's operating leases commenced prior to such date). The depreciable lives of operating leases and leasehold improvements are limited by the expected lease term.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, the Company reported operating lease <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMzIwMw_e12ce3aa-c3f3-4f18-b044-bf8fda01a7e9">ROU assets</span> of approximately $1.2 million in other non-current assets, and approximately $294,000 and $913,000, respectively, in current portion of lease liabilities and lease liabilities long-term on the condensed consolidated balance sheet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease costs were approximately $169,000 and $135,000 for the three months ended&#160;March&#160;31, 2022 and March&#160;31, 2021, respectively. Operating lease costs consist of monthly lease payments expense, common area maintenance and other repair and maintenance costs and are included in general and administrative expenses in the condensed consolidated statements of operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities was approximately $123,000 and $112,000&#160;for the three months ended&#160;March&#160;31, 2022 and March&#160;31, 2021, respectively. These amounts are included in operating activities in the condensed consolidated statements of cash flows. Further, at March&#160;31, 2022, operating leases had a weighted average remaining lease term of 3.13 years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, future minimum lease payments under the Company's operating leases are as follows:</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:445.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,391,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512251563736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CRADA with NICHD for the Pivotal Phase 3 Study of Ovaprene</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a Cooperative Research and Development Agreement, or the CRADA, with the U.S. Department of Health and Human Services, as represented by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or NICHD, for the conduct of a multi-center, non-comparative, pivotal Phase 3 clinical study of Ovaprene, or the Ovaprene Phase 3. The Ovaprene Phase 3 will be conducted within NICHD&#8217;s Contraceptive Clinical Trial Network with NICHD contractor Health Decisions Inc., a contract research organization, providing clinical coordination and data collection and management services for the Ovaprene Phase 3. The Company and NICHD will each provide medical oversight and final data review and analysis for the Ovaprene Phase 3 and will work together to prepare the final report of the results of the Ovaprene Phase 3. The Company is responsible for providing clinical supplies of Ovaprene, coordinating interactions with the FDA, preparing and submitting supportive regulatory documentation, and providing a total of $5.5&#160;million in payments to NICHD to be applied toward the costs of conducting the Ovaprene Phase 3. NICHD will be responsible for the other costs related to the conduct of the Ovaprene Phase 3. In accordance with the payment schedule under the CRADA, the Company has made aggregate payments of $5.0 million of the total amount payable to NICHD, $3.5&#160;million of which was paid during the first quarter of 2022. At March&#160;31, 2022, the remaining amount of the Company's payment obligation under the CRADA was $0.5&#160;million. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3 above, in connection with the acquisition of MBI, the Company agreed to pay additional consideration of up to $46.5&#160;million to the former stockholders of MBI contingent upon the achievement of specified funding, product development and regulatory milestones. In June 2021, $1.25&#160;million of that potential additional consideration became payable upon the achievement of certain of the funding and product development milestone events, $1.0 million of which was previously recorded as contingent consideration on the Company's consolidated balance sheets upon the completion of the MBI acquisition and $250,000 of which was expensed in 2021. In July 2021, the Company&#8217;s board of directors elected to make these milestone payments in shares of the Company&#8217;s common stock, to the extent permissible under the terms of the merger agreement with MBI, and, in September 2021, the Company issued approximately 700,000 shares of its common stock to former stockholders of MBI and paid $75,000 to the stockholders&#8217; representative in accordance with the terms of the merger agreement in satisfaction of the $1.25&#160;million in milestone payments associated with milestones achieved in June 2021.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Payable</span>In April 2020, due to the economic uncertainty resulting from the impact of the COVID-19 pandemic on the Company's operations and to support its ongoing operations and retain all employees, the Company applied for and received a loan of $367,285 under the Paycheck Protection Program, or the PPP, of the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, administered by the U.S. Small Business Administration, or the SBA. Under the terms of the PPP, the loan proceeds could be used for "qualifying expenses" and, subject to specified limitations in the CARES Act and under the terms of the PPP, certain amounts of the loan, including accrued interest, may be forgiven if used for qualifying expenses. In January 2021, the Company was notified that the principal balance of its PPP loan and all accrued interest, which together totaled $369,887, were fully forgiven by the SBA. The Company recorded a gain on extinguishment of note payable and debt forgiveness income with respect to such loan forgiveness in the first quarter of 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512251565576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Awards<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_GrantAwardTextBlock', window );">Grant Awards</a></td>
<td class="text">GRANT AWARDS<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NICHD Non-Dilutive Grant Funding</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received notices of awards and non-dilutive grant funding from NICHD to support the development of Ovaprene, DARE-PTB1 and DARE-LARC1. NICHD issues notices of awards to the Company for a specified amount, and the Company must incur and track expenses eligible for reimbursement under the award and submit a detailed accounting of such expenses to receive payment. If the Company receives payments under the award, the amounts of such payments are recognized in the statements of operations as a reduction to research and development activities as the related costs are incurred to meet those obligations over the period. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ovaprene</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2018 through 2021, the Company received approximately $1.9 million of non-dilutive grant funding from NICHD for clinical development efforts supporting Ovaprene. All funds under the final notice of award had been disbursed as of December 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DARE-PTB1</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company received a notice of award of a grant from NICHD to support the development of DARE-PTB1. The award in the amount of $300,000 was for the "Phase I" segment of the project outlined in the Company's grant application, which is ongoing. Additional potential funding of up to approximately $2.0 million for the "Phase II" segment of the project outlined in the grant application is contingent upon satisfying specified requirements, including, assessment of the results of the Phase I segment, determination that the Phase I goals were achieved, and availability of funds. There is no guarantee the Company will receive any Phase II award.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded credits to research and development expense for costs related to the NICHD award of approximately $17,000 during the three months ended March&#160;31, 2022. At March&#160;31, 2022, the Company recorded a receivable of approximately $19,000 for expenses incurred through such date that it believes are eligible for reimbursement under the grant.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DARE-LARC1</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company received a notice of award of a grant from NICHD to support the development of DARE-LARC1. The award in the amount of approximately $300,000 is to be used to explore device insertion and removal in non-clinical studies, which is to occur during the period of September 2021 through August 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded credits to research and development expense of approximately $165,000 for costs related to the NICHD award during the three months ended March&#160;31, 2022. At March&#160;31, 2022, the Company recorded a receivable of approximately $173,000 for expenses incurred through such date that it believes is eligible for reimbursement under the grant. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DARE-LARC1 Non-Dilutive Grant Funding</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MBI Grant Agreement </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's wholly-owned subsidiary, MBI, was awarded $5.4&#160;million to support the development of DARE-LARC1 under a grant agreement with the Bill &amp; Melinda Gates Foundation, or the Foundation. The funding period under this agreement ended on June 30, 2021. Expenses eligible for funding were incurred, tracked and reported to the Foundation. MBI received aggregate payments under this agreement of approximately $5.4&#160;million. At June 30, 2021, all payments under this agreement associated with research and development expenses for DARE-LARC1 had been incurred and reported to the Foundation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 DARE-LARC1 Grant Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into an agreement with the Foundation, or the 2021 DARE-LARC1 Grant Agreement, under which the Company was awarded up to $48.95&#160;million to support the development of DARE-LARC1. The 2021 DARE-LARC1 Grant Agreement will support technology development and preclinical activities over the period of June 30, 2021 to November 1, 2026, to advance DARE-LARC1 in non-clinical proof of principle studies. The Company received an initial payment of $11.45&#160;million in July 2021. Additional payments are contingent upon the DARE-LARC1 program&#8217;s achievement of specified development and reporting milestones. At March&#160;31, 2022, approximately $9.7 million of deferred grant funding liability under this agreement was recorded in the Company's condensed consolidated balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_GrantAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Award [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_GrantAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512251509192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">NET LOSS PER SHARE<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes basic net loss per share using the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under outstanding options and warrants to purchase shares of the Company&#8217;s common stock. Common share equivalents are excluded from the diluted net loss per share calculation if their effect is anti-dilutive.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect:</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:367.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:66.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:66.25pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Potentially dilutive securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,277,282&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,311,291&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,381,015&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856,143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,658,297&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,167,434&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512251551624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of Common Stock</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Between April 1, 2022 and May&#160;10, 2022, the Company sold an aggregate of approximately 751,000 shares of common stock for net proceeds of approximately $1.2 million under its ATM equity offering program. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commencement of Phase 1/2 Clinical Study of DARE-HRT1</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2022, the Company announced commencement of its Phase 1/2 clinical study of DARE-HRT1. The open-label study will evaluate the pharmacokinetics (PK) of two versions of DARE-HRT1 in approximately 20 healthy, post-menopausal women over approximately three consecutive months of use. The study will also collect safety, usability, acceptability and symptom-relief data. The study is being conducted by the Company's wholly owned subsidiary in Australia.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512250037880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#8217;s opinion, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, or the 2021 10-K.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_GoingConcernPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The Company has a history of losses from operations, expects negative cash flows from its operations to continue for the foreseeable future, and expects that its net losses will continue for at least the next several years as it develops and seeks to bring to market its existing product candidates and to potentially acquire, license and develop additional product candidates. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and reclassification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of the Company's ability to continue as a going concern.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company had an accumulated deficit of approximately $118.5 million, cash and cash equivalents of approximately $39.3 million, and working capital of approximately $31.4 million. For the three months ended March&#160;31, 2022, the Company incurred a net loss of approximately $8.4 million and had negative cash flow from operations of approximately $12.3 million.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects its primary uses of capital to be staff-related expenses, the cost of clinical trials and regulatory activities related to its product candidates, costs associated with contract manufacturing services and third-party clinical research and development services, payments due to third-parties under the Company's in-license and acquisition agreements including upon the occurrence of commercial milestones for XACIATO and development milestones for the Company&#8217;s product candidates, legal expenses, other regulatory expenses and general overhead costs. The Company&#8217;s future funding requirements could also include significant costs related to commercialization of its product candidates, if approved, depending on the type, nature and terms of commercial collaborations the Company establishes.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects its expenses, and in particular its research and development expenses, to increase significantly in 2022 compared to 2021 as the Company continues to develop and seek to bring to market its product candidates, with a focus on its product candidates that have reached the human clinical study development phase. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has one FDA-approved product, XACIATO, and has generated no revenue. Commercial launch of XACIATO in the U.S. by the Company's licensee, Organon, is expected in the fourth quarter of 2022. Under the terms of its license agreement with Organon, the Company will receive a $10.0&#160;million non-refundable and non-creditable payment following the effective date of the license agreement and will be entitled to receive tiered double-digit royalties based on net sales and up to $182.5&#160;million in milestone payments as follows: $2.5&#160;million following the first commercial sale of a licensed product in the United States; and up to $180.0&#160;million in tiered commercial sales milestones and regulatory milestones. The Company has devoted significant resources to building its portfolio of product candidates and to research and development activities related to these product candidates. The Company or its licensees must obtain regulatory approvals to market and sell any of its product candidates in the future and to market and sell XACIATO anywhere outside the U.S. The Company will need to generate sufficient safety and efficacy data on each of its product candidates in order to apply for regulatory approvals and for such assets to be attractive assets to potential strategic collaborators to license or to acquire, and for the Company to generate revenue through license fees, royalties on net revenues and commercial milestones related to such product candidates.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on the Company's current operating plan estimates, the Company does not have sufficient cash to satisfy its working capital needs and other liquidity requirements over at least the next 12 months from the date of issuance of the accompanying financial statements. The Company will need to raise substantial additional capital to continue to fund its operations and to successfully execute its current strategy. The Company may continue to seek to raise capital through the sale of shares of its common stock under its ATM sales agreement or through other types of equity transactions. However, when the Company can effect such sales and the amount of shares the Company can sell depends on a variety of factors including, among others, market conditions, the trading price of its common stock, its determination as to the appropriate sources of funding for its operations, and the number of authorized shares of common stock that are available for issuance, which is approximately 27&#160;million as of the date hereof. For the foreseeable future, the Company will evaluate and may pursue a variety of capital raising options on an on-going basis, including equity and debt financings, government or other grant funding, collaborations and strategic alliances or other similar types of arrangements, to cover its operating expenses, and the cost of any license or other acquisition of new product candidates or technologies. The amount and timing of the Company's capital needs have been and will continue to depend highly on many factors, including the product development programs the Company chooses to pursue, the pace and results of its clinical development efforts, and the nature and extent of expansion of its product candidate portfolio, if any. If the Company raises capital through collaborations, strategic alliances or other similar types of arrangements, it may have to relinquish, on terms that are not favorable to the Company, rights to some of its technologies or product candidates the Company would otherwise seek to develop or commercialize. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company and its stockholders. In addition, equity or debt financings may have a dilutive effect on the holdings of the Company's existing stockholders, and debt financings may subject the Company to restrictive covenants, operational restrictions and security interests in its assets. If the Company cannot raise capital when needed, on favorable terms or at all, the Company will not be able to continue development of its product candidates, will need to reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If the Company becomes unable to continue as a going concern, the Company may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its condensed consolidated financial statements, and stockholders may lose all or part of their investment in the Company's common stock. The Company's condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are described in Note 1 to the consolidated financial statements included in the 2021 10-K. Since the date of those consolidated financial statements, there have been no material changes to the Company&#8217;s significant accounting policies.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract, assesses whether each good or service is distinct, and determines those that are</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company develops estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration and licensing agreements under which it out-licenses certain rights to its products or product candidates to third parties. The terms of these arrangements typically include payment of one or more of the following to the Company: non-refundable, up-front license fees; development, regulatory and/or commercial milestone payments; and royalties on net sales of licensed products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license&#160;to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from non-refundable, upfront fees allocated to the&#160;license when the&#160;license&#160;is transferred to the customer and the customer is able to use and benefit from the&#160;license. For licenses bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. To date, the Company has not recognized any license fee revenue. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of product for commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The evaluation is based on the degree the Company controls the specified product at any time before transfer to the customer. Revenues are recognized on a gross basis if the Company is in the capacity of principal and on a net basis if the Company is in the capacity of an agent. To date, the Company has not recognized any revenue associated with product supply arrangements. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestones.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement in which the Company is a licensor and that includes developmental, regulatory or commercial milestones, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments not within the Company's control, such as where achievement of the specified milestone depends on activities of a third party or regulatory approval, are not considered probable of being achieved until the specified milestone occurs. To date, the Company has not recognized any milestone revenue.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Going Concern</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512251512776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following tables present the classification within the fair value hierarchy of financial assets and liabilities that are remeasured on a recurring basis as of March&#160;31, 2022 and December&#160;31, 2021. There were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 2) or using unobservable inputs (Level 3) as of March&#160;31, 2022 or December&#160;31, 2021.</span></div><div style="margin-top:8pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:485.25pt"><tr><td style="width:1.0pt"/><td style="width:216.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:7.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:7.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:7.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,330,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,330,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,666,064&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,666,064&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Represents cash held in money market funds.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512331779752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Common Stock Warrants Outstanding</a></td>
<td class="text">As of March&#160;31, 2022, the Company had the following warrants outstanding:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:169.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:19.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:18.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:118.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:18.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:157.00pt"/><td style="width:1.0pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying<br/>Outstanding Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/04/2026</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374,515</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/15/2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,381,015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512252778440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity for Amended 2014 Plan and Related Information</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes stock option activity under the Amended 2014 Plan and related information for the three months ended March&#160;31, 2022. The exercise price of all options granted during the three months ended March&#160;31, 2022 was equal to the market value of the Company&#8217;s common stock on the date of grant. As of March&#160;31, 2022, unamortized stock-based compensation expense of approximately $5.3&#160;million will be amortized over a weighted average period of 2.98 years. At March&#160;31, 2022, 642,175 shares of common stock were available for future awards granted under the Amended 2014 Plan.</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:376.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,717,602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,277,282&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,597,775&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense related to stock options granted to employees and directors recognized in the condensed consolidated statements of operations is as follows:</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:376.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,613&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,911&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors</a></td>
<td class="text"><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the three months ended March&#160;31, 2022 are as follows:</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:442.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:45pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of options granted</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.38</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512251416984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leased Properties (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, future minimum lease payments under the Company's operating leases are as follows:</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:445.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,391,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512251540776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect:</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:367.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:66.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:66.25pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Potentially dilutive securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,277,282&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,311,291&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,381,015&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856,143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,658,297&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,167,434&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512251399128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512251742920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (118,525,572)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (110,126,902)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">39,316,911<span></span>
</td>
<td class="nump">$ 7,660,151<span></span>
</td>
<td class="nump">$ 51,674,087<span></span>
</td>
<td class="nump">$ 4,669,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_WorkingCapitalIncreaseDeficit', window );">Working capital</a></td>
<td class="nump">31,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">8,398,670<span></span>
</td>
<td class="nump">$ 7,323,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Cash flow from operations</a></td>
<td class="num">$ (12,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PeriodofInsufficientCashandLiquidityRequirements', window );">Period of insufficient cash and liquidity requirements</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dare_OrganonMember', window );">Organon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_UpfrontLicenseFeeAmountPaid', window );">Upfront license fee paid</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payment paid in common stock</a></td>
<td class="nump">182,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount', window );">First commercial sale amount</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount', window );">Sales based milestones amount</a></td>
<td class="nump">$ 180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MilestonePaymentsContingentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments, contingent amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MilestonePaymentsContingentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments, Contingent Amount, First Commercial Sale Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments, Contingent Amount, Sales Based Milestones Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PeriodofInsufficientCashandLiquidityRequirements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of Insufficient Cash and Liquidity Requirements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PeriodofInsufficientCashandLiquidityRequirements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_UpfrontLicenseFeeAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront License Fee, Amount Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_UpfrontLicenseFeeAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_WorkingCapitalIncreaseDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working Capital Increase (Deficit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_WorkingCapitalIncreaseDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dare_OrganonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dare_OrganonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512247993800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Financial Assets and Liabilities Remeasured on a Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 36,330,411<span></span>
</td>
<td class="nump">$ 49,666,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">36,330,411<span></span>
</td>
<td class="nump">49,666,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512235649480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFee', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,537,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,136,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PaymentOfAdditionalConsiderationInBusinessCombination', window );">Payment of additional consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member', window );">Microchips Biotech, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AssetAcquisitionContingentConsideration', window );">Asset acquisition, contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Common stock issued to microchips capital stock holders (in shares)</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Business acquisition transaction value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business combination shares issued (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AssetAcquisitionContingentConsiderationCurrent', window );">Current portion of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration', window );">Potential additional consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PaymentsToStockholdersRepresentativeInBusinessCombination', window );">Cash paid to stockholders' representative</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PaymentOfAdditionalConsiderationInBusinessCombination', window );">Payment of additional consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member', window );">Microchips Biotech, Inc. | Upon Achievement of Specified Development and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AssetAcquisitionContingentConsiderationCurrent', window );">Current portion of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member', window );">Microchips Biotech, Inc. | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Business acquisition transaction value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member', window );">Microchips Biotech, Inc. | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Common stock issued to microchips capital stock holders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember', window );">ADVA Tec Agreement | Upon Achievement of Specified Development and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | ADVA Tec Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfRoyaltyRate', window );">Percentage of royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | ADVA Tec Agreement | Upon Achievement of Specified Development and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | ADVA Tec Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfRoyaltyRate', window );">Percentage of royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_MilanaPharmMember', window );">MilanaPharm | Upon Achievement of Specified Development and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payment paid in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_BayerHealthcareLicenseAgreementMember', window );">Bayer Healthcare License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payment paid in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_UpfrontLicenseFeePaid', window );">Upfront license fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from grant for notice of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementInitialTerm', window );">Initial term of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | ADVA Tec Agreement | Upon Reaching Certain Worldwide Net Sales Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsTerm', window );">Milestone payments term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | MilanaPharm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payment paid in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFee', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFeeToBePaidUponContingency', window );">License fee to be paid upon contingency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_RoyaltyAgreementTerm', window );">Royalty agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct', window );">License agreement termination periodic discontinued sale of product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure', window );">License agreement termination period due to performance failure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementNoticePeriodOfTermination', window );">Certain clinical and regulatory development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | MilanaPharm | Upon Achieving Certain Development Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payment paid in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | MilanaPharm | Upon Achieving Certain Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payment paid in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | MilanaPharm | Upon Achieving Certain Commercial Milestones | Upon Achievement of Specified Development and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payment paid in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | MilanaPharm | Upon Achieving Certain Commercial Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payment paid in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | MilanaPharm | Licensed Product or Process for Vaginal or Urological Use</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payment paid in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember', window );">Assignment Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFee', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">512,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember', window );">Assignment Agreement | Hammock Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFeeToBePaidUponContingency', window );">License fee to be paid upon contingency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember', window );">Assignment Agreement | Hammock Pharmaceuticals, Inc | Upon Achieving Certain Clinical and Regulatory Development Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payment paid in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement', window );">Percentage of rights to inventions by employees under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payment paid in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payment paid in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Upon Achieving Certain Commercial Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payment paid in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Upon Achieving Certain Commercial Milestones | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payment paid in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member', window );">Juniper Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_UpfrontLicenseFeePaid', window );">Upfront license fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne', window );">Potential annual license maintenance fee, payments in year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter', window );">Potential annual license maintenance fee payments, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member', window );">Juniper Pharmaceuticals, Inc | Clinical and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MaximumPotentialMilestonePayments', window );">Maximum potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member', window );">Juniper Pharmaceuticals, Inc | Sales Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MaximumPotentialMilestonePayments', window );">Maximum potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dare_OrganonMember', window );">Organon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_UpfrontLicenseFeeAmountPaid', window );">Upfront license fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payment paid in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount', window );">First commercial sale amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount', window );">Sales based milestones amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsTerm', window );">Milestone payments term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dare_CatalentAndMilanaPharmMember', window );">Catalent and MilanaPharm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Annual maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmountPayableNet', window );">Net amount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dare_CatalentAndMilanaPharmMember', window );">Catalent and MilanaPharm | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payment paid in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AssetAcquisitionContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AssetAcquisitionContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AssetAcquisitionContingentConsiderationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Consideration, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AssetAcquisitionContingentConsiderationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Initial Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementNoticePeriodOfTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Notice Period Of Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementNoticePeriodOfTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement, termination period due to performance failure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Termination Periodic Discontinued Sale Of Product</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseFeeToBePaidUponContingency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee, To Be Paid Upon Contingency</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseFeeToBePaidUponContingency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MaximumPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Potential Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MaximumPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MilestonePaymentsContingentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments, contingent amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MilestonePaymentsContingentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments, Contingent Amount, First Commercial Sale Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MilestonePaymentsContingentAmountPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments, Contingent Amount Payable, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MilestonePaymentsContingentAmountPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments, Contingent Amount, Sales Based Milestones Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MilestonePaymentsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MilestonePaymentsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PaymentOfAdditionalConsiderationInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of Additional Consideration in Business Combination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PaymentOfAdditionalConsiderationInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PaymentsToStockholdersRepresentativeInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Stockholders' Representative in Business Combination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PaymentsToStockholdersRepresentativeInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of rights to inventions by employees under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PercentageOfRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PercentageOfRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Annual License Maintenance Fee, Payments In Year One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Annual License Maintenance Fee Payments, Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ResearchAndDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ResearchAndDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_RoyaltyAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_RoyaltyAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_UpfrontLicenseFeeAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront License Fee, Amount Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_UpfrontLicenseFeeAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_UpfrontLicenseFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront License Fee Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_UpfrontLicenseFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the maximum potential amount of consideration, undiscounted, that could be transferred under the registration payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383193&amp;loc=d3e16207-108621<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_MilanaPharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_MilanaPharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_BayerHealthcareLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_BayerHealthcareLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponReachingCertainWorldwideNetSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponReachingCertainWorldwideNetSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_HammockPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_HammockPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dare_OrganonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dare_OrganonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dare_CatalentAndMilanaPharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dare_CatalentAndMilanaPharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512246702872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Feb. 15, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfAggregateCommission', window );">Commission percent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Issues shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_DeferredOfferingCostsUnamortizedPortion', window );">Unamortized costs related to legal, accounting, and other fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant, exercise price, decrease (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature', window );">Deemed dividend from trigger of down round provision feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,863<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NumberOfCommonStockWarrantsExercised', window );">Number Of Common Stock Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">52,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Warrant exercises, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201711Member', window );">Accounting Standards Update 2017-11</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_EstimatedFairValueOfWarrantsRecordedInEquity', window );">Estimated fair value of warrants recorded in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=dare_LincolnParkMember', window );">Lincoln Park</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Obligation to purchase common stock</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dare_April2021AtTheMarketSalesAgreementMember', window );">April 2021 At The Market Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Issues shares</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dare_PurchaseAgreementMember', window );">Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Legal, accounting and other fees related to purchase agreement</a></td>
<td class="nump">$ 374,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Dividend From Trigger Of Round Down Provision Feature</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_DeferredOfferingCostsUnamortizedPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs, Unamortized Portion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_DeferredOfferingCostsUnamortizedPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_EstimatedFairValueOfWarrantsRecordedInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Fair Value Of Warrants Recorded In Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_EstimatedFairValueOfWarrantsRecordedInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NumberOfCommonStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Common Stock Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NumberOfCommonStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PercentageOfAggregateCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate commission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PercentageOfAggregateCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201711Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201711Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=dare_LincolnParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=dare_LincolnParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dare_April2021AtTheMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dare_April2021AtTheMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dare_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dare_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512246657480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares underlying outstanding warrants (in shares)</a></td>
<td class="nump">1,381,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember', window );">Warrants Expiring on April 4, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares underlying outstanding warrants (in shares)</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Apr.  04,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember', window );">Warrants Expiring on February 15, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares underlying outstanding warrants (in shares)</a></td>
<td class="nump">1,374,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Feb. 15,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights warrants expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ClassOfWarrantOrRightsWarrantsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512246592520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Unamortized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_WeightedAverageAmortizationPeriod', window );">Weighted average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 532,409<span></span>
</td>
<td class="nump">$ 365,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Options to purchase number of outstanding shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,046,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual percentage increase in outstanding number of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease', window );">Increase in number of shares authorized (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">2,201,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember', window );">Amended and Restated Two Thousand Fourteen Stock Incentive Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,277,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,717,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">642,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_WeightedAverageAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Amortization Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_WeightedAverageAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) of non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512245991112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Details) - Amended and Restated Two Thousand Fourteen Stock Incentive Plan - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding beginning balance (in shares) | shares</a></td>
<td class="nump">4,717,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,759,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled/forfeited (in shares) | shares</a></td>
<td class="num">(200,012)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding ending balance (in shares) | shares</a></td>
<td class="nump">6,277,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">2,597,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 1.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">1.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled/forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">1.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">1.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">$ 1.45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512246963992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details) - Employee Stock Option - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 532,409<span></span>
</td>
<td class="nump">$ 365,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">174,613<span></span>
</td>
<td class="nump">115,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 357,796<span></span>
</td>
<td class="nump">$ 250,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512248073384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">6 years 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.65%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">122.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted (in usd per share)</a></td>
<td class="nump">$ 1.38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by Share-based payment award fair value assumptions forfeiture rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512246634168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leased Properties - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th">
<div>Jul. 01, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Square footage of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term of operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating lease, right-of-use asset, statement of financial position [Extensible List]</a></td>
<td class="text">Other non-current assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">$ 294,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities long-term</a></td>
<td class="nump">913,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Non-cash lease expenses</a></td>
<td class="nump">169,000<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for measurement of operating lease liabilities</a></td>
<td class="nump">$ 123,000<span></span>
</td>
<td class="nump">$ 112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease weighted average remaining lease term</a></td>
<td class="text">3 years 1 month 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Non Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=dare_MBIMember', window );">MBI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term of operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=dare_MBIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=dare_MBIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512247952392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leased Properties - Future Minimum Lease Payments (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 288,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">422,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">384,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">297,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">1,391,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: accreted interest</a></td>
<td class="nump">183,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 1,208,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512247225288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PaymentOfAdditionalConsiderationInBusinessCombination', window );">Payment of additional consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,537,856<span></span>
</td>
<td class="nump">$ 3,136,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived', window );">Loan under paycheck protection program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 367,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NotesPayableCurrentPlusAccruedInterest', window );">Notes payable including accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 369,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member', window );">Microchips Biotech, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PaymentOfAdditionalConsiderationInBusinessCombination', window );">Payment of additional consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration', window );">Potential additional consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AssetAcquisitionContingentConsiderationCurrent', window );">Current portion of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Common stock issued to microchips capital stock holders (in shares)</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PaymentsToStockholdersRepresentativeInBusinessCombination', window );">Cash paid to stockholders' representative</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dare_NICHDMember', window );">NICHD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentAgreementCommitmentAmount', window );">Total payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Other cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dare_CRADAMember', window );">CRADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AssetAcquisitionContingentConsiderationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Consideration, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AssetAcquisitionContingentConsiderationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NotesPayableCurrentPlusAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Current, Plus Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NotesPayableCurrentPlusAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PaymentOfAdditionalConsiderationInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of Additional Consideration in Business Combination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PaymentOfAdditionalConsiderationInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PaymentsToStockholdersRepresentativeInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Stockholders' Representative in Business Combination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PaymentsToStockholdersRepresentativeInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ResearchAndDevelopmentAgreementCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Agreement, Commitment, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ResearchAndDevelopmentAgreementCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the maximum potential amount of consideration, undiscounted, that could be transferred under the registration payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383193&amp;loc=d3e16207-108621<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dare_NICHDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dare_NICHDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dare_CRADAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dare_CRADAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512235558920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Awards (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ProceedsFromAwardOfGrant', window );">Amount awarded for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,731,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,542,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dare_GrantDAREFRT1Member', window );">Grant, DARE-FRT1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ProceedsFromAwardOfGrant', window );">Amount awarded for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AdditionalPotentialFundingRelatedToGrantAward', window );">Additional potential grant funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Initial payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,950,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dare_GrantDAREPTB1Member', window );">Grant, DARE-PTB1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred', window );">Credits recorded to research and development expense for costs related to award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ReceivableForExpensesEligibleForReimbursement', window );">Receivable for expenses eligible for reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dare_DARELARC1Member', window );">DARE-LARC1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ProceedsFromAwardOfGrant', window );">Amount awarded for grant</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred', window );">Credits recorded to research and development expense for costs related to award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ReceivableForExpensesEligibleForReimbursement', window );">Receivable for expenses eligible for reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDevelopment', window );">Business development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AdditionalPotentialFundingRelatedToGrantAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Potential Funding Related To Grant Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AdditionalPotentialFundingRelatedToGrantAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ProceedsFromAwardOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Award Of Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ProceedsFromAwardOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ReceivableForExpensesEligibleForReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable For Expenses Eligible For Reimbursement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ReceivableForExpensesEligibleForReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of customer funding recorded as an offset to costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dare_GrantDAREFRT1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dare_GrantDAREFRT1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dare_GrantDAREPTB1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dare_GrantDAREPTB1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dare_DARELARC1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dare_DARELARC1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512248080776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">7,658,297<span></span>
</td>
<td class="nump">6,167,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">6,277,282<span></span>
</td>
<td class="nump">4,311,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">1,381,015<span></span>
</td>
<td class="nump">1,856,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140512248142872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event - ATM Equity Offering Program<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>May 10, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued (in shares) | shares</a></td>
<td class="nump">751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Shares of common stock for net proceeds | $</a></td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dare_ATMEquityOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dare_ATMEquityOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>dare-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dare="http://darebioscience.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dare-20220331.xsd" xlink:type="simple"/>
    <context id="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i94263204e2654add81cafbf53b703aaf_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="ic0c2931b38c749a8aac31ab58ed72510_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie30a938a64fd46cd98becdc1551973ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ida978f25ba59408b9386363eb6d6eed4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b251f7c118549ba9202433ab6104a64_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i60a512d483cf43099a491a6ccc8400a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if3bd3370ad994990ad0bd8c17e41e612_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i81a6b1d8921a4c34b493ef15f6ac3565_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2cdccf0de4054bd5be8b8f6ca8068dcd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifba16de9b31d4bb4b84e89fdde96c11f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3a6c19246dbd43918fe1d5bdaf45781d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i00586b33add54084bb2dbf880a0f3571_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i923566bd281646fdb2dc3656b54543af_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2ccd4e062a2e4af6bc25a6f55d4bbc88_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6063f716c8274a639d5c2235427b50d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66dc24f087884625adfebe658a8e451b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d33e15987224e8e864a9bb0d4e41246_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie18313b3160d472981c6193072f6baa5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if0526bb23c864be7babc6b325d2ae2b3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i09b399c6925442f9bf8bab14218dd545_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i11c9582a92634557be12814380daffe8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7777562075814792bdb540658b8e6a06_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7234840ac886468bb69f5d05bd2db206_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i91f25005c087421eab865393d5efc0bc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i70732a14fa594410af98fbfbbfc49572_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie20c398f1df046b288658ed72f3fea03_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i68e625c64183408d9d544a2b64fc1d4a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7ab03b72e1c442f393d5f68da2cd04dc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib8e755817cb04a57a08c4f99adb8ffd6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:OrganonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1c840e118dda4da0839c1173ced12675_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:OrganonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4d128dda6aad45f6928caa2a8b0ac74d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if261222bb7c7445a96aa0768ee93bdf6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaa56362091f34c8cb0ef0c7d93a4dea5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i753c4d96be1e4ba3967076ff69f73d0d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id64ecf9188364d48a0817d2f74ce0032_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36a1700da3be4028993f5fe8ba965b06_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieae613e2bfc34e51b675c0145659b974_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a58ac7dc95d43f7af582f30cbdc5d98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie39ad353b32c4dc891e544e148bc9b66_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:BayerHealthcareLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i8b96da1d703849ca87cb722301f4332a_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia36cb4e021c8477c9cdd5cd2270d26f0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id7e84f1a2279490fb994ed669d2a5794_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie1a197ace83745b5af0af06d9e6a03ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ica0953b3410b4366b3dd008e5682c91c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie54bf079d17049f89f976bde3354e8eb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1377eee01ae54f288857d7190cc24095_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:LicensedProductOrProcessForVaginalOrUrologicalUseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i96570265e6d94bafb524501622be0afa_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i52d0dedfaf874adfb961664b9bce5b92_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id84a19a7b61f49aab03e5421a920942c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i45bf9ce3d7014dd4a8cc904a8d6fdfe3_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i24bd5f0c2d834a5386e1ac19b19670c4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:HammockPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib3040a789d9a4c049500fc9df1a161d5_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:HammockPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie890f0c1b2d94ab1b54648bda60c9b9e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie4e5b11922fb45baae7deef39cf719d8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id40ce46b765846a5aa2e57368b8b8e2e_D20170301-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i3cba105a870f4df89d49f7bf4d41b3b3_D20170301-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i2502d37404a542acb2be44f30462a6db_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3c82657d880d4e1fa411c307e0109b6c_D20170301-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:UponReachingCertainWorldwideNetSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i33b5825a9b744e5d8bdf4464e25fdeca_D20170301-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i2c11228dbbd544df9e87f818ade25d08_D20170301-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="ib4370da4fa5342028ed801f0a9fa0408_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="ic670d6c2f83e480aaccaa11002b3fd82_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="iaac673f0f7dd48318f3456c2bd5051e6_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="i4e73b75602364a808872b80c92bb1c3d_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="i88690cf0663d46c2a1f6398cdafd4e30_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="ia6e9a4923f614a9492dd0238e4cca80f_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ic39a296e2a1e45a29ed3a2a13c728ab9_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i18e026cd749c470d865e295625b2d49f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:CatalentAndMilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i130fa20b36a240b182234edcc27974bf_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:CatalentAndMilanaPharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i05dcf861082b438c816582ce5fd7e46e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:CatalentAndMilanaPharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idb8485972ede4668ac56f750cad9b2ea_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:SalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="if0d7024baebb42f3921f362b71af0807_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="id9429fbf089249aeb34b9943fccfb3aa_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i4550db8657fb446599597be07760a4e9_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="id246537752c543dc90f3ce1157fa81db_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i4871de07797e4ead9c91bde6f6f1da64_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i0088c2d5b3d841d79733a7ba7eb77c3f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id046ca48ded64152a085f277ffdbdbd8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3b39b4e982ff415dacb98beb58f1a039_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4e1024a3a3274602a0b50c48b9aa2f4a_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8375b393afa24fd4b4172cd82f83fced_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i027223a9458b44d887cea8de9f1d3556_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:April2021AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="iba344274a14c460b96e230f0cbc5d2bb_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i06ac362092d24b6bb3af02efaf7065e2_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:LincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i860c63444c524b589d982ed7ae48fd65_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i10618bb6d8c14b5885277741ae4a3091_I20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="i7d4b21210fae4311928f3d408e82529a_I20180215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201711Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-15</instant>
        </period>
    </context>
    <context id="if840484cdcd14e6c9fa54cfcf591c465_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i32d71d006cd64f2da751eaec03afcb7e_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i9b97f0e3d65145168bade1be8778dd8a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3314d2bef75a49b1a150ea0c2b067414_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iea4b068280ea4864aa871809e542b4c1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifc86055f4ef84234810f28d2d776d7ae_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idf23d7941e8f4965a9fcb43805fcc930_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia882bdf1215042478edd6c0cd729a9d8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ide7f913a931341588fd2f90818d1cee0_I20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="ia0d3fa77cb2945be89df99f83cc05ff3_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i409dea6286e3437c8531176fdea88602_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i20fdc0f111514e9491d559f7b5252a54_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="if170fdedc89840ffbe1185f85069788b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5bcbbadf58fc412c9319a78f2b9da62f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf2231aefe254fee96b7aeae2d91ae6e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ied5f9449859d4a96a3953aabaec51ac8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i29bec700eba84708bf53a7ae61f8afcc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibafd6f2e17734e039ee794c367b91ef1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia79e904977c04b448a641740a5804fd5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if248f08c609e432db641de162429b03e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib6a8c036f5354223a3849ead24935854_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia70cb47052db467ab271c5cebe1a8cb5_I20180701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2018-07-01</instant>
        </period>
    </context>
    <context id="i10a03a7421004d2d9b8fe72bbc336117_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="i8152258bc79f4460a437ec7e86255593_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:MBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="ie288d155ad8e4f839c40e7b4157edee1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i715e356f19e949be97608ee8258262cb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifa2f7c9e3aba42cea0f0485646d7bae0_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:NICHDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="i39725376a360492eb4ee1a813cb8c93c_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:NICHDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i0417ba5df1e4483f9533526585cde1af_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:NICHDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4de0e117c45544bba3f02be2df728a46_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:CRADAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i328c1592bccd48bd90299695bcc0f38e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1668c60b90eb40c1b26a55cdec6001a8_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i2bda66626a774b0baba97582a51cae04_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="ia85f04efe0484874ad1aa6775fdee9cf_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8dab52c413224c10ab210ce9f3988ef2_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREFRT1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="ie5c7aa9a64ff4a88b42de5c106336b62_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREFRT1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i18d65ffa0cea435eacda2d0f47db2080_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREPTB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2a168cd74d64472ca8597b5ad0dc79dd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREPTB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i33bd9119af634fbe93377ca5a92bc751_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i316cb86d094b4f0ca01c73b2980e9033_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i45c466b7177d4d4c87ff8c12edc1f3ce_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:DARELARC1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaeedb8a01d9247389d7cf8d46e7e6514_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREFRT1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i010eed1efee345f4bd75243e4aa2a9c3_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="ie858a3b9009b46719e1b0cd4afebc54a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4385c5c549b145f4b28516d3328b7fae_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3581e3652c314104b3dfff05b889fd6e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i13cb5e160bd84532b3e28a94c5995894_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4b95783721914c71aa6fe27dd4fcf58c_D20220401-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:ATMEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>dare:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80L2ZyYWc6MWMxMTA1ZWNmNzA2NGI1MmIzNTgzMjljMzU5YTliYzcvdGFibGU6NTg2YjdlNGI3ZmY3NGZlZWI4OGEwNDYwMjQ2OTVlNjMvdGFibGVyYW5nZTo1ODZiN2U0YjdmZjc0ZmVlYjg4YTA0NjAyNDY5NWU2M18yLTEtMS0xLTM3NDkx_54127fec-8e70-4c0f-a2b0-59c195e6ac1e">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80L2ZyYWc6MWMxMTA1ZWNmNzA2NGI1MmIzNTgzMjljMzU5YTliYzcvdGFibGU6NTg2YjdlNGI3ZmY3NGZlZWI4OGEwNDYwMjQ2OTVlNjMvdGFibGVyYW5nZTo1ODZiN2U0YjdmZjc0ZmVlYjg4YTA0NjAyNDY5NWU2M180LTEtMS0xLTM3NDkx_b599f137-5fef-42b2-973a-0186335dd0b9">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80L2ZyYWc6MWMxMTA1ZWNmNzA2NGI1MmIzNTgzMjljMzU5YTliYzcvdGFibGU6NTg2YjdlNGI3ZmY3NGZlZWI4OGEwNDYwMjQ2OTVlNjMvdGFibGVyYW5nZTo1ODZiN2U0YjdmZjc0ZmVlYjg4YTA0NjAyNDY5NWU2M181LTEtMS0xLTM3NDkx_644a86fe-77f9-4c67-b6d4-64ce03193910">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80L2ZyYWc6MWMxMTA1ZWNmNzA2NGI1MmIzNTgzMjljMzU5YTliYzcvdGFibGU6NTg2YjdlNGI3ZmY3NGZlZWI4OGEwNDYwMjQ2OTVlNjMvdGFibGVyYW5nZTo1ODZiN2U0YjdmZjc0ZmVlYjg4YTA0NjAyNDY5NWU2M183LTEtMS0xLTM3NDkx_2ff89c94-1a66-4a51-8207-d5b311019e00">0001401914</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80L2ZyYWc6MWMxMTA1ZWNmNzA2NGI1MmIzNTgzMjljMzU5YTliYzcvdGFibGU6NTg2YjdlNGI3ZmY3NGZlZWI4OGEwNDYwMjQ2OTVlNjMvdGFibGVyYW5nZTo1ODZiN2U0YjdmZjc0ZmVlYjg4YTA0NjAyNDY5NWU2M184LTEtMS0xLTM3NDkx_35689c6f-13fd-4d0f-89e6-e521fcab00ad">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMzIwMw_e12ce3aa-c3f3-4f18-b044-bf8fda01a7e9">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGV4dHJlZ2lvbjowNzRlODY5NDZjN2E0NWI2OTMwMWQ0MDk0MjNmMDFmMl8xNzMz_703bd075-3a64-4e6b-a183-e4665639897b">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZGFkZTkyZmNiMTNmNGVjMzg0NzhlNDFiMzMwZTM1ZmQvdGFibGVyYW5nZTpkYWRlOTJmY2IxM2Y0ZWMzODQ3OGU0MWIzMzBlMzVmZF8wLTAtMS0xLTM3NDkx_1f42e577-c7e5-4e5a-9c3d-c1dc7d4d361b">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGV4dHJlZ2lvbjowNzRlODY5NDZjN2E0NWI2OTMwMWQ0MDk0MjNmMDFmMl8xMzE_f6ab0bc9-5bea-4617-9eab-68f29dee4a69">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6NTY3M2E2ZjBkYTRiNDg4YmE2NWUyY2QzOWQzZDQwOTcvdGFibGVyYW5nZTo1NjczYTZmMGRhNGI0ODhiYTY1ZTJjZDM5ZDNkNDA5N18wLTAtMS0xLTM3NDkx_1262f5d3-e265-4439-917e-da357fd597f2">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGV4dHJlZ2lvbjowNzRlODY5NDZjN2E0NWI2OTMwMWQ0MDk0MjNmMDFmMl8xMDk5NTExNjI5NTM3_4d59ef31-8c99-4c4a-8184-3806304fa183">001-36395</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl8wLTEtMS0xLTM3NDkxL3RleHRyZWdpb246ZDQzMjY3NGViYzFmNDI5MGJiMDI2NmQxYmNkYWQyZjBfNQ_a9832d2f-f750-40a6-a3bf-d89a2f9d9889">DAR&#xc9; BIOSCIENCE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl8xLTAtMS0xLTM3NDkxL3RleHRyZWdpb246YjExMTkyNjYxOGIyNDA4YTljMjM3YjZiNzIzNjg3YWZfNQ_71afc81d-9f85-402f-abec-3571bcf4f086">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl8xLTItMS0xLTM3NDkxL3RleHRyZWdpb246YTRhYWNjOGViNGZlNDA4Mzg3NTUxNWNhZTRjODFkOWNfNQ_8f9abf5a-fcea-4bca-be7b-fac3cdb42c26">20-4139823</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl8zLTAtMS0xLTM3NDkxL3RleHRyZWdpb246MjYxZWRjMTM4NTdkNDBhOWIzZWE2OGZkNGMwNzRmNWVfNQ_325f1e88-d394-4052-8b69-98389f74ddca">3655 Nobel Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl8zLTAtMS0xLTM3NDkxL3RleHRyZWdpb246MjYxZWRjMTM4NTdkNDBhOWIzZWE2OGZkNGMwNzRmNWVfOQ_89c5ae3b-8b54-46e5-a4f6-1e1b2ec60e45">Suite 260</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl8zLTAtMS0xLTM3NDkxL3RleHRyZWdpb246MjYxZWRjMTM4NTdkNDBhOWIzZWE2OGZkNGMwNzRmNWVfMTI_7d5b159e-63a1-416e-934a-1e231daacc95">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl8zLTAtMS0xLTM3NDkxL3RleHRyZWdpb246MjYxZWRjMTM4NTdkNDBhOWIzZWE2OGZkNGMwNzRmNWVfMTY_dbee1c87-fd41-46ed-9261-45952f39924b">CA</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl8zLTEtMS0xLTM3NDkxL3RleHRyZWdpb246NDliNjFkMzM4Mzk3NDY0NmIzNzQzMGU3YzFhNjRlOTNfNg_f7ca049d-2b8b-4643-abc1-213fff65f17a">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl8zLTEtMS0xLTM3NDkxL3RleHRyZWdpb246NDliNjFkMzM4Mzk3NDY0NmIzNzQzMGU3YzFhNjRlOTNfMTA_d9238a26-75e2-4b0d-ab0b-fdf0525fcdbf">926-7655</dei:LocalPhoneNumber>
    <dei:EntityAddressPostalZipCode
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl8zLTItMS0xLTM3NDkxL3RleHRyZWdpb246ODgwZjIwOGE5OTJhNDI1OWE0NThlNjIwNjJhYTk2ZGFfNQ_e819e588-1d0d-4742-a579-e136074b7de2">92122</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl84LTAtMS0xLTM3NDkx_b1959cc3-2407-4e65-86eb-1d417833e4aa">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6ZmQ4YWQ5NWYwZmU5NDJmNzlkMDliZWJmODkzZDZjYTIvdGFibGVyYW5nZTpmZDhhZDk1ZjBmZTk0MmY3OWQwOWJlYmY4OTNkNmNhMl84LTEtMS0xLTM3NDkx_93038d53-ef34-407e-bde7-f2b8c5f77192">DARE</dei:TradingSymbol>
    <dei:EntityCurrentReportingStatus
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGV4dHJlZ2lvbjowNzRlODY5NDZjN2E0NWI2OTMwMWQ0MDk0MjNmMDFmMl8xNzM0_e2845123-8c34-4f6d-94aa-5982718af0ae">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGV4dHJlZ2lvbjowNzRlODY5NDZjN2E0NWI2OTMwMWQ0MDk0MjNmMDFmMl8xNzM1_2a62144e-5722-48ea-abe5-3613cfa2b78e">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6NzI5MzRlZGUxYTEzNDJkY2EwZWRlMjU3NTkyMmNiZjgvdGFibGVyYW5nZTo3MjkzNGVkZTFhMTM0MmRjYTBlZGUyNTc1OTIyY2JmOF8xLTAtMS0xLTM3NDkx_48c446fd-5c6d-448b-b6ce-99ab028cefce">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6NzI5MzRlZGUxYTEzNDJkY2EwZWRlMjU3NTkyMmNiZjgvdGFibGVyYW5nZTo3MjkzNGVkZTFhMTM0MmRjYTBlZGUyNTc1OTIyY2JmOF8xLTUtMS0xLTM3NDkx_1ad42086-90c3-4d1e-979a-2be5e3976475">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGFibGU6NzI5MzRlZGUxYTEzNDJkY2EwZWRlMjU3NTkyMmNiZjgvdGFibGVyYW5nZTo3MjkzNGVkZTFhMTM0MmRjYTBlZGUyNTc1OTIyY2JmOF8yLTItMS0xLTM3NDkx_248cc766-7071-4459-908f-43bebf898914">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGV4dHJlZ2lvbjowNzRlODY5NDZjN2E0NWI2OTMwMWQ0MDk0MjNmMDFmMl8xNzMy_2bdc0a09-45c6-4a1c-b13c-1d23209fa0bc">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i94263204e2654add81cafbf53b703aaf_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xL2ZyYWc6MDc0ZTg2OTQ2YzdhNDViNjkzMDFkNDA5NDIzZjAxZjIvdGV4dHJlZ2lvbjowNzRlODY5NDZjN2E0NWI2OTMwMWQ0MDk0MjNmMDFmMl8xNjQw_2ade7488-d291-4d16-b7e1-b2647ff87056"
      unitRef="shares">84711346</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfNC0xLTEtMS0zNzQ5MQ_c8c01a90-95bf-4a5e-a4fc-18aeaac2b4c1"
      unitRef="usd">39316911</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfNC0zLTEtMS0zNzQ5MQ_3b526d9a-66a7-4e52-aa82-0b08a92d9bb6"
      unitRef="usd">51674087</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfNS0xLTEtMS0zNzQ5MQ_cdd0ef99-750f-4d57-82cc-675bdbffae71"
      unitRef="usd">1729851</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfNS0zLTEtMS0zNzQ5MQ_b31a78a9-d8ff-43fb-b92b-eb493aa087a0"
      unitRef="usd">1145317</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfNi0xLTEtMS0zNzQ5MQ_384b8a3d-5e47-42b2-a23b-aabd6167b3a0"
      unitRef="usd">6770426</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfNi0zLTEtMS0zNzQ5MQ_666d65ac-82b3-4be4-89a7-e1d91c0d3553"
      unitRef="usd">2476612</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfOC0xLTEtMS0zNzQ5MQ_0dd4ee5d-16a6-4e69-b51b-e00ae57d6a2b"
      unitRef="usd">47817188</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfOC0zLTEtMS0zNzQ5MQ_5835f1ce-47b8-4cd4-96e1-ca2ba7a53e2d"
      unitRef="usd">55296016</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfOS0xLTEtMS0zNzQ5MQ_2dc1f59d-ea8b-40f4-87fd-602f6d28bd6d"
      unitRef="usd">25366</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfOS0zLTEtMS0zNzQ5MQ_913d4633-b1e3-4123-9473-716370a010a9"
      unitRef="usd">26041</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMTEtMS0xLTEtMzc0OTE_424cac2b-aced-47f4-b74c-f4c41ea412bf"
      unitRef="usd">1344028</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMTEtMy0xLTEtMzc0OTE_2b82380e-af02-4109-af34-02d433edf63f"
      unitRef="usd">485120</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMTItMS0xLTEtMzc0OTE_0109c0c5-bec1-4f6a-bd71-b96bdff2ffdc"
      unitRef="usd">49186582</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMTItMy0xLTEtMzc0OTE_c6a0ba0b-8e1c-4106-b0ea-9c3ec20aa907"
      unitRef="usd">55807177</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMTUtMS0xLTEtMzc0OTE_eb4a44d2-e72e-437b-a090-4d5386f0a0b9"
      unitRef="usd">2830866</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMTUtMy0xLTEtMzc0OTE_9891d66a-0c2c-4ced-bfcc-81d91e19aac6"
      unitRef="usd">2103083</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMTYtMS0xLTEtMzc0OTE_2d3699a6-fddb-47a7-8e92-b6d2ee35ca6e"
      unitRef="usd">3537856</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMTYtMy0xLTEtMzc0OTE_9f0311f1-85de-4ba0-843d-68728bb84935"
      unitRef="usd">3136244</us-gaap:AccruedLiabilitiesCurrent>
    <dare:DeferredGrantFundingCurrent
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMTctMS0xLTEtMzc0OTE_0a286aff-187d-455c-9d9d-d56fd451a930"
      unitRef="usd">9731363</dare:DeferredGrantFundingCurrent>
    <dare:DeferredGrantFundingCurrent
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMTctMy0xLTEtMzc0OTE_f8f4bf63-a804-485a-abb5-94164429ed78"
      unitRef="usd">10542983</dare:DeferredGrantFundingCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjAtMS0xLTEtMzc0OTE_924307de-c9a2-4350-8062-2f862c4316e9"
      unitRef="usd">294474</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjAtMy0xLTEtMzc0OTE_a97f6a44-b62f-490b-8785-dbc0fd88d251"
      unitRef="usd">270546</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjEtMS0xLTEtMzc0OTE_9d045794-bc91-46c1-a5ab-2930f49a59a4"
      unitRef="usd">16394559</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjEtMy0xLTEtMzc0OTE_942b8f42-414a-4cf1-ab4a-4153fd0e5d8d"
      unitRef="usd">16052856</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjItMS0xLTEtMzc0OTE_1c138e18-8752-4180-92e4-7cfc17b8bee3"
      unitRef="usd">1000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjItMy0xLTEtMzc0OTE_7602a92c-f56e-402c-a2c6-008eb29f6a21"
      unitRef="usd">1000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjQtMS0xLTEtMzc0OTE_aa56631a-aaa8-42a3-a139-5ea2cdca1723"
      unitRef="usd">913113</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjQtMy0xLTEtMzc0OTE_e6342501-e7ee-43af-8ded-45ada8e2e2ae"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjUtMS0xLTEtMzc0OTE_7064301a-6110-4779-a7b1-805f564d9de9"
      unitRef="usd">18307672</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjUtMy0xLTEtMzc0OTE_fed555a4-46f8-45d2-943e-324b4aedd794"
      unitRef="usd">17052856</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjYtMS0xLTEtMzc0OTE_31ca97e9-b3f0-4804-9a7f-e53ad7af906d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjYtMy0xLTEtMzc0OTE_96b20822-dd6e-47f9-b008-e200bfd12fb1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjgtMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1YTFjYzQyOGNmNzU0MGNjOGU0MjhiMjE2MTM1MDIzNl8yMQ_2f014e27-e8f3-4f34-8d7a-769c1db5fb9f"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjgtMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1YTFjYzQyOGNmNzU0MGNjOGU0MjhiMjE2MTM1MDIzNl8yMQ_9277fed5-75df-4333-a8d4-ee717272be7b"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjgtMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1YTFjYzQyOGNmNzU0MGNjOGU0MjhiMjE2MTM1MDIzNl8zNQ_65280670-4943-4685-82e2-8de0f65f0065"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjgtMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1YTFjYzQyOGNmNzU0MGNjOGU0MjhiMjE2MTM1MDIzNl8zNQ_6b6662c1-42b3-49b9-8643-2acbf4c513b0"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjgtMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1YTFjYzQyOGNmNzU0MGNjOGU0MjhiMjE2MTM1MDIzNl81Nw_0f2d01d0-22c0-49f3-97eb-7f9e810d747a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjgtMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1YTFjYzQyOGNmNzU0MGNjOGU0MjhiMjE2MTM1MDIzNl81Nw_37c90d13-ce05-4da4-91a0-af13018a2da2"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjgtMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1YTFjYzQyOGNmNzU0MGNjOGU0MjhiMjE2MTM1MDIzNl81Nw_5f2e1bc9-b544-4474-a9b6-bb559e1b0325"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjgtMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1YTFjYzQyOGNmNzU0MGNjOGU0MjhiMjE2MTM1MDIzNl81Nw_92d6868f-8266-4866-b167-abf33a1f6623"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjgtMS0xLTEtMzc0OTE_64da2957-5c42-4760-9670-b65dd7e95929"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjgtMy0xLTEtMzc0OTE_7381e110-6c8e-4cba-9b7f-4ac5fd44e6f5"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjktMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1NDgwMzRkOTllMjI0OGFlYjg5Y2EzZGJlMDgyNTExM18xOA_69ad7aea-81c3-4b79-b9d0-e7859ef54e75"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjktMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1NDgwMzRkOTllMjI0OGFlYjg5Y2EzZGJlMDgyNTExM18xOA_b6dec743-ed02-4527-8a3c-575ebc569f06"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjktMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1NDgwMzRkOTllMjI0OGFlYjg5Y2EzZGJlMDgyNTExM18zMg_9a1fff98-fbca-4ff2-aff5-b4b6c0e7c012"
      unitRef="shares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjktMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1NDgwMzRkOTllMjI0OGFlYjg5Y2EzZGJlMDgyNTExM18zMg_9c74f87d-ec6d-4555-9a83-c752d9737a4b"
      unitRef="shares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjktMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1NDgwMzRkOTllMjI0OGFlYjg5Y2EzZGJlMDgyNTExM181NA_4baa8c6a-ee6b-4511-8fc4-61906d21674a"
      unitRef="shares">83944119</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjktMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1NDgwMzRkOTllMjI0OGFlYjg5Y2EzZGJlMDgyNTExM181NA_ba3b518c-57a4-4afb-b6fb-12bcf73fc70b"
      unitRef="shares">83944119</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjktMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1NDgwMzRkOTllMjI0OGFlYjg5Y2EzZGJlMDgyNTExM181NA_f66c1c94-a033-4568-b41e-9766dc6a1efc"
      unitRef="shares">83944119</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjktMC0xLTEtMzc0OTEvdGV4dHJlZ2lvbjo1NDgwMzRkOTllMjI0OGFlYjg5Y2EzZGJlMDgyNTExM181NA_f918e475-42ad-42f2-b655-843ef2cf18c1"
      unitRef="shares">83944119</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjktMS0xLTEtMzc0OTE_d9b1ab0c-7c49-406d-80ba-05d86f283652"
      unitRef="usd">8394</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMjktMy0xLTEtMzc0OTE_e430e126-bd32-4c52-8a79-6c57bde73565"
      unitRef="usd">8394</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMzAtMS0xLTEtMzc0OTE_a80bf04b-1c30-452b-b926-299f00de779e"
      unitRef="usd">-164123</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMzAtMy0xLTEtMzc0OTE_2cbb52c8-0f94-4893-aaed-b2c66a183244"
      unitRef="usd">-154973</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMzEtMS0xLTEtMzc0OTE_5401a489-37b7-4be1-8ce5-629051cf99c3"
      unitRef="usd">149560211</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMzEtMy0xLTEtMzc0OTE_87fc7de8-05ef-45aa-aa34-fa1459c6f726"
      unitRef="usd">149027802</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMzItMS0xLTEtMzc0OTE_b804c9fa-efa7-4609-9640-20395dd0c19f"
      unitRef="usd">-118525572</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMzItMy0xLTEtMzc0OTE_a447a3fe-cd25-4f70-84b1-303235aca578"
      unitRef="usd">-110126902</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMzMtMS0xLTEtMzc0OTE_9354dda9-789c-44fc-ba2c-b50010b49f2b"
      unitRef="usd">30878910</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMzMtMy0xLTEtMzc0OTE_6bb8f9bf-3e35-485c-b365-730daff83f50"
      unitRef="usd">38754321</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMzQtMS0xLTEtMzc0OTE_f1f76730-b37b-40f4-add2-e70a3f33c004"
      unitRef="usd">49186582</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8xOS9mcmFnOjI3N2I3YmVhMmIxMDRiMGI4NmU1NmI3Mjc2ZDgxYzkzL3RhYmxlOjk4MjRkYTJmMWRmMjRjNTc4ZTQ0MDQ4M2VmZWVmYzQyL3RhYmxlcmFuZ2U6OTgyNGRhMmYxZGYyNGM1NzhlNDQwNDgzZWZlZWZjNDJfMzQtMy0xLTEtMzc0OTE_dcb4af6a-9e22-4190-bfff-0cb714c1e77b"
      unitRef="usd">55807177</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMy0xLTEtMS0zNzQ5MQ_66e7e68b-da0e-4e8a-ada6-62f318ee783b"
      unitRef="usd">2569987</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMy0zLTEtMS0zNzQ5MQ_b09457a3-75e5-4abc-8d70-7c346cf8d669"
      unitRef="usd">1940328</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfNC0xLTEtMS0zNzQ5MQ_1f4a7244-5f16-4e42-a7c3-b649128c6d9f"
      unitRef="usd">5805462</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfNC0zLTEtMS0zNzQ5MQ_0a385fdd-316f-4fd9-bc07-64c893ac3b2b"
      unitRef="usd">5728206</us-gaap:ResearchAndDevelopmentExpense>
    <dare:LicenseFee
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfNS0xLTEtMS0zNzQ5MQ_8cefbc49-0e27-43d5-820c-3083464c83d3"
      unitRef="usd">25000</dare:LicenseFee>
    <dare:LicenseFee
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfNS0zLTEtMS0zNzQ5MQ_356a4d13-648f-4802-ae77-7ce289a11d06"
      unitRef="usd">25000</dare:LicenseFee>
    <us-gaap:OperatingExpenses
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfNi0xLTEtMS0zNzQ5MQ_1095b15e-8fd5-44a5-8848-22703a571d46"
      unitRef="usd">8400449</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfNi0zLTEtMS0zNzQ5MQ_ab525eaf-f8de-4f19-ac2d-7184c1a90acb"
      unitRef="usd">7693534</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfNy0xLTEtMS0zNzQ5MQ_4069f23f-8b00-426a-aae8-1c23b5763cf6"
      unitRef="usd">-8400449</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfNy0zLTEtMS0zNzQ5MQ_280944aa-e18e-454e-b5da-1188a34d72c0"
      unitRef="usd">-7693534</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfOC0xLTEtMS0zNzQ5MQ_fc7eea8d-c956-4341-8eda-2e03a3d1ccd7"
      unitRef="usd">1779</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfOC0zLTEtMS0zNzQ5MQ_f8d07b13-97e5-49a8-bb2b-972ca2bf501a"
      unitRef="usd">3</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfOS0xLTEtMS0zNzQ5MQ_9de197d0-075f-4fd3-b3bb-ab98bbfd415d"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfOS0zLTEtMS0zNzQ5MQ_54a7550d-8956-4ff8-b81c-487f44ab7f6c"
      unitRef="usd">369887</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NetIncomeLoss
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTAtMS0xLTEtMzc0OTE_e6860b9b-deab-472b-aeee-87994e7c62da"
      unitRef="usd">-8398670</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTAtMy0xLTEtMzc0OTE_473c0c2d-888d-4183-abc5-eca12d29704f"
      unitRef="usd">-7323644</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTMtMS0xLTEtMzc0OTE_82760853-40dd-47c2-a8b7-998f6dc3a596"
      unitRef="usd">-9150</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTMtMy0xLTEtMzc0OTE_d6e8c6ba-756a-496f-84d6-661da9ebc145"
      unitRef="usd">-6841</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTQtMS0xLTEtMzc0OTE_a88a3b0e-a2ab-4425-98b1-d9224be437f5"
      unitRef="usd">-8407820</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTQtMy0xLTEtMzc0OTE_f8f94d49-09c2-4a15-9e07-ce16a073030f"
      unitRef="usd">-7330485</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTUtMS0xLTEtMzc0OTE_0b236db2-895e-4a29-809a-32e78eaa6d89"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTUtMS0xLTEtMzc0OTE_4a56e04e-af3b-4f56-be8e-51b5db1efdc6"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTUtMy0xLTEtMzc0OTE_805ebb27-d52c-4f4a-8890-b33e388f26c4"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTUtMy0xLTEtMzc0OTE_a7e58472-a609-4f59-abd4-c0d0f39527b4"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTctMS0xLTEtMzc0OTE_15a2d933-3fbd-4e92-bcbe-c9f7d5465f1e"
      unitRef="shares">83944119</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTctMS0xLTEtMzc0OTE_434c5638-1214-4500-a7bd-b5bc35eb0389"
      unitRef="shares">83944119</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTctMy0xLTEtMzc0OTE_0a63dd9b-fe0d-4c96-98c6-f18d11551ac7"
      unitRef="shares">44502582</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yMi9mcmFnOjI4YzcxYTI3MGQ1YjQyYTI4ZmRmMjhjODdkMDc4NDQ5L3RhYmxlOmQ4NzAzMzM3YTYzZTQ4M2ZhMzkxODU5M2Y2YTBlYzkwL3RhYmxlcmFuZ2U6ZDg3MDMzMzdhNjNlNDgzZmEzOTE4NTkzZjZhMGVjOTBfMTctMy0xLTEtMzc0OTE_8469daf9-57fd-4c5a-8ed0-a089b0532ba6"
      unitRef="shares">44502582</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="ida978f25ba59408b9386363eb6d6eed4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfNC0xLTEtMS0zNzQ5MQ_67418d7f-dbb3-4b31-a01d-4b6c87be8951"
      unitRef="shares">83944119</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ida978f25ba59408b9386363eb6d6eed4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfNC0zLTEtMS0zNzQ5MQ_1ed3d349-f700-462b-81af-6a9f8aeaeb88"
      unitRef="usd">8394</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5b251f7c118549ba9202433ab6104a64_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfNC01LTEtMS0zNzQ5MQ_10f0e4b2-e887-4c5a-9442-672c26008da9"
      unitRef="usd">149027802</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i60a512d483cf43099a491a6ccc8400a1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfNC03LTEtMS0zNzQ5MQ_d34e9f54-1a36-46fc-b7d9-086143973797"
      unitRef="usd">-154973</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if3bd3370ad994990ad0bd8c17e41e612_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfNC05LTEtMS0zNzQ5MQ_5f0f516b-c768-4f4e-b743-cbc01bb7787b"
      unitRef="usd">-110126902</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfNC0xMS0xLTEtMzc0OTE_f68c52b4-2836-4aa2-b6c0-c44a09609574"
      unitRef="usd">38754321</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i81a6b1d8921a4c34b493ef15f6ac3565_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfNS01LTEtMS0zNzQ5MQ_e24bb004-36b4-4eed-9580-0fa76afcbeb1"
      unitRef="usd">532409</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfNS0xMS0xLTEtMzc0OTE_903064b4-c9c3-4696-b8c5-fda42a529c13"
      unitRef="usd">532409</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i2cdccf0de4054bd5be8b8f6ca8068dcd_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfOS05LTEtMS0zNzQ5MQ_21a1b6d2-3e52-45f1-a651-4c05002bdb44"
      unitRef="usd">-8398670</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfOS0xMS0xLTEtMzc0OTE_a6a1353a-0693-440b-a3f3-dae6920c2efe"
      unitRef="usd">-8398670</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ifba16de9b31d4bb4b84e89fdde96c11f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfMTAtNy0xLTEtMzc0OTE_fd655f3c-4b28-41f3-98d5-162c8d5815ef"
      unitRef="usd">-9150</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfMTAtMTEtMS0xLTM3NDkx_c017ba73-2f7f-4cee-bb50-4180bb49da47"
      unitRef="usd">-9150</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i3a6c19246dbd43918fe1d5bdaf45781d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfMTEtMS0xLTEtMzc0OTE_06bea791-8ac5-410d-910e-85f877081634"
      unitRef="shares">83944119</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3a6c19246dbd43918fe1d5bdaf45781d_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfMTEtMy0xLTEtMzc0OTE_9a696a6c-37ba-454f-9f4d-8fb152202e5e"
      unitRef="usd">8394</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i00586b33add54084bb2dbf880a0f3571_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfMTEtNS0xLTEtMzc0OTE_f1da40d3-af70-45d5-80d4-02aa5e527fa5"
      unitRef="usd">149560211</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i923566bd281646fdb2dc3656b54543af_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfMTEtNy0xLTEtMzc0OTE_8828a802-f419-4de0-88ca-ff31caf167e5"
      unitRef="usd">-164123</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2ccd4e062a2e4af6bc25a6f55d4bbc88_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfMTEtOS0xLTEtMzc0OTE_a3792f30-9698-4f2d-b5b0-51445e8ff0b9"
      unitRef="usd">-118525572</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOmQ2OGY5YjViZThhYTRhYjg4MmNiNjA4MzNiYTY4NGRhL3RhYmxlcmFuZ2U6ZDY4ZjliNWJlOGFhNGFiODgyY2I2MDgzM2JhNjg0ZGFfMTEtMTEtMS0xLTM3NDkx_e3610e3e-edc5-48ff-a310-6dfb288f8a25"
      unitRef="usd">30878910</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i6063f716c8274a639d5c2235427b50d2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNC0xLTEtMS0zODYzNA_725fc3eb-1313-48bd-a705-9f88d789d9ff"
      unitRef="shares">41596253</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6063f716c8274a639d5c2235427b50d2_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNC0zLTEtMS0zODYzNA_b0c8f544-1164-4a22-be8e-ac967372b20e"
      unitRef="usd">4159</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i66dc24f087884625adfebe658a8e451b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNC01LTEtMS0zODYzNA_6b352569-a208-4ee4-85cd-73104cec47c2"
      unitRef="usd">70366293</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8d33e15987224e8e864a9bb0d4e41246_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNC03LTEtMS0zODYzNA_bc131462-70a3-4bfe-b9ca-d340920e2031"
      unitRef="usd">-91388</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie18313b3160d472981c6193072f6baa5_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNC05LTEtMS0zODYzNA_ffb9f334-2652-4f70-8451-2574ef82039c"
      unitRef="usd">-71430797</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if0526bb23c864be7babc6b325d2ae2b3_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNC0xMS0xLTEtMzg2MzQ_a388f2d4-9409-4862-b8e5-34694e74732e"
      unitRef="usd">-1151733</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i09b399c6925442f9bf8bab14218dd545_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNC01LTEtMS0zNzQ5MQ_3905931a-d811-44ea-97b6-edcc8fb7f271"
      unitRef="usd">365911</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNC0xMS0xLTEtMzc0OTE_f1239863-5158-40eb-9dc0-204b1c45288b"
      unitRef="usd">365911</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i11c9582a92634557be12814380daffe8_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNS0xLTEtMS0zNzQ5MQ_13ef03ad-2814-4e4e-bfd3-82de826955cf"
      unitRef="shares">5664069</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i11c9582a92634557be12814380daffe8_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNS0zLTEtMS0zNzQ5MQ_7cdff880-4548-46d4-b745-56ce0f519518"
      unitRef="usd">567</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i09b399c6925442f9bf8bab14218dd545_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNS01LTEtMS0zNzQ5MQ_f679ef95-c046-4db7-a38a-bbb49fdc0277"
      unitRef="usd">11323573</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNS0xMS0xLTEtMzc0OTE_41ec0559-b58b-4c6a-98fc-d90db651b21a"
      unitRef="usd">11324140</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares
      contextRef="i11c9582a92634557be12814380daffe8_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNi0xLTEtMS0zNzQ5MQ_9818e075-b479-43ca-b370-7432e66ec678"
      unitRef="shares">52500</dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i11c9582a92634557be12814380daffe8_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNi0zLTEtMS0zNzQ5MQ_03a4f1cd-f50b-4398-8e34-94b61269cf48"
      unitRef="usd">5</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i09b399c6925442f9bf8bab14218dd545_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNi01LTEtMS0zNzQ5MQ_44377aea-cc57-433d-bed1-29798127e71a"
      unitRef="usd">50395</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNi0xMS0xLTEtMzc0OTE_d2203bf2-bf54-4c44-a465-eae021a47961"
      unitRef="usd">50400</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="i7777562075814792bdb540658b8e6a06_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNy05LTEtMS0zNzQ5MQ_6b911e74-fdb0-4caa-b261-019c8c7e00f0"
      unitRef="usd">-7323644</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfNy0xMS0xLTEtMzc0OTE_1e34c5d7-ab9e-4521-9235-8d00658921ce"
      unitRef="usd">-7323644</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i7234840ac886468bb69f5d05bd2db206_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfOS03LTEtMS0zNzQ5MQ_e6713c87-2362-4d9b-b3a3-fefa43a14729"
      unitRef="usd">-6841</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfOS0xMS0xLTEtMzc0OTE_68b26f12-01eb-4824-b1c8-e60b74e37de4"
      unitRef="usd">-6841</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i91f25005c087421eab865393d5efc0bc_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfMTAtMS0xLTEtMzc0OTE_399b349d-ae27-48fd-a9c1-6080722665cc"
      unitRef="shares">47312822</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i91f25005c087421eab865393d5efc0bc_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfMTAtMy0xLTEtMzc0OTE_ae6a20ec-6048-4a51-bf9b-a137c333bc4e"
      unitRef="usd">4731</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i70732a14fa594410af98fbfbbfc49572_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfMTAtNS0xLTEtMzc0OTE_6d6bd0b4-3b62-43f0-826e-59b49912665a"
      unitRef="usd">82106172</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie20c398f1df046b288658ed72f3fea03_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfMTAtNy0xLTEtMzc0OTE_9e0e0583-84cc-4b19-9b93-4fdb2710f692"
      unitRef="usd">-98229</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i68e625c64183408d9d544a2b64fc1d4a_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfMTAtOS0xLTEtMzc0OTE_cc6defa6-85f4-4c93-9ced-742718e4b3f0"
      unitRef="usd">-78754441</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7ab03b72e1c442f393d5f68da2cd04dc_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yNS9mcmFnOjRiY2VmYjliY2FkYzQ0Y2Q4N2QxZDU5ZWExYjcwM2Y0L3RhYmxlOjk3NGJmNTFmMTQwNTRhZTc5NDU1MGQ2OTgwMGYyZTg5L3RhYmxlcmFuZ2U6OTc0YmY1MWYxNDA1NGFlNzk0NTUwZDY5ODAwZjJlODlfMTAtMTEtMS0xLTM3NDkx_5e15910e-be25-4c5e-bffc-8e550581027a"
      unitRef="usd">3258233</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMy0xLTEtMS0zNzQ5MQ_bf8658ac-af77-46b4-99e9-0ec9dc54315e"
      unitRef="usd">-8398670</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMy0zLTEtMS0zNzQ5MQ_f6593161-ad39-4577-95a5-de138d4da871"
      unitRef="usd">-7323644</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfNS0xLTEtMS0zNzQ5MQ_10712a74-87e1-48a3-bfff-45b8bb5d0c2f"
      unitRef="usd">5227</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfNS0zLTEtMS0zNzQ5MQ_35830973-bb9b-405d-824b-11e6ba8cc95d"
      unitRef="usd">6410</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfNi0xLTEtMS0zNzQ5MQ_653f6193-8dcf-4d70-b300-f71f3f975970"
      unitRef="usd">532409</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfNi0zLTEtMS0zNzQ5MQ_74a674ae-7c63-49e9-8ef1-3a7fec4c1a5c"
      unitRef="usd">365911</us-gaap:ShareBasedCompensation>
    <dare:NonCashLeaseExpense
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfNy0xLTEtMS0zNzQ5MQ_1105b432-3923-4df5-8565-76a6cc63faa7"
      unitRef="usd">-9758</dare:NonCashLeaseExpense>
    <dare:NonCashLeaseExpense
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfNy0zLTEtMS0zNzQ5MQ_aff36155-16c1-455d-8d9b-ed525d9e2d17"
      unitRef="usd">-24224</dare:NonCashLeaseExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfOS0xLTEtMS0zNzQ5MQ_b6e6d6a1-bb52-4629-ae58-fbfc58fd8db8"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfOS0zLTEtMS0zNzQ5MQ_50b12372-256b-4060-b1c7-45b63cf86c26"
      unitRef="usd">369887</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTEtMS0xLTEtMzc0OTE_5999d859-7a10-44ef-b44d-7155714fcfb2"
      unitRef="usd">584534</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTEtMy0xLTEtMzc0OTE_2e808ad4-459e-4b16-9680-411c02b6ed6e"
      unitRef="usd">-158333</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTItMS0xLTEtMzc0OTE_4ca15624-2c6f-4f52-8103-443f4ac3b834"
      unitRef="usd">4293814</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTItMy0xLTEtMzc0OTE_d396c580-50bd-4ab9-bcda-358ac0d2b4d9"
      unitRef="usd">-217188</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <dare:IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTQtMS0xLTEtMzc0OTE_42aa408d-c7b1-4567-8ee9-4b9b93249d51"
      unitRef="usd">-87891</dare:IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges>
    <dare:IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTQtMy0xLTEtMzc0OTE_252eb7ff-686a-4ad0-894f-1aeff3efe709"
      unitRef="usd">128086</dare:IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTUtMS0xLTEtMzc0OTE_184cd36e-ac40-4821-a36f-4784535b3462"
      unitRef="usd">727783</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTUtMy0xLTEtMzc0OTE_a754b62d-6449-4607-85a1-cb82ec3d3cbb"
      unitRef="usd">450298</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTYtMS0xLTEtMzc0OTE_a7ce3c43-8aae-4cbf-9e73-f824a2b78259"
      unitRef="usd">401613</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTYtMy0xLTEtMzc0OTE_b036ac00-3705-4b08-8f87-f24c9a577de3"
      unitRef="usd">-837191</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <dare:IncreaseDecreaseInDeferredGrantFunding
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTctMS0xLTEtMzc0OTE_cdd73bb2-9784-40a0-94dc-4ba481fce65a"
      unitRef="usd">811620</dare:IncreaseDecreaseInDeferredGrantFunding>
    <dare:IncreaseDecreaseInDeferredGrantFunding
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTctMy0xLTEtMzc0OTE_b205b2e6-8c2d-49e9-a8c3-bf024d7eb060"
      unitRef="usd">892123</dare:IncreaseDecreaseInDeferredGrantFunding>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTktMS0xLTEtMzc0OTE_8400c6bd-239b-4fc2-9ddf-81f7d52e8043"
      unitRef="usd">-12343473</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMTktMy0xLTEtMzc0OTE_70d31648-c5fa-4277-b612-2474bde893d2"
      unitRef="usd">-8377015</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjEtMS0xLTEtMzc0OTE_b36408ff-ff3d-4115-8116-9d4c36f3b9b6"
      unitRef="usd">4553</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjEtMy0xLTEtMzc0OTE_c950e68e-2e19-478b-8b24-6857999fae6a"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjItMS0xLTEtMzc0OTE_0beb9ffe-beb3-4a61-9246-20ef5accefe4"
      unitRef="usd">-4553</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjItMy0xLTEtMzc0OTE_0513c638-098b-4073-bcd0-913590648d2e"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <dare:NetProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjQtMS0xLTEtMzc0OTE_c071cd33-34f3-41e9-a51a-2714f8d9c703"
      unitRef="usd">0</dare:NetProceedsFromIssuanceOfCommonStockAndWarrants>
    <dare:NetProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjQtMy0xLTEtMzc0OTE_42bc697f-822c-4a3a-858e-f5878554f030"
      unitRef="usd">11324140</dare:NetProceedsFromIssuanceOfCommonStockAndWarrants>
    <dare:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjUtMS0xLTEtMzc0OTE_c8255b0b-0f81-4085-a7e3-def01fe469a4"
      unitRef="usd">0</dare:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <dare:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjUtMy0xLTEtMzc0OTE_44a33c88-5383-4504-ad75-08e5d8ea6ae5"
      unitRef="usd">50400</dare:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjgtMS0xLTEtMzc0OTE_279b1dbb-2f9e-4ed8-b96a-1a380742b6e4"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjgtMy0xLTEtMzc0OTE_36f0d40b-f312-4539-b7bc-c594bff73323"
      unitRef="usd">11374540</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjktMS0xLTEtMzc0OTE_ba149b16-57dd-41b9-9ea0-6c0e5c0f6e6d"
      unitRef="usd">-9150</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMjktMy0xLTEtMzc0OTE_599ef1fb-70ed-4792-8b20-678b64147c3e"
      unitRef="usd">-6841</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMzAtMS0xLTEtMzc0OTE_c9db7134-663d-48c5-ae4e-a8b324dc99ae"
      unitRef="usd">-12357176</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMzAtMy0xLTEtMzc0OTE_35eac2c4-e836-4439-9136-3877eb8238b4"
      unitRef="usd">2990684</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMzEtMS0xLTEtMzc0OTE_14fe3530-ed38-4793-b864-692083793f3b"
      unitRef="usd">51674087</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if0526bb23c864be7babc6b325d2ae2b3_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMzEtMy0xLTEtMzc0OTE_8581a302-9fe8-4b96-aa07-11ddaf3a9ae1"
      unitRef="usd">4669467</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMzItMS0xLTEtMzc0OTE_c586b08b-da42-4504-8e4b-c38633e98028"
      unitRef="usd">39316911</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7ab03b72e1c442f393d5f68da2cd04dc_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMzItMy0xLTEtMzc0OTE_fd2b3b9b-9f90-42cc-8424-776b1189f394"
      unitRef="usd">7660151</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <dare:ForgivenessOfPaycheckProtectionProgramNotePayable
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMzMtMS0xLTEtMzg3MzQ_e5d9d136-9213-449f-ac6b-3481f79bbefa"
      unitRef="usd">0</dare:ForgivenessOfPaycheckProtectionProgramNotePayable>
    <dare:ForgivenessOfPaycheckProtectionProgramNotePayable
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMzMtMy0xLTEtMzg3MzQ_e3ff3d3b-7e0b-42bf-a9c3-99402062b192"
      unitRef="usd">369887</dare:ForgivenessOfPaycheckProtectionProgramNotePayable>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMzQtMS0xLTEtMzc0OTE_96cf839f-4924-4909-baf3-76b57dec546f"
      unitRef="usd">1043590</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8yOC9mcmFnOjFlMzY4MjUyZDBmMDRmMWI5ZWQzOTgzODQxMjQ1ZTE4L3RhYmxlOjkyYThjMDI3MTMxZDRjYjdhMjgwMzViZGM3YzYxZTc3L3RhYmxlcmFuZ2U6OTJhOGMwMjcxMzFkNGNiN2EyODAzNWJkYzdjNjFlNzdfMzQtMy0xLTEtMzc0OTE_762906c7-daac-4ef3-82b5-3a14291c59d5"
      unitRef="usd">308533</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNC9mcmFnOmJkYWQzNmVkZDE5MDQ0OWFiNmEyYzk0MTBmMTk2OThjL3RleHRyZWdpb246YmRhZDM2ZWRkMTkwNDQ5YWI2YTJjOTQxMGYxOTY5OGNfMTQ5MDM_c820155c-4e31-4a53-9a1d-0e7cc750555c">ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dar&#xe9; Bioscience, Inc. is a biopharmaceutical company committed to advancing innovative products for women&#x2019;s health. Dar&#xe9; Bioscience, Inc. and its wholly owned subsidiaries operate one segment. In this report, the &#x201c;Company&#x201d; refers collectively to Dar&#xe9; Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company began assembling its diverse portfolio in 2017 through acquisitions, exclusive in-licenses and other collaborations. The Company's programs target unmet needs in women's health in the areas of contraception, fertility, and vaginal and sexual health, and aim to expand treatment options, enhance outcomes and improve ease of use for women. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has not generated any revenue. The Company&#x2019;s primary operations have consisted of, and are expected to continue to consist primarily of, research and development activities to advance its product candidates through clinical development and regulatory approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's first product, XACIATO&#x2122; (clindamycin phosphate vaginal gel, 2%), was approved by the FDA in December 2021, as a single-dose prescription medication for the treatment of bacterial vaginosis in female patients 12 years of age and older. In March 2022, the Company entered into an exclusive global license agreement with an affiliate of Organon &amp;amp; Co., Organon International GmbH, or Organon, to commercialize XACIATO. XACIATO is expected to be available commercially in the United States in the fourth quarter of 2022.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's portfolio includes drug and drug/device product candidates and potential product candidates in various stages of development, from pre-clinical to advanced clinical development.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNC9mcmFnOmJkYWQzNmVkZDE5MDQ0OWFiNmEyYzk0MTBmMTk2OThjL3RleHRyZWdpb246YmRhZDM2ZWRkMTkwNDQ5YWI2YTJjOTQxMGYxOTY5OGNfMzg0ODI5MDc2NjgyMw_0fd5afba-f65d-49d9-8f82-39acfec9ccf1"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMzg0ODI5MDczMzAwNw_2e3b9a9e-b530-469f-b21a-1fe0b5a1c183">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#x2019;s opinion, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, or the 2021 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The Company has a history of losses from operations, expects negative cash flows from its operations to continue for the foreseeable future, and expects that its net losses will continue for at least the next several years as it develops and seeks to bring to market its existing product candidates and to potentially acquire, license and develop additional product candidates. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and reclassification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of the Company's ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company had an accumulated deficit of approximately $118.5 million, cash and cash equivalents of approximately $39.3 million, and working capital of approximately $31.4 million. For the three months ended March&#160;31, 2022, the Company incurred a net loss of approximately $8.4 million and had negative cash flow from operations of approximately $12.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects its primary uses of capital to be staff-related expenses, the cost of clinical trials and regulatory activities related to its product candidates, costs associated with contract manufacturing services and third-party clinical research and development services, payments due to third-parties under the Company's in-license and acquisition agreements including upon the occurrence of commercial milestones for XACIATO and development milestones for the Company&#x2019;s product candidates, legal expenses, other regulatory expenses and general overhead costs. The Company&#x2019;s future funding requirements could also include significant costs related to commercialization of its product candidates, if approved, depending on the type, nature and terms of commercial collaborations the Company establishes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects its expenses, and in particular its research and development expenses, to increase significantly in 2022 compared to 2021 as the Company continues to develop and seek to bring to market its product candidates, with a focus on its product candidates that have reached the human clinical study development phase. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has one FDA-approved product, XACIATO, and has generated no revenue. Commercial launch of XACIATO in the U.S. by the Company's licensee, Organon, is expected in the fourth quarter of 2022. Under the terms of its license agreement with Organon, the Company will receive a $10.0&#160;million non-refundable and non-creditable payment following the effective date of the license agreement and will be entitled to receive tiered double-digit royalties based on net sales and up to $182.5&#160;million in milestone payments as follows: $2.5&#160;million following the first commercial sale of a licensed product in the United States; and up to $180.0&#160;million in tiered commercial sales milestones and regulatory milestones. The Company has devoted significant resources to building its portfolio of product candidates and to research and development activities related to these product candidates. The Company or its licensees must obtain regulatory approvals to market and sell any of its product candidates in the future and to market and sell XACIATO anywhere outside the U.S. The Company will need to generate sufficient safety and efficacy data on each of its product candidates in order to apply for regulatory approvals and for such assets to be attractive assets to potential strategic collaborators to license or to acquire, and for the Company to generate revenue through license fees, royalties on net revenues and commercial milestones related to such product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Based on the Company's current operating plan estimates, the Company does not have sufficient cash to satisfy its working capital needs and other liquidity requirements over at least the next 12 months from the date of issuance of the accompanying financial statements. The Company will need to raise substantial additional capital to continue to fund its operations and to successfully execute its current strategy. The Company may continue to seek to raise capital through the sale of shares of its common stock under its ATM sales agreement or through other types of equity transactions. However, when the Company can effect such sales and the amount of shares the Company can sell depends on a variety of factors including, among others, market conditions, the trading price of its common stock, its determination as to the appropriate sources of funding for its operations, and the number of authorized shares of common stock that are available for issuance, which is approximately 27&#160;million as of the date hereof. For the foreseeable future, the Company will evaluate and may pursue a variety of capital raising options on an on-going basis, including equity and debt financings, government or other grant funding, collaborations and strategic alliances or other similar types of arrangements, to cover its operating expenses, and the cost of any license or other acquisition of new product candidates or technologies. The amount and timing of the Company's capital needs have been and will continue to depend highly on many factors, including the product development programs the Company chooses to pursue, the pace and results of its clinical development efforts, and the nature and extent of expansion of its product candidate portfolio, if any. If the Company raises capital through collaborations, strategic alliances or other similar types of arrangements, it may have to relinquish, on terms that are not favorable to the Company, rights to some of its technologies or product candidates the Company would otherwise seek to develop or commercialize. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company and its stockholders. In addition, equity or debt financings may have a dilutive effect on the holdings of the Company's existing stockholders, and debt financings may subject the Company to restrictive covenants, operational restrictions and security interests in its assets. If the Company cannot raise capital when needed, on favorable terms or at all, the Company will not be able to continue development of its product candidates, will need to reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If the Company becomes unable to continue as a going concern, the Company may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its condensed consolidated financial statements, and stockholders may lose all or part of their investment in the Company's common stock. The Company's condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant accounting policies are described in Note 1 to the consolidated financial statements included in the 2021 10-K. Since the date of those consolidated financial statements, there have been no material changes to the Company&#x2019;s significant accounting policies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The&lt;/span&gt;&lt;span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; following tables present the classification within the fair value hierarchy of financial assets and liabilities that are remeasured on a recurring basis as of March&#160;31, 2022 and December&#160;31, 2021. There were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 2) or using unobservable inputs (Level 3) as of March&#160;31, 2022 or December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:485.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:216.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:7.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:7.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:7.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,330,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,330,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,666,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,666,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Represents cash held in money market funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract, assesses whether each good or service is distinct, and determines those that are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a contract with multiple performance obligations, the Company develops estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaboration and licensing agreements under which it out-licenses certain rights to its products or product candidates to third parties. The terms of these arrangements typically include payment of one or more of the following to the Company: non-refundable, up-front license fees; development, regulatory and/or commercial milestone payments; and royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fees. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license&#160;to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from non-refundable, upfront fees allocated to the&#160;license when the&#160;license&#160;is transferred to the customer and the customer is able to use and benefit from the&#160;license. For licenses bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. To date, the Company has not recognized any license fee revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that include a promise for future supply of product for commercial supply at the licensee&#x2019;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The evaluation is based on the degree the Company controls the specified product at any time before transfer to the customer. Revenues are recognized on a gross basis if the Company is in the capacity of principal and on a net basis if the Company is in the capacity of an agent. To date, the Company has not recognized any revenue associated with product supply arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestones.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At the inception of each arrangement in which the Company is a licensor and that includes developmental, regulatory or commercial milestones, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments not within the Company's control, such as where achievement of the specified milestone depends on activities of a third party or regulatory approval, are not considered probable of being achieved until the specified milestone occurs. To date, the Company has not recognized any milestone revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMzg0ODI5MDczMzAwNQ_8e587e65-c130-4459-8689-2a81529e0f9b">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#x2019;s opinion, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, or the 2021 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <dare:GoingConcernPolicyTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMzg0ODI5MDczMzAwNg_84686727-90b7-46c3-925e-7744e82e5c3c">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The Company has a history of losses from operations, expects negative cash flows from its operations to continue for the foreseeable future, and expects that its net losses will continue for at least the next several years as it develops and seeks to bring to market its existing product candidates and to potentially acquire, license and develop additional product candidates. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and reclassification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of the Company's ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company had an accumulated deficit of approximately $118.5 million, cash and cash equivalents of approximately $39.3 million, and working capital of approximately $31.4 million. For the three months ended March&#160;31, 2022, the Company incurred a net loss of approximately $8.4 million and had negative cash flow from operations of approximately $12.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects its primary uses of capital to be staff-related expenses, the cost of clinical trials and regulatory activities related to its product candidates, costs associated with contract manufacturing services and third-party clinical research and development services, payments due to third-parties under the Company's in-license and acquisition agreements including upon the occurrence of commercial milestones for XACIATO and development milestones for the Company&#x2019;s product candidates, legal expenses, other regulatory expenses and general overhead costs. The Company&#x2019;s future funding requirements could also include significant costs related to commercialization of its product candidates, if approved, depending on the type, nature and terms of commercial collaborations the Company establishes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects its expenses, and in particular its research and development expenses, to increase significantly in 2022 compared to 2021 as the Company continues to develop and seek to bring to market its product candidates, with a focus on its product candidates that have reached the human clinical study development phase. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has one FDA-approved product, XACIATO, and has generated no revenue. Commercial launch of XACIATO in the U.S. by the Company's licensee, Organon, is expected in the fourth quarter of 2022. Under the terms of its license agreement with Organon, the Company will receive a $10.0&#160;million non-refundable and non-creditable payment following the effective date of the license agreement and will be entitled to receive tiered double-digit royalties based on net sales and up to $182.5&#160;million in milestone payments as follows: $2.5&#160;million following the first commercial sale of a licensed product in the United States; and up to $180.0&#160;million in tiered commercial sales milestones and regulatory milestones. The Company has devoted significant resources to building its portfolio of product candidates and to research and development activities related to these product candidates. The Company or its licensees must obtain regulatory approvals to market and sell any of its product candidates in the future and to market and sell XACIATO anywhere outside the U.S. The Company will need to generate sufficient safety and efficacy data on each of its product candidates in order to apply for regulatory approvals and for such assets to be attractive assets to potential strategic collaborators to license or to acquire, and for the Company to generate revenue through license fees, royalties on net revenues and commercial milestones related to such product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Based on the Company's current operating plan estimates, the Company does not have sufficient cash to satisfy its working capital needs and other liquidity requirements over at least the next 12 months from the date of issuance of the accompanying financial statements. The Company will need to raise substantial additional capital to continue to fund its operations and to successfully execute its current strategy. The Company may continue to seek to raise capital through the sale of shares of its common stock under its ATM sales agreement or through other types of equity transactions. However, when the Company can effect such sales and the amount of shares the Company can sell depends on a variety of factors including, among others, market conditions, the trading price of its common stock, its determination as to the appropriate sources of funding for its operations, and the number of authorized shares of common stock that are available for issuance, which is approximately 27&#160;million as of the date hereof. For the foreseeable future, the Company will evaluate and may pursue a variety of capital raising options on an on-going basis, including equity and debt financings, government or other grant funding, collaborations and strategic alliances or other similar types of arrangements, to cover its operating expenses, and the cost of any license or other acquisition of new product candidates or technologies. The amount and timing of the Company's capital needs have been and will continue to depend highly on many factors, including the product development programs the Company chooses to pursue, the pace and results of its clinical development efforts, and the nature and extent of expansion of its product candidate portfolio, if any. If the Company raises capital through collaborations, strategic alliances or other similar types of arrangements, it may have to relinquish, on terms that are not favorable to the Company, rights to some of its technologies or product candidates the Company would otherwise seek to develop or commercialize. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company and its stockholders. In addition, equity or debt financings may have a dilutive effect on the holdings of the Company's existing stockholders, and debt financings may subject the Company to restrictive covenants, operational restrictions and security interests in its assets. If the Company cannot raise capital when needed, on favorable terms or at all, the Company will not be able to continue development of its product candidates, will need to reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If the Company becomes unable to continue as a going concern, the Company may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its condensed consolidated financial statements, and stockholders may lose all or part of their investment in the Company's common stock. The Company's condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant accounting policies are described in Note 1 to the consolidated financial statements included in the 2021 10-K. Since the date of those consolidated financial statements, there have been no material changes to the Company&#x2019;s significant accounting policies.&lt;/span&gt;&lt;/div&gt;</dare:GoingConcernPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTA5OTUxMTYzOTA4NA_774231ba-3bdd-4f32-8857-39f626447788"
      unitRef="usd">-118500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTA5OTUxMTYzOTEzMg_8f18f492-189b-4570-b433-788d5034e541"
      unitRef="usd">39300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <dare:WorkingCapitalIncreaseDeficit
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTA5OTUxMTYzOTE3NA_0586e054-fa13-49b3-a2d4-129d10060fa9"
      unitRef="usd">31400000</dare:WorkingCapitalIncreaseDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMjE5OTAyMzMzMTE2Nw_6f5ae751-3687-4f87-b2fa-6fd2306961a2"
      unitRef="usd">-8400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTA5OTUxMTYzOTMwOA_68121f7c-ad90-4738-a55e-3c1c612a4a31"
      unitRef="usd">12300000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <dare:UpfrontLicenseFeeAmountPaid
      contextRef="ib8e755817cb04a57a08c4f99adb8ffd6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTY0OTI2NzQ3OTQ0OA_5be3749c-3ef2-41a2-9a57-90865d40810d"
      unitRef="usd">10000000</dare:UpfrontLicenseFeeAmountPaid>
    <dare:MilestonePaymentsContingentAmount
      contextRef="ib8e755817cb04a57a08c4f99adb8ffd6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTY0OTI2NzQ3OTQ2MQ_eae2e1f0-bbee-46c1-aabf-ff7aa0b6a776"
      unitRef="usd">182500000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmountFirstCommercialSaleAmount
      contextRef="ib8e755817cb04a57a08c4f99adb8ffd6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTY0OTI2NzQ3OTQ1Nw_8d2a81c2-a5c0-455a-89fd-15287eedd442"
      unitRef="usd">2500000</dare:MilestonePaymentsContingentAmountFirstCommercialSaleAmount>
    <dare:MilestonePaymentsContingentAmountSalesBasedMilestonesAmount
      contextRef="i1c840e118dda4da0839c1173ced12675_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTY0OTI2NzQ3OTQ2NQ_a989e32d-958b-4a59-a948-78597e174dbc"
      unitRef="usd">180000000</dare:MilestonePaymentsContingentAmountSalesBasedMilestonesAmount>
    <dare:PeriodofInsufficientCashandLiquidityRequirements
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTA5OTUxMTY0MTg4OQ_9147acdf-a9ce-4468-bc96-ea35a69a86e2">P12M</dare:PeriodofInsufficientCashandLiquidityRequirements>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTA5OTUxMTYzNTA1Nzg_55299eec-58b6-476c-b217-1c088c86212d"
      unitRef="shares">27000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTAxNzY_c1900e9c-777f-41dd-9a97-e76dd27860d5">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTAxODY_e2b8270e-bc28-4da0-be66-36b6c40af6bc">&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The&lt;/span&gt;&lt;span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; following tables present the classification within the fair value hierarchy of financial assets and liabilities that are remeasured on a recurring basis as of March&#160;31, 2022 and December&#160;31, 2021. There were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 2) or using unobservable inputs (Level 3) as of March&#160;31, 2022 or December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:485.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:216.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:7.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:7.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:7.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,330,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,330,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,666,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,666,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Represents cash held in money market funds.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4d128dda6aad45f6928caa2a8b0ac74d_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RhYmxlOjE3ZWJiYjY5YjgwNzQ5ZWViN2VhODdkM2ZkYWJkMGFlL3RhYmxlcmFuZ2U6MTdlYmJiNjliODA3NDllZWI3ZWE4N2QzZmRhYmQwYWVfNC0xLTEtMS0zNzQ5MQ_e745cb34-a600-460d-ba04-3c93777bba29"
      unitRef="usd">36330411</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if261222bb7c7445a96aa0768ee93bdf6_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RhYmxlOjE3ZWJiYjY5YjgwNzQ5ZWViN2VhODdkM2ZkYWJkMGFlL3RhYmxlcmFuZ2U6MTdlYmJiNjliODA3NDllZWI3ZWE4N2QzZmRhYmQwYWVfNC0zLTEtMS0zNzQ5MQ_e5f18ba8-17d6-4f7c-b4f7-16cad609dbd6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaa56362091f34c8cb0ef0c7d93a4dea5_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RhYmxlOjE3ZWJiYjY5YjgwNzQ5ZWViN2VhODdkM2ZkYWJkMGFlL3RhYmxlcmFuZ2U6MTdlYmJiNjliODA3NDllZWI3ZWE4N2QzZmRhYmQwYWVfNC01LTEtMS0zNzQ5MQ_1dc54f21-2d49-40ae-ab9c-857b58c4daa7"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i753c4d96be1e4ba3967076ff69f73d0d_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RhYmxlOjE3ZWJiYjY5YjgwNzQ5ZWViN2VhODdkM2ZkYWJkMGFlL3RhYmxlcmFuZ2U6MTdlYmJiNjliODA3NDllZWI3ZWE4N2QzZmRhYmQwYWVfNC03LTEtMS0zNzQ5MQ_3d006eef-5d0c-4ba7-a4a8-dad5b2150cbe"
      unitRef="usd">36330411</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id64ecf9188364d48a0817d2f74ce0032_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RhYmxlOjE3ZWJiYjY5YjgwNzQ5ZWViN2VhODdkM2ZkYWJkMGFlL3RhYmxlcmFuZ2U6MTdlYmJiNjliODA3NDllZWI3ZWE4N2QzZmRhYmQwYWVfOS0xLTEtMS0zNzQ5MQ_1bec6aa0-43f1-4d3d-b69b-7f008b3593ab"
      unitRef="usd">49666064</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i36a1700da3be4028993f5fe8ba965b06_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RhYmxlOjE3ZWJiYjY5YjgwNzQ5ZWViN2VhODdkM2ZkYWJkMGFlL3RhYmxlcmFuZ2U6MTdlYmJiNjliODA3NDllZWI3ZWE4N2QzZmRhYmQwYWVfOS0zLTEtMS0zNzQ5MQ_4c46fafa-7b32-40d2-a4be-be8063cad3a6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ieae613e2bfc34e51b675c0145659b974_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RhYmxlOjE3ZWJiYjY5YjgwNzQ5ZWViN2VhODdkM2ZkYWJkMGFlL3RhYmxlcmFuZ2U6MTdlYmJiNjliODA3NDllZWI3ZWE4N2QzZmRhYmQwYWVfOS01LTEtMS0zNzQ5MQ_44e90ab6-5258-4898-b1ee-9f7b353b8f6d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3a58ac7dc95d43f7af582f30cbdc5d98_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RhYmxlOjE3ZWJiYjY5YjgwNzQ5ZWViN2VhODdkM2ZkYWJkMGFlL3RhYmxlcmFuZ2U6MTdlYmJiNjliODA3NDllZWI3ZWE4N2QzZmRhYmQwYWVfOS03LTEtMS0zNzQ5MQ_c8a012d4-36fa-443f-bcf6-9ce32601f0d6"
      unitRef="usd">49666064</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV8zNy9mcmFnOjZiNDg4NWFkOTkyNzQyMWZhYjRmMWYxYmExMzk4ODA1L3RleHRyZWdpb246NmI0ODg1YWQ5OTI3NDIxZmFiNGYxZjFiYTEzOTg4MDVfMTAxNzg_0b1ff99c-ddb9-40c8-8b50-a72eab6f76c2">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract, assesses whether each good or service is distinct, and determines those that are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a contract with multiple performance obligations, the Company develops estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaboration and licensing agreements under which it out-licenses certain rights to its products or product candidates to third parties. The terms of these arrangements typically include payment of one or more of the following to the Company: non-refundable, up-front license fees; development, regulatory and/or commercial milestone payments; and royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fees. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license&#160;to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from non-refundable, upfront fees allocated to the&#160;license when the&#160;license&#160;is transferred to the customer and the customer is able to use and benefit from the&#160;license. For licenses bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. To date, the Company has not recognized any license fee revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that include a promise for future supply of product for commercial supply at the licensee&#x2019;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The evaluation is based on the degree the Company controls the specified product at any time before transfer to the customer. Revenues are recognized on a gross basis if the Company is in the capacity of principal and on a net basis if the Company is in the capacity of an agent. To date, the Company has not recognized any revenue associated with product supply arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestones.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At the inception of each arrangement in which the Company is a licensor and that includes developmental, regulatory or commercial milestones, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments not within the Company's control, such as where achievement of the specified milestone depends on activities of a third party or regulatory approval, are not considered probable of being achieved until the specified milestone occurs. To date, the Company has not recognized any milestone revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzg0ODI5MDc0MDMzOA_1fa57158-8a49-4967-8864-7f6429b58dc2">STRATEGIC AGREEMENTS&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Strategic Agreements for Product Commercialization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organon Exclusive License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, the Company entered into an exclusive license agreement with Organon pursuant to which Organon will obtain exclusive worldwide rights to develop, manufacture and commercialize XACIATO and other future intravaginal or urological products for human use formulated with clindamycin that rely on intellectual property controlled by the Company. The effective date of the agreement will occur following the satisfaction of closing conditions that include receipt of all applicable approvals, or the expiration or termination of all applicable waiting periods, required under applicable antitrust laws, including the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of other terms of the Organon license agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Upfront Payment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company will receive a $10.0 million non-refundable and non-creditable payment following the effective date of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty and Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company will be entitled to receive tiered double-digit royalties based on net sales and up to $182.5 million in milestone payments as follows: $2.5 million following the first commercial sale of a licensed product in the United States; and up to $180.0 million in tiered commercial sales milestones and regulatory milestones. Royalty payments will be subject to customary reductions and offsets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The royalty period for each licensed product will continue on a country-by-country basis from the first commercial sale of the licensed product in the country until the expiration of the later of (i) the date that no valid patent claim would be infringed in the absence of the license granted under the agreement by the sale of the licensed product in the country, (ii) 10 years after the end of the month in which the first commercial sale of the licensed product in the country occurred, and (iii) the expiration of regulatory market exclusivity for the licensed product in that country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Regulatory Interactions and Product Supply.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company will be responsible for regulatory interactions and for providing product supply on an interim basis until Organon assumes such responsibilities. Until such time, Organon will purchase all of its product requirements of XACIATO from the Company at a transfer price equal to the Company's manufacturing costs plus a single-digit percentage markup. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Term.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Unless terminated earlier, the agreement will expire on a product-by-product and country-by-country basis upon expiration of the applicable royalty period for each licensed product. In addition to customary termination rights for both parties, following the first anniversary of the effective date of the agreement, Organon may terminate the agreement in its entirety or on a country-by-country basis at any time in Organon's sole discretion on 120 days' advance written notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The terms of the agreement provide Organon exclusive worldwide rights of first negotiation for specified potential future products of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%"&gt;Bayer HealthCare License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the Company entered into a license agreement with Bayer, regarding the further development and commercialization of Ovaprene in the U.S. The Company received a $1.0 million upfront non-refundable license fee payment from Bayer, and Bayer agreed to support the Company in development and regulatory activities by providing the equivalent of two experts to advise the Company in clinical, regulatory, preclinical, commercial, CMC and product supply matters. Bayer, in its sole discretion, has the right to make the license effective by paying the Company an additional $20.0 million, referred to as the Clinical Trial and Manufacturing Activities Fee. Such license would be exclusive with regard to the commercialization of Ovaprene for human contraception in the U.S. and co-exclusive with the Company with regard to development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded there was one significant performance obligation related to the $1.0 million upfront payment: a distinct license to commercialize Ovaprene effective upon the receipt of the $20.0 million fee. The $1.0 million upfront payment will be recorded as license revenue at the earlier of (1) the point in time the&#160;Company receives the $20.0 million fee, the license&#160;is transferred to Bayer and Bayer is able to use and benefit from the&#160;license and (2) the termination of the agreement. As of March&#160;31, 2022, neither of the foregoing had occurred. The $1.0 million payment is recorded as long-term deferred license revenue in the Company's condensed consolidated balance sheet at March&#160;31, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of other terms of the Bayer license agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone &amp;amp; Royalty Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company will be entitled to receive (a) a milestone payment in the low double-digit millions upon the first commercial sale of Ovaprene in the U.S. and escalating milestone payments based on annual net sales of Ovaprene during a calendar year, totaling up to $310.0 million if all such milestones, including first commercial sale, are achieved, (b) tiered royalties starting in the low double digits based on annual net sales of Ovaprene during a calendar year, subject to customary royalty reductions and offsets, and (c) a percentage of sublicense revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Efforts.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company is responsible for the pivotal trial for Ovaprene and for its development and regulatory activities and has product supply obligations. After payment of the Clinical Trial and Manufacturing Activities Fee, Bayer will be responsible for the commercialization of Ovaprene for human contraception in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Term. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial term of the agreement, which is subject to automatic renewal terms, continues until the later of (a) the expiration of any valid claim covering the manufacture, use, sale or import of Ovaprene in the U.S.; or (b) 15 years from the first commercial sale of Ovaprene in the U.S. In addition to customary termination rights for both parties, Bayer may terminate the agreement at any time on 90 days' notice and the agreement will automatically terminate if the Company does not receive the Clinical Trial and Manufacturing Activities Fee if and when due.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"&gt;Strategic Agreements for Pipeline Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%"&gt;Hammock/MilanaPharm Assignment and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, the Company entered into (a) an Assignment Agreement with Hammock Pharmaceuticals, Inc., or the Assignment Agreement, and (b) a First Amendment to License Agreement with TriLogic Pharma, LLC and MilanaPharm LLC, or the License Amendment. Both agreements relate to the Exclusive License Agreement among Hammock, TriLogic and MilanaPharm dated as of January 9, 2017, or the MilanaPharm License Agreement. Under the Assignment Agreement and the MilanaPharm License Agreement, as amended by the License Amendment, the Company acquired an exclusive, worldwide license under certain intellectual property to, among other things, develop and commercialize products for the diagnosis, treatment and prevention of human diseases or conditions in or through any intravaginal or urological applications. The licensed intellectual property relates to the hydrogel drug delivery platform of TriLogic and MilanaPharm known as TRI-726. In XACIATO, this proprietary technology is formulated with clindamycin for the treatment of bacterial vaginosis. Each of the Assignment Agreement and License Amendment was amended in December 2019 and the License Agreement was further amended in September 2021 and March 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of other terms of the License Amendment, as amended:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fees.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; A total of $235,000 in license fees were payable to MilanaPharm, the final installment of which was $110,000 paid in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company paid MilanaPharm $300,000 in the aggregate upon achievement of certain clinical and regulatory development milestones, $50,000 of which was paid in 2020 and $250,000 of which was paid in 2021. The Company may also pay MilanaPharm up to $500,000 upon the first commercial sale in the United States of the first licensed product for each vaginal use and urological use, and up to $250,000 upon the first commercial sale in the United States of successive licensed products for vaginal or urological use. In addition, upon achievement of $50.0 million in cumulative worldwide net sales of licensed products, the Company must pay $1.0 million to MilanaPharm. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Sublicense Income.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company will pay MilanaPharm a low double-digit percentage of all income received by the Company or its affiliates in connection with any sublicense granted to a third party for use outside of the United States, subject to certain exclusions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; During the royalty term, the Company will pay MilanaPharm high single-digit to low double-digit royalties based on annual worldwide net sales of licensed products and processes. The royalty term, which is determined on a country-by-country basis and licensed product-by-product basis (or process-by-process basis), begins with the first commercial sale of a licensed product or process in a country and terminates on the latest of (1) the expiration date of the last valid claim of the licensed patent rights that cover the method of use of such product or process in such country, or (2) 10 years following the first commercial sale of such product or process in such country. Royalty payments are subject to reduction in certain circumstances, including as a result of generic competition, patent prosecution expenses incurred by the Company, or payments to third parties for rights or know-how required for the Company to exercise the licenses granted to it under the MilanaPharm License Agreement or that are strategically important or could add value to a licensed product or process in a manner expected to materially generate or increase sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Efforts. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company must use commercially reasonable efforts and resources to (1) develop and commercialize at least one licensed product or process in the United States and at least one licensed product or process in at least one of Canada, the United Kingdom, France, Germany, Italy or Spain, and (2) continue to commercialize that product or process following the first commercial sale of a licensed product or process in the applicable jurisdiction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Term.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Unless earlier terminated, the license term continues until (1) on a licensed product-by-product (or process-by-process basis) and country-by-country basis, the date of expiration of the royalty term with respect to such licensed product in such country, and (2) the expiration of all applicable royalty terms under the MilanaPharm License Agreement with respect to all licensed products and processes in all countries. Upon expiration of the term with respect to any licensed product or process in a country (but not upon earlier termination of the MilanaPharm License Agreement), the licenses granted to the Company under the MilanaPharm License Agreement will convert automatically to an exclusive, fully paid-up, royalty-free, perpetual, non-terminable and irrevocable right and license under the licensed intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to customary termination rights for all parties, MilanaPharm may terminate the license granted to the Company solely with respect to a licensed product or process in a country if, after having launched such product or process in such country, (1) the Company or its affiliates or sublicensees discontinue the sale of such product or process in such country and MilanaPharm notifies the Company of such termination within 60 days of having first been notified by the Company of such discontinuation, or (2) the Company or its affiliates or sublicensees (A) discontinue all commercially reasonable marketing efforts to sell, and discontinue all sales of, such product or process in such country for nine months or more, (B) fail to resume such commercially reasonable marketing efforts within 120 days of having been notified of such failure by MilanaPharm, (C) fail to reasonably demonstrate a strategic justification for the discontinuation and failure to resume to MilanaPharm, and (D) MilanaPharm gives 90 days&#x2019; notice to the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of other terms of the Assignment Agreement, as amended:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assignment; Technology Transfer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Hammock assigned and transferred to the Company all of its right, title and interest in and to the MilanaPharm License Agreement and agreed to cooperate to transfer to the Company all of the data, materials and the licensed technology in its possession pursuant to a technology transfer plan to be agreed upon by the parties, with a goal for the Company to independently practice the licensed intellectual property as soon as commercially practical in order to develop and commercialize the licensed products and processes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. A total of $512,500 in fees were payable to Hammock, the final installment of which was $137,500 paid in 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company will pay Hammock up to $1.1 million in the aggregate upon achievement of certain clinical and regulatory development milestones, $100,000 of which was paid in 2020 and $750,000 of which was paid in 2021. The remaining milestone does not relate to a bacterial vaginosis product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Term.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Assignment Agreement will terminate upon the later of (1) completion of the parties' technology transfer plan, and (2) payment to Hammock of the last of the milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ADVA-Tec License Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, the Company entered into a license agreement with ADVA-Tec, Inc., under which the Company was granted the exclusive right to develop and commercialize Ovaprene for human contraceptive use worldwide. The Company must use commercially reasonable efforts to develop and commercialize Ovaprene and must meet certain minimum spending amounts per year, including $2.5&#160;million per year to cover such activities until a final PMA is filed, or until the first commercial sale of Ovaprene, whichever occurs first. ADVA-Tec will conduct certain research and development work as necessary to allow the Company to seek a PMA from the FDA and will provide the Company with clinical trial and commercial supplies of Ovaprene, either directly or through a CMO, on commercially reasonable terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the license agreement, in addition to an exclusive license to ADVA-Tec's and its affiliates' intellectual property rights for all uses of Ovaprene as a human contraceptive device, the Company has a right of first refusal to license these patents and patent applications for additional indications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of other terms of the ADVA-Tec license agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company will pay to ADVA-Tec: (1) up to $14.6 million in the aggregate based on the achievement of specified development and regulatory milestones, $200,000 of which was paid in 2021; and (2) up to $20.0 million in the aggregate based on the achievement of certain worldwide net sales milestones.  The remaining development and regulatory milestones include: the FDA's approval to commence a pivotal clinical trial; successful completion of such pivotal clinical trial; the FDA's acceptance of a PMA filing for Ovaprene; the FDA's approval of the PMA for Ovaprene; CE Marking of Ovaprene in at least three designated European countries; obtaining regulatory approval in at least three designated European countries; and obtaining regulatory approval in Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. After the commercial launch of Ovaprene, the Company will pay to ADVA-Tec royalties based on aggregate annual net sales of Ovaprene in specified regions, at a royalty rate that will vary between 1% and 10% and will increase based on various net sales thresholds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Unless earlier terminated, the license the Company received under the agreement continues on a country-by-country basis until the later of the life of the licensed patents or the Company's last commercial sale of Ovaprene. In addition to customary termination rights for both parties: (A) the Company may terminate the agreement with or without cause in whole or on a country-by-country basis upon 60 days prior written notice; and (B) ADVA-Tec may terminate the agreement if the Company develops or commercializes any non-hormonal ring-based vaginal contraceptive device competitive to Ovaprene or if the Company fails to: (1) in certain limited circumstances, commercialize Ovaprene in certain designated countries within three years of the first commercial sale of Ovaprene; (2) satisfy the annual spending obligation described above, (3) use commercially reasonable efforts to complete all necessary pre-clinical and clinical studies required to support and submit a PMA, (4) conduct clinical trials as set forth in the development plan to which the Company and ADVA-Tec agree, and as may be modified by a joint research committee, unless such failure is caused by events outside of the Company&#x2019;s reasonable control, or (5) enroll a patient in the first non-significant risk medical device study or clinical trial as allowed by an institutional review board within six months of the production and release of Ovaprene, unless such failure is caused by events outside of the Company&#x2019;s reasonable control.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%"&gt;SST License and Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, the Company entered into a license and collaboration agreement with Strategic Science &amp;amp;&#160;Technologies-D,&#160;LLC and Strategic Science &amp;amp; Technologies, LLC, referred to collectively as SST, under which the Company received an exclusive, royalty-bearing, sublicensable license to develop and commercialize, in all countries and geographic territories of the world, for all indications for women related to female sexual dysfunction and/or female reproductive health, including the treatment of female sexual arousal disorder, or the Field of Use, SST&#x2019;s topical formulation of Sildenafil Cream, 3.6% as it existed as of the effective date of the agreement, or any other topically applied pharmaceutical product containing sildenafil or a salt thereof as a pharmaceutically active ingredient, alone or with other active ingredients, but specifically excluding any product containing ibuprofen or any salt derivative of ibuprofen, or the Licensed Products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of other terms of the SST license and collaboration agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Invention Ownership.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company retains rights to inventions made by its employees, SST retains rights to inventions made by its employees, and each party owns a 50% undivided interest in all joint inventions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint Development Committee.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The parties will collaborate through a joint development committee that will determine the strategic objectives for, and generally oversee, the development efforts of both parties under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Development.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company must use commercially reasonable efforts to develop the Licensed Products in the Field of Use in accordance with a development plan in the agreement, and to commercialize the Licensed Products in the Field of Use. The Company is responsible for all reasonable internal and external costs and expenses incurred by SST in its performance of the development activities it must perform under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; SST will be eligible to receive tiered royalties based on percentages of annual net sales of Licensed Products in the single digits to the mid double digits, subject to customary royalty reductions and offsets, and a percentage of sublicense revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; SST will be eligible to receive payments (1) ranging from $0.5 million to $18.0 million in the aggregate on achieving certain clinical and regulatory milestones in the U.S. and worldwide, and (2) between $10.0 million to $100.0 million in the aggregate upon achieving certain commercial sales milestones. If the Company enters into strategic development or distribution partnerships related to the Licensed Products, additional milestone payments would be due to SST.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Term. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s license continues on a country-by-country basis until the later of 10 years from the date of the first commercial sale of such Licensed Product or the expiration of the last valid claim of patent rights covering the Licensed Product in the Field of Use. Upon expiration (but not termination) of the agreement in a particular country, the Company will have a fully paid-up license under the licensed intellectual property to develop and commercialize the applicable Licensed Products in the applicable country on a non-exclusive basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Termination.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to customary termination rights for both parties: (1) prior to receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including NDA approval, the Company may terminate the agreement without cause upon 90 days prior written notice; (2) following receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including NDA approval, the Company may terminate the agreement without cause upon 180 days prior written notice; and (3) SST may terminate the agreement with respect to the applicable Licensed Product(s) in the applicable country(ies) upon 30 days&#x2019; notice if the Company fails to use commercially reasonable efforts to perform development activities in substantial accordance with the development plan and do not cure such failure within 60 days of receipt of SST's notice thereof.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Catalent JNP License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018,&#160;the Company entered into an exclusive license agreement with Catalent JNP, Inc. (formerly known as Juniper Pharmaceuticals, Inc., and which the Company refers to as Catalent), under which Catalent granted the Company (a) an exclusive, royalty-bearing worldwide license under certain patent rights, either owned by or exclusively licensed to Catalent, to make, have made, use, have used, sell, have sold, import and have imported products and processes, and (b) a non-exclusive, royalty-bearing worldwide license to use certain technological information owned by Catalent to make, have made, use, have used, sell, have sold, import and have imported products and processes. The Company is entitled to sublicense the rights granted to it under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Upfront Fee.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company paid a $250,000 non-creditable upfront license fee to Catalent in connection with the execution of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Annual Maintenance Fee.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company will pay an annual license maintenance fee to Catalent on each anniversary of the date of the agreement, the amount of which will be $50,000 for the first two years and $100,000 thereafter, and which will be creditable against royalties and other payments due to Catalent in the same calendar year but may not be carried forward to any other year. The Company made the first payments in April 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company must make potential future development and sales milestone payments of (1) up to $13.5 million in the aggregate upon achieving certain clinical and regulatory milestones, $1.0&#160;million of which became payable in the third quarter of 2021, and in accordance with the license agreement, the amount payable was offset by the $100,000 annual maintenance fee, resulting in a net amount of $900,000 paid during the third quarter of 2021, and (2) up to $30.3 million in the aggregate upon achieving certain commercial sales milestones for each product or process covered by the licenses granted under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. During the royalty term, the Company will pay Catalent mid-single-digit to low double-digit royalties based on worldwide net sales of products and processes covered by the licenses granted under the agreement. In lieu of such royalty payments, the Company will pay Catalent a low double-digit percentage of all sublicense income the Company receives for the sublicense of rights under the agreement to a third party. The royalty term, which is determined on a country-by-country basis and product-by-product basis (or process-by-process basis), begins with the first commercial sale of a product or process in a country and terminates on the latest of (1) the expiration date of the last valid claim within the licensed patent rights with respect to such product or process in such country, (2) 10 years following the first commercial sale of such product or process in such country, and (3) when one or more generic products for such product or process are commercially available in such country, except that if there is no such generic product by the 10th year following the first commercial sale in such country, then the royalty term will terminate on the 10-year anniversary of the first commercial sale in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Efforts. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company must use commercially reasonable efforts to develop and make at least one product or process available to the public, which efforts include achieving specific diligence requirements by specific dates specified in the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Term. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the term of the agreement will continue on a country-by-country basis until the later of (1) the expiration date of the last valid claim within such country, or (2) 10 years from the date of first commercial sale of a product or process in such country. Upon expiration (but not early termination) of the agreement, the licenses granted thereunder will convert automatically to fully-paid irrevocable licenses. Catalent may terminate the agreement (1) upon 30 days&#x2019; notice for the Company&#x2019;s uncured breach of any payment obligation under the agreement, (2) if the Company fails to maintain required insurance, (3) immediately upon the Company&#x2019;s insolvency or the making of an assignment for the benefit of the Company&#x2019;s creditors or if a bankruptcy petition is filed for or against the Company, which petition is not dismissed within 90 days, or (4) upon 60 days&#x2019; notice for any uncured material breach by the Company of any of the Company&#x2019;s other obligations under the agreement. The Company may terminate the agreement on a country-by-country basis for any reason by giving 180 days&#x2019; notice (or 90 days&#x2019; notice if such termination occurs prior to receipt of marketing approval in the United States). If Catalent terminates the agreement for the reason described in clause (4) above or if the Company terminates the agreement, Catalent will have full access including the right to use and reference all product data generated during the term of the agreement that is owned by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adare Development and Option Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018, the Company entered into an exclusive development and option agreement with Adare Pharma Solutions (formerly known as Adare Pharmaceuticals and Orbis Biosciences, and which the Company refers to as Adare), for the development of long-acting injectable etonogestrel contraceptive with 6- and 12-month durations (now known as ADARE-204 and ADARE-214, respectively). The agreement provides the Company with an option to negotiate an exclusive license agreement for the programs if the Company funds the conduct of specified development work by Adare. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;MBI Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, the Company acquired Dare MB Inc. (formerly, Microchips Biotech, Inc.), or MBI, to secure the rights to develop a long-acting reversible contraception method that a woman can turn on or off herself, according to her own needs. This candidate is now known as DARE-LARC1. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the closing of the acquisition, the Company issued an aggregate of approximately 3.0&#160;million shares of its common stock to the holders of shares of MBI's capital stock outstanding immediately prior to the effective time of the merger. The transaction was valued at $2.4 million, based on the fair value of the approximately 3.0&#160;million shares issued at $0.79 per share, which was the closing price per share of the Company's common stock on the date of closing. The shares were issued in exchange for MBI&#x2019;s cash and cash equivalents of $6.1 million, less net liabilities of $3.5 million and transaction costs of $202,000, which was allocated based on the relative fair value of the assets acquired and the liabilities assumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also agreed to pay the following additional consideration to the former MBI stockholders: (a) up to $46.5 million contingent upon the achievement of specified funding, product development and regulatory milestones; (b) up to $55.0 million contingent upon the achievement of specified amounts of aggregate net sales of products incorporating the intellectual property acquired by the Company in the merger; (c) tiered royalty payments ranging from low single-digit to low double-digit percentages of annual net sales of such products, subject to customary provisions permitting royalty reductions and offset; and (d)&#160;a percentage of sublicense revenue related to such products. The Company agreed to use commercially reasonable efforts to achieve specified development and regulatory objectives relating to DARE-LARC1. In June 2021, a total of $1.25&#160;million of that potential additional consideration became payable upon the achievement of certain of the funding and product development milestone events, $1.0 million of which was recorded as contingent consideration on the Company's consolidated balance sheets upon the completion of the MBI acquisition and $250,000 of which was expensed in 2021. In July 2021, the Company&#x2019;s board of directors elected to make these milestone payments in shares of the Company&#x2019;s common stock, to the extent permissible under the terms of the merger agreement with MBI, and, in September 2021, the Company issued approximately 700,000 shares of its common stock to former stockholders of MBI and paid $75,000 in cash to the stockholders&#x2019; representative in accordance with the terms of the merger agreement in satisfaction of the $1.25&#160;million in milestone payments associated with milestones achieved in June 2021. See Note 7.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Pear Tree Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, the Company completed its acquisition of Pear Tree Pharmaceuticals, Inc., or Pear Tree. The Company acquired Pear Tree to secure the rights to develop a proprietary vaginal formulation of tamoxifen, now known as DARE-VVA1, as a potential treatment for vulvar and vaginal atrophy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company must make contingent payments to certain Pear Tree licensors and former stockholders of Pear Tree that become payable upon achievement of specified clinical, regulatory and commercial milestones, which may be paid, in the Company&#x2019;s sole discretion, in cash or shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;Royalty Payments. Subject to royalty reductions and offsets, (a) the former stockholders of Pear Tree will be eligible to receive tiered royalties based on percentages of net sales of certain products and a percentage of sublicense revenue and (b) certain Pear Tree licensors will be eligible to receive royalties based on percentages of net sales of certain products and a percentage of sublicense revenue.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <dare:UpfrontLicenseFeeAmountPaid
      contextRef="ib8e755817cb04a57a08c4f99adb8ffd6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTY0OTI2NzQ5NDI3NQ_5be3749c-3ef2-41a2-9a57-90865d40810d"
      unitRef="usd">10000000</dare:UpfrontLicenseFeeAmountPaid>
    <dare:MilestonePaymentsContingentAmount
      contextRef="ib8e755817cb04a57a08c4f99adb8ffd6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTY0OTI2NzQ5NDI5OA_eae2e1f0-bbee-46c1-aabf-ff7aa0b6a776"
      unitRef="usd">182500000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmountFirstCommercialSaleAmount
      contextRef="ib8e755817cb04a57a08c4f99adb8ffd6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTY0OTI2NzQ5NDI4Mg_8d2a81c2-a5c0-455a-89fd-15287eedd442"
      unitRef="usd">2500000</dare:MilestonePaymentsContingentAmountFirstCommercialSaleAmount>
    <dare:MilestonePaymentsContingentAmountSalesBasedMilestonesAmount
      contextRef="i1c840e118dda4da0839c1173ced12675_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTY0OTI2NzQ5NDI5MA_a989e32d-958b-4a59-a948-78597e174dbc"
      unitRef="usd">180000000</dare:MilestonePaymentsContingentAmountSalesBasedMilestonesAmount>
    <dare:MilestonePaymentsTerm
      contextRef="ib8e755817cb04a57a08c4f99adb8ffd6_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTY0OTI2NzQ5NDM0MQ_2d39210e-0863-40da-99f2-b836decd1959">P10Y</dare:MilestonePaymentsTerm>
    <dare:UpfrontLicenseFeePaid
      contextRef="ie39ad353b32c4dc891e544e148bc9b66_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzAy_cb039012-c8db-45d4-b15a-f59ebc0027f9"
      unitRef="usd">1000000</dare:UpfrontLicenseFeePaid>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie39ad353b32c4dc891e544e148bc9b66_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzg4_d84d6796-45e5-4f53-b56a-7d4b1bee9db9"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dare:UpfrontLicenseFeePaid
      contextRef="ie39ad353b32c4dc891e544e148bc9b66_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTA5OTUxMTYzMzQxNzI_cb039012-c8db-45d4-b15a-f59ebc0027f9"
      unitRef="usd">1000000</dare:UpfrontLicenseFeePaid>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie39ad353b32c4dc891e544e148bc9b66_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTA5OTUxMTYzMzQyNzI_d84d6796-45e5-4f53-b56a-7d4b1bee9db9"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dare:UpfrontLicenseFeePaid
      contextRef="ie39ad353b32c4dc891e544e148bc9b66_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTA5OTUxMTYzMzQyODU_cb039012-c8db-45d4-b15a-f59ebc0027f9"
      unitRef="usd">1000000</dare:UpfrontLicenseFeePaid>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie39ad353b32c4dc891e544e148bc9b66_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTA5OTUxMTYzMzQ0MDY_d84d6796-45e5-4f53-b56a-7d4b1bee9db9"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dare:UpfrontLicenseFeePaid
      contextRef="ie39ad353b32c4dc891e544e148bc9b66_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTA5OTUxMTYzMzQ2MDE_cb039012-c8db-45d4-b15a-f59ebc0027f9"
      unitRef="usd">1000000</dare:UpfrontLicenseFeePaid>
    <dare:MilestonePaymentsContingentAmount
      contextRef="ie39ad353b32c4dc891e544e148bc9b66_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfOTcw_56015707-8cb8-4d4a-b058-3aac3d059c4a"
      unitRef="usd">310000000</dare:MilestonePaymentsContingentAmount>
    <dare:LicenseAgreementInitialTerm
      contextRef="ie39ad353b32c4dc891e544e148bc9b66_D20200101-20200131"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTk4MA_ac5a9d5d-a289-46aa-bf35-4b9012a5d761">P15Y</dare:LicenseAgreementInitialTerm>
    <dare:LicenseFee
      contextRef="i8b96da1d703849ca87cb722301f4332a_D20191201-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzczNQ_dd0c16d7-e0b2-456c-be5d-b1e071e1954f"
      unitRef="usd">235000</dare:LicenseFee>
    <dare:LicenseFeeToBePaidUponContingency
      contextRef="ia36cb4e021c8477c9cdd5cd2270d26f0_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzg4OQ_ca9f5ef2-9d0f-4c9c-ac46-6f5de82eaa57"
      unitRef="usd">110000</dare:LicenseFeeToBePaidUponContingency>
    <dare:MilestonePaymentsContingentAmount
      contextRef="id7e84f1a2279490fb994ed669d2a5794_D20191201-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzk1MA_84826cb6-9482-4e41-ac3f-3ccb0a17f624"
      unitRef="usd">300000</dare:MilestonePaymentsContingentAmount>
    <dare:AssetAcquisitionContingentConsideration
      contextRef="ie1a197ace83745b5af0af06d9e6a03ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfNDA0Ng_b173c65e-08f2-400d-acc0-ab9858dfc1df"
      unitRef="usd">50000</dare:AssetAcquisitionContingentConsideration>
    <dare:MilestonePaymentsContingentAmount
      contextRef="ica0953b3410b4366b3dd008e5682c91c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTA5OTUxMTYzMzc0MTM_54a96e65-ce72-4065-97ba-0b359220109f"
      unitRef="usd">250000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmount
      contextRef="ie54bf079d17049f89f976bde3354e8eb_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTA5OTUxMTYzMzc0MDk_2029c24f-1485-40c1-bfb2-29d268bc0325"
      unitRef="usd">500000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmount
      contextRef="i1377eee01ae54f288857d7190cc24095_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTA5OTUxMTYzMzc0MjQ_1af0f308-0231-4bb4-857e-4fa0c699c0df"
      unitRef="usd">250000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmount
      contextRef="i96570265e6d94bafb524501622be0afa_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTA5OTUxMTYzMzc0MzI_e1c38da8-83a0-429f-84d6-1332cae793f3"
      unitRef="usd">50000000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmount
      contextRef="i52d0dedfaf874adfb961664b9bce5b92_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTA5OTUxMTYzMzc0NTA_e9b34fc8-1b99-4d77-837e-f78c94e18d44"
      unitRef="usd">1000000</dare:MilestonePaymentsContingentAmount>
    <dare:RoyaltyAgreementTerm
      contextRef="id84a19a7b61f49aab03e5421a920942c_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjE5OTAyMzMxNTk1MA_c141befc-4495-4fb3-a307-51f5d72079f4">P10Y</dare:RoyaltyAgreementTerm>
    <dare:LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct
      contextRef="i8b96da1d703849ca87cb722301f4332a_D20191201-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfNzQzOQ_eb79e9da-d6bc-42f1-ae74-712ee63e0983">P60D</dare:LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct>
    <dare:LicenseAgreementTerminationPeriodDueToPerformanceFailure
      contextRef="i8b96da1d703849ca87cb722301f4332a_D20191201-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfNzgwNA_ffa2a415-94d3-483d-a09a-eef52492c45b">P120D</dare:LicenseAgreementTerminationPeriodDueToPerformanceFailure>
    <dare:LicenseAgreementNoticePeriodOfTermination
      contextRef="i8b96da1d703849ca87cb722301f4332a_D20191201-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfODAxMg_1ea58c61-fa16-40e8-8c3d-f187a601ecbf">P90D</dare:LicenseAgreementNoticePeriodOfTermination>
    <dare:LicenseFee
      contextRef="i45bf9ce3d7014dd4a8cc904a8d6fdfe3_D20191201-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfODY5OA_369c471c-d93c-4938-9219-fca885c043d1"
      unitRef="usd">512500</dare:LicenseFee>
    <dare:LicenseFeeToBePaidUponContingency
      contextRef="i24bd5f0c2d834a5386e1ac19b19670c4_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfODg0Mw_5e318eb8-fc17-4b9b-a12a-53edb99eaf16"
      unitRef="usd">137500</dare:LicenseFeeToBePaidUponContingency>
    <dare:MilestonePaymentsContingentAmount
      contextRef="ib3040a789d9a4c049500fc9df1a161d5_D20191201-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfODkxNg_8ff9088d-8913-4186-8515-4e23cacc4329"
      unitRef="usd">1100000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmount
      contextRef="ie890f0c1b2d94ab1b54648bda60c9b9e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzg0ODI5MDc0MDI2Nw_a1995f13-8569-4bb1-90db-ed0722ed2edc"
      unitRef="usd">100000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmount
      contextRef="ie4e5b11922fb45baae7deef39cf719d8_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzg0ODI5MDc0MDI3Nw_f9f6b703-024a-4a81-abe5-a00c243c7d4a"
      unitRef="usd">750000</dare:MilestonePaymentsContingentAmount>
    <dare:ResearchAndDevelopmentMilestonePayment
      contextRef="id40ce46b765846a5aa2e57368b8b8e2e_D20170301-20170331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzg0ODI5MDc0MDI4Nw_76d49942-8929-4c1d-a65a-8e67436189d1"
      unitRef="usd">2500000</dare:ResearchAndDevelopmentMilestonePayment>
    <dare:ResearchAndDevelopmentMilestonePayment
      contextRef="i3cba105a870f4df89d49f7bf4d41b3b3_D20170301-20170331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfOTg3Nw_28e69737-5b60-4724-ad2a-e349e0e98218"
      unitRef="usd">14600000</dare:ResearchAndDevelopmentMilestonePayment>
    <dare:MilestonePaymentsContingentAmount
      contextRef="i2502d37404a542acb2be44f30462a6db_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzg0ODI5MDc0MDMwMw_9f4b767a-615b-4014-8b85-8eefc79dbc63"
      unitRef="usd">200000</dare:MilestonePaymentsContingentAmount>
    <dare:ResearchAndDevelopmentMilestonePayment
      contextRef="i3c82657d880d4e1fa411c307e0109b6c_D20170301-20170331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfOTk4OA_bfe4da5e-6449-453e-b231-e95f10c02095"
      unitRef="usd">20000000</dare:ResearchAndDevelopmentMilestonePayment>
    <dare:PercentageOfRoyaltyRate
      contextRef="i33b5825a9b744e5d8bdf4464e25fdeca_D20170301-20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTAyODk_e408b0f1-952d-4775-9d17-c30df998de2e"
      unitRef="number">0.01</dare:PercentageOfRoyaltyRate>
    <dare:PercentageOfRoyaltyRate
      contextRef="i2c11228dbbd544df9e87f818ade25d08_D20170301-20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTAyOTY_2c6ffc3a-eb0a-4a1d-9adb-5f1c84469ddf"
      unitRef="number">0.10</dare:PercentageOfRoyaltyRate>
    <dare:MilestonePaymentsTerm
      contextRef="i3c82657d880d4e1fa411c307e0109b6c_D20170301-20170331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjE5OTAyMzMxNTk2Mw_25e2485b-9aa6-4bd1-ab38-c4cf0308b829">P3Y</dare:MilestonePaymentsTerm>
    <dare:PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement
      contextRef="ib4370da4fa5342028ed801f0a9fa0408_D20180201-20180228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTMwNzc_2bfb6e8a-a8e7-4db9-a5bd-fdb010f94c3f"
      unitRef="number">0.50</dare:PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement>
    <dare:MilestonePaymentsContingentAmount
      contextRef="ic670d6c2f83e480aaccaa11002b3fd82_D20180201-20180228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTQxMjk_38aa2243-4c24-4dc9-865c-007da3c25ccc"
      unitRef="usd">500000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmount
      contextRef="iaac673f0f7dd48318f3456c2bd5051e6_D20180201-20180228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTQxMzU_4461c913-eaf3-4b30-926c-0053ca1bf086"
      unitRef="usd">18000000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmount
      contextRef="i4e73b75602364a808872b80c92bb1c3d_D20180201-20180228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTQyNTQ_be55f95b-dbef-4cea-ac00-6dc7a453e8f8"
      unitRef="usd">10000000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmount
      contextRef="i88690cf0663d46c2a1f6398cdafd4e30_D20180201-20180228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTQyNjA_46265100-4c7f-4f32-a446-353018a5cfd8"
      unitRef="usd">100000000</dare:MilestonePaymentsContingentAmount>
    <dare:UpfrontLicenseFeePaid
      contextRef="ia6e9a4923f614a9492dd0238e4cca80f_D20180401-20180430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTY4NTU_4ea2c031-f235-4ce8-ae08-fff6cb1bf945"
      unitRef="usd">250000</dare:UpfrontLicenseFeePaid>
    <dare:PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne
      contextRef="ia6e9a4923f614a9492dd0238e4cca80f_D20180401-20180430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTcxMjU_e93b1f67-5075-4cbf-89e4-95e561fcfb80"
      unitRef="usd">50000</dare:PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne>
    <dare:PotentialAnnualLicenseMaintenanceFeePaymentsThereafter
      contextRef="ia6e9a4923f614a9492dd0238e4cca80f_D20180401-20180430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTcxNTY_2a7b1d35-a476-4e54-9f6c-322fcd83c9da"
      unitRef="usd">100000</dare:PotentialAnnualLicenseMaintenanceFeePaymentsThereafter>
    <dare:MaximumPotentialMilestonePayments
      contextRef="ic39a296e2a1e45a29ed3a2a13c728ab9_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTc0NDI_f7a019af-e9e6-4875-b367-1290b2714cd8"
      unitRef="usd">13500000</dare:MaximumPotentialMilestonePayments>
    <dare:MilestonePaymentsContingentAmount
      contextRef="i18e026cd749c470d865e295625b2d49f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTc1MjE_87212a04-3e27-4627-b283-1343899743de"
      unitRef="usd">1000000</dare:MilestonePaymentsContingentAmount>
    <us-gaap:CostMaintenance
      contextRef="i130fa20b36a240b182234edcc27974bf_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTc2NjE_bc903b3e-5aff-4e32-816d-467390e42387"
      unitRef="usd">100000</us-gaap:CostMaintenance>
    <dare:MilestonePaymentsContingentAmountPayableNet
      contextRef="i05dcf861082b438c816582ce5fd7e46e_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTc3MTc_62e33fb3-5f6e-4355-8217-700adab30f74"
      unitRef="usd">900000</dare:MilestonePaymentsContingentAmountPayableNet>
    <dare:MaximumPotentialMilestonePayments
      contextRef="idb8485972ede4668ac56f750cad9b2ea_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMTc3NzM_749b2c94-6b4d-4033-97be-b3a4df229c9b"
      unitRef="usd">30300000</dare:MaximumPotentialMilestonePayments>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="if0d7024baebb42f3921f362b71af0807_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzg0ODI5MDc0MDMxMw_c4c6d13f-6e59-44b9-a2aa-edea96be102a"
      unitRef="shares">3000000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
      contextRef="id9429fbf089249aeb34b9943fccfb3aa_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjIzNDE_eabb490e-8179-476d-a2fa-e691368f02a9"
      unitRef="usd">2400000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="if0d7024baebb42f3921f362b71af0807_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMzg0ODI5MDc0MDMyNg_ea4759d5-22bc-4e8c-9ec4-e2e631627746"
      unitRef="shares">3000000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="id9429fbf089249aeb34b9943fccfb3aa_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjIzOTY_7d6b5e62-dfa1-4aa3-a890-3d2b23640ac9"
      unitRef="usdPerShare">0.79</us-gaap:BusinessAcquisitionSharePrice>
    <dare:BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="id9429fbf089249aeb34b9943fccfb3aa_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjI1NzY_eaccb52c-1bde-4416-9d74-2eb6c31fa05a"
      unitRef="usd">6100000</dare:BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id9429fbf089249aeb34b9943fccfb3aa_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjI2MDQ_27aa31bc-0122-421e-9da2-27551e0f33ec"
      unitRef="usd">3500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
      contextRef="i4550db8657fb446599597be07760a4e9_I20191130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjI2MzI_4f4a7ca3-8398-4c57-bf1c-28b48ed729ee"
      unitRef="usd">202000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <dare:ResearchAndDevelopmentMilestonePayment
      contextRef="id246537752c543dc90f3ce1157fa81db_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjI4NDk_44b36914-d166-404c-b018-b56c5fe45678"
      unitRef="usd">46500000</dare:ResearchAndDevelopmentMilestonePayment>
    <dare:AssetAcquisitionContingentConsiderationCurrent
      contextRef="i4871de07797e4ead9c91bde6f6f1da64_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjI5NjM_80752dbf-c1d2-4c95-956a-8533653761df"
      unitRef="usd">55000000</dare:AssetAcquisitionContingentConsiderationCurrent>
    <us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration
      contextRef="i0088c2d5b3d841d79733a7ba7eb77c3f_I20210630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjM1NzA_94c69993-d5a8-4288-ab17-cda52b96c25f"
      unitRef="usd">1250000</us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration>
    <dare:AssetAcquisitionContingentConsiderationCurrent
      contextRef="id9429fbf089249aeb34b9943fccfb3aa_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjM3MjA_7d324695-7e7d-4a55-95fd-59df2edaf9b0"
      unitRef="usd">1000000</dare:AssetAcquisitionContingentConsiderationCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id046ca48ded64152a085f277ffdbdbd8_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjM4NjU_9a67a436-6fe9-495c-8e1c-1550a1f65855"
      unitRef="usd">250000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i3b39b4e982ff415dacb98beb58f1a039_D20210901-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjQyMTg_eda7055a-81ca-4b93-988d-681ed83e8bc3"
      unitRef="shares">700000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <dare:PaymentsToStockholdersRepresentativeInBusinessCombination
      contextRef="i3b39b4e982ff415dacb98beb58f1a039_D20210901-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjQyODc_e50254d8-3235-4c13-9c98-8bac6b572bbe"
      unitRef="usd">75000</dare:PaymentsToStockholdersRepresentativeInBusinessCombination>
    <dare:PaymentOfAdditionalConsiderationInBusinessCombination
      contextRef="i4e1024a3a3274602a0b50c48b9aa2f4a_D20210601-20210630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80MC9mcmFnOmM3MGJhOWRmOGMwNTQyZWQ5NTE5ZjUxMzVjMzM1YTU3L3RleHRyZWdpb246YzcwYmE5ZGY4YzA1NDJlZDk1MTlmNTEzNWMzMzVhNTdfMjQ0MTA_99e6e2f5-99bc-4dd4-91ef-1479437123e2"
      unitRef="usd">1250000</dare:PaymentOfAdditionalConsiderationInBusinessCombination>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfNTc0Nw_feb5a245-c979-4d74-9d92-d40fa116ff63">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;October 2021 ATM Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the Company entered into a sales agreement with SVB Leerink LLC to sell shares of its common stock from time to time through an "at-the-market," or ATM, equity offering program under which SVB Leerink acts as the Company's agent. The Company agreed to pay a commission equal to 3% of the gross proceeds of any common stock sold under the agreement, plus certain legal expenses. Shares of the Company's common stock sold under the agreement will be issued pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-254862) and the base prospectus included therein, originally filed with the SEC on March 30, 2021, and declared effective on April 7, 2021, and the prospectus supplement dated October 13, 2021 relating to the offering of up to $50.0 million in shares of the Company's common stock under this sales agreement, and any subsequent prospectus supplement filed with the SEC related to this ATM equity offering program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022, the Company sold no shares under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;April 2021 ATM Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company entered into a sales agreement with SVB Leerink LLC to sell shares of its common stock from time to time through an ATM, equity offering program under which SVB Leerink acts as the Company's agent. Under the sales agreement, the Company may issue and sell up to $50.0 million of shares of its common stock. The Company agreed to pay a commission equal to 3% of the gross proceeds of any common stock sold under the agreement, plus certain legal expenses. Any shares of the Company's common stock sold under the agreement will be issued pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-254862) and the base prospectus included therein, originally filed with the SEC on March 30, 2021, and declared effective on April 7, 2021, and the prospectus supplement dated April 7, 2021 filed with the SEC on April 8, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022, the Company sold no shares under this agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 ATM Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018 the Company entered into a common stock sales agreement with H.C. Wainwright &amp;amp; Co., LLC, or Wainwright, relating to the offering and sale of shares of its common stock from time to time in an ATM equity offering program through Wainwright, acting as sales agent. Under the agreement, Wainwright was entitled to a commission at a fixed commission rate equal to 3.0% of the gross proceeds per share sold under the agreement. In March 2021, the Company provided notice to Wainwright to terminate the agreement, and the agreement terminated in April 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Line&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, the Company entered into a purchase agreement, or the Purchase Agreement, and a registration rights agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park. Under the terms and subject to the conditions of the Purchase Agreement, the Company had the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park was obligated to purchase up to&#160;$15.0 million&#160;of the Company&#x2019;s common stock. The Company incurred legal, accounting, and other fees related to the Purchase Agreement of approximately $374,000. These costs were amortized and expensed as shares were sold under the Purchase Agreement. As of December 31, 2021, the Company had sold and Lincoln Park had purchased $15.0 million of the Company's common stock under the Purchase Agreement, there were no unamortized costs, and no more shares of common stock may be sold by the Company to Lincoln Park under the Purchase Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, the Company closed an underwritten public offering in connection with which the Company issued to the investors in that offering warrants exercisable through February 2023 and that initially had an exercise price of $3.00 per share.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The warrants include a price-based anti-dilution provision, which provides that, subject to certain limited exceptions, the exercise price of the warrants will be reduced each time the Company issues or sells (or is deemed to issue or sell) securities for a net consideration per share less than the exercise price of those warrants in effect immediately prior to such issuance or sale. In addition, subject to certain exceptions, if the Company issues, sells or enters into any agreement to issue or sell securities at a price which varies or may vary with the market price of the shares of the Company&#x2019;s common stock, the warrant holders have the right to substitute such variable price for the exercise price of the warrant then in effect. These warrants are exercisable only for cash, unless a registration statement covering the shares issued upon exercise of the warrants is not effective, in which case the warrants may be exercised on a cashless basis. A registration statement covering the shares issued upon exercise of the warrants is currently effective. The Company estimated the fair value of the warrants as of February 15, 2018 to be approximately $3.0 million which was recorded in equity as of the grant date. The Company early adopted ASU 2017-11 as of January 1, 2018 and recorded the fair value of the warrants as equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2019 and July 2020, in accordance with the price-based anti-dilution provision discussed above, the exercise price of these warrants was automatically reduced to $0.98 per share and to $0.96 per share, respectively, and as a result of the triggering of the anti-dilution provision, $0.8 million and $6,863, respectively, was recorded to additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022, no warrants were exercised. During the three months ended March&#160;31, 2021, warrants to purchase 52,500 shares of common stock were exercised for gross proceeds of $50,000. As of March&#160;31, 2022, the Company had the following warrants outstanding:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:169.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:19.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:18.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:118.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:18.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:157.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying&lt;br/&gt;Outstanding Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;04/04/2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,374,515&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;02/15/2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,381,015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <dare:PercentageOfAggregateCommission
      contextRef="i8375b393afa24fd4b4172cd82f83fced_D20210401-20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNTc0Ng_772c5f73-e87b-44ee-94e0-11697a4a2804"
      unitRef="number">0.03</dare:PercentageOfAggregateCommission>
    <us-gaap:CommonStockValue
      contextRef="i027223a9458b44d887cea8de9f1d3556_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNTc1MA_bf14221e-668e-4d12-b3b3-24e7a29e51dc"
      unitRef="usd">50000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i027223a9458b44d887cea8de9f1d3556_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNTg1OQ_bf14221e-668e-4d12-b3b3-24e7a29e51dc"
      unitRef="usd">50000000</us-gaap:CommonStockValue>
    <dare:PercentageOfAggregateCommission
      contextRef="i8375b393afa24fd4b4172cd82f83fced_D20210401-20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNTg2Nw_772c5f73-e87b-44ee-94e0-11697a4a2804"
      unitRef="number">0.03</dare:PercentageOfAggregateCommission>
    <dare:PercentageOfAggregateCommission
      contextRef="iba344274a14c460b96e230f0cbc5d2bb_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTg1OA_a285b093-a1a3-46cc-936b-8fbeaf59616b"
      unitRef="number">0.030</dare:PercentageOfAggregateCommission>
    <us-gaap:PurchaseObligation
      contextRef="i06ac362092d24b6bb3af02efaf7065e2_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNjYzNA_269120b5-5001-44e5-9c20-ea776a9bdd3e"
      unitRef="usd">15000000</us-gaap:PurchaseObligation>
    <us-gaap:DeferredOfferingCosts
      contextRef="i860c63444c524b589d982ed7ae48fd65_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNjcyOA_d76633c4-5caf-46de-99e5-382853b2cf4f"
      unitRef="usd">374000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PurchaseObligation
      contextRef="i06ac362092d24b6bb3af02efaf7065e2_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNzU2NA_269120b5-5001-44e5-9c20-ea776a9bdd3e"
      unitRef="usd">15000000</us-gaap:PurchaseObligation>
    <dare:DeferredOfferingCostsUnamortizedPortion
      contextRef="ie30a938a64fd46cd98becdc1551973ba_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzODM2OQ_e8c2fe68-be5d-4228-bea3-9f16bfc8d2aa"
      unitRef="usd">0</dare:DeferredOfferingCostsUnamortizedPortion>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i10618bb6d8c14b5885277741ae4a3091_I20180228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNzU3NQ_8b338965-cb11-4e69-80cd-491e71a2d21c"
      unitRef="usdPerShare">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <dare:EstimatedFairValueOfWarrantsRecordedInEquity
      contextRef="i7d4b21210fae4311928f3d408e82529a_I20180215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNzU3OQ_ce705af4-0afa-426f-abc8-6b4df774e1cc"
      unitRef="usd">3000000</dare:EstimatedFairValueOfWarrantsRecordedInEquity>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="if840484cdcd14e6c9fa54cfcf591c465_D20190401-20190430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfNTQ5NzU1ODE0ODg3Nw_b1b60632-46a4-4851-a5ac-e00197b03cd9"
      unitRef="usdPerShare">0.98</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="i32d71d006cd64f2da751eaec03afcb7e_D20200701-20200731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfNTQ5NzU1ODE0ODg5MA_77d32c51-c9eb-4b1e-93ef-2127d6f3a91a"
      unitRef="usdPerShare">0.96</us-gaap:WarrantExercisePriceDecrease>
    <dare:DeemedDividendFromTriggerOfRoundDownProvisionFeature
      contextRef="if840484cdcd14e6c9fa54cfcf591c465_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfNTMxNw_b053d27d-85f1-46da-b281-70a46db894ad"
      unitRef="usd">800000</dare:DeemedDividendFromTriggerOfRoundDownProvisionFeature>
    <dare:DeemedDividendFromTriggerOfRoundDownProvisionFeature
      contextRef="i32d71d006cd64f2da751eaec03afcb7e_D20200701-20200731"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfNTQ5NzU1ODE0ODkwNA_607a41b7-ee96-4a10-8306-1893b12175eb"
      unitRef="usd">6863</dare:DeemedDividendFromTriggerOfRoundDownProvisionFeature>
    <dare:NumberOfCommonStockWarrantsExercised
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfNTQ5NzU1ODE0ODkxMQ_d765d306-fecd-4f68-ad7f-5bea47e1f82f"
      unitRef="shares">0</dare:NumberOfCommonStockWarrantsExercised>
    <dare:NumberOfCommonStockWarrantsExercised
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNzcxNw_65259f20-92b7-4352-abc4-de7df2069cf9"
      unitRef="shares">52500</dare:NumberOfCommonStockWarrantsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfMTA5OTUxMTYzNzcyMQ_1cc7be67-55ab-40e7-90ce-cdd04f6e4fd4"
      unitRef="usd">50000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RleHRyZWdpb246ZTQwNGUwOThiZjUwNGFjOWJmMmUzN2Y5ZDIzYzNlNjJfNTc1MA_df6c5d78-828a-40c3-906e-78e1c401f44a">As of March&#160;31, 2022, the Company had the following warrants outstanding:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:169.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:19.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:18.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:118.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:18.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:157.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying&lt;br/&gt;Outstanding Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;04/04/2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,374,515&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;02/15/2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,381,015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i9b97f0e3d65145168bade1be8778dd8a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RhYmxlOmNmNGQ4N2ZhYjYzODQ3ZjNhNWU5N2UyYWJjZWVlZGRiL3RhYmxlcmFuZ2U6Y2Y0ZDg3ZmFiNjM4NDdmM2E1ZTk3ZTJhYmNlZWVkZGJfMy0wLTEtMS0zNzQ5MQ_2e987df5-5d73-4815-96ff-5fcf3aad8c84"
      unitRef="shares">6500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i9b97f0e3d65145168bade1be8778dd8a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RhYmxlOmNmNGQ4N2ZhYjYzODQ3ZjNhNWU5N2UyYWJjZWVlZGRiL3RhYmxlcmFuZ2U6Y2Y0ZDg3ZmFiNjM4NDdmM2E1ZTk3ZTJhYmNlZWVkZGJfMy0zLTEtMS0zNzQ5MQ_dca4a184-85ca-4395-813e-fb6954f57a87"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <dare:ClassOfWarrantOrRightsWarrantsExpirationDate
      contextRef="i3314d2bef75a49b1a150ea0c2b067414_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RhYmxlOmNmNGQ4N2ZhYjYzODQ3ZjNhNWU5N2UyYWJjZWVlZGRiL3RhYmxlcmFuZ2U6Y2Y0ZDg3ZmFiNjM4NDdmM2E1ZTk3ZTJhYmNlZWVkZGJfMy01LTEtMS0zNzQ5MQ_7ae3cb12-95e7-4998-b185-9f9ea8cfac6d">2026-04-04</dare:ClassOfWarrantOrRightsWarrantsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="iea4b068280ea4864aa871809e542b4c1_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RhYmxlOmNmNGQ4N2ZhYjYzODQ3ZjNhNWU5N2UyYWJjZWVlZGRiL3RhYmxlcmFuZ2U6Y2Y0ZDg3ZmFiNjM4NDdmM2E1ZTk3ZTJhYmNlZWVkZGJfNC0wLTEtMS0zNzQ5MQ_89fc51df-d55c-47b1-b83c-399520ad0137"
      unitRef="shares">1374515</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iea4b068280ea4864aa871809e542b4c1_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RhYmxlOmNmNGQ4N2ZhYjYzODQ3ZjNhNWU5N2UyYWJjZWVlZGRiL3RhYmxlcmFuZ2U6Y2Y0ZDg3ZmFiNjM4NDdmM2E1ZTk3ZTJhYmNlZWVkZGJfNC0zLTEtMS0zNzQ5MQ_fa43a1f6-1b62-4d57-b555-9352bc9a1bfd"
      unitRef="usdPerShare">0.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <dare:ClassOfWarrantOrRightsWarrantsExpirationDate
      contextRef="ifc86055f4ef84234810f28d2d776d7ae_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RhYmxlOmNmNGQ4N2ZhYjYzODQ3ZjNhNWU5N2UyYWJjZWVlZGRiL3RhYmxlcmFuZ2U6Y2Y0ZDg3ZmFiNjM4NDdmM2E1ZTk3ZTJhYmNlZWVkZGJfNC01LTEtMS0zNzQ5MQ_d545a40e-97b5-4411-b731-abc93787e015">2023-02-15</dare:ClassOfWarrantOrRightsWarrantsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80Ni9mcmFnOmU0MDRlMDk4YmY1MDRhYzliZjJlMzdmOWQyM2MzZTYyL3RhYmxlOmNmNGQ4N2ZhYjYzODQ3ZjNhNWU5N2UyYWJjZWVlZGRiL3RhYmxlcmFuZ2U6Y2Y0ZDg3ZmFiNjM4NDdmM2E1ZTk3ZTJhYmNlZWVkZGJfNS0wLTEtMS0zNzQ5MQ_936925db-b9fb-466d-bece-ac79b588cfb7"
      unitRef="shares">1381015</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMjI1NA_b04d5d29-b15c-4e28-922b-36961018ae27">STOCK-BASED COMPENSATION&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s 2014 Employee Stock Purchase Plan, or the ESPP, became effective in April 2014, but no offering period has been initiated thereunder since January 2017. There was no stock-based compensation related to the ESPP for the three months ended March&#160;31, 2022 or March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amended and Restated 2014 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains the Amended and Restated 2014 Stock Incentive Plan, or the Amended 2014 Plan, which provides for the grant of options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to employees, officers and directors, and consultants and advisors. There were 2,046,885 shares of common stock authorized for issuance under the Amended 2014 Plan when it was approved by the Company's stockholders in July 2018. The number of authorized shares increases annually on the first day of each fiscal year until, and including, the fiscal year ending December 31, 2024 by the least of (i) 2,000,000, (ii) 4% of the number of outstanding shares of common stock on such date, or (iii) an amount determined by the Company&#x2019;s board of directors. On January 1, 2022, the number of authorized shares increased by 2,000,000 to 2,201,855.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes stock option activity under the Amended 2014 Plan and related information for the three months ended March&#160;31, 2022. The exercise price of all options granted during the three months ended March&#160;31, 2022 was equal to the market value of the Company&#x2019;s common stock on the date of grant. As of March&#160;31, 2022, unamortized stock-based compensation expense of approximately $5.3&#160;million will be amortized over a weighted average period of 2.98 years. At March&#160;31, 2022, 642,175 shares of common stock were available for future awards granted under the Amended 2014 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:376.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,717,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,759,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,277,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,597,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense related to stock options granted to employees and directors recognized in the condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:376.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the three months ended March&#160;31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:442.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:45pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value of options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idf23d7941e8f4965a9fcb43805fcc930_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMjQ0_3bbbbad5-7705-480b-a8de-6591575ef6ea"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia882bdf1215042478edd6c0cd729a9d8_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMjQ0_5d3c74b8-e6c6-43cf-a990-db288d1eebbd"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ide7f913a931341588fd2f90818d1cee0_I20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfNjc0_2c54b71c-370b-4293-a49a-6c9d1df8175f"
      unitRef="shares">2046885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ide7f913a931341588fd2f90818d1cee0_I20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfOTg4_60880fe9-8b99-431f-8a06-0fd572738e2b"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="ia0d3fa77cb2945be89df99f83cc05ff3_D20180701-20180731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfOTk3_aeaf4323-af72-4068-a29a-345fece861fc"
      unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease
      contextRef="i409dea6286e3437c8531176fdea88602_D20210101-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMTE5Ng_f87f3665-dc9d-4a3b-97b4-3c39ef5c95b0"
      unitRef="shares">2000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i20fdc0f111514e9491d559f7b5252a54_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMTIwMg_9134e70a-c995-4857-92e5-94c450673e32"
      unitRef="shares">2201855</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMjI0OA_4555de9a-4513-4bd0-aefa-a3194a6c5d6f">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes stock option activity under the Amended 2014 Plan and related information for the three months ended March&#160;31, 2022. The exercise price of all options granted during the three months ended March&#160;31, 2022 was equal to the market value of the Company&#x2019;s common stock on the date of grant. As of March&#160;31, 2022, unamortized stock-based compensation expense of approximately $5.3&#160;million will be amortized over a weighted average period of 2.98 years. At March&#160;31, 2022, 642,175 shares of common stock were available for future awards granted under the Amended 2014 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:376.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,717,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,759,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,277,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,597,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMTY3Ng_52cdbb9e-041c-4993-8222-995bdca7b20b"
      unitRef="usd">5300000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <dare:WeightedAverageAmortizationPeriod
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMTczMQ_7def18e5-a518-4390-a7f5-166c06997e9b">P2Y11M23D</dare:WeightedAverageAmortizationPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="if170fdedc89840ffbe1185f85069788b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMTc0Mg_82ab4198-0c91-48e1-8ebe-4f8c12fa01de"
      unitRef="shares">642175</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5bcbbadf58fc412c9319a78f2b9da62f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfMS0xLTEtMS0zNzQ5MQ_e95c7f7d-b1dc-4c6a-93de-603735f8ae6e"
      unitRef="shares">4717602</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5bcbbadf58fc412c9319a78f2b9da62f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfMS0zLTEtMS0zNzQ5MQ_f3f4ad40-6acb-4df9-9516-406db70e29fc"
      unitRef="usdPerShare">1.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="idf2231aefe254fee96b7aeae2d91ae6e_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfMi0xLTEtMS0zNzQ5MQ_88e4c68a-3a65-4b8a-bc55-23ef31b35139"
      unitRef="shares">1759692</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="idf2231aefe254fee96b7aeae2d91ae6e_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfMi0zLTEtMS0zNzQ5MQ_5be37296-ada5-43b8-9b20-43152e4113ba"
      unitRef="usdPerShare">1.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="idf2231aefe254fee96b7aeae2d91ae6e_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfMy0xLTEtMS0zNzQ5MQ_597d8755-4218-4255-8f86-b7c542d442e4"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="idf2231aefe254fee96b7aeae2d91ae6e_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfMy0zLTEtMS0zNzQ5MQ_08f03225-f234-4c08-84e2-35b73f5da292"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="idf2231aefe254fee96b7aeae2d91ae6e_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfNC0xLTEtMS0zNzQ5MQ_01b01dad-a8b2-40f7-af86-c9e96600bd7b"
      unitRef="shares">200012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="idf2231aefe254fee96b7aeae2d91ae6e_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfNC0zLTEtMS0zNzQ5MQ_be9b89e6-964d-4321-8d57-6e45d764dc28"
      unitRef="usdPerShare">1.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="idf2231aefe254fee96b7aeae2d91ae6e_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfNS0xLTEtMS0zNzQ5MQ_939d62f5-4027-416f-a2f9-db772297e97f"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="idf2231aefe254fee96b7aeae2d91ae6e_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfNS0zLTEtMS0zNzQ5MQ_c1a2f83c-54aa-465d-bf92-452033ab2608"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if170fdedc89840ffbe1185f85069788b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfNi0xLTEtMS0zNzQ5MQ_df29fe62-438d-4aca-a38f-3989a2ef5ae0"
      unitRef="shares">6277282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if170fdedc89840ffbe1185f85069788b_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfNi0zLTEtMS0zNzQ5MQ_04fc7efb-42d6-4316-8858-74bf312cd2b8"
      unitRef="usdPerShare">1.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="if170fdedc89840ffbe1185f85069788b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfNy0xLTEtMS0zNzQ5MQ_21699bc3-245a-4eaa-8291-091d46c36237"
      unitRef="shares">2597775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="if170fdedc89840ffbe1185f85069788b_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmY0MWI5MWE1ZTQ1MDQyZWM4MTFjMWVjNDQ2NzZkOTkxL3RhYmxlcmFuZ2U6ZjQxYjkxYTVlNDUwNDJlYzgxMWMxZWM0NDY3NmQ5OTFfNy0zLTEtMS0zNzQ5MQ_cbe8966b-e79f-45cf-a562-ff60eee1a8f3"
      unitRef="usdPerShare">1.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMjI1Mg_dc2f7f9e-d233-4b72-b66b-2748393dc874">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense related to stock options granted to employees and directors recognized in the condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:376.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ied5f9449859d4a96a3953aabaec51ac8_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOjk4ZjA5ZGU0ZGY4NDQ3ZjA5NjVkNjVkMGY5MzBhZTlmL3RhYmxlcmFuZ2U6OThmMDlkZTRkZjg0NDdmMDk2NWQ2NWQwZjkzMGFlOWZfMi0xLTEtMS0zNzQ5MQ_37775cf7-d144-464f-9465-864ea25bb536"
      unitRef="usd">174613</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i29bec700eba84708bf53a7ae61f8afcc_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOjk4ZjA5ZGU0ZGY4NDQ3ZjA5NjVkNjVkMGY5MzBhZTlmL3RhYmxlcmFuZ2U6OThmMDlkZTRkZjg0NDdmMDk2NWQ2NWQwZjkzMGFlOWZfMi0zLTEtMS0zNzQ5MQ_4613bc8a-5cb2-4a4d-bf50-f45873ea26de"
      unitRef="usd">115625</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibafd6f2e17734e039ee794c367b91ef1_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOjk4ZjA5ZGU0ZGY4NDQ3ZjA5NjVkNjVkMGY5MzBhZTlmL3RhYmxlcmFuZ2U6OThmMDlkZTRkZjg0NDdmMDk2NWQ2NWQwZjkzMGFlOWZfMy0xLTEtMS0zNzQ5MQ_055dd0d7-efdd-4d77-8dc4-546d70917d95"
      unitRef="usd">357796</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia79e904977c04b448a641740a5804fd5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOjk4ZjA5ZGU0ZGY4NDQ3ZjA5NjVkNjVkMGY5MzBhZTlmL3RhYmxlcmFuZ2U6OThmMDlkZTRkZjg0NDdmMDk2NWQ2NWQwZjkzMGFlOWZfMy0zLTEtMS0zNzQ5MQ_b51fb7ab-9d9b-4137-b03f-16ff8515c99d"
      unitRef="usd">250286</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if248f08c609e432db641de162429b03e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOjk4ZjA5ZGU0ZGY4NDQ3ZjA5NjVkNjVkMGY5MzBhZTlmL3RhYmxlcmFuZ2U6OThmMDlkZTRkZjg0NDdmMDk2NWQ2NWQwZjkzMGFlOWZfNC0xLTEtMS0zNzQ5MQ_1a0a03c0-6a04-430d-81d6-4788ffbd89fb"
      unitRef="usd">532409</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib6a8c036f5354223a3849ead24935854_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOjk4ZjA5ZGU0ZGY4NDQ3ZjA5NjVkNjVkMGY5MzBhZTlmL3RhYmxlcmFuZ2U6OThmMDlkZTRkZjg0NDdmMDk2NWQ2NWQwZjkzMGFlOWZfNC0zLTEtMS0zNzQ5MQ_43c3427a-938b-429b-8e21-e1fc5c119d8e"
      unitRef="usd">365911</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RleHRyZWdpb246NWYwZTdjNWEzOTA3NGUzYmFmZGViNGIwMGQ2MDg1ODVfMjI1NQ_6430c2ee-6874-437b-9907-b270ee14731a">&lt;div style="margin-top:7pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the three months ended March&#160;31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:442.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:45pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value of options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmQ0NGZlMzk3OGY4NTQ2MGU4MWM2Y2IxYzU0NmUyMGQ1L3RhYmxlcmFuZ2U6ZDQ0ZmUzOTc4Zjg1NDYwZTgxYzZjYjFjNTQ2ZTIwZDVfMS0yLTEtMS0zNzQ5MQ_51533d08-1409-4d51-acb9-8765fff8caf9">P6Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmQ0NGZlMzk3OGY4NTQ2MGU4MWM2Y2IxYzU0NmUyMGQ1L3RhYmxlcmFuZ2U6ZDQ0ZmUzOTc4Zjg1NDYwZTgxYzZjYjFjNTQ2ZTIwZDVfMi0yLTEtMS0zNzQ5MQ_83dbfe75-c0ce-4c43-aa4e-f526c9f529d8"
      unitRef="number">0.0165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmQ0NGZlMzk3OGY4NTQ2MGU4MWM2Y2IxYzU0NmUyMGQ1L3RhYmxlcmFuZ2U6ZDQ0ZmUzOTc4Zjg1NDYwZTgxYzZjYjFjNTQ2ZTIwZDVfMy0yLTEtMS0zNzQ5MQ_b64e912f-9c71-4a6a-a52f-3d9132faa9f1"
      unitRef="number">1.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <dare:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmQ0NGZlMzk3OGY4NTQ2MGU4MWM2Y2IxYzU0NmUyMGQ1L3RhYmxlcmFuZ2U6ZDQ0ZmUzOTc4Zjg1NDYwZTgxYzZjYjFjNTQ2ZTIwZDVfNC0yLTEtMS0zNzQ5MQ_e13e7aa7-f6c3-4b12-920f-362b210840b7"
      unitRef="number">0.000</dare:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmQ0NGZlMzk3OGY4NTQ2MGU4MWM2Y2IxYzU0NmUyMGQ1L3RhYmxlcmFuZ2U6ZDQ0ZmUzOTc4Zjg1NDYwZTgxYzZjYjFjNTQ2ZTIwZDVfNS0yLTEtMS0zNzQ5MQ_b20e1fd4-0e22-4689-9cee-59e733077262"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80My9mcmFnOjVmMGU3YzVhMzkwNzRlM2JhZmRlYjRiMDBkNjA4NTg1L3RhYmxlOmQ0NGZlMzk3OGY4NTQ2MGU4MWM2Y2IxYzU0NmUyMGQ1L3RhYmxlcmFuZ2U6ZDQ0ZmUzOTc4Zjg1NDYwZTgxYzZjYjFjNTQ2ZTIwZDVfNi0yLTEtMS0zNzQ5MQ_25963115-d4c0-4d23-8d8b-fee397daef79"
      unitRef="usdPerShare">1.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMzIwMg_11688a93-8850-48f7-8fc1-513914357068">LEASED PROPERTIES&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease for its corporate headquarters (3,169 square feet of office space) commenced on July 1, 2018. In February 2022, the Company entered into an amendment to extend the term of the lease for two years such that the term now expires on August 31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MBI, a wholly owned subsidiary the Company acquired in November 2019, leases general office space in Lexington, Massachusetts and warehouse space in Billerica, Massachusetts. The Lexington lease commenced on July 1, 2013. In February 2022, the Company entered into an amendment to extend the term of the lease for three years such that the term now expires on December 31, 2025, subject to the landlord's right to terminate the lease on December 31, 2023. The Billerica lease commenced on October 1, 2016 and terminated on March 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under&lt;/span&gt;&lt;span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the terms of each lease, the lessee pays base annual rent (subject to an annual fixed percentage increase), plus property taxes, and other normal and necessary expenses, such as utilities, repairs, and maintenance. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. The leases do not require material variable lease payments, residual value guarantees or restrictive covenants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The leases do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. The Company uses an incremental borrowing rate of 7% for operating leases that commenced prior to January 2019 (and all of the Company's operating leases commenced prior to such date). The depreciable lives of operating leases and leasehold improvements are limited by the expected lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022, the Company reported operating lease &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMzIwMw_e12ce3aa-c3f3-4f18-b044-bf8fda01a7e9"&gt;ROU assets&lt;/span&gt; of approximately $1.2 million in other non-current assets, and approximately $294,000 and $913,000, respectively, in current portion of lease liabilities and lease liabilities long-term on the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating lease costs were approximately $169,000 and $135,000 for the three months ended&#160;March&#160;31, 2022 and March&#160;31, 2021, respectively. Operating lease costs consist of monthly lease payments expense, common area maintenance and other repair and maintenance costs and are included in general and administrative expenses in the condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities was approximately $123,000 and $112,000&#160;for the three months ended&#160;March&#160;31, 2022 and March&#160;31, 2021, respectively. These amounts are included in operating activities in the condensed consolidated statements of cash flows. Further, at March&#160;31, 2022, operating leases had a weighted average remaining lease term of 3.13 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, future minimum lease payments under the Company's operating leases are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:445.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,391,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accreted interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,208,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:NetRentableArea
      contextRef="ia70cb47052db467ab271c5cebe1a8cb5_I20180701"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfNzk_74dbba02-3d73-4f0e-83dc-70a944a944a6"
      unitRef="sqft">3169</us-gaap:NetRentableArea>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i10a03a7421004d2d9b8fe72bbc336117_I20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMjI0_86740e7f-9687-4bf6-bcc7-9504f4ffe752">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i8152258bc79f4460a437ec7e86255593_I20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfNTg3_5f8f640c-6ed3-4f99-b137-bbd0704bdca1">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="ie288d155ad8e4f839c40e7b4157edee1_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMTc4NA_860db538-6b41-4d5b-af3a-388ef04cf4e3"
      unitRef="number">0.07</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i715e356f19e949be97608ee8258262cb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMjEwMA_32e16cb8-32c3-44c4-8071-9b5d6f6cfdaf"
      unitRef="usd">1200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMjEzNg_1c220bae-f134-4e6c-a6ef-c3901ca641b5"
      unitRef="usd">294000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMjE0Mw_ee181927-9c97-40d1-b1fa-78155def5fd9"
      unitRef="usd">913000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMjMyNQ_2edecc1b-8b7e-4a27-9716-27eda28120f5"
      unitRef="usd">169000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMjMzMg_36a547ed-cf8c-4c63-90a1-ac18bb5450cc"
      unitRef="usd">135000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMjc5MA_0615ed0f-c810-44f8-a35d-b0b300a56017"
      unitRef="usd">123000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMjc5Nw_f7e23bae-7853-4d48-9a33-b6fd88e447d4"
      unitRef="usd">112000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMzEwMg_2bdeaef0-bf5a-40e7-9ff4-fa38eedf6526">P3Y1M17D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RleHRyZWdpb246OTIwNDc5ZTVjYjBmNGM1NzlhNmU2ZmEwMmQ3ZmY4ZDVfMzIwNg_706de8ca-da05-419d-ab37-57067e88cf33">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, future minimum lease payments under the Company's operating leases are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:445.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,391,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accreted interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,208,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RhYmxlOjY0NTgxNzNkY2Q5MDRlNDY4OWUxMDY3M2Y4N2NkNmQ2L3RhYmxlcmFuZ2U6NjQ1ODE3M2RjZDkwNGU0Njg5ZTEwNjczZjg3Y2Q2ZDZfMS0xLTEtMS0zNzQ5MQ_074aca47-2633-42ed-80ef-cf9687a44f70"
      unitRef="usd">288000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RhYmxlOjY0NTgxNzNkY2Q5MDRlNDY4OWUxMDY3M2Y4N2NkNmQ2L3RhYmxlcmFuZ2U6NjQ1ODE3M2RjZDkwNGU0Njg5ZTEwNjczZjg3Y2Q2ZDZfMi0xLTEtMS0zNzQ5MQ_b9e596c9-bb5a-4129-8ca8-319f7c72446c"
      unitRef="usd">422000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RhYmxlOjY0NTgxNzNkY2Q5MDRlNDY4OWUxMDY3M2Y4N2NkNmQ2L3RhYmxlcmFuZ2U6NjQ1ODE3M2RjZDkwNGU0Njg5ZTEwNjczZjg3Y2Q2ZDZfMy0xLTEtMS0zOTM4OA_a628ec06-0947-43dc-a09c-5167a681e2b7"
      unitRef="usd">384000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RhYmxlOjY0NTgxNzNkY2Q5MDRlNDY4OWUxMDY3M2Y4N2NkNmQ2L3RhYmxlcmFuZ2U6NjQ1ODE3M2RjZDkwNGU0Njg5ZTEwNjczZjg3Y2Q2ZDZfNC0xLTEtMS0zOTM4OA_9014055c-2dec-4c8f-b167-32405dd33876"
      unitRef="usd">297000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RhYmxlOjY0NTgxNzNkY2Q5MDRlNDY4OWUxMDY3M2Y4N2NkNmQ2L3RhYmxlcmFuZ2U6NjQ1ODE3M2RjZDkwNGU0Njg5ZTEwNjczZjg3Y2Q2ZDZfMy0xLTEtMS0zNzQ5MQ_65379c65-5393-423f-a124-553c3195a7ec"
      unitRef="usd">1391000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RhYmxlOjY0NTgxNzNkY2Q5MDRlNDY4OWUxMDY3M2Y4N2NkNmQ2L3RhYmxlcmFuZ2U6NjQ1ODE3M2RjZDkwNGU0Njg5ZTEwNjczZjg3Y2Q2ZDZfNC0xLTEtMS0zNzQ5MQ_d61068ed-acdd-4322-9bea-197fe92e3f1b"
      unitRef="usd">183000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV80OS9mcmFnOjkyMDQ3OWU1Y2IwZjRjNTc5YTZlNmZhMDJkN2ZmOGQ1L3RhYmxlOjY0NTgxNzNkY2Q5MDRlNDY4OWUxMDY3M2Y4N2NkNmQ2L3RhYmxlcmFuZ2U6NjQ1ODE3M2RjZDkwNGU0Njg5ZTEwNjczZjg3Y2Q2ZDZfNS0xLTEtMS0zNzQ5MQ_550c9951-e865-48de-bf3e-e37437d8d50d"
      unitRef="usd">1208000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsDisclosureTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMzgzOA_3d2f885a-0c41-4cf3-9d33-87d4c099d016">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CRADA with NICHD for the Pivotal Phase 3 Study of Ovaprene&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the Company entered into a Cooperative Research and Development Agreement, or the CRADA, with the U.S. Department of Health and Human Services, as represented by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or NICHD, for the conduct of a multi-center, non-comparative, pivotal Phase 3 clinical study of Ovaprene, or the Ovaprene Phase 3. The Ovaprene Phase 3 will be conducted within NICHD&#x2019;s Contraceptive Clinical Trial Network with NICHD contractor Health Decisions Inc., a contract research organization, providing clinical coordination and data collection and management services for the Ovaprene Phase 3. The Company and NICHD will each provide medical oversight and final data review and analysis for the Ovaprene Phase 3 and will work together to prepare the final report of the results of the Ovaprene Phase 3. The Company is responsible for providing clinical supplies of Ovaprene, coordinating interactions with the FDA, preparing and submitting supportive regulatory documentation, and providing a total of $5.5&#160;million in payments to NICHD to be applied toward the costs of conducting the Ovaprene Phase 3. NICHD will be responsible for the other costs related to the conduct of the Ovaprene Phase 3. In accordance with the payment schedule under the CRADA, the Company has made aggregate payments of $5.0 million of the total amount payable to NICHD, $3.5&#160;million of which was paid during the first quarter of 2022. At March&#160;31, 2022, the remaining amount of the Company's payment obligation under the CRADA was $0.5&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 3 above, in connection with the acquisition of MBI, the Company agreed to pay additional consideration of up to $46.5&#160;million to the former stockholders of MBI contingent upon the achievement of specified funding, product development and regulatory milestones. In June 2021, $1.25&#160;million of that potential additional consideration became payable upon the achievement of certain of the funding and product development milestone events, $1.0 million of which was previously recorded as contingent consideration on the Company's consolidated balance sheets upon the completion of the MBI acquisition and $250,000 of which was expensed in 2021. In July 2021, the Company&#x2019;s board of directors elected to make these milestone payments in shares of the Company&#x2019;s common stock, to the extent permissible under the terms of the merger agreement with MBI, and, in September 2021, the Company issued approximately 700,000 shares of its common stock to former stockholders of MBI and paid $75,000 to the stockholders&#x2019; representative in accordance with the terms of the merger agreement in satisfaction of the $1.25&#160;million in milestone payments associated with milestones achieved in June 2021.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Note&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; Payable&lt;/span&gt;In April 2020, due to the economic uncertainty resulting from the impact of the COVID-19 pandemic on the Company's operations and to support its ongoing operations and retain all employees, the Company applied for and received a loan of $367,285 under the Paycheck Protection Program, or the PPP, of the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, administered by the U.S. Small Business Administration, or the SBA. Under the terms of the PPP, the loan proceeds could be used for "qualifying expenses" and, subject to specified limitations in the CARES Act and under the terms of the PPP, certain amounts of the loan, including accrued interest, may be forgiven if used for qualifying expenses. In January 2021, the Company was notified that the principal balance of its PPP loan and all accrued interest, which together totaled $369,887, were fully forgiven by the SBA. The Company recorded a gain on extinguishment of note payable and debt forgiveness income with respect to such loan forgiveness in the first quarter of 2021.</us-gaap:CommitmentsDisclosureTextBlock>
    <dare:ResearchAndDevelopmentAgreementCommitmentAmount
      contextRef="ifa2f7c9e3aba42cea0f0485646d7bae0_I20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMTE2OQ_dcc85168-af8d-47ef-ac29-d7bbee4bbf4c"
      unitRef="usd">5500000</dare:ResearchAndDevelopmentAgreementCommitmentAmount>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="i39725376a360492eb4ee1a813cb8c93c_D20210701-20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMTQ0Mg_b0f8438b-2465-4d0f-ba75-f8404b626164"
      unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="i0417ba5df1e4483f9533526585cde1af_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfODI0NjMzNzIxMjcwNg_ba5d1b9b-f884-4a0a-8dca-68bf3bf20c37"
      unitRef="usd">3500000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i4de0e117c45544bba3f02be2df728a46_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMTU0Mw_55d946ad-59d7-4e53-bddb-905968dad9d5"
      unitRef="usd">500000</us-gaap:RevenueRemainingPerformanceObligation>
    <dare:PaymentOfAdditionalConsiderationInBusinessCombination
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMTcwNQ_e2fbf94e-cfb7-4cf1-b558-8f6dd726990b"
      unitRef="usd">46500000</dare:PaymentOfAdditionalConsiderationInBusinessCombination>
    <us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration
      contextRef="i0088c2d5b3d841d79733a7ba7eb77c3f_I20210630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMTg2OA_4d4d251c-e6fc-4709-9a39-15e87e18b285"
      unitRef="usd">1250000</us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration>
    <dare:AssetAcquisitionContingentConsiderationCurrent
      contextRef="i0088c2d5b3d841d79733a7ba7eb77c3f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMjAxOA_0bc6205d-95e6-41c0-bfa0-5b1c1a630293"
      unitRef="usd">1000000</dare:AssetAcquisitionContingentConsiderationCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i328c1592bccd48bd90299695bcc0f38e_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMjE3NA_2492b5e5-1ad8-440e-a1cd-19e344d8d9ca"
      unitRef="usd">250000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i3b39b4e982ff415dacb98beb58f1a039_D20210901-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMjUyNw_eda7055a-81ca-4b93-988d-681ed83e8bc3"
      unitRef="shares">700000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <dare:PaymentsToStockholdersRepresentativeInBusinessCombination
      contextRef="i3b39b4e982ff415dacb98beb58f1a039_D20210901-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMjU5Ng_e50254d8-3235-4c13-9c98-8bac6b572bbe"
      unitRef="usd">75000</dare:PaymentsToStockholdersRepresentativeInBusinessCombination>
    <dare:PaymentOfAdditionalConsiderationInBusinessCombination
      contextRef="i4e1024a3a3274602a0b50c48b9aa2f4a_D20210601-20210630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMjcxMQ_99e6e2f5-99bc-4dd4-91ef-1479437123e2"
      unitRef="usd">1250000</dare:PaymentOfAdditionalConsiderationInBusinessCombination>
    <dare:CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived
      contextRef="i1668c60b90eb40c1b26a55cdec6001a8_D20200401-20200430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMzAzNg_634c72e2-481e-4278-b958-6a9f542552c9"
      unitRef="usd">367285</dare:CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived>
    <dare:NotesPayableCurrentPlusAccruedInterest
      contextRef="i2bda66626a774b0baba97582a51cae04_I20210131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81Mi9mcmFnOmExNTQwNDk2Mjg2NDRjZTk5NWQ1NGUwNmU1Nzg1MGE2L3RleHRyZWdpb246YTE1NDA0OTYyODY0NGNlOTk1ZDU0ZTA2ZTU3ODUwYTZfMzY0NA_d0fde9b3-0b0a-402b-8e5e-b3e2418fcccf"
      unitRef="usd">369887</dare:NotesPayableCurrentPlusAccruedInterest>
    <dare:GrantAwardTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfNDI5MQ_593f79a6-ec67-42f0-ab09-8e883165d3fb">GRANT AWARDS&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NICHD Non-Dilutive Grant Funding&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has received notices of awards and non-dilutive grant funding from NICHD to support the development of Ovaprene, DARE-PTB1 and DARE-LARC1. NICHD issues notices of awards to the Company for a specified amount, and the Company must incur and track expenses eligible for reimbursement under the award and submit a detailed accounting of such expenses to receive payment. If the Company receives payments under the award, the amounts of such payments are recognized in the statements of operations as a reduction to research and development activities as the related costs are incurred to meet those obligations over the period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Ovaprene&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From 2018 through 2021, the Company received approximately $1.9 million of non-dilutive grant funding from NICHD for clinical development efforts supporting Ovaprene. All funds under the final notice of award had been disbursed as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;DARE-PTB1&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company received a notice of award of a grant from NICHD to support the development of DARE-PTB1. The award in the amount of $300,000 was for the "Phase I" segment of the project outlined in the Company's grant application, which is ongoing. Additional potential funding of up to approximately $2.0 million for the "Phase II" segment of the project outlined in the grant application is contingent upon satisfying specified requirements, including, assessment of the results of the Phase I segment, determination that the Phase I goals were achieved, and availability of funds. There is no guarantee the Company will receive any Phase II award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded credits to research and development expense for costs related to the NICHD award of approximately $17,000 during the three months ended March&#160;31, 2022. At March&#160;31, 2022, the Company recorded a receivable of approximately $19,000 for expenses incurred through such date that it believes are eligible for reimbursement under the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;DARE-LARC1&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company received a notice of award of a grant from NICHD to support the development of DARE-LARC1. The award in the amount of approximately $300,000 is to be used to explore device insertion and removal in non-clinical studies, which is to occur during the period of September 2021 through August 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded credits to research and development expense of approximately $165,000 for costs related to the NICHD award during the three months ended March&#160;31, 2022. At March&#160;31, 2022, the Company recorded a receivable of approximately $173,000 for expenses incurred through such date that it believes is eligible for reimbursement under the grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;DARE-LARC1 Non-Dilutive Grant Funding&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;MBI Grant Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's wholly-owned subsidiary, MBI, was awarded $5.4&#160;million to support the development of DARE-LARC1 under a grant agreement with the Bill &amp;amp; Melinda Gates Foundation, or the Foundation. The funding period under this agreement ended on June 30, 2021. Expenses eligible for funding were incurred, tracked and reported to the Foundation. MBI received aggregate payments under this agreement of approximately $5.4&#160;million. At June 30, 2021, all payments under this agreement associated with research and development expenses for DARE-LARC1 had been incurred and reported to the Foundation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021 DARE-LARC1 Grant Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company entered into an agreement with the Foundation, or the 2021 DARE-LARC1 Grant Agreement, under which the Company was awarded up to $48.95&#160;million to support the development of DARE-LARC1. The 2021 DARE-LARC1 Grant Agreement will support technology development and preclinical activities over the period of June 30, 2021 to November 1, 2026, to advance DARE-LARC1 in non-clinical proof of principle studies. The Company received an initial payment of $11.45&#160;million in July 2021. Additional payments are contingent upon the DARE-LARC1 program&#x2019;s achievement of specified development and reporting milestones. At March&#160;31, 2022, approximately $9.7 million of deferred grant funding liability under this agreement was recorded in the Company's condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</dare:GrantAwardTextBlock>
    <dare:ProceedsFromAwardOfGrant
      contextRef="ia85f04efe0484874ad1aa6775fdee9cf_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfNzQ1_098564c3-651d-4f73-93cf-718e14c69dae"
      unitRef="usd">1900000</dare:ProceedsFromAwardOfGrant>
    <dare:ProceedsFromAwardOfGrant
      contextRef="i8dab52c413224c10ab210ce9f3988ef2_D20200801-20200831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMTM2MA_ecf880cb-7982-4a8b-b053-cecf7579fe1b"
      unitRef="usd">300000</dare:ProceedsFromAwardOfGrant>
    <dare:AdditionalPotentialFundingRelatedToGrantAward
      contextRef="ie5c7aa9a64ff4a88b42de5c106336b62_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMTU0Ng_f3d91a71-6390-4cbe-a04e-8a9330672aa5"
      unitRef="usd">2000000</dare:AdditionalPotentialFundingRelatedToGrantAward>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
      contextRef="i18d65ffa0cea435eacda2d0f47db2080_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMTY0OTI2NzQ1MDA1OA_751a1cd3-1916-4b3b-a0f7-f8eaaa0a4ab5"
      unitRef="usd">17000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <dare:ReceivableForExpensesEligibleForReimbursement
      contextRef="i2a168cd74d64472ca8597b5ad0dc79dd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMTY0OTI2NzQ1MDA2Mw_d7de227a-416f-44b5-83aa-1e96cb643989"
      unitRef="usd">19000</dare:ReceivableForExpensesEligibleForReimbursement>
    <dare:ProceedsFromAwardOfGrant
      contextRef="i33bd9119af634fbe93377ca5a92bc751_D20210901-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMjQwMA_328ab36c-d38c-4ff8-8134-cdbe2fc2a611"
      unitRef="usd">300000</dare:ProceedsFromAwardOfGrant>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
      contextRef="i316cb86d094b4f0ca01c73b2980e9033_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMTY0OTI2NzQ1MDA3NQ_c10503b0-5d12-439b-be98-8864c05d2e8e"
      unitRef="usd">165000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <dare:ReceivableForExpensesEligibleForReimbursement
      contextRef="i45c466b7177d4d4c87ff8c12edc1f3ce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMTY0OTI2NzQ1MDA4MA_e3fd26f1-4ee4-4392-b7dc-78494941e7f5"
      unitRef="usd">173000</dare:ReceivableForExpensesEligibleForReimbursement>
    <us-gaap:BusinessDevelopment
      contextRef="i316cb86d094b4f0ca01c73b2980e9033_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMzA2NQ_2e95f632-18d3-4147-bef2-a2ebcb70f6cc"
      unitRef="usd">5400000</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="i316cb86d094b4f0ca01c73b2980e9033_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMTY0OTI2NzQ1MDE1MQ_2e95f632-18d3-4147-bef2-a2ebcb70f6cc"
      unitRef="usd">5400000</us-gaap:BusinessDevelopment>
    <us-gaap:GrantsReceivable
      contextRef="iaeedb8a01d9247389d7cf8d46e7e6514_I20210630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMzY5MA_8b7d1dc5-9c8b-45cf-a0a3-9b419159fa6a"
      unitRef="usd">48950000</us-gaap:GrantsReceivable>
    <dare:ProceedsFromAwardOfGrant
      contextRef="i010eed1efee345f4bd75243e4aa2a9c3_D20210701-20210731"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMzk5Nw_85cb04b5-cc4c-4461-97d7-0d54702b0efd"
      unitRef="usd">11450000</dare:ProceedsFromAwardOfGrant>
    <dare:DeferredGrantFundingCurrent
      contextRef="ic0c2931b38c749a8aac31ab58ed72510_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV81NS9mcmFnOmNkNGEyNjYwYTM0NzRjMDM4Zjk1MGE2ZTEzNWQzYTlmL3RleHRyZWdpb246Y2Q0YTI2NjBhMzQ3NGMwMzhmOTUwYTZlMTM1ZDNhOWZfMTA5OTUxMTYzNjU1OA_c9376d96-f953-4ad2-8097-5fb3f659d8ec"
      unitRef="usd">9700000</dare:DeferredGrantFundingCurrent>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82MS9mcmFnOjJlYjJhNzM2ZmJlNTQ5MGJhNjJlMDUxODE5M2QzODU1L3RleHRyZWdpb246MmViMmE3MzZmYmU1NDkwYmE2MmUwNTE4MTkzZDM4NTVfODQ2_dcc3a8a9-bc1d-437a-bec5-808038701bd4">NET LOSS PER SHARE&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company computes basic net loss per share using the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under outstanding options and warrants to purchase shares of the Company&#x2019;s common stock. Common share equivalents are excluded from the diluted net loss per share calculation if their effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:367.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:66.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:66.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,277,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,311,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,381,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,856,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,658,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,167,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82MS9mcmFnOjJlYjJhNzM2ZmJlNTQ5MGJhNjJlMDUxODE5M2QzODU1L3RleHRyZWdpb246MmViMmE3MzZmYmU1NDkwYmE2MmUwNTE4MTkzZDM4NTVfODQ5_5f9dc5a2-5b51-49a5-acd1-358173ffce66">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:367.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:66.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:66.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,277,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,311,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,381,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,856,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,658,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,167,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie858a3b9009b46719e1b0cd4afebc54a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82MS9mcmFnOjJlYjJhNzM2ZmJlNTQ5MGJhNjJlMDUxODE5M2QzODU1L3RhYmxlOjZjYzBmMTVlMjJhODRmMDZiOWJmZTk0MDAyODk2OTMyL3RhYmxlcmFuZ2U6NmNjMGYxNWUyMmE4NGYwNmI5YmZlOTQwMDI4OTY5MzJfMi0yLTEtMS0zNzQ5MQ_bb0609ba-ae24-4bd7-8e85-d44a94bfafcc"
      unitRef="shares">6277282</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4385c5c549b145f4b28516d3328b7fae_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82MS9mcmFnOjJlYjJhNzM2ZmJlNTQ5MGJhNjJlMDUxODE5M2QzODU1L3RhYmxlOjZjYzBmMTVlMjJhODRmMDZiOWJmZTk0MDAyODk2OTMyL3RhYmxlcmFuZ2U6NmNjMGYxNWUyMmE4NGYwNmI5YmZlOTQwMDI4OTY5MzJfMi00LTEtMS0zNzQ5MQ_99afb26e-593a-4c41-a07e-a0d87777f880"
      unitRef="shares">4311291</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3581e3652c314104b3dfff05b889fd6e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82MS9mcmFnOjJlYjJhNzM2ZmJlNTQ5MGJhNjJlMDUxODE5M2QzODU1L3RhYmxlOjZjYzBmMTVlMjJhODRmMDZiOWJmZTk0MDAyODk2OTMyL3RhYmxlcmFuZ2U6NmNjMGYxNWUyMmE4NGYwNmI5YmZlOTQwMDI4OTY5MzJfMy0yLTEtMS0zNzQ5MQ_d113534a-cd18-4cfb-97dd-b9cb01f52164"
      unitRef="shares">1381015</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i13cb5e160bd84532b3e28a94c5995894_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82MS9mcmFnOjJlYjJhNzM2ZmJlNTQ5MGJhNjJlMDUxODE5M2QzODU1L3RhYmxlOjZjYzBmMTVlMjJhODRmMDZiOWJmZTk0MDAyODk2OTMyL3RhYmxlcmFuZ2U6NmNjMGYxNWUyMmE4NGYwNmI5YmZlOTQwMDI4OTY5MzJfMy00LTEtMS0zNzQ5MQ_ea2fac58-7f1a-4cbd-b9b4-2c9e2f5e862a"
      unitRef="shares">1856143</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82MS9mcmFnOjJlYjJhNzM2ZmJlNTQ5MGJhNjJlMDUxODE5M2QzODU1L3RhYmxlOjZjYzBmMTVlMjJhODRmMDZiOWJmZTk0MDAyODk2OTMyL3RhYmxlcmFuZ2U6NmNjMGYxNWUyMmE4NGYwNmI5YmZlOTQwMDI4OTY5MzJfNC0yLTEtMS0zNzQ5MQ_4473c806-8b67-48f7-9c19-49b181951d22"
      unitRef="shares">7658297</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i828cf9ede1974e24a95f4e4392e1e310_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82MS9mcmFnOjJlYjJhNzM2ZmJlNTQ5MGJhNjJlMDUxODE5M2QzODU1L3RhYmxlOjZjYzBmMTVlMjJhODRmMDZiOWJmZTk0MDAyODk2OTMyL3RhYmxlcmFuZ2U6NmNjMGYxNWUyMmE4NGYwNmI5YmZlOTQwMDI4OTY5MzJfNC00LTEtMS0zNzQ5MQ_ac0bbb7e-f1e7-42b4-81e0-c337fbd1815a"
      unitRef="shares">6167434</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82NC9mcmFnOjNmYjI4ZDNjM2E2MjRkYTY5MTRlYTY5N2I1NGVkMDI1L3RleHRyZWdpb246M2ZiMjhkM2MzYTYyNGRhNjkxNGVhNjk3YjU0ZWQwMjVfMTE5MA_f088db69-8c4a-45f2-9fe2-75b6ade8d475">SUBSEQUENT EVENTS&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Between April 1, 2022 and May&#160;10, 2022, the Company sold an aggregate of approximately 751,000 shares of common stock for net proceeds of approximately $1.2 million under its ATM equity offering program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commencement of Phase 1/2 Clinical Study of DARE-HRT1&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2022, the Company announced commencement of its Phase 1/2 clinical study of DARE-HRT1. The open-label study will evaluate the pharmacokinetics (PK) of two versions of DARE-HRT1 in approximately 20 healthy, post-menopausal women over approximately three consecutive months of use. The study will also collect safety, usability, acceptability and symptom-relief data. The study is being conducted by the Company's wholly owned subsidiary in Australia.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i4b95783721914c71aa6fe27dd4fcf58c_D20220401-20220510"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82NC9mcmFnOjNmYjI4ZDNjM2E2MjRkYTY5MTRlYTY5N2I1NGVkMDI1L3RleHRyZWdpb246M2ZiMjhkM2MzYTYyNGRhNjkxNGVhNjk3YjU0ZWQwMjVfMTA5OTUxMTYzMDgyOQ_362909ba-2a19-4b16-9601-10dcbe485070"
      unitRef="shares">751000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i4b95783721914c71aa6fe27dd4fcf58c_D20220401-20220510"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjYzQ5NGM0NTBlMTQ1NzI5YjA2OTViMzdiOTUxYTBhL3NlYzo4Y2M0OTRjNDUwZTE0NTcyOWIwNjk1YjM3Yjk1MWEwYV82NC9mcmFnOjNmYjI4ZDNjM2E2MjRkYTY5MTRlYTY5N2I1NGVkMDI1L3RleHRyZWdpb246M2ZiMjhkM2MzYTYyNGRhNjkxNGVhNjk3YjU0ZWQwMjVfMTA5OTUxMTYzMDg5Nw_51a3e38c-0d82-4733-bcfc-b350511c6239"
      unitRef="usd">1200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>54
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MN2SH.>!AN\_P'^T3S4N9(^B;2+R*,DY5;0'%6O+B,"EAEQ3*,+9#C5JHT7\
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MI2':'60G&_"]<*"DG\@!VR?ZR9]02P,$%     @ :8"L5$$RW\JD%@  2T0
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M;%Q8A%]X&QFKQ:.O+(% *W#CK\N0@JC\.B]@#\7*>A;R:0M VJRX6YMR37A
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MPO?DL-"HN*/>N,>Y_6KZD.TY;D@('!@F,A?%VP 58N-K6&VB>(K11?0:+$>
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MG:^)!8!8PA#(:VU)C _,0V\'RUUX&)_\P#T,W==P^C-:/5[NKY"R-#G8E<^
M/+R$TW@K[4TO\^7*&(>PH6+9[4/$WK9$5#BY*,#C-U\-L'E QT;]&*K' X1D
M]-J<<U+?9U^%#&_ZII-BWJ49$,2SV\Z,^ZBP%QYOPX?[.L>%Z4IF,3PL<S,H
M'#M+!Q"QDK_A[S@I.XBC%\[N>0MG])[3SJM:!.R#K\EMJ0-G,H-2+NOGY.7M
M:1$%"8:V'W*5K6_]3M^_+XL#Z^BE03J5E$V2#%AA-Y0484+[T$-'K9XP/1A;
M01+=8E!S&V8PV/HY@"W^[*L51\*='6DS]QWJG118Z(QC5:.IC$)_JLG#>%F
MT\2%VG<FO;6].\!D.-?(9^D/W&,7(E__RFQ0^2"M0 "DPR$330QJ]4JUH26@
M";=!0.S?,3PYQ.UY$8/VHGB(V)$4E3.OHI7B"OA-L+Q(GAVD<>S.SGG8Y/:M
MIM$$C"_(N/N8.Q290:$EQ)!1H[B"1/F@\2F^D<H,%\_Q"]D\%XH9QS>J8C0*
MG*FD5,-E"WO'\_Q^]#W,1!ZBC-[H\UIP=#;&_2\ZS4/@H[:2+$4%2DQJ98Y*
MB>AE</ R]%C<4X=_\HRKIIAC9.29-$_2HA&1Y,\DNX\5B#T=Q0A,5HT.+MP5
M(_&A+ CDY@)3OD'"3C0B.*Q+<VS2Y8M>U_9=F'XCHJ7LD96<L[K>P3*SG[$K
M_(R=SS+#_(S,+N35<=3,H:!U,I$P]8(TMM&2D;<Q>L]"]$%UXNEHGF9&[N"8
M>$H'Y3WS9[D]S0;M_Z8Z'52^)V9:Q WN==VE:\D3N,.!%7K_'_[R5UJGRF"@
MZ$"!!07>&F%2+X/1I.^H5:2>HV@::5YP5UG]BMW;0;<N88?QW]K)/.2@)[(7
M _I&^CZ+A</@[+Z["J^,7=_P ;TDQ))M6AXBI-1'"Q\ HWWEM/>#F0O=Z*7)
MWNW/EO9E5.(%D5J'25//&HE=1QZL[TS-#\Y=DT0->0/**R$IR8*E\"T8&4*.
M;]F8^^6$EZ$H/X)4AA("F;ANMM> WM#5B'&6OECCY_8%7N%&MWV[M7X\.(A=
MQCT%.[\J]D,N)*MY^?$GN91=2\M?.V%BY!LUX2GQFT$S7Z_=/RACG#@U&6>9
M"/+O&4KDODAR"WFGEAZ59@_?!U,7O1HB%W_](HR_ @*.96@NXD/>0YT8D%OD
M4S92@\.H TY*@T&Q3I];3P4 #Q@@!4Q=631"H!Z=WJ1DBN/&"%C"K:]9>^&_
M5X.U/(Z !"=:<>"X1SW,/7.UB?.:N.JP90A=HW9-(E,$)%WKB"CQHV0=#WQC
M0<I0\?.'WR?U<&>4^#OOU&YZS(A1I')0Y"I "<O)C\$YWI8/_"V'3L4O"!SV
M\WD1^A'6M1+J(,U(WZ/,OCZ'@LEV(MV(28X)GC8,6F"PS3#)L<;/;GV$U&)1
MM-O966H-^1)_J+L30N';7-Q=_Y8D*$%" $()BO;J[FJ5M80R2_,Q=ZI(FY'I
M5!H1S;#U";]F:[D%29/XO" 3@"GR,Z#H@@.QU!X8>:.3%&Y)H2ZJCWQ-K<4W
M/:1(9X9M/Y.R:+55I>F\6H0G\W!;X[\P\ATGH**R$KY\CZ('TQY]_2*P).AE
MINXGQ>ML%G8N&ALS=)[  )AG6T!N@IWL&6&6U[:I8.OM:-"F5?4@)CL0CXU\
M][Z&$5E&WX;1E6SXT0?CWI D7_*SURDSRW)S0=AQ!VX_BY0Z)U^&[E%M/F'6
MRA\B3IB#/U']>*^4$T;CQ,&/D5=W:-AS(PL2]5#K:]A!BLFQQ!;,5^G-))O<
M$:[(BMJ#QBN,*?4^?"N)F:Q#K#ZTM$15/IZ7!IHYCTNI HMZ8A9W%ML:4V+#
MUS0UIS1"2E6@%5D?)(49Z+[/;M+NX"*F_G&!T^P?>.!I ?PS%OP]F::3?^LA
M?AK_I8RY_ ,1:;G\,QNO5;LRA-FU7M+6LY.??CP2L Z_=';+_US$PG:$4/PC
MOLNC6RR@O^-[Y.$77!#__9 7_PM02P,$%     @ :8"L5$$U\QE7(@  L'P
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M[6L4X5*($0\XT(^A:/=C8<@EXIX,C_@!HY^^"L6JQSR?<QEKW &&:^"VHXJ
M*=CT='P=>OV2+(Q+NRR A4'\\P!V)RU_^V+??"?M1<^L= /Q_!86@LH;='S3
MFE"+1?YI[H.8*%*@SVX:H&;<L+4$7Q768_47U%;E+?B0M6>OA_"&/-!JQWF@
MK=?4HCF\\B*I>DS'51 #8N!3&DL8GJ_.?6-T15CW'U@(!H3VW-<U6Y(=5V\I
M#NU'4Y6Z5N"<9E<PWR;/+F9/_H*G9+ 3W=A0$4QHQZ&.7:03YB<X3.(YJUN.
MOM!W2.JM?>H Y4$<2!L6A&.A9:#6L5:C)XW16#I&)>T8:(Y6>(D&8]E5PY:/
M_0!:S<YCP*N8G!37C\<BEF/DH[X=6Y]9]/#I4M=NJ[1 . -SS:5K"'*[9X;E
MW+X5_VOB3-051XCV<U 6KL3X]YM:MW9MML-^6MR-C2[.,>X5M" E94>HJ1J,
M8W.K4:IQ]J]YCYJFL&J1Z]6:&VSSR1Z#KPP:P"!4,L#_0<K^E)9 -_8L^X4^
MB5L(KIP1XZVY<AK!?1QE=(27\*BQA?6&,/+L?;$8)PZ]QFNHJHBR,B!"N:@.
MK&!!MD' R[J>Q'@*YVI@X7+DS(XYZ[-X?]^._8VRG;.^L9X@JA?8;<@-[IR2
MV/%$?'B?-$*,U)L<.>W!7BU%M^CX+1*3U.*.Z2_R!U_(P!^-U&$AU[KT3=QL
MN]PYJ BHQ%9!JB3E-\;/:K=F$N?R[8K@G!I)=0PNUAD)4T,)J>7FI]U8=9*D
M7&KIVO0DX;4Q9=J_]PTM>,>TWXW!7(?(X4OB, 9I5;TB= 0QU?MG$:[,U_?L
M@YE\OH8NZ#B0JDE@(JZY<JV='HH*J0H7X:=7.-&2SO9"7U$6*5G5]'U#$!PO
M=YTZRSY=4$,QRS8M]7Y#Z,.5B*A;1-_;;-!$OL,_>0R CK2R^H[[DJO*X#CC
MW-'0N74L\0V 0R@3=<!Z[&/LKQ8=;F_LKK+I6MBT_#7I-=P9>%23#:NG?-%3
MA&N<[%X,0H4R9!$*X,\V5+SL8%UK15>));5(=RXD.ISIC8K1)A5.](R_Z0CW
M@:%<2![0*3/#R/Z_&?T!-<% C%,B<E^=@QDIU(WQQ[Y;@R\/^PYQ_7* MX12
MO,F3!L/(EHF\PKB^,7;8?\,<D*QDT)1P *4*Z!0IC6=[,2=42L%I_/]+A?GW
MAZ&WBQ.R,0=1P*AN[0"//[ GTUS^ +CPA%=W,5J6,P&R'>NW.6]CRBG!DJH%
M0G+4ESUTV$;!(TIS-J2(BK[5*8*Q6ZH6L1,0]COKZXTX^IIE5ZKC2VU^^>W]
M> [^$LZK.HA0''$K:#P5I^2S!T@>W0(!?</A+WUM,/$\T<;++<J[",,2#2M?
M3>/F.4D1"3]]G.IW TAW\30Z<;#O-#$X/LT+FV*O%1N]W.!55&L+2W8+R]VE
M/3G;!HR^I!F>_D9H*I<:/OK -HAC2(,\WUJ P3#]/5G:$S<[)_K]F"T[UI<]
M^\(0J3[B6Z1)\;A]>ZK_*_:V$W_HZ(J1R,G%DQ>C--YB@:%[U  ME^.\T8,(
MAQ*I*K3D#6[]=)?JQ)=71><]UB/&#H[K0QFYFX;CB'<*O8&:=,7.JGPF3?D.
M++>"3?3><#54RDV%%#N7NDT 0_0G%9-$^64)#URGIJN 8U\/K\V2ZQJQ2,K5
M4I$VHHKB6,#=4!%%U0K!BKC7+-SWZ]U<\6YC,E-4I38ZO<2$H"*T-:A-<2+5
MMH;[<V[D+J@ ?.$+P[91J0GAO?GY3:0SGQUNI>6*';RK:^<:N&%N?!!@A"FE
MALL5&%RD-[8>%\<<C*[RM ?3'_E"%TA:5PDH$W)+U-][\/4X%L!J@UQJ0T=M
MW4@M2\1A;GBZ=(N"65=YZ=E(F'W Y+DT@,E=.(J"\,"V]Y^=10W096B2W+.!
MJ%SBXFQV\8^,&4-+\$@--H4QH<I\IW7B*%0CNVLKJ!>D#<0H7],&.M'_.='(
M\E6;?(N)3MW[X+$=M!$>VMI13<"1!9%^X)$L1[@P(GH</3&V-V,9_6$'\#^N
M\_5?T/#ZK^YS]1GHR5[7T9ZNHYI2_GF-K;F/;^A^'<ED8,.$;TI-FO"GAL6>
MSB3P4-?@^SN]F\X(GIW>=HR#<R##2<Y:2#*8V G<_ S(1^;Q&!+LS-KA_H::
M95B"+%PP/SNEB49<CJ-F^]:FT@%X0D8XZ>4<.P%/< D^MR3F3D+=T.X6_J#\
M74XJ*TUE5I1J32XW!O*'1TA60@'3$*@_L@US]*:O.]T[/G:[U]<)[($V\B$^
M>&>-D_+%)'J'I+K=C^%-]26B_$A N;?7D!"]4RZRC+H%W8!1S+T/YV!_;A*9
M&'26>-"VQTP)6L]6R_TY'*C(176APF;$$+$&G,(\R*WBDFLIDP$3T4LW,VHV
ML\$J#]@)D,'W& S79_#BRFO@_EN'YX+42?VCJJ7UB-;J=NAN])PHP>#HH&FM
M%$5AJT3]N>VW78&78G.7OR]+IU$Q$26!1#2BD^#X'>28TMB-L5;[BA.!\YB)
M'YTD=64CI\1-K'PJKCG)'<]NNZ#\;VRG'(=$UQ".NT)IB#+-8/L%WZV<M28N
M=&5(C3D8;[!3="C&6]O,2$^E5/B/8;^A'3 N-J6L3MRC?T+)E8 N! \CW:7C
M(ME'J"NCD(?023Q#JC(;*:N;&C</4P<P'P6?ZH2MS=*Z#]]'XN[W(<"**Y:K
M4#.!'6S^#H4T&!G5Y&S:;4!;HJ7/LLL2O857@QCR]^UN'9)OLSD:XAM&ILUV
MK!B)5\!(7O:QJ7IFVQ'4+W[28WZ\WG8!.WQI&LOU2?8H#)#&.\E#%V><8UOR
M[;N(Q%),B$E4]@L@!&M6X)BV>EB02?MY<LI5P>>G_,,2<$ BB0]@(]%N7EU^
M>'UZ?O9(ROKHK_FCW'FEA &>L*CNW"F?=B3+S4&.P+ [=XV\/@2Z^LM16ZR&
MVM@=S0[JPTHF@,L9)UL,J)D&^(O(.LO>O7R;7>+U?)8U);#0;_AK/>Z>M8F+
M_%[A&;][.8!^L9V] #M.*4XX9P05&>T](14+D^7<ID. =X3=Q>Y;<J28Q&ZY
MZB"]&%7NO>'K4;#2"^O>L22S;^FW = X+)?9&BL_*NQR)YB"A+#)!,^% ]!4
MWKVF@L&ZI&N8V5I$/$"'_NOEAZLY2"(;&O>+34Z. P53@H&UZ;E:+LJ(2S[H
MB]FPA;V(H!@+<L,QM>FX.10_[+ -S]T%V%2EYF+=\#!0%F^55EO3414LM>WU
M'28D:,^Q0?>JFEP_7S+&]YE*>Y]N5UHP,NH3E-^J0L2&KIBA2U7NG\\>A5OE
MDWX2<#5:N8S&D>C0EAVI.JPP>/J,6M;HJSSJ=XEISS\,XA\;V-KO!M23A3FG
M5 ;A+<H*;CBJHF7P'5QK5:_8] .!@Y^B+#>IT3_"KPG02=Q_$OI7\XQ\>H1*
M*J/<;ZC04S&NYWNSA<I<-8-/G9^=(Z 54P"+:@NY+#PB.!44X#&.4-YBN4A\
M":=KI@Y+XA]]*5.7@R[2"TW<U-&QCLOBHAH%O,8<-)[XZ,)<K!=(Q] A".L^
MIQR-H&Z/GD24X%!FA7K*NYV3C5.H]*C8U-O<8_J/7E#"Q%T'^#CBPSM-[CHO
M49B]9(]C8@@PM5NJ!!078*(IW!W0P)44GXEE\@5=NIT4*T4W;"6%.@B#'<3X
MCBANB@&,J5(E,GAT7QV.B&5[I+SW%3!)GK@\Y@KQN%XF6<Z 83VO'@D9R/$>
MUXT7U1BRM+$MB:T#6,]?^EH[?#GJN)_/SA_'>#M?_.2S!).2-$#DIQC3P=$.
M<NFE/S@ A^-M\%(</Y4/0(43_]1!)"+I,M,0D7_@8.)G#:(+_G<;U5%51,8T
MF[X#5 H*HR9\(GYU*\0?"[NXVP"&X99=C#3I5V?=Y6>?78?J2%[&Q+9Y-'J-
MK$WNS>L7OI$.9<*R&Q,BO:1^F,5[Z':3QP1$H.KX] ;;<4<CL;)/)1^RWZD0
M+1UK:'$II$/7T"4([DI8,GJRO?@=%RMB[;S[C=;KT?+5PWM'8@]^(Y/30[$4
MF8D?,+1-8<*-Q?%O!LK/+%#+HQ/3&9!5@\\+ZOOI+'N/&.8G[(@:.,7OU%AK
MA^M/DJ;KZ!58<1AK^AYS_\Q D3E3$,8X[#;'MSB[5K1!/T$'9NN+H=+W70_W
M;W^[G.=2Q.\54VASH ME^^I:\<^VN!E4!].N;X^X\"-D1R,U$E^]Z)18V#2;
M@:;U/VPWQJ@1C5"I@L9LAAISTHR/_:[3L/D_3INR_I$V+I2,W)GGH3K8^5$G
M)SI->P=%,AO[ >.'T:](D^C@;V5;!H#X!Z7]I_[GN"_Y5ZC#X_Q;WN]42^FA
M2B_A5?"[']]CWG)_=,V6?I-ZT71@ZNF?:ZV ]/@ ?+]L@%7D#YS _TCY3_\'
M4$L#!!0    ( &F K%0J_)?C#0D  /0;   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;.U9;6_CN!'^*X2;W@N@V+(=)[Z])$ VR6+W+MM-U[MW*(I^
MH"7:9D.).I**D_[ZS@PIF7)LWQYZA_9#@2"V)'+>GV>&UOE:FP>[$L*QIT*5
M]J*W<JYZ-1C8;"4*;ONZ$B4\66A3< >79CFPE1$\ITV%&HS2]'10<%GV+L_I
MWKVY/->U4[(4]X;9NBBX>7XME%Y?](:]YL9'N5PYO#&X/*_X4LR$^US=&[@:
MM%)R68C22ETR(Q87O:OAJ]<GN)X6_"3%VD;?&7HRU_H!+][E%[T4#1)*9 XE
M</AX%-="*10$9OP29/9:E;@Q_MY(?T.^@R]S;L6U5C_+W*TN>M,>R\6"U\I]
MU.NW(O@S07F95I;^L[5?.P*-66V=+L)FN"YDZ3_Y4XA#M&&:[MDP"AM&9+=7
M1%;><,<OSXU>,X.K01I^(5=I-Q@G2TS*S!EX*F&?NYPYG3VLM,J%L5^SVU]J
MZ9[/!PXDX_-!%J2\]E)&>Z2,V7M=NI5EMV4N\N[^ 5C4FC5JS'H].BCP/3=]
M-AXF;)2.1@?DC5LWQR1OO$>>=XS]_6ING8%*^,<!F2>MS!.2>?(?ANZ@% 3=
M*UOQ3%ST %56F$?1NYQ]^G#]X]L/=S>W'V=?_6DZ&IY]SV[_^OG=I[^Q#YG3
M<V$P,$-V]>D]FW$E++M:&B$ +(Z]*SMK$N96@EWKHN+E,X,%PHB<R=)IQIFE
MO;S=NY9NQ68_O69W0AA9/K"[NVL&*P%%BMD5!P.97C#I+,MT40"J+ :!+8PN
MF .PXF+_N3*Z7JX8+UF/NV.PX1A _R!<TF/:H.$)$SXI>K% 94M6&;TTO& U
M%)%AZY7,NL9 WL!8&SOT-5H/EO?9I\A+<BA'6RH.5V2KM,0CH),K?#+^,WJ"
MHI9&6XO*,]A$_J&,CG\6LAS,PAUMP!)6J1IB(8P#_F-*+$&X> +&M,+VV:R-
M6-?D+Y(-R8"@SP4#RVOPIJJ-K3G<QQ!WQ 'ZU0(8<BFQN(GLK./.2X$+I"\V
M.QZS;]Y()=A?-$!K/#X>34ZFIZ-OP=N<!"*Y81AL!8P)7LDR4W4NZ*$1LDP@
M<7(I2Z[4,UN I-S7"^Z=W5ZC)H MY&R<)J'T4'0N,L6QY@3DF3@85UY51BIV
M%B]$.9%Z6U>5\C[DX$S>5O5P['>!QPJ\A<()$6D+"0)>5WCW:)+V4Z!-I3 H
MD"'[)1EIDB'M-D"\H5@>MIY;J"6T;K?-.P)$]OJZ).&(WCT8Z+.;FJYQ+V!)
M"%9XAA7(L$V@ T%V,4X%5>K&U\B;UH]^B/\A$MFL^.]3R.]/%Y];P+U(<>QL
M ?Q!^*/$DP^[*@L<VN_:_R8W76&E_)^??D=^ZFS98X!?,_5K_G"0C]+A=!^\
M?^!E#5.X7W, W]U:V 7VM_WK/OL9:FQM< 1F7_&B^A[$]1/$/F8E>IKL9VU"
M&"@XC*8=1 '5[3EB+T4T5!+;@><!U+HA^2UBB) 4>;?FF!XGG?(H[B"8.[A>
MR"=X%-V%FA<1N/OI/GA7H)D\WPNZ/J;.U\5+9@8YCQ(+I]1.9A2?R'",EC!P
MA$!KMOQKRGN3V78I%D+4"_IAT&5W,,=VVD1ZL$T .V0K!'"D57OG[IM'5UMM
MMDL9Y,6+X@,SX A4LGL8+MDUKZ2#*+^!R&V*+UX2YQ==M+[JZOD_ =1-16:Z
MS"7J;*EQEXFQLRONXQ=*:UX[S($O[[F22_(@:=L@?,9&>7<[GF"5A9VA6306
MA/8SG'3;3V1-.# <:D*@JC:8'>H*B(5,UR7BP=NBD5+90@ L.D/+KDA04ZJ@
M]IXD')(%<._1^.PD2=.4=%J,IX7$K:$<&"^T<?)?(B<UH1OE!$*/>%JU5?TO
M=4+[HMS<B$P4.!,&DAR^3 O)>A%??-*$-#\8S7W#X=ZB /O)"2#GNMSX2T'P
MT84G<%M$)-?1@#/'/ 1A_MQQ:*MP?B5&UUXJG5.!"8R![FP1LV_$W+3DWPU9
MIC0EI/2R@3N<$R7$"HHQVQ K< *@I P_K1 2_0 6RPJ#0:@<63X*<-!@XX8;
MW&VDK1O;Q),PF;1\KC;C7V3L:!R8"C;+$B!*K1YS"?:&O=BCD?P@JD= M>F&
M5#T$6EUA?$!NP@W'<^X==_(XEZHFQXA1+6'7NQ<HUI(-24P<[9PE"XEX$4^9
MJ(A$?(!?FN=B:YIA"D!99[B=8S#]&+P548NDACQBV3?P#5I^CAFG0/M9-3S_
M%OX#SB%.L&<!-SDKA</$6? AT.JFYT 3)+_*O?9":<3Q"Q,3DP5HEQ[[L!II
M'8BN!@?0'%YFWB+HLM2^>.[9=6?XXK#)Q0[GD^ Z2*068T.':49KW[VV(A$'
M@GJT=\KG])$;Z8.*R'O$4FO'-O^;13=G.Z?FG:2;Q#EFX:<BJ-='L>D6/E9S
M"Q-%#8V9PH86$0:\WD5HE =+"+^7FZ0TW-NF"S,<PTN7."6#Y(S;50)HI_3S
M?6-ZIA]%.ZN&" 1\UY6.T+==V%">V K;X3I!&WW@,^2KSN) ?8VP'$=F3A:2
M=0!1B4>7/\)(:HBE@Z"TIG9[)I 7-3C?Z1=<&LB3JE\*XU0;+6T-)TD8LC7Z
MMMTJH\;CHX*MWXA,F]S/7F&FY78S-/)PYM@RD!N0R'-=T6ED]AG5GAT/AV%O
M,_$/@SU(I:VB7_?)V]&/9[[A=R3DAUH]APD01_$,11+J6QA] <.R7-JLMK1B
MKK%.]I9\7-88+5X[#?&4&;6#AD%Q2DK[WTTCAJ/FX6^?;F[CD80.=9!R]1QF
M3P\%6RO7Q,(!7)?M[TLT+>_K%:!@VF85Q1V=)M/3\;:B3J:1PP(QP@1;<9D?
M8Y/U$^UO/2G"A+&)D# 1HGZ3I&&R$1//H)-1,H'.NF=^Z2HDCGGY,\;1)/4C
MHA_D#AUUF^%ZH972Z\Z\H&L'Z(=IO5R^:GYMI0%?/>.ZVZ9Z[JEZ;I\J&3CC
M!@]!I^3%$1NF.">D)P/X _6G@!"<8"?#"3RD6DE'@^%D0 ,(/)L.DQ2>[7J%
M,(C>Q!3"+.E]$S8%F*[]2YGV;OM*Z\J_R=DL]^_#("1+"4<0)1:P->V?37J^
M8S073E?T7F>N'=0_?5T)#L[C GB^T-HU%ZB@?=%W^6]02P,$%     @ :8"L
M5-A0AL>G!@  Y \  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N>&ULK5=M
M;]LV$/XKA)=N+:#8EOR:+@G@O'1KAS9&W:T?AGV@)=HF0HDN2=GQ?OV>(R79
M29JT!?;!ED3>'>^>>^Y(GFZUN;4K(1R[RU5ASUHKY]:O.QV;KD3.;5NO18&9
MA38Y=_@TRXY=&\$SKY2K3M+M#CLYET7K_-2/3<WYJ2Z=DH68&F;+/.=F=R&4
MWIZUXE8]\%$N5XX&.N>G:[X4,^'^7$\-OCJ-E4SFHK!2%\R(Q5EK$K^^Z).\
M%_A+BJT]>&<4R5SK6_IXFYVUNN204")U9('CL1&70BDR!#>^5#9;S9*D>/A>
M6W_C8T<L<V[%I5:?9>969ZUQBV5BP4OE/NKM[Z**9T#V4JVL_V?;(-OOM5A:
M6J?S2AD>Y+((3WY7X7"@,.X^H9!4"HGW.RSDO;SBCI^?&KUEAJ1AC5Y\J%X;
MSLF"DC)S!K,2>NY\YG1Z>WR!N#)VJ7/DVG*"Z[3C8)UD.FEEZ2)82IZPU&/O
M=>%6EET7F<CNZW?@5>-:4KMVD3QK\#TW;=:+(Y9TD^09>[TFU)ZWUWLJU!4W
MXGCN0YWR'9CEV,087BR%?_][,K?.@";_/+-8OUFL[Q?K_P^X?L/2IYO+/XXO
M)K/K*W9Y\WYZ_6$V^?3VY@-@B?OL.E\KO1."^079M#3I"HNRJ>(%^[02?G%>
M['[^:9S$HU_MM[4BI@UST+R>3:<1FXN4YX*)Q4+X F*R8).UD<I;PGSI6*&9
MQKR1Q9*M\= 9@SFHB@+BTDGN  -L&E&"'.@)LD@%>\>+$HV #(W:Y*P1; L]
MF+,>OI"K]  ^] $5C.G&1[:H''8K@Y#RP$)!+&3@4+IJ2$21W1N)VVR2!TE>
M9.RCL,Y;]R %;-["T\('_A!21CW/X6?]ZC]FJ$&Y5O.286:[DG!Q;?1&9L(V
MX2U!50>@F5X3%#8**#&^1CM.984/=2%,&7A@9$H^>*G'(ZQ$9JQW5U-J[F'.
MM]QDEE 6%55@$SF6J3!!)Y-8U&F#<?I,X1 :(3P,TSS;2(O9)J_TET3=_C :
MCP?,4BU:"@;91<;J4$JWTD;^"P\H:FEMR8DI@35?A0MH$<N<9PY!H3>8GN^\
M=)6I7VRPO](J(_]!X7>E\L0;>P=94>9SK !_#ERHG 17L=U908&!L J*<)C,
M+Z2QCF5\1XJ"(VD+:5.NV$YP Z>=5 $=F%!EAO*(*KV]%,*ALKD2J? N5,SL
MUR$H+.VS_E*^(@"[7?_#)[[[+VC&W0L .R_(%ZP^ 3.]E/ V T<]$6$,U@ F
MSS7<QK;FA,%N\PC)IHW,-0A"AAL>M-E-T91T57#1 ]^>!M<OU(1'Q$LBI"<:
M#P9M-@LG!K(0:NG&5P";4$>2;N=3Z/A<"?0<'#.J(P;6L77$Z_T9@!2>(Q0E
MK&XSL@CG'E+^[C83*"7NA$DEFBJ:)2A,T2M5UVXH9FAFI>^:W]>^B.+B"RA8
MMS\$>8N#VX:K4M1,>)BIAYDG&4H\R7LOT ,]1>XO%@$CL,&XD*VG^K&XH_<0
M'A7?G01: B5R-&CW<&!1BJ2V>"(U;&\056H81UN@?D4-!]\X!-;;!\PE[9.Q
M+Q$P:^(>>3?L)U$\>K*3^'[#-UPJ3PO*W:)T)0V&UE8GX!DFM-F'AKFSL,SG
MVM])Y>_-0;5Q]ZB,8]:/1O$H&G83=L3B]G# ?JL6CJ/1X"0:GB08'IRPZXHN
M&?.92WYMGI?4 I7(.@AB(23IODRH3N+D%71/AM!=HPH?:SYP[@&;AE$R&D7)
MN/*L5[O@ 7LLGD2#DU$T N0DWA_<.]:0"YX'G[0#/;])EX-M_+! ]VDYW'GN
M[S?03?6R\"R2@<[8?#(R&[8AK63&PS:'!QWM;-@UD;&PB(1)VE<5>H5]C6JE
MPCL\O5814_ZPE0L/A'=";-!?UOZX"!1&_6@8]^@M'D3#!+D5!191U0Z(!BKI
M1.DW_2/6&P ^9.N()8,N<!]68!VQ02^)^MT3DAD.HI,X]@V$8_?+*UA*NX_V
M0G& .TNQFQ'QO<0Q-1E*<ZXSH3S=OQ-7#.RAE73 LFM\$6*AQUMA-FA@]L=:
M%:=*>QYCHHP_CBBY\,=*7^QLV$:M?)3V]GA!*CAB"3JZ,$,]BRKHQ5YSHT$C
MJ:BCQTGR@KT)%4)E[L6[[>X+=B7I'(50=U*H+(S5=7Q<]YT%EV;?1Q^B=A2W
M>^.OW0HZ!S>O7)BEOU]2S\4N&BYAS6ASA9V$F]M>/-Q_ >"2SI)*+*#:;8\&
MK7":JS^<7OM[W%P[W K]ZPK7<&%( /,+K5W]00LT%_OS_P!02P,$%     @
M:8"L5,;YP2?+!@  &!$  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
MM5C;;MPV$/T58I&B";#8NQ/;L W8CH,ZL&O#3MJ'H@]<B;MB0XD*2>VE7]\S
M0VEO7B]:M 6<6)2&PS-GS@Q)G\VM^^8SI8)8Y*;PYZTLA/*TV_5)IG+I.[94
M!;Y,K,MEP-!-N[YT2J8\*3?=0:_WOIM+7;0NSOC=H[LXLU4PNE"/3O@JSZ5;
M7BECY^>M?JMY\:2G6: 7W8NS4D[5LPI?RT>'47?E)=6Y*KRVA7!J<MZZ[)]>
MC<B>#7[1:NXWG@5%,K;V&PUNT_-6CP IHY) 'B1^S=2U,H8< <;WVF=KM21-
MW'QNO'_BV!'+6'IU;<VO.@W9>>NX)5(UD94)3W;^DZKC.2)_B36>_Q?S:-N'
M<5+Y8/-Z,A#DNHB_Y:+F86/"<>^5"8-ZPH!QQX48Y4<9Y,69LW/AR!K>Z(%#
MY=D IPM*RG-P^*HQ+US<*824BD>'-+N@E3_K!KBEC]VD=G$570Q><3$4][8(
MF1<W1:K2[?E=P%EA&C28K@8''=Y+UQ'#?EL,>H/! 7_#58Q#]C<\%*,7OUV.
M?7"0P>\'?(Y6/D?L<_1O>#OH@LKMU)<R4><MU)-7;J9:%W<WE\\W'\7CT\/C
MS=.7VYMG\253XMKFI2R6/WIA:%V!8A0Z>)%85UHG@Q(9"O)[)5U0SHNWPW;_
M_0D4CA<PIMJV$_Q,=*($+_D.4W/45H(84!N?*[,43'C_N"-N"_%)C1TF+SD%
M;1'6&(0JL :FZ2)8(5%7<)/B7Q 8JT7 B.UAE=.R]+Q&'>96+)4$2%\E&3[*
ML+8ND .U*#78(%27U10%T"AAU!'W5[=M(<4\LP9X[;P #%^-O4XU8=U$*9/O
ME8XPQ<]VIO*Q<A3>23N"\6*J"N6DV:*%K._40A?38(NVN)?>RR2KO H@6R*P
M.0C-+%ZL[:^T,<KI1.[8=SAS*V\U!Z_1/OR?:<^<4G^;^(\JB835U!^UB>8_
MT$AI,?8,,HQU*13IJ._Q>WC2!8EQO?8>9\-(S(JV?<0\),'2E,C->Z9^Y9XM
MT",01=,D.N(K>H];!>2) 8541.?M&I'W(*&42\^-'%Z+"@)P1.+;C0")W?AI
MHA=8#A6>P 9[%-A/''E\UQ:EJ;PH8_U#>W*A?)N!6BSF0"GV#,,O"C  82"M
MX!C[&1ER$J075=!&4_]H T<IM:N=T'Z*G$HPTMEL 4+-I*G @B?<:DX"+FE_
M@SY#325 JC+N>063A8!L,;40(@6NHY1A9:ITCQ^6AL8/?9+>%G(,F28($YBB
MVD"(YH6X"U%4">4E+A\3,,]4(1*#BM"3):U<EQT'A\?*K5X*H^6XIB$&6]NF
M%C0&H.!:!B=PK8%T)O%K;!J1(:-4"$PA>D'%%J928HI:DJ"15.WH8X#@Z!0
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MH_TP6.W/JY#S3.J\L7$(#^PC@\\H0@[-@Y*%Q-,,YBS(:M%8!P$UN@@VF H
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M.!R?V7_VOI,O>V;P7HG//+?E*E@$D&/!&F$?U/$]=OY,'5^FA/&_<&QMTW$
M66.LJCHP*:BX;+_LI8O# +!X"Y!T@,3K;@_R*M\QR]9+K8Z@G36QN8%WU:-)
M')<N*3NK:9<3SJX_4=X_*&-@BQIV)=.XC"SQNMTHZSCN6H[D#8X4/BII2P,;
MF6-^B8](3R\J.8NZ2ZX2?F1Z!&D<0C).DBM\:>]DZOG2-_@V3$LN#P,GX8_;
MO;&:[L2?5_@G/?_$\T_^5Q"O<KCBNS$URW 54'49U,\8K#]M'N'#K[L=;#</
ML'M_^["!QQ+A7E4UDR?(Z-M8-.Y>\@PDR1!.1DTRC'>S,>0W6,(<_?W$'-@S
M:BHWD$VU)SM5.)J*"L0C#%#E&LMD[H!YH\]XXN0J'\$[+AI'XP[CDJ X.(Y[
M*;3;U$3XGXZE$Z%6%J7E3(@3Y.X<*E@PF)$*R\GFNR$$\$O#GYD@A/G^:ZKO
MWP .<2%5LT5-1>8<Z -GJ=>91I^ :C%[@@IMJ?(0')&+O^;.7W*G\\.6S%*!
MGF#OPF$:QT5EH2\4JMJUI-;I(].:.2E60=WHK*0 ]KDHO(0NW]]^LTCB^4^F
MCYP3=,4W/W_)1$-5"856E2?+!PG\QVW)F,@:P7R[Y/YHK@&+@CJH2RVIY#^<
M\S+R-[%0@MJZ<^G5W U]'N3QB/]2]JJJBW33 S1(*=V]G&?,0?:8L89BILZ*
M+W1V^F]@^Y7+]5AJQ(M.YMN/^XEAYW-_3MLL3.;S,%DD, G3. Z3'V/X?$YC
M'*:+.!S'4QHMIK,PGJ3PJ"P3, ]GTP49SXD@GLW#23J!U[I/-&CG%>J#?[1<
MUAMIV\[>K_;OXFW['/QMWCZJU$D/G!0++ @Z'LVG >CVH6HG5M7^<=@K2T^-
M'Y;TMJ-V!K1?* I;-W$']/\6UG\!4$L#!!0    ( &F K%3[(UM?8P,  #,'
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;*65;6_;-A#'O\I!&- -
M2"Q93M:NL W8J8<60P8W3MH715]0TEDBP@>5/$7QM]^1LEVW6;,!?2.)Y-WO
M_G<D3]/>NGO?(!(\:F7\+&F(VM=IZLL&M? CVZ+AE:UU6A /79WZUJ&HHI-6
M:9YEOZ=:2)/,IW%N[>93VY&2!M<.?*>U<+LE*MO/DG%RF+B1=4-A(IU/6U'C
M!NFN73L>I4=*)34:+ZT!A]M9LAB_7EX$^VCP06+O3[XA9%)8>Q\&[ZI9D@5!
MJ+"D0!#\>L K5"J 6,:7/3,YA@R.I]\'^I\Q=\ZE$!ZOK/HH*VIFR:L$*MR*
M3M&-[=_B/I_+P"NM\O$)_6";_Y% V7FR>N_,"K0TPUL\[NMPXO J^X%#OG?(
MH^XA4%3Y1I"83YWMP05KIH6/F&KT9G'2A$W9D.-5R7XTWW2%QR\=&H+5 S_]
M-"7&AL6TW".6 R+_ 6("U]90XV%E*JR^]4]9SE%3?M"TS)\%7@LW@LGX#/(L
MSY_A38XY3B)O\G]SA$^+PI/C$_'Y&?S%$7\1\1<_4\+_0-PM-ZOW=ZN_;V'U
M@9\;V B%'NP6KJS6?'HW9,M[6"+UB 86K9,*]A4"82JX%CL89\/$&5"#P;$5
M9@?>JHI-0-2UPUH0!JIH6V<?)9]J5#MX>3D^R[(,?"/<$+4<HOH8E:\^&.X/
M[%(B5OXIX)?Q*.?3J52X:!T? P>2R[RXO0:NC*0=NVS125,'2.V$'L7$T)2H
M0^&8N&[X<L$XS>&*RR-+H3CIK@JN\&9QLSI_>W,[AG>'Y)\F*HRQ'0.KJ/X4
M';1\Q9<'O'^"'\$M T/'.U>BP(-)SYD!/@C5A?*%F"U72HO2WO-&DBP]_+K^
MZ[> HM[" [K0L_RWRJ7YKFAY!@T*1<WN#%KKZ9SEVE9TGJ7UE@=@F?2=$S4.
MD1,T'LLN-#30P^7C6)W'(8$3U4)YR^8J=$'P8HO$T3A$(94,GZ(LL:7],)XD
MO],M=YUSATKB%BKN*J=4Z:' L)&LH>I*XG(7N]-]>.&A;S@@5[8WO.KY>LA*
M<L</)5ATX>(I*4;_=O/2DT:FT=6Q77L.U1D:>MIQ]OA'6 R-\*OY\#OA)E)+
MW@.%6W;-1B\O$W!#BQX&9-O8%@M+G&[\Y.W@HQL,>'UK+1T&(<#Q/SG_!U!+
M P04    " !I@*Q48LCQ[;D5  ":0@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6RE7&MSW$9V_2LHQI65JX9#D;(M19951=GQKBOKK"+9FZU*Y4,/
MT#/3%@8-=P.DQK\^]]S;+V PE)C](I$8=/=]GOOJX:M[ZS[XO=9#]?'0=OZ[
MB_TP]"^OKGR]UP?EU[;7'7VRM>Z@!OK5[:Y\[[1J>-&AO;IY^O2;JX,RW<7K
M5_SLK7O]RHY#:SK]UE5^/!R4.[[1K;W_[N+Z(CYX9W;[ 0^N7K_JU4Z_U\.O
M_5M'OUVE71IST)TWMJN<WGYW<7O]\LUSO,\O_-WH>U_\7(&3C;4?\,M/S7<7
M3T&0;G4]8 =%_]WI[W7;8B,BX_>PYT4Z$@O+G^/N/S+OQ,M&>?V];?_;-,/^
MNXL7%U6CMVILAW?V_B\Z\/,U]JMMZ_G?ZCZ\^_2BJD<_V$-83!0<3"?_JX]!
M#I^SX"8LN&&ZY2"F\@<UJ->OG+VO'-ZFW? #L\JKB3C302GO!T>?&EHWO'ZC
MO/&5W59OG?:Z&Y3(JFNJ]Z(F?/;>[#JS-;7JANJVKNW8#:;;56]M:VJC??4D
M_O3EJZN!B,+65W4@X(T0<'.&@&?5S[8;]K[Z]Z[1S73]%3&3.+J)'+VY>7##
MGY5;5\^N5]7-TYN;!_9[EB3TC/=[=F:_)8;_YW;C!T<6];\/'/!5.N K/N"K
MQZA@29#_CVVJ7_::++^VAUYU1_ P=FILS*";JK8D\<[+3YY8:Q0>;TVGNMJH
MMO*TAR8'''RU5W>ZVFC=5>3ZO7+TGNEX8]?0VYJL=MA7.]UII]KVB$]TC]U4
MEE[O#.W;MR0_6CL08;]V3,A[G.-7E775K^OWZ^K/M[=O5Y7R\"YBLJDV1W[]
MQT19H1-:W#7*-;YZ8^D_WN7'V_=O5A4A%ATT:&<.!5.F$R2+9LZ$8W?3D4I'
MQ@I?#;:"TU?73R__BU^[=8.I6UV]@(3?Z=W8RA;O+_^Q9G)<0]2TQQ7V.E:-
MK3H[T)YU.S:D@;;%.CEF>O[6VH%>):$X_?MHG+ +$3 #T%RK![VHEG7U4T=@
MT!%ZXO=__9<7-]?/OR4CZ$U'^S,M4^T_1N<$C\!.)EXUOQ$6\?,5+S6>I4],
M=6"GI;?KT3D\.WVWT6"KT[7V'I "QE2U5<;!G+*Q!A'1(\)4GR4F.NSI7TMZ
M#DMT _;GZHUKR419 _%00T9INH8P#%$ 6Z<WR8[(+$4.(*PCS*-SW>Q@&!8^
M!TG;D61RU$":$P=[C(C]WHXM*1P\*W8I6O/;V$G$2J89/79Q#QB1&!"(UF2Y
MP>J:Z&;?"W%_\M5MUXVT^IWNK1LJ.B(:^7\DUL!5I8'%U0\DN\.&!!'0])J=
M"R_A%UZV?@#_OD[X]_6#P/5G"[%];PE&W"+N/6(YJR/P6T 5B>G3RH!#5CL;
M=,B[;8"IJ^I^;^H] 1)E+BQF-91R)3VU,#S5FC\TGT5OZJ 93_;FMT=^W!JU
M,:T93$; X#R$9LZS56Y&3_QYOYYPLB<P5-6>G,Y*1&XM'>&KK;,'\G8"78:M
M5:4_]N2RGLQ^)X9>*[^OMI1ZA9=!1UX G"->R95'G8W;PL&TVK0P]&%T>L6L
MQ+V9?\.'#)$0%L%D)WJGU<J+I#K]<:B\OD-T8 N#C&@/0O@[R@O[("NM/S!)
M&\81^H$2D ]:#M,? ^3TSC8$T\09N3/4*8OI[9Z\@"@( 8C!=$5"K^&-_$XX
MC1"*_(GX)V).=V/)TX+:N'H\D'V0*1 8*D//_+C! YQ!$#]N"!PWE.G.O$RT
M?)P(EQ4X,:X%Z%@TRWDH(7,H$!:'1* &%3WIPV3-57J[9:79+D!K;:&%0"&$
M0H]:,EC.[R(*!P,.!J$."+8BYNF[C-&E6;-M'-0QH*O8'/8@*1&C.F+Z"!$,
M5#,,Q_CH\?*[Y>,IWR/GC G?:N*9>P)5Q7G*>$#$U@WG%#59'KCL2?L?#05C
M31;SQ?7UB_77E&.W+<=.]AQF&3\@-M^I5H#B9.FS?UL_RRLYK:!:A(E5O1E4
MN[3F>OU57+,&$#/EP]YI71TD)188?HA!L@J*NLBSDC<N'/4BG\3$02RG"#%'
MDR41W60^IP@5P0&N2HD>5PXCD($VB3* 9VN8]G9[Z;2H ^O(/;VP55O/FJD)
MY,G$:(DC;_#!3CGI @!R*2<&%_=!V..CY^Z\XDT9DRVY%M[EN K+0@:/_&G<
MT@\C@X[7[L[4$5/VQC67%$/(&!-) $?62($H<,6T=%7UZAA\ERR7*,O[@.21
MM.IF)F^ZRQ*H&+V\D21Q1Q8AVPD&<!;?!X>V-1L 4G#(S1X.VC&"D)8TA8L.
M48)LZQ^WW_]T^\O?3HB>O590E;+))9FV9#UMH3Q)F H5Q8_XP% 75(">/1(=
M5LG$@-)I ;>V)"4P&I)BX;_F;(D,(N4XE2]*4U%T81%9'.:/A&WGS,0$:[_3
M5$0TFLAG H*<AV-/P:133!S;AG8'/Y,Y%>,M!8047$O_(+/?M(8*=7_><;(\
M<0*E"&PR-<G4\>=G3:_P(A8-)2-^(AO.?AD_N*+@K(A>Y3Q.32F-D,NA)47,
M$)[/1><E@;*;49IOZY'CS_)[$C*XOB2JZST((VKV(_EE=CH_C,UQPG)/.9$F
M41*-M,T<]G$@%8P_W%Y&G<:C5]$55@$*?3!/V$R'8'JGB?LU-HMZ;17%JSV4
M'=TH%K H5T-UFITY>#(1]3>W4QU"@O%!T3DKWU+.1P+Z?20=D^_0YE#/FHKB
M" _)Q"1Y#/ 0X4#DFTY82$AK#7Q7!-M/UT]3 *"W"7WA7YSA2?G079+-4%+$
MCP)\$84MA056]CYF$M@1 H]1^Y0L*:J) ,)ZI&-#*[86Z2$,A/4A?6KU96-V
M%(R=/:J6P1$=M@;6@G#F51L09.RQQ1?7+VYRB(8@$WQES%4^$.Y?5E^4KT_9
MV1KGA])Y<1B'O,A3,IG%=L6W4[I*">-U87*VO2_A=A;3\B>GJ3_9O<7))=@1
M%I !U>*FF]&TC%;L8U3;$:_&@IOSV?)9,%F.K@,GQ6?2Y42M=:6Q@N$1$7V#
M5&\2P=DK$=HSC@C&H-G0'<\#=7*?,4/QZ18YW!WO414C_T0?(GOM+W-_Z;0P
M&M& DOTM4D4.[6JK0[JL\5#51WB!@J$"M!XFUSKV: NN6^E^+(I"VD'HF$NU
MJ26])S]2 ^<J[,[I>2IW*O0B![TS=1&!K..7HG]:(2!61?&H$C5*W@,*(AVU
MXVZ?MMEJ('MVU^"HX?50(BPF(84I,7]+EO0F.O\43R7#&6)JBAJPI>! .W-B
MZJ?@UU@Z#143QY1"B9SHXOBB))^GZ3 "X4(RFM:0P!H4(Y-$!(G,0H5[?1,S
M]U3W1*PTWH\J9&DG7;GEWMY9"SVM18N"MDBV4_%$/P/OY\5_\!U2!WIDZ&DA
M'='U.$@;(\H]F-=Q2A*JO/*$F!X(=8F,8$#@.2*LWU/^D0(;S(543F92?PBY
M,1[?_O)SQ/\46MA@93]1#[(RW@C*0<7H5.>5]'#7U5_L/5H.Z-_H;IKCP'PX
MGHDQYD"3Z]V"TOE2AAA)$4/;Z$XYHZ6612T!YTO)^@H;(I,$R62L :O0)S2A
M;</1WJDFM,G%3.;"6?&31B,M((.1XL ';!88H;6,7"$R@)J01V\#,I?-HLAO
M-W*7#[%O'/;6F3\0:Y*2)@KB; W-576G3"L](FP=S#OVRBC?F9:.-\]S!9HZ
MN^P<@&>[S17P4OOI)+G1!)@C5H,'6&(_.H\V0:F):(.P2$[E^U#7H@JF?R^E
MGQ":?+FX"L8D<7$S1/?L=O36#J[?16L4*]PY!.0@Z=6\"N"8E !:D0RDHY26
M>T.2484Q*T<;2DM?,GKNV93J Y&36J$LGB&D O;ED+*B1-->WR\%*ZA U_O.
MMG9G8FP/[L#'$*G2]9\A] 0^\[ HY8(E4(CC5'NSVY-A6)Y@'*/;E'K@?E8@
M<I+Z.TLB/\S\<F^MEVQ(;$&LIE>U#JE6&BJP8\7*8E)&;<GXAM(S<KU'^*X%
M%$CR2H;2YZ)^3L&DK.P(.G^:R$Q0TI_ Y-1V5O^4X1CIQ+$V.-\CEF$$^Q6'
M6"XNDCLC8&[5'9T,OPN8$HBE@(_9-LO6AR8>^"Y-!50M%G>%XW+USJ3?<P +
M 2/6F#+M2@6[9NMSFA%W PJY ^\XBC+=47BQVLB0Q( /8]2-! TUB";B&RR=
MN$[2TY!YL%C.24+J<@QN (9[VU*TDBE<C,"KB!YT[ P\LC94U9AVY'0N1*&0
M\V!'?O7$PU+[NSQYM811? PE![_%EG"1WY$3#!1>I.]'H$)K8"DI*$A[2UY)
MV(7!'CCB<9CVW(<JQAPGIDWZ@C5-\X!"(VQ^A82ERN5\BHQ\ >RQ&]0;])&P
MI'3=!QH[T]Q)I]#![U,BR9J?9D4085S14.)*+N!K9"\;13&0:"5?XABL@T.X
M..*5$'V*5>1#FBC3!6YO30B>&]5]<&,_U/ T;5'1D_E3HJ#=+DS6J<9GE^>"
M^LASN)I[/)GP$SUL-#KNZ#>>2.ZTFSX5>XD;D@)'@8G.Q? .0(4T^)IVFRB?
M8G01NX;(D6 -(3W@&;EBWW84KIO8'GK$['05 FOV!J:ZM3Z,VQUWSX(G&4QS
M[[0,34[GHF6*,\ER__0HFCXYJ^'I2)#: _,1X\L!R7*?M.P%E)<LXA452+?1
MOG9F(SVG_Z1RL;J.@/9I7N93Y#SSK=X;P>"R%02Y?X;2>$9=9 @=:G>,V5&Z
M[!&]_ QS/Y?CAT;1WZ11]#</SI)_Q)6$O\-8P52^;_(3WPUA%I8&U/_TIG+?
M0ZZ[>+D8P2X3>[-2$[#YW.<; ]Q/BY<6Q#/CR(["Q;"XJE=&VCFHE+9(#-/\
M[A@U'2[J*':B [)*U=R1U-5.V]&GMJ]DT>AMM)/*BXX9[J';\*(TL6F_+L\A
M#P1>HU33H7_+8P]T]HM.>;PD(K+8&X(Z5^^/ 41"10[$#K@HG2"J.8!'/&:4
MH;K=8#;#*&BZ?AQXI*_+(D9\C(=OERW@NSB--I"083@_H)R'$)&.S81*"TI8
M*BDV^0I3V96$1=]\\VWU5S[H^F4@BEV6P)H!@Y;\/G+3C[7HY;H5!VX1J\QK
M3 /.D<?FD6TQCUW/SKI)9X7Z&0 =R,BY8!8793.&7VQ(T#5PG>]4Q=]6L57U
M6;3&=+6X'5&0NIKM,>7N=/F44>X%A[,F.:W0L<I)<^!_@5D.JI)KUM8YRVFX
M7,<J7@I&S=T_:=:E-DQ[S)>#D-5,)^D/J.792]+[B9%F&OW8HZ(06FB+08CM
M<M]36K;'4+C$905@!DPMC#,VHA8)? !+GR<L??X@[+T++<1WE(80'><N-3YZ
MDTD3RLGS/[C!**]RIDGH%Q&.D\*#00#?6=P?@]+BE!=)$5^RU<X'1 OE+DLQ
MW*SP*63B*EL  AM;'4.^&6,G0P_:3W^4H!::K0B2)T3($"NT=7+KU14LRTU
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M0^T"R%\H98^&*]"_C^D_4$L#!!0    ( &F K%0N('\C004  .8,   9
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;*U7;6_;-A#^*P<O&5I L2W9DN,T
M,>"\M.N'KD'2KA^&?:"ELTV$$E62LN/]^MU1LNRTB9<!^V*)U+T\=_?<D3Y?
M:_-@EX@.'G-5V(O.TKGRK->SZ1)S8;NZQ(*^S+7)A:.E6?1L:5!D7BE7O:C?
M3WJYD$5G<N[W;LWD7%=.R0)O#=@JSX797*+2ZXM.V-ENW,G%TO%&;W)>B@7>
MH_M:WAI:]5HKF<RQL%(78'!^T9F&9Y<)RWN!/R2N[=X[<"0SK1]X\3&[Z/09
M$"I,'5L0]%CA%2K%A@C&]\9FIW7)BOOO6^OO?>P4RTQ8O-+JF\S<\J)SVH$,
MYZ)2[DZO?\,FGICMI5I9_POK1K;?@;2R3N>-,B'(95$_Q6.3A]<H1(U"Y''7
MCCS*:^'$Y-SH-1B6)FO\XD/UV@1.%ER4>V?HJR0]-[EW.GTXN:2X,KC2.=7:
M"I^N-U_$3*%]>]YSY(:%>VEC\K(V&;U@<@"?=.&6%FZ*#+.G^CV"UV*,MA@O
MHX,&/PG3A4$80-2/H@/V!FW, V]O\%+,2V'P9.9COA4;HIB#J3&B6*!__W,Z
ML\X07_XZX&S8.AMZ9\.7G-5L!ST'GVOX7/K\3IF.TFV &@NFY)=R10&&0[A5
M@MA:9'"'2CC:_5C4S4=JSU7CH']NZC-;BA0O.M2U%LT*.Y,O2P3']849MV73
MDO)OM& ]2%WN>H9!5@3/@".UYZ&:!JK<0?6!L89;&D3(:T[4RE31=-F6M N,
M!Q_1I-(BE$:FR/D22C5 +"RH/.P@JXPL%J^S"VM!'[Y70H'37H6"?*!!MQ*J
M\AYXCUDOBLVOOYQ&X>B=A53G9'.;A\++9!0<RWL479A:7CQU%E".1*Z-HRQF
MM79#L72_K?"1W^OPRM+H1TG90K6!H[@[H 97BJ76]*32P,Z@7E'^!:S]E*&U
MH#4-32C12)VQN:@[/H4-"F,)H/L)73*,@G 4@V7R>_Q/ EVC(7<K(96G!==N
M7KF*-]?"9+L"'&!"%WZO\AE]9:[7;KYM\4X;O)\K9QTQAHLH'%QCBEZE 1K"
M,!B%HR#I1W $83>)X4/C. Q&\3A(QA%MQV.X:>B2@:]<]*Y]7HDBI:F?]2B(
M.4K6?4-G5- /H[>D.TY(MY3F&<T?P/W IB2(1J,@.FV0#;80?,)^%H^">#P*
M1I1R%A_&<&"8Q.TPB5\[3.XPU8O"<^/%&7[3D&T[2*@+]F>0;7-+'V[R4ND-
M4LVXGZ\I/ZG3QCXW< YB?&'@:$==^*]=879 ]^?0CGWT 9\ S;9 2;=-B*R[
M-M7$SZ)V5EBM9.:-4XF='_2^"^AZ8T3M1)))2]17-!+M&0TEGB_[9UE36*;I
M'47FZ^U!X(K&:.D/#RKV:!@DX8#?PCA((J(P%N1$>5F1T2DN^7SAZP@)#6)B
M"9'R"**X3_1*H$[6$<2#*!CVQRR3Q,$X# ]1*&DIE+R60E-+<[])\%=;Y^U2
M"2K1?;K4=/@W/#FYI8G,/?%)9ZC\;/@_:'08)Q\)8@]@97>%?0JRYLA)V8#,
M6Y"OI!!M[%@D^:II2UIQAF::9A\PA^E(LO_M\!$\.P_3B?LS94Q*SI%=^_$-
M29>FWYVT#R=S5I$$FS Y,'P*\4P\WFFN-'6,5'Q&AU%T#._KF<>#VXOWN_UC
M*L-*4B=DL)&HLGIO.YE/MB?)7$BS.QE_S-I1V!V</D>_WM[=,T>S\#=L/D6K
MPM77T':WO<1/Z[OK3KS^!T )7$CRJ7!.JOWNB :-J6_5]<+ITM]D9]K1O=B_
M+NF/"!H6H.]SK=UVP0[:OS:3?P!02P,$%     @ :8"L5*'KT&V4 @  D@4
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M:+P#G5=:N[WA"88QO'@!4$L#!!0    ( &F K%1&J>%ZT0(  /@%   9
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M+W-H965T,C0N>&ULO5=-;^,V$/TKA-%# G0C49]V8!N([2RZP*8UUDCW4/3
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M4&DVP/-""/UZ80QT7T+S_P!02P,$%     @ :8"L5"Z923S- @  R0D  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C4N>&ULS59-3^,P%/PK5K0'D(!\M8&B
M-A*T0HL$JXH*]K#:@YN\-!:.76RGA7^_MA-,^&@6B0N7QH[?3&;>5+;'6R[N
M90F@T&-%F9QXI5+K4]^760D5ED=\#4RO%%Q46.FI6/ER+0#G%E11/PJ"Q*\P
M85XZMN_F(AWS6E'"8"Z0K*L*BZ=SH'P[\4+O^<4-697*O/#3\1JO8 'J=CT7
M>N8[EIQ4P"3A# DH)MY9>#H-(P.P%7<$MK(S1L;*DO-[,[G,)UY@% &%3!D*
MK!\;F *EADGK>&A)/?=- ^R.G]DOK'EM9HDE3#G]37)53KP3#^50X)JJ&[[]
M":VAH>'+.)7V%VW;VL!#62T5KUJP5E 1UCSQ8]N(#B <[ !$+2#Z+"!N ;$U
MVBBSMF98X70L^!8)4ZW9S,#VQJ*U&\),C LE]"K1.)6>8TDDX@6:"Y# %&Z:
MRW*T:((U:PNR8J0@&68*G649KYDB;(7FG)*,@$2'Z((PS#*"*3J3$I2T#%<$
M+PDERI3<0 58U@)R9/CU/*N%,"R-@KT9*$RHW#=DF ATAVD-!^BZ0>D_CI('
M'=0ANEW,T-Z/_;&O=!N,&3]K+9\WEJ,=EJ^Q.$)Q>("B((H^@$_[X3/('#Q\
M#?=U\UT"D4L@LGSQ#KZNVQW-N^ZT[J4%INH79^)-)_]<Z0^@2P65_-LC+W;R
M8BMOL$/>%,L2P4---IB:$#[J=\.06 :S;VS2.(GC8!#J_FRZG7U?.!@E21(D
M U?X2N3 B1STBKR"#5#4E\;0,0V_8QJ)DY=\.8V&8?C_--X7]J=Q[$0>?R*-
MJ,?NB6,Z^8YIC)R\T9?3&+UK<O FAKZ*5[+"X&53#SZ10-QC,>P<$.%WS"!\
MV3_#Z,LIM!1)3PR])8TTOW/.FDN./DE6A$E$H="8X.A8ARB:>T,S47QMC]XE
M5_H@M\-2W[5 F *]7G"NGB?F-'>WM_0?4$L#!!0    ( &F K%2&ZMX$=0P
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MK_> _D^!VU7-79;,LB#0TD4<T.$X 'C4(QMT)/.K:!4(!X),(N!>M\;B)@+
M=1C WY_.U(RWTADVY^LTC\!N_7U).3./G"Q"KR\@6!]+EJX+!-9A!/Z8C/BJ
M?NI6&@.-)T,@M $C].G%MU/T.Y5*@A^.S8; 9F,LV&P(;#;^!FR^J9FTB@2=
M!I-J*C T3\F/<+E:,BNU30>]H$!8PQR+T@7Z&G"R_4 SGR=4<\I=,4O6)"K6
MB%>SE<J'F6'M2-/^"<DE$-B $1@RQL>/(X'*AC,6DPKT-N $>N X:F?*V+2A
M@22@VH"A>AK&[QE(IH!64QN)UDV!J"9< =EO(/4PPSWCR!2@:O:"*HG) PN
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M$'Z&O^(4(;%)T,1)?PVUE;9N""0FIDW  ^+!2ZZ--<<.MK-V_SVVDZ8=M)E
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MRU6\=17_6RV2;9LCR7]08^/D<?\9]0>'^@_9=D?2W1[_2).-S=$.G:AW,CS
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M#M667NUT6NI42%L'W=:]K+6\WKIML\#_3[>XQ#WMPKP?A,=BLFT7V-TO0$J
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MJ_^4@# 3]/,UYVI_8Q:H_^;,_@!02P,$%     @ :8"L5-1Q^M ' P  #0D
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M.5YU.JHJ*2>5 A."!MT1O6U5=8]J8F3I*O9&&JK_;IA1PT5E#]!^(J4Y36R
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M1L3UT2QDU !_[X9_7*==\$KX<*%__8E$P]\=\Q34Z158WJ UO91B[ 1LFIW
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MMRD/J.U;;N,P_P8VI8*LM-UFC1P,^4QN&VPTD#M><=E(XI>0%7NU>X&&G-T
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MN+-_%=!N@7U?*H5O$]?I^O]4_A=02P,$%     @ :8"L5/"S8PZ'!   9!$
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M,4/B,>.K2BY/$,W%NG.^K\B^&G9FT]LYB>5,KJIC/&B%L5L?4)JGS:>":75
M?O?\ I]=U@?^UDS]_0%V\"M>*)2Q)9CLGT8PQ[(^TM<W6I35>>]1:#@]5I<I
MHZ %9@"\7PIH;?;&.&@^K$S^!5!+ P04    " !I@*Q4/SS.,0X$   X$
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M)>7ZF,'#%FIX2@;[WMN.[YVTQ0V]KG=^./ ]O[?G\:' 0:_O1^&>R6[G_"M
MKNRU0*&$BNOZ&&A'VZO'M3UP]\:GYDIBS]4WF/H^@YO\BG%%<E@BI'<9(RM9
M7Q'JCA:E/66?A<8SVS8SO%:!- 'X?2GP4&TZ9H+VHC;Y#U!+ P04    " !I
M@*Q45P3OOW("  !9!0  &0   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6R-
ME&U/VS 0Q[_**>(%2(P\0&%";20*3)NT:A6%[<6T%VYR22S\4&RG!6D??F<G
MS3H$U=XD]OGN?[]S<C?>:/-H&T0'SU(H.XD:YU:7<6R+!B6S)WJ%BDXJ;21S
MM#5U;%<&61F"I(BS)#F/)>,JRL?!-C?Y6+=.<(5S [:5DIF7*0J]F41IM#7<
M\;IQWA#GXQ6K<8'N834WM(L'E9)+5)9K!0:K27257DY'WC\X?.>XL3MK\)4L
MM7[TFR_E)$H\$ HLG%=@]%KC-0KAA0CCJ=>,AI0^<'>]5?\4:J=:ELSBM18_
M>.F:2?0Q@A(KU@IWIS>?L:\G !9:V/"$3>^;1%"TUFG9!Q.!Y*I[L^?^'G8"
MLO-W K(^( O<7:) ><,<R\=&;\!X;U+SBU!JB"8XKOQ'63A#IYSB7+YHEQ:?
M6E0.;M?TM'!X@XYQ88_@ [P^)=/5_0QNGUKN7N!;5:'AJH:YT;5A$FS##%K@
M"NX;W5JF2GL,!WX_XT+01[#CV!&T3QT7/>"T \S> 4QAII5K+-RJ$LM_XV,J
M=J@XVU8\S?8*SM@+I,DQ9$F6/2QNX/#@J./>HWTZW.9IT#[]S]N$GU_) [XX
ME/;7'OVS0?\LZ)^]I\\$@JZ ?HOB\1A4*Y=H@J&_>6M;+.&0;KRS',%O>*NZ
M[J*Z9*.0S'?O.K\8I>-X_0;A:" <[2?L0 BIT%)2VP54H.D!BD;,RN@"L;2$
M=? 642>>)CM(Z4GV"BG>^=TEFCHTM:6$K7+=GS]8A[EQU;7+7_=NZ,R8J;FR
M(+"BT.3D@@!,U\C=QNE5:)ZE=M2*8=G0[$/C'>B\TMIM-S[!,$WS/U!+ P04
M    " !I@*Q4R%R<'!T#   P$@  #0   'AL+W-T>6QE<RYX;6S=6%%KVS 0
M_BM&':.%4<=QZ\9K$M@"A<$V"NW#WHH2RXE ECQ9[I+^^NDLQTE37<CZL*5S
M2"W=I_ONT]VY,AE69B78W8(Q$RP+(:L161A3?@S#:K9@!:W.5<FD17*E"VKL
M5,_#JM2,9A4X%2+L]WI)6% NR7@HZ^*F,%4P4[4T(W+1F0)W^Y*-2)1<D,#1
M353&1N3A]/W/6IGK=X&[GWPX.>D]G%WOVD\;X(R$7M++ TC/>SBOQ3#JY##J
M_>0X_=5!]'NX&^*PS?UXF"NY*4%,G,%&I@4+'JD8D0D5?*HY>.6TX&+ES'TP
MS)10.C"V]E9*!);JR<&1FT%;M#P%ETHWL5T$]W?:+M\!UC,0R(7H!/:),XR'
M)36&:7EC)\WBQO@""MKQ_:JT"N>:KJ+^)=DX-#<;9*ITQG07)B)KTW@H6 YR
M-)\OX&Y4&0)HC"KL(.-TKB1M-*P]VH&EG3$A[N"9^9$_XU[F6S7M045E-[2"
MVJ&C<1/@WV9SW-NTK^,-2OZHS.?:;D<V<^@5=JM9SI?-?)EW C#V"&>G92E6
MGP2?RX*YS1\<<#RD:[]@H31_LM&@56;6P#0)'IDV?+9M^:5I><^69MU.RQS7
MW'^#FO]NGN=,,DW%MFC;^\><Y5<KCJ_^E>3FO\JN8*_&]B \=I&7;T%D<OPB
MX_3X-;8O(T<G,FR/QJWS]]GIVUD#>,L9D>_P/B4V08-IS87ALITM>)8Q^>(0
MMO2&3NWK\#-^NSYC.:V%N>_ $=F,O[&,UT7:K;J%1+2K-N.OL+THZ5ZQ;"PN
M,[9DV:2=ZOFT&09V8*.V%SCL(C?-Y4<P'X?Y$<"P.)@"S,=Y87'^I_T,T/TX
M#-,V\"(#U&> ^C@O'S)I/E@<OT]J+_].TS2.DP3+Z&3B53#!\I8D\/6S8=K
M XL#D?XLUWBU\0[9WP=83?=U"+93O!.QG>*Y!L2?-_!(4W^UL3C@@54!ZQV(
M[X\#/>7WB6.H*J8->X)Q)$TQ!'K1WZ-)@F0G@8^_/MA3$L=IZD< \RN(8PR!
MIQ%', 6@ 4/BN#D'=\ZC<'U.A9O?B,:_ 5!+ P04    " !I@*Q4EXJ[',
M   3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!
M5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]I
MSI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z
M3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=
MQ_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( &F
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M.@S?NNGX<?G81 GG(\X6;L9WOU!+ P04    " !I@*Q48]:*%)L!  "4%P
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M;%!+ 0(4 Q0    ( &F K%2DT6Y@[0   "L"   1              "  :\
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M2P$"% ,4    " !I@*Q4)_M9M-8"  "]"0  &               @($S$P
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ :8"L5$Q4J09&
M!   <PX  !@              ("!/Q8  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( &F K%3FJ8@R$@4  %$4   8              "
M@;L:  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !I@*Q4
M/Z<QP30&  !)%P  &               @($#(   >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ :8"L5&A-ZY-C!0  K@L  !@
M     ("!;28  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M &F K%1!,M_*I!8  $M$   8              " @08L  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " !I@*Q4037S&5<B  "P?   &
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M970Q,RYX;6Q02P$"% ,4    " !I@*Q4.BQ V"P'  !T%   &0
M    @(%-@P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M &F K%1*PE#\D ,  #D(   9              " @;"*  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ :8"L5/LC6U]C P  ,P<  !D
M             ("!=XX  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " !I@*Q48LCQ[;D5  ":0@  &0              @($1D@  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( &F K%037K7\5 ,
M )X'   9              " @0&H  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ :8"L5"M#$C9_ @  *P4  !D              ("!
MC*L  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !I@*Q4
M+B!_(T$%  #F#   &0              @(%"K@  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( &F K%2AZ]!ME (  )(%   9
M      " @;JS  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ :8"L5$:IX7K1 @  ^ 4  !D              ("!A;8  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !I@*Q4-9M8QR<"  "5!
M&0              @(&-N0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( &F K%35BB)9$ 0  !4-   9              " @>N[  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ :8"L5"Z923S-
M @  R0D  !D              ("!,L   'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " !I@*Q4ANK>!'4,  !O4P  &0
M@($VPP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( &F
MK%2+KI?KXP0  )D2   9              " @>+/  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ :8"L5+/KBS8W P  O0H  !D
M         ("!_-0  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " !I@*Q4BRC%PD $  !4$   &0              @(%JV   >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( &F K%2C2(#%H@,  /(,
M   9              " @>'<  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ :8"L5-1Q^M ' P  #0D  !D              ("!NN
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !I@*Q4GP33
MI?T"  #.!P  &0              @('XXP  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( &F K%1LB@C[500  "0/   9
M  " @2SG  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M:8"L5!J_O=B! @  LP8  !D              ("!N.L  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " !I@*Q4\+-C#H<$  !D$0  &0
M            @(%P[@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( &F K%0_/,XQ#@0  #@0   9              " @2[S  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ :8"L5)W&['SU @
MM D  !D              ("!<_<  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " !I@*Q45P3OOW("  !9!0  &0              @(&?
M^@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( &F K%3(
M7)P<'0,  # 2   -              "  4C]  !X;"]S='EL97,N>&UL4$L!
M A0#%     @ :8"L5)>*NQS     $P(   L              ( !D  ! %]R
M96QS+RYR96QS4$L! A0#%     @ :8"L5.6X*)-_ P  QAD   \
M     ( !>0$! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( &F K%2WO<)+
M@0$  "D7   :              "  24% 0!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( &F K%1CUHH4FP$  )07   3
M  "  =X& 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     N "X >0P  *H(
$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>137</ContextCount>
  <ElementCount>223</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Strategic Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StrategicAgreements</Role>
      <ShortName>Strategic Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Leased Properties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LeasedProperties</Role>
      <ShortName>Leased Properties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Grant Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/GrantAwards</Role>
      <ShortName>Grant Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2131110 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/StockholdersEquity</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/StockBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Leased Properties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LeasedPropertiesTables</Role>
      <ShortName>Leased Properties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/LeasedProperties</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2329305 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/NetLossPerShare</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization and Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/OrganizationandDescriptionofBusinessDetails</Role>
      <ShortName>Organization and Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://darebioscience.com/role/OrganizationandDescriptionofBusiness</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Financial Assets and Liabilities Remeasured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Financial Assets and Liabilities Remeasured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Strategic Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StrategicAgreementsDetails</Role>
      <ShortName>Strategic Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://darebioscience.com/role/StrategicAgreements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Stock Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Leased Properties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails</Role>
      <ShortName>Leased Properties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Leased Properties - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leased Properties - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://darebioscience.com/role/CommitmentsandContingencies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Grant Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/GrantAwardsDetails</Role>
      <ShortName>Grant Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://darebioscience.com/role/GrantAwards</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="dare-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://darebioscience.com/role/SubsequentEvents</ParentRole>
      <Position>38</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="dare-20220331.htm">dare-20220331.htm</File>
    <File>dare-20220331.xsd</File>
    <File>dare-20220331_cal.xml</File>
    <File>dare-20220331_def.xml</File>
    <File>dare-20220331_lab.xml</File>
    <File>dare-20220331_pre.xml</File>
    <File>ex101_10q033122.htm</File>
    <File>ex102_10q033122.htm</File>
    <File>ex_102noneedirectorcomppol.htm</File>
    <File>exhibit311_20220331.htm</File>
    <File>exhibit312_20220331.htm</File>
    <File>exhibit321_20220331.htm</File>
    <File>exhibit322_20220331.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>dare-20220331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="296">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "dare-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "contextCount": 137,
   "dts": {
    "calculationLink": {
     "local": [
      "dare-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "dare-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "dare-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dare-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dare-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "dare-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 378,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 1,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 6
   },
   "keyCustom": 51,
   "keyStandard": 172,
   "memberCustom": 33,
   "memberStandard": 18,
   "nsprefix": "dare",
   "nsuri": "http://darebioscience.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://darebioscience.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Stockholders' Equity",
     "role": "http://darebioscience.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Stock-Based Compensation",
     "role": "http://darebioscience.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Leased Properties",
     "role": "http://darebioscience.com/role/LeasedProperties",
     "shortName": "Leased Properties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Commitments and Contingencies",
     "role": "http://darebioscience.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dare:GrantAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Grant Awards",
     "role": "http://darebioscience.com/role/GrantAwards",
     "shortName": "Grant Awards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dare:GrantAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - Net Loss Per Share",
     "role": "http://darebioscience.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131110 - Disclosure - Subsequent Events",
     "role": "http://darebioscience.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://darebioscience.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "ic0c2931b38c749a8aac31ab58ed72510_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "ic0c2931b38c749a8aac31ab58ed72510_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://darebioscience.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Leased Properties (Tables)",
     "role": "http://darebioscience.com/role/LeasedPropertiesTables",
     "shortName": "Leased Properties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329305 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://darebioscience.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization and Description of Business (Details)",
     "role": "http://darebioscience.com/role/OrganizationandDescriptionofBusinessDetails",
     "shortName": "Organization and Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "ic0c2931b38c749a8aac31ab58ed72510_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)",
     "role": "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "ic0c2931b38c749a8aac31ab58ed72510_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "dare:WorkingCapitalIncreaseDeficit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i753c4d96be1e4ba3967076ff69f73d0d_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Financial Assets and Liabilities Remeasured on a Recurring Basis (Details)",
     "role": "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Financial Assets and Liabilities Remeasured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i753c4d96be1e4ba3967076ff69f73d0d_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "dare:LicenseFee",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Strategic Agreements (Details)",
     "role": "http://darebioscience.com/role/StrategicAgreementsDetails",
     "shortName": "Strategic Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "ie1a197ace83745b5af0af06d9e6a03ef_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "dare:AssetAcquisitionContingentConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i8375b393afa24fd4b4172cd82f83fced_D20210401-20210430",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "dare:PercentageOfAggregateCommission",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "role": "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i8375b393afa24fd4b4172cd82f83fced_D20210401-20210430",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "dare:PercentageOfAggregateCommission",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "ic0c2931b38c749a8aac31ab58ed72510_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)",
     "role": "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails",
     "shortName": "Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "ic0c2931b38c749a8aac31ab58ed72510_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "ic0c2931b38c749a8aac31ab58ed72510_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Stock Based Compensation - Additional Information (Details)",
     "role": "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "ic0c2931b38c749a8aac31ab58ed72510_I20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "ic0c2931b38c749a8aac31ab58ed72510_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "ic0c2931b38c749a8aac31ab58ed72510_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i5bcbbadf58fc412c9319a78f2b9da62f_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Details)",
     "role": "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "idf2231aefe254fee96b7aeae2d91ae6e_D20220101-20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "if248f08c609e432db641de162429b03e_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)",
     "role": "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails",
     "shortName": "Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "ied5f9449859d4a96a3953aabaec51ac8_D20220101-20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Details)",
     "role": "http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails",
     "shortName": "Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "ia70cb47052db467ab271c5cebe1a8cb5_I20180701",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetRentableArea",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Leased Properties - Additional Information (Details)",
     "role": "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails",
     "shortName": "Leased Properties - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "ia70cb47052db467ab271c5cebe1a8cb5_I20180701",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetRentableArea",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "ic0c2931b38c749a8aac31ab58ed72510_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Leased Properties - Future Minimum Lease Payments (Details)",
     "role": "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails",
     "shortName": "Leased Properties - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "ic0c2931b38c749a8aac31ab58ed72510_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "dare:PaymentOfAdditionalConsiderationInBusinessCombination",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://darebioscience.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i1668c60b90eb40c1b26a55cdec6001a8_D20200401-20200430",
      "decimals": "0",
      "lang": "en-US",
      "name": "dare:CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i010eed1efee345f4bd75243e4aa2a9c3_D20210701-20210731",
      "decimals": "-4",
      "first": true,
      "lang": "en-US",
      "name": "dare:ProceedsFromAwardOfGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Grant Awards (Details)",
     "role": "http://darebioscience.com/role/GrantAwardsDetails",
     "shortName": "Grant Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i010eed1efee345f4bd75243e4aa2a9c3_D20210701-20210731",
      "decimals": "-4",
      "first": true,
      "lang": "en-US",
      "name": "dare:ProceedsFromAwardOfGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Details)",
     "role": "http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails",
     "shortName": "Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i4b95783721914c71aa6fe27dd4fcf58c_D20220401-20220510",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - Subsequent Events (Details)",
     "role": "http://darebioscience.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i4b95783721914c71aa6fe27dd4fcf58c_D20220401-20220510",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "role": "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i6063f716c8274a639d5c2235427b50d2_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Unaudited)",
     "role": "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i6063f716c8274a639d5c2235427b50d2_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Description of Business",
     "role": "http://darebioscience.com/role/OrganizationandDescriptionofBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Strategic Agreements",
     "role": "http://darebioscience.com/role/StrategicAgreements",
     "shortName": "Strategic Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20220331.htm",
      "contextRef": "i90db0cf196ec4f5a901b1df201c7dfc2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 54,
   "tag": {
    "dare_ADVATecAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ADVA Tec agreement.",
        "label": "A D V A Tec Agreement [Member]",
        "terseLabel": "ADVA Tec Agreement"
       }
      }
     },
     "localname": "ADVATecAgreementMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_ATMEquityOfferingProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Equity Offering Program",
        "label": "ATM Equity Offering Program [Member]",
        "terseLabel": "ATM Equity Offering Program"
       }
      }
     },
     "localname": "ATMEquityOfferingProgramMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_AdditionalPotentialFundingRelatedToGrantAward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Potential Funding Related To Grant Award",
        "label": "Additional Potential Funding Related To Grant Award",
        "terseLabel": "Additional potential grant funding"
       }
      }
     },
     "localname": "AdditionalPotentialFundingRelatedToGrantAward",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares",
        "label": "Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares",
        "terseLabel": "Issuance of common stock from the exercise of warrants (in shares)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member]",
        "label": "Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member]",
        "terseLabel": "Amended and Restated Two Thousand Fourteen Stock Incentive Plan"
       }
      }
     },
     "localname": "AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_April2021AtTheMarketSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "April 2021 At The Market Sales Agreement",
        "label": "April 2021 At The Market Sales Agreement [Member]",
        "terseLabel": "April 2021 At The Market Sales Agreement"
       }
      }
     },
     "localname": "April2021AtTheMarketSalesAgreementMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_AssetAcquisitionContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Contingent Consideration",
        "label": "Asset Acquisition, Contingent Consideration",
        "terseLabel": "Asset acquisition, contingent consideration"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsideration",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_AssetAcquisitionContingentConsiderationCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Contingent Consideration, Current",
        "label": "Asset Acquisition, Contingent Consideration, Current",
        "terseLabel": "Current portion of contingent consideration"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsiderationCurrent",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_AssignmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assignment Agreement [Member]",
        "label": "Assignment Agreement [Member]",
        "terseLabel": "Assignment Agreement"
       }
      }
     },
     "localname": "AssignmentAgreementMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_BayerHealthcareLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer Healthcare License Agreement [Member]",
        "label": "Bayer Healthcare License Agreement [Member]",
        "terseLabel": "Bayer Healthcare License Agreement"
       }
      }
     },
     "localname": "BayerHealthcareLicenseAgreementMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents.",
        "label": "Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_CRADAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CRADA",
        "label": "CRADA [Member]",
        "terseLabel": "CRADA"
       }
      }
     },
     "localname": "CRADAMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_CatalentAndMilanaPharmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Catalent and MilanaPharm",
        "label": "Catalent and MilanaPharm [Member]",
        "terseLabel": "Catalent and MilanaPharm"
       }
      }
     },
     "localname": "CatalentAndMilanaPharmMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_ClassOfWarrantOrRightsWarrantsExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or rights warrants expiration date.",
        "label": "Class Of Warrant Or Rights Warrants Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsWarrantsExpirationDate",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "dare_ClinicalAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical And Regulatory Milestones [Member]",
        "label": "Clinical And Regulatory Milestones [Member]",
        "terseLabel": "Clinical and Regulatory Milestones"
       }
      }
     },
     "localname": "ClinicalAndRegulatoryMilestonesMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dare_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received",
        "label": "Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received",
        "terseLabel": "Loan under paycheck protection program"
       }
      }
     },
     "localname": "CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_DARELARC1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DARE-LARC1",
        "label": "DARE-LARC1 [Member]",
        "terseLabel": "DARE-LARC1"
       }
      }
     },
     "localname": "DARELARC1Member",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_DeemedDividendFromTriggerOfRoundDownProvisionFeature": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed Dividend From Trigger Of Round Down Provision Feature",
        "label": "Deemed Dividend From Trigger Of Round Down Provision Feature",
        "terseLabel": "Deemed dividend from trigger of down round provision feature"
       }
      }
     },
     "localname": "DeemedDividendFromTriggerOfRoundDownProvisionFeature",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_DeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding Current",
        "label": "Deferred Grant Funding Current",
        "terseLabel": "Deferred grant funding"
       }
      }
     },
     "localname": "DeferredGrantFundingCurrent",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets",
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_DeferredOfferingCostsUnamortizedPortion": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Offering Costs, Unamortized Portion",
        "label": "Deferred Offering Costs, Unamortized Portion",
        "terseLabel": "Unamortized costs related to legal, accounting, and other fees"
       }
      }
     },
     "localname": "DeferredOfferingCostsUnamortizedPortion",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_EstimatedFairValueOfWarrantsRecordedInEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Fair Value Of Warrants Recorded In Equity",
        "label": "Estimated Fair Value Of Warrants Recorded In Equity",
        "terseLabel": "Estimated fair value of warrants recorded in equity"
       }
      }
     },
     "localname": "EstimatedFairValueOfWarrantsRecordedInEquity",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_ForgivenessOfPaycheckProtectionProgramNotePayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forgiveness of Paycheck Protection Program Note Payable",
        "label": "Forgiveness of Paycheck Protection Program Note Payable",
        "terseLabel": "Forgiveness of Paycheck Protection Program note payable"
       }
      }
     },
     "localname": "ForgivenessOfPaycheckProtectionProgramNotePayable",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_GoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Going Concern",
        "label": "Going Concern [Policy Text Block]",
        "terseLabel": "Going Concern"
       }
      }
     },
     "localname": "GoingConcernPolicyTextBlock",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dare_GrantAwardTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Award [Text Block]",
        "label": "Grant Award [Text Block]",
        "terseLabel": "Grant Awards"
       }
      }
     },
     "localname": "GrantAwardTextBlock",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/GrantAwards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dare_GrantDAREFRT1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant, DARE-FRT1",
        "label": "Grant, DARE-FRT1 [Member]",
        "terseLabel": "Grant, DARE-FRT1"
       }
      }
     },
     "localname": "GrantDAREFRT1Member",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_GrantDAREPTB1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant, DARE-PTB1",
        "label": "Grant, DARE-PTB1 [Member]",
        "terseLabel": "Grant, DARE-PTB1"
       }
      }
     },
     "localname": "GrantDAREPTB1Member",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_HammockPharmaceuticalsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hammock Pharmaceuticals, Inc. [Member]",
        "label": "Hammock Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Hammock Pharmaceuticals, Inc"
       }
      }
     },
     "localname": "HammockPharmaceuticalsInc.Member",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_IncreaseDecreaseInDeferredGrantFunding": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Deferred Grant Funding",
        "label": "Increase (Decrease) In Deferred Grant Funding",
        "negatedTerseLabel": "Deferred grant funding"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredGrantFunding",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in other non-current assets and deferred charges.",
        "label": "Increase Decrease In Other Non Current Assets And Deferred Charges",
        "negatedLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_JuniperPharmaceuticalsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Juniper Pharmaceuticals, Inc. [Member]",
        "label": "Juniper Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Juniper Pharmaceuticals, Inc"
       }
      }
     },
     "localname": "JuniperPharmaceuticalsInc.Member",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_LicenseAgreementInitialTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Initial Term",
        "label": "License Agreement, Initial Term",
        "terseLabel": "Initial term of license agreement"
       }
      }
     },
     "localname": "LicenseAgreementInitialTerm",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dare_LicenseAgreementNoticePeriodOfTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement Notice Period Of Termination",
        "label": "License Agreement Notice Period Of Termination",
        "terseLabel": "Certain clinical and regulatory development milestone payments"
       }
      }
     },
     "localname": "LicenseAgreementNoticePeriodOfTermination",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement, termination period due to performance failure.",
        "label": "License Agreement Termination Period Due To Performance Failure",
        "terseLabel": "License agreement termination period due to performance failure"
       }
      }
     },
     "localname": "LicenseAgreementTerminationPeriodDueToPerformanceFailure",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement Termination Periodic Discontinued Sale Of Product",
        "label": "License Agreement Termination Periodic Discontinued Sale Of Product",
        "terseLabel": "License agreement termination periodic discontinued sale of product"
       }
      }
     },
     "localname": "LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dare_LicenseAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Collaboration Agreement [Member]",
        "label": "License And Collaboration Agreement [Member]",
        "terseLabel": "License and Collaboration Agreement"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_LicenseFee": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Fee",
        "label": "License Fee",
        "terseLabel": "License fees",
        "verboseLabel": "License fee"
       }
      }
     },
     "localname": "LicenseFee",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_LicenseFeeToBePaidUponContingency": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Fee, To Be Paid Upon Contingency",
        "label": "License Fee, To Be Paid Upon Contingency",
        "terseLabel": "License fee to be paid upon contingency"
       }
      }
     },
     "localname": "LicenseFeeToBePaidUponContingency",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensed Product or Process for Vaginal or Urological Use",
        "label": "Licensed Product or Process for Vaginal or Urological Use [Member]",
        "terseLabel": "Licensed Product or Process for Vaginal or Urological Use"
       }
      }
     },
     "localname": "LicensedProductOrProcessForVaginalOrUrologicalUseMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_LincolnParkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lincoln Park",
        "label": "Lincoln Park [Member]",
        "terseLabel": "Lincoln Park"
       }
      }
     },
     "localname": "LincolnParkMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_MBIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MBI",
        "label": "MBI [Member]",
        "terseLabel": "MBI"
       }
      }
     },
     "localname": "MBIMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_MaximumPotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Potential Milestone Payments",
        "label": "Maximum Potential Milestone Payments",
        "terseLabel": "Maximum potential milestone payments"
       }
      }
     },
     "localname": "MaximumPotentialMilestonePayments",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_MicrochipsBiotechInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Microchips Biotech, Inc. [Member]",
        "label": "Microchips Biotech, Inc. [Member]",
        "terseLabel": "Microchips Biotech, Inc."
       }
      }
     },
     "localname": "MicrochipsBiotechInc.Member",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_MilanaPharmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MilanaPharm [Member]",
        "label": "MilanaPharm [Member]",
        "terseLabel": "MilanaPharm"
       }
      }
     },
     "localname": "MilanaPharmMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_MilestonePaymentsContingentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments, contingent amount.",
        "label": "Milestone Payments, Contingent Amount",
        "terseLabel": "Milestone payment paid in common stock"
       }
      }
     },
     "localname": "MilestonePaymentsContingentAmount",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Contingent Amount, First Commercial Sale Amount",
        "label": "Milestone Payments, Contingent Amount, First Commercial Sale Amount",
        "terseLabel": "First commercial sale amount"
       }
      }
     },
     "localname": "MilestonePaymentsContingentAmountFirstCommercialSaleAmount",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_MilestonePaymentsContingentAmountPayableNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Contingent Amount Payable, Net",
        "label": "Milestone Payments, Contingent Amount Payable, Net",
        "terseLabel": "Net amount payable"
       }
      }
     },
     "localname": "MilestonePaymentsContingentAmountPayableNet",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Contingent Amount, Sales Based Milestones Amount",
        "label": "Milestone Payments, Contingent Amount, Sales Based Milestones Amount",
        "terseLabel": "Sales based milestones amount"
       }
      }
     },
     "localname": "MilestonePaymentsContingentAmountSalesBasedMilestonesAmount",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_MilestonePaymentsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Term",
        "label": "Milestone Payments, Term",
        "terseLabel": "Milestone payments term"
       }
      }
     },
     "localname": "MilestonePaymentsTerm",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dare_NICHDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NICHD",
        "label": "NICHD [Member]",
        "terseLabel": "NICHD"
       }
      }
     },
     "localname": "NICHDMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_NetProceedsFromIssuanceOfCommonStockAndWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds from issuance of common stock and warrants.",
        "label": "Net Proceeds From Issuance Of Common Stock And Warrants",
        "terseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "NetProceedsFromIssuanceOfCommonStockAndWarrants",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_NonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Lease Expense",
        "label": "Non-Cash Lease Expense",
        "terseLabel": "Non-cash operating lease cost"
       }
      }
     },
     "localname": "NonCashLeaseExpense",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_NotesPayableCurrentPlusAccruedInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable, Current, Plus Accrued Interest",
        "label": "Notes Payable, Current, Plus Accrued Interest",
        "terseLabel": "Notes payable including accrued interest"
       }
      }
     },
     "localname": "NotesPayableCurrentPlusAccruedInterest",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_NumberOfCommonStockWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Common Stock Warrants Exercised",
        "label": "Number Of Common Stock Warrants Exercised",
        "terseLabel": "Number Of Common Stock Warrants Exercised"
       }
      }
     },
     "localname": "NumberOfCommonStockWarrantsExercised",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dare_OrganonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organon",
        "label": "Organon [Member]",
        "terseLabel": "Organon"
       }
      }
     },
     "localname": "OrganonMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_PaymentOfAdditionalConsiderationInBusinessCombination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of Additional Consideration in Business Combination",
        "label": "Payment of Additional Consideration in Business Combination",
        "terseLabel": "Payment of additional consideration"
       }
      }
     },
     "localname": "PaymentOfAdditionalConsiderationInBusinessCombination",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_PaymentsToStockholdersRepresentativeInBusinessCombination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Stockholders' Representative in Business Combination",
        "label": "Payments to Stockholders' Representative in Business Combination",
        "terseLabel": "Cash paid to stockholders' representative"
       }
      }
     },
     "localname": "PaymentsToStockholdersRepresentativeInBusinessCombination",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_PercentageOfAggregateCommission": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of aggregate commission.",
        "label": "Percentage Of Aggregate Commission",
        "terseLabel": "Commission percent"
       }
      }
     },
     "localname": "PercentageOfAggregateCommission",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of rights to inventions by employees under license agreement.",
        "label": "Percentage Of Rights To Inventions By Employees Under License Agreement",
        "terseLabel": "Percentage of rights to inventions by employees under license agreement"
       }
      }
     },
     "localname": "PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dare_PercentageOfRoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty rate.",
        "label": "Percentage Of Royalty Rate",
        "terseLabel": "Percentage of royalty rate"
       }
      }
     },
     "localname": "PercentageOfRoyaltyRate",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dare_PeriodofInsufficientCashandLiquidityRequirements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of Insufficient Cash and Liquidity Requirements",
        "label": "Period of Insufficient Cash and Liquidity Requirements",
        "terseLabel": "Period of insufficient cash and liquidity requirements"
       }
      }
     },
     "localname": "PeriodofInsufficientCashandLiquidityRequirements",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Annual License Maintenance Fee, Payments In Year One",
        "label": "Potential Annual License Maintenance Fee, Payments In Year One",
        "terseLabel": "Potential annual license maintenance fee, payments in year one"
       }
      }
     },
     "localname": "PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Annual License Maintenance Fee Payments, Thereafter",
        "label": "Potential Annual License Maintenance Fee Payments, Thereafter",
        "terseLabel": "Potential annual license maintenance fee payments, thereafter"
       }
      }
     },
     "localname": "PotentialAnnualLicenseMaintenanceFeePaymentsThereafter",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_ProceedsFromAwardOfGrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Award Of Grant",
        "label": "Proceeds From Award Of Grant",
        "terseLabel": "Amount awarded for grant"
       }
      }
     },
     "localname": "ProceedsFromAwardOfGrant",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_ProceedsFromIssuanceOfCommonStockAndWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and warrants.",
        "label": "Proceeds From Issuance Of Common Stock And Warrants",
        "terseLabel": "Proceeds from the exercise of common stock warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement",
        "label": "Purchase Agreement [Member]",
        "terseLabel": "Purchase Agreement"
       }
      }
     },
     "localname": "PurchaseAgreementMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_ReceivableForExpensesEligibleForReimbursement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable For Expenses Eligible For Reimbursement",
        "label": "Receivable For Expenses Eligible For Reimbursement",
        "terseLabel": "Receivable for expenses eligible for reimbursement"
       }
      }
     },
     "localname": "ReceivableForExpensesEligibleForReimbursement",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_ResearchAndDevelopmentAgreementCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Agreement, Commitment, Amount",
        "label": "Research and Development Agreement, Commitment, Amount",
        "terseLabel": "Total payment"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAgreementCommitmentAmount",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_ResearchAndDevelopmentMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development milestone payment.",
        "label": "Research And Development Milestone Payment",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "ResearchAndDevelopmentMilestonePayment",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_RoyaltyAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Agreement, Term",
        "label": "Royalty Agreement, Term",
        "terseLabel": "Royalty agreement term"
       }
      }
     },
     "localname": "RoyaltyAgreementTerm",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dare_SalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestones [Member]",
        "label": "Sales Milestones [Member]",
        "terseLabel": "Sales Milestones"
       }
      }
     },
     "localname": "SalesMilestonesMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by Share-based payment award fair value assumptions forfeiture rate.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate",
        "terseLabel": "Forfeiture rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dare_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dare_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dare_StockholdersEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders' equity.",
        "label": "Stockholders Equity [Line Items]",
        "terseLabel": "Stockholders Equity [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityLineItems",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dare_StockholdersEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders' equity.",
        "label": "Stockholders Equity [Table]",
        "terseLabel": "Stockholders Equity [Table]"
       }
      }
     },
     "localname": "StockholdersEquityTable",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC.",
        "label": "Strategic Science And Technologies D Limited Liability Company And Strategic Science Technologies Limited Liability Company [Member]",
        "terseLabel": "Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company"
       }
      }
     },
     "localname": "StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fourteen employee stock purchase plan.",
        "label": "Two Thousand And Fourteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2014 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandAndFourteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_UpfrontLicenseFeeAmountPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront License Fee, Amount Paid",
        "label": "Upfront License Fee, Amount Paid",
        "terseLabel": "Upfront license fee paid"
       }
      }
     },
     "localname": "UpfrontLicenseFeeAmountPaid",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_UpfrontLicenseFeePaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront License Fee Paid",
        "label": "Upfront License Fee Paid",
        "terseLabel": "Upfront license fee paid"
       }
      }
     },
     "localname": "UpfrontLicenseFeePaid",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upon achievement of specified development and regulatory milestones.",
        "label": "Upon Achievement Of Specified Development And Regulatory Milestones [Member]",
        "terseLabel": "Upon Achievement of Specified Development and Regulatory Milestones"
       }
      }
     },
     "localname": "UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upon Achieving Certain Clinical And Regulatory Development Milestones [Member]",
        "label": "Upon Achieving Certain Clinical And Regulatory Development Milestones [Member]",
        "terseLabel": "Upon Achieving Certain Clinical and Regulatory Development Milestones"
       }
      }
     },
     "localname": "UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_UponAchievingCertainCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upon Achieving Certain Commercial Milestones [Member]",
        "label": "Upon Achieving Certain Commercial Milestones [Member]",
        "terseLabel": "Upon Achieving Certain Commercial Milestones"
       }
      }
     },
     "localname": "UponAchievingCertainCommercialMilestonesMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_UponAchievingCertainDevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upon Achieving Certain Development Milestones [Member]",
        "label": "Upon Achieving Certain Development Milestones [Member]",
        "terseLabel": "Upon Achieving Certain Development Milestones"
       }
      }
     },
     "localname": "UponAchievingCertainDevelopmentMilestonesMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_UponReachingCertainWorldwideNetSalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upon reaching certain worldwide net sales milestones.",
        "label": "Upon Reaching Certain Worldwide Net Sales Milestones [Member]",
        "terseLabel": "Upon Reaching Certain Worldwide Net Sales Milestones"
       }
      }
     },
     "localname": "UponReachingCertainWorldwideNetSalesMilestonesMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants expiring on april four two thousand twenty six.",
        "label": "Warrants Expiring On April Four Two Thousand Twenty Six [Member]",
        "terseLabel": "Warrants Expiring on April 4, 2026"
       }
      }
     },
     "localname": "WarrantsExpiringOnAprilFourTwoThousandTwentySixMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member]",
        "label": "Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member]",
        "terseLabel": "Warrants Expiring on February 15, 2023"
       }
      }
     },
     "localname": "WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_WeightedAverageAmortizationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Amortization Period",
        "label": "Weighted Average Amortization Period",
        "terseLabel": "Weighted average amortization period"
       }
      }
     },
     "localname": "WeightedAverageAmortizationPeriod",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dare_WorkingCapitalIncreaseDeficit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working Capital Increase (Deficit)",
        "label": "Working Capital Increase (Deficit)",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapitalIncreaseDeficit",
     "nsuri": "http://darebioscience.com/20220331",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails",
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails",
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r35",
      "r37",
      "r73",
      "r74",
      "r162",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails",
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r161",
      "r170",
      "r215",
      "r217",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r392",
      "r394",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r161",
      "r170",
      "r215",
      "r217",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r392",
      "r394",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r126",
      "r200",
      "r202",
      "r355",
      "r391",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r126",
      "r200",
      "r202",
      "r355",
      "r391",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r161",
      "r170",
      "r204",
      "r215",
      "r217",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r392",
      "r394",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r161",
      "r170",
      "r204",
      "r215",
      "r217",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r392",
      "r394",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r36",
      "r37",
      "r73",
      "r74",
      "r162",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails",
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201711Member": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2017-11 Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.",
        "label": "Accounting Standards Update 2017-11 [Member]",
        "terseLabel": "Accounting Standards Update 2017-11"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201711Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r25",
      "r340"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails",
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r40",
      "r41",
      "r42",
      "r383",
      "r402",
      "r406"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r39",
      "r42",
      "r48",
      "r49",
      "r50",
      "r76",
      "r77",
      "r78",
      "r277",
      "r397",
      "r398",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r247",
      "r248",
      "r249",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r79",
      "r80",
      "r81",
      "r82",
      "r91",
      "r130",
      "r131",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r148",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r260",
      "r261",
      "r262",
      "r263",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r334",
      "r356",
      "r357",
      "r358",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r218",
      "r220",
      "r253",
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r160",
      "r183",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of common stock from the exercise of warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r220",
      "r241",
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r72",
      "r115",
      "r118",
      "r124",
      "r132",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r275",
      "r278",
      "r302",
      "r338",
      "r340",
      "r375",
      "r382"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r11",
      "r34",
      "r72",
      "r132",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r275",
      "r278",
      "r302",
      "r338",
      "r340"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r221",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r214",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r214",
      "r216",
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned",
        "terseLabel": "Business acquisition transaction value"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Common stock issued to microchips capital stock holders (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business combination shares issued (in usd per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r267",
      "r268",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration, liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessDevelopment": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service.",
        "label": "Business Development",
        "terseLabel": "Business development"
       }
      }
     },
     "localname": "BusinessDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r23",
      "r66"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r61",
      "r66",
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r61",
      "r312"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r70",
      "r72",
      "r94",
      "r95",
      "r96",
      "r98",
      "r100",
      "r109",
      "r110",
      "r111",
      "r132",
      "r149",
      "r153",
      "r154",
      "r155",
      "r158",
      "r159",
      "r168",
      "r169",
      "r173",
      "r177",
      "r302",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r186",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price (in usd per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Shares underlying outstanding warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r186",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r271",
      "r272",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Strategic Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r29",
      "r147",
      "r377",
      "r387"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r76",
      "r77",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16",
      "r340"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 120,000,000 shares authorized; 83,944,119 shares issued and outstanding at March\u00a031, 2022 and December\u00a031, 2021",
        "verboseLabel": "Issues shares"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets",
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r44",
      "r46",
      "r47",
      "r52",
      "r379",
      "r389"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r188",
      "r189",
      "r201"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred license revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostMaintenance": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered.",
        "label": "Cost, Maintenance",
        "terseLabel": "Annual maintenance fee"
       }
      }
     },
     "localname": "CostMaintenance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent",
        "terseLabel": "Unamortized stock-based compensation expense"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r33",
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Legal, accounting and other fees related to purchase agreement"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r64",
      "r142"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r53",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r92",
      "r94",
      "r98",
      "r99",
      "r100",
      "r104",
      "r105",
      "r292",
      "r293",
      "r380",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Loss per common share - basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r53",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r94",
      "r98",
      "r99",
      "r100",
      "r104",
      "r105",
      "r292",
      "r293",
      "r380",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Loss per common share - diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails",
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r48",
      "r49",
      "r50",
      "r76",
      "r77",
      "r78",
      "r80",
      "r88",
      "r90",
      "r108",
      "r136",
      "r183",
      "r185",
      "r247",
      "r248",
      "r249",
      "r262",
      "r263",
      "r291",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r397",
      "r398",
      "r399",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r295",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r294",
      "r295",
      "r297",
      "r298",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r163",
      "r205",
      "r206",
      "r211",
      "r213",
      "r295",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r205",
      "r206",
      "r211",
      "r213",
      "r295",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r295",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r299",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r64",
      "r166",
      "r167"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Gain on extinguishment of notes payable and accrued interest",
        "terseLabel": "Gain on extinguishment of note payable"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "verboseLabel": "Initial payment"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r144",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Incremental borrowing rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: accreted interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term of operating lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leased Properties"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedProperties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r26",
      "r72",
      "r119",
      "r132",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r276",
      "r278",
      "r279",
      "r302",
      "r338",
      "r339"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r72",
      "r132",
      "r302",
      "r340",
      "r376",
      "r385"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r28",
      "r72",
      "r132",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r276",
      "r278",
      "r279",
      "r302",
      "r338",
      "r339",
      "r340"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r61",
      "r62",
      "r65"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r61",
      "r62",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "negatedTerseLabel": "Cash flow from operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r43",
      "r45",
      "r50",
      "r51",
      "r65",
      "r72",
      "r79",
      "r83",
      "r84",
      "r85",
      "r86",
      "r89",
      "r90",
      "r97",
      "r115",
      "r117",
      "r120",
      "r123",
      "r125",
      "r132",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r293",
      "r302",
      "r378",
      "r388"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedTerseLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net rentable area for properties owned.",
        "label": "Net Rentable Area",
        "terseLabel": "Square footage of office space"
       }
      }
     },
     "localname": "NetRentableArea",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r115",
      "r117",
      "r120",
      "r123",
      "r125"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r327",
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Non-cash lease expenses"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets",
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities long-term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets",
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r323",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for measurement of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating lease, right-of-use asset, statement of financial position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r330",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/OrganizationandDescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Non Current Assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r221",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15",
      "r340"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r139",
      "r140"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Warrant exercises, gross"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r143",
      "r340",
      "r381",
      "r386"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Obligation to purchase common stock"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]",
        "terseLabel": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the maximum potential amount of consideration, undiscounted, that could be transferred under the registration payment arrangement.",
        "label": "Registration Payment Arrangement, Maximum Potential Consideration",
        "terseLabel": "Potential additional consideration payable"
       }
      }
     },
     "localname": "RegistrationPaymentArrangementMaximumPotentialConsideration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r212",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r212",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r212",
      "r335",
      "r337",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "auth_ref": [
      "r257",
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross",
        "terseLabel": "Other cost"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of customer funding recorded as an offset to costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.",
        "label": "Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred",
        "terseLabel": "Credits recorded to research and development expense for costs related to award"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r256",
      "r354",
      "r409"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r185",
      "r250",
      "r340",
      "r384",
      "r401",
      "r406"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r76",
      "r77",
      "r78",
      "r80",
      "r88",
      "r90",
      "r136",
      "r247",
      "r248",
      "r249",
      "r262",
      "r263",
      "r291",
      "r397",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r113",
      "r114",
      "r116",
      "r121",
      "r122",
      "r126",
      "r127",
      "r128",
      "r199",
      "r200",
      "r355"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue from grant for notice of award"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation, amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r329",
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Shares of common stock for net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r220",
      "r240",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r220",
      "r240",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r221",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r224",
      "r231",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity for Amended 2014 Plan and Related Information"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r186",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Options to purchase number of outstanding shares of common stock (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Canceled/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value of options granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r226",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding ending balance (in shares)",
        "periodStartLabel": "Outstanding beginning balance (in shares)",
        "terseLabel": "Stock options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding ending balance (in usd per share)",
        "periodStartLabel": "Outstanding beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Annual percentage increase in outstanding number of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r219",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled/forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r235",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of increase (decrease) of non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease)",
        "terseLabel": "Increase in number of shares authorized (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r68",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r70",
      "r72",
      "r94",
      "r95",
      "r96",
      "r98",
      "r100",
      "r109",
      "r110",
      "r111",
      "r132",
      "r149",
      "r153",
      "r154",
      "r155",
      "r158",
      "r159",
      "r168",
      "r169",
      "r173",
      "r177",
      "r183",
      "r302",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r31",
      "r48",
      "r49",
      "r50",
      "r76",
      "r77",
      "r78",
      "r80",
      "r88",
      "r90",
      "r108",
      "r136",
      "r183",
      "r185",
      "r247",
      "r248",
      "r249",
      "r262",
      "r263",
      "r291",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r397",
      "r398",
      "r399",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r108",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r183",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r183",
      "r185",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r183",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r20",
      "r21",
      "r72",
      "r129",
      "r132",
      "r302",
      "r340"
     ],
     "calculation": {
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets",
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r71",
      "r169",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r185",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r319",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r319",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r319",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r319",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r341",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r79",
      "r80",
      "r81",
      "r82",
      "r91",
      "r130",
      "r131",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r148",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r260",
      "r261",
      "r262",
      "r263",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r334",
      "r356",
      "r357",
      "r358",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StrategicAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Warrant, Exercise Price, Decrease",
        "terseLabel": "Warrant, exercise price, decrease (in usd per share)"
       }
      }
     },
     "localname": "WarrantExercisePriceDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r93",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average number of common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r92",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://darebioscience.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=123465656&loc=SL109261606-128450"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99383193&loc=d3e16207-108621"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6806780-109447"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r410": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r411": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r412": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r413": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r414": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r415": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(6))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001401914-22-000051-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001401914-22-000051-xbrl.zip
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M,!L^Q>@Y#DF!#@?_AV(62$>EP3BAQEE,XH0O;B!I7C1[D'@1@]D.)(B5L@P
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M67!%I,-1N:P$6NM<E77"+K:SU Z0,O8W4-:UQD>!OOMN6)9<FMS74'2!]K,
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M#_W^0P+W S2]1=TI4RKNYMZ&V'=C*+Z#; WX/3CXD0;\%DL>XF3EY8.<(-=
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M%! -?"6UC$0,'$:4T9X9CJE&*R_YG4E&-V&N8K66NJ#_'XL$=UM%,;[.DDT
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M2:&76ROM-@5=[Z](75+9=82MXRXT-;HN#5WG$YTHY"I@$H T$ **>:H5[R5
M%A/#!"<V7*E3W;R.:UTK\1G)__U5JEK^GT3^9[4K+*&*EI0&'LFH73'J@6%.
M X2DU(0Z@2V\2KM:%_E_!KK5JA5X7(PBN9]<H\C26Z<6/;#[*:WU?J?=F0;-
M.B%AR;AY,)];%*SP7LO(M8IQ0 E%0/J(F]A#HHE#UCJ1TC&%6)8?:DU=3<]1
MCI?N4+I&CFM1O8VHSJHX03HH#") B90YK;0$QF 3_\168Q,81'IC:[ZSYJJ)
MZ3-085;-/73)N3U=M!L1 >*HXB@'1>\XI?DU.B'7VVN<ZO-4>Z'.(GK@XV^1
M"KUD__G>0?OM%"D.PHXW,RU^0O'+.W#ANYT:+V^#E_.I12KO:PX"*%C.M23
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M,U\C(BPAQ%B:NS\*,J\^UI!<0W(-R:L+R0(*@C6B03-%*8(Z*!E,,"98JIC
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M0 M/XI80( J><J7I*H8,ZB#@ZNDBM2+R9%(]JXA$W8-8*0$C,EH8#%*@G6
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MW_G(OOR]B[\<_NO[P6%4U=]_^75P^(4=O-\/<?SQV7NI]"E$C"5MF2! -2-
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M.C=JCSM*E!VWQWU3:KKQLX/19&H6NQ[$]LX.MK]QB3 *P@+M4C%%0230C'E
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MZS2JI>W^G^78WWF_G1WV'W3A:IUNL4[W)8YM%\?GDX/#CS#J=,QX(JBR@/B
M 8U& E"1,$!!R9FC4"+HHDX'-R\K@30T'E*-YJY/.UD.H)7Y!VT04<X5N7;"
M4%&(E&E%DR+#T_$P4)-8R549ZNG3>7XL,XHBYT6M*D6[^JT2'8>,&+6-A)=E
M-63@BJ.BW^AVSG4KJR%&I]2+-,R(A3W=JO;JP6EZQ--Q\-Y0(?E0*5&E?1(A
MHU_R<LW'-^!CO/?QF]<>>Q0@,,;[E-: @-8F@!"$UM!P+02/?"SQ F?N-"-'
M !WIB6/E5O<JONV]6F5^>9=.S(SWEL^1/6I&NC$CH?VS;]*E=%N+HVEKHY'+
MF 92!0<0PU)X[QRE..7_7\=&TRA7GF2:T)X3!F4ORA#J1BK$PA3.UW>$*V0E
MA1XAZ9RF+C(?418A0:QW"'/!;N0"OI;K$IOU_D@0.[JT5[/=S?%K_^,WK:3R
M!#N@F#2I6H$"6E$)A&1*>"2H,S;AU_4;<6*?<B^<8;?>I/T[XV08?S.?@!,5
M^D[BQ$GK,QHY4<&TI?UA!D7+#8_CCD\WI7YCE^:LW.1LY(1QV\^I*9<DK8Q&
MV^E.*K-IPH/D8LE5[!8=D^Q-&$BE\91R<=OGEUO.(_5Z,+:-YQ\Q]C^<GZ7L
MRY0%DM)TQUK]X:P^G4X0IT<-K85&;Q!2B"7[6G3P5=**3Q]J>YZ4)9WTF62-
M73W<W"TB'_(Z/6V5R<$+EZ+,EN[&%Y<Y7[Y,LDEG^/K9>935_='GXV-HO7X:
M\%'.XARZ!#K=?-%0C>N4 QCF)@U?-6E53,Z]LI)&1U^'CPD^F:QCK:[2YZK+
MJT2=A5ZA"5;*\UO 26MKI#;^&"JWTX9BZ2OK3]0P/FVE@Z-QR">E\3^Y_J[C
MR\/3V<J?X+X<!$CK-I'1-QNF+,^_C\_0MXI(:9=RF:9<6LDEMB!![B%S@<M&
MYIVPVQY/*<4*XEC_' [RT\08YVMIN$$WA]I>W!XU\O_#O?C9P<=O"E&AK<N%
MS:..3;D$QBH.O"9,<Z4E]SCY_V=STH:ARE%2W-#2*WJ]@:Z\N7-G*1:?R+@4
M..<3%2>R'2><\I/']I.U.IL96D%Z1(ET1""E]"?WG[>#?IGC.I2J"O7.IX>4
M4@ GWS!TQY6C&PVCPK4TYZ$B&%FRZT?^F(1BG80?'?NC\J&GC[</]X;6Z\@P
MSCA:/J\4ON2]S0]*;)W2";L17$I5(2[@_W3.4CYJ2N[U[6F?8@*';(V7&#DV
MD\?)D!,CG;TU[WRE*[G**4XGD7V9Z)AB#FE/&#GUF^F!R>.<AARAJ-I"TS&)
M8:&.\GR]=M4)IY)-9A>G6=8 \<F;5;2K<S^]2F4H=[=X;]Y0*X4EC:;RMX=*
M89C,)![.MYVK[605?= _[G0C(+L)(DT1*'M'T]F2\6GW_.B*O8>)U$5O)FAZ
M>4FA_)[EI'/PN92@//3/:>155L?G_+I//@5UO'O7Z;[+ZLUN-?Y:B;\N0+I_
MN!WG<O2-,:R4]Q9$)9X#*KA-IXX%0!9*:27'"+MH/%[6_V$4B!\=SLI(F53(
M3ACG?RQ*5)]ST/JHU W2W8FA$RR=#KJ]E% \*99#0$KPE.,_IU5X/R4#Q)^@
MS#RNC@.,(W(5LI2ZN^F/.['%JX[2+M\>0E,)24?=9#148M><#1UEO7FD1.JX
M!F7N^>CV7A%71D\@F^YV4S7JZA!<1O6??DJ6TR"G C63$=>T2!.J:?F2R3!D
M.G?GSQ8IU(D$WAZWHT9W5 SMCPH;\VOB4,N#>S/*V)2F-#[T.7)K3NX:)8HV
MCJ.2ETK)Y$.(YT,,G:1#SGRO!CD5=QE5*9H$Z>-.IU=:;"4OE%QSJJVOS,'1
MN<",LHOJS<3](=IWDS Y#A)&H*H*H>021;VK0I!C,[&,1;;C/KH[M6;EEMF;
MVS.G>:=Y+\8IRIS]3(ULD\8I)R8X;F9M.@=(1MB>=..@?\8W)[FK-IAJL,VR
MLTA>VUZ5[I_F/<DJ:50+(VL3@IM#OA/%O2KM81C@*P^LC@NPS$;6YG/_Z],
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MR39Q61^^ZCI:O;D*VVS"17VQRR\QXL-[%WY_Y<U7?LGD)KSKO5=^*1[HN?6
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M:*T3VM=@>W2\4_ .4+BK=G;5XGJ]"F,H=6KH_6/-&/L%XM::V=,ZF.:=Y^H
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M,3 5YGY[P29^.=)/*HZ49=<7-J]"F]=7P?9VD)NDY$E?F.WP/-A^?R,%3?'
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M54=T_&76+&1MP$F;=(!#"5]K DL7V&$#DW'9J"J0MGXNX"ZA_2E>XS6T"T4
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M[W5\E"CXCS0\RK(87,0\5A&V5(E2#NHEX]:E5JZ/NW665^8Y5<812GC,*,O
MA3$I^#?@R @I3'[U8I'M\G[[\G*3@$>I\LBF.HU8HETDA8@CHVB>&V*M4F9I
M#=*26A'4.P5%@6[,?Y>Z%750Q2)SM8(W5%]+BI?N,37=SFEX62R+?6,]:8P)
M>CRH[Y<CM/%1-S^0PZIW*@<C)%4*?:(V>__J_"HO\]\,GW2HL$K!"MPD8]<;
MEP1.H70)&6] F32INWT1Z@SL*AQ#0974_8O7:-,&*7%3VN6YG!A?0&>+0QCN
M":?G0"/#DF^=,H"'(HE>**Q'TJOY<!8(3;#0WGP>8-_WZL1<R_6Y-$)D;.8$
M2:1(2,((SW-GJ!-Q3F 7@S\9%WP\V:7:=+D2W<%XT;$G-OKC8L$WV,$)*,OV
M NIW9SX[&4^0LO)^A)1^M/;=_ZCC(ZHY4QG149+!N<HH=DQ@0D:I%@9\NIQD
MW($MVX]9VL_SQ8#0JOH\64V^WP\5\5G-\[FPD6 ?H647.G-X6JC/MLL;BAV*
M&J56:#86S#4D#PQ H?F&I^*NAU!R7XT"=0>*/!B)R#0S#NQN;C"9(H\0MAP)
M7'-N@&+1P\A^#PG!AV'?!)8\3P\>KJN_90.@O,O0S,I7&,*CO3[X9?#XWFVM
M@Z##&G':_:++R79K+6ZM@\-C=I3&>1X[*Z)<"0&&#7%1+N,TBIWA&<V2'+Q;
MO[7BY>6+?1"4=9*RM,V,C$WB9)9I107CRN;"."%<GF@-WHM+BC8S6=EFYC(&
MG&L+3+-!34-J_-FZ)[\,3N>G=Z=)S8^7CT_)D;32L82"PG49C5B,Q??@@$0)
MX^ 5VSPE3C]ZRE8WJ*E57:-F<95"QA^02Q$SE]Z8 >$:8,,V9*B?(XF:#6UE
M%G1NY>2K,:PKWKBR)9[T#D9M+K6RT/(J:M@_:#-%R&)AK$QIGMJ$)9G.>4)(
MECKX8YZG,>VZ;O#?JVA$=;F JQ4:L6USO/)QBI?%"]9445LEN<3[.WS.]X^/
M7)ZY)$UY9,#DB)A,%.:"693H1%C'M> J7J<FU[;B6BI$%#2PCATAA!-F!1/$
M<"Y<ICCE5')6-#2X7'8:]!!%?YT@!>!.V D8+R_&DQ=S9/)Y69@_6T%8+@CP
M^_$1&#C,9K&,M! 8Y^%9)"AV.O"IF#1+;$)1$.#<ZN=\T12]Q[[XV_GI*:I0
M4)?!^0S*I;>#P='![&(AVOYC2 V6GOU^@(7R*\=WB+FVGS@[$Q_L'#'.N;%P
M?C-.DH@I$T?2.AG)A @FD?D@==ULRST+I(3*=66'XW,P)E!DX0;3TL ((BL+
MD5CKZ06ZU6'1P2[H1+QXLYA<</@6Z47!L2MC+B$( Y>;31FN0G_(LM=C@_NZ
M10J[CNVZ]"W1XL+O^Z&4?7R6,E0TNVRLC&46+82^K=G4]= \\:I>4RW]4%E+
M#2-J^O= JL$0Y.)9X)7>&9G]\:@@F;X?S(<__EA\GX!]Q*DV2@D;Q8QH+.-(
MHIQ2&L$AJ8R6F:*QPDS^(K5=$*^*4;E@U*]%#-G!>[(7MCT&$>%W\-?*9!L(
MV'<Z:CSX\M_BL3OAJ3MA6%Z$@A7=D@I06_HWV,1W &GYX^5 ?\5R'F,=R<$>
MDISD6"<'YTOF>$325,>I$)D5&$YHD.N6N7H?GD*>^-E-4/DYDH'];(W.1<YB
MYY0E).<N!Q--9'FNK@X$W%K/-R0>,5C/.96*$9%'L18$K&=+HMPJ&S&7:T*=
MC(D!@R-EM$^RJX=Q0PN[SW(P]$<_GL_.KTF9<2C/US6G_=7L\E7L//>'+2?)
MTN_$$),FWXLAYCO1^VPRX!7$,^(*Q#,/@XEDOPJ5!?WWTU&QE)9 KS %/$?/
M&GJ:FX3YKYD>Q&W> 8!KDZQ(SA8;@*X4%WJ#;!%Q;\D$^=SU'9BAS>P7KC3"
MB1S/G6:$:G"#A,QR1Y4P,J7NTJZ4VUS:=>R;HO+A?;SW[TL.]R(?8%Q[NZ_!
MYMEC>X<O/N[]^P\\_S7=__KAT\'AIR_=RH</'U]_@7' N/\9XCCW=_^"L1]_
MV?MW[PO<(][?!7?I]#4_.'SA]M[&7SJ5#U9PG;G,1."D@!NE4QF)!%%D<9(E
M8+Y*FX)]Q/H9R?II3%<X4]W-=I-T+'Z+Q5??8#=9%?!]%<4=T:0+M<<W]];W
M2BVNKD2^GFZ\N:3QHF;L1 E:Q<Q;E;B92ERH7$X<DX;%42JUBIAQ(A*<I)B*
M-BJ++168@"9/TD5_\8YJP^_(4A+T6O .+]-M\((_=*?_&9SP:UF"2][V 1E[
MQE%05M(Z2SESV!Y$9=)*2XT@>.)OCN3_5MWFUVKZLHAQ_HF<]5N[[\:4W&#!
M[LMS"\9>+J-$ICQB"GY2FO.()M9A H231&#%:\9%/Q7?;/>M41[?R[2[*B'$
M3Z$%5MLVWZ@*-C=RIAMI@JVA<W,ZH&OH<&63C(HTDD:"#DA4'@E%8\1D<FH9
M(8F2:.AP<8>V_W>,<MUE6Z;JK_,M<:W[K\=^E#6#69Z7OB5T:-P4E%$(1#>1
M/O>GK=:]T%$7"W8*%YG),S!,&,7T+H6?<I>GD<HT9]0P!HH*V0YR2NCO-^2/
MW:$ U,^UN^^1E5+UK+J:H;)5#C>A'+H&3)R[.*&41XXF+&(ZSJ.<61HE7&6)
MXT920>^B<OA)XS'/$*TRM.97V W.#GZ6T,POMV[-?&-LYD58KOFDUG;;V,Q-
MJ;7]9PLV3TQ43(PTD<P55D"Y+))H\V@!PI#&L3(90MJP\(,L1F8>;X,R=VO_
M/P1S9XD*V$9F;DX#= T;987*A4TCD3(3L822*$<&W=0R;C+XFZ8Y1F:6D.=N
M(S,_/#)S-IALXS+WPI*IN8M76#);W^QZ*FP16"0285+J.-@O-(L825TDJ1.1
M45E&*<+R,W<7?;-MX.9A6S)+5, V=//]U4/7PM$$M %V$>%,RHBEW$3*"?!V
M.,J 5#2-\[NH'GY0PY^[8-AT$-:^1JJ$5]-OB=S\C/#J&RL/V\*K[ZZ:6X39
MP/$GG,4&*$F.+!X:"]]S%R4B%Y):QZ6-L6,HS;(^S6\*9G-GX-67A'N^.<1S
M[Q#4RU[L7BFWU9;>]33<%B1]/Q3;0NJ-.9U9;)9!#=+3DC3*<YY'&5,N(50;
MJGR$*EU5?__ (E1WS7@KA-U7"=^,\7:-!D!+/MV:=]\[PE6M^]:\NV$MN(A.
MHB050NDDHHR#%VO!E<VI(%$LB&&I3E**K3%IGXNLGRWA%_BF>I&;V()WO+[N
MX1F RU[L7JF_.V\ -C3@U@"\.=6W$,!#$MTT59'-A(L8Q_X$'!Q=Y]+86DMD
M[A(T -E-:;T;,P"K%EB>=Z7;P&<%#TMR\[QR&Y(A-G=#KVB=<3L$B&5#F[=V
M\AEVTHH-&WI_P$\'[HW5X^,1DFN%@+OO8_43\R*2O>,CHZG+G+"1H0GR(F8T
M4KB=:,;R1"2@13-VGWD1QR#7E[/U-3J0-.D2:P*E9NN&=L,&N+:4*N2[1XXE
M$'F#MPU]'##J)4.?"/B7SPV%MA.VR/_T!G!+;$P!HGH^_>U>\3$E):?2M?B8
M;I_>Z-[Q,2VW>,L%!;UK[\8W5_!&D6_AC1+WB3;IT/.8[@4>T^?(N>:)DZH(
MR!5XI+['"B##\J4K<!OQD.ZL?F/GU7L@(6M#8 ^536PM)];]4VB;!FV=BYV^
M![1FR/+I-96W=>QG.QR?H>ER8YPB#S>F<L57OF_1EDZ4Q1KN!&,BY\*WCY6)
MX(F42EK-B=3Y)8"J!:[JZ_1H?)!1Y(^?V(>/._S#G^_B#W^^9_N^^_P.W__X
MSR?\9^_/]WSOZQ\G'PZ'I]U0RL'AR>G>[O#3A\,WGSY\/(Y]]_G=3W3_W]?X
MS_F'CY^^[OWY8GCP[X=E7!Q)EF5<NRPRA+&(I<Q%@J4\RE-F)>5*\21]])1D
MK)^2;TZG;;19[GAX>*OD'JB2HT)9#7:,53)G69PK!SHNDS8E+I=.ZTM:T6Z5
MW.TKN6Z\F('N4CJ7$==8U"89 CYY'#G&\RP!/9<B$3<AO)_2[TZL]AV5W ,U
MH*\'6;T%+?.G'=F)'!;=6T\'H\%TAO&^S_:;0%H/X@QY".BSSDFAI#.IHY9D
M6<)LG AK,\%TDF9*$.O(UAR^XR?%(J@BYMR8V&21=<9$S&19E!O-(LY2D\6"
M9$;P1T\3GO6S.U7_N 7%;M52U6\V$U;$3&29CIEB+)<I P<NECR/F3-\:\#>
M>;6T4)/-B5.95)$P0D6,)%FDXL1%)'4NYX1K(<RCIY3'?9K??;7T0,W4Y7%>
M/V^93R+>047I4^4WB@'\B0,CWS8A]_S4<93E+LYU&@O+$FH4'#K&DI0R*D!7
M759LNSUU;OG46<(%1&0LXT0C&7W,(I;$)LH)5EQD>>Z<,KEPV.8PH7T6?S--
MZPUNI?L1.=ZJSZWZ;,024IGK.$D=3SBC-)%)SH25AC*1\)RSK=%^Y]7G0M0Y
MT0FC&38URK%6#2SWW%(26>(TUX0(DX,!FJ2\+PAYL.KSCAK[ZX'8^#MNS\%H
M[K=+"Y)9;'%&@U%_-IX.\#N_>3SIX+,M<)*%"FA<6*Q*7%\B%:S!?+;ZDF5P
MSQ\'I"59&Y?:_/^3RELZD\<V4A,K/T72P1!_D\-S>3%]]&L;R#H819V9Z[YT
M>+6G'C*W[,&=10E*R;I8QY09153&A*.*II8J[8Q26DJI'OTX;/KRTI F9?<_
M<AC&OC.=SD_#WPY1$']F0/K^ZZ,4C$M-K8W2/$-+,U.1$'$6*9K%UA*6)41>
M$9">E3;1K:'/3VQ/ULO;FT]KD/@?0U#<$4C,>(B=??TWHC.02N0Y.1T;._3]
M?*\(1X<_U(AT>,+$3L_@-P2:JS%(7F\:BB2F/>.)Y/T09AZB>AH@JJ$M\)(.
MU#V)_81_.GPZ ]7T??H%/U08^?+(&5L7.;L&MO5AP& O0X>OKX^_S5CG!IPN
M=] A16='HP8=#IQ%17EAY>2&>SI?V;3^L8*YF:/ZW4PD-(S4Y66UJFL[O9"#
M"=I,MF$OE:MY:">GI.7 PMOKW^"HP^6]GW9445C[.M[_\\,0OI\<H,MZ"/;2
MG^_8WK][]#U]^>7]UW?Q_NF["["CR$)A[>[K^,/I.["[-+B]QV1_%VVQ8[CF
MP\?W'U]\Q'M].'QY_@%MK[?Q1;?C">%)8N(\(BP6$3.<1%(K$>59RIUSN99.
M/'J:/JF;\=8NTQU46_<8BC^8?HH<'A<#5!%V.NM-Y&P!1O1_V7L7I[:1K5_T
M7U'ESG?/3)7%UOLQ<\]4,4 R[#U  F3F)+=NI5I2"Y38DK=D0YR__JZUNEL/
M6S:&0+ 3G^_L"6!+:G6O]^.W'O+2ZPBS!VS<ILFRQ:!;+C%)OEZZ-7$WY]$0
M!/I$'5+!2R""8TD#YT "=51.MW8R[FX9ERW(N,!.HI3[KAX;,=>=V+%UQARN
MIZ[EQ2'\-TR")2-V_V<3I=SF"[/:_KHI,$(VS":S[Z@%;A/%TN,!FZRRP/ZN
MCW,GF.XMF&8+@BGR'!Z:5JJ'L6_J#O.8SESXU4Y"T[92QL+4!,%D+2)U;J1<
MVF+KJYDXLK.Z-EJ\)2"R'E>V-4>_DVGWE6FG!PLRC9LV]QGS]=2+$6G&M/30
M,D"F>59DF4;@&)'_XG=CS]@.F;;YHNLPN\D2GB?:+./#Y8-A=F;6]IA9ZDAW
M NG> FDQPA59!C?3Q-$-;EFZXP4AF%N<ZV[(?=LV?-_RK"T22%ML9"F 1)T)
MA$0M!1[0;I )!%16)_NYL\'6*;R[/W#FQDA 62'Q"H][V70<^O 0Q& M+K^/
M&K5O)0X7@V&6&WJV:;IZXL2&[B26K0=)$.DIYW;H)XRG?HC!,#M8D(??1AP^
MI$Z+""&(8R=T8L<%>>^X/A:A>Z$;V7X4NEC8_,$)7RRO9Y %!XANV*YP0#Z4
MDD!',4J)[KOP#W69#7\*0= /U^GM::*<8_&_3YSI^XM7%>=G N8PO_J+ YMO
M#-KFV87BT4^SD\,W]MD_;TW@K]OW'^'ZR]A]=_E^>#IZ?WUR^.]/I];[T9G@
MMTYQTQGPTNEA[+Z__!OXZX\1K!76.+P&_H0KCFY/1F_L]Z-W#L5XOAS?GEQ]
M,$TO"%AHXY "X+$@]?4@C4W=->W0=&S7-[Q 2&4@8Y!UF,STN,'2V(XL;B6.
M[85!8ON)[T3<,RS/<Q>*H?XZVK\X.M1>GY^]/CJ_/#ZZ6)J?6UY)=_<SNVL,
M03.:L>/'L6T"H_DL#(!>F!W[8> &MMM;HB49*^PRUD:BB%YS#748RV?_J]*&
M2,E4G)5-*MB(<EQ@:$B[YBSY[Y258 %4VHIIV_]-)PMMFD8<.;[A6DGD>#Z+
M+-^,W9A'B%\<1RY"5IN!X1NK"[U/.=PO)RFY7W*V'17=WYH33[]\^N [210Q
MP]+MQ+=U)S6X'MA)K/L&"QV'_N>]^-T>F-YB+XM6X1G#^7-.Y75%FF8QUX 8
M8_X+HLN"&1/S1(,C__=T.-.HEL<,]K3C7'O)HQ(NGE%USX!J\"19:60X4G7@
MI-" KN%@\P0M(JKU^SQ!/YYJ]G@YPL?BSPTAKA+E)G;N,-^QP#($K9Z$49!R
MWXJBV+8]T_0E'KIE!>M(<" P?LN&6''16W!Q6Y1)Q?,?C*A./AX;'P+/=PSN
MIWKH!;[N1*FG1W'LZZ%K.*F38J(1_,G);:&*CKIB6:NF\36<*YLT!YT7MXA1
MG)58(IIK^],K$(>J/LS9T]:IQ=Q$@7KRQ_% 8]KM=3$$%BEN<X1'GD95EF3(
M'FW&8/%_IYG@#.VTN.$8ND&."@>"_L$ME% K;4[$;__%/P/53HI\H)VPJF+Q
M];3BDXDHF 4_@U\7\(?F^W]DPR&>!)O[_IZ&\K^^FV2[99QN/Q^G!Z9K66X0
M@=9-'<<SF&/[//9YX%FNZX;VCM,?07U<7MD?W#1(/<>(=8\GJ#_"4(^H$3]*
M0$D[41(S$SB=:CP?RNN'/!:T+KG='2"'?,2B;J 3(@J@8V#2!$P2:LFAO\.=
MLARMD89L>FYF"YJN*;Z/IL_B28&7"++V1)FYNCU]HUNMNKW2Z"T\MU2+[WFL
M&9JQF3[Z8^NC)SQX#O)&',- GAVRI#9FLTK#8DC8?S#1AUJ)DN+G%BF@"!$?
MT5A@#9@8PU 81LORN,0[_C+0QL-II8U+1)V?@(!EGWDUH",MX&$E$!_PMT"K
MRH%60/J![)+H^-5 D"NKM"GE^#/\4\G'+"OE348,:]-R!K33D,&SV.<:OZ'&
M&H[ _"3 ZO A,)L@<]@63G\3&X#_P'^O"NR+@*W.A(: ;PVG2<]]B&VS"<+V
MX^X6.1C<,RV&C678VX%"7 QX0:6"+@*OBX[I\>+(;Z]YKL5#4#1 __ADJ<UH
M.^%'T:8AKAAF+)(;+QA7?C<IX. FL I2D7 *<&O83.V&P3_8:"$N'XO8&AT:
MJ-@I?0-CJU>@HC"DBA*GQ \G( RP;PTDP0T>)RJ_;>7JQ7T"\L?T"1YW-AH/
MLS@3I92"AI$/..@YWM'64[P>#Y%X";<1=B\JRK*XQ?,AQX]5=$F257$QS<4]
MQ?DV!UDHW;KL2%?<'U@-SH8&1\#2X90R/&EE&W2J0CMKORVF0Z+C:=D0OY+Q
MRN(0SQ*&"*T>B F6H'1,AX"(5S1JTYF@R45#+P3' +V42\R6VVQRG>&%8X9A
M\>F0E1HL"=@J1FOH)BN+'&\O]J&S\7A2R_<%GG*_'!^W@B Q79<E 7?2P YC
M--@CQW1]GG!NDI\=FM8=@>T^:^E0'OYF9>:^N1]T&3NG^^ )&4GDVH'NP=YB
M[7BDL]1FNAT$/#6<.'6X_>)W?S&O1B;N'*M(@=O8)N,R@V\!@?Z;Y=+&-D/M
M9T):' X5[37QFH7[]=R*%!R.:?E%4&&"+!=+(0H"L3VRI2NKZ4?P8Q*4*24Z
M*()12[QPE*'8CX1'TZ,&]K95N.Y/^EH%NXX.B*VB)%-Q3O9UUHGNA)Y]UJ^S
M!%[EUQ^'53 B?/N!FU;,;<;TV$[1E3 #/3(<1X_ Q4B883*?AR]^/S][BXVD
M?*):E9 <V1CH[3/I K _5F;\YN2@;[K<=KW4#'GHA!$/?<\(. _ >;0\*UXR
M(D^WYP7AG,.(]'&6OJVP<H%/U@L_>C^:A/P(O^]_L"UN>G$4Z+:%Q5!.[.B!
MX9MZ&+F)EWHQG'V*R;;% D\->'A(@?J\MMUS7>C3B2028= \G#YB([9"VXSL
M(/:=D 6,Q;;)(C?@B6^YIO$P^OA+FCRS ['877QZ"8%\.;WZ8,:PP1'C>FK:
MCNYP+]:9QU,0$Z%AQ@CC&+DO?K="9P#B?9%(\/PWZ,1/BSS>'?K*0S=0&7 S
M,$/+U\,X]'7'2$P],E.F^P$8K0E/W30!91":=N^A#U37/]@KP]D !802"ZB(
MD0) :RRX'XT5T_GK$#QB71CS*Z?:16R(;K]677,^V5I[1LP)G#=48AP0J=UR
M!$!XL##]RK*:NW@,AUCNF*J?J4YFIV\^6.#:Q;$9Z4'D<]UAR%Z^Z>D6^'S,
M"N#\4Y"DIA<^CB0-K"!.0WBF&?H.MQP6NN#N.'8(&I_;($E7HW?MCOLKCOO+
MR=4'VV.N T>KQVD0ZT[LV7IH,&Q>-H,H<AW7B&,X;MOM/VYT0/NQ482KTPN0
MDO<!IYA=>;RGG?5*%Q2F646I9'H:2)>YH(L,PP[(;\4(3,E9.^+:"N.*H.Q\
M2%8^B6S"DJO )F74KI:.*:BCOP^<:KJ]@<,#5EW#[F<)$8.(BE6=7</M$*$]
M$49;C UT5.DMJS97?\C"RVHG5/J%2NR"NV9XX#$G!IC?@6F NY8&.K/=!%SU
MR#8,YGJ&Z6,_7K]AMFDZ9'?D=QWYZ>V'U.>6C0Z8'[C@H2=.H(?,MO7(2Y,@
MX([C)PX."K)ZCUQH@B=4)I?7''."4CC-B_5&&N%Z;H08NH\<CU$&IHCWM:>]
MG):H7 :80^@-^BW$1:]9@M4=LF);4U7]("U!*34R4J4*5M4TW,<Q747S<^7C
MYVHI].%&X\=\^\#D$9:J6E'"&4\-'(_%=,R3Z&&:.J!H[8#S)/5<"VOD]II1
M@'5Q Y4\S+F".QA- :,9;#Z,YAK%O-^^<KP.)9VPR;2$?S<**_,YD@>G5Q]\
MPTMX$#,]88:K.V:8Z"RR?1WKR'T>@!%AVVMB96ZB(;Y/JJA7Y:13:LE'AV4T
M'<U[3%,LZ+DK"[C-L):60GI\ *RE^T2PEO>!G_R*?NN'0D4N>:1SOX[*+MQ_
M&R);GLD&=E<*6P<Y KBI#U?R/J_[74T;^)ZF!CPL@[/00[)2]RK'L::HL_1E
MAF[B.S*3OV-O4@X0> ?WOOI\^N7TTSOKC7MR>#X\/7SGP#T^GQS"6UCOG%/K
M]-/IZ(TUWYQY^O&->79X!-\Y__C^\-/MZ:NWQNG'*]#V1[#.^,O[CU<VW--Z
M?_@>T1@7AA'Z#HN9X^N6!SZH8_%$#PQ,!Z;8;, <)_6-%[];0;#"&_T:[GCH
M((!'D;HKII!MKM3%*NNE?;'6_=ZV5^CN9-1*&74XY:?PX,M;/KSA FAY)Z$>
M34)E"Q(J"KD;>G&H1Q'&"TPKU,$S"73;#%,_]BW'\>(7OSO6JGC9<\PE_''M
M0FPA>Y"$6M<LW$FHNR04VDV7M\5.,#V:8&K-<3Z[/''.]C\PSPIX;'BZ$8+]
MY&"?+S/"6'=-SV=>8'(+<<?LH+^2:F<Z/8M@<G>FT_,+)LQ:[4338XFF]E1-
M*9I"PW0,UXUU"S94=^(@U2.02KIMP9^3Q+8#W\,B3_]'LYG"9Y9+2X:V4)'@
MRM#SU]A3:X]6V<FT!\FTG2A["BM+NG^>:_MA[+FZ:X<8H+)3G9F6H[NN#8<:
MNLSG6'8WL$/S$>VL^TPC>DQ)=S\<QG[)NX&&%W+2KQJ+XY)/!$(%=9;N;+%O
M+[?>YJJ=F"='G[$C?Y]J?79"["GL,2G$$L\TO !Q2.,D 5?1LO0PXDPW0S_E
MH<7MU(RPAJ._S&]GCSV+/;:B\O911R:O985MB"!_W+GK"V^^D]\K>MUV$OK1
M)/1B'M1UC3@,75/G =B:3I!P/4IMKG/;=VP_"1+72-#,M(S'S(3>BSN^2H@_
M'<8M8L^M+FX*M@/1UM][)D#;@V(TRB;"FP3;;%A@_\>&5"":)YGDY]'1Y]/+
M-[>GAY^LDX]7UNDA\-GE)_?T'WC>J[>WIZ.W\-PK\^35D35?@?CN\L@\/=R'
M9[Z;G1T"C[\Z'9Y=?C+?'[XUWE_N6^\OW]IGL!:0#>G)EZLO9_L?[,1*@\!E
MNA$CTD><VGJ8V+8>^(@B'8:)87KS8+$\LB/NIIYMIMRQ#8?9\+W$1LD+ M@P
MYBL6#\Y.3HXO3XY.+R^T_=-#[>#L]/+X]-71Z<'#P&WO?GYWO4'$K,@).'<1
M0#,!(1,PQPB="$1.''%_:4TE$?0B_SPVM]!]?LW %LKB-?CGX'S_<)] >;33
MXX,_#^N6M]?9#1E4KZ_1C+*UB\DTF6'-V-D-&R,(UEHEDOWO_+R%I,<2H5$T
M4BP'8X0_2VORAFOGO.($<(<=&8?\A@^+,75[[5^5G#HE!IK<.=K2@=A3_/WM
MWL4>7()X1ZH_[$_.AA-QKS^G(WCQ"SF0?8!%J#7"4X,6<P0&3,RU__ \YW ,
M%]=EAA!+IT3(<$K'.6SL9"I@D ZNLV&R^(S6JFFM=-Z#^L"Q$V0JAL0S;30=
M3C)=5+0.!*8$[I'8C($VGB..&'8951D<X!R5U+NB_J"N$<@Z\W^%71L.M:A>
M#>R !(RBU?[?_U=@F?YO%1Q-/@$MCL!M<#@'ZO&7!'AVRB>W1?FI3=6Q^/X$
M%B/WY1!,L(H0W([S>&] 2%;B.]A;(\ZZ**]8GGVA31Y(P#!T+>K7C0NP!1 "
M4<'')6PB(+%X7/\-]IZ)$0=:)8^YWO3^7:G13N%JL7[:%@(%5+!E(Y[0$A!J
MJR+ 1_QVFB$UT"I*?I/Q6]'+"7^<(2[7LL<*$%1\!FW<I+CBU$$*;##&+E()
M@R;N+I!\%+(2;!;02J5^7?U"!))7C;')%0TF7$[/KE;3\7B8"92EAHZ:O8;O
M4C!*6'%5PVDOD>_$@JG;*2<<65#3= W>%I$/;G#15],A VJ8@>T63PE03!PR
M7M,LB<$.D%>9WJMC+V56ZL<AMUG$'"OFS$@-)W ]QTO\B''A4IB&/]>HYW:F
MERF)LY\G+<ZMQ4UC?]PG%/3, #O?WC"Y/++.WGQ(XCAP32_061HDNN/S5&?@
M]>EP'!'G3A2E3OSB=W=O<;*KL"5;*#MU6P'PAN!-A,TC2 B@V01^PZ$E4J)6
MLG]."#.DJ'X>:3%YQ!=8!*\1'=WBCM0(18^:%]S]=P>%Q^(8N(?:OVMND6\"
MI''-DRD\J]4H(5186S?"S4"2(5[B%9#@%2+N-4" ]V,/.P3'VO8]9GN&$UH\
M<CA"VYM@/P5Q:,>RH=57#:U+^439XDM8I9DM(]7%Y+)XS4ODDY=%>88[6B&"
M0G4L\&B25V51K5D7^.,QTAOCY.I#9*2!8P>1#I>#QXU-T!'S71W^:CB19WFF
MYR C];0]*QZ29"H$JT29!$JBGAG%4X-[T9/AF"!6W20UN>,$=AJZMNU:GANX
M<0*$E=[5$[^CIV]/3V>'Q\;IQY,O\ Z?3S[&V+^&1VA&803$%#BZPPRF!TG,
M="^(4CL"YSRVL33K3B$-!'9[G8&IA$@+A-R0"-158<*4U423@SE4"\R>M@K!
ML&E4EM2Z@"FI)&D1@9?#)+EV9"FMY3XT[23<X*;IQX[K.J"@F)T:5L2M)/4M
M<#B])1!</:1\P\%WK3N<);VB)CBK5[LCT7Z1]Q9AN%PW"1V/);H;)K[N<-?6
MHR2)]-!P0R](6!(F+@X&O(,LUT- ,:W'=X;O&Q&@<,<5TO,!6B&)Q'#96G]_
MOR(PYFE5J;D1$W)YH@)=6<1%*\"K%AQ9&T<T:$)TD5/;*8ZHZ RB0#N<3#!@
M?@WCI-(3C]M[AI=.Q_BM;XGQTO4C9,W+6;I?+[)SKL?Y'],*-JT"W36*I#.[
MDPC]$@$4U9L/W$JC-'2X'J>1CV%.4X]<-]"#U$L2W_+"T(A>_.YX=VHJ:<#C
M5G/,UQ;Q)\0.QHE1@N9D[)&8<3J6T'LLOL[X38TUA#@@68JN1PI*![Y,D0KR
M"))6G H=VY;;"TO@\, < <<I( 8.@PB(W<OR,H(@MA(WLI/ ,1,_]&V;@2WF
M\\CW8SN5CJYG&QT"=1:UU)6$FBIR-?NQL;9.V&<LKGL-? N[,4>^.TKMI]0K
MZVS_@Y,XB>6:L<Z]- :_UP@1MB;439<'/C>#R I< I9=PZ8BW.VQ.H/E(B_B
M,9QM;=(O(ULU(4$:4Y)V5?QE@7QK>M70H$%0VV] IUU!2CC&^XU>:!1EAR#O
MA6?[P]'EQ_W/0)=&%'N6X29ZZ')/=\P8@668H;N1&9L,CL$*;:3+U6YDR\K'
M8&<QK8:(,XZ1#L09JMK2<TXMYW,6_'(0TZJA8 R!#_DD:YQ8%-%M2^&^T%ZV
M%<2F&UI1'"=.$"4AO'B(F=HX-E([X((NYT<0+-0>[,=Q.>7)7TVMRS:!*C\#
M$1[9I_L?+ <VWN6N;K(DT!W'X#HSXT0W0VX[3A(D8<Q>_&ZY1C^,6X< )3PB
MV9=X9%*I]F69ZAQ&5&"@$&Z39$"TH)7A-D,Q$P ,@Q'[1$'WBK=D7QUQ@\=4
M."VYFG-&ZYM+=$BR*0;*T*!Y8A.<"33**A%?;/S4>O:0P#,LK^#O3$6;A6$L
M!K7E"5G-%WP\4?/7YA-I</<IG\<<7SX#D]YDGC4B.XP<'@96FCJFF[ X"H.(
M1VZ0FLRP0QDD#%60,.S*[@4>449N2X ?P4^3V;&L:ZV.:=%G)?Z+JNN4AH:<
MI3266GZZ8ZA^AGH[.[W]P!/F&Z[+],",F>Y$H:V'09#HV%:7!#8/HA@'?1A+
M&*HA:#%)M2%@I-\51C+9#!CGN9?H?23Z:OM8U65QT5K?N<KC4M;T*_RL'Y">
MW-.K#]PU+!<$L6Y;M@M^EFDC%#KX61&+O<C%J:4<Z&D)=J^4>6V"D=*Q2;"+
MW'[6GQ]9+1!1 L/E52I)37[O7C$^;AJ6PVQF6[[C&18S(M>(P0X(&;-2ATD2
M]!0)+G6C=G[^8]-?_/GDS8<PY![X^JX>AA%X3TGBZ*')4]UT_-"Q?3#+N+66
M]P2TTJ/#6545<<94C4/+)5>^$ID3M6N^PU#LQ5 ,-PI#<658M[< [<Z"LKD"
M-#=RS<1.HP"_'T=^!#]QGMB)&3M DM$SAX\QNMHW\W%IR\.W7J#V6D0FZM-;
MX*.[3G+C(MS]A'4WH8"/LC\NLR&*%V.@)5->>PIPNV*4Q:"^9*!F,I.E/ABE
M2<MB),8-@KW?E!X<G/U]? C^$\@XV F\?,'1;B#AQ9C%0I7ED-&GYF[.?:OD
M%"K">6X<7/!BQK%2KA..E]47A-%.5\0\0P'*M&'!\OM6*)B>%\2>$84&CQPC
M-B/+8RYFD^&/ALD"TLRPJT(SPP^KC,.#H@1E?).5TVH_2\XY+#2%-1[)+;[@
M,4&8[L>3OV"IK\LBAE,"XU&\P<Y"["\XWL>Y2)[MQ+[%+=T!%T-W+#_0H] -
M=(^%J>M8KFO%X8O?;<\?6,&BDFXYOR 3XFL.G@9L_T3F@N#'JY*-Z@K&UZ]?
M#QIWNSY3#0YUH(EC%?5CZF0U=;0:G"W=YF#__.A"_*;F*U#!J:SRI$K1BQ'2
MN;+5M/W6' 8L4).+N?AC?T][V^^\TT)IXB:2_E@2%% X#@"-. [3%)SR H=[
MRH&S:L##"^'@MT8*-PD&&F$H^5+BA]=O1&^^))I "U(!7X52KJ:"PAH'$JY<
M0)13+*MN-QUH(S;#5<."KX A0+BES1OTO( (O=3#(.=#$QBMR8N)>*%ZYC9(
MP3S.QCA55 ;_I!L*2Q?;J 9*+JY/1(%:-9.@B?C]G%$K2ICG>2!E?-^)C(A%
M+/3=P&(N>-+<<&1\VEP2!R0Q@XJWDKI-AO]>#T'DB/6J*,=.G/2+$_A\_T-B
MI D/(ULW(@-1SJU(#[@+AB,8^HX9I'$<IRA.PD$0+,XK'8C94.ET.)PUU"I9
MF_BU70K;Q*FU*\J#Y!B> T*>9M6U2I+DQ:3)I%!],8\F];U1/ #9%B/IM,J9
M /4$4Z+;[I>7UL"@=S%O"/54+*S97>1^)]U%P;?N+B).?H5CN/>QC'13^HE.
M57_@Z/33Z:NCV>G'=\ W\*POYQ]/#D^<]_A=X$&XSQ?@S2_O+H>C!7ZTWACO
M+H^MTX]_7)]\>6/#6F]/OER/8%W(@[#F$^#-T^NS?]ZGIX?'U-\7VJD?,D\'
MN\L']9X:.HN,$)@R"&S3<]&ZG7>/?-=*7,,"L0FBU/?L$$=TF)YO^C9.-$WG
M^XE>G>^?7FK[_^R?'SZD?>CNQW67%[+(!B:Q M^"/4GBT#4B[IF^$</5GATL
M;Q\*-K%]2!0NGQ:Y?I@-IQ1-(^K57HI\[M*BH?5=J#Y?^T$W^G:#YMLUT[4G
M@D9'+.+;#'E;N#;86I.HK;NBK5.I<'*RZA)SY2;1;/E68KS3(W$(UIC^^O(/
M4[0IX6]_[9\?F*K"G/(R5<]2I-NG%DYN5,OP$S:;L&[;WQO!CJN1\O@1J,)/
MS:@P,(FOZB+VDF>C:%I6(GK:&(JT@%:K!CPW07</32B,RDXIA4N%+JC3ZIO#
MBN76JH@:&'Z=7)CZO.H;!4"/%99ARR"E1S0!NI*3FK[*:;2]U)[+1IQAPAF[
M;JC27Q3WE.VFL4XQ3C.'AU6RR%34],OA;&*"#Q414S*0<SSYHN*M&M.*>G^$
M^0JT6B3KEQ@^8P2C7XYL?5/A2V16T.D!CG<JIE?7/:Y'$Y1X\/@W%KBIX? 4
M?(+ "7R')29CGN^[8+CR,*92=S.0IH49S%<.S)<&2M<0%T_VQEE*TGL[L@+?
MW"CY\L;\8(38QQ7;NN>:B>ZDOJV'=ISJOAF ,1Q[8<(XY@3"E94KZTE]%)MU
M4UQ;?/ 4/@(QH3K:X#+%0'O:_G!(-VM+.]&X)\1^+?5I,%?$P4=)LHI$,Q7-
MP,>'0*B4V5?SQM::Y+N1@J76B%LK63!(.[U"12NBM/T29>%PJ8U7DM:ZAD2]
M6<)5%3>2:J_I?;C7[,*$1:X5.Z8-YFYL&BRR3"/F86J'0<!32P92 Q5(#9;-
M+GP$>?7<08UO+:_@9^MD_P./TR PXDCWP\#2'19$>F2XMA[#![[KARE'&"M[
M657&+6O:AE^(EL)CV%)^I8A&A,\*BA86TPD2<$TT3=Q?4"*%Z6,9R11QLZR.
M^H/H:FI*FT)3)1CK4OJ':T_NQCYCX% Z:0H;$42.E<#?,+-N>Y%G49AMD0CG
MRD#K1=8%R=+9.1<VW&71./ [3=I/F6^-TZL/J9V$)O--'=QF0W?BB.L,C!L]
M8*%M&YYO,>:^^-U:504Z3YGKD^8"02(ESI?;BPH/"B\WSE#)_SO-Q*S?JA6Y
M1N@&<$RJ]L/GFN/E(M42!^CI8"V>!!"HH]'J>U<%$*"<."\K H0/QF[ 09((
M4WASTO<DM-%Q0 =/NYHR?$/.N]%O;#%6?A/^0>V;$/9KZ?E-' [7&UF-P7O*
M)M5*3TSZD\+6ZNNN%GJST:D/%CYFD'ANFC)0?\RQ7<[BA%F)D3I^$EF@ >\]
MN?G.+M5_LLGU2X[U/\-7Z"KFU+H*QU6,>"EEUF5QEJ85GW3Z5G?ZM%]JO8.U
MP7?!#S@YW#?/]C_XKHDEP[9NAJ:G.Y$=@01+?3T-.&/,8 Y8/^ -]"-VM]M2
M%V<"]_6CKNY3[<DL"$ZG[,%7T:[%3"^($]])/,?QK1C<T-"/7)882>R'2;*D
M&]6> [10BWE9E$<RCG,D8T3PI_-VA&A'@FN0H'5R^R'Q$VY9/@[9\5+=<2)7
M#VS&=).'7AQY#AC:(59)]9,@BKTZI-9$G&0(@\)AV!,A5%,V 7=QB&I(1*C6
MBN^1GMT"O;+"?:00ZC;[CZM*]9_"A90QYQ4^Y,-%D6U'8#6:(4L]VTDC#J:B
M[\?,9=A% _+XCKKMG4?Y->+GXYM;\"AM*V"1[<5Z8@>Q#KY4H >F[>AQ$G$K
MC2WFF>8*CS*K)&0.57' CR" @ &(E)#^,A!&9=U.!89V<0-N() 0P9"UD<8R
M+ .KW4BX4Q%C*J*E5T5@'"FNRP.UB&M"*]9ZX?/OTOK].HXT0=$$7H(UJTYJ
MQ SSW'9DA8'!0[ )[C!L%SIU=G;MLQH5]NF;#[%IN(8=&;J;F)8.-D2D@Z0%
M-@\\)S;<Q.(!1KF]):T7:SE3VV/].F[L>%[DF[Z?.(D3!SZ(O-BT>!*;J1WS
MG?7[+(3J8'#33A/+2TW=X=Q!0K7TR$]BW0^<$/[/Y'Y*#E@_1O_#S=]LS>RV
ML'ZU7>=&C]:RC(WJW.@M[WEXN<[S _DTIOA#"G1Z$WO/Y89AEZ=8=HU_^3T8
M:_^K NNU& YG>G&+H>EJ&E59DK%R-A"]UIA\(6UYSWKBKS3)%F'$5#EZRR#;
MI39Z==27?0L,*(N'B"ENZ6:0V+IC.CX84*FE,XM'<>0;J1<3X*AS-T+06LZV
M5#G*79_KV\=+_\#(___-1N/?M!-077G"M%>@VBKM)?9D=9L+FC\))UZEX*0W
MI=0;*,'F0<)L*V2_HFW(P@'MJ+<:3-V1<AM*\0Y$ 1E/I..'K]W8CNU%H3QH
M A>+@*2]*WQ.)V?'48]D]1V9)X_&7>10=,AU0"T>J\EHOFWW+N=:I,];K%J7
MW=0&YQWDOOF:KE]K4Z"E]>)S&GSS7VO%_( :+FWY_("\3PSW2-L[MFD@R5"V
M&<VU,BGKX/XH@XSS) I CB6AY?AV$"9^G :)XW&?>Z[IK(O=1LNM&O=V)\7Z
M[8)W+OBK 7BG9A*[>A@'D>ZX<:HS@]EZ&#EF:+IARCSVXG<GV O7P Z\1QC^
M#AH3=0'U_7A\G0,+7<T6$ 3'H'55!+95Q#Q7B(PKZ,A5 G:&+U'\581M/$(E
M8LD-==NUEC8?Z 6-C776J>K1&W(5^UUHJ)+V $K6C&J':F#>^U6M@1H'YC!Y
MRKGMN*D3);YK.39W&+-8&-MW 90[NRK;KV"43^[I[8? C2,#DYEQ[,2ZXWBF
M'OJ)KQN)Z_B&%1D\Q=%>YIZS!OA&#<35+3%KU_GW 6VVB'(L>H%K>*VE&)R+
MD)NJ0K>-N+DLD/EP^_1A4^SF2ML.@>(%;CF0IPP0;!6<X;>W3?==7"_8J%].
M/[[%DI XM'TO"3T=8>AUAR66'ABAK[MI9*>>&R8!CCX.]Q;[1]L%XHD\B;GB
M<#7-<M9OFMZ*?B,1_UXHP<0Y$0*D;CG:X5H8,^LU@7KF=]($&C[7B+DC5B)D
M>_6:EX1!MR'=H-9)/2WRW\-W'_]]??KEQ'H_^O?P]/*->_(*?H>_GQR^_7QV
M>.2>6&^^G!V^->>Y[&0$ZQ@=V2=?WH_>81?WX:?;=Z,CZV3T]O;T\L@YN?ST
MY3UP[.GEW^G9X1L+1[C8(-9"/8JQ\<+V&?A\8$@%1F#8 :CB*''FFRTM&\>0
M\\A-+ 9: WSW)&5I$"<&C^.8F?.]H*='E]I?9Q<7VNNC<^WB3Q#_#^@(O?.A
M&]H_<7=J&?%/IQ@RBE@%Y)[SB38LJ@J-/@'>IV%,0Z3TQ$W1&@/3D%UQ+2<T
M13$-1R#[2;B_Z:2:,"'>%A+W>QI%K;%[DD]4KWOSN(R60MZ/5-EK/Y:,656_
M#;JV[L:I!&8'6K4_MR_1L.KW!K0<6 R_W+7J@R47MJ]KJG_Q!>J-FY2<5=-R
M)I$/1WQR76#5;RGP9\L,WQ=-#O$>E)F2"!D2=5.HAO8*BW&#I0,&*#EL!%T_
M!1L$ZW_7QQ)=\6[T^V>LAD9P#H40E+0.<(Y:P&:($8^<6(<>G978VX3EVJC7
MX&SJ+JF]!<Y[0L%[(2<BG:7[L :UA(N:,H[D6Z)%?T!,02]QENXD=BVQW0]N
M&H*GRRP=@:AT,$I=G*1NZK8;F+Z=IC'WO'D)O$5A( J,%\-A<4NA\3Y9TN;!
MEERAH'>74WJYI"-^5*>#]+#AK;%O >TW'K.IJ.$1'-3A&\E/OSX@V"92PGV;
M3&.)F[PSC4/&H8=L7/%?U0^_)5DU'K+9KUE.FT<7_28?)Y/5:._-C4&FQXF/
M90K7->T]PQ /+ML3FF6&=T]\-C>^67QH>[ZZMO?SE1??\:'O/L5]/6_/>I(;
M;\B"@3R0$O_W"_N%^J(B%)#H?#.^2=.W)W4-@N1[RQ%$V'N;N:'?;49"WV;I
MM.]OXL=0$<3KU>;._!CT%>]HX!OV[6JXSG9(N?*$&Q*LM1^75'5V(JK.CC!]
M2;4A%)C!SN<U-N0IJ,QT5U"9%+;D+HPG&GGQR^;./RL)+NA,VG+I-C\"I7W]
MEFP*&:(1NL:.K/6:/\9VF4_.F9O"[0N8N7&:&FF\!9Q../C*\5R'O.]ZU:6D
M;=U]C[5IWM!Z=K3$U]J +;W?_ P>N &SH] PPLCQ?#/D)KC%B<-2'L6N!)>_
M1U7^5WK"]QE2_<QUS0_UEJ_?C3X/SSZ^A[7],3JY_'MX M>>'9Z/3@[?9V?_
M_'OT_O*3<7*X/SL[_ 3K/)FI:^!9T_?66^]T=/KQY-6[SZ?_O)V!I^V<OGIW
M>SJ"]QJ]'YY=OKD].3QVSB[?N2=?_IV>9,;LK\NCR<F%\>44]N+DS8<H,CPX
M;*8S;CDZ)BT1*,_5$\=AH1.E+,6J&&]@^0B':RU)F\WSZJ/Q%GY*/+8^;^WD
MQ;>3%XX=N#'\GQ-&)N6\+9R8GMBV%41^RKC,>9LJY[V3%]LF+XPY>1&&+(TL
MC^MN:#/=B1U39X:/&!Q)X,/_0]B8%[\[ ]LT!U9H;K>\^"[LP<TW^_Z1V87'
M</&LWO?^CD0N!L*Y[;E6;)N.:3B1G:3 )&X4!&&:>'QGHFVWR)TMF&B):=JN
M[3 ]3LP )P='6-64Z%$81X:9NI;I.2]^-P=V8 X,<UEETQ*1^W3"<\>JIAU'
M+H?-CY+ <6T+$>$#L*IC-PS=('1VUM&VL^J\=<29E;+8#70_-=$ZBI!+(T>W
MXA!G@O' LQBR:N!Z ].Q-X55OPL[9XOC7I<X_6-#XETRR6H#@27%%%.VZJU_
M1 ?W074A.Q&^+2+\]&#!VG(<WXX#P].#",='!*FOA[$9ZACB",S0-1/+>O&[
M/_#< !S<Q8+<KW)P'X'YMB]BMI,X'?!C*XC3D"?<#'V'6PX+W=3A"%+!P>\S
MC9W1N.T29]YH9+$119'/]=3D.+ &[$5P\0T]MFT_C<#G,UV&(7C3\P>.O:P]
M]7N1.!MJB_Z+*M':+0Z= N^O:7EPOI.6!]-XKIZ'BVE4\?].X;6/;FBB^H94
MT)X>*(%T.GKW\=AY?PB"PCJR3CZ>?WJ' N'R?(C_GEK'YNFKOS^!H%BLH+7>
M9R<?KS^=6"=?X+NSTU?G(,@^?8;OX[_PO+?&^W] R'S\.SVY/,)^T=0(@B3R
M0CV('?!"W=32PY1;NN]&'DMXD#B^.]_UP%V?>YX7I=PS':#4P#4#9OJ6Z25!
M$'(V7W-[\?:/BZ,W;X].+[6CO^&_#QF#=><S[]GT\,S0.1>@!*D<7A:[4S7#
M-B* FBZ\S1]\<HMX V+6KVPVI&: $S837&T:?5AJH"@2T<>N$#86,#3NF60$
M2>D'-M!%:#JQC[-K@)K])''2.'6#6 H(1PD(UUP"WEF+"X95^G0\I]3I ;_0
M@X^I%^(XORQAX\3:ML/R^?:"IFEA/#F\FIV]^6![5DB%!!9#;RDR/3WTX$A,
M(XDC#KQM^ ;X3:[9#ZK6-).T&T>H@!W+V^MYM%^'R?>5E+2 Q]*BI(,BK[)$
MSO52<YC/[D]*S]P-^]RDA&W<8!?9'%%BC02'C_BVK4=Q&NN1[<*1F+%GV8A.
MO;=8C5)WPXIV)D0RW;\\H88CFGF0<NJZDHW97S7Z[)F5#>H8GL=U,[D8R6#^
MR](.% ;"Q62:S&I<AS_/+[<2CIJ447OF_)RZ87E>X+SYA 1'>TMH$G.]+1T,
MX.ZV"$B(8LQS?<@BKKY"\!;\A@VG LV1:V,04B,6%Y]@@>#75-K/K__S"_70
MW!8:^#J5&+#7NC4V5'?EE65HUYP-)]>S@38NJHD.RRW&;%K!TFX+^$7@8G0O
M$EBGV($-'CR5X$O<TX+&6HL7:*T:Q%6![LT0N^(JEO()/ T>(?K !S@CD8\G
MJBV<YBC.1F/PS?221I(C@"5KWQ6;)CFR#O:#3^-),WY\'I5.FT>EPRW8G^(L
M\F'&UFH5__% +<WEH);W<"3]VI'\&B3,A\!@WDN4?%.G]'C"1YJU!T9KS@00
M-%#J85;%TZI2:.'[.1O.JHRXZ666LSQ&&!A0Z +U@[YSW@SE.:NG=ZXC3_LG
M\#ZY.%VJ3M;I2TRZ^\-:^Y/6^Q-W]J<UM*@UW;2Z+J9#[#:$SQFA2\!5'T%<
MTW6$;U5,2]#6; KW$B 3?7 3S5-;@U3%)-P)]3/SDD\*.59)P5C @M^(<>4@
ME<X)4@6A!E^"$::9AOZ&;H"/5P]?\RFJJ7+&62D1#-7LPPXTB]E9#SYH/P<Y
M-^Q9RW_6ORDA@.'-Z EX[0 6/E3 <C0VOND:Q=4??8ZO$06=_-*,CI5N<G%T
M,,!%U+U+$C#[-:LFZA"!&-3)8C\I; 28XS&O*@;:>*8:2JEM-:V_6;>7"V1]
M>/ET.IF6J@VUVF1LNGORC;:4<>39$Y ?XC?IPP+MAJL6;<EPV06H=FR;MXS?
M#O;?7AZ?G>Z?O]-.SRZ/M/.C5_OGA\>GK[279^<X;5S_Z^SL/_C[Q>7^Y=$)
M!EX&=*WYF\8BL!SVD*:6/*\^PGK,EV#I^G#(/T%8EYHSX@D2K#I8/-,D0RM:
M0\.D%&V!LFL?YPS' O=G.*-^XC@;$_?BW>A+P)*3HB0K3-TRX6!V4:\SP3$P
M[08HB\L!9?#XHNR.2XNF$WJ%83;*!/#A0#Y;[KW@MM? ]]KQ0"/Q;^[O:>=9
M]4E[*6Y(0JK+0;A$R:15'4Q$OL)<2(NSD&7JU= LM)['-L\5_=59)1&=6AC?
M8 /2+>3!MY=7'Z@ [Y-CG8L2[D#;B6((GA4A>AD<!9J\F\Q1=\$BMO9GH+;C
MEM>;(/\RK>;_ F<U_Z=#!L+2LNW?U-^E4%7<U4!4X(>T>\I*!A&&=G:AU??0
M_LB**LYP>^$\\WA/$,EDF:%+<T6F^1"$HU:@KKC-*CGX.U$+D=&(UN=R+F E
M1O!FN0@1H  9(T9H/FEI,TE$-8!)(0@VS3!T0)IC3WO;OX!!0RL"Q(-A8F8Z
M!&6#U\'*_RM4)?RD7(M2R6NY4S@JI?LXFKN 5-R:_5N/>V]!GB[<FX!4Y,V)
M19"!VS?>6H+N(Q_U+H^PBG"M18!>\9W?'O&Q:[X\ ;  M5R!G"=,4W#Z$@XG
M]HF<XM6<]7_V#X[W+\^ .YW ^DW<:MWK):8N/K>4W",H<T^;'Q+_(Q\"V#3"
MN%XMYU 2D0!I+@76A>70I"7ZE00:?D@!T0K#%<"V* KFA!5J+SE1%1A>Z'6!
M. +B;2P$+TE2X'GM+2*2E)I,PJ*&FPIE38LAF<4KB3"T_MIHM"D"04V$74TP
MNXF6%%Q^,!JCP2+&SJ#;<IV-B:+(2H9K"CFB@^Y<C=$Q*>E+18I1%14)J1?4
M74]W.>I=%^7;>DX^!M$WWNE6,.7 ?+@1_'8; X_T)O]PHF"F15DAHW]\2B4-
M!*PE <[ %)4@W *:5O!!7MP(UPAH'V-F M.;8GPU2I8(!>YI\CE)"=\GTXYI
MTE7#NV;X\K 7 X442@0<"02Q@JB, ZL!XV 0$AX(G =.2580*B09[ 3B08L$
M5F+C3*& C4$)HZ_XA8N5_2^U)H'[Q8=#G0)_ T0F)]4.GOQ$A%A%G[8TGD?P
ME@*]"/'6X*]PYY'R$H5!@"!E(L.3(V8_'PM$ZQ2+1.I Y T#@D"@8 Q*\L_H
M?JA-.@/K(U*D19*>7\WD$#<@(BG=R#^NS1\6DWTE!BOCP=*WY_9$'I 6(^Q2
M0@,.I#-0KSDMP,H'QD8L.?A5F.;7#+&2/H.@I=!H!WQ8A_\/+XIO2=%40BZ>
ML$]<N4K-L]3HH%%&-(3#K\ /12"Z^I8=I&:4G5>(@5:4,Q$HOF%#<0PX&*_"
M4I6L$B<XY!+33NX755\,A^ KJA@-4JT IA41]!(C(-D7.33AG\897&KVRF !
MITW+>>N,Q,CJM8RYC63_,[)WRVJB2&2@S!3M__W"KO7JFNO[?\+Z^?^G_1S3
M@(S1#-A?&\,9@[R /5'T?,7AB*S_^47.9Z%3:Z+H+P_W<?=J.UK.%4!-CB!_
M0ZXG2#3H$\1E1HRCC7BBII"KZ%&+.5-P$F+AHXLU%!C!PU@,Z*@ACKT 98HZ
MS;2D+8^IU2MYW$/P4_? &I#!(9%VN>4+8/4$2%:AD+L:%A$\2C'A'(H]U@.D
MZ$[+>H"S\HKEL' Q6^2@V!O4?SK&1XCAYG"_5Z/H3]+#\F-BHS:=<G4B>_71
MX)RMSVA;")D<<37Z?-@F\48PO<TIE' Q49P_H:#.M(2%2]<%UTS1L:TF927G
MQMD8I[GP)DA5:PZ1&97*80+OQ#%J,>(8]\/\.^S.G)YX'.DN LW92([V7*)I
M>'Y-\2FE93JJAS,!:#>5D]EIG;5J;=01B7+A/M/K@J12.)IS@/@H]6KQOJ@D
MZGM3NDT,)!7(F:B L0XA$]ZV?"&\7:.:@?.E<*904E5QH9N$:@%>N\9"&JFS
M4*=%$Y;E%)&M]5C.;^65 \%G=5&7>$LLQL&X1C%_:D*9RG!=:U$U06!&LU\M
M2O3]I%<YW0D9*'-SZ+K/<TRGQ-%? ]=6Q\K(;VK84NC(>U*GKN_!W:TQG3TJ
M[7P"SW9-60*:":BS'(&RUU.0\S*N,YRUF?^&_X;L>0^"V"@"6.;4;Q !7&2@
MIG,&:E4[ %DY&FCVGO<_ST,.Z-]CX!X3_C$NAHJ=%% O0@\WBR5KI1B+>2#)
M"*1(';:1<XQNIL,;UE(8XI*V<2.M&*E#&!C06$"19!55K9/%\/)B__!.?;U"
M'FVD!J\E->F<5I*II=Z[\EJ6P"SU)4C3@[J18TI)H<EK=,S:SG8R_=NQ]$*I
MUK?E8C"JHDS8WACQT$7@ 8F&(XLF63&4$WV**X[AQ8*,2/A(&78EQ0J K([_
M/A_T^R6M@B=9==1.\0''@Y-=3##45G\*EB5&__!JJ7=D'&/62KZJ^_+?EA)L
MN\;E>ZXGLI;7$SU_:=!.7#RNN/C[[_UG$A>2Z1$:&)3'#44&YM3^A(V*SUG*
MA6I',2"4>]FX@A,P':YG%.S(I:O7^&_"K5'&)H[K&J-H$)P(V@KIMR*5%_-R
M.>/O2.])2._E<VFJ?%'KD.\A/>2N[NIH*Z2LJ"P8%F*@",?/Q3@+.<BNI6OH
M,=I-!A2JXAA?I)U:*[3QD.7W=70VFO:VP/$AVGM]^<<VTIY(AG+L4Y0B$G[#
MD2YP83FYWMX XS&&AD1%Z& NU-5$E:ZYB&+KK7)\##K7DS!ZG)BUQE \/Q]9
M6\1']EY0\Q'-*GPN=Z,5+:(\/,ZMD[8$C:[C-T5>E,A!8*7+5 (:!BS78Y6+
M ,*"\Q5^+$ARP6$U/<D$@#8LX.VQ30C]DQF?X,.!"3,U<Q'\!IQ' @O"@K!D
M;FW"++G3OM@,2MQ"B;Y/I&@9CBC(%[^9SG.0999_Y+$85M.R92FUP2= C8H8
M!=F)%!,F($#F=W,?HI''TRDV2N]E6O(76?LV:!7!#&=K61$["OL:F^'\SV>2
M=#G0PE!D?1D.Y"YH7+%P:T0O18MNR$0M@$S0_Z$R#/*$,%5,"3F5K3I@DPL<
M^8378(E_SH=;6S<ITI.8HINU&TBHP@);0;"8+9%-!IQRTE3#U1Z<VTR6;LV(
M[AHB9&TM!$E5_45OA%0TMRR46U#N3V29Z1E+EX7?R2L<X(6->2H_ATLLN2SQ
MI<,<L8]8B#-3><>F :.^ ](%Z+@A>;QX38ZUQ)-;/JP; JG\7Q2[\!'+Q%"_
MM)6_%RNF''JS$I$KE*\!_V"1<%%G^E3<3N6;Z!7[<P^#NEA$ENSU;3:IZ1MJ
M"<*1>:(<?@HJ?;Y'L[V-Y*-114)C9';>!VQ,+-X'@LY2N =<<O>1*'M\<69S
M_1%M<45YVJ$JE<8>A-LFZTL]EE-X3O>HH]JE%&4>R/#U!"4UFU<J#C5_D<G1
MO:WJB;F:"QI,G8O9[%O+[)<%ED1Q.D$B!6I* =(J9;\(MC: <39]TMQF?Y"E
M:0K_YE6&U33Z**E945R959_J69IHRBXI0Z3F@R:&+KIJ. G 7/O$9QH'X[J8
M<?Q:]\/)=58F.D8\9JW*,.R2$34:HI!5TBE2/SX0=)#05-C5(UB]M0[!-\(R
M4@6+G;J;FXS,J[HN$JL*M$DVXD-1)1)C7[2804B]SJC:RD'=6:#N+2HB0"#P
M_U*+MI(,N"MLC#U<)-RF\K*YXHZ[ZCG6.(VY-U>E,,!6V.\\:Y\(UES",GA\
MG0,I7<TTT9,WZ-,MK=512TG,2WQ1H1M4L:?HX*9#;'\;!%%,#2"I.%E5-:W6
M)BXG)ZC"!"K)1LR_9B#59$"BE4OL.V\L_8/?IY/6"5*I(1HG'4+ 'X<9+9)<
MMRNTB',Z /G:HJP';C/A<1,/:5+)S88-5.*)#JV>:;Z],A -N+._CP]U,]2P
M/(B/LEAJ;8J$@^L[O!%=9DE#!$2#JA5'%5H.%MLU!TL[=06P"NQPC+@!+4FL
M$L#D/ZL%D66*M"'KF[5J6-Q2#QM5_\DJNPQKG3!XPP0]\AR]:#IH64@K,LI6
MU(/#T&]*2*T]9+-*] UWP1TZMU&=KJ!BZ[\#/]-^H"(?%50!S$1YJBKL8B6\
M;ZG-5=JJ"CBAYC&>@,KIFB58DBV;'M$RHG(Y.7=8-F+5=:]4MXGELAPG'ZN*
MK#8C(S)2F=1E9U-9_B#+V5@\46.5ZX.0LZK?[EV(=AE9;\GA@(H1<9NH[(I)
MD\S 7,9WN"W*3^,AG@K/;[*RR)NF9B4BA40@+N04IB/]"[\DF6!)5JFR#" L
M0J2HWWMQC>U]V-.PM5547@/1BG;.GN[,A7Y,T 63(3:M/8DJ?D!K_"*C$F$@
MO)5H'!2'QI,Y.LB305U/2EVV ^JA;37/4MFCH";\3>YKA[?O:KF?8^JVUHFP
MQA7+<>H*1U2M0I&BNL4G$(?@$WO='\4.R^7LCY)3MS<YI_X-@8I66L^R!'O-
M7!C=].XW>/:\QMI%\$NJWU5I^WA:5E/T[^HR7_4)>8S2GFUN!])[F-QB8+'5
MNB*8$P5)/D61BKW[PFCN+8I'\=68THFLOZ>*[=8B\>D$UM"4T^!7*F#B*F6U
M:18/BTJA &6R?03]>9G@T3 _GXU%[G1(\2[8$;+UE6U;#50O-!@/F51[^!=>
MCE3ET>+5MRP3-=A-W)3:>FJ_N?4@4+>3$@@'[-';CE.$#_T3-(]^$0/YZ><%
M_+70]NOO'XLZ<J$A]X5Z,T/?$WT8(VH>)!>!MJL4$&^@Z'\RC3VC1AY#-[_D
MZ'3(Y9!9HL>H3T54><QFM.MD3"L"Z.[['0<VD-0SU^A0PVW0T:%ED,SW+PQD
M6Q>Y.9@A03TK@E'UZUA[;OTV\"_846@UU:ON+%0TQS2D)YP*/,"FV539['W=
M%E_1M(&&T.I>C?JLR)^#.X+"N\KPAJT75N@7=<)HX94%RM88+_K)#-IG+?2H
M2$(1>+*>P / N2EF8(JA55HWZB.((>[-W9WM;=FX:;+P;8U?T:9%7@>\,)V!
MP5J9/&D[M]A^*V'ZA,F"GXNP0KN[ D-FHF%!Y-EAG2/<12"/*9S/L&885E53
M[ "AR%O]7/0),R2KM_1E^A MG4%7TH(@CLDA03DCH>+4"J1HJ4]>$2BQZ[3"
M""PUIN=52A%.#(]@ &*HO+)&, M16>'-A]-V+Q=1"0@SM&/0^T ;?#IN"#:=
M#E.2R=.RPUQR<R*@"-6])V/7"ET"M[BM&DK5YBGCC(W?A/?*>/<5I24XSFYP
M(HETVFP1'_WC[Y?G1T<]_ENM:M3JT6'J(085+:DF-<ZGTE>X4?5M%ACD&QDP
MIB7S$*]E>]2O-9:B?D'']%H:PP\U;YZ)I>\%+2E6DX#V$,KY5]*P^*W%CI.%
M]W]N0^W?0/@8-JI--1&8$$%E[3B_P:# E>HM/.04VSSZS$>R60WKE@^/T+S
MKG6!.ENU\'^P39.R,-H(?6%9@S 0&A[C7B5Y/8,%#EKD&F%>(3(C24/0^/!Y
M/.LD6BBS3*5"^.\5NH$ST;D%J\0XG.H1QY;2!K=(].$@]KY".Z#O8]E-ZYJJ
MD$U^\KUB@FKC^152.D5D6XW"-[R-;47[,:U:48P,PPT2^ MMJ8BBL=A:1P9
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M-CFT_+TZ,ZN[IS?>3D$O0)G#=7+U_.CB]=GIX?I)5@7G(<0.=DRC;&F7MM8
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ME6\"=QIQAJU18*M(@UYA0S<1".5R+9SJHK,%>RY3&:@&&[R<!FR>R1B_\A)
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M\67Y/%A.,;VZAL]GXE/3D)_>DE/%P9)-%DOSK'85!3K1W67M7YZLM3$_>G[
M-K8S/_#L3L.35:&@]+NK$$4%MS2**O.K6<W@->N*2 %Q3UW;8[5J)5;EN>>M
M=WE]T"U=:KVB,GOQ0I!0>FU4M,T)8#_*FO^U?WY@MI[_[VG.A7$$5CE6R*AU
MU#&S;F ,-TC:26+?ZPV6DH2JC-B0KV;]U@H:8=$X%P/MNKC%8!L&*SGE&43
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M$_4#Q3 6/SQB:L,_/F1KDT57&-ORB-0VO'^%H.+FYH8HU[X+%QZWZJUUIJB
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M3-)X*,<X60O?TZXR+HC/2AH-3Q>&22OM="OG<2O900J[X!NWL(B8V>!'9NM
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MU$](-33JZZ(:]4L\"+IHN8I6'/4M'>OO%>I;6XOUS:[$_-^-OG%B$(E !QR
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M?DQ^>1?RUJWU\M8[%*K66L\KGVFM9ZWUK+6>7[76<VE]DY]>K6]ROO!=)YB
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MA".XOV$V'<X%GU.A&)59(Z\13 7U/A^@16LE-NP/GXP_ "=)DQR!507$UX<
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MCW8^&Z>AK0A\/T>Z]F0H@#4K_Z>NG?/OL^.^E[I^3Q4>_1Q0\3"%@:X^_.N
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M>YF*_LH54P8,;Y^?^8V .CK?:Y^<W0S7!&%N]//T(7R=!TJU\:6^HPEG4_<
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MFAK95RQ/W%2T7!=-4X<C?X1@\Q6K)I ?=F>4ODY6.E,Z(U]^^C]02P,$%
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M1S4CWEH6&7-<ZMR$&7<$>AOBB,=)G)8NJ\>KE+IB&C]^Z[OT>OK<'W=S/[Y
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M-E'P&Z!V5#759T8MQU1CRKK^\00<VR,N.X,XO"!>14/ "2Y3\I[Q-F,)-T7
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MQB0AY5UV3B_9GMW4M_Q<#H$\9?1%&LVFEY\4Q5,@=&GR_WTSEH5B'S^[=^.
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MJ8" B,E@-+I_#%V_3 EAEK$J'+@#9?_A1 \J:OJ4;X5,B@V;+4MPS*KDG&+
MN H@.*Z!UJ*C[!1G@>,B*:KMC]T#ZRD0H3^Y5[ ")R',S^>CDO6V*<I= C62
M$2<8 14$!M!91K"4!M!>:\*TLM[762$Z0WP29*FBCPKI%Q_3#.>:XALW&6/
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MM6Q:A;C,(^H"<IO\_4Z4Z QOOWG\_6BRV9<:#L89HWER2DG0&HTL+G84[:O
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MLL/70N"[P1V([ -8ZBAD2V60++),.U6'_1ZXLFT_\/I4V4;Z=?N!<RFLC]&
M9:7LBW ,?& 2YRI227SCSKM.SOQWT0]\*[EO[@>^C= J%+%U8_?ALYN<+]&$
MF'EV*8(K53L$T02LDA*TM]E&AY3UW2HFW7GTDU/C;L+K^TU\Y6;MB2%Z.&N
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M]1@"MD!05-= %(DR!"/!><;+%H@%[ZV#P*@2C,ND17^OX*VAOT,5/EIR538
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M0Q /E,+?AT([D&1W;>S)CJP 9<%+RG%QD@8-74"3Z83PH)Q03!$?#*USC_I
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MD74(VX\;1,X@7#4^'(\P+Q)](D$2=)T8^@F6*' $["=4HL@143_08TR= /S
M4+$BF6"3%:)DD)2?-(EREZ35)$)4$++$IFBBFB%G 'DVI1*\2#;5%$34?%+U
MTWFBD2$M-=TB!(/LLFF4$)/DD*5*A&20"$NU"25# FHF0:A^/$5D)$*KQ_-^
M!AF/T$C&RWZ6(\QPO.%G!X3MQ%M$KDBTU;BCYKJ$6X_[;#Y/>%P<(?(NT><"
MG1TP<%!/9%C:(T9J@O4+# $YB?%>5@M#(H(D-+7($]%,PE6+40(3$V&?48.Y
M)@"630<2D,P0K$<FNLDR4:J2:3HILB6 S/A)2RT[9+Z>'!"5R@P@64P&+*@
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MP84O #)8Z,@U*8N7B[K0$J%R6"\B) %DAPRI0*B*.\+(S_ S@$R'R<)VH]9
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M4HO"01B3$5$1S#"%_JB!]?OU: PP$ CT@SV=%*U,-#_^\DG@ 00V2TGA@-B
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M\9_C;RZ++O.67;;L'_LMW<_8[Z+]_KY\C^7R\O.6/[%BR0IAQ=DK'ELYM?+
ME=]?^=BJG5<)J\Y9]9?]=]E?VO_\_9\B]B)TXD?$"V28=,DKR=?CR^('QV],
MS$JD$T<G[DANEN22IR;_G%J24E,7IUY,H^FOIF^DYE YZGCJ@<P.&3%S8>;%
M;"Q[</:6W,)<.7=J[B_YO?-N_CIZDL[2)]*/%'8KV(6KBZ%BIGAB\4_,'DR'
M^1D[EV78T]B_E:#20:5;RXO+J\L7E5^KD)7C*@]S>W(][J;J)M4O52^LOLXG
M^!/XQVI@[>#:;?5MZUK]FL:\1K5Q?N/5 Y('?.> )[^$?NG(+]W_Y3V^//CR
M;[^R[5?,K_QB]2:KA=67'SCG0/[ BPY\1R@*YPBO-C/-TYLOBG'Q%/%9:7_I
M).EI>85\@OR4LD(Y0?F[ND(]47VZM:IU<NLY+:Z=JKVD4_I9^NM&T;C 6&/R
MYJ76!M:!UK7V9K9AW^+LZ R<N]I ^\CV8YUEG>]T7G1S[OG=B>Z7N]=XFP?.
MU.V]/7M?[SW>7]D_K?^&7_4O'RP:V(/;AWL/CQH^-4J-?O#5V5\5OWK303L?
M=/A!CQ],''SV(1.'- ^YZ=!=#CWBT"</2Q_VP\,7'&X<_ONOA;]VPM=>^2_^
MOZX[8H<C#COBB:^GOW[QD1L?Z1[YP#?V^\99_SW[O[7_ON.HR%'?.^J]HZ6C
M?W=,^)B3CWGGF^(W?W<L=.QWCUWS+>5;=QP7/>[,;\_]MOWM^X]?=?P/3UAT
MPNB$)TZD3[SJI*F3CC[IE>^L_LYO3T9./NN4!:?T3GGLN_GO7O.]7;_W[>^]
M<VKKU/M.(T^[]/3M3S_J]-?/D,ZX^\S]S[SDK!W..N:LM[ZO??_!L]-G7W7.
M[N><?.[<<_OG_NV\ZGFW_@#[P87G;WO^,>>_>X%]P6,_+/WPE@MC%UYXT?87
M'7?QY,6]BY_^T9=^](<?)WY\S25++SG[TBTO/>8GH9_T?O+,3P_\Z?V7Y2Z[
MZ7+L\DNNV.V*TZ]<?.715TU<-;SJQ:M;5S]V3?V:NZ[-7GO3=?M==^7/]OW9
M!3_?^>>G_6*+7QQW_8+KC[A^S0VC&UZ]L7WC<[]4?_G$3:MO>OCFVLWWWL+>
M<L>O<K_ZS:]3O[[Y5N+6&WZSXC<__^VRWU[[.^QW5]\6O>VJV]';K_P]^OLK
M[XC><=6=L3NO^0/^A^ON6G[7]7>ONON7]R3N^?6]F7MONZ]PWUWW<_<_^,"7
M'GCL0>G!O__1_.-+#_4?>OOAPQZ9\\C1?]KT3R?_>?L_G_/H7H]>^ECTL5\\
MGGC\]K^4__+P$^(3S_ZU^]=WGCSB;QO][>2G=GKJPK_#?__YTZFG__#, <\\
M^6S[V;>?._+Y1<^?_L*>+USQC_W_<?N+M1>??,E]:<T_O_GR-B]?\ KRRDVO
M,J_^^37KM;=?/_J-;=[XX9O8F[>^Q;_UU-O^._/>^>Z[>[U[W7NY]QY98ZU9
ML^:%T,8S9YDAZ<9I_V'-PZ$C@O#B,]/DAS3K WJ_;*9X8MV2STAK;@PMVF!R
MASGI61.+0I.+)F8MFEAS2^C-P+UY'WNM<[/!_ 7SYLZ9/6MR.FO6^/*^XS-O
M@_E!T>2L!1.;AB9F3T[,FIR<,V_.@@WGS)T7FIB<-3OXOVBS#79>#,U?LOF5
MTZ\![G+%%C$?)K>\BN^4[D%[W[EOJZVW$2+Q74^^_QNGW$K5FKM%J^<?7KYW
M]PL>.%[LGH@DKP[&-@,T:Z-YF\R;/V_6G!G<17/F[@QM-H]@A<4;=)9<=CA,
M-MU=+M_<0WO1V/%G_[1T4V2+7][UM1/BW1/OV16Y@JMNM?4Y9?&D>[^SY>-W
M_]>YY^WV]=3\%Q,5Z99?]8^X;_>7;KX2VV;-0Z&%P;0F%\U:%%H5>O3&3_<@
MOZ OZ OZ@OX_I./^7'GA[?1V;[QTVW[WGW+BN\=>:2S[T9O[[%Y^IO;.<?=>
M<ME]M8=C][KW@>*/7I&^5?CCV<>?></D\K_]>GCJTV=^Z6]OOI;AK_G]CZWM
MGZX\?L0;T@^V.&XCZG>;/?CGWR8ON8G]Z_FG__9*'W57Q'[8>D?<[>?7'[OL
MWC>>*GYK8]CJW'W2WFG] ''/Z^]9=M8_=GVY^+:Z)O3*LT>O>F:OTQ[]BWC&
MHP\<^MI^F[Q6YM>$;HI]X]+GUH3>_1F\)F3N])&Z>ZX)+=[^A?=^MB;TTP</
MO>RX%X]]_-FW5ZT)V;??\/"\MW^[_)[W_ABT6_:7X]XZ>M4MM^YWPR5K0L_U
M=WKNW'=V&8S>NW--Z.'+P==NSKSSC2O4]D&[7&Z]<?&CW(,_?>=0,5;<Y56]
M^S:>:FZG777]A<K/[Y6>7O9Z?]D>Z3?W&XVV??R\O<J_!^%G^&=_?L&7[WKB
M /%7MYRRU8]_^:/.WV_>^+\6XF=\M7O!%:_Y!Y]XV[7777YN=V_XE\7#[_G+
M8P,ZDUNXU26EX@6;_6#5PYO\YM'G%Z\)G>>M?NLGM;->6!.BUH1>/.O5*V_X
MYIY[O/[R[P]]=O7;Z%EO8\&,5^URZ!7%]XZ_Z]!G;GSO'Z\<MR8T?TWH@ />
M^.6[[[R\^JT'WON]^MX='X5;];-W=PE6[=#[[W\O?.BARQ]X[\HUH<OKP>>4
M_<Z1+OF;=W ,.N&T9_'M+[GPDK]>^N!K?_G&LULYS;T>NC)V^5>P[Q_SIS/Y
M_:X\UMCN@7.6[)$ ?JVFSKA>[CA)(77&Z/BC'WJ1/2W3?,F9?=U7=EL3NH?W
MMSGR]-O^\<*3M_I?^=W7,[?-ON:"9>Q)9R[*['. ,_N$+\_?Y;ZSYC]_V']:
MO#\_+;G@]-5'7-]_^SCCU8=VI>]<?=D^:T)_W>R5<^@SMS_DD2L>N)M]97>I
M=>L3O5!H5O/TR]\P'UD3^GKUO1NU7S1F/;7PW#\=\-X&9]U^];*5%SZS^L2O
M'%*/RU?#-X9"2/'7._VLL/SM8R\\^/#C]OY*[^5?/?H[_2T7+:</9GYW_;%7
MO;'UCG]]>>-O_Z?G_OEI8HOE?WEGMY>O?N2KJR^Y:XD]>O?X8'M.G?*#S<P7
MGWCMR?.O/^&XLR.[I%9M]\-0:+O-GSSK9N6I=_:^^K59]#-_V F3=WSFT1<3
M[\G7WO5JL?3.J2__\W?;+;WVY #SG$/"[S[4>>H1*_?<PF'IY4O/W/>],G_/
M\1>=NM\S1W*O6%??>./K>WS7.^P_/??/3QM<^-16CX-G7/_$0^_VCUK<?>"Y
M8U:].?L7>YZH?F.GJY>BKYQT\/SO;0N]\:?]0Z$'+]CGO>UBJQ[G;OC)MD[U
ML#=OWO/UZIK0U_9X>>D=QUTT.N6O#YQU,O-'Z_:?A$(;+7[I&R_<<]S*)_35
M!XJ_.^6,@U[R_WGJ]:<?6[GKT0I\Z;G6]7/G7;O\YO/^TU/_-RA9Q&Z8?]#S
MK^_XP+-74*>=>8,4Z+'?[/9TXK3EV+O7:I>>=^[?\[^YZ[A?/Q,*S?T5KK[X
MQVO7A!;\^-W#[AE=,>^.;=+77?W.HE7?L[V#R_?>L/O/W[GLR-ML^;!0J'76
M-U?U3Q^^OEWI[5D[5G[^[%/'W'#2?:_\53__6V^=_9V#M[->#*_X[=]VF/I/
MS_WST^3>PU^]D7O*N>:U&[Y\3N*15]]><N=[!)C=]8^/W_K\;?3!N^U$*JEO
M'A)C0J'H7K>M.O+W=[[!.<_-/>V^[Z]L_V[%?3<\=M0[MW7/?>;,'[R)/O7D
M2=$#NOL$"B[QCO#V%4_<><U#ISRX]3]_\-3JY5]^Y_Q++]B%0_S[%E[\]X>=
MPP]_H1A^^C\]\W^#%I7O &]:O=_!MU[YUO.;[?[4I7_<\M!_SA^QN]^Y\2J[
M83R]YUN+841\Z;K#0A,_+=3?B=J'WG3QH0<B?_[QQ,M'LB_\>$UH=O%O!YRQ
M4^55\+>7KMKG[,L>_MZ!H="V>SRQR9\NV/'@7]][_8VW?@=<]N9?_O$D>C"^
M[87G7O]#>77JX8,6;N(.OT']IZ?^;]#19W8.V>S-AU]8<>D#K>-C*P[YS>5K
M0M_.W7U4=-!YV[UG=2;]A^\=?^Y.Q]X;**.CW3L?O[S[WA8'O#UQ_JNM34Z'
MC^LY;RPY%'[D[V]=<.$A]/!->:.3'[DMP+QKU=:'/(^]_$+T!Z_-77[A\($[
MMSITKXN?_LU]] ZOQO=^*_KP8P=^]<3;E^W_GY[ZYZ?9E9>/>?&4.Q[M/'_(
MSQ)'7?OL:\FSWOG:5T[*7'[S<0^??.I;V95'W'[LUN_8WP^%S/+)AVYTVEDO
M7O3H@QO%+M[_H,=/^NK%A_YR\9LG/Y6^;T7NG\:=M^UI7O6W6J#>CGKCYM>U
M6\_J7 G^!'HR=\?U@Y^]2:\NI"YJ_>.B;?B[KGITUJQ'SA3N_D_/_-^@+YRM
MST-?.%N?A[YPMCX/?>%L?1[ZPMGZ'/39G:VK]MYF815(WBI=?O*%=]]\U_W0
M:V[_GYM\:QGZ=/+8PU_^O?7R(4?]!$8X]V?WG'T=OL7>KS[WXST?3I6N^<ZV
MV;WW>[CSK?G"U8O?_/5]6U6K_/#K?Y:7><_M=?^/]S[AM.RBKYU^^NFG/7C"
M 2\]^'^(><^HMK)T6Y0*+F>[;+))99.SR1FZ;).$D0Q")!$,(AB)G$&$+MM@
M$P1&9)"@0 B!1#!!(D,!1F0P08B,R3F#B(;G/F?TZ3/>[3M>W7/'&S7'_KE_
M[&^M^<TOK;5]1KS[XX[.UM60<ZEE&S8,JQ[$B[\Q'A%,:^B"T5?%B)=,PJ60
M\W:K/4FH0;]I5>?\P W4UPT+SG;H7LGR VG93F[+<;SIE%"3T^#AW8/D<\_Q
M6H6/.UGMV_Q()&?N8LHSQ-=\<=9".^N)1PPR^,OVLT.M/@U;&+F^*XZO2;?J
MXR431 J\C&3QW9Q(-:X@Q4VRS_MN6!.Z.X^;YQFM=VN$>5[B''K7>6)YBE(X
M&XMA4 %@BX-HRU;6N%BP."3X4'LKP'9*UQ).TG]9LD:I%<)IU;6S73(Q]OAX
MEH6#;#.&YE(@KCC!<A-'XU13VF3?31S98SWP2 (HE<7,&MLRC_,U/]?13)&*
M!27LU8KYBNL:%[FG:/NB53X\&S93@70/$4\QM&":%*)OKH):K%^COS4A'#.V
MZ("".7ND6AAU;S*CBF^\(/PX$?CDGE%TVV:@ *6A-._TZIKF[W\US_X/H=XW
M5KMZRO;(ZF*[<GT\\C[K9J)D^9+,\?-@K5R2O8$%%^ML2/^S4PDX:;+Q?30A
M-7,Y2#&[(B@2&>#F#.,Y%#>)$('1VA13I',D2W-XJ;J$BDW#4.Y2H(6U[9+L
M%& Z:1UTI_&!5Z*^+^6CM41I'.BD,)"6I]JF\>N$EMCBHVT8.[2M[M[?73>T
MO_+$+G6>J3H_*P%&20)2.9I8($_JX-ELW&4=F(*%OG7%6O/2H'<!!JR?UT:^
M!"+AOFM210:&N!"6?:11P:1S5[] ><KM<WL"TO;JT /%KW/MXS22?G'_3[^B
M4I>F>M5LD#PQ [[6?$\^V789$5>];R9,^G/,EL%%N!,6G!.O1VB;ZA$;1MNE
M;;#LN=*^=]./FT9.R%_5K");6J4K"DUEJ"$!"FAO X<)/(B0'[,RT<0EF!3(
ML;BEGP)I&*Y)<4R?&<2IV-W9&GGC%8-\F0RO&YSRI, J_-F&_EL ]E#Y9R8,
M4/H?B^35X;9E.7/]T',IF.C[;*+:=-N"Y/SB&E95NL;X539-57CQ_-U*L9N;
M#R]7M&<A;Z&V?NA!?WF_3(_LZE%-:/"PF-\0YO>+#4MG>WI]QK*;8X^E>O+'
M21C[B.1K<T4GC:;D..O7MV(+:"!0[A(Q3/MI=MU K?VN)J,OR=:*F;"BC&OH
MJFGJP>24QC@=01[5BBM/"H]MK^'.4 H#OSU2 *7=.?IU0+MZ=7RIW;KAP<DN
M\Q3=6PJ(9;/@$5LJ,. WHY,_/*&'J%;-8;!'8GM=A=W2U<4ZH6! 7DBFLD"#
MZ5=CDTYUT!K4*2?;W-)Z$+H( .=HB;<WO E5%M'6F%!"EP+VP6\9Y.A&L&#B
MH$='0;^S4^Y"[BK[_.9B67R'4;0 :'G,LO.2Z6IKZ=VTO76CT7G5GR-Z!8>
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MD_^:ZI/^IU-]WE366G=E=IECC0K'5E4%.'7#-$ TSA?>U]=F/T2^0;;8K"*
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M)(RJ8W8F?&BW?+W)Y:EUP@RILMAK5@>>Q\&26;*+2]Q*1736!O/$)@QAG"T
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M^I!Z<*!M-V/ZH#)J9/(++?"F]/%B@-G,8IZ/S@,]LFD+AW*I8+WSX[]JE&*
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M.8/D]$,O.ZX(C188FEKD0_9UV=\;K1@ "Z6G+4I*B1(DWUGN,D^POC.;\!I
MER_[=0IZPDI2C"!?5-=CZEZ(NFG5+CV67=P';"5'Q[UTR1&;K7E7:*^N>O>?
MJ"60=Z@8DW 6H?3*Z:R3YTI3V!M*0_E !/541>]NDHK$[)XW;XL9=4Y*PN#H
M]U3VICXD@R'TX'"_7M]L]?;=G*%A;L2<[TF<Y&=">38/R&2UW4?/J]53!RJC
MIW]=1]8JK?K;A/WGP,#JS_3JLGKJFH1'D @(KL!=Y;Q60H^4CO1L_3X)>Y)2
M<" T)YTV$99R^KQ"/N/.U4\*RXCVQI48\=Q5CL>ZLA(4;B#$H8GHL!#5PTHW
MM=S2CK0IC W.Q'=ONCM,CG;E]%WA"7GN^@"/=PFQ#V+7<]U(Y:HZMB&^WQ,A
MB^D_"-CHZOW!DE0?9VFE8K6"K ..3\U^X#4=U<-!'\(RD5$NL2/L#\NI3])_
M^?+T?X75Y$;[M)HU+2X?N^>-9)<@J[;H9W<3OQTK9[CV"I#JEFB<>4, 3H&Y
M]-FCN+#N#*VU.V](]?-KUDL-":U?FB=3SJ2H6@$EVP<O/S"ET]((%MT[) Z'
M',LX/X.$\:,;LG5I;F/QAFX4<>N:FQ/+;U\LJB0S[([,(:9?2^[[]4TOYUR_
M]HR+XG<+T2@,2DG[6B]LI+$;-&Q#F)%6<WC3C$(UDQ'TJOC8TEE7CEE/GZOA
MV$?;J:KW#1TX;H,*&!JXV\_[L[GGIY4F571MWUO2/&472,"),[F&4N5U:]#F
MZ#1U"F4*\!$Z7Z-O^7V+(P62\<*+XQ2;I FUWK:"".$Z]Y2\N0YW]RW)#4R,
M>%K:D,5A19]0B@.;L"5S(WGJAN=*#G SUFS*O2\Z)1,T?HQJSU6=K\4Q?>L/
MCJ;JHGB)E2G$A-&=2NR0J5U9I=]S5<IECDAU4O?DUR">&[BJ=^2K3U N$^!\
MNRE"Y+K@Q:X^P\ 5MJ@L6:LDR9SZ9A4Q5&_Z6U,_^M: NKDF()$2H1*&+CS4
MO[J^ZJG/AF$W1 CO68Z0N8=UR,5Q2,N/<4@C54%!D0+!AU^4XD<;<W[:^^I'
M_^$IV,V*C"MV/\;.*DD&<97-6T^6?GAH+2 ,YY\>-7S&X%#[O&;=G+M^7_?G
MX\IG%>?]/U@ I)WLYM(5T[68F7'A>OT*(+&]8\![4;MD/=<Z;V*POBHH93XF
M)N1)4IM'>G4X6FJH/(#1%DO!WNY#1]N$.7YI2RCW,\O1K"R?FWUAUOS*?L[>
M3 .L97(X&.4:M[*B-13XZM3^\\C14%Q:0+O.RCJ$@^H5RA P/_.<#1VU$UN2
M#=:P64A9=585HS?V",5BW<Y7]T<.5ZJ:3L5W/"#@=D>#BM<_6.)/A-SF^M*J
M^XH="CMG_NR+GS([ B90:;KH(@JSY$@A#6= *\"BY_UT*8LO1^K4UAFB9?WK
M3,>P*ZJ&J$.CD/LQR\A-C3[YB=]SQ/%R4UQ9[<I=>%4S&7\]:9>?VJ-J5=>[
MX$(G+X>3ZQ%]9CM/$7$^BJ^4BPR".\$5'_AJ>,$SSVJ1),2^"2P6:MZCURD9
M=&W8)4X;F5BAL.[J.ASH=02"G</F^VO2I')>5!N$%J97).@<1,.;V)A+3W;=
M;!=ZGO1,8,,,A&'O_?M39B;GL!(\6".)1^4&.IXI9DXJ\RW_"7[B!S[['2_%
MA'5GF:V9RR*86GM!,W[ZVZ^*+L4N/;I; NKVB[-[6N_.^)!JQ[>JGCA7]F[A
M/4]>:7!E?XALJ0)>\$!I!59_VMS<_$^*,:]ZU"[G[;8'U\8M4E$\%#NET-8O
M0,"9QW-Z;ZB[[!BL>Z[CJ1"D% DAD0&^,D8\CQ(/3O7UK!#Z18M,0\FB\Y/9
MILM',F,+IW[%!%(@Z/$B2;Y4Q2=-=.@UJ7B3LW'0W0Z:8UFK(&R@$27!!PPH
MAXM1V3#5K@W\!V4VX]79F-)^=Q'ID!A?Z\DFUB$ /1_Q"((P<];1ON7JXDF^
MQ_TQ(K:\K+)'TM[9_AJM^MU8^HSKUL]KPST@=WPZ( OQJI_HGF.:0[&W-*>"
MSP:CIQYTN,3:I=A5/XK"ML+8%@^7X1N\16?UE"997;LT\C\?J4E9<@IJ)-EX
MEWJ]@7=%YSWM\ZG!^IFV[\.6UXQ1W!-MX(IN-J0U(1[- $E/S*[-N*F+.XV[
MZK5Z,=JG[7/;<E&E4_KJ1',]CC7'#D@+U_S)Y^:B'+.:/NQB]_AA#AK!_>MC
M]<=9I'F?<^2]Z.-B,Z0P68AGC,&YT= \K3/J7M"CMI!H3"NYN<B5<XFTGEQD
M=S:ML<KM&&>O%Z\0$YQ;4'47I'&(2W5)OIV8D)!Y'7_'P&4NNYKJ=4CS2H>O
M#H0??ODY:^?8=S=?ZUL.RU@0[)3:-0+F';X9L,69 MG*7\;'OYRFFYCB  #I
MDA,=<'C*]XE,_Z)J^5.:UHV4DA$L0 '--90$[RBD&0;"U^'[1<_XWVZC#2;M
MR%GS#B6%+E.D]$/C!X>K ?!Z?&(\GM4A]%>SX'L'YF6"(J5\$%B23LZBHFTZ
M57&\D[TO=U-ZRJZ1-$KLUI1V_68&>^,?V"5W;"@S9,7EZ_D^9,)PCBY@'-TQ
M&%)%>[>"C?$"8%V&?>/^]89,W##/JN5=5-E K5FXVZ<V]:Q/8NV45'E\A$T!
M'>K2P>XK="+8H[REHL_5WL\>K.!:5$-JSIS.7#%X7&^D+]<8HT+C*MPM78W0
M=Z$F,[A<=O5DH<*<D3+9T)AEQSA_/#/\!/E@4Y;)&U/4#5H670URK3E(.H^.
MBVQFU5!KL@G5?J%W.-WD['6HUSQ'WOIXT!P1=VU I=LV@CT6-P3KQ/3?W GC
M%A_9BN\%DR?3EESU5ZNJ(BMP3+_'^:XHR;T@M$[E2M;4#9++3)929SC&?N$9
M]/?_[>CIQN))X99^\3$FHZU#5M<]47'#QC".NV1+TEQBH'H&!:7S?JIO)JUW
M;49_3!8R*VBZP9@C:5[<I5J./$ECKQ2G<JR1(H"3AL-M'VZ&CDNE0 6NG"+W
MM]1<][@ZN;D,XOIHJW.>IF4PB'B\,N'2/K0CXZ/LY-C?A9TNNAWQ,LYWCX\Z
MN/_UUTOI.3)OR.2:6I!5EE3K3)F+JQ=.:#K1J2*9TN&G&^2"\ ;EL#JI&&'2
MXI@C1MAL?S?1\3:(V2FB=H0PL8U7$8Z?O#]5VWK'!\F%G$8X9^;K1X\T[<]J
MS_]@:?C6%G&G(P[@D=SNS.KNMM>2=(_S?[[^_S2'X=^B8R.U7[1IQ4765 9;
M16(/0CKYMWKNVT)^L) 7((:PX=%U*"SOSH*VS9_C;R4ZF*>9[]QO0'8P4M-:
MT!\LYG^]X-VG]6@Q.];S^<7Q_#S%OG[F1Z3CZY ##]&%BB+4SP[^>:KN,#Y5
M[6'&YX!)="@W_#7S(M7K(/'12.G8%TH%"6(&5' )]@+@#KPTV$-,\*?]W>:K
MR'H9\V>0H(X?+"]3#@-X,P]N2RU<>NPU0YEF*'\ZUG52G\03H!?=2:;<,-_R
MGSNL;.1M_0^WW\!1[U[O]</2C1\LO,I[HHN(^JD1N>3=%*RV4T?%4)K8')WK
MD11LW;0<(0^-@UQ( 7.B1RX@'*_V=X#]>AGD"Y EG%KKJ$AK.RVT6<)K%Q4_
M;D'E"V_%C)M:24JM<2%$WL<_&^KVHEHQZ-[&_<25FG3C3,:S:3C6BW8Q,B=]
MPR"0X?<U:ZLL0IGM2\N'%W/]@.F /-^OGD=\WY?ZUS.B^#;:N0LAHL91EC6R
MXTC2Q:]J[$_C=?7EHS_F&!%T-7KMZS5$"O<V7'.-:/5>X40YU0$[J- UDC6X
M,+?KOYGJ@;N9HY8KS3;PB5,L9)+"$*V!0AEB?:<3)G]5#^.5*I[$3VW,/J#J
M _G%@YMJT9T3M5/I;_&Z22IVBAU.UEGB1H];U])9R6MWLB*JZ)%XO$9Q7)>Y
M_593GQF%/'80(=^><LGGG2XM!N[=,S?N/?!J S6]G->+K9EU!4&%VHY,,WV@
M!ATTL(<%7W\+V^E,)@3O<"*_RN3FJV%W!YF;DFZ/3='CQSTE//-_+2X<=L!1
M >BR9^VI+G_/SS7WA<YP7J6%G)L_'?Y:[TUM<YLSM42?"86Y[GJJ4J'D^-MR
M.G[#Y%X?0J6RKAK*+6Y;?A<"YEP,$]RWD9-<@BVFN)!%;GYO1+-A.P9GGGK@
MMJ>BLXSU'0#/[X<M_&#Y.!5&%<?YCOA@/L,UA:?-1[-S-'E]SV'NT::TF??O
MO!D,<.JK>YENP3M[2>J>4TM# :QLGS1?9/;_2TMW,L]FPM.H9T-))+SQ>-[B
M030!^%=B::5%OPZ5@JLAVN_]*STP*ZUNO4(#J!]IR 7&\UIS[]/:XU/*S/<]
MM3'*BBESY>9K,Q(!V,(Z,E:HN H3*EHJ! O?AFS@%!+\+*\W\E]R==3[W'>[
MGW;WSN\>A;$AL8>MF1.RU:BL.WHC-C(^J5"4L,_E1@\2E,WV)FUX]>,9AR;!
MXN,)C)AD)EBWB:+WVU0^Z95&0>ML%A6<+7<1ZL;)%/!L]#NO(,9L-,604Z3:
MH'I\VS$#9I,T_ER26MP6$:$D<L/#_)FZ5\K$3[N_ R2SA]LUCF'8DHZ7*"&+
M7QK_.)?<OKN--3CC+J_@S3H3H\V\8 1S/W'.TW+E1J\TM$0D"D6)1OW!\D_U
M$XV%QW7S9JQ.)ZR*8R1'K0Y5W\:5)#%?#=R"G!I?PFH\4 C]SQ=GG,+N9MI@
M+O;BI4.9P0'YNIBTW<Z7H\-^W28-YU--O!X^^&[-:S[%I;RK0-<XY>Y"9ELV
MOKO9U&ER>I1CPEC*"^-XPL =VQ5#GQ)W0T!>'<88S@J(,-M$ EL:T._B"+%P
MT?-FQL^EZJ0)[=0%3*0NB,!R=IMX>!76ON:A\3IQ;\>O^)M'\?ZF0Y&Y1W@A
MR_IZZ:2ZI)^H\&N )60/BHOW>7P*6TB:>D 1T[D'%6(K2 +R9&'V^X%HKYO6
M,MBW.C./*PM+:.&!]R>8(LW&V5G9B^<K_>"4+-=<]9T$?[+-S5"K@-RW^"CF
M'0=?7;.Y-2#?.D>3A;6A\PS@8#-ZB'IX]ODV;.:%Z=AR-?$Y'5GX*MA7W[Y;
M^K9?_40JGS%!K<= 7%U8+S9XXLAH.4W:%7!_.9>/^7(#V\[)C1'=N3DW(,W<
M0)PJ_0$PJ^]_T$8."#@\!*_$WW0,^KC?SK^94@V93W%^\<TTJG-"]P'2V^>.
M)GW[-*TFWMG5Q90;#6@CF;Q(HI>PUG><';(WT2QR=LTS+JR%)ID0^>>_T^KX
MTWK$%DY]1^)R+8 !52L=VO8T,8V]K!FQ/JI7D./CPPQDB0^H8,2BR>K,9-K*
MQNG )@=<FIW+=R_ZH"S<3R>;S?9*A8R^[;JAP]]&]!^+2GSB1@M\H8?X1J2_
M*\FZ6Z>T[D/_-U(B!G!85YJ1:&Y_$>/AA^N01W3GA^G*]'D)YL)020ZG,5(E
M*4O5PVZ[$_CKQO@KRLW8]]!'-13]Z]H;,8;P]07N#QI#XQCU+9#UI/GB,.P)
M7L<+JS"2%6/>,1N>+V$O7 '$_OF,W^F\JD+=U5B\^_P*O[[=(*ZZX^+#LXPA
M!T5)G127I([8> Y&ZH@OGV^ABTF2")I$MQ/*7I,X>A2C%3 Z&[_T:A"/"PC&
M32X\H?@0^.4([FQ9*(RTM66LZ7$C@F:NN-H9_9J6=[=9FJ#@$\BME+$95U28
M%2L**WWX;-6UF)+S]G2"?6$F2W16!TT1 Z?_XOP:HR;MN>RC0;(;K+9Z/%OB
M2'Q3;8 2@HI']A@E,RI!&V;H^2"S@HJ7TSD6C]QU=27<4/RC,M289297M>.G
M16^Y[(*JC3TU1#1&]9._GFS,V)GQ)*T#J,3U.$LW-=<AP_3_8N^]HMK,EG51
MNMUMM[,QT033)I@,)B.1V@$PR( )$AELA, @@A$9$=H!,""!2<($@0E"2"*#
MR((V.0H3)#*8#"+GC*][K;WO6GN,\[#/&/>,LQ_N?)[C_V>H6?5]-:MFY71*
M(7BV0U72LM83"#2< LKQL@37BIX[*MX(%9=@$:<'EVXV$-R<U-^ZJX1X4VPX
MYG%;^\W4IHRWL]W^4_$V@343]'I@5%C/'[MEAHS")W#LE6K[,/V4Y8Y)AQ%/
MD'8_-;/)0#F+)EX#&H;H*(D4G$V %P>0/DH7QS,%;@+6.B6:XE,8%1EY\\8"
MA5BX6.\!R%\'=T>AC)(UY MV:<D;U'F4(Y/PGOCHV]^*WCB<JG0 ;[(-EOO.
M]$++^.:=[TP06=LDVJ&@;2]3AN7>I;[RX#O)YW)?!Q^9;7+$'_7R*9/2R11)
M>MZ&545=4%C3ZG. G;7CY??A07I)XOH^ *$HX-+.WN><A?U\J<0=<ONA6702
M(*A'_-QZ6>TAQC[-:V=U=B9AF6ZI$FF2.!5D).D*?DWZK1]^@T/41$^76?_F
M0LC][4FG%6N95 ;;E10X_^&>1;E0Y2P;244Z:B %R<OS:A!KOV5LB!;FX(IS
M%B;^+^X&^!7'_"ASW^) OU;MU4A%5&X[T#[T>SV[?I;TBCI\7"'''(WF4Z7"
M>24&0 +C[6(#I N\@@.="X^OZ7E.+I#9C(?:$==FC1<&$:IADS@ZW$.*T_AM
M"^53Q=@7+1F=3J-X0Y1Q0HI.6>-@3>J]OB.A($V"&\%\COYUA@#)_B)9)1C7
MTFGDJG4K$I&6@C)V%7A\+G):7K7R807J>\.N*'*.JK,:.>A7"^Z?C"*8+;55
MB'&NN*P.;WOG:*[XC#NQ6/>]?*LD(Q2,WDYJ8D_MVR4X JGR97IZ;^/>)[$5
MU YOOA<L+E!NF!"38MW\AN>X"X!IJ]39.O=X6U0\_NQH*=RO7%43FW1]OMLG
MW]%(FHMUK@&!D[I?LB'6 7JK^)9.1L,YZ24H9P64LX %G0Q4*'#VTB+G89E9
MOEEX)1BA(,R:\@EIJ0FI"'?V*9WSF-WO_R#75U5GMK/P*"MCH>XG9(EMMX6*
MXM&+4FTN! NS6<<U/>*\-R,.2FYWD6EOT72AS[\5TF][NO!(=6^!<A>RK&31
MTVB1=1")Q2E5AN(6A^*60UD'FKR(NFFV*7.TT,WI#HO367KGY+G"O>S2<ZY*
MLD!9A.))[2M0%LZ7/=7RI:["_;IY-@G"_/;1LW-382S57@I6!DC=WTYVR7W4
MC"FR1Y@NQM'&AB2Z%[OL:"39ZFVUSD+/-&*NWJ2-M0.'M_L&49^\YAQ',/)T
M,TY;&,>)ZJPA?A@+2D&=7G%Q26GGZJOY:F\Q+]F3 $.\;AI_]A6O:3;.1\QF
M(JTR.IJ2$1(WFWC<$U<C[ZOK""*AT<JC18$Q =EFK3)YA9[C\TL?THGX)10,
M(-*B=']3Q]V=P/<,QZE)=141BG*WTW%WW16T#@]KD'!P($P?:72(^:Q\)?,
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M8Y]L8F28;_[)Q'3AR[8TYRN>R@*+00"?2=/:Z%DYHD""#.D\+B/Q<KO-2LE
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M2L%><E(>^:(3T3/E:-W#<+"A2-76!++4>'6XD;E1QOJR:\M,E^36XY;(X[U
M=V&$NEK9*L0N>J&DP.8-1"WX#O?$#5-Q"Q]^#8 X&^\U??V$T;SY%2"^Y,8*
MUEV\NO=^IW!HEI\)@>.H;8"3O,H!VD=2W LK ^/G6B2(B;PO2:*B#F6Z/OL[
MEB+"-;BGY(HR2RA[<4Y%0V!3;?%;$4G._S@ %Z)V;']CU WE=T1TM_#RS"O/
MQ5N/?'X3TQ!>D4>D P)*]K=\^);5' %<N\=ZD*=T-0I[VF#2*&++M-(-TA]\
MI->@"-\3I*!JE%2-G=I.&^<G0=T2F<-3+<;=3KE+5H)IRR!29F=:1E'NY'57
M?3G#N&RU*=WAJHU7G<Z6FL)?NV<DD @RF_7U#U810I:[^"=/TA/;P:5/=@_)
M 6("L882%9:?1AWHSQM*DW@IFF4%ZI_(7P>&AQAW6O+*]^$XSY21NYYZ_0V9
M$GPFF$/JS9%'/^C9GEJ5JE%%R"W MKX^/6= ,0JNN$$PCC :WS#M+7G!M3_T
M[OZ!"BFG'3JY-%U.6N&O!P!)Z>?#XK9.L+A)B=9.91AY;E]R<)'2-MX%CX%<
M=P-Q4]K3'7K-8#<-%EEF!B'R0VF3H[L>TV ^JV^;H=J4V<LSX[CW/0*-(?_5
M<?R35@A K0!B<[5O.C[;\NX*><YNZ3L3&%FLC)+_4!][QAI]++V-961T&,P;
MWN0"E,VT(T34(JR&4L8&)HQSCVO$]H^ 7E%_77Q:I2"5G5=1Z>2JM[JT0:19
M!\D'8-H:LJ([15[]H+@^WYFX=K6V'34\+L;(\YGCTJ?([=M?3YS$-"[IGII+
M')B-1\-3QA5$:<A8RSZU(""V5Z*4C7#T+M[>.(;M*JHQ,J^XC<LP!6N=06E%
M[GO'#BEY2Y2'2,BM:>M;<;"/6/OJS(:QX2_I1T]-.5X?"ZA(O:?X_J\__C7+
M__MOVS!=FNZ$$AUDDGDT#\]& ;J*6T/\NP8('&,;4L)'% M2AID<2C>?E8OK
M3Y:+]_N!WR?$KQFP'?3MV%@\;R@C01%5!23C1$!A%55*UH;H0KWHSN9X(;GK
MV[K7\22W< @;/$M,F.Y!G\=K/+$U,?!ADYPG^UE;#E3CCVH^HI+B=!0.DN.3
MT8E6E0^*DJR"@R?+E[LF'NE+;V0O\%4=_L7T\WC=S]0SWZA]U-6YC:1?J_4<
M%$G'^2:>ROG(:3OM+2ADC5M*\Q!@58\U!+]P<QH]\*==S:D;K5CVMQ*2"-[-
MLK&]9I[4*N^Z8"Z,6BL:QTQ\)>E?EP!R\(BITZ>,A3TX,?^H7/%;]D*XAO9L
MT057%;2X3$N5 V=*^KNKM3P'KH!/PBX ]N9=3_L8VVS6@_%H32B]%FIKSI(/
MHE)?:F..?]X 9 J6I73-[$<YJ)T]V4R_&8#[5:R(-^:-YO&<WB0?P%8=OJ/8
M]7O5.\QCMW.Y@/WI+6<]Z#7(HHT;*^0FVR2@R*([=J3,;CYB;2P=#EG3DTR%
MY'<>K9J7J$Q(#/3*%WK%Z\E'FP*HX!^TA$AY]I9@A'..*[ PPIIW5.M4C+G.
MC+G#7==<UUS&&2:$YS@N5@'.Y^]-H)PYV9RXMRBCX3C+VY:WAV-*2"N B0'H
M%X9%JV(KU&Y$MKRXRLK:Q+D7*11;W$F#E]@LM'&IF[-4;T!*T(Q%,04VX]7.
MTMK3#=G,!)@7SE*VFL3E-<V[G3:*,EHRJR17Q%E:ZB@& J@>F.75W,4?K/C1
ME%AY-I#L#/(2;90RBF]BWP39Z51LZBCV*R!G."(#\%'CWJ;,-ESFZH][P23X
M1Y_#&5.]N Y^"4)X:X^LX->53Z;M)1#T;0U_B[+VU@Z!V)JQCDECF"IIX'49
MGLO;F[=90+SV?045>5*E1#;$Q5QCITKPZFCJZDD\7FQ0D:OW=*Z> B?J B&C
M"#2:A!0=F)@<!$&+S(7$XOY^(2%;^+?[\P3I6Z_^0^ZO;7/_*1\C<#@EWC:&
M== Z,CL)F&RYQ@Q*I"G^-HLPZIZU%=;V@M>'?D*FC('3#M,(X]'NE[K=;.:L
M.@<4RM>]65.M3.""6%VVN!WGAPW5RC,)W\8MS69RTL&>CPVWDR!?:<!@UU9)
MK9EW\2;KKY06^_.2)O"JW'A#+2=5+G^1^72I,67HQXI@A0FG,P,-TAR?OJ_,
M7;(LFSW<L0VVU?^4#@QTLT"5]%Z@,4, S#P?YDR>A=)&397Z@)$KSQ8_?NN6
M='Y=)S.=9C-L\@XY;22I+TU8TYG!S"\%.<;N7-(=89RI&-=U;HB*2KR>>1\_
M3=#-,ILV2AC,5*B-4.764Z+JNZPP7?SO.X@O2(7(]-Z;6YCTZX /6[W+7^(Q
M%.K1MHF^@R38R\4^H[N.77M%\T( %_1+32*U2,E"NH9J%)6)(7%574\NBT5;
M6E<^T<-I-;-S,M*@!VORG2D!8GTSTF-]9L!I '=9VJHG;3.Y,P^Q@O'RM&J,
M"\NC#DJ1*HK31,CH@DO]5:(=M 0+?06XOC0]7WRUZ-<<R<?S+=-H&^=>G6Z>
MU$A8O>0@0@/2^&)#BV0:,.J\WWFXVDS,,*?O[4&  U;IM-H;+E<G6\WM+#:N
M!R;@"N4NY9,UV=1$'8W#$D6E%1EU/F2AU;S^X86,5"-7XYTL8C,N6%+U(61^
MP:R</:9PND":X $IN+1H/@:R\PANG:FGZ14!$UA("YTF]KM('I<(5.1]6>5L
MZ-\,_^_*RP)_,_R_*R__8/@?PA);9=Z;_!X7:298(9CT2!9BE#"WJ#@^UO+C
M$!U4'%MJC)QG?/BG4%Y$JL/2.4UF4>]/OS.U#(<-]I6-_)8U11[W]M'6?CXL
M>[N4:V0\\!:Y@%"T:BJH!>)PKX2<?D"91#=[:&*#A0'"VGI6H$\6D,BPQQZ&
MXC4/=+0FRT<-2;]07+GZ_715,L$Y&=>?MG)E3%]JY@VRA-\U70&NY^94Y$PD
M^G=43SQ_ZV;B,%58].@J9]==L03^\20V4:KW+\9QA_'&?TW=6]S:27^@N*VD
MAKX9B$E/I6C*=[ !!]W'H3*6/,0#0<.._#F<#I8_J[I\ZB5Z>5U4"7'I$PW@
M6[2V8M4;_GLWCVMAO)^63%J2K_EL"9#%6=^2IF0D/L2VV-PK1O TP/C*2XIN
M.;N4RM66.4%%]9G=<+^&T0M%\;_R4HDXX97K-ES#=B)_+Q+K] [Z;'1S: KU
MG6F8.:&I-82&2IK?"[[,L?.7,/WLX:XK7YA#"&I7X193T)JM>:\;DIW%F+:%
M*;-D;XDG?&BR6Y8;+T/>"W#X8O/; %$A;[&!E#ZO)9-7B,@V!*N?DL2[Y>HZ
MPPP3C;"!G0OY3@-X-A0.H'K;IG!_4\=N3$?1O_J'SG-:S9W]3YTG1G;6F^9\
M=+E:B2$983?V17#L*4TZ[/QWYW0I)^:<OC[J=GJ3T1U?O29&'_"IM<#+Q./Z
M6MB64,TH7=TO=8A(/G!T;!"W/!;)I-\ _2"7\Y G533@<>'"Y?'QU_D09:5'
MJ)09-*=\#=9<:EO'_V.8J.=)!F *L,>]/@%RY7!2+)#T2[]YS:BJB/40YJ%<
M2<_[<O#:O1>KDZ('"_X'4#VT(%N@X1QN!FP6B;^GT$AR[<.?BRSJW##^"XD,
M5+2(G5TU%?SDB3XQN(;L]!4GMI>3J<6,2$C](HB1K#@0K*@('I5W'H>$4NI@
MP#W!;,X6NWE1U=LZKJX5<2"DK-#\E(;MMER:8L&\R[!/@5'3WMK%]Q/=#AH&
M+0;R?LNW+_%+L)?)UH/V+2A6(ZO5V!_0_UG XLT';H#XPL*==5%5XFTOU]_W
M7UL.N#Z<[A.+X2HS8,<IEGR14'*,52TBSRM)291/_<+N;72%LDH?4B%&  JE
M/O7KRCN1W[[.Q87)QGN@HB(^U!E@#,+D"^@M1^(=AQ4CWYG2SJ 1"BM]163N
MY>X%J9. VGI4J6*W<[?Q72QGOG>Y,Y$>6UG4>""X!,&!DD=SDSBPT;9:(+OI
M$.I<C>UMY[=(]AL5-R=SRL);A3^H1+*1$.%:]-<[RI[ 3:1%2MO,\[CQ*@M?
M25<_(F<.27/R);)[XC\0U;DBW+3:)@#S+8P&>MYE0;.4D0W8AU/;-.59FL2M
M>;[V<"<6PF,M%HA9^,>;!'VL,R+;0@9[IX6@F3.@]V+  *KGXK3ZZBR!2*LD
M<>T*B9B^3\@6J<#=$8Y,L/B2F]*B0%;+ZR[J%F_Z5.<[#G>WN"[*W<Q-&['+
M-B1)$')6N[A7A^FP%.VGRS*^F=$@SA&>]5UTW%_GI NP5.E S6T[U2IJ=H;3
MH4)VT<*@ /G4HOZ&T>>Q-BZ$#C7*_2X;T'W'V7@XY,KI689"Z>7E @-#-7_,
M@#YBN%[)/1+E=MM,R.AZGI5@\<QK H]*VQ7O>DC6*"9CNWQ;S$9IGE#E_J)A
M;3FM6M7#CMO.5"C0@!\2RM^L=P5P/A[2GQ)[3DWDH@72+76 V5";BMK&#%FA
M7')@N0W4^%J\<IS)%E)T4BA4L>);[6'A@ID$3.&QLR%,8BN[\X/SVO6[+V F
M)8-W6"U)C76,"ED_FH&#]$Q_T*F'WZ/4JN%Q#-=#^>*.W_^[09H\?06F8@IY
MA9Z)7'_7\.XD]3$SJX'!!E"?H:JYVZ[?*BIL3*/&Q6_>\MB#=9A E5RS@$?6
MN;[D^C,%3[9=A7T*<+\E/ RLP\QF2,\0CP43FW5I!=X\9:=TZ^Z&]='KK2E+
M(6CC+L4*))BM@44; .@:#6 !?9GX(OG8+]MHNL&:]U-CF)I)_$XEWK!G9NC&
M;9/9B-?_XC_&MLFJPC=YW#ZN _<4AP9]_1<3X7\UNP:JMS<?E+(*0"W0;PL?
M*1SW^.PM16W(Y*'0>6;Z-@R PY%GU_H\^JP4Q%'O=:!E7:A>85OB#H?]NK@A
M+;JL]I#G1"PW,]9!-GX:U(.S=DV[O80:JG_H?1"KHW7Y[NP7*8M@;EB[AY9-
MYWG72']@!7F]&NF\:K)R,(GC(F:;W[6]8VW+H*@Q>N#&->"5A1TE?E/VU[TB
MVE-+TUR?O ;<>T)*XILZ[D^V8_G")CS$KTT61M1G;*MT.X_-KL(;E:E7"6 \
M3Q!-/J[5A=QX7:KJGS%"=4?A(=%^E:?)Y&#RN_N%QM^9E"@'7@V_=+K/9"Q>
M2SU(S="-Z*Z[=79@<8)./WE\$:E*/:[D2VCJ2V[W@Y\\R>@C4X!"[6R;]?^X
MEV(2'>@I-$M"S-DNW5?LK[6>/= Q\IM%2)@J$H8SR/DZ8P,4#Y>UW&:$6(N
M\-IN+.A"%RH2X&-\K%\>DCCA:NT<MT?:MZ%,4Y1GJS*#[^W5[9R!OS-='S7@
M(8F[R8*\UBT.1M3KUU[J"*_8$U^6/CNOYWS]WNI-A5Z#2\(8U+B_H#F!..P8
M%$CM1\%2?M#6LSO.+^V0$MVT7:^8-\08:([3X0Z+$4BLQ-PZK;BA.JJE8!-?
M7=^FA#)>TC6 ZF1DA)];/S9>1 R.D!4DXJ53OJ$J6@NH5PRCK&5R4@B"^P"@
M$T&S@^/:'[]N_4M<;FUT2]T.C]TUK[PFJ57KU<<PJV7)LCL90?L(!J%R[RWU
MXN3WS*++P$! ^WZ](MX\T>B/^?,<C&%R?OV"[8%W=YS?>JAVJ>RJ ;VK[.*9
MTP7/V:2$/8=4##+I2TCS'2\AA;=CD+>M8%%5I:I\9^/)+:/WIO6*)D,\[N9N
M"A-[$T/7%H/<+WV,;";WK7#+LO+1>3"ROOS23V7E[>,XI#4A!P?"VOQB^M7U
MYH^5N^"P(;Y4TL7X4W-W5)(+[-W>@W$C26&"M%=T5OF@XO6#?9I)FL<7_9LP
M7??2UX@H1AL;6> 1UWH(!_G%ZY/[[(T6S8L>Y=M51P-9XHR)-QC^ \[(^O%N
M^(E-R_&S '%3&BO1U(><[T8T'R_DVLV=%1I-OSG("!)WRCN".#IB8>5R@?6!
M/DKR4*/;*ZC^N!8OA>CK[@:L^]FK&8"#/YG^K?V4:IOJ@]S/B%>6 /'1)>&1
MY!KIF.P:Q?G3]8%/*9JF6M3".-PARU+UVA.[@.S:6#F5EKWO3*W5F>X.&<FN
M"7W1=T>]X8/NOL\<K_<48/VRK>JNP3)8YO9Z=I,R_+'C>AKP*XJ#<9,'NBQ(
M(V1 ,<PJT:SZ+Z:?[+XSB>M9*]Z4? U0>A)7J3N@I)<94++QE!X8:(%"%,%Y
M6L7M1U/[;$<'$7C-]37-4G76;=RGG8#)Y7PP.K$GJ-?A 61YS[V(\JUD[2_"
MN;QG4N*V+*,'=.G3 COFI+_M<FUN19U-EV.D69U,R\L(?+S1,_=_3?I_0LP:
MDXAQ1[[L"__%^+QLPPCUUM/>)\N,6EY@ZE7L;A"0,J*_T;NRPK#@Y?;8*I"&
M&1-C+FVZ#IS&RQTU).57)ONWU)AY6-<T-#4J;.TAN_59O9K=F)C8U;:W.H&J
M#<+38*O\RFBZ+,J92#);#4IKT6$CK/,K].?J82<X*1,1-.,L_F;5X<_8J^+I
MGZ@Y(2Z?SP^N+B]+QH1&M7&O+DH'5W@5,*2HE\%1R\L;["J*WRKR%4>9KW+P
M_#WP:W.G(T=NKF5IKZU,=0>2KK:DK/D7#=E'K36XCDT7)%5+H.RC6#,@0_$\
M[2>I4]Q3LH%W<UW\:NDL/7L3UX4?V;:7IMHOE RO2[$ZZU"JU+G4.LWR[<:/
M[^1/7I*75(W!' #I,U=WP[Q]A2XKD"TMJHW>ZN6;L@6?=5UZ'X<?N$W0_62=
MM7IN=%?C8<B]\B.VXG[[_,8>^--9.I5:/VD4\+&KPN56=FPA? 7JUA+S5NM
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M6S+5;$Y/"4UNK=RG+A9#B\'W8Z,#Y9/=''!UV-P2PQ40FTZI>48EC3]B0LT
MJ;O<M6:=MUI.M3S=WY]AS9JDW15>U#=SG<;S.$HH;K:DT<MHYF[A_<EAA3VI
M9WQ)HX,%@NDWW,1[\#P^'H,9UY6A99$@%NBXY^>5-,LL1IT_P4378C\S%!_:
MVM)7OQI+B]D=<J44..N%"#CUEMCI8V'III0@J]RO3A0-S/*SL %]V*UO7?E+
M6FD<($-+F%0UU8R*V#>*=X<_X(8X!XY9.%M.@-,-ZGK<UX4AV4OZ!O;\Z4O&
MT;?PO'WOH6PE=P?WJ7[_J:07%<\,?J(PQBXFE\].=Z[4JM_?YY")P19X2ABV
M_W&\(P!NWW!V$#C)CE5/0R@4.6>G1/I7MQHF+1Z!6T$I VBK"@:*8/)N?%9^
M8%LA6@8YTP]WUB[XN)B<GD(M\+X(@IC(60(W"W0]INXTZH(ZTSEUI>VSQFU$
MRZ'X-#^\3"-/2=V6FX>M)$4;H"8V9,U'/C&^^3)V\J\%SMYW=S"-HV_;G+U7
MS56"17)EX10A9*:W]WE"?0N]K'#VSLMP7J7W!),F(@[PR,\+&OZP/JV*3N=I
M_7KD5MY5C+ZZ @,\5$76E+BQ$93ZE\&HZ1B#&VK"(@"!"H6";Y62.MW!,EL5
M3<&=YKW?2OI?C8G3GV <87L<2AQL)'<&L5)V&&)"$3;17"=O+O?I^<\I%F'*
MYWW,DZU 40\J<]?@=1Y!\PV?<-*N1BEX\'YO7I/M[0 NK@MI_O5@UQO7"A>(
M=95F+VI)18$>D:<68&L+F:G2#!O!FONW+S/];^0,,W$,;&=OQ54H77+OT*N\
MVR$[0F[_]@,)/L].X@U]:]HWK/CAME91I:>DF^BKAP*&1;!7CDN%L+CO3'ZZ
M\T'B\#L[2DJYV(E@($071#?6:R5[1R^;Q"6**+Q[CM;;RG,P15,](+7=3MOA
M_$0:NL'7]H%'2!JQ'WO5,>RP/PKMU#*#U3$:QCVM0:S?6?JG3KIPVN'O;".Y
MY>N,CZY@5*^#:@VB96+05!U+D!QO*E+E6"X[3M0[T+NF\SP/%=?U@Q0PPP\B
MT+:2HIVU-8H#W[KE=%JIG.[3>6DD"O;&>[''=\.5]X4=505>O8+K>YI;67\Q
MD.A8[CS/0E8M*[=.N(Y$5A%T<[DMT0!OQ5(J3*8\_,4W-3[PG)M-'UERQ65H
M%WW_W$&%VZVCS+%DE"Z;7HN*?H:!E"&.0&"QH0Z8,\U;-\B*M$>8W3715)&R
MM3?7SZ$KWM$*\G6'Q@[F8UN<]UYJ,6?_LFBD-C?/21A$60.108'99=?TKR8?
MQP/[ V[*]LK3T'1H'L&R:G1LK(_@8>3-4-!/PXIY).#TTW*(M)&C*I";,E=Q
MRQ''#)WC3G23G?_*FY+#?#VN3]VP*W4%GS4MHM5#_1C]>)O[BR?0M^17*:T*
M:LP%3Q0P0\D\A!(R'N:8)WO%)\&I]=9[]S56Z&]"G"U2!W8H(QUO 19W?P,J
MJG6[\&50KH*"Y>@>S"AG'C-9K>\9GS O/.Z:D#/FCBL[""D_0-L>AWV;.AG]
M&C*PV'>VC.@ZT?[XG:E.4@.M[K[NGCHU8JUSODHY__V_=IT]Z9]/VH^Y]T-B
M+$*X-*KKW4-@WL(GI0>';\X')A5"&-SO0C;@#[\S&<1L@#"VHZKA9]-.IZ_.
M%XXH9XF#&>M=4S.73@S\:-^9\MRN?V>B%%PZ4]>@2)F'O-KF.PC%;V6?I"X<
M[)L:A=1*AWS@6U.;-3W/K%(ZWR_GVST\WZV&G66WATRR9[3&_ \9(L!6$:$4
MH3K=4IO!X3+Y<-,"NI__A/9[[3FY_,[]IOEIR-B713&R(KO82-/\Y[ F2QJW
M<$5^" 307I=>-9CV>2C Z$!W(27JWB%E@H--.F9423]KAP".:0A@>+,Z8!;#
MK[9*XD>W-W1V>I.X!J3I_NJ8P0:NTD*<2#":HEL@O$#/EO8+=K70?^Y^#=K2
MPB,8;Z[9!<WXT#FW)6O1-AG/\;$V.FA<;UC6CQ2#<]"EDE'M-,\5>YE]7HY
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M]:4C6PG+2_?6?$5(-)ZEK6O=%@6AA86:)B:D#V]_BS4,\'H9Q=-"G<_;6_?
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M%^;@AHQY=Y?D7S6?+ W::F4I9=U7WDFALO/0!]EW^Y_[X_Q7)S;*O&W.1XZ
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MIW+(OOM)6Z\]\8RK2W9^6Q)V<BCYS@B8537^)24/*_Y\7@^$!&%,T O*\Y4
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M&DI7"*1-'!GX07F("_L(/#A%VY%";+3IFH>5RNJKH1!^O6-.YDH8$)R';#L
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MX(_[XFZ!D/&MBEV+T9"JR7@UX_-T5*5"WS/O>8+"_IH>K<BTY4 :;S;Z3:E
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M^2[14.&MH<8R 7&_$N%>N?_9QUOT"5E%5-<X2+E+FFW(VM3P8?I$SX?CP+_
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MKTHJ"A%X.V[^+D0@(1BH)KK=JIN>>_X@]*'%+C/9T[7[4+?;THB3]EE:=NK
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MUSY$]IP<F*^0K*)YKL,4%?'IY<\/M"D;(7?:@C/'G%3\=EFJRM0$> +ZO/W
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M""^II984;RNM#I2U\A,L=4L'>P]D#N']GOZR""D9"U)9^^1MEA$"DOJ%%_J
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MS>:,4=)^+AZR/:Z;Z,!#SZP)&5^51;3\AH$R7GY VR'ZO8#E^>9SAP1B<;W
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M= :H/?S)>/6KD)JSX.KT]K,+9VK_@0GX+&MOE\$G0TW_\<_\\$?G8SY+$Y[
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MJ]5S?G 630DA8AH3R)$TP1(B@!@1!D6(" ]C%J%$N/!$3U]S8XMF;7,GZ^X
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M!UQS"TJT"2 9#&5 DU0F+,!.3L)1^[,CDM5JJR? Q[V$9O7 C4N.(;0CCBN
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M:AQ=XKG1G)$1*BTDR!LI@7X4'+?8QA]G2^]J3J,WMF=F%(&FJI< 76U!1UW
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MP?^^\1R9]E\,2@>.]PWI1-1^/;1NA.X"4R^/6S4T'7V[Z'7 VDXW#ES0,!E
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MR;_+7]I=%AZ<+=9E3"QH=$2D1R98)Y"')H=U0=LQ+^Q(J$^9$M8?^NXY80?
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MLTG=@/)JH5IV/:F]Z@;'L?7J>/<POGJU+?.5+,M;_H]MWIQ(-,LTD6(\H*F
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MX[\^Z:[Y0RZ_&=M6%AN:KTPHJBQX3I?/ZMV$/.0X"2E,>&QJ;&8QI"GBYI%
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MB!FC4*04JT"0A#)NO=#8W]?<6$E+V[XOK;SM@HK#,M8%?"V6"?VA-O96_GG
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MW"9:G>M*VU;J\[749H%$[SI:W_W3+9)9:'&P F9SO1M9EL5F\4N^RA^W;9X
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M&( NU.$=]1CW%.=WZ]UR]_+N46Z_:7/OK]O-'[OO9C2Z?EE DL<B3P3(>*P
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M)XVCQ;_*M7[TZGXM[L7C<KTT#S7UCYI:(TUD3::9$"8)!R(OM+6L$ 5%2A7
M.$Y01K-,4:<(3JM1YT9^C="5/X\>B>U&>7:0V[&<=R #$UL7PV.)VQ)$ <*>
MG$#R2EQV(T_*54Y@G-*3V\UC#Q^_?)>KE2FU1M<O"U9@CA+* $Z123#.$:"0
M2D 0@@GE*4ECJ[K'EQ\_-XYI#M$J$:-&1M<CQB/X;,\6QX(RS:&B'1XC#A(O
MJ7WC">+1(R<^.KRDSOF9X<6K;G2L5VDD'YM3KI<WIL/6>K> 3,D4\P0H"#.
M$L5!4208%"2.B4P0Q+E52J_=<'/[F!NQ(E.#H2E6NJH.L3JG@2/=[Y?A=O3$
MWPSB9$[Y)IEL+^M=U$@;P$'?BTH87_WE(5_';=^K_E4/?O]=8]-+5OH_-[6%
MT2F\?JF5".,T%ES& '.<  13!JAD0E..+-(B3V66.Q78=AA[;JSSQ=AD\MN2
M1_??MK*2VI%E7("WHYQ < ;FGR.INZ7_PW=Q&0&8YQP.^_$GSNYP!N8\[\/]
M$2,K)YFRT.RT[55GR%]>#I<T+2;N_Z#;@SO\OBR?'^L&'6:/Q7=2?)7;QV21
M% J)7-M36"::YA!+C4<F QPCJ)(XAJEPZR@03-2Y\6,KG+;"E#2'FB^2;AT9
M,N#$VA'J/*8K,/]V&[!TU3RB8O8276S48I2]ZY[\=12^B_8O@='98ZVIX-/B
MMU)5.'&GK7,5'/:S*EGA1QP1 ?-QN>:;U?H3W>[SB6&*.(4Q@(1#O4PD##"I
M%"!"Q4(4<:X2JW+ EQ\_-VIO!#2-ERV3B:_ -N UNQF,P,39Q6'8GVX#B$/4
MR$W 3!0:8O6BN,5\7%6[-[#C_*[IHC>N2GP4HG']JI%%J Z^K]9ME= BS@JS
M0D&% :*F_QZF.9""09Y"RD@6NT3BG@_A1%03!.)^-6-$O/$/CG8'7L#2SGR\
M#:'@[+47+H"?[[KJ?FM%G0\S;76HJVJ>U8.Z?N5(O]V*EN6#J@HKO-T\TN5Z
MD4&&%<4$X)AP$TG% (TS 10G>AN+&.5VI3VO#S$W4Z22\-#:_O=:2L>"P!>0
MM/2WW81/:+>:(S3NSK.KVOOUD9T/,ZTK[*J:9QZOZU>.V&7L'<Q?^%)J2>_7
M>N?"OZ\WJ\TW32)O/RX?EZ8!V/XTH#YIU)>=WMF][<I=C?V)\T0RAC,@)58
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M;J0QIW3+;^NE6G*],;WG?/-L8MR^?=JLEKRJ^KR6'_2*52XPER)+20P2GC*
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MED\5P4FL63*%:0H09A@PQ1E(,"$J386*I54!S:.GSH[VC#.CW"U-*<A?)36
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MC[%L$/'*3;T#3LI"-JJ?\HW5/6-VEF6Y_+:N=K4G%C^5,10HEP#36&\N"96
M::L*Q!3&K)")S(A]>?JKP\R-30Z"CMMA7H739I/I Z30^\P+^(S:9EX%RF6G
MZ0.PJ3:;HX!SW'8.X=&_\[QZ]X2;SR$-CO>?@U>/+$3?5J;^:.CUL_'I/2AM
MX.GQY&Y?]_9!O6^+CWW:E$OS^KS[N9/K<LE6\N.RW"V@IL^$H!B(&.M]:2(H
M*!3#@!:$((&S(B&)4\5Z/W+-C7,/#:Q71J^[:&LT QL%GLNJY8_4%DFY+^>\
M49VJ;T^-AM'O!QTCHZ1C3IRO*;<S!U]A(@.O"X<Y_%C/X>=V#K5:T7T]AU^Z
M<[C7+?IT:0[?K34KUYGB'O?)GH'W6]G?DVS3M@#P"^A9KP#/CP\4D#!P2/3N
MY].R:;+>GA0M"FU5)XE*09PI"1!,)"ARD@"9)83'28I9JMQRA@)(:44PDR89
M54(V00;57K[T'5TP8BX]11$$FI_Y1 O8!@MT-#U$#$P8$#!^(J8]^!\AY[P.
M^,<#[7R0?\-0([.XI%ZCY/$"UJ:BO/Q*=\];_>^JY/E7^7/WB\;M'PM(<8)H
M7 "*)->+@F* $2Z!2E1&2!8K&EL=Z-\@P]PV!VV%^<ID?*ZZ??ZZ7%=%8"IU
M6A)QS18;,3MV-!\8\\ T7DMON/C$GM^K<!>U2C3](2*C1U0IXM%2OP%&OYEM
M(^28-@-N/%!GF7(W/&ILNR[]C.^;E;ZC-&5M=R\+!2F'2D"0Y8@!E"<9H'DL
M029C3G"*<ZZP2\;K^1!.%#=9XFO9D?/?JK+8NQ?7_EUG8.:*4)4F""BA8H!,
MZ1"2*/V>PRR+D21"I6SQ5"UW>C>UW4T!Z>EPX8#]17Y;KM>&Q!C5O^@)*K7%
M,TME$0O]2G)!3,$J)$!1)+E>JO6^+2,)H[3%\]W:=M_F <UVL( ;K[J#JB\@
M+;=,-T$3>L=S],'6XD7WN]UVR9[K+A*[C;9._#2<'4;$<_NYLV$F;D%W3<WS
M-G17KQQS'"K^G^=RUY9?%Z+R)='5)[H4']9OZ--2,[7>8#QNUM6X]VO1',R6
M'\KR68IJCU$N&"UX :$$<4X(0%)*0'B>@Q0G.4Q)AI+4X>S4BTQSL^N-;(9)
MC%W/*^GK%;".5S-=4_;Q'/J*/QJ-W/T^/J?5Y@QW\LD*?>![4"CZNHD.*D5&
MI^C#.FJTNHMJO:)*L4AK%K6J1;5N=[7SQZ4LNZ>)<SE3GGP"ISJ GG B'8^M
MO4+>?\;M9Z@)#\2]8G-\>N[WT6/KQN\'J)]7/WN!F4IA:DJI()[H%90H4,0R
M!05$L" 9R;'*W6HL7!G)Y4N=IM3"F\YJ>-<L=M&R$G;\L<<UG.WL< _8!5ZF
MNI35TM-=0U<^"\'WXN"Y_/OEL28N^MZK\'FI]_[+QUCD3]OERD!TO_OZ7?Y*
MM_^0NR]T)<O3N#$B12*Y)(#I/P'*4:S_%D.08,DR!9F*(;&WN2U'G9M57<D=
M&<'U3M0T/8QJV:-*^'$AC;838&,=!X UM/UKB>BH($A;:%WLUP 03V6AWOKR
M.IJ=CDCU&Y:V#YO0='34[]@X=+UY9$--C:G<;K4Q>6:9< @Y@PKII3'# "$:
M Y(K9E)<4DE9@E.6NIR%7A]J;B2^E]2S#=@#MIT9Z ?"P(1]0._(&/1N"PZ#
MX;??Y?7AINUO.:CV63_+X3L<[4*Y7+Q9[E[NMY*^V0BYR&&:D10Q0'A"M.DG
M!- $D0)1Q$I2+)*46+46.WWPW(CA377"H(6+C'26AL8I6 -FV@T0A-[BV6EO
M;P1<4?7"9UM*_I=OFQ__E[ZE^F+_B<Q?0?W7V@@X?=@TZ_P5%?9+^;7?CRR@
MU_48?99&N.5*_B9W']9\\R@_;DK]\TMIL?N0@@M9XA0IB%(, 4RKOK(J R3F
M!,B"(YKD!9<4.=7A"R#DW(B@Z\O=;4S-_5K+:*VMY976T/S4_+UJ2/M<-NWI
M]S$]AR( _^Y8#S#$&V!G?+SVO$YXSJ(G;Z]@9$H,U"I&?S)*_MG\NJ?FP"%R
M*W#-@9 3XK=V8@A!IRW!&!#JLTJ.(<<:X0#\N.1R7<KW4BYB*@G-: )PD@J]
M5! 3?0-34%2%L#"**;>S\XZ?.S=V;R2+E'0Z*^T 1;,$)SG.08QR!A"F&6",
M,)#$/..TB%%60+O3DQN@FN:TI /6.*PLW);C] ^\8+2*OQ^KN(-3<1P $[D-
M;8!P\PR>J]OK^^M</IUW[US&(__=A5][Z7FQKP6=BB1F""D@49:8_+4<T%A2
MD$A6%#&&*,F=:FY=&6=NW'S6W<&]IO8U1.W,8 \X!2:FBQ!Y+[D]@$/(+ABO
M4X9[0.&!3A@WEN:N..7+\MMZJ9:<KG?WG&^>J[;>GS:K)=>F7I46L)!8$<08
M!'DF)$ )DH#D>0KR0J1IP3,%26%MH0V/-SMV.$@<'42.6IF;A!F7(T(+S"T,
M&+](AN:/UP#1P1CR"^9$1E(75'H ]:D1VU?A4WML>BTJB\=,9VG9ZW1D@3G<
MYJ-*C6D_O*!IEC"92B (R@'*-/T6E'%00()SF$J,W>H G@\Q-\;];;,&E9.S
M*AT3R9\F]]>UMND%).V,L=OP"<RC9RF<1KY0I52ZN@>LBE(-\XH%3KIJ]M<J
M.;K2_7SSG::+W<N]$/J-*,T1SL/VZ^:/]2)E"1&"<KW9PIDVL&(&J!)Z%\:2
MC%.4$6H9Y79]C+E]XK6842.G?HW-?VVVD9'5_@ST&J##QZ$>8 K\I8]"R.F<
M= "#T4>FUYX[V>GI@&+=@]2A2\>MXI]E*?5-W^_7XJW\(5>;IZHTQ:%PQ9O-
MNO*A?]U\DENUV3Z^WVRKAL/E+R][WT&>881P$H-$FG#Y%%) 4VEZFW&,<_U_
MB:T2SKQ*-3<B:96*Z%I$';6Z)6K,*EEK5F5OUKI%^H^Z);?^N-P=/GZFV,XB
MF7SB E.;OSGS[H'R"K57F\F/9).:65[!/+7,_#Y\A.?L;T]:X_7NX)0W25:+
M#'(JL[P *N;:EF." )81!N(,YXH6DA/$K)UE%X>8&P,W0D:KPZ%=]*3E=/#E
M7(;2P@=V,T"!F:[%IG.<565FWHR-@VOK9HPF\F8Y8^7FQ>J%H==Q=?G.Z7Q5
MO9(?N:?ZKQQGR_Z5+M>E"1"1Y8.IP*GWPL_+\GM=HO.M9+M%D<<Y3C,"(,48
MH (24+"< JY0BDA:F+@%%SMU<,2Y,: 1.-JL(WDDJREQL-[L#!F^]':3'@D[
M+TB>$HA-@+34L L$J$@H4)CAF/!<"2G=BHWZ 7[2TJ']T)<M]I6E23G?/E<!
M=?JED#UNLY$38F?,>WV[ R]?%;I-@*(&^=T9R$9>CUW2;:'QVS9]<-1I^ZC;
M@G#66-WZQA'&[J%?N[:BWS4.^7>KY;=E_://<OG(GC75FN$6&2\$-S7R.8US
M@.(<@B)C$L0L1QG),Y3']J5RG(:>V])P$+[:N[9'&9%LY*]^NNUJX& :NDV*
MA3D=#.K@#H4]REK*J)4\:D6O?OIY$I0=#/-@:$]DL'M$W<V4'P5<KXGO]L3I
M3/]1FAYM"<8]8<0*\6F[X5**\KW6H"["K*H^R@L8TUPRS$RG*0(0,8L!S&)
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M"CAQ7P#_T)XW$P@PQK4EHOO6Z;O^\3_^6_L3_8?I5OT__MO_"U!+ P04
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MD0T K1V4T2BLKC?7E:H\NF/$Y(Q"U].P,N/:%B1(@A*46=DZ<<$3A U](S8
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M- ;WT-;0S2RZG K7'EN.IO%W-Y\[_/6U&-;;;Y0HQHD!;;\/Q)=<O8C^>##
M1!:$:Q&CN.6]/M (HQ]Z!J^JJH[(H937@,GLPO6&STUO21]YBIY[(#$C@Q'M
MG&?, "<\:)HUR]4>T[8D=? RK*;<T=VUV !,;Q;O"BVRD38@4@1!Y]CQ=2&C
MQ'\H. V2T#J92-N72-<LTCH8O':7?@/0J51":[FWG@H+D1.'?HG1X)CAD*/R
MFDFADZQ3#S%@Z73-DK&#@;D!/#21,G/W]E=Q3]"G1L197GJ0$V0A^@R<AYAL
MD"[=]CN'O8.O64TVX"7\-FK8\]+TYVFL=07/G?62$P$RE%-">PE&:@N9*:6,
M=B&*.JTE=KR"IR_C26<_1?0*I\/7UKQVBZ]O)[,_*_?FOF>90U72/,5A_P4T
MERM>UD=0+B.1EH")HG1_#Z5O"&- >4PI%$S$RG4 ]U#50X!1/O/C?/9MC/)[
M=?X;:N'=]+(EWA%Z =_6TTDONS,JXR*E'DI3J3(!/H#+:+:U).@"V.Q=I69R
MV]/:2&[$OFBZ)RZIJ;0&@I>;D1?1B8F4-#"#H;J(FA=9>3 D4L<YBRZW$O=6
M U-MG3\:^FZC@ ;0<^-:J#PQ3L-XDFZP]&6VK31%RD8E@1C)7I2;H]*4EL@B
M4DF\<$;K.E,7:G S;';&@;$\.!P:V!)O$JX<QBL5C[(HK9!Q$TNN)(C2&<%&
MCC%[<9F=$4KQ.E"^3L6PYG1X3,QZ4E #X+KH;'4SXV-4!.!I1BY(N1IR* G#
M2R9Y8CHZ;:A0E;(>[J5G6)O7'.!Z4-K0[\Z_SJ9%8N_+[<)%BV6G2? &"<Z2
M:Q BX-9A%$-=EK1Q05)"GHR$'_KP8?.\FD%0+[)OP&P]W5!9\T2(1E\CD)A!
M))W!)I8@6:HTUX%K]T_9WKH9*-91Y?;8M&ML3M-QN;FJ5*]R*;S-R_95YXYH
MK!(&=QL)"B4G;1F)XM![P"WHG;8AUBD1[T[CL.E=S>&UDG(;,*KW<%8>'E'H
M:?RME*$M1HG@'N3!0IG+A!R529U.)5"!R$ X4];7F6;R-&VM%<'T@XJGP;>/
MBAJUEA_GZ=2-XX5O0AR/E$H.A)>J-)H]F!@9!"EH2:FT2==YY'V*LM8*90X$
MN3W4,RC@5L[O SNH^,2K%(KE$7HBR\5J3-V:OM<8;1V7C24U421IX-Y@9.]0
MG$9D"BXZZ06/R8MNX<G.)+16K-(KW@ZHG4;-WE$(LS/T<SZZ\U71=^!>6JD]
M!F%ED!45 1S'OTJ6L\T^^U2IZ.I)TEJK.CF0X=M'04WZ=\C0_ SI&#L_GJQ<
MY%&DECGT$2"7D@7!- ='M8+D>!*I/'%6FMO<A;K6*DT.A[M]U#3T7=]=ABZ,
M]]]+>O?;LTTE-Y&12HI[*)3\;IO0<371H4'GT7'GN(IJQ_/UOO5:JQ$YQ&&Z
MM]SW/3F_])EFT#'J'W$;#*6> \WE_LAK] H"$:"<)YPFYEFL$[1VIW%8S^[P
M"0HU5-? H)X'.'LW_986#PC2JJ31/95 =$F=I=3A/C<"0M24E)X#.A\4G(_0
MVDA'I .E9/6EM 8</_17+PJMPC_.QO.$O.)F6YY_G. Y@,%4R;M=S6,?.8SD
M*<,MG8TH@]B%*H>- :J(#@&=VT3K9 AVI[')9*[>T#([B.J:B("[BW+$DL8(
M'OU;[:4!(9!!QP4#1:GF69MD29V.7MUI;#(OJQ8L*ZFNW2/\[7CJIN$!7XA0
MYTUF0 POG1P- :^E1B^:6J*2,Z)2L\OM:1W6SSST$=Z7TH8.H)$]9"VD%!=O
M4:BE'AKY2BC%>XO[1\&PY!7R)E5"K]D5Y]SH #0&ZHEUUH5;2=</)=)LMW"3
M)W-O()@=2"-#HVTKQJS(DF81(/DR HD:A_O71 P&@PI.H7@E[P2UWG%VZ*.V
M"LZJZ:*!J*2['$=$.QL<[AR9-;JVA!DP-.KRL$V$<V7PA![XA&WR!J=O3%96
M70/NW\\YIX#^R<_?PU<W/4Z?T&/YL$J7+/]?@JUO;E("LD_HZ,[' 6.A\@/<
MAC>_<>TW1SIE3FD@P)5 X\]=!I^XAHR2-]:[1"JUVZ_ S+ O?]4<R*'5WH Y
MWHO9=1^TNP\.87)6WABNBW4MZI'DFL3R7J]*-9H06H-Q0@'G7(6DDLF5$A\/
MR^>P+Y;5]DO#8&G@$-G/;B2B5#".0Y8Q@#!*@%6*@4%.HU9<\=OOH"WLC&&?
M4]L$^E:J;*:9]'XL.Z$M*\GZGD44ME6F7/<12.@#6HY'7F9UWK/JH[=:W[U&
MT;N-*EOIZG-V>CI9B=)-+D3Y;IIG\Y.U,B^%&KP1$>,>&;TJZ3,1]V2.0(A(
MB5 I!:O4-ZH;@<,VZJN&QQKJ&?JZ["U^ZOA;FJ;%XD/^Z,[#UQ3^P,AXF59=
MV/"KX[D[^17_?I$V*)761MHR*;.<"C9@8!"H@QQ\]$(BHZY;HM/62P_<5*6&
M]F<'4T4#,=JG,I_^0_YMD59YT!_\>@S8N^F%SXP2N$RC6=5W7N0,GJ,U9TRG
M@%QJE*40F:-=3PX8=Y0X%B+W=3JQ[$'TP!DG%?%Z:(WV!M[>6Z1]F!^[Z?B_
M5I_D2E[_(LS'I^5OL_SJ;#$NN_DF%]UZHG7ZW)Z:H&W/0T]=SZXO?-6 ;=W\
M\^,UAC[DS=VLFUSU9KL$,"_]/E,R$!C/912A!\]5!"9)=HJ3,NJTBFGHA?R]
MN^WN0\2;\2),9HNS>?J"*GV%G_O'2,5LT1-20!F1(&0I+!5!X^9T(0F;O+!U
M4NC[YF18=^'PV+[3=W=(9#QOB_VF3"B=5#/<%Q]_0/M]+T=-F7'&&1[\5@%7
M#OT05Q*ZF$U@T<'5691RS#I->YHPX[^>E1FX'_*EM_0Y'9^L[S&RXAXE #Y2
M@?Y9Z8M#H@2EI7*2Y9@KU=$]2-)+,*S;H.W.^W$ONFK70KYRB_%BEJ\+$\W*
MY[.3$S<_G^7/X^/I.(]#R>!=EQ2644*HAE 2"78PF7NMUY,-[8_GGHSJW64N
ML8M!O[&Q3 7S48-(AI3JE0!.L6@U0_RY.A[:PS3M??/YF'RO/!!KO;9"8K@H
MBSMDN *?A($8=0Q*Z<AHI<9NG>@;N+-@/XBY<^O9OVI>IND;R@2V9 J',HG4
M4,,S]:!-F9Y<Z@)<D@*R89K&S$A2=5Y$ZIG$E1H^Y%L+G*__O-IWR%](UB00
M5-+2,"=#&1L-$O?[NII:U)GCW8V^9DWB-HBY;1(KJ&;H=Z"_STKM]@P-P7QZ
MFP^G@R4N"2 F(S,A17#61'1R)>'*!D^2?<K /;7(P#U2^\5)KQ)MX.'FK1O/
M5U-"?TFN7 F58.=^R$>F*)?" 4L,70&?.3@7/#@I9? I)>WKI#IW)G'@5JIU
M#%(=!36 O$_I6YJ>I5) @%MI):C?Q\NOK\\6R]E)FM_FCFH>T=5$QFRQN 8M
MKB/9X@X+R1>YAERGO_AV= [<0[4.!BNJZF7&"U_6C1\/'"U\N=9N<MA8X3[^
MZT<*THB0#3IEQ%*U2<:E0F"<&@U-7! OZM1BUXL4+JW_NKW<Y@R('Z:?4CB;
MET'?*S5=[3UCT-)G+Y'*:$ X3\$I+H%)03T-C I?Y\5T6TJ;C1ZV0=&#AW4-
M=;U,4[G'>UP?RS9@+&N^WSV"<Q65D@$W<B;H*0IIT%/,9<*ZSU$&)Q3Z"\_$
M6JZ"LJ</I)%EE!J#1'&,RT!H2\$DW.G1N)AUT([K;OF-3Z_5K'G;1NTW@MZ>
MY3M@!+*8+T>O"P-ICN)<GO_J3M+1]_%B%+3F!HF%K%UI."<MF!!+/W\C36*!
M\=OYK_=O"5S@VG; O]W>"@]1, QJJJAWUJ.L!\;*IW1Z-@]?W2(='<_3*@*_
MS=*;V8D;3T=&\^1P?X'6!C>71UE9+E!,N.$<E<IXU<G[Z@2@SF0-@ZI^-#^K
MK8:A;V=7.0^SZ2^I)!Z,;& ^$2:@M.\%P5@H]>@2+&4HG!QTOAW"/'!"W?C8
MX0!026>S7@0XM.H?-;GH@:9WRW2R&(E@=<93&2,#C3$"YQDEDRE(PX,S0A)C
MNMW1=UMOF.OZFF=0+6$W<8FZ3LO_V<VGR,\"63L[.9N43GAO$G([7HY8Z7+A
M$RLE<@(PMN7@59F'X"G"P[ED<IVJW:=I:]7=V1$.=VY->]5- VC;L^;8HFDG
MUH+GN3!+.5@='"1/G TQ9E4)B/4+< <PA_U@]' :'?JP_7TV_^.JA_E5CX?U
M1D070VBM,W#M<\E_M^#$*C3F*D4> PW=_*Y'EQGF@;(VEGH6;P-V[N:@<LF,
M<V5:5>2FI+^5*7\D("]""8G?(T96RM+>>E)\[P^+A[)#NTO\.3;^+X^HX^D9
M?F_SP]ET,?(6 V#E!9!8*B<CI>@+>%4&G1J?N.>VTES0_>@>IH_0 7%Y*)T.
M#^254'\[12E/E^_'H<Q0>YO2T4F1[$<WCB.7G":E4(T(PD"(Z# \9Q%TL"&D
M* C7N=,I^<@BP[3K.<@9V9=HAW:E?AE/T"6<3=-%#_@U]H_QRS5'(X[05E9I
MY*$,X:#*@4-7$2*167*GT V0G8#RY%+#],<Y"%SZ%7/SH'D[GB^6I8%LFJ\*
MNS#&V+!)=&2K$8Z9EA'@! VHB3E 3MZEC*&R#[H?-#U(PS!M;]J 63^*:1Y_
MA:_%*PQ:XN6O+C9\8N1BE)01)"_]+/!(!Z,MA^A2)+0D5^9NO:3W(*(3 NW+
M1&!/JAD:@NOVDK/\;KHXRR4P+J\AZ%VZ:7P__L?9.(Z7YY_2:IC*NN84Y1FC
M4Q&(-P3W%X;-UDA?AH,'F8V.R74;[+KMRMTN9LFS1%M5+31P>7&M!_OF-N;S
M5^2[W.NE^;<4W\[F;\^69_-TT;9]1-".:\<Y!$<X"&T\V,P,>,\R3SER7ZLS
MXK:D=L/ELWTQJ*NZH<W?G?!G%?A$CTXLIQ)2Y!+EE3-XGA1D)J3593C%[32T
MKC%EYVB2/KOK^Y[DV8"U>J*TX.?OF][+):$6_Q>_N.^CK#)#E,LR0*RDL$53
M>N.QDC3@)7&4&U:G$FD'8KL!\-G=^1]*?2\SY_FR>\DZ37SE>5Q.4/Z$;L<Z
M;1P_\6;>^$"YTON2VT".=:\2KY^;C3&U]C%K2%H6ES-%#*PMA4AMED%Z9W2=
M)Z>#5;(<W=# /842^ N_SJ;SFW43JQ2@:$P2W/O2T =/.)4M&.HD!.985AS=
M(7J0$I?=66@V.7P;W#U1^W(@!3?@PEPR_NK\6HWNVSG&D&C SE<YK\)3$2U1
M)4DB@7!$@E>(,&50WD[:(%.=OCX=B!L6C0/!YB'P]J3#EF!Y'T.;I%M+DU.A
M;/!,R@PL$XOKYX$'3831AC%5Y\VY W&-P+(O0'0HZ]]'.XT";G&Y;S?YV3$J
M%)0/B(GB\B<>P><<$2?>88"J0LYUIBMUH:X1R/4%B0Z0VTL_+6'NU?GEE_\^
M3G,DZNOY>PQ.)ZN=ZI.GQF4%DI7B H<,6<DT!!ZUSSIK$RJC[E'ZANV0T]P)
MW)<F6\+G]3UWE[_-[O;>.:I(ABS1!Q>:('/$"Y".I:"Y)D36Z7&R%9F-6,D>
M<=+%4/:BM)80^6YZ>K9<K"1&-\9?&2&]E0)TM@*$31SWK\)-;+2,/O(<=9V'
MH$>(:@1M_4/A(=#MJ9=&(<8VK!BK+9/60Z*B%'\* <;I4C)0$AJ#0K;J=!UX
MA*A&CM]!(+:+7AJ%&-^P0I2GV4D%-I92*JX]>)D-J&"BX8$I[2J?HG>)&K8U
MW; 0VT4O+4%L#[?XZI%-!Y55Z4>O5SV4HW#K44R4:",38Y:QRG:O#S8:@7$;
M@<K!<=' IMB4!-XJ!+P4R=5HF9'SU+.@$D2K*0AJ$[C@(WB119:FY+77L<*=
M26S$LSP\C.ZI >U?I^V^W']>SMTR'8_#94N*G5[4[_N8GEZZGZ2PJ>D^&'Z(
M:(,$KI0!05@H$U@]!"6"D8'I6.D]MHGI/J]G$_SNK%1\?4M'\WD9C5@6N&_*
M%C&>!(^>59"*@'#H!GE9IBD(11WC,L=<Y[EE"R)?P@2@;1!Y-P>SCCZ?E3W<
M(]'HD4^K9QW;'X%6VA=9EQT07_K62,'!"L,@*AZS,HP(]8)'H'T.7U,\FZ0/
M^:'MM5C[-^&!'W_!KQ9N-2SYHA%0IC)9$H#Y@!Z/U0:,9!ETB%8:XZ.O-!JT
M?UY>@LG=!M]WQA -BXX6.U$F(9-WQD#B-I09=GB"X;H0/,^:$66S[F0NGEDG
MRE80\53SRFW4\VR:5RK<OB@2@7+A#D3V 2QU%+*E,D@66::=KJA>=//*K32_
M4_/*;=0P=$G/S=Z+7 KK8S1@F< M)AP#'YA$V8C$'5'<>?>4^_@\FU=NI;.'
MFU=N(\"A5?_+>.*F[N-7-S_94!]BYMF5>4>^I X13< J*4%[FVUTN#UNCQYX
MN$KZYD</\T!W( CL)\BA8?#:+5?WA7@<W\-((C(&B@&Q"A:$<@[Q[#@8QZ6U
M-GL:N_5;?VR58=XD#@2.WL3;P-O!%_R]#_F:D[8Z4*DP427$N7<2P:ZI!L.2
M H4L)*V-C;=["O44Q]U+SK"I (VXO?TIK '4W16>NU]>%XD0WJ3D% <J2F9W
M$A2LQT V)>6$SM$*5^=>84M"APW0>H#&['!Z&OJ0?.7.T_S?DYLLOP;\^Z9B
M^_+0N##GU.6@ P6_>I2F%LVYB10HY>@39I8)[W9:=EINX!JTFMJ>515] S9M
MS45Y%+Z\ =\PPI@2S"(/T9<I?RHF<,(ED(%D$UP@C*<JUNM!D@:>_GH G/6K
ME:%MU=%B,3Z>KDSZK4VBF,_"8AS"HRLMRJ,"HQAZGQ[W"K%>4<,ZV:<'EQAX
M@.NA;%(_(AX:*!>F=!JO.:NHJ=LL>2&M%QF<6?7R51YL%!K0KD9D2F=)NO4,
M[;;>P/-7#P6A"L(?&D__ZVPZ/DWS58#K0CI;CH.;+-Y-PU\N1KL0/'I*MQ!5
M*BV%- E\=@%YT]$$FZ(SL1.2GEIIF);&!\=0KP)OP"OZE%:S-3Z6NY?K<GIU
M?OTGZUM\RK6BS ,UDI>N@0P,T0X<#\IE%3(/LHJ;U)W&8<_"QFXB*JFV,=!N
M+@N9H.@$\ BV3$43@AIP60207C$9N0^XXZN#LX52OUI:?P1<.ZA@Z'/S[KVP
M9QC/<A, 0]H((E@#GD<!S&0C2/+<WQY8T>M#S$'PL(NB'G]UV49J0^O\W]W)
MR2S\\?#131VA@:(K$&@@('+RX W:7FL(M4098@CI!(&G5AHVO.\3$;W*=&B
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M3))")46E2YUJQ+M5X5PL.^R39R,AYNZ*: $]&]#GI%+ W84;+?DR$S* 2XI
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M,4.3<EKY0T*QA<.O-^5W ]4.FF@ 5O<_-/_\_;34;5UD,"OCL[(!_"H15JL
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M !H??UTNOLS>3;_AMXJ07IW_?'(ZF9VGM/AMBCJ];;)'07+%B$+9A52&*M$
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M9XOE*D?H[6S^:_KS*(0BH_'T^.-\-L4OPR:#J.PB&I5Q,7@@,3K<14&"$R9
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M:I4A8K!X $-D-I9D4@<N" 71>*D)4=J3.K7!V_?'.4 +N,%@\7BOG"UTU #
M=K\L>:0G1@B9*6,SL. 3"$Y*$J=FD*77D7'*2/CO0;,[]<K9!ER'Z)6SC:8;
M0/O##5>L5%DRZH'*A 9 $SRI$O'@RL6!)H)I7J<<ZI^I5\Y6:.G<*V<;U36
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MI#,)3*N/),>)+ZGP(C0(S>NMON+@D&EPW&3%O.56A7$E$NZ[M&%=\:&WSVA
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ME06#D+" 5YD<Y1B**Z(1!XZE>>C+JJ,1=%!%0G]B&\$QO-=*7UWC!]KFG_[
MJ^_X?CY;?5E.BLVIZ.*@:"2CU28#D1OR>6+6F4S8*'R;D.^Q% ]]\75><)XJ
MLF<$S;KM/OTQGW!57"AD\687R-:PF,!K*\!):84O3"9VONK0)P@=^GKL[$ \
M1D#/#7\$*)R@M-%PK<%H(T QVF7.)DV?I$5.!T-P U0//D3JT!=>PV#P8"$]
M(Q1.>)2),TG^/_?D_X? (:)3P$42F:%2OE'&TKX4#GV_=7;,'222XZ$V7X6K
M]E#[YRQO$ATPO_XST:]>?*W_FW#OBW*1#-Z HK[4X< %^I*"SH9I-,:VB<L<
M1>[0MV#G 6$OPAJ!\GMD>1/!BE),!$A"V=I"WI$ERRTPH9Q2-7/U++'F6X*&
MOO?J#55],/QO%,>;["0>-(KD3?A@L;S=%=Y&\_YQ/)M?SK]^G:ZZ6<(LOR3G
MDP!%OW)DGZ:GANN);7M3W%.P\\Y\%SOS;5N1;5^O5KPH^@+2*0G*,0/>Y$(;
MVN:"D?RH1H4-!Y%YJJZ_,]EV\&W##Q6-B9Q<QA(CV5+6> C>&A!2\$PZ!)&U
M>:#H:;J&#7FVP]'NP="C=,9[/CRA!DZXV-ECU/9JK.75S6$HM,$8K7F 6 QY
MW3E+<#EY($^)'/+ 1-'/6)MU5>1/S+0NO!*\""<"@HE=@:BPX&W,8+DL0OH@
M5&0_@]5>,STG]70(,.X5[??*[@&]GN5B16NI3MN"^+OZJ[Y8W=436Z541E*G
MVGM2W*'V[,R9M"NQAWNRP#W;J[LC37!GN]#_=K?*8Q0,U-:A?^'.>^3TP$CY
MB-^N%^D+F?07GQ?8I?'O+FE3/VQ2#+(V5N:1CGQ5;* C/PK(DB?N&)W]KO0&
MG[W)&@93_4A^WEH,0_>(^?#VY?^^VI2)1V^DU:C7S;F5X0HB<PDP1YXMQMI/
M>*_#ZLZ@PPF_D;SF/3!O:*&__'CQZF)#M]>2VZ0<N&*[6Q(&06D% J4.*?CL
MB]W/0MD..LP-_)F$?BSS1A!E?7&]G,YJC#C]YWJZKOY:/R1OM)+")/(2K04E
MG()@=*I])QC*(*2);5SN1P@:!C_MK) ^^3]2&-6/M.$VFTN*%#67I >UHWV1
M:(<%I2*8H(PP+";'VU1&_92T@7N_] & /4!UO#2&/IK>3XF?Q,5ORQ?3^0K3
ME[>S]-\;;2LLTLY3"JS@=,XBEQ#I>R"3,F3+,9-CW.NH>F*2\>'C!%G.&S!V
M:( \H:#?W::^E^P-VIR!F7H?G[ VC:XME10GU4V[S7NQGU&SQVS#I'FU.ZW:
ML'EHW'PDL=#L7V@UK_ [7LV_=0^L;*W$F_5N+M"SREDP3@:\CO4-A.PAQ!A!
M!,.P\&!DV$_9'#CQ.",P1\I\?B8!C, H>F1YV^=]*C]K^//3_%=<U/[H;^:+
MKFG;LGMUZ.VZOC3_LI@OB<N:UI@YAY@9+=Y:#=$J#\:%PFPNJ54O\UZ7,4X[
M_C0L#R_O48#].\ZNMX5@FQ76OH:7\6KZN9/Q1&IGC#,1DJF%BO76,/I(9D41
M:+B7B7SE1B#>@[QQ'MM]@;-O^0Q]?&^R62[+]I4)XMMRFKLTIOGL[>S&=B;F
MQNELO4*5O,Z)3@X9%5G+/)-?9<G.E;98HYP71>_W7NM1TP^3>WV&H[R],$:A
MXSY/ZX5EI?WF.;ZM=G\?_JR95K^2*T6\W5G_Q*ILDY8(209%KEI]FRN3%>-R
MDC$53B9YFU?:3B!ZF*SM<^G#\\AR:"W9]5FZ$SRX9>7JWIIN&N8@V1C,"^*F
M4JPV9"H0I"X@:D]]Z<GWWWU,\!'U>-B\PZ1FGT$O-F3_"!3B14J+:YIUDRM,
M++M9B"[2,U\$,<QYLEXU@DO:D0EK& _*6[4;F.M)W3U*TC!YVN=19OW(802
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MD ]SJ_M%S-MQ:N'#?-:-=D(F[UGH:J.AS\##U@H_6L9\M@@^Q5R?D@\0F##
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MU;W(9&NCE6KDD_$2I#,YB\"PT:OV?:U@-(G0S]QV/ X2SW\K;-J>>]3)>\S
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M#L&>Q=3^JF3S@_HEAB7^SW_]/U!+ P04    " !I@*Q4+3(I'$GZ  #H;0@
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M@C'X"B,#/2UR)3%NDNFKV1D6J9AQE +UW#)+T,\MK%[A+UCKWLF:+LM6*1Q
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M)^5,>2<-MC+ KM)95J2Z)"QGIN+1:0XPC&H$*F&V0,'20PS*=H*%9A@&!,6
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M ^3"ID.-WXNKW T3,(:ZT8N-X#FY#.K06Q. J'.M<&$C!XM=-'0R$W8T!Y?
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M%+ TY^UA>E17ZACY)A= ;U%'F.F$:\=/Z1^ZO,A]9_AM_,/14S=NL(\,"TQ
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M*^R:;$QM*_K56W]<5\Q: R\,YME*WB"8E/? J8L'HOQ=T1B4C910Y1^( ]&
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M0>6#.*FX0FXF458Y_)<3=RZHHP>_B+K>U:A>]/_T9LD:'1^V"C\H5B3CNPM
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M;+7SH*'5M^EL>2=GI]EI4\PS1(#C\7H4"3JV#)LQNN'P[PLF185_'4=(%6!
M-U<EG&"&_YY<XJ(RA=)X@_<I40G0>85)F*.-4DO?V^D4[^U#M/G]U;OKMUZ$
MEPF!U+-4YT(W;S41!G+:IM3,%!6,QAY,52+CVI>C]W+5$M&F4[" VXLU6G?6
MG/7""@(7.UMY("P@28+YN*X0<(SJZ$6K>!7,S9=>?.;V@!_VBS_[X2=3N:SQ
M?8@1:\^I\P%"7_HZ-,-U7JP;&PD+@U*5">>UB$H B<RTAX;='>Q,]P3*-@2^
M7,8 )\97!_/<)5AP) U69FB;0=AXFUY!$TSB8J^"8KV89!@[H0#-;6-#M5 '
MZ^P"UWPGMURYV]NZ-\2!&F1.X393Y'39$ N/]OD=#N1ZF/"YZO:()]'=F^Q_
MV<:[E ,@"0S)$*!2@0*1ZO!/ZX>X9.,;_((-P>0[ L?M3/4]>H4RJ 4=%QA_
M'P0ZFF=PIYV67 ]3$.\W9N@VF*D=#[A' $-7^N) 8BU!)&DEU,FSD#;:;@:O
M203]!TT4W?'^71(?O#=BN*'89-NPNM(]!R@HD,@9$1O5A3<W[#B4XH.TIY+/
MX;#*=CC::A^BUD9$9-1P6QP\.7F?<LIE+C.!#VH$\[.E"4)KZ#A)DTS=<I >
M9!PL=KQXI7/*^!0*N+BU0YUBE ]2+EWG*;Y1J,NT%5? I%2%A7<WC4 :KFLG
M=ERUC1V9Z_ZPK4%WL5P&P:5!Z#T5V<SD&^H7,LQ\\"8T7U&VU 54E+L3RU9S
M.2XNZWZ^3_U@K<_>\_GZC=@=SQ-Z0R_+5NP9J^2'[Z?81FK,4'7I/CU.ZL\6
MZ]$BF,@HHS;R8H5K2,NV2J?(9FQ=ZRT,'^U;;4BXK^8,JM#E7@XVA'8RQP'#
ML%JOC3?-DB1;F36T]19[MVE(70SI&VYR"N]WDZ^"+(!?5^@Y&_5,G'B[O>Y?
M^+7N3[(,-@!2S8^S=Z[_1KZ'[NEYRB@]E^Q_L\G8MM*1#U,7GW,#6U2 L/)E
M46#G4J)"+%1NJGDCD>.O.L+6H;ET_.,NZ /MSD:UNWX@#,DH(*QU=L![MH]!
M80M]8RR9C9T18J\ M6\A)2%JKANIS9=VC-P4&UNT8*'#C00(Y&!C@48.YN+P
MQV6VHOZL<+-EKF[ *9])RU"S":"XIV! =<-2#LMS&3V.TC0*1GY%;"IL6IUV
M9[ VTO;&<,>)[2^&N4D[ ^9^M).E!_I/FHB">:],'',AL(S56-GU';JFK^%(
M-5>6C2O!#5S2-JEKTQM?@X>I,QU@KX(70N7^((,Y^1H$=L,,QDVF8CHO,G67
M<'XDI:Y+9>GLY5PEP;R>JSS6Y-,T[8?[IK!?]V2+98)/Y3_A)%@^^"1A7"4F
M,6B,'B>M6BR(.N&.#Q::F/2TPJ+6WJ4!,Q9V/BS#:V]9M&U3HNV4]268>E;R
M@"/R'$?TPX C&G!$ X[HB]B(#P0D^F+64J,$@G>47&)] MZU-B:,BH^SJ#*L
M,=K.,:[QA@QD*VJFG[?+QKJ'$?GC+6.Y' I&R3$?G'A^P!8AB7'!SF$PJ:C5
M%Y<U+BF05W]@ME(HLF+,:?=@I'U&<MO1MDO$"J0/38B-%A[:VYOS4TYHL6VW
M:"P$$XH[.(FJD/MU6@%&/($QX^@HYIK"]]"I+H+&Y4SC4TMV(R;9L94VUEN0
MF6Y"))VN:ER5PP ]"H_&-CH:8<Q%IC,=3X=I!R-7Q=HLU7<4=9_@6V& M!X9
M>,-\3ZKD0E2+;-<GZG="B?FMRE41*](>HT]H%5Q;FE.5%V4=\Z%JD-NB9GT^
M'4$JM(G<D!.6$>)ABG RC%&MQ0!-8]$%S#3!3WVQJ"\-E/"?CL6;0A1+Q^(2
MPII>BX\SZ.1_H-$COGI=B-3A%7[4Y4@Z3-#N:PF>OM3=.$445;1)NMTNM5Y5
MH+Y:'(:6;9DR@43EMA"8MKL1*C'&85WXE%OJ-XK)YUFJ(NY,E&?9(HCK/HYQ
M!?\?M"=H=U#3B12<P3.4!@ZI81]9GNW0X<1&VDV^G!A)]WW:0#H] [_(Q#E%
M6QG-S,*]$MM(\F6:E7;;D&[#?,;T,%G*%)W$\^5.8W\[3)R*NB%1/2TP[K-T
MEB#+(X,2#1\G4RD2$4W]W5@MTO3T" 0WV),W*JL*&+IY7%SGP'A26H1C]GK>
MKP5L_[+8:0Y CRC(:L1_0?CY!]9UYPV#B+1"W4.O7PU9NL[.:N(Z>(H_$B\?
MW!=.VI)<4-"4N.O$0%K)Y< 'XHS%.G*\0:9;76BU-K^?0:NF+=728255BTF5
MNWPZE.RD#H3:DY8Q#9L( YA-%,9PD$T/EEGT02(A:*$;3V@G"U%ML,Y8T8E&
M.'K*L>P;91$6PHH/A@BB7$V,9=\(!% HP *2:,;T<^'C@N(XX)AZ0[F.VA.X
MPX:P-V5 UA"^DYMKL(K_(%'PSBHVAIDG/+';FTNZWSH%B<C<)1M$6\ .ULV)
M,U+JRY3QZ\.U;MU(G>*6*]4PTDWGDQYM*O8.(%GO.HUZ-29*UWE7$;PBHZF>
MA.#* %FZM^LS5$,B-*^MU4^X7\\0F]P;=[QEGT&[^=;8ED_>B*32<3VL7T$R
M[')N84\$-9<?F(F<,[:?\1%Z^,KVY/[GOZ)A8L^F'2-!$Q1Q!\0VC5N5&B_K
M<X2 7 7,S$YS'32O:?^+:K*$K3Z@(@ '%6:ZH#9?UJ(WV<;'7I4AAFP7E69$
M)M!"JNA=X(FA\46J0D-1XSC'@B/B9%(Y6"QL3!1M)Q#<.J$STU0KR.GBO%[S
M1'Q7F$5-;X=!2W; M+'2/U=@<?!X^<Y,N[_3&XQG+LA5-4$(0B[H2WFRRU $
MI4O!)=.9F#'RT#6,B_H5& 2BFP$P1#$W406TRUW6?,>!J2,0YD9U]]X,QV3V
MFK ^ =ZWFL(_. +0.(MY5\#12$3->*0-<*0;IVX?#BD8'2I,01@I)[L:+$K4
M;5@M;GE_5@L3C [!WJ*,)NATWXBRG"N%Z+V;0VBW$K"=*0Q)#=QPR@PVPG;
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M</9?@(%3,!:>*S3J6O8UZE3Z?6C"4?^JKPBDK.3DQL7DN14.(/K8!358S\7
M,F7A1ACGQK5M:F@V&O,79#4XMY+W&F$*4!"CB-.!PYX*39 M([\1SR$71K=5
M]Z8,:T6WQHRG\:7\^64=H,N2X^BVN >E5<9VFK"N(G32F+YI_C(8#TX/G(8;
MZ'036@+S8Y"ND9#O8L$7TN#AW^:9PG^F61B:"+0&\0B^,&80X XGID_-%NN]
M27_TWLG!RZ,5B@]4 NBK:9>=%-"!5AU9X!\L5)FK);7'K(AY(W:/5E(QB[Q.
MA']Y NHH1[@TZZJBK$QW("2U,=$ D!U"%UBD\/<_"+'8 GW S\;"_*2QE>%Y
MB%=IP4<-"A\6&-7/J;B>8N;ZK>Z^HQ"N(S"[H3KK 1( %K,1+(#V?"8J0>1.
M%7D!ERK8>JI&CWDZ#;>S$C8LE+<9'.>$R>7Z7*1[ ?%"7C/S-!1M<LNK6Z[\
M\AA"\,X@ZZI$3G=VWJFLP**-$0_GUY&&)&.1BS I[[6%)UK89D$4YU-24T@>
M+WQOSS&\79NNOL-37N_@*3MXR@Z>LF6IR%[6**2)8>_X1%6&1"YJ#^0-9R4U
M:/ODX- Q#1)-6#GT.,(Z(@-9I4E_R3#VRYIBM_VNQPT,M]>N2^PP?W4]1:ZH
M@J$^-O2XB)7**\>*<P:Z"-O<MO5+C&M42GWA-NRUD)Z11K?!(+>8&L>?+L-T
M*U[+&X?7X[Z%28[]6BEJ"3M3>3,/:NT3VPVH.<&K[6?#4M,Y;:6MB1T7UE;*
M<ID%JHU#1T,7A';/$\^-6\$??LM8-WJ@Y:^8JX/6B.ARK&GE_;PEC5AA5X%C
M<4-N%?4PH[9'CF@=/#T<9E-&?LK.+;XK\>_@XJ%72?/L;.38I?HQ$]'B_/.)
M@*NH(P;AUSK[N($N;@9JSBNAPE;;MT8%@B4SY7@BL46$PXG-+:>;1O'6T#&L
M7R+N,X&;.M:2BV7=@IGH(H/F,$>HE')K1*B]@2IG13LYK>%H%67"-#XN1\YB
M])?#-+]FX )$SY'7@[_E#'QS<'BR5D"NY875Q1PLF8.W =-\E("'2;R>&Z0;
MA8=O+\3OI#_\/<:,:U=&;MAJ:S#EK\ER\46I>5>EIW?.XF$P:3#HFRN)5&R2
ME57M0]B<<\+\ZB!ZW]E7WBUH]<ZIP#-A0'-C/)M8I\Y9.)UB2"?!"/RD"[^/
M,VG$B]:REXJN=]YF_&9O:'/L;K/P,)2EZX_1YWF%EN-,#N>BW+379/BGQU\T
M?67E,<_@V=HAWD/?!#-%CGZK*1.IMOVJL.T ^ )Y\NDVP=!]&5V7V8?B)ANC
M@%N;#:ZC"/C21K\#DZB>HJM _\6[-TAQ(]Z?*+"<88+NU9M_?.9$VGD"C_U[
M[*"U38KSPD5FBC)47ZG!FO3V,?(9MP64I%S3$L)YX#;CU5A0SS%=B$^2)]@Q
M\;J$WX&\?2$F@Y0_QF=.BYM"CZ9P;]F 6O#PLE([".B=*M@&Q5*I/<VBZ3I&
M!!OSQA!^,+K<=B]/1069YK]SO9X4Q)@5[-SGZAZC(E.5,/K1F5F?5*'9])<X
M4,2H!BU18\ZN#:Y67Y&7I#(@:SH=O9R$-U46N"V+U!VO>?J<6(^TP>O>:8.!
M4'Y12&SCK5V% VY2(!V%9D#V.STPM8,/9P')6V!Z5CJ232,63BW^M\F=OA=F
MK%'0O<:,/6_<\&QBT[DP[\UZ"*%D8):]GK-LA70Q:9'/0'@P2_*D50R'2\)T
M-;J2HRZX^8.D2!-7A/&BL2ISO>#O&./)%HSU473_+1,X//L*FEK3-019KT)=
MTAM=3@6G0430A!5/&I*XY_;\5!WB*D@_"UEN3K304432&*ZCT\Z^?;G 1,'\
M8_,JE?/F"9)%-V(PKV.W.SLJ<EH%=YR"AW?2_7(:N'$_#S5"[])Z_^YANT>1
M4*A'EH4U</14!1RDR#]8M0;R#8_G^!/<JEPHX4$KD6[R ,T7/R *:XAHAALG
M- 7G>[D,T#H[1G9CAD6SM8<8&EQB\R"Q00U83_RO17HSDTHH"].*0RD3*Z8:
M_0J*J')8;G44#;_[G!/IV55-9A#(RZ)DGA6<G[.OW!B2]IZV$-R$C"7-O2%B
M-6J92K@>Q*O20A@2;_])W*":MDI=C+^@D<&/0ML)K$8"CV KH16 B!_?I'C3
M.Y/B4MMV_<DR#B>>.^!E#)U<S2K_E[7%2&380 $_'UP=K"GS+,SX6-!5>,=.
M^NDZQ$K*1TV[NZFGH]^TDJ@22!, X-@X5LR?-=?G'6UMZ18:< P:2#]E"7G1
M_X&-YKL8]G!ACJ34."NENLN*117^6<AU,S-'H356];:6PBU399"]3WAM%+9I
M.);8MF)8-+C#2O4=*_5FAY7:8:5V6*DM,UO>]LYL^63K@S=MKES9I'8+O=!)
MV7J$#IJ4O*_GB 0260&R:X^(V0%,,8J929:9M3WQ&29<-P(N&<.K$B\\N4WZ
MCS2ID[C%\QH"001([!\8#ML;W<]]^+$A<@KM@7(*DDS"NC:Q$6O-Q%[%N1V7
M8834<STAV^LN4_=AMO$643A?_.CGI0I-6Y WTQP5W]E-!QFCKHFU$?.OTD3<
M3:GL1$E1BR?GNU!NE8JHT<T5W)PQS[Q$+ICPU+9 OZ#479LJ7*]OBA02T&U:
M3<RS(FV2&>/;3J3&AIJ9*.[&]J@Y9C\C72B&)H&1GZ5N42\ZXA2P<9UR:A\V
M\?+7#:3@@TMK%F<OV5^Q$A.7WO>!1:%DR]YHOY$)(%$5CO)H3N GJ23%3E-4
MP'E+?35&6*JU )U!T=I<D@8&63C/2C,H)NKUZG&\.&&@*Y?-5396D9ZU]W4_
M,A!.8G-UWSU5TH-X^:13M=S'.R?+=@AL]=II67<?CY/<VO/2(81=+S5/=#U)
M;CVPB5D439/+C\BU ^BN9&.'Q[8J)78&R34J$@ZSH$OIHL3WP-9KN7BG6L68
METO(JZUNL[DE\TG@7<RN"_6HH\9"\.AJG.&TPY;77456N&L_NDFDJ<5ZDR(R
MU&*?!G]^/#N_ON*2OLN+/P<?KH=G5T0Q=GGVZ>+R^FI[E^5U#PG&-(#BO>(8
MM)/C0(0&:+PB=W''F[!BAZ#T,2N2<(LQ4*"EU6ZHCX0+H;+8*0W O2F3O/8[
M$@K)ET[!N(I?8W#]3HU6.U,7(AO7XYB]E.FZ%:S\B*8%/$^6GAT2_<?ARQAF
M#O\7[?6 8/[S?%+B8S\E2US_/M#)AWN[=J6I8ANW2V88]F?++G]1J@FLMRF\
MQ8_&I8*%PX^V6>'TL(Q(*Q4M9M7!9N''#VQ2+B#6.>N9&?U<1L]9.RSD3AWO
M+_0+=4?72S\RMVR]5>[^'<R ?>\;!C+9GV.0^X:])^_;)O2CJP0415].OX<.
MD:/X1,X0?1R&WR<+YCW1T&^&*K:W:1T*7V]4(@L?KDUEA:WJM[3IYF*^CN/#
MEBB>KNF0I7G&>$1Q'^WA;^!D[D,+G<9D]\K2:9@X%<5V*H?[L=7RC0.P[NE#
M1TRO9_SLKB?SO7XMY<N#@.7WYN#D56]RA$>_O/J6'"'89&]/7JV5(WS,;5\=
M'KQ^<_+DMST&N^%-]T\?S&C^\F^-):&%?'D DXQ<4%D::>&3[\F%7'4!UM:%
MOGYD8A1N\V"&S[>E#]Z<.)_Q..5#YUEC8I=]\I/VY5K[WCT'@CJ W6?M W1E
M5U>DI==;Q&]8(VVT!)?I[YW+ELHZQE1T8^:B\\)::+(5?NX)NH"IP1LV92QZ
M9X%)3S=C3Z47(OSO\<&;-^NJB)Y,;<-HVFU6;\(.=UO3G0[/:.W?'NSUW/U'
M]^3M]IN>I*/=?MOMM]U^>[9).M[MM]U^V^VW9YND5[O]MMMON_WV;)-TLKY0
MF?APYX3\#!.VVY'/MR-?[T3P"47P^R=O)Z2M"JA=U6/OJA[?/@;/T8^,YJ[J
M<5?U^-Q5C_(1JNP?$]G4&[)11C9=6CX."V_J"=EA%YC.Q]@0WMO_:(_I=,:W
M@K5AZH,1%XW91C/C*7:5X3(JS'/OC?9[ L@)K4H?\#CQWPU[HSO^5U;#_AVO
M,:Z.=E,;A2HW23P><Z[_\-JM-^2NK-W.G0)2)@%O #EIW_=1!VYQ-\0>-IWW
M3YQF^2E"9I'W$L^,!TI=%-8V(5S[%!E_TJ2,_F>1E/@MWH,*:?&R(-A*"LP+
M)*ZII+ZR PM+*'*"^3JGG.E>EPI5&9R<Y!)\CT;ZP62KAXWJOU.V?&I,6/(,
M5ENSNI$(A-27%%G1(XFTCW[L])1IU<@$G[[=PM*_QO5GN)[MI3$[6^]HZEYC
M"ATUJV1#.&3)-<^?#T*W#Q&B9%T>X&D1VTZ96U\:XD=BL)BK!*M4&H\EC61N
MO\UU>[UQY2P37[%,IDA+M\W50<=]*TTSLX[',^VU7PV[QX8IUJ_\;CG!DN@
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M5$HYG<E'GK]53"88+/-O8"N<&!!!AW"WC;&#CO0".G+\<@<=V4%'=M"1+3.
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MVM58L?/6VEW;S+K7FR[Q =:][O+L:L?(MV/D6RW7?6/D:\" 5M,/Q)%7NNC
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M[V<PE5>?X6\9X)#INTYABM_1M,+U_FD -[T\.ST;?B*:*;AX"$]Z?WGQT2S
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ME.IV&A7?)*=VO6 :A::1>E[X7X >6TR3<DI-.[.*6V"0NJR3>F%6KVM2W)P
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M,14+C"E?Q9O,2;IAPM.^*&749K)=74M2=K?87S(39KS4QE?=X%.=#FG:6,O
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M'L>83 4U:)ND>'BTD>F'_/VCV&'+>HXM.]IARW;8LAVV[ ?&EKF*GH%= D0
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MQ8BB:39#_-:,&@"3'EQ3TE>^.T'@WQX=/5<()*SG^J1":#H.84X5W.1G(2%
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MD-[&5+1RF)G;6UA"7%_3#=#BAB><<$L_#-13E2Q%T\>$*DIU8W:/%-U6_B[
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M36+#S$I!]<2'!">NC,C]$/H1P&'K4@YJ9+#%IT,/W7L6+8LH;V&Y8R'P8D@
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MQN&_U%%W,&IWL<C*@V&W#TH#W<Q&]?)5+=FHO@)LMN3WUA.!\^A3"8?W\;O
M4Q'J(&8@@7]22!E_]<OOBH)W*?W78(.>Q\E<9QO,C?V"N@NJZKFB[H)6&$MW
M&QZ[WSKOT,+<Y_C=L[]W0Q_8T=^[Z#NVW./NN"<C/D>(%0P=#Z;3*"A2A[8C
MM'X>;&AG"MNS2$\=9/#J3#X4GOD;RTZ^F\?X65_Q08^Y7NTCQ\OJX-#L S\_
M<>#G'Y,XO(-_9MEB_OO_ 5!+ P04    " !I@*Q4OOT^M&$[   \[ $ $P
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M+"D4Y:%9=$^B!@4R\@2-+F,X4EJHKX@_8]">Q"V0TB0!47IAOD#%S=ZHB$&
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M)(S+(IU>IJ9I=M, Q9BM@[8ISV3N%MJ1SFQC80NG)H#0COC ,(YA%21-F0(
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M<\Z&I54MR6ZP!:LTHIM3%&8T5AE)W7PCNM%OY>" 6R-6B0FZ;(F\YKH\01T
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M02LR_VL5R1CR_GA(;[IVE4[P77;!?E& =<QC3[RXX+QS-)8%04GCUA0$Y5;
MKH33DI1G)Z4L"':5E$WQUX?E*P+;&X)6;07 LX@:N_!'TB@]>7&A>.=H+-/_
MDL9M2?_+7P*M)-:]%3[M^K7C+X:7U&X;M>N_6+@+U+XLV3X1M9L2@=9?@-I1
MX5(LJE,CR+=E"^VU6VB;Q9:>"9]0!TX9PU<MN&O?.E"I9N(O;"D&?[05.IS
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M,8:EHY1S'W!X:L^;\! =H;!/-WD(-IIE[2,',\M/?T;4G58]_QM02P,$%
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M8CMOL%\:Q7:]_R6$++%;2OUPR+UYX=\.C ??A^O/ZM7<_DAP\C=02P,$%
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M<F4M,C R,C S,S$N>'-D4$L! A0#%     @ :8"L5.>;6"TZ$   +)   !4
M             ( !RH<! &1A<F4M,C R,C S,S%?8V%L+GAM;%!+ 0(4 Q0
M   ( &F K%1(I5ME)D4  %CD @ 5              "  3>8 0!D87)E+3(P
M,C(P,S,Q7V1E9BYX;6Q02P$"% ,4    " !I@*Q4-<<)2?Z@ 0!B_P$ %
M            @ &0W0$ 9&%R92TR,#(R,#,S,5]G,2YJ<&=02P$"% ,4
M" !I@*Q4&XBP]CNP  #6<@< %0              @ ' ?@, 9&%R92TR,#(R
M,#,S,5]L86(N>&UL4$L! A0#%     @ :8"L5%"X0D>09@  ^H@$ !4
M         ( !+B\$ &1A<F4M,C R,C S,S%?<')E+GAM;%!+ 0(4 Q0    (
M &F K%0M,BD<2?H  .AM"  3              "  ?&5! !E>#$P,5\Q,'$P
M,S,Q,C(N:'1M4$L! A0#%     @ :8"L5+[]/K1A.P  /.P! !,
M     ( !:Y % &5X,3 R7S$P<3 S,S$R,BYH=&U02P$"% ,4    " !I@*Q4
MTB5&A$P.  #FA0  '@              @ ']RP4 97A?,3 R;F]N965D:7)E
M8W1O<F-O;7!P;VPN:'1M4$L! A0#%     @ :8"L5!$?-LU*"   _#L  !<
M             ( !A=H% &5X:&EB:70S,3%?,C R,C S,S$N:'1M4$L! A0#
M%     @ :8"L5%5B#%PI"   "#L  !<              ( !!.,% &5X:&EB
M:70S,3)?,C R,C S,S$N:'1M4$L! A0#%     @ :8"L5 8H/?^W!   ?Q
M !<              ( !8NL% &5X:&EB:70S,C%?,C R,C S,S$N:'1M4$L!
M A0#%     @ :8"L5-=NO.*I!   <Q   !<              ( !3O % &5X
K:&EB:70S,C)?,C R,C S,S$N:'1M4$L%!@     .  X K@,  "SU!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
